<SEC-DOCUMENT>0001628280-23-015763.txt : 20230504
<SEC-HEADER>0001628280-23-015763.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504161934
ACCESSION NUMBER:		0001628280-23-015763
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		77
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			X4 Pharmaceuticals, Inc
		CENTRAL INDEX KEY:			0001501697
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273181608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38295
		FILM NUMBER:		23889054

	BUSINESS ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134
		BUSINESS PHONE:		857-529-8300

	MAIL ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsanis, Inc.
		DATE OF NAME CHANGE:	20100920
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>xfor-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:6d137f82-7ad4-4f5a-a1d8-483327cb893c,g:a70c2544-a714-416b-95fa-518d19b53207,d:31a6b5aa29ee4f3785de4e1e0f908a81--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xfor="http://www.x4pharma.com/20230331" xmlns:dei="http://xbrl.sec.gov/dei/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>xfor-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80L2ZyYWc6ZjZhNzE2OTM1NjBlNDBhMmI1YzY3MDdjZDY1N2Q1MDUvdGFibGU6Y2U0MjVjMWM1ZjRhNGE5YWE5YWQ4MjQ4OWY1MDMzNWYvdGFibGVyYW5nZTpjZTQyNWMxYzVmNGE0YTlhYTlhZDgyNDg5ZjUwMzM1Zl8wLTEtMS0xLTY4NTg1_68177959-6286-4b21-9986-c6beec79801a">false</ix:nonNumeric><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80L2ZyYWc6ZjZhNzE2OTM1NjBlNDBhMmI1YzY3MDdjZDY1N2Q1MDUvdGFibGU6Y2U0MjVjMWM1ZjRhNGE5YWE5YWQ4MjQ4OWY1MDMzNWYvdGFibGVyYW5nZTpjZTQyNWMxYzVmNGE0YTlhYTlhZDgyNDg5ZjUwMzM1Zl8xLTEtMS0xLTY4NTg1_678f4766-ea67-4219-9ec2-4a0dc069621f">2022</ix:nonNumeric><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80L2ZyYWc6ZjZhNzE2OTM1NjBlNDBhMmI1YzY3MDdjZDY1N2Q1MDUvdGFibGU6Y2U0MjVjMWM1ZjRhNGE5YWE5YWQ4MjQ4OWY1MDMzNWYvdGFibGVyYW5nZTpjZTQyNWMxYzVmNGE0YTlhYTlhZDgyNDg5ZjUwMzM1Zl8yLTEtMS0xLTY4NTg1_bedf9fbd-4a01-4434-a286-78939292545d">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80L2ZyYWc6ZjZhNzE2OTM1NjBlNDBhMmI1YzY3MDdjZDY1N2Q1MDUvdGFibGU6Y2U0MjVjMWM1ZjRhNGE5YWE5YWQ4MjQ4OWY1MDMzNWYvdGFibGVyYW5nZTpjZTQyNWMxYzVmNGE0YTlhYTlhZDgyNDg5ZjUwMzM1Zl8zLTEtMS0xLTY4NTg1_1fc6ed3e-70c2-479f-ad8e-befaa21bb094">0001501697</ix:nonNumeric><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80L2ZyYWc6ZjZhNzE2OTM1NjBlNDBhMmI1YzY3MDdjZDY1N2Q1MDUvdGFibGU6Y2U0MjVjMWM1ZjRhNGE5YWE5YWQ4MjQ4OWY1MDMzNWYvdGFibGVyYW5nZTpjZTQyNWMxYzVmNGE0YTlhYTlhZDgyNDg5ZjUwMzM1Zl80LTEtMS0xLTY4NTg1_886c9b5f-209a-4ec8-946c-dbc13bf487ac">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="xfor-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia80ce664878241a6a1f41c82e266dff4_I20230501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8402c14812aa4792af598dc3f27820a4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i1ca029d12cad45af98e015984da7cdeb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i553e6350cf6c429980b87aeb902c6c55_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i148ac761490846059a641c4096bff174_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b29c1af764d49dd8a2b25cd40f9c5e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd2737e0aa5e4ceda68812a691c9447b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if43cc4ccf2b647bfba5772dafdf4d1df_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bcc5907b6014b9d93c0ce335d74d143_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id687fd50375c4b9289fc38f39c37c931_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7da3eb074b8d4cb09f155d7cbd131475_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c39f890c41047c9a65d791fe89d7f5c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2699357e209d4ca393deb31d5b50ef76_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4f97645aff94169b01a7e55e7ad5b86_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib174ac43e0694fac9a20163af9e3c6c1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id108597db204485299a9f94cb8127d3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51c1bc362afa49eeb95ed63f82caa21b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fed87c65647480c8d625fffe1b0ea5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b481bc1391f4635a7c7fc91a64f1e08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i127a474f92264d58b7e85a4321f95964_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06ba2f0164234d80aef6eb30ab849e77_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4b750c506b44cbda93e01a7505ed761_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec90ace9f4384f59bd0e68d11db46c7a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia32dbc78288b4274b74a087a419e35ff_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cb4dfe1750c4c539b0698f339b61a94_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83228390dcb849b29ea600f914617cc1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f2a6bfe01ec46bc85d75976e40b1ab0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a25074b350146a4adca9401db84ac82_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5139ec8cd3c4c57a78f7ac8c654556a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7ba5290654141e4b61b83ad34d08c17_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i810c7142f18049f48bf12b8c5fed906f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied52c772cd6240a0a1fae6e51f2ddfb4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i654563320ef74399a7b67534f01c3d1f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57677a75b59a47908ea0dc176c8f9bcd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide51a96471e14846b0eafc7204f8f180_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65095af2a0774d4ca62250a84f77486a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0808869d78f44fcb077f2e781a826d0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4569714abef741429d743af4a4bf2be0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c1816e489194f42bdd5f5bf10009b9c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2ab8413e7e84528b4f5fdcb13e35002_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeef5c014ddc40deb4afa45ea2116298_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i381526f76190408a9511bfe7c72a7ff0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i135f5bb1ba83401da08651bc765c88e9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfb4d92d12744b63a445624d8eac9b0c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73a291db2a214ab8bd5e5491ada2141b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5dd8502aef84153bdcb16bdbd51c805_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia57db8f000ee4e0db6a8ea78cb129405_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4afbc3f95ef42a4b901ae73cd5145db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3668be13a034a95babcca27311d8576_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5e321b38d9d409c9c0f8404d848b3dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d6a3b6f090b4a87bcfb08e640d71bba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b09f270112741469f241038cd756330_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3b2a90a4f734a278a5d983fe879b015_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e93d6b488d5402094357867417eaf30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6a0892801fe4d00ba9b8e44831c13dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i416807bcc91c4426b94694508810dfe8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7ba75f2aa194fdfa790914ca3e5f732_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d93fbb6a1a344a8b945a2a6d090a483_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81add40f359a4d498e9c203424802dfe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64eed22c85fc47188e427943319310db_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id13c30409f644883bc0984bf6cca3669_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id99d965540fb4a3d8b3bf165eb026ad5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf55d74b96f44b02b711f225b809780f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i600de8e95d2f4f32915317e0807fd211_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4adf5f56124545d5a93d3519e1e8f047_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08cceb6ad460483886bad3c9fcd6710e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fbe040e10eb4417b2f7665f9b30f4e7_D20230331-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i8067028e2bde498d90d62f8632965d93_D20221231-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i833765a4f0bd42efb5804d15e1b6865f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64189e1012e04d2a966fd7a2f71a3db9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13aa4785edcb43ea8c372564342c427b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e5c556c18904363b107b9fc923ba681_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7410737db5a84986b20145230e3dfa68_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6c7932d5157432c9771d0031da998c3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94a2b42432f045c69a6a314871000d9c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i121a3bffe8da40d3bfa57370f4d064ce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17c81259a02f42f0875544b1198e4095_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06a2ca03978148dc9bd965d74ecd6189_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e9d1a47182c4c47854e138d3c2b5d17_D20181001-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie15dfe94dd9d4fe39d6d8e1f3b74ce9a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8e87f99c10e4fb881a7bed5735567ff_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28f0cf51fe7e42fbb78f10ac69a552e6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia310f627aef34b0faca97728c514f3c1_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i792dfc869c4b408e892ad399f14978bb_D20240701-20240701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4e98937b5cb4858b0ac41a2a5352c45_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">xfor:MinCashTestDate1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2d3052cd5e24327abde1e8113a23cd2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">xfor:MinCashTestDate2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i758d637f0af747e88e3b2ef6d3eae458_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8529518add445d8a6792e09b74e9bf9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if95bc8592c8940cab11430e303f438e5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaAustriaLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqm"><xbrli:measure>utr:sqm</xbrli:measure></xbrli:unit><xbrli:context id="i44b39b28bc5548a2886646bbc220829d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaAustriaLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25a8d7091c814a1188d29fe34e7e629d_D20191111-20191111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-11</xbrli:startDate><xbrli:endDate>2019-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i23498fecf6314534a7194a398e3e01ba_I20191111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25e5f6ca21c44724bd4163d8dc79dbe2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02b354bcacc54b7baa76c20057184051_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d0d898499ff4bda99b5eb41e4b472d0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:IndemnificationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib84837e886bd42e9be166c81d4c7ebdf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:IndemnificationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c446d1ebf6c4761a059bfe41f76a3e8_I20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:Q12022PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59fa5f3cd8cf463cb6ab5a26e83105b0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iade75dd12e4e4311828ad8732615848a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7ff88f12eeb444480a302991cd38a77_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica711cd3944d444d8e90591b4f36f165_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i659abfcb1f9b4bab9b076ba940943d85_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f782c581af34e0bbaf1f1c156ed8abd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id50d3ea6ecda45bb92708c1a5fcceadc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberNineteenTwoThousandEighteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i831b8fe131874b52b6235c73b19040d9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberNineteenTwoThousandEighteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44c6c0606f1e473a95f0fd0e8f1f0ceb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarchThirteenTwoThousandNineteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie46fdfe3fed3486d838e54a83d18ef93_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarchThirteenTwoThousandNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61d35b6a71594a80acb565c214ebd4d8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassAWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnAprilSixteenTwoThousandNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57d428ba32094371b2dd937c8006e5f0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnAprilSixteenTwoThousandNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e73b6bdb52e4b4289aa86a4856b47d5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7df7eb9e7da8482fafec0c3a38337782_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb769b89cd694464bdd20ebea31ac73d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarch232021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i721101088e744db48fa346c2c77fd85b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarch232021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3c41890d3204b10bab8bd252409ac92_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberNineTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9018c6d85d24e0dba02aaac05afaddb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarch32022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5011564a8640482d8512bf19c9642f10_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnJuly20221Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7edde0006e1e454d8fea426452b3b54e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnJuly620222Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i818c42fab04d4637b93d77e2ac2f2974_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnDecember92022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21bf4eefdb5f491ca5fc00294f5db16a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnDecember920222Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib89426f0e382467982b04ef21eb04de6_I20191129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b8255b9ad4e4346b4353461add65217_I20191129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a0759706aef4898bfd9353dc9c1c0cf_I20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd18ae94cc92493599001fb5cde340a6_I20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b76566d4b4d440f9b96f6bd007aea3e_I20211109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fe40bc1e0fd489aa6756bc0c4fcb174_I20211109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f7f41a7ee2c446eb9fdb515a92b8d90_I20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4705077c59e44584ac747abb1c31531c_I20220303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie54bb572558c468f842e439ada8634bb_I20220303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac8921647cac40fbafd7ae760b99dccc_I20220706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i057e951826ef4df4b14c1200eeac39f1_I20220706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bda35ba3715478cb44dadfb584bfff4_I20221209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c915254cae9474f9c1872cf496e414a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3afe5f2291441f68f12e2ab64cf0818_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4740594349684b0589e4efe56fcf1e5b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f9fb24c8bb04a26883c4eb1d92a0d6b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86fbb46408bd4a3db8bc2da79cf7f762_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21e6f989318241fbbefaf5468e259ca9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19a10edec5d54b3ca68a4c28e1bf34a1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15e8f73d1083480daefae46435fca891_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2770b271c4ae4bbb9a3c41d6903a369a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e768118a7db47359a07259561180c69_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4221465155da49fe9746bea8dd9a5099_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i543a1b3b9f974153b5b0d78f5aa7e65a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f3437aea96f4fe886c79fb94a8059fe_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcded639cedf4a788b3eecce804bc350_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81603c1b6ca6430691c2b72f0262d107_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c0ed81ded19458591eb27f59b52093f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac5b1bc09d7c443491ee3a29c39946f6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie95358238f73468db9f71aef1ce13baf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjYtMS0xLTEtNjg1ODU_af199409-8a84-4abd-a25e-eefab0bb9286 id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjYtMy0xLTEtNjg1ODU_78ba9af6-ba6b-4906-bb66-1087f9aac6b1" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzEtMC0xLTEtNzQ2ODQ_b30ab6e2-479e-4fee-926d-dba7a9de7c0e" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8yMzU1_0204fd1b-0b94-41e9-837e-e174980513bf">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6MmVhNWY1YTI5N2FlNGQ5MzgxY2EyMzEwYTE5MTU1ZDkvdGFibGVyYW5nZToyZWE1ZjVhMjk3YWU0ZDkzODFjYTIzMTBhMTkxNTVkOV8wLTAtMS0xLTY4NTg1_9d3a41a6-f75d-4082-b10e-f3e8b6c1584f">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8zMDQ_b553e18a-5ec3-4216-a389-b7edecd5ff36">March 31, 2023</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6YWMyZWYyOTA2ZTEyNDhmNDhmMTJmMGU5OTUzZmE2MDIvdGFibGVyYW5nZTphYzJlZjI5MDZlMTI0OGY0OGYxMmYwZTk5NTNmYTYwMl8wLTAtMS0xLTY4NTg1_81883e9b-2ad4-4ccf-a9f9-eb4fd8acbdb6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from __________ to __________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8zOTI_260061d6-15f0-45c1-9933-c02f2a22ee80">001-38295</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________________________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8yMzU2_b005df42-f686-4d6f-b037-4bb9535f0ff8">X4 PHARMACEUTICALS, INC</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6MTA3YzM1MGU3ZTAzNDgxNmI4MDY3YWIyYTdjNjQ3YTAvdGFibGVyYW5nZToxMDdjMzUwZTdlMDM0ODE2YjgwNjdhYjJhN2M2NDdhMF8wLTAtMS0xLTY4NTg1L3RleHRyZWdpb246NzZlMTQ1NWM0ZGRkNDJhMDk4Zjc0ZjY0Yzg3ODgwOGNfNQ_ed9c57d6-ccac-451e-82fb-04689c70708d">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6MTA3YzM1MGU3ZTAzNDgxNmI4MDY3YWIyYTdjNjQ3YTAvdGFibGVyYW5nZToxMDdjMzUwZTdlMDM0ODE2YjgwNjdhYjJhN2M2NDdhMF8wLTEtMS0xLTY4NTg1L3RleHRyZWdpb246MzdkMWM3YThiZmEwNGE5YjkzY2RiNmZkZDk1ZDU0YjVfNQ_3944cd9a-731d-4786-af36-d01bf7b3e3f6">27-3181608</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6MTA3YzM1MGU3ZTAzNDgxNmI4MDY3YWIyYTdjNjQ3YTAvdGFibGVyYW5nZToxMDdjMzUwZTdlMDM0ODE2YjgwNjdhYjJhN2M2NDdhMF8yLTAtMS0xLTY4NTg1L3RleHRyZWdpb246MWM3YWRkZTE0MGMyNGUyODljNDAzMzA2MmNmMDJhYmVfNQ_918b7f33-b45d-4012-a53f-b0d0a0957973">61 North Beacon Street</ix:nonNumeric>, <ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6MTA3YzM1MGU3ZTAzNDgxNmI4MDY3YWIyYTdjNjQ3YTAvdGFibGVyYW5nZToxMDdjMzUwZTdlMDM0ODE2YjgwNjdhYjJhN2M2NDdhMF8yLTAtMS0xLTY4NTg1L3RleHRyZWdpb246MWM3YWRkZTE0MGMyNGUyODljNDAzMzA2MmNmMDJhYmVfOQ_a5234ff6-8531-4a2e-8df7-a9f3b5bbd053">4th Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6MTA3YzM1MGU3ZTAzNDgxNmI4MDY3YWIyYTdjNjQ3YTAvdGFibGVyYW5nZToxMDdjMzUwZTdlMDM0ODE2YjgwNjdhYjJhN2M2NDdhMF8yLTAtMS0xLTY4NTg1L3RleHRyZWdpb246MWM3YWRkZTE0MGMyNGUyODljNDAzMzA2MmNmMDJhYmVfMTI_32640648-0e97-4e17-b5fd-4152a997fade">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6MTA3YzM1MGU3ZTAzNDgxNmI4MDY3YWIyYTdjNjQ3YTAvdGFibGVyYW5nZToxMDdjMzUwZTdlMDM0ODE2YjgwNjdhYjJhN2M2NDdhMF8yLTAtMS0xLTY4NTg1L3RleHRyZWdpb246MWM3YWRkZTE0MGMyNGUyODljNDAzMzA2MmNmMDJhYmVfMTY_90b71b49-579f-402d-8743-d00baf62564c">Massachusetts</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6MTA3YzM1MGU3ZTAzNDgxNmI4MDY3YWIyYTdjNjQ3YTAvdGFibGVyYW5nZToxMDdjMzUwZTdlMDM0ODE2YjgwNjdhYjJhN2M2NDdhMF8yLTEtMS0xLTY4NTg1L3RleHRyZWdpb246YjgzM2U2NzM1ODJjNGRmMDgyNzJhNGFhYzIyYTNiN2RfNQ_29527345-06d5-44aa-90a3-0ccc587e6fa1">02134</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8yMzU3_c405cf2a-3158-4f64-9840-5b0f78226e09">857</ix:nonNumeric>) <ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8yMzU4_820c362d-c4e1-4231-8b8b-f577a6cd07fc">529-8300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">____________________________________________________________________________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6NzRmMWM2ZGNkYTIzNGQzNTkxYWQzY2RiYTYzYmM5OTcvdGFibGVyYW5nZTo3NGYxYzZkY2RhMjM0ZDM1OTFhZDNjZGJhNjNiYzk5N18xLTAtMS0xLTY4NTg1_347e4462-4894-4ebb-bfa8-826ba6f90f59">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6NzRmMWM2ZGNkYTIzNGQzNTkxYWQzY2RiYTYzYmM5OTcvdGFibGVyYW5nZTo3NGYxYzZkY2RhMjM0ZDM1OTFhZDNjZGJhNjNiYzk5N18xLTItMS0xLTY4NTg1_f68b217b-a8a3-4386-b043-c705af2186e7">XFOR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6NzRmMWM2ZGNkYTIzNGQzNTkxYWQzY2RiYTYzYmM5OTcvdGFibGVyYW5nZTo3NGYxYzZkY2RhMjM0ZDM1OTFhZDNjZGJhNjNiYzk5N18xLTQtMS0xLTY4NTg1_309d842f-99c9-4516-a5f7-d2c20c853004">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8yMzU5_4aba160b-26ca-475d-a70b-52cee664d229">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8yMzYw_c2325269-33be-4297-b99c-0969e8a9a46e">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:24.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6ZDE5N2Y5NTA5ZGZlNDBjOThkOTQ5NmM0MWRlZDdkNDkvdGFibGVyYW5nZTpkMTk3Zjk1MDlkZmU0MGM5OGQ5NDk2YzQxZGVkN2Q0OV8xLTAtMS0xLTY4NTg1_9dab57ca-fbc3-4d4f-b123-79a4b0f2a08c">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6ZDE5N2Y5NTA5ZGZlNDBjOThkOTQ5NmM0MWRlZDdkNDkvdGFibGVyYW5nZTpkMTk3Zjk1MDlkZmU0MGM5OGQ5NDk2YzQxZGVkN2Q0OV8xLTQtMS0xLTY4NTg1_ab24df31-3c04-4a30-82f1-f4268930daf8">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6ZDE5N2Y5NTA5ZGZlNDBjOThkOTQ5NmM0MWRlZDdkNDkvdGFibGVyYW5nZTpkMTk3Zjk1MDlkZmU0MGM5OGQ5NDk2YzQxZGVkN2Q0OV8yLTQtMS0xLTY4NTg1_eeac65c6-71a1-463e-90bd-2991ed5b98f1">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;&#160;&#9744;</span></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8yMzYy_f48133af-5b75-4bbf-b930-c968b53f12d8">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of May&#160;1, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="ia80ce664878241a6a1f41c82e266dff4_I20230501" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8yMzE3_5cef4be6-3464-4105-ab36-1b821c85531b">122,207,488</ix:nonFraction> shares of common stock outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:38.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.660%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_16">PART I: FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_19">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_19">FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_22">Condensed Consolidated Balance Sheets (unaudited) as of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_22"> </a>March&#160;31, 2023<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_22"> and December&#160;31, 20</a>22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_22">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_25">Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_25">Months Ended </a>March&#160;31, 2023<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_25"> and 20</a>22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_25">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_28">Condensed Consolidated Statements</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_28"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_28">Stockholders&#8217; Equity (unaudited) for the Three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_28"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_28">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_28">March 31, 2023</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_28"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_28">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_28">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_28"> </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_28">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Condensed Consolidated Statements of Cash Flows (unaudited) for the Three Months Ended March&#160;31, 2023 and 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_31">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_34">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_34">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_76">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_76">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_76">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_97">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_97">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_97">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_100">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_100">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_100">29</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_103">PART II: OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_106">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_106">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_106">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_109">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_109">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_109">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_112">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_112">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_112">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_115">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_115">DEFAULTS UPON SENIOR SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_115">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_118">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_118">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_118">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_121">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_121">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_121">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_124">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_124">EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_124">67</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_127">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i31a6b5aa29ee4f3785de4e1e0f908a81_127">68</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the (&#8220;Exchange Act&#8221;), that relate to future events or to our future operations or financial performance. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. These statements may be identified by such forward-looking terminology as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, including risks described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this report, regarding, among other things</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and related preparatory work and the period during which the results of the trials will become available, as well as our research and development programs;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">the potential benefits, including clinical utility, that may be derived from any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">the timing of and our ability to obtain and maintain regulatory approval of our existing product candidates or any product candidates that we may develop in the future, and any related restrictions, limitations, or warnings in the label of any approved product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">our plans to research, develop, manufacture and commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">the timing of our regulatory filings for our product candidates, along with regulatory developments in the United States and other foreign countries;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">the size and growth potential of the markets for our product candidates, if approved, and the rate and degree of market acceptance of our product candidates, including reimbursement that may be received from payors; </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">the benefits of U.S. Food and Drug Administration (&#8220;FDA&#8221;) and European Commission designations, including, without limitation, Fast Track, Orphan Drug and Breakthrough Therapy;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">our ability to attract and retain qualified employees and key personnel;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">our competitive position and the development of and projections relating to our competitors or our industry;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">our expectations regarding our ability to obtain and maintain intellectual property protection;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">our estimates and expectations regarding future operations, financial position, revenues, costs, expenses, uses of cash, capital requirements or our need for additional financing;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">our ability to continue as a going concern;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">our plans to in-license, acquire, develop and commercialize additional product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">the impact of laws and regulations;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">our plans to identify additional product candidates with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">our ability to raise additional capital; </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">our strategies, prospects, plans, expectations or objectives; and</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">other risks and uncertainties, including those listed under the section titled &#8220;Risk Factors&#8221; in this Quarterly Report.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should refer to the section titled &#8220;Risk Factors" in this Quarterly Report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:90%">SUMMARY OF SELECTED RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business faces significant risks and uncertainties. If any of the following risks are realized, our business, financial condition and results of operations could be materially and adversely affected. You should carefully review and consider the full discussion of our risk factors in the section titled &#8220;Risk Factors&#8221; in Part I, Item 1A of this Quarterly Report. Some of the more significant risks include the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We have incurred significant losses and have not generated revenue from product sales since our inception. We expect to continue to incur losses for the foreseeable future, and we may never achieve or maintain profitability.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Our liquidity position raises substantial doubt about our ability to continue as a going concern and we will require substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate any product development programs or commercialization efforts.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Raising additional capital may cause dilution to our investors, restrict our operations or require us to relinquish rights to our technologies or product candidates. Future debt obligations may expose us to risks that could adversely affect our business, operating results and financial condition and may result in further dilution to our stockholders.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We depend almost entirely on the success of our lead product candidate, mavorixafor, which we are developing for the potential treatment of chronic neutropenic disorders, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome and, contingent on a potential strategic partnerships, for the treatment of Waldenstr&#246;m&#8217;s. We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, mavorixafor or any other product candidate.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">The regulatory review and approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, including mavorixafor, our business will be substantially harmed.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We depend on license agreements with Genzyme, Beth Israel Deaconess Medical Center, Georgetown University and Dana-Farber Cancer Institute to permit us to use patents and patent applications. Termination of these rights or the failure to comply with obligations under these agreements could materially harm our business and prevent us from developing or commercializing our product candidates.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">The results of clinical trials may not support our product candidate claims.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We may fail to enroll a sufficient number of patients in our clinical trials in a timely manner, which could delay or prevent clinical trials of our product candidates.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">If the commercial opportunity for mavorixafor in chronic neutropenic disorders, including WHIM syndrome, is smaller than we anticipate, our potential future revenue from mavorixafor for the treatment of any of the diseases may be adversely affected and our business may suffer.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">A breakthrough therapy designation or Fast Track designation by the FDA for our product candidates may not lead to a faster development or regulatory review or approval process, and neither of these designations increases the likelihood that our product candidates will receive marketing approval.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Product candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including marketing withdrawal.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">If, in the future, we are unable to establish sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We face substantial competition that may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval for our product candidates outside of the United States, which would limit our market opportunities and could harm our business.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Even if we are able to commercialize mavorixafor or any other product candidate that we develop, the product may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We have no experience manufacturing our product candidates on a large clinical or commercial scale and have no manufacturing facility. We are currently dependent on a single third party manufacturer for the manufacture of mavorixafor, the active pharmaceutical ingredient (&#8220;API&#8221;) and a single manufacturer of mavorixafor finished drug product capsules. If we experience problems with these third parties, the manufacturing of mavorixafor could be delayed, which could harm our results of operations.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We rely on third-party Contract Research Organizations (&#8220;CROs&#8221;) to conduct our preclinical studies and clinical trials. If these CROs do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Disruptions in our supply chain could delay the commercial launch of our product candidates.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">We may depend on such collaborations for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">If we are unable to protect our intellectual property rights, our competitive position could be harmed.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Our future success depends on our ability to retain executives and to attract, retain and motivate key personnel in a competitive environment for skilled biotechnology personnel.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Our term load contains restrictions that limit our flexibility in operating our business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;padding-left:14.5pt">Our business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises such as the COVID-19 pandemic, political crises, geopolitical events, such a the war in Ukraine, or other macroeconomic conditions, which have in the past and may in the future negatively impact our business and financial performance. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Our stock price has been and is likely to continue to be volatile and fluctuate substantially.</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I  FINANCIAL INFORMATION</span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_19"></div><div><span><br/></span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMy0xLTEtMS02ODU4NQ_d42e01e3-dae2-4eb9-844c-d087438d36c5">93,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMy0zLTEtMS02ODU4NQ_8aa33a30-e97f-4264-9dd0-f9dbbec5ce10">121,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development incentive receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="xfor:ResearchAndDevelopmentIncentiveReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfNC0xLTEtMS02ODU4NQ_eb2bed05-8463-4034-bb6e-7a2b53bd424e">658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="xfor:ResearchAndDevelopmentIncentiveReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfNC0zLTEtMS02ODU4NQ_1082ce18-6b00-45f1-b6fd-5e7217b36ba6">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfNS0xLTEtMS02ODU4NQ_edb2b047-6dd3-4a1a-85c0-67333f3923ee">4,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfNS0zLTEtMS02ODU4NQ_2387f451-3dcf-40f3-a112-e958eae95b97">5,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfNi0xLTEtMS02ODU4NQ_a1cc5308-4e63-43d0-a206-ad84e6ec0d0c">98,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfNi0zLTEtMS02ODU4NQ_a57e00a9-c913-4acb-9495-d8e2953bd067">128,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfNy0xLTEtMS02ODU4NQ_52739be3-a351-472a-b9fa-0ed547b32c4a">986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfNy0zLTEtMS02ODU4NQ_38b11f8a-4b22-4e52-85c5-fc0e016c8933">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfOC0xLTEtMS02ODU4NQ_b90b7eba-5315-43d4-ac7a-ac6d923e93b0">17,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfOC0zLTEtMS02ODU4NQ_57b394bd-e732-4b63-be46-0ab65111a044">17,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfOS0xLTEtMS02ODU4NQ_37bc5acc-f3a4-4f6b-964a-cde742614111">6,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfOS0zLTEtMS02ODU4NQ_948b07d9-4cbd-483f-89f7-2c220043b252">7,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTAtMS0xLTEtNjg1ODU_6e715919-8615-4685-9285-d8e6128cca89">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTAtMy0xLTEtNjg1ODU_d98d732d-1500-40d4-8ef6-3dbd9f1ba0ac">1,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTEtMS0xLTEtNjg1ODU_fb630e2d-7bd8-4eea-b117-0958a229f0be">124,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTEtMy0xLTEtNjg1ODU_71f0a39b-e581-478a-959b-08a562ccafea">155,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTQtMS0xLTEtNjg1ODU_4cad02d7-4ab8-4084-a0a7-2adbc6e4dcb7">5,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTQtMy0xLTEtNjg1ODU_7b2eb224-98a8-4f70-99cb-1dc8ade8adb1">7,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTUtMS0xLTEtNjg1ODU_5ebfbe01-6946-4df4-8211-8350f9c42b8e">11,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTUtMy0xLTEtNjg1ODU_ff0e236e-6625-496b-9d41-260046b5c1c7">12,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTYtMS0xLTEtNjg1ODU_578cbafa-d783-4693-b449-a4561c6533c2">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTYtMy0xLTEtNjg1ODU_c5ca83d0-0b56-4157-a15c-fb9a6e9c90e0">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTctMS0xLTEtNjg1ODU_86125327-6edf-45ea-8052-ccfabf5a8576">554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTctMy0xLTEtNjg1ODU_041840ec-5ed4-475a-ba4b-a1eb7211a4ae">1,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTgtMS0xLTEtNjg1ODU_73e68121-600c-4705-92d8-50875df7f5ee">19,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTgtMy0xLTEtNjg1ODU_c607b88e-426f-4c35-87c7-0d05bfff5872">22,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, net of discount and current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="xfor:LongTermDebtNonCurrentIncludingAccretion" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTktMS0xLTEtNjg1ODU_fdfbfa75-8b80-4a90-a8c9-70fc24a2c781">31,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="xfor:LongTermDebtNonCurrentIncludingAccretion" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTktMy0xLTEtNjg1ODU_15208393-af03-4c26-8a74-bdec975ae52c">32,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjAtMS0xLTEtNjg1ODU_eba3ce5f-e380-41b0-b083-ceae71ee3efc">3,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjAtMy0xLTEtNjg1ODU_1c26d77b-77f6-41e2-8067-8de794058c35">3,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability (Note 4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjEtMS0xLTEtNjg4NTA_39de351c-fecc-405c-a64f-805e7fdfe0a0">17,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjEtMy0xLTEtNjg4NDI_a4dc0d21-cb3e-447d-8864-23659223860f">23,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjEtMS0xLTEtNjg1ODU_c9164059-0f5c-4699-9708-a2b276a5c806">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjEtMy0xLTEtNjg1ODU_151c96d1-9e43-4a4d-b826-492a2b5e6551">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjItMS0xLTEtNjg1ODU_a917e22a-4ad3-4acc-923b-3fe48e0eed12">72,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjItMy0xLTEtNjg1ODU_e008032d-0504-4555-b49a-7cdc7ee9345c">81,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjMtMS0xLTEtNjg1ODU_d4e9954f-4305-4ae1-a39a-66e3fc16b7c7"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjMtMy0xLTEtNjg1ODU_1fc0f2e7-8084-4fa6-b51f-42f48610b00e"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMC0xLTEtNjg1ODUvdGV4dHJlZ2lvbjo3N2Q1OTMwNWQwNWM0NThmOTkxOGEwNmEwYTY5YTZiOV8xOQ_0fcacf9e-5d77-4fb9-b368-0f547a21a1aa"><ix:nonFraction unitRef="usdPerShare" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMC0xLTEtNjg1ODUvdGV4dHJlZ2lvbjo3N2Q1OTMwNWQwNWM0NThmOTkxOGEwNmEwYTY5YTZiOV8xOQ_d26dced0-d313-4551-a42d-990bab881426">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMC0xLTEtNjg1ODUvdGV4dHJlZ2lvbjo3N2Q1OTMwNWQwNWM0NThmOTkxOGEwNmEwYTY5YTZiOV8zMw_e046814b-63df-4c47-8fe4-b3575a337bef">500,000,000</ix:nonFraction> shares authorized as of March 31, 2023 and December 31, 2022, respectively; <ix:nonFraction unitRef="shares" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMC0xLTEtNjg1ODUvdGV4dHJlZ2lvbjo3N2Q1OTMwNWQwNWM0NThmOTkxOGEwNmEwYTY5YTZiOV8xMjM_544e4f42-555c-4f7a-985b-0784ab1f85f9"><ix:nonFraction unitRef="shares" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMC0xLTEtNjg1ODUvdGV4dHJlZ2lvbjo3N2Q1OTMwNWQwNWM0NThmOTkxOGEwNmEwYTY5YTZiOV8xMjM_cad2b812-71be-4cd9-a555-297768f312da">122,207,488</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMC0xLTEtNjg1ODUvdGV4dHJlZ2lvbjo3N2Q1OTMwNWQwNWM0NThmOTkxOGEwNmEwYTY5YTZiOV8xMzA_079accea-89cd-44b7-a5c3-1ebbf3302745"><ix:nonFraction unitRef="shares" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMC0xLTEtNjg1ODUvdGV4dHJlZ2lvbjo3N2Q1OTMwNWQwNWM0NThmOTkxOGEwNmEwYTY5YTZiOV8xMzA_c7b74d24-96df-4745-84d3-3dcd94bcd11b">121,667,250</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMS0xLTEtNjg1ODU_19c8d478-660f-4f0f-b9f6-8acab4e57f81">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMy0xLTEtNjg1ODU_b8118228-23ce-48dd-bc38-5b6cad7a9eb8">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjYtMS0xLTEtNjg1ODU_bf0f9e77-f12b-413b-a7f2-5f9c6d45353c">452,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjYtMy0xLTEtNjg1ODU_4d2ec06c-5924-4556-9446-e7fbdc74b91d">450,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjctMS0xLTEtNjg1ODU_442471c3-d906-476d-a8da-1b824c44d364">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjctMy0xLTEtNjg1ODU_ed8aa81e-2170-4fb3-b155-7529d750d09a">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjgtMS0xLTEtNjg1ODU_0fb5cc31-5148-4910-b439-ae677bf59011">400,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjgtMy0xLTEtNjg1ODU_70fc51c8-6d81-48fd-9b52-76b8c6e43eb8">376,738</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjktMS0xLTEtNjg1ODU_97bc3817-0766-42e3-8244-ef57cc188251">51,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjktMy0xLTEtNjg1ODU_c7b1f5a5-6328-42be-a28d-1c28f040912f">74,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMzAtMS0xLTEtNjg1ODU_ff90d5d3-535f-44eb-9ef9-4a8de312d95c">124,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMzAtMy0xLTEtNjg1ODU_004d514d-166e-4dcd-9dda-4a099d488ded">155,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:70.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.012%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfNC0xLTEtMS02ODU4NQ_82813d04-f3b9-4eb9-b6de-b22cda0ac5e6">22,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfNC0zLTEtMS02ODU4NQ_d09ae21e-71b7-435f-8aec-e1c7c3770922">14,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfNS0xLTEtMS02ODU4NQ_78ffe44c-697a-42fc-b8ba-f9f1c5139683">7,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfNS0zLTEtMS02ODU4NQ_8b89d77a-e5bb-4981-a277-98816c037fdf">7,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of non-financial asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfNi0xLTEtMS02ODU4NQ_b15a49a1-b8cd-45b1-a345-e030bbdcf7f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfNi0zLTEtMS02ODU4NQ_f24331f8-3e7e-497e-ba44-f2999e24caa4">509</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfNy0xLTEtMS02ODU4NQ_9e87c4be-3324-4786-b063-4f497ba6d145">29,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfNy0zLTEtMS02ODU4NQ_a841f7bd-c551-4eee-bf6f-0b3c168c386a">21,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfOC0xLTEtMS02ODU4NQ_2f8b0404-d5ac-4ab5-8107-f7ecc4697428">29,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfOC0zLTEtMS02ODU4NQ_ab45bf31-89a8-4e63-a12e-6ab2e91f157a">21,268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTAtMS0xLTEtNjg1ODU_87100774-1066-4e22-8a38-cab9d68f071f">835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTAtMy0xLTEtNjg1ODU_7dedd71b-2742-4698-83e8-e771b1dec00b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTEtMS0xLTEtNjg1ODU_c42ab8bd-62a5-40c7-b44a-2afd49deca6d">1,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTEtMy0xLTEtNjg1ODU_eff25d84-37bd-4318-bf9b-df496a8ec8cc">913</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTItMy0xLTEtNjg1ODU_a61858f7-16e1-468b-b1e3-6d2dcdc63c1a">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTMtMS0xLTEtNjg4NzA_484acca6-d286-4e62-8379-24c6529144a8">5,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTMtMS0xLTEtNjg1ODU_ff7c7667-1040-4537-9561-96e8075058c1">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTMtMy0xLTEtNjg1ODU_1b4ffb5d-c5e4-4c24-be4c-52974c821ba5">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTQtMS0xLTEtNjg1ODU_365d4fd5-7a29-48d9-8416-b36c7b168f7c">5,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTQtMy0xLTEtNjg1ODU_b8ad88f6-387f-43cb-a194-8d8e0b2afc4e">674</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTUtMS0xLTEtNjg1ODU_dedc3bf5-1245-4436-be7f-4d50273be918">24,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTUtMy0xLTEtNjg1ODU_033e60b2-bf4c-4d84-ad52-d0a268cee8ab">21,942</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTYtMS0xLTEtNjg1ODU_f28fc1a9-0c28-4f17-9653-3598424b8742">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTYtMy0xLTEtNjg1ODU_a9b6bf82-785d-4fc7-8936-6f03970e72a6">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTctMS0xLTEtNjg1ODU_9c6eb2f1-78bb-4ee6-b0c0-79cacba35364">24,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i553e6350cf6c429980b87aeb902c6c55_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTctMy0xLTEtNjg1ODU_23e06e56-16fc-48cc-9c84-833776fa5ef2">21,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend on Class B Warrant price reset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTgtMS0xLTEtNjg1ODU_399e9f08-e684-41a8-95af-7524fcccfca1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTgtMy0xLTEtNjg1ODU_bb192a03-7773-4298-bf68-a9a3843b124e">2,259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTktMS0xLTEtNjg1ODU_cef952ec-768a-42d8-86ca-9bde04ceeeb6">24,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTktMy0xLTEtNjg1ODU_f3af3137-5a86-452d-a4ff-56e2cebd3835">24,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders&#8212;basic and diluted</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMjAtMS0xLTEtNjg1ODU_87694fac-5dc2-496d-afd5-5522a909e40f"><ix:nonFraction unitRef="usdPerShare" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMjAtMS0xLTEtNjg1ODU_ed33fe2e-291f-434f-ba52-2eb441d83fad">0.16</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMjAtMy0xLTEtNjg1ODU_0ca1e1ee-2900-40c8-8c39-24473c5cd995"><ix:nonFraction unitRef="usdPerShare" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMjAtMy0xLTEtNjg1ODU_99257dc1-51aa-40bf-a68a-e1f292a3f5fb">0.72</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding&#8212;basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMjEtMS0xLTEtNjg1ODU_9913c6b1-740a-49a0-9d66-02b450e87cf7"><ix:nonFraction unitRef="shares" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMjEtMS0xLTEtNjg1ODU_efcdb0fc-e665-4c87-a4d4-d62fe2084fea">145,967</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMjEtMy0xLTEtNjg1ODU_18e87532-38cc-40b7-a47f-72aac1a93af7"><ix:nonFraction unitRef="shares" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMjEtMy0xLTEtNjg1ODU_a8cfc3d8-5785-48f9-a3ba-6b2a1ed1cbbe">33,737</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_28"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.259%"><tr><td style="width:1.0%"></td><td style="width:39.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.331%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i148ac761490846059a641c4096bff174_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfMi0xLTEtMS02ODk0Mg_abc37aec-23c5-43e8-bf46-d977e636a6a4">121,667,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148ac761490846059a641c4096bff174_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfMi0zLTEtMS02ODk0Mg_368b9b1f-a600-4b82-9b8e-f3b1aeffac28">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b29c1af764d49dd8a2b25cd40f9c5e9_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfMi01LTEtMS02ODk0Mg_4f3e754d-82cc-4c8a-948b-0b3856637f3b">450,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd2737e0aa5e4ceda68812a691c9447b_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfMi03LTEtMS02ODk0Mg_0c8f6f2e-e8f7-4ed3-8375-32d214ffeb5c">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if43cc4ccf2b647bfba5772dafdf4d1df_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfMi05LTEtMS02ODk0Mg_77dbf774-2cfb-46b3-8ceb-17c70da57822">376,738</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfMi0xMS0xLTEtNjg5NDI_40b7be14-8ffe-41b9-83f5-d88bc053dc0d">74,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3bcc5907b6014b9d93c0ce335d74d143_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfNC0xLTEtMS02ODk0Nw_805b8eee-30f0-4438-9ff0-caf188ae40e2">540,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id687fd50375c4b9289fc38f39c37c931_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfNi01LTEtMS02ODk0Nw_5dc7a418-0311-40c2-ad4a-dd5c8b8139e5">1,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfNi0xMS0xLTEtNjg5NDc_a9532f32-7e82-4931-8d90-8119411958e5">1,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7da3eb074b8d4cb09f155d7cbd131475_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfNy05LTEtMS02ODk0Nw_4c227654-e7fc-466e-be43-e0c2b6fc366e">24,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfNy0xMS0xLTEtNjg5NDc_770e063e-df2a-4ef9-bd96-f6eb3413e509">24,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c39f890c41047c9a65d791fe89d7f5c_I20230331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfOC0xLTEtMS02ODk1NA_b5ef5e8a-324e-4803-989a-8111ffade192">122,207,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c39f890c41047c9a65d791fe89d7f5c_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfOC0zLTEtMS02ODk1NA_d3bb44b6-da0e-426f-b8ed-217cc116aadc">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2699357e209d4ca393deb31d5b50ef76_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfOC01LTEtMS02ODk1NA_eaad301d-5a1c-4a4f-a279-c20ef3f4128b">452,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4f97645aff94169b01a7e55e7ad5b86_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfOC03LTEtMS02ODk1NA_41591d85-7368-4137-95d5-b59e2e8cde6e">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib174ac43e0694fac9a20163af9e3c6c1_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfOC05LTEtMS02ODk1NA_3b7a1300-3262-4c3d-a92c-f1f48bad8bd4">400,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfOC0xMS0xLTEtNjg5NTQ_328435e5-1e62-49ad-8de1-1bd05d4c387c">51,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.259%"><tr><td style="width:1.0%"></td><td style="width:39.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.331%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id108597db204485299a9f94cb8127d3a_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMi0xLTEtMS02OTAzMw_8e8bdd1e-a0f0-4a44-bb70-b9b7665ef72f">28,127,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id108597db204485299a9f94cb8127d3a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMi0zLTEtMS02OTAzMw_91ff242e-0935-4d85-b8c0-e3284b1ed67f">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c1bc362afa49eeb95ed63f82caa21b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMi01LTEtMS02OTAzMw_e294687a-96ae-49c1-86f6-515d9df18be8">347,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fed87c65647480c8d625fffe1b0ea5c_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMi03LTEtMS02OTAzMw_8c34483d-0b32-4280-830e-a14b54cd2285">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b481bc1391f4635a7c7fc91a64f1e08_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMi05LTEtMS02OTAzMw_af05e438-c38c-407a-850a-4b0cb079b793">282,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i127a474f92264d58b7e85a4321f95964_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMi0xMS0xLTEtNjkwMzM_9a8fe18a-0833-4e0f-a2b2-45ae36dd3379">64,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, redeemable common stock  and pre-funded warrants for the purchase of common stock, net of issuance costs <ix:nonFraction unitRef="usd" contextRef="i06ba2f0164234d80aef6eb30ab849e77_D20221001-20221231" xsi:nil="true" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMy0wLTEtMS02ODkyMC90ZXh0cmVnaW9uOmI1YmRlYWNjNWEzZTQwM2FhMjM5NmE2MzEyNjU1NzNkXzEzNQ_850c7d02-1bce-4d8d-b378-1e61e986acb2"></ix:nonFraction> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4b750c506b44cbda93e01a7505ed761_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMy0xLTEtMS02OTAyNA_8e806444-7567-4e97-a98e-940d3924d48a">2,512,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4b750c506b44cbda93e01a7505ed761_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMy0zLTEtMS02OTAyNA_2165d0f5-5d49-4a0e-adb4-5128aa4e7176">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec90ace9f4384f59bd0e68d11db46c7a_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMy01LTEtMS02OTAyNA_216e4981-e1f8-4803-9255-e41211768158">5,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMy0xMS0xLTEtNjkwMjQ_8a637e30-b0f1-4dae-9fae-2421d948fe32">5,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4b750c506b44cbda93e01a7505ed761_D20220101-20220331" decimals="INF" name="xfor:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNC0xLTEtMS02OTAyNA_9249f0ee-6a21-44dd-8856-3e8a34f9066f">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted stock units, net of shares withheld and retired to satisfy tax obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4b750c506b44cbda93e01a7505ed761_D20220101-20220331" decimals="INF" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNS0xLTEtMS02OTA0OQ_e97ab6cb-3081-479b-ab3f-32ff4f4a40c6">168,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec90ace9f4384f59bd0e68d11db46c7a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNS01LTEtMS02OTA0OQ_df82d842-fe61-48c8-9c6b-07d9fdd2452f">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNS0xMS0xLTEtNjkwNDk_a0d218fd-9df2-48a1-b13d-f64845ace8e2">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec90ace9f4384f59bd0e68d11db46c7a_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNS01LTEtMS02OTAyNA_b97c3e8c-1687-42b0-83b1-da31a2d3529b">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNS0xMS0xLTEtNjkwMjQ_129e164b-79e9-4a60-8ee9-44c65140bd41">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i553e6350cf6c429980b87aeb902c6c55_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNy05LTEtMS02OTA1Mg_563704b7-717f-49bd-9db2-101538caf1f9">21,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNi0xMS0xLTEtNjkwMjQ_560edaee-d690-41f5-bb15-3ae59c9828cf">21,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia32dbc78288b4274b74a087a419e35ff_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfOC0xLTEtMS02OTA1NQ_d551c92d-cbb2-47dd-ba6b-48b4511e890b">30,809,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia32dbc78288b4274b74a087a419e35ff_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfOC0zLTEtMS02OTA1NQ_8b5df98e-f73a-480f-9e79-049773876a16">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cb4dfe1750c4c539b0698f339b61a94_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfOC01LTEtMS02OTA1NQ_2670ec27-d7f2-426f-aedb-cb11a12c8039">354,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83228390dcb849b29ea600f914617cc1_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfOC03LTEtMS02OTA1NQ_49566e19-caa4-44d8-8a4e-93cff5ada169">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f2a6bfe01ec46bc85d75976e40b1ab0_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNy05LTEtMS02OTAyNA_e8e7de2d-397a-45b5-b5c3-9c7442087160">304,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a25074b350146a4adca9401db84ac82_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNy0xMS0xLTEtNjkwMjQ_d167db52-b7aa-4c23-8200-19a39a6e59fd">49,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMy0xLTEtMS02ODU4NQ_3ab1216e-3869-42e4-93f3-07a7e7f6e777">24,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMy0zLTEtMS02ODU4NQ_23507738-f924-47e4-8a29-974174707882">21,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfNS0xLTEtMS02ODU4NQ_d9450cca-d352-4100-911a-e3ce23f2e78c">1,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfNS0zLTEtMS02ODU4NQ_306609ce-aa68-41dd-97bb-2824fb80614c">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfNi0xLTEtMS02ODU4NQ_e17e6b68-b961-4e0c-8e86-04073b0cb7e4">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfNi0zLTEtMS02ODU4NQ_af48f850-ad7e-4b88-b512-8fbca15c37c2">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="xfor:NonCashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfNy0xLTEtMS02ODU4NQ_4426a5c0-be57-46c1-a600-697d486ded40">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="xfor:NonCashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfNy0zLTEtMS02ODU4NQ_82e6cebf-bb88-4a1b-8dc0-83d3c74621f6">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="xfor:NonCashInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfOC0xLTEtMS02ODU4NQ_1e45b321-682c-44e1-bf87-f80355a23e21">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="xfor:NonCashInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfOC0zLTEtMS02ODU4NQ_d2494531-6aab-4991-8046-ce912d3c0a94">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfOS0xLTEtMS02ODU4NQ_9677dacc-32d0-4e70-8bcd-5ef56d7d06be">5,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfOS0zLTEtMS02ODU4NQ_074e7637-3871-4dde-9689-e4872d00a0bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTAtMS0xLTEtNjg1ODU_2614c90b-9271-4cca-a7c4-35b4b8f485d6">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTAtMy0xLTEtNjg1ODU_afe39ab5-2a37-4d2c-bd45-af2f07d40f92">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses, other current assets and research and development incentive receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTItMS0xLTEtNjg1ODU_d16032ea-5070-4c50-a880-c4ef9907c6cb">2,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTItMy0xLTEtNjg1ODU_4f0315c2-9e73-4c65-809e-4f017cc37da1">1,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTMtMS0xLTEtNjg1ODU_e9c80d56-1863-4370-94a5-9ff44266a06f">1,714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTMtMy0xLTEtNjg1ODU_3bc1d2d8-b38f-46a8-9678-ef971abbf97d">713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTQtMS0xLTEtNjg1ODU_428844e7-aef7-4ce5-86bd-a7e4c0c846bf">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTQtMy0xLTEtNjg1ODU_1d142526-404a-4a76-8cb9-7d9af3d7735d">984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" sign="-" name="xfor:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTUtMS0xLTEtNjg1ODU_b99affbb-631b-4868-8516-f37ae0f7c13d">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" sign="-" name="xfor:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTUtMy0xLTEtNjg1ODU_7336896c-8ffe-4585-b257-920490384073">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTctMS0xLTEtNjg1ODU_288a7a1c-3d53-4db1-b7e4-99774dc8f063">26,512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTctMy0xLTEtNjg1ODU_6603e921-2da2-44e3-b495-a8514b97574f">20,229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of property and  equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTktMS0xLTEtNjg1ODU_fb2434f3-e2d1-4765-b1d6-612a2022478d">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTktMy0xLTEtNjg1ODU_331493f2-0a18-4e83-be0c-80ac274c376e">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjAtMS0xLTEtNjg1ODU_d79f7cde-faa8-4ade-af9b-f40c3ee17442">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjAtMy0xLTEtNjg1ODU_c2560fb0-2146-45b9-8778-2cd8d5c65eed">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee taxes paid related to net share settlement of vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjMtMS0xLTEtNjg1ODU_f2cf11d4-e289-4621-993c-f25bb694dc8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjMtMy0xLTEtNjg1ODU_60ab4cb7-7b27-42e7-99d8-30ea0f96d200">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fees paid to amendment loan and security agreement and issuance costs related to the sale of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="xfor:IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjQtMS0xLTEtNjg1ODU_23a0a4d3-2b53-4574-8ad0-d682de458d89">381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="xfor:IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjQtMy0xLTEtNjg1ODU_9b0101e3-a527-44fd-90c9-30485e059a3b">114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of borrowings under loan and security agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjUtMS0xLTEtNjg1ODU_16b2c633-de66-4321-9bb7-489a996e060e">1,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjUtMy0xLTEtNjg1ODU_3506fab8-62da-4d22-8e9f-c501960f99a8">795</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of shares of common stock, and pre-funded warrants, net of issuance costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjYtMS0xLTEtNjg1ODU_af199409-8a84-4abd-a25e-eefab0bb9286">443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjYtMy0xLTEtNjg1ODU_78ba9af6-ba6b-4906-bb66-1087f9aac6b1">5,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjgtMS0xLTEtNjg1ODU_398586e7-6775-4356-831d-3df4facf359e">2,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjgtMy0xLTEtNjg1ODU_19a51e16-685a-4bc5-a61c-eba0f52cde34">4,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjktMS0xLTEtNjg1ODU_7377b561-aa6f-4003-b704-ce64caf6fad7">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjktMy0xLTEtNjg1ODU_7521ac3e-9a36-4ae8-97d1-d25e848a6874">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzAtMS0xLTEtNjg1ODU_c53aef03-7b5b-4399-a1b0-7413db6dce7a">28,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzAtMy0xLTEtNjg1ODU_21177061-60e2-499f-bd91-0841e29c3ea9">15,364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzEtMS0xLTEtNjg1ODU_c64be81f-5466-4d65-bf8a-0c2df322bfe6">123,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i127a474f92264d58b7e85a4321f95964_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzEtMy0xLTEtNjg1ODU_714f2950-73ac-4d08-b6ba-1dae0d22fa5d">83,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzItMS0xLTEtNjg1ODU_904f6440-4c7e-49bd-be3f-39eab78453c1">94,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a25074b350146a4adca9401db84ac82_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzItMy0xLTEtNjg1ODU_d38f8ff4-47eb-460a-ba9a-bb3e65aa9eda">67,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzEtMC0xLTEtNzQ2ODQ_b30ab6e2-479e-4fee-926d-dba7a9de7c0e" footnoteRole="http://www.xbrl.org/2003/role/footnote">(1) For the three month period ended March 31, 2023, includes payment of issuance costs related to December 2022 public sale of shares of common stock and pre-funded warrants</ix:footnote></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_37"></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zNy9mcmFnOjQ2MzdiMGI1ZjBiYTQ1Yjk5MTdmMDdkODdiMmJmNWNkL3RleHRyZWdpb246NDYzN2IwYjVmMGJhNDViOTkxN2YwN2Q4N2IyYmY1Y2RfNTk4Mw_77c974dd-389f-4e68-aca9-4024807809e5" continuedAt="ia6cebcb9aeb547c285ad52ab53c7ed53" escape="true">NATURE OF THE BUSINESS AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><div style="padding-left:45pt;text-indent:-45pt"><span><br/></span></div><ix:continuation id="ia6cebcb9aeb547c285ad52ab53c7ed53" continuedAt="i179361af542f45c3b143d57dc2ecfb43"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X4 Pharmaceuticals, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) is a late-stage clinical biopharmaceutical company focused on the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company&#8217;s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. Due to its ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream, the Company believes that mavorixafor has the potential to provide therapeutic benefit across a variety of chronic neutropenic disorders, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (&#8220;WHIM&#8221;)) syndrome, a rare, primary immunodeficiency, and certain cancers. Following announcement of positive top-line data from the Company&#8217;s global, pivotal, Phase 3 clinical trial in November 2022, the Company is preparing a United States regulatory submission seeking approval of oral, once-daily mavorixafor in the treatment of people aged 12 years and older with WHIM syndrome. The Company is also currently enrolling participants in a Phase 2 clinical trial in people with certain chronic neutropenic disorders following positive results from a Phase 1b clinical trial evaluating mavorixafor in people with idiopathic, cyclic, or congenital neutropenia that were presented in the third quarter of 2022. The Company also conducted a proof-of-concept Phase 1b clinical trial of mavorixafor in combination with ibrutinib in people with Waldenstr&#246;m&#8217;s macroglobulinemia (&#8220;Waldenstr&#246;m&#8217;s&#8221;), a rare form of lymphoma. The Company reported positive results from the Waldenstr&#246;m&#8217;s Phase 1b trial in the third quarter of 2022 and concluded the trial in December 2022. Any further studies of mavorixafor in Waldenstr&#246;m&#8217;s or other oncology indication will be subject to completing a strategic partnership. The Company is headquartered in Boston, Massachusetts and has an additional facility in Vienna, Austria. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern Assessment&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2014-15,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2014-15&#8221;), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. Since inception, the Company has incurred significant operating losses and negative cash flows from operations. As of March&#160;31, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zNy9mcmFnOjQ2MzdiMGI1ZjBiYTQ1Yjk5MTdmMDdkODdiMmJmNWNkL3RleHRyZWdpb246NDYzN2IwYjVmMGJhNDViOTkxN2YwN2Q4N2IyYmY1Y2RfMjEyMA_35910066-59ee-4ccd-8e7a-5bc63a7ffc4f">93.4</ix:nonFraction> million of cash and cash equivalents, an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zNy9mcmFnOjQ2MzdiMGI1ZjBiYTQ1Yjk5MTdmMDdkODdiMmJmNWNkL3RleHRyZWdpb246NDYzN2IwYjVmMGJhNDViOTkxN2YwN2Q4N2IyYmY1Y2RfNTQ5NzU1ODMxMDMy_dcd4cca0-f8f6-4188-9e45-d599ddf96e61">400.8</ix:nonFraction> million  and net cash used in operating activities of $<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zNy9mcmFnOjQ2MzdiMGI1ZjBiYTQ1Yjk5MTdmMDdkODdiMmJmNWNkL3RleHRyZWdpb246NDYzN2IwYjVmMGJhNDViOTkxN2YwN2Q4N2IyYmY1Y2RfNTQ5NzU1ODMxMDM5_33a3668e-7387-4b96-b770-e74abc165367">26.5</ix:nonFraction> million.  The Company has a covenant under its Second Amended and Restated Loan and Security Agreement with Hercules Capital Inc. (&#8220;Hercules&#8221;) that requires that the Company maintain a minimum level of cash of $20 million, subject to reduction to $10 million upon the achievement of operational milestones. Based on its current cash flow projections and with no additional funding, the Company believes it will not be able to maintain the minimum cash required to satisfy this covenant beginning in the first quarter of 2024. In such event, the lender could require the repayment of all outstanding debt.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has assessed the Company&#8217;s ability to continue as a going concern in accordance with the requirements of ASC 205-40 and determined that the Company&#8217;s accumulated deficit, history of losses and future expected losses met the ASC 205-40 standard for raising substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company does not have adequate financial resources to fund its forecasted operating costs for at least one year after the date that these condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To finance its operations, the Company will need to raise additional capital, which cannot be assured. Unless and until the Company reach&#8217;s profitability in the future, it will require additional capital to fund our operations, which could be raised through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other collaborations and strategic alliances. If the Company is unable to obtain funding, it could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which would adversely affect its business prospects, or it may be unable to continue operations.</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zNy9mcmFnOjQ2MzdiMGI1ZjBiYTQ1Yjk5MTdmMDdkODdiMmJmNWNkL3RleHRyZWdpb246NDYzN2IwYjVmMGJhNDViOTkxN2YwN2Q4N2IyYmY1Y2RfMjE5OTAyMzI3Nzc0NQ_ee07d4b9-d35d-4737-9a26-56a1d8de623b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including X4 Pharmaceuticals (Austria) GmbH, which is incorporated in Vienna, Austria (&#8220;X4 Austria&#8221;), and X4 Therapeutics, Inc. All significant intercompany accounts and transactions have been eliminated.</span></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i179361af542f45c3b143d57dc2ecfb43"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet at December 31, 2022 that is presented in these interim condensed consolidated financial statements was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying condensed consolidated financial statements are unaudited. The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial statements. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s&#160;audited financial statements and the notes thereto for the year ended December&#160;31, 2022 included in the 2022 Annual Report filed with the SEC on March 21, 2023. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&#8217;s condensed financial position, condensed results of its operations and cash flows have been made. The results of operations for the three months ended March&#160;31, 2023 are not necessarily indicative of the results of operations that may be expected for the year ending December&#160;31, 2023.</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zNy9mcmFnOjQ2MzdiMGI1ZjBiYTQ1Yjk5MTdmMDdkODdiMmJmNWNkL3RleHRyZWdpb246NDYzN2IwYjVmMGJhNDViOTkxN2YwN2Q4N2IyYmY1Y2RfMjE5OTAyMzI3Nzc0Ng_bff93c5e-8eae-4d30-8af2-878e57165cf5" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the impairment or lack of impairment of long-lived assets including operating lease right-of-use assets and goodwill, and assumptions underlying the fair value of warrant liabilities. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#8217;s consolidated financial statements.</span></ix:nonNumeric></div></ix:continuation><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_40"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RleHRyZWdpb246MmQ5NTYzN2ViYTIyNDAxZGJkYmNlZTg5YTQxZTU4NTNfMTA1OTk_1ce2fc95-d277-44b8-b149-ef2b8d4da914" continuedAt="ia8dc560c3fbc4121b2c58756acecf91f" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="ia8dc560c3fbc4121b2c58756acecf91f" continuedAt="i5e7e0bd1bee341a48f509c09d418e761"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 21, 2023. Since the date of those consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies.</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RleHRyZWdpb246MmQ5NTYzN2ViYTIyNDAxZGJkYmNlZTg5YTQxZTU4NTNfMTA1OTU_515c0efe-cf2f-4002-87d1-ae35019685d7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of March&#160;31, 2023 and December&#160;31, 2022.</span></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:ScheduleOfCompensatingBalancesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RleHRyZWdpb246MmQ5NTYzN2ViYTIyNDAxZGJkYmNlZTg5YTQxZTU4NTNfMTA1OTY_c4d6d973-9ef5-4a05-9667-28e5bcd3e190" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:60.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Waltham lease</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5139ec8cd3c4c57a78f7ac8c654556a_I20230331" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfMi0xLTEtMS02ODU4NQ_67036e94-eeb4-4cca-badc-1d0876aacb51">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7ba5290654141e4b61b83ad34d08c17_I20221231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfMi0zLTEtMS02ODU4NQ_1bb04740-fc8c-4c40-8d3f-2dcc92166f51">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Vienna Austria lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i810c7142f18049f48bf12b8c5fed906f_I20230331" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfMy0xLTEtMS02ODU4NQ_cf926557-e6e5-48ba-a3a2-a27e5ab36fd5">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied52c772cd6240a0a1fae6e51f2ddfb4_I20221231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfMy0zLTEtMS02ODU4NQ_213d8acc-6bf7-44fb-a33a-08694ff24737">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Boston lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654563320ef74399a7b67534f01c3d1f_I20230331" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfNC0xLTEtMS02ODU4NQ_0a0fed6b-bafc-4d69-9e55-e2a14cafb5dd">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57677a75b59a47908ea0dc176c8f9bcd_I20221231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfNC0zLTEtMS02ODU4NQ_cbe3d856-6f6b-4af7-a8bd-f931bae1ae45">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfNS0xLTEtMS02ODU4NQ_fb0777b4-bae5-4093-aa99-898953367967">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfNS0zLTEtMS02ODU4NQ_014e3c16-71f1-41b6-8258-f97eb4b3f4d8">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfNi0xLTEtMS02ODU4NQ_602261e6-3a0b-4cdb-a6c1-fa3838b59ae3">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfNi0zLTEtMS02ODU4NQ_bc6d9016-785f-4b5e-a097-99240adc264e">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfNy0xLTEtMS02ODU4NQ_33f649da-4002-4777-8a8a-d9e15395a34f">777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfNy0zLTEtMS02ODU4NQ_6da2deb8-7f98-45af-a0b5-2c088a88b782">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s lease agreements for its facilities in Massachusetts and Austria, the Company maintains letters of credit, which are secured by restricted cash, for the benefit of the respective landlord. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i5e7e0bd1bee341a48f509c09d418e761" continuedAt="i7c1dd646c6ae455caade8fdda0d534f8"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="xfor:ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RleHRyZWdpb246MmQ5NTYzN2ViYTIyNDAxZGJkYmNlZTg5YTQxZTU4NTNfMTA1OTc_b173c0d2-8519-4f0d-8491-ecd0de467eba" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the sum of the total of amounts shown in the Company&#8217;s condensed consolidated statements of cash flows as of March&#160;31, 2023 and December&#160;31, 2022:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:62.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.758%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOjNmOGY2ZGVmYjYxZDRiNGJhMWQ1OWYyMGIxYTRjNWQ0L3RhYmxlcmFuZ2U6M2Y4ZjZkZWZiNjFkNGI0YmExZDU5ZjIwYjFhNGM1ZDRfMS0xLTEtMS02ODU4NQ_2f66ba1b-4fdc-4d8d-8e58-41c4cbf1c5b2">93,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOjNmOGY2ZGVmYjYxZDRiNGJhMWQ1OWYyMGIxYTRjNWQ0L3RhYmxlcmFuZ2U6M2Y4ZjZkZWZiNjFkNGI0YmExZDU5ZjIwYjFhNGM1ZDRfMS0zLTEtMS02ODU4NQ_015c077f-1fc9-44f7-9411-a04fe6b1e566">121,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOjNmOGY2ZGVmYjYxZDRiNGJhMWQ1OWYyMGIxYTRjNWQ0L3RhYmxlcmFuZ2U6M2Y4ZjZkZWZiNjFkNGI0YmExZDU5ZjIwYjFhNGM1ZDRfMi0xLTEtMS02ODU4NQ_84ac6458-2362-4ba7-aa3d-98ee08f6e29c">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOjNmOGY2ZGVmYjYxZDRiNGJhMWQ1OWYyMGIxYTRjNWQ0L3RhYmxlcmFuZ2U6M2Y4ZjZkZWZiNjFkNGI0YmExZDU5ZjIwYjFhNGM1ZDRfMi0zLTEtMS02ODU4NQ_9c8ba91d-7aef-4c65-823f-a4534ddb379c">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOjNmOGY2ZGVmYjYxZDRiNGJhMWQ1OWYyMGIxYTRjNWQ0L3RhYmxlcmFuZ2U6M2Y4ZjZkZWZiNjFkNGI0YmExZDU5ZjIwYjFhNGM1ZDRfMy0xLTEtMS02ODU4NQ_402247cc-5b7d-4ddc-afb0-669d6617e020">777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOjNmOGY2ZGVmYjYxZDRiNGJhMWQ1OWYyMGIxYTRjNWQ0L3RhYmxlcmFuZ2U6M2Y4ZjZkZWZiNjFkNGI0YmExZDU5ZjIwYjFhNGM1ZDRfMy0zLTEtMS02ODU4NQ_d295e415-616e-4f5a-aacb-2afdb47723d4">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOjNmOGY2ZGVmYjYxZDRiNGJhMWQ1OWYyMGIxYTRjNWQ0L3RhYmxlcmFuZ2U6M2Y4ZjZkZWZiNjFkNGI0YmExZDU5ZjIwYjFhNGM1ZDRfNC0xLTEtMS02ODU4NQ_07200cc9-2e4a-4835-8352-d628eb0d36b9">94,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOjNmOGY2ZGVmYjYxZDRiNGJhMWQ1OWYyMGIxYTRjNWQ0L3RhYmxlcmFuZ2U6M2Y4ZjZkZWZiNjFkNGI0YmExZDU5ZjIwYjFhNGM1ZDRfNC0zLTEtMS02ODU4NQ_07471363-63f7-4bbd-9191-f183c345cff4">123,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RleHRyZWdpb246MmQ5NTYzN2ViYTIyNDAxZGJkYmNlZTg5YTQxZTU4NTNfMTA1OTg_2ca8d9dc-59ee-4b63-a4bd-fae3656f2ad5" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" xsi:nil="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RleHRyZWdpb246MmQ5NTYzN2ViYTIyNDAxZGJkYmNlZTg5YTQxZTU4NTNfMTA2MDM_8cf4db74-cf51-4092-8057-492df4c337e7" escape="true"></ix:nonNumeric>Goodwill&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then the Company would perform an interim quantitative impairment test, whereby the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than its carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no triggering events during the three months ended March&#160;31, 2023 that necessitated an interim impairment test of goodwill.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RleHRyZWdpb246MmQ5NTYzN2ViYTIyNDAxZGJkYmNlZTg5YTQxZTU4NTNfMTA2MDQ_ab13cdc8-30b4-4b2e-a481-baba0ac713bb" continuedAt="i5ac708e3753e46338d994e43c8913633" escape="true">Recently Adopted Accounting Standards</ix:nonNumeric></span></div></ix:continuation><div><ix:continuation id="i7c1dd646c6ae455caade8fdda0d534f8" continuedAt="i563dbd984a074fe195c4cb3eb6ab548c"><ix:continuation id="i5ac708e3753e46338d994e43c8913633" continuedAt="i15997b751979416fa1dcc09600dac544"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i563dbd984a074fe195c4cb3eb6ab548c"><ix:continuation id="i15997b751979416fa1dcc09600dac544"> (&#8220;ASU 2016-13&#8221;), as amended. ASU 2016-13 requires that financial assets measured at amortized cost, such as trade receivables, be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. The Company adopted ASU 2016-13 on January 1, 2023. As the Company did not have accounts receivable on its consolidated balance sheet as of the date of adoption, there was no impact to the adoption of ASU 2016-13.</ix:continuation></ix:continuation> </span></div><div style="margin-top:12pt"><span><br/></span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_43"></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80My9mcmFnOmVlNGVhODkyNTQ1ZjQ5NzNiZDhhMTA5N2RkNmYxZmU5L3RleHRyZWdpb246ZWU0ZWE4OTI1NDVmNDk3M2JkOGExMDk3ZGQ2ZjFmZTlfMjEwMQ_0145665f-1508-4aeb-8dd8-86816cd515c7" continuedAt="ia8a66ec9a1094fadaf83122d45590328" escape="true">LICENSE, COLLABORATION AND FUNDING AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="ia8a66ec9a1094fadaf83122d45590328" continuedAt="if56d82830773414fb5af66f0b7d292ac"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Incentive Program</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in a research and development incentive program provided by the Austrian government whereby the Company is entitled to reimbursement by the Austrian government for a percentage of qualifying research and development expenses and capital expenditures incurred by the Company&#8217;s subsidiary in Austria. As of March&#160;31, 2023, the amount due under the program is $<ix:nonFraction unitRef="usd" contextRef="ide51a96471e14846b0eafc7204f8f180_I20230331" decimals="-5" name="xfor:GrantAndIncentiveReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80My9mcmFnOmVlNGVhODkyNTQ1ZjQ5NzNiZDhhMTA5N2RkNmYxZmU5L3RleHRyZWdpb246ZWU0ZWE4OTI1NDVmNDk3M2JkOGExMDk3ZGQ2ZjFmZTlfNDY4_e5ed1e7f-9a68-489b-9260-7cc0eccb1f87">0.7</ix:nonFraction> million, which amount is included in research and development incentive receivable in the condensed consolidated balance sheet. During the three months ended March&#160;31, 2023 and 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i65095af2a0774d4ca62250a84f77486a_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80My9mcmFnOmVlNGVhODkyNTQ1ZjQ5NzNiZDhhMTA5N2RkNmYxZmU5L3RleHRyZWdpb246ZWU0ZWE4OTI1NDVmNDk3M2JkOGExMDk3ZGQ2ZjFmZTlfNjU0_103f6c49-fea0-46b3-a59e-cffdb0ea30d7"><ix:nonFraction unitRef="usd" contextRef="i65095af2a0774d4ca62250a84f77486a_D20230101-20230331" decimals="-2" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80My9mcmFnOmVlNGVhODkyNTQ1ZjQ5NzNiZDhhMTA5N2RkNmYxZmU5L3RleHRyZWdpb246ZWU0ZWE4OTI1NDVmNDk3M2JkOGExMDk3ZGQ2ZjFmZTlfNjU0_f5bf99d7-7183-4a98-9d45-dce3bdb83e99">121.0</ix:nonFraction></ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="ia0808869d78f44fcb077f2e781a826d0_D20220101-20220331" decimals="-2" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80My9mcmFnOmVlNGVhODkyNTQ1ZjQ5NzNiZDhhMTA5N2RkNmYxZmU5L3RleHRyZWdpb246ZWU0ZWE4OTI1NDVmNDk3M2JkOGExMDk3ZGQ2ZjFmZTlfNjYx_53d8bc39-cf35-4228-af36-625a2e0312b4"><ix:nonFraction unitRef="usd" contextRef="ia0808869d78f44fcb077f2e781a826d0_D20220101-20220331" decimals="-2" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80My9mcmFnOmVlNGVhODkyNTQ1ZjQ5NzNiZDhhMTA5N2RkNmYxZmU5L3RleHRyZWdpb246ZWU0ZWE4OTI1NDVmNDk3M2JkOGExMDk3ZGQ2ZjFmZTlfNjYx_d94c87f9-2e32-4717-a630-4f9c96d03e68">135.3</ix:nonFraction></ix:nonFraction> thousand, respectively, of income related to the program within the condensed consolidated statements of operations as other income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, the Company entered into a license agreement with Genzyme (the &#8220;Genzyme Agreement&#8221;) pursuant to which the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company was granted an exclusive license to certain patents and intellectual property owned or controlled by Genzyme related to the CXCR4 receptor to develop and commercialize products containing licensed compounds (including but not limited to</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mavorixafor) for all therapeutic, prophylactic and diagnostic uses, with the exception of autologous and allogenic human stem cell therapy. Under the terms of the Genzyme Agreement, the Company is obligated to use commercially reasonable efforts to develop and commercialize licensed products for use in the field in the United States and at least one other major market country.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span><br/></span></div><ix:continuation id="if56d82830773414fb5af66f0b7d292ac"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to pay Genzyme milestone payments in the aggregate amount of up to $25.0 million, contingent upon the achievement by the Company of certain clinical-stage regulatory and sales milestones with respect to licensed products. During three months ended March&#160;31, 2023, the Company accrued $5.0 million related to a development milestone under the Genzyme Agreement as the Company believes that it is probable under ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that the milestone will be achieved. The $5.0 million accrued payment has been recorded within research and development expense on the condensed consolidated statements of operations. An additional $7.0 million of regulatory milestone payments are not yet probable but are reasonably possible of becoming payable with the next twelve to eighteen month period under the Genzyme Agreement. The Company is also obligated to pay Genzyme tiered royalties based on net sales of licensed products that the Company commercializes under the agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain on Sale of Non-Financial Asset</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, a third party, who had previously acquired rights to certain intellectual property from the Company, terminated the arrangement and transferred these rights back to the Company. Also during the three months ended March 31, 2022, the Company transferred these rights to another third party in return for $<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80My9mcmFnOmVlNGVhODkyNTQ1ZjQ5NzNiZDhhMTA5N2RkNmYxZmU5L3RleHRyZWdpb246ZWU0ZWE4OTI1NDVmNDk3M2JkOGExMDk3ZGQ2ZjFmZTlfMTE4Mg_a696082e-c0ee-4d0e-91d7-5428a9a081f7">0.5</ix:nonFraction> million. The Company has no continuing involvement in any ongoing research and development activities associated with the intellectual property. The Company concluded that these third parties are "non-customers" as the underlying intellectual property transferred to and from these third parties supports potential drug candidates that are not aligned with the Company's strategic focus and, therefore, are not an output of the Company's ordinary activities. Accordingly, the Company accounted for the sale of the intellectual property as the sale of a non-financial asset under ASC Topic 610-20,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Gains and Losses from the Derecognition of Nonfinancial Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 610-20"), and included the gain in gain on sale of non-financial asset for the three months ended March 31, 2022. </span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material modifications of the Company&#8217;s license or collaboration agreements during the three months ended March&#160;31, 2023.</span></div></ix:continuation><div><span><br/></span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_46"></div><div style="margin-top:12pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RleHRyZWdpb246NjFiYjk2ODAyZGQ4NGI0ZWJjYmQwOWFjZTRlNGI2OTNfMzA1NQ_189a4b36-f5a2-48f0-923c-cfc1f239040e" continuedAt="i1d57131b0dcf4e228606f42329c53116" escape="true">FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES </ix:nonNumeric></span></div><ix:continuation id="i1d57131b0dcf4e228606f42329c53116" continuedAt="ie201e635015d4a8a8dfe1b603081c5b3"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RleHRyZWdpb246NjFiYjk2ODAyZGQ4NGI0ZWJjYmQwOWFjZTRlNGI2OTNfMzA1MQ_2170683d-c213-4347-90ba-bef8d0a5e95d" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of March 31, 2023 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4569714abef741429d743af4a4bf2be0_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfMy0xLTEtMS02ODU4NQ_0b1364d0-b457-4bb9-9c3a-0b3ebb7ea96e">70,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c1816e489194f42bdd5f5bf10009b9c_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfMy0zLTEtMS02ODU4NQ_56a19e95-ac48-4cac-b08f-892f95e4f5c6">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ab8413e7e84528b4f5fdcb13e35002_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfMy01LTEtMS02ODU4NQ_9a34103c-8afb-481f-8038-6087a354a4f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeef5c014ddc40deb4afa45ea2116298_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfMy03LTEtMS02ODU4NQ_55a21b49-75e9-432f-af28-11b465696829">70,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4569714abef741429d743af4a4bf2be0_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNC0xLTEtMS02ODU4NQ_96f87efb-d7d8-4780-92ed-138e7b8a7358">70,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c1816e489194f42bdd5f5bf10009b9c_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNC0zLTEtMS02ODU4NQ_109b7fa0-6dec-472b-899a-e4c60bca8794">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ab8413e7e84528b4f5fdcb13e35002_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNC01LTEtMS02ODU4NQ_e9eb1633-320d-480c-9039-5e2342b6f03c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeef5c014ddc40deb4afa45ea2116298_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNC03LTEtMS02ODU4NQ_34fd92c7-ecc4-4afa-9d65-7dc0c94bb7dc">70,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i381526f76190408a9511bfe7c72a7ff0_I20230331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNi0xLTEtMS02ODU4NQ_b94240e9-19a3-4976-bc5d-623c134b2ddf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135f5bb1ba83401da08651bc765c88e9_I20230331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNi0zLTEtMS02ODU4NQ_a20438ff-fc90-483f-b2dd-41aba5bddf59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfb4d92d12744b63a445624d8eac9b0c_I20230331" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNi01LTEtMS02ODU4NQ_baa2017e-7692-4990-98a3-08f67ac7b4f2">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a291db2a214ab8bd5e5491ada2141b_I20230331" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNi03LTEtMS02ODU4NQ_1e863789-4dbe-4b11-a736-d586a1cb725e">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class C warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5dd8502aef84153bdcb16bdbd51c805_I20230331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNy01LTEtMS02OTQwNA_6cc4ef01-5371-4e51-9b94-82fcef39f3d4">17,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia57db8f000ee4e0db6a8ea78cb129405_I20230331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNy03LTEtMS02OTQwNA_37a567b7-d42d-4bd9-bcee-277f031f7abf">17,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4569714abef741429d743af4a4bf2be0_I20230331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNy0xLTEtMS02ODU4NQ_30adc716-125d-41a2-9b9d-c7b8e481364e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c1816e489194f42bdd5f5bf10009b9c_I20230331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNy0zLTEtMS02ODU4NQ_71b2ee5a-3ad3-4a0b-9d71-ff6566a296db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ab8413e7e84528b4f5fdcb13e35002_I20230331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNy01LTEtMS02ODU4NQ_aa1fb4b5-eee0-4e2c-8010-e9b4e3cef6a4">17,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeef5c014ddc40deb4afa45ea2116298_I20230331" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNy03LTEtMS02ODU4NQ_d807f519-b7b1-49de-af03-b42e8ee2d1ce">17,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2022 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4afbc3f95ef42a4b901ae73cd5145db_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfMy0xLTEtMS02ODU4NQ_21f89fa7-8351-478e-8bc3-c8d56390325e">70,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3668be13a034a95babcca27311d8576_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfMy0zLTEtMS02ODU4NQ_94e5bb1c-82cb-4cf5-a4ec-3383ef908317">2,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e321b38d9d409c9c0f8404d848b3dd_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfMy01LTEtMS02ODU4NQ_186598ce-d536-4338-b3e7-466dc4313976">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6a3b6f090b4a87bcfb08e640d71bba_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfMy03LTEtMS02ODU4NQ_eff07696-e653-4bca-852a-31be473b9f89">73,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4afbc3f95ef42a4b901ae73cd5145db_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNC0xLTEtMS02ODU4NQ_77a67c25-f3ee-4257-a6ef-f9bf71aa8b87">70,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3668be13a034a95babcca27311d8576_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNC0zLTEtMS02ODU4NQ_a30f6e3b-1dc2-4355-9abf-1e2d6e056488">2,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e321b38d9d409c9c0f8404d848b3dd_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNC01LTEtMS02ODU4NQ_b99932d6-c2ac-4585-8a76-41256c372149">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6a3b6f090b4a87bcfb08e640d71bba_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNC03LTEtMS02ODU4NQ_22104a9e-a337-4f63-b445-fce46f15dd51">73,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities: </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b09f270112741469f241038cd756330_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNi0xLTEtMS02ODU4NQ_ba713139-a35c-4756-baef-ffdfd0247abc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b2a90a4f734a278a5d983fe879b015_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNi0zLTEtMS02ODU4NQ_6b151348-f03c-4eaa-a19d-fd4c55fd43bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e93d6b488d5402094357867417eaf30_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNi01LTEtMS02ODU4NQ_f612f288-bb7d-403c-b22f-2127546b99e8">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a0892801fe4d00ba9b8e44831c13dd_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNi03LTEtMS02ODU4NQ_4f187d2b-109d-4025-984a-62ece51bc098">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class C warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416807bcc91c4426b94694508810dfe8_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNy01LTEtMS02OTQ2MQ_43acd8d5-83cb-47fc-af51-8492ccf5e3a0">23,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7ba75f2aa194fdfa790914ca3e5f732_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNy03LTEtMS02OTQ2MQ_1461fb47-3bd0-4aee-9c5f-e5d18412d74a">23,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4afbc3f95ef42a4b901ae73cd5145db_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNy0xLTEtMS02ODU4NQ_7ba8fce2-14b8-41ce-b432-95d98ff3e613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3668be13a034a95babcca27311d8576_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNy0zLTEtMS02ODU4NQ_320bb405-993c-4a66-adb7-8085b4ede6cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e321b38d9d409c9c0f8404d848b3dd_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNy01LTEtMS02ODU4NQ_021add62-c5a4-4d4f-a38b-4a8560f4253a">23,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6a3b6f090b4a87bcfb08e640d71bba_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNy03LTEtMS02ODU4NQ_495d10ff-629c-4ae4-add4-66161d00eb54">23,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:2pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ie201e635015d4a8a8dfe1b603081c5b3"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash equivalents consisted of money market funds invested primarily in short term commercial paper, asset- backed securities, certificate of deposits and repurchase agreements. The money market funds were valued based on reported market pricing for the identical assets, which represents a Level 1 measurement, or by using inputs observable in active markets for similar securities, which represents a Level&#160;2 measurement.</span></div><div style="margin-top:2pt"><span><br/></span></div><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RleHRyZWdpb246NjFiYjk2ODAyZGQ4NGI0ZWJjYmQwOWFjZTRlNGI2OTNfMzA1Mg_5a382f8f-2ae2-43da-81b0-e0f1d43400f6" escape="true"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll-forward of the aggregate fair values financial instruments for which fair values are determined using Level 3 inputs:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:38.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.009%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Embedded Derivative Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class C Warrant Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d93fbb6a1a344a8b945a2a6d090a483_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfMS0xLTEtMS02ODU4NQ_277bc9e7-d515-4f18-b65c-e6376b453273">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81add40f359a4d498e9c203424802dfe_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfMS0zLTEtMS02ODU4NQ_419b93d2-89ee-44d8-a26a-5f5807c9745b">23,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfMS01LTEtMS02ODU4NQ_ad9688e1-43a4-4a42-8cc8-9149e7fdf87f">23,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eed22c85fc47188e427943319310db_D20230101-20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfMy0xLTEtMS02ODU4NQ_a6983062-2931-49a6-8cca-9ccc7587fd10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13c30409f644883bc0984bf6cca3669_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfMy0zLTEtMS02ODU4NQ_c27f5dfc-7515-4f4d-bc86-424b227d4803">5,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfMy01LTEtMS02ODU4NQ_c689ca10-5ac2-4dd6-be82-78e653de20ee">5,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31,  2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d965540fb4a3d8b3bf165eb026ad5_I20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfNS0xLTEtMS02ODU4NQ_b0bc3be5-dd3b-49f9-b928-c306741eeead">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf55d74b96f44b02b711f225b809780f_I20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfNS0zLTEtMS02ODU4NQ_af973faf-ac3b-4a5a-8fc6-6cebb284d15a">17,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfNS01LTEtMS02ODU4NQ_9d4800bc-0bc8-437e-8d31-997e12d48abe">17,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Embedded Derivative Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of the embedded derivative liability recognized in connection with the Company&#8217;s loan agreement with Hercules (see Note 7), which is associated with additional fees due to Hercules upon events of default, was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of this embedded derivative liability, which is reported within other non-current liabilities on the condensed consolidated balance sheets, is estimated by the Company at each reporting date based, in part, on the results of third party valuations, which are prepared based on a discounted cash flow model that considers the timing and probability of occurrence of a redemption upon an event of default, the potential amount of prepayment fees or contingent interest upon an event of default and the Company&#8217;s risk-adjusted discount rate of <ix:nonFraction unitRef="usd" contextRef="i600de8e95d2f4f32915317e0807fd211_I20230331" decimals="2" name="us-gaap:DerivativeLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RleHRyZWdpb246NjFiYjk2ODAyZGQ4NGI0ZWJjYmQwOWFjZTRlNGI2OTNfMTc0OQ_f120b11a-7714-439e-a8df-dbbba8a518d7">14</ix:nonFraction>%. </span></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class C Warrant Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company issued Class C Warrants for the purchase of shares of its common stock in a public offering of common stock. The Class C Warrants are accounted for as a liability on the condensed consolidated balance sheet and are adjusted to fair value at period end through &#8220;other income (expense)&#8221; in the condensed, consolidated statements of operations and comprehensive loss. </span></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculated the fair value of the Class C Warrants using the Black-Scholes option pricing model, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which represents a Level 3 measurement within the fair value hierarchy, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the following inputs:</span></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RleHRyZWdpb246NjFiYjk2ODAyZGQ4NGI0ZWJjYmQwOWFjZTRlNGI2OTNfMzA1Mw_9431074a-6252-4a1f-baf9-192bb01a3b0a" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:54.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4adf5f56124545d5a93d3519e1e8f047_I20230331" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfMS0yLTEtMS02OTU0Mg_34c562db-b046-4a51-8c5e-dc3859e5027a">0.87</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i08cceb6ad460483886bad3c9fcd6710e_I20221231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfMS00LTEtMS03MDY0NA_41160f81-3cb7-40a2-b2a3-3f1b46d04906">0.99</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6fbe040e10eb4417b2f7665f9b30f4e7_D20230331-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfMS0yLTEtMS02ODU4NQ_de1f8499-c647-4b0a-b261-1ba51b87e3d9">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8067028e2bde498d90d62f8632965d93_D20221231-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfMS00LTEtMS02ODU4NQ_4101f2ed-e98f-4194-b367-7ba7d5778682">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fbe040e10eb4417b2f7665f9b30f4e7_D20230331-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfMi0yLTEtMS02ODU4NQ_277c54b3-1868-46e9-bd8a-594c8f92b2ac">4.7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8067028e2bde498d90d62f8632965d93_D20221231-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfMi00LTEtMS02ODU4NQ_41d69478-d1c8-448e-8b43-b4d5784dfabe">4.9</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6fbe040e10eb4417b2f7665f9b30f4e7_D20230331-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfMy0yLTEtMS02ODU4NQ_ec802efa-e42a-4dde-9718-59a3175ad158">91.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8067028e2bde498d90d62f8632965d93_D20221231-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfMy00LTEtMS02ODU4NQ_87a4ad97-b17d-412d-b304-461695a7667b">101.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6fbe040e10eb4417b2f7665f9b30f4e7_D20230331-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfNC0yLTEtMS02ODU4NQ_b5ce9be3-7afb-4f09-aa4e-ec3d08a826fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8067028e2bde498d90d62f8632965d93_D20221231-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfNC00LTEtMS02ODU4NQ_fd25c4e6-ee24-4bc1-bbd4-50b459be8229">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span><br/></span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_49"></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RleHRyZWdpb246Y2E1MDlhZWY4ZTVmNDdkOTllYWNkZjVmZjI2MGZlOGVfMjMy_216223d9-97e7-4637-9e7e-44e071b36cfe" continuedAt="i627c26202324431f8904466a6622b0b4" escape="true">PROPERTY AND EQUIPMENT, NET</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i627c26202324431f8904466a6622b0b4"><div><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RleHRyZWdpb246Y2E1MDlhZWY4ZTVmNDdkOTllYWNkZjVmZjI2MGZlOGVfMjMz_0cf2333c-0d5f-4525-bbf4-4b0ae5df236a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:58.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.635%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i833765a4f0bd42efb5804d15e1b6865f_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfMS0xLTEtMS02ODU4NQ_6929bcf2-c02c-468f-b40d-3483f4260635">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64189e1012e04d2a966fd7a2f71a3db9_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfMS0zLTEtMS02ODU4NQ_722bbf83-02fb-44cd-b732-fafb16c3532b">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13aa4785edcb43ea8c372564342c427b_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfMi0xLTEtMS02ODU4NQ_bfc999e4-d69a-49ff-bdb0-60907388202b">1,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e5c556c18904363b107b9fc923ba681_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfMi0zLTEtMS02ODU4NQ_d088a5b6-9632-4bfd-a5ed-cb8caf90bf2f">1,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7410737db5a84986b20145230e3dfa68_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfMy0xLTEtMS02ODU4NQ_e3035add-127d-4608-905f-4bdb8de8c366">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c7932d5157432c9771d0031da998c3_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfMy0zLTEtMS02ODU4NQ_7d4e78fe-e57d-43c4-88bb-1af6245435c9">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94a2b42432f045c69a6a314871000d9c_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfNC0xLTEtMS02ODU4NQ_f83615cb-55dd-4c0c-b1fb-fb854d626ea8">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i121a3bffe8da40d3bfa57370f4d064ce_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfNC0zLTEtMS02ODU4NQ_835c1dbc-b6c5-475a-bd0c-ffcc604c235d">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c81259a02f42f0875544b1198e4095_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfNS0xLTEtMS02ODU4NQ_a0bd4b54-957c-4bbe-bcf0-3ded2df55dff">642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a2ca03978148dc9bd965d74ecd6189_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfNS0zLTEtMS02ODU4NQ_0ba7afa1-f8f3-4b9a-a2f9-5788b4cdeabc">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfNi0xLTEtMS02ODU4NQ_fd02e17b-0c2f-41d0-b406-e20b8a7e0ad3">2,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfNi0zLTEtMS02ODU4NQ_afa0f6c9-3db2-41bf-8236-afaab94acee3">2,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfNy0xLTEtMS02ODU4NQ_631c2086-a271-4ede-baaf-f571d980970f">1,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfNy0zLTEtMS02ODU4NQ_1fcde24a-16d3-4337-82f8-eed4f698e8dd">1,228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfOC0xLTEtMS02ODU4NQ_c25d49b3-f8c5-4206-aeb9-1880491caf68">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfOC0zLTEtMS02ODU4NQ_b480a93d-99ca-4deb-abe0-1174552d8ea8">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RleHRyZWdpb246Y2E1MDlhZWY4ZTVmNDdkOTllYWNkZjVmZjI2MGZlOGVfMTcw_4bf7cfb5-627f-4159-88ec-1a77d3c03845">127</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RleHRyZWdpb246Y2E1MDlhZWY4ZTVmNDdkOTllYWNkZjVmZjI2MGZlOGVfMTc3_f1f34756-f723-458b-b02d-afe9905cfe4c">133</ix:nonFraction> thousand for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div></ix:continuation><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="xfor:AccruedExpensesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RleHRyZWdpb246ZTNmYzAzNWI3ZjAxNDY2N2IzYTM3Yzg2ODk3ZmIwMTBfNzI_20a67432-18e8-4376-ba8b-9ee71b2c920a" continuedAt="ic7ae2b58676245f2afbe485452e589ea" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-top:6pt"><ix:continuation id="ic7ae2b58676245f2afbe485452e589ea"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RleHRyZWdpb246ZTNmYzAzNWI3ZjAxNDY2N2IzYTM3Yzg2ODk3ZmIwMTBfNzA_92c4dce7-00af-4d59-b961-9c305c99eda4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfMS0xLTEtMS02ODU4NQ_94f5b9dc-79bd-4f71-9d43-89346fcd86ce">2,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfMS0zLTEtMS02ODU4NQ_9d48b830-3379-44f2-8153-9bedc0224697">6,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="xfor:AccruedExternalResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfMi0xLTEtMS02ODU4NQ_7d17c530-441b-4d26-8529-fae791d2a468">7,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="xfor:AccruedExternalResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfMi0zLTEtMS02ODU4NQ_3b8fa3c7-447d-4c9e-9f56-876e4269ec77">3,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfMy0xLTEtMS02ODU4NQ_f586f5c1-2a96-4096-a815-42b5798d7596">924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfMy0zLTEtMS02ODU4NQ_ad48ea7d-211e-4451-9b4d-fc096c0b5cb4">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued deferred financing fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="xfor:AccruedLeaseConstructionCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfNC0xLTEtMS02ODU4NQ_5c78058f-fc31-49bf-b67d-e56b895ff169">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="xfor:AccruedLeaseConstructionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfNC0zLTEtMS02ODU4NQ_4fd76fc7-f4d9-48e7-ab45-3f96a2004c5b">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfNS0xLTEtMS02ODU4NQ_f6c35983-d095-48fe-8f45-66d4ab54ee21">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfNS0zLTEtMS02ODU4NQ_ab8c9da2-5e46-4584-88f3-42ea00d227bc">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfNi0xLTEtMS02ODU4NQ_eb0bffdc-b710-4caa-9d53-20a006347e01">11,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfNi0zLTEtMS02ODU4NQ_135cba7a-5bd1-471a-878d-c00ae932774a">12,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;LONG-TERM DEBT</span></div><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNjAzOA_75bbb41f-f9e4-4015-9c02-be14b2021418" continuedAt="i11662958cf43468ab36ed772382cbd23" escape="true"><div style="margin-top:6pt"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNjAzNA_e8d90bb4-8373-4ef5-a5f6-0a58d5a263f9" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:58.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.635%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfMS0xLTEtMS02ODU4NQ_0c644e88-6023-4efc-b9e5-e557b6a8864d">32,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfMS0zLTEtMS02ODU4NQ_b409eb84-aa89-4b6e-a99c-085638ae99c0">32,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount, net of accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfMi0xLTEtMS02ODU4NQ_926a408d-38ed-45db-80f2-df5832767abd">767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfMi0zLTEtMS02ODU4NQ_be252114-349f-4705-94cd-42e1a8ccc6e3">196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative accretion of end of term payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" sign="-" name="xfor:AccretionOnLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfMy0xLTEtMS02ODU4NQ_bb44f6d3-3c48-4db0-9050-aa5b7711cc5b">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" sign="-" name="xfor:AccretionOnLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfMy0zLTEtMS02ODU4NQ_f669cc31-8ac3-4a83-8f6b-dd61c4a7a3d2">1,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="xfor:LongTermDebtIncludingAccretion" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfNC0xLTEtMS02ODU4NQ_cef1fa2f-4c81-4e11-9fb2-a6462a5fea41">32,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="xfor:LongTermDebtIncludingAccretion" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfNC0zLTEtMS02ODU4NQ_e00b53b2-e5f9-484c-b007-531e504217a5">33,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfNS0xLTEtMS02ODU4NQ_e6ed6e69-ef53-46db-8395-c5a08b54cd65">554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfNS0zLTEtMS02ODU4NQ_7c7bf469-48ab-477c-902d-6b5ad428d94a">1,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfNi0xLTEtMS02ODU4NQ_bc60142f-e5ab-4abd-b247-12b3009742e7">31,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfNi0zLTEtMS02ODU4NQ_e42a349e-ba8b-4a43-a3c8-93d412244f83">32,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hercules Loan Agreement, As Amended</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into a Loan and Security Agreement (the &#8220;Hercules Loan Agreement&#8221;), as amended most recently in January 2023, with Hercules, under which the Company has borrowed an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i4e9d1a47182c4c47854e138d3c2b5d17_D20181001-20210331" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfMzcy_a52aa468-fabf-4d3d-b2c5-f2952f0a4df9">32.5</ix:nonFraction> million of term loans to date representing the maximum borrowings. Borrowings under the Hercules Loan Agreement accrues interest at a variable rate equal to the greater of (i)&#160;<ix:nonFraction unitRef="number" contextRef="ie15dfe94dd9d4fe39d6d8e1f3b74ce9a_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfODAx_641693d2-f832-4a49-8d7c-d1be9629c339">10.15</ix:nonFraction>% or (ii)&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;prime rate plus <ix:nonFraction unitRef="number" contextRef="ic8e87f99c10e4fb881a7bed5735567ff_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfODUz_64e525a8-ae54-49ee-a181-005fa6dc2dc3">3.15</ix:nonFraction>%.&#160;In an event of default and until such event is no longer continuing, the interest rate applicable to borrowings would be increased by <ix:nonFraction unitRef="number" contextRef="ie15dfe94dd9d4fe39d6d8e1f3b74ce9a_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfOTkx_4e7ff89d-8e46-4b8c-8ca2-a38464c64bac">4.0</ix:nonFraction>%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Hercules Loan Agreement are repayable in monthly interest-only payments through September 2024, and in equal monthly payments of principal and accrued interest from October&#160;1, 2024 until the maturity date of the loan on April 1, 2026; provided, however, if certain conditions are met and the Company achieves certain operational and financial milestones, </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i11662958cf43468ab36ed772382cbd23"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the maturity date will be extended to July 1, 2027. The Company may prepay all, but not less than all, of the outstanding borrowings, subject to a prepayment premium of <ix:nonFraction unitRef="number" contextRef="i28f0cf51fe7e42fbb78f10ac69a552e6_I20230331" decimals="INF" name="xfor:DebtInstrumentPrepaymentPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfMTM4NA_ef4e5a4b-2c06-4ce4-a219-7d5dfc1555f6">3.0</ix:nonFraction>% of the principal amount outstanding as of the date of repayment. In addition, the Hercules Loan Agreement provides for payments of $<ix:nonFraction unitRef="usd" contextRef="ia310f627aef34b0faca97728c514f3c1_D20220701-20220701" decimals="-5" name="us-gaap:LineOfCreditFacilityPeriodicPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfMTUxOA_ddcf39a1-4dc9-4105-b558-5f35e6bba767">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i792dfc869c4b408e892ad399f14978bb_D20240701-20240701" decimals="-5" name="us-gaap:LineOfCreditFacilityPeriodicPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfMTUyNQ_bb3e064d-4c05-4851-9f43-99d0f336dc31">1.3</ix:nonFraction> million payable on July 1, 2023 and April 1, 2026, respectively, which payments are accelerated upon the prepayment of the borrowings upon the Company&#8217;s election or upon default of the loan. Borrowings under the Hercules Loan Agreement are collateralized by substantially all of the Company&#8217;s personal property and other assets except for its intellectual property (but including rights to payment and proceeds from the sale, licensing or disposition of the intellectual property). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Hercules Loan Agreement, the Company has agreed to affirmative and negative covenants. Pursuant to the Hercules Loan Agreement, the Company is required to maintain cash in an account or accounts in which Hercules has a first priority security interest, in an aggregate amount greater than $<ix:nonFraction unitRef="usd" contextRef="ia4e98937b5cb4858b0ac41a2a5352c45_I20230331" decimals="-3" name="xfor:LineOfCreditCovenantMinimumCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNTQ5NzU1ODIxOTg5_333d46e5-ce4c-404c-9e2b-61a0d0a69d76">20.0</ix:nonFraction> million. Upon the FDA&#8217;s approval of the sale and marketing of mavorixafor for the treatment to patients with WHIM syndrome with a label claim that is generally consistent with that sought in the Company&#8217;s New Drug Application filing, the required level shall be reduced to $<ix:nonFraction unitRef="usd" contextRef="ie2d3052cd5e24327abde1e8113a23cd2_I20230331" decimals="-3" name="xfor:LineOfCreditCovenantMinimumCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNTQ5NzU1ODIyMjM5_de65f9ab-1367-4446-9086-fbe133bb36e1">10.0</ix:nonFraction> million. A breach of any of the covenants under the Hercules Loan Agreement could result in a default under the loan. Upon the occurrence of an event of default under the loan facility with Hercules, the lender could elect to declare all amounts outstanding, if any, to be immediately due and payable and terminate all commitments to extend further credit. If there are any amounts outstanding that the Company is unable to repay, Hercules could proceed against the collateral to secure such indebtedness.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hercules Loan Agreement also restricts the Company&#8217;s ability to incur additional indebtedness, pay dividends, encumber its intellectual property, or engage in certain fundamental business transactions, such as mergers or acquisitions of other businesses, with certain exceptions. </span></div><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNjAzNQ_4a17feed-4266-469b-b79f-39bcdd4597e6" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized interest expense under the Hercules Loan Agreement as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15dfe94dd9d4fe39d6d8e1f3b74ce9a_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjJiYWJkNzIxNjMwYTQ4M2FiYmYxNjhmYWE5YjA1M2FhL3RhYmxlcmFuZ2U6MmJhYmQ3MjE2MzBhNDgzYWJiZjE2OGZhYTliMDUzYWFfMi0xLTEtMS02ODU4NQ_4852daaf-02a7-40a5-bda3-6f5218d8764b">884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i758d637f0af747e88e3b2ef6d3eae458_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjJiYWJkNzIxNjMwYTQ4M2FiYmYxNjhmYWE5YjA1M2FhL3RhYmxlcmFuZ2U6MmJhYmQ3MjE2MzBhNDgzYWJiZjE2OGZhYTliMDUzYWFfMi0zLTEtMS02ODU4NQ_2392068c-ee8b-4528-b256-54769287b50d">909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15dfe94dd9d4fe39d6d8e1f3b74ce9a_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjJiYWJkNzIxNjMwYTQ4M2FiYmYxNjhmYWE5YjA1M2FhL3RhYmxlcmFuZ2U6MmJhYmQ3MjE2MzBhNDgzYWJiZjE2OGZhYTliMDUzYWFfMy0xLTEtMS02ODU4NQ_5544b2f7-98f6-403c-b2a6-3262d8c4233a">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i758d637f0af747e88e3b2ef6d3eae458_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjJiYWJkNzIxNjMwYTQ4M2FiYmYxNjhmYWE5YjA1M2FhL3RhYmxlcmFuZ2U6MmJhYmQ3MjE2MzBhNDgzYWJiZjE2OGZhYTliMDUzYWFfMy0zLTEtMS02ODU4NQ_98f3cfc6-c114-4406-b0c5-9bfdf6059c3a">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual effective interest rate of the Hercules Loan Agreement as of March&#160;31, 2023 is <ix:nonFraction unitRef="number" contextRef="ib8529518add445d8a6792e09b74e9bf9_I20230331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNTY1MQ_becb6abe-2bab-4fbe-80f5-2100126653c3">13.8</ix:nonFraction>%. There were <ix:nonFraction unitRef="usd" contextRef="ie15dfe94dd9d4fe39d6d8e1f3b74ce9a_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNTY2Ng_e1769699-20d8-47fe-afa3-ff55a76086fc">no</ix:nonFraction> principal payments due or paid under the Hercules Loan Agreement during the three months ended March&#160;31, 2023. An end-of-term payment of $<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNTc5Mw_b2900d44-225b-4805-9440-1551633fbb01">1.3</ix:nonFraction> million was paid during the three months ended March 31, 2023 in conjunction with the second amendment and restatement of the Hercules Loan Agreement, which was entered into on January 6, 2023. The Company concluded that the amendment and restatement represented a modification to the debt. Accordingly, fees paid to third parties directly related to the amended and restated debt were expensed as incurred and fees paid to Hercules in conjunction with the amendment and restatement were deferred and are being amortized to interest expense over the life of the debt arrangement using the effective interest method. </span></div><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNjAzNg_5952d25b-bea1-477c-bd51-fefce14b313f" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, future principal and accrued end-of-term payments due under the Hercules Loan Agreement were as follows (in thousands): </span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjI1YjYzZDc5MTM4ZTQwNjU4MmRiNmMwNzYyOGI0MTA3L3RhYmxlcmFuZ2U6MjViNjNkNzkxMzhlNDA2NTgyZGI2YzA3NjI4YjQxMDdfMS0xLTEtMS02ODU4NQ_34319520-cacc-481f-b220-804792608666">554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjI1YjYzZDc5MTM4ZTQwNjU4MmRiNmMwNzYyOGI0MTA3L3RhYmxlcmFuZ2U6MjViNjNkNzkxMzhlNDA2NTgyZGI2YzA3NjI4YjQxMDdfMi0xLTEtMS02ODU4NQ_fab7f6e5-5b5b-4840-b572-1c21f2376e87">4,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjI1YjYzZDc5MTM4ZTQwNjU4MmRiNmMwNzYyOGI0MTA3L3RhYmxlcmFuZ2U6MjViNjNkNzkxMzhlNDA2NTgyZGI2YzA3NjI4YjQxMDdfMy0xLTEtMS02ODU4NQ_ae20536d-dd59-47e7-9667-d5c3a1dd0554">20,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjI1YjYzZDc5MTM4ZTQwNjU4MmRiNmMwNzYyOGI0MTA3L3RhYmxlcmFuZ2U6MjViNjNkNzkxMzhlNDA2NTgyZGI2YzA3NjI4YjQxMDdfNC0xLTEtMS02OTgxNA_fbb41347-adc5-4cf1-ae52-d03d830c8a89">7,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="xfor:LongTermDebtAndEOTPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjI1YjYzZDc5MTM4ZTQwNjU4MmRiNmMwNzYyOGI0MTA3L3RhYmxlcmFuZ2U6MjViNjNkNzkxMzhlNDA2NTgyZGI2YzA3NjI4YjQxMDdfNC0xLTEtMS02ODU4NQ_ab28f4f3-d59a-4b45-aab0-033a8eda4010">33,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:18pt"><span><br/></span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_58"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfMjYxOQ_c7e36a33-2f16-4412-970a-c2808b7b6783" continuedAt="i3d46d8d513e1402b832dddec4501f2d3" escape="true">LEASES</ix:nonNumeric></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i3d46d8d513e1402b832dddec4501f2d3" continuedAt="i5dfc0070bde1446782513325705c2a08"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements for its facilities in Boston, Massachusetts, which is the Company&#8217;s principal executive office; Vienna, Austria, which is the Company&#8217;s research and development center; and Waltham, Massachusetts, which the Company has sublet to a third party. There are no restrictions or financial covenants associated with any of the lease agreements. </span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Vienna Austria Leases&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for approximately <ix:nonFraction unitRef="sqm" contextRef="if95bc8592c8940cab11430e303f438e5_D20230101-20230331" decimals="0" name="xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfNDYz_b0830f8e-8b00-4ceb-8aee-d67ff6d02f55">1,200</ix:nonFraction> square meters of laboratory and office space in Vienna, Austria (&#8220;Vienna Lease&#8221;), which commenced in February 2021 for a term of <ix:nonNumeric contextRef="i44b39b28bc5548a2886646bbc220829d_I20230331" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfNTk1_1cf4b6e0-0f6a-4698-aabb-8e0e1e8bb8f6">7</ix:nonNumeric> years. The annual base rent for the Vienna Lease is approximately $<ix:nonFraction unitRef="usd" contextRef="i44b39b28bc5548a2886646bbc220829d_I20230331" decimals="-3" name="xfor:LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfNjU4_f21293cf-9b68-4166-8c9f-3874bc8016fd">285</ix:nonFraction> thousand.</span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Boston Lease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i25a8d7091c814a1188d29fe34e7e629d_D20191111-20191111" decimals="0" name="xfor:CurrentOfficeSpaceUnderLeaseAgreement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfNzA5_992940c5-37f0-46ee-be7a-93e56c3e333a">28,000</ix:nonFraction> square feet of office space in Boston, Massachusetts (&#8220;Boston Lease&#8221;), which serves as the Company&#8217;s headquarters. Base rental payments are approximately $<ix:nonFraction unitRef="usd" contextRef="i25a8d7091c814a1188d29fe34e7e629d_D20191111-20191111" decimals="-3" name="xfor:LesseeOperatingLeaseLeaseNotYetCommencedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfNTQ5NzU1ODE2NTE0_f96539e2-0d6f-4747-81da-d5d6736de2bd">1.1</ix:nonFraction> million  annually, plus certain operating expenses. The term of the Boston Lease will continue until November 2026, unless earlier terminated. The Company has the right to sublease the premises, subject to landlord consent and also has the right to renew the Boston Lease for an additional <ix:nonNumeric contextRef="i23498fecf6314534a7194a398e3e01ba_I20191111" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfMTE1MA_6decf1bf-7b78-4ddd-ae83-d7d8be0f8a1d">five years</ix:nonNumeric> at the then prevailing effective market rental rate. The Company is required to maintain a security deposit in the form of a letter of credit for $0.6&#160;million for the benefit of the landlord. </span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Waltham Lease&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i25e5f6ca21c44724bd4163d8dc79dbe2_D20230101-20230331" decimals="0" name="xfor:CurrentOfficeSpaceUnderLeaseAgreement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfMTM4NQ_e166d456-e8c0-4380-a7a2-1f595a940e87">6,000</ix:nonFraction> square feet of office space in Waltham, Massachusetts (&#8220;Waltham Lease&#8221;). The Waltham Lease, as amended, commenced on January&#160;1, 2019, and expires on December 31, 2023. The base rent is approximately $<ix:nonFraction unitRef="usd" contextRef="i25e5f6ca21c44724bd4163d8dc79dbe2_D20230101-20230331" decimals="-3" name="xfor:AggregateBaseRent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfMTU5Nw_888c79e1-2dcc-42c2-871d-081f9d3342d6">0.3</ix:nonFraction> million annually. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, which costs are not included in the determination of the leases&#8217; right-of-use assets or lease liabilities. The Company is subleasing the space to a third party for the duration of the lease. The right-of-use asset is being amortized to rent expense over the <ix:nonNumeric contextRef="i02b354bcacc54b7baa76c20057184051_I20230331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfMjYyMA_f011fcf1-d8c9-428c-979f-26fa73ff7171">five-year</ix:nonNumeric> term of the lease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As the Company&#8217;s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment.</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfMjYyMg_2990020b-f36d-437a-884f-c6a56b1b67a3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three months ended March&#160;31, 2023 and 2022 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.182%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfMi0xLTEtMS02ODU4NQ_21fa4d33-8ca9-4545-9e29-f2fa29e12a1f">522</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfMi0zLTEtMS02ODU4NQ_8f1972a3-7ad2-42b6-bd4a-7c8ff20d3f8c">530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfNC0xLTEtMS02ODU4NQ_b6a0f8d6-4701-458b-8a99-95bf2aa63481">522</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfNC0zLTEtMS02ODU4NQ_588bfafc-c1fb-4fe9-b555-8e75ae2941d1">530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfNy0xLTEtMS02ODU4NQ_05df67a3-1893-45db-9b8f-09fc61a85a8e">346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfNy0zLTEtMS02ODU4NQ_75214acd-c05d-4c43-9d13-c9072e267f2f">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfOC0xLTEtMS02ODU4NQ_c1f5d757-12d7-48fc-8d1c-1a9ac7e7648b">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfOC0zLTEtMS02ODU4NQ_4334ae6b-c386-4263-8d0f-82752705c258">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8212;operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfOS0xLTEtMS02ODU4NQ_6fe68743-0a5c-4089-be36-e76295e8c8c4">3.8</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfMTAtMS0xLTEtNjg1ODU_a35234b7-8d3f-4872-969f-0d415503910d">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i5dfc0070bde1446782513325705c2a08"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfMjYyMw_0c89f34e-b618-4623-8c08-eb8c52be3d79" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities due under lease agreements that have commenced as of March&#160;31, 2023 are as follows (in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:78.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder of the year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfMS0xLTEtMS02ODU4NQ_773137f9-338a-4c09-b3a8-124e168d3618">1,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfMi0xLTEtMS02ODU4NQ_60fa5684-8ce8-4970-ad67-64bbfbd1436b">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfMy0xLTEtMS02ODU4NQ_8d19d5e8-7144-4b92-b425-5a8947af7415">1,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfNC0xLTEtMS02ODU4NQ_d692d9a9-fc0e-4b10-831b-2163781adb77">1,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfNS0xLTEtMS02ODU4NQ_c703e3da-066a-476e-8326-33d7580dfa59">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfNi0xLTEtMS02ODU4NQ_712e8191-d6f0-4b19-8834-1ab87b6edab7">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfNy0xLTEtMS02ODU4NQ_3fe5e108-10ea-4a5b-8e4e-f3b2f97468c5">5,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfOC0xLTEtMS02ODU4NQ_3f224605-25cb-48b5-a2db-7c23c05fd5a6">1,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities as of March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfOS0xLTEtMS02ODU4NQ_e5335ce5-953c-46fd-9a6e-bb716a60f530">4,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_61"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82MS9mcmFnOjg4ZTBiNWEwZGNmMzQ2ZDg4MzZiM2Y5Mjk3N2ViOWM0L3RleHRyZWdpb246ODhlMGI1YTBkY2YzNDZkODgzNmIzZjkyOTc3ZWI5YzRfMjIwMQ_796cdfe6-825e-4ca1-906a-1023299937b4" continuedAt="ia3d0ad6c4461402a8ff6b07bf42dbeee" escape="true">COMMITMENTS AND CONTINGENCIES </ix:nonNumeric></span></div><ix:continuation id="ia3d0ad6c4461402a8ff6b07bf42dbeee"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with contract manufacturing organizations (&#8220;CMOs&#8221;) for the production of mavorixafor for use in clinical trials. The Company&#8217;s agreement with the CMO who produces batches of drug substance for use in the Company&#8217;s clinical drug supply contains cancellation provisions that would require the Company to pay up to the full contract value upon cancellation. As of March&#160;31, 2023, the Company has approximately $0.8 million of such commitments in place subject to cancellation provisions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company to, among other things, indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification obligations. The Company is not currently aware of any indemnification claims and has <ix:nonFraction unitRef="usd" contextRef="i9d0d898499ff4bda99b5eb41e4b472d0_I20230331" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82MS9mcmFnOjg4ZTBiNWEwZGNmMzQ2ZDg4MzZiM2Y5Mjk3N2ViOWM0L3RleHRyZWdpb246ODhlMGI1YTBkY2YzNDZkODgzNmIzZjkyOTc3ZWI5YzRfMTYwOA_67aed9c5-e9d9-4c7d-876d-a8d2879ffa4b"><ix:nonFraction unitRef="usd" contextRef="ib84837e886bd42e9be166c81d4c7ebdf_I20221231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82MS9mcmFnOjg4ZTBiNWEwZGNmMzQ2ZDg4MzZiM2Y5Mjk3N2ViOWM0L3RleHRyZWdpb246ODhlMGI1YTBkY2YzNDZkODgzNmIzZjkyOTc3ZWI5YzRfMTYwOA_d12539ca-6bd4-4165-bbab-23d8178fedc4">no</ix:nonFraction></ix:nonFraction>t accrued any liabilities related to such obligations in its condensed consolidated financial statements as of March&#160;31, 2023 or December&#160;31, 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to any legal proceedings.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_64"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzk5MA_cef644ef-2410-4d9b-b60d-fe300943553e" continuedAt="iaa6d18557e7a4ee8ac80b082ebea6f31" escape="true">COMMON STOCK AND COMMON STOCK WARRANTS</ix:nonNumeric></span></div><ix:continuation id="iaa6d18557e7a4ee8ac80b082ebea6f31" continuedAt="i6e5aa5e598b4491bb89b96ed60a13a49"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company&#8217;s Restated Certificate of Incorporation authorized the Company to issue <ix:nonFraction unitRef="shares" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfMTU3_cfcb2bf7-d196-4504-af36-54bf6cc240f2">500</ix:nonFraction> million shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfMTk0_5c9dd5d7-9e36-4bcb-9b67-0236fcb656ae"><ix:nonFraction unitRef="usdPerShare" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfMTk0_8dc105a5-7631-4180-84a4-bfdf7d06af1b">0.001</ix:nonFraction></ix:nonFraction> per share. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of the holders of any preferred stock that may be issued. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. <ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="INF" name="us-gaap:DividendsCommonStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNjQ2_78c2fa1c-57bd-4fd6-9ef8-19431769bd0e">No</ix:nonFraction> cash dividends have been declared or paid to date. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with previous public and private sales of shares of its common stock, the Company has issued warrants and pre-funded warrants, which are exercisable for the purchase shares of the Company&#8217;s common stock. All outstanding warrants and pre-funded warrants are currently exercisable and do not have price reset provisions. Upon the closing of these public and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i6e5aa5e598b4491bb89b96ed60a13a49" continuedAt="i1bb5d5efd4bb4055b9d871d4184f8fbb"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">private offerings, the Company received approximately 99% of the exercise price for the pre-funded warrants, for which the remaining exercise price is equal to or less than $<ix:nonFraction unitRef="usdPerShare" contextRef="i0c446d1ebf6c4761a059bfe41f76a3e8_I20210323" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNjgyMg_03c7ffbf-b73b-423f-9681-55e3178c2c1b">0.01</ix:nonFraction> per share.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzk5NA_7c4a949b-4c57-402f-80df-6e15a9b65ec4" continuedAt="i95a583f0ea08497487fd147a7e5e95eb" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the Company&#8217;s outstanding warrants and pre-funded warrants to purchase shares of common stock consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares of<br/>Common<br/>Stock Issuable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 25, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59fa5f3cd8cf463cb6ab5a26e83105b0_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMS0yLTEtMS02ODU4NQ_c926c199-f307-4baf-b1ba-3b388ba3627f">5,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iade75dd12e4e4311828ad8732615848a_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMS00LTEtMS02ODU4NQ_d64e5687-1047-4cee-9a73-48b6770d062b">19.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 24, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 28, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7ff88f12eeb444480a302991cd38a77_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMi0yLTEtMS02ODU4NQ_1cc2c5bc-b92f-4a03-ba43-8e68a028b63d">115,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica711cd3944d444d8e90591b4f36f165_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMi00LTEtMS02ODU4NQ_91967fad-8038-4c0a-8ad4-9f8c98b58f49">19.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 28, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 12, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i659abfcb1f9b4bab9b076ba940943d85_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMy0yLTEtMS02ODU4NQ_f5d6d3d6-3cac-4106-a57c-7b1c20c5e9a2">20,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f782c581af34e0bbaf1f1c156ed8abd_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMy00LTEtMS02ODU4NQ_d9011a9c-53f8-45d0-8b9d-06f53baa840e">19.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 12, 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 19, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id50d3ea6ecda45bb92708c1a5fcceadc_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfNC0yLTEtMS02ODU4NQ_8181b7de-0ece-4c99-9db6-7992e5930116">20,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i831b8fe131874b52b6235c73b19040d9_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfNC00LTEtMS02ODU4NQ_06b68b16-53d8-46ab-bf35-c223b8ddda77">19.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 19, 2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 13, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44c6c0606f1e473a95f0fd0e8f1f0ceb_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfNS0yLTEtMS02ODU4NQ_37552924-d9a6-4ff5-984a-3456a6e74301">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie46fdfe3fed3486d838e54a83d18ef93_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfNS00LTEtMS02ODU4NQ_38a838d8-1e66-42e7-b583-dd3df9e88d11">19.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 12, 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 16, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61d35b6a71594a80acb565c214ebd4d8_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfNi0yLTEtMS02ODU4NQ_29525a69-780f-4a5d-bda5-ee2b23c87e37">3,866,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i57d428ba32094371b2dd937c8006e5f0_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfNi00LTEtMS02ODU4NQ_a074ed4a-9d3c-4978-bd0c-3a0cb90aadd6">13.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 15, 2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e73b6bdb52e4b4289aa86a4856b47d5_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfOC0yLTEtMS02ODU4NQ_f060fce5-aaae-460c-a211-9602900bada7">1,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7df7eb9e7da8482fafec0c3a38337782_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfOC00LTEtMS02ODU4NQ_7299721c-b80e-45e7-a455-609fc39e2ffe">12.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 23, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb769b89cd694464bdd20ebea31ac73d_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfOS0yLTEtMS02ODU4NQ_47dff035-edf8-46cd-b48f-dbca2503ab02">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i721101088e744db48fa346c2c77fd85b_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfOS00LTEtMS02ODU4NQ_01111638-18ef-43dd-9f65-f7c310d0e2e8">8.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 9, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3c41890d3204b10bab8bd252409ac92_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTAtMi0xLTEtNjg1ODU_50deb184-c797-4dae-8d12-84f224e2a320">2,008,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3c41890d3204b10bab8bd252409ac92_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTAtNC0xLTEtNjg1ODU_d60a60d1-444a-4562-857c-99c52ef289a5">4.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9018c6d85d24e0dba02aaac05afaddb_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTEtMi0xLTEtNjg1ODU_5df655b4-36d0-45a3-86c8-a63287aa1403">766,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9018c6d85d24e0dba02aaac05afaddb_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTEtNC0xLTEtNjg1ODU_ab441db3-679a-4272-a998-6a18196eb0e9">1.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 6, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5011564a8640482d8512bf19c9642f10_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTItMi0xLTEtNjg1ODU_68d7f37c-8687-42c4-af7d-a28ffce23aab">13,276,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5011564a8640482d8512bf19c9642f10_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTItNC0xLTEtNjg1ODU_7da6608a-17ac-4ebb-ae53-783548a76771">1.095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 6, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7edde0006e1e454d8fea426452b3b54e_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTMtMi0xLTEtNjg1ODU_4eb0c453-843a-4986-bde1-8242c5a314bf">50,925,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7edde0006e1e454d8fea426452b3b54e_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTMtNC0xLTEtNjg1ODU_38e66f27-74e0-4288-b3f5-08e133c28e22">1.095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 6, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 9, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i818c42fab04d4637b93d77e2ac2f2974_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTQtMi0xLTEtNzA5OTc_1cc38552-f085-4947-9b4b-90a7af0715d0">32,762,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i818c42fab04d4637b93d77e2ac2f2974_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTQtNC0xLTEtNzEwMDY_904a2ef3-a932-4ce4-8f91-4290e729593b">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 9, 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 9, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21bf4eefdb5f491ca5fc00294f5db16a_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTUtMi0xLTEtNzA5OTc_902c6281-b07f-4f55-aeae-11cd43e4ba1c">6,800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i21bf4eefdb5f491ca5fc00294f5db16a_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTUtNC0xLTEtNzEwMDY_e6e3d200-844a-4c59-bf82-65eaac672a5c">1.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(f)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTQtMi0xLTEtNjg1ODU_ceafe3a7-73b6-413d-ad5f-8a259a1ca83b">111,871,750</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) In November 2019, the Company received $<ix:nonFraction unitRef="usdPerShare" contextRef="ib89426f0e382467982b04ef21eb04de6_I20191129" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzExMQ_8c63d58a-4f82-4a67-bc10-7566830ac14f">11.999</ix:nonFraction> per pre-funded warrant, or $<ix:nonFraction unitRef="usd" contextRef="i7b8255b9ad4e4346b4353461add65217_I20191129" decimals="-5" name="xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzE0MQ_ad918977-6842-4627-a54b-9aea38691fb2">21.0</ix:nonFraction> million in aggregate proceeds. Each pre-funded</span></div></ix:nonNumeric></ix:continuation><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i1bb5d5efd4bb4055b9d871d4184f8fbb"><ix:continuation id="i95a583f0ea08497487fd147a7e5e95eb">warrant may be exercised for an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="i7b8255b9ad4e4346b4353461add65217_I20191129" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzIyNg_b090b716-72fe-4794-98d5-3372b8365aa9">0.001</ix:nonFraction> per pre-funded warrant. (b) In March 2021, the Company received $<ix:nonFraction unitRef="usdPerShare" contextRef="i4a0759706aef4898bfd9353dc9c1c0cf_I20210323" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzI5NA_237e0fbb-00f9-4a35-99bf-61ee262c8cee">8.69</ix:nonFraction> per pre-funded warrant, or $<ix:nonFraction unitRef="usd" contextRef="ibd18ae94cc92493599001fb5cde340a6_I20210323" decimals="-3" name="xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzMyNA_e856a27b-5123-46a3-ad7f-a1d62ce415f5">435</ix:nonFraction> thousand in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="i0c446d1ebf6c4761a059bfe41f76a3e8_I20210323" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzQwOQ_03c7ffbf-b73b-423f-9681-55e3178c2c1b">0.01</ix:nonFraction> per pre-funded warrant. (c) In November 2021, the Company received $<ix:nonFraction unitRef="usdPerShare" contextRef="i7b76566d4b4d440f9b96f6bd007aea3e_I20211109" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzQ4MQ_28fe951e-40fc-4e1f-aef3-d27f231e93e3">4.97</ix:nonFraction> per pre-funded warrant, or $<ix:nonFraction unitRef="usd" contextRef="i0fe40bc1e0fd489aa6756bc0c4fcb174_I20211109" decimals="-5" name="xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzUxMQ_bb19a800-cd9d-4046-a90b-d2083fc676ad">10.0</ix:nonFraction>&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="i3f7f41a7ee2c446eb9fdb515a92b8d90_I20201102" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzU5Ng_4729ab44-1784-41ea-9df1-7d3e1983b395">0.01</ix:nonFraction> per pre-funded warrant. (d) In March 2022, the Company received $<ix:nonFraction unitRef="usdPerShare" contextRef="i4705077c59e44584ac747abb1c31531c_I20220303" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzY2NA_67e804b1-c839-40dd-9ef0-e90029cd4e25">1.79</ix:nonFraction> per pre-funded warrant, or $<ix:nonFraction unitRef="usd" contextRef="ie54bb572558c468f842e439ada8634bb_I20220303" decimals="-5" name="xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzY5NA_004e14f1-d628-4339-99c2-5c138e4697af">1.4</ix:nonFraction>&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="ie54bb572558c468f842e439ada8634bb_I20220303" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzc3OQ_98947300-20d9-4b6d-84d0-2e9048dfdb93">0.01</ix:nonFraction> per pre-funded warrant. (e) In July 2022, the Company received $<ix:nonFraction unitRef="usdPerShare" contextRef="iac8921647cac40fbafd7ae760b99dccc_I20220706" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzg0Ng_b181785a-e40a-45d7-b271-4e95d94a5a78">1.094</ix:nonFraction> per pre-funded warrant, or $<ix:nonFraction unitRef="usd" contextRef="i057e951826ef4df4b14c1200eeac39f1_I20220706" decimals="-5" name="xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzg3Ng_85c51af8-3faa-439a-b630-dfd224066006">14.5</ix:nonFraction> million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="i057e951826ef4df4b14c1200eeac39f1_I20220706" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzk2MQ_4c34e3b0-29ba-4ef5-8fb3-4950e30b7f8d">0.001</ix:nonFraction>  per pre-funded warrant.  (f) In December 2022, the Company received $1.099 per pre-funded warrant, or $<ix:nonFraction unitRef="usd" contextRef="i9bda35ba3715478cb44dadfb584bfff4_I20221209" decimals="-5" name="xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNTQ5NzU1ODI5Mjc4_887e4e8d-407e-487a-8459-23e7ec4b8c4b">7.5</ix:nonFraction>&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="i057e951826ef4df4b14c1200eeac39f1_I20220706" decimals="INF" name="xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNTQ5NzU1ODI5MjA1_4c34e3b0-29ba-4ef5-8fb3-4950e30b7f8d">0.001</ix:nonFraction> per pre-funded warrant.</ix:continuation></ix:continuation> </span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_67"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMzU4OA_40a4488d-bdfc-4674-82ed-8d997b3d8f4a" continuedAt="i55812dc497334c7b85c9f430130fc38d" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i55812dc497334c7b85c9f430130fc38d" continuedAt="ie96ccf5baa164763af4af3932cdaec0b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Plans&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the following equity incentive plans:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The X4 Pharmaceuticals Inc. 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (the &#8220;2015 Plan&#8221;);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The X4 Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;); and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The X4 Pharmaceuticals Inc. 2019 Inducement Equity Incentive Plan (the &#8220;2019 Plan&#8221;)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company also has the following employee stock purchase plan:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The X4 Pharmaceutical Inc. 2017 Employee Stock Purchase Plan (the &#8220;2017 ESPP&#8221;)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These plans are administered by the Board of Directors or by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the term of the stock option may not be greater than ten years. Incentive stock options granted to employees and restricted stock awards granted to employees, officers, members of the board of directors, advisors, and consultants of the Company typically vest over four years. Non-statutory options granted to employees, officers, members of the board of directors, advisors, and consultants of the Company typically vest over three or four years. Shares that are expired, terminated, surrendered or canceled under the Plans without having been fully exercised will be available for future awards. In </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ie96ccf5baa164763af4af3932cdaec0b" continuedAt="if79757fcbeca46ebacffdfd09002460a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, there are an aggregate of approximately <ix:nonFraction unitRef="shares" contextRef="i9c915254cae9474f9c1872cf496e414a_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMTc4NA_6314dbc1-653f-4f4f-8176-bc8a50406f54">1.0</ix:nonFraction>&#160;million shares of common stock available for issuance under the Company&#8217;s equity incentive plans. Approximately <ix:nonFraction unitRef="shares" contextRef="if3afe5f2291441f68f12e2ab64cf0818_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMTg5MQ_70286dd4-a640-46fe-a1af-e79cef363d63">150,000</ix:nonFraction> shares of common stock remain available for issuance under the 2017 ESPP.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Valuation&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMzU4OQ_ff5cc5d8-b956-4f18-8993-0341ff169b5d" continuedAt="i90fe2a7e0bd447a794a2fc0b486a22a6" escape="true">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees, directors and non-employees.</ix:nonNumeric></span></div><div style="margin-top:18pt"><ix:continuation id="i90fe2a7e0bd447a794a2fc0b486a22a6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.961%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjVjNTBmZTM2ZGNkYTQ1NGY4ZTVjZGUxZjIxYzNhMGE5L3RhYmxlcmFuZ2U6NWM1MGZlMzZkY2RhNDU0ZjhlNWNkZTFmMjFjM2EwYTlfMi0xLTEtMS02ODU4NQ_370de8b6-673e-405a-8b41-7d2841d4597a">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjVjNTBmZTM2ZGNkYTQ1NGY4ZTVjZGUxZjIxYzNhMGE5L3RhYmxlcmFuZ2U6NWM1MGZlMzZkY2RhNDU0ZjhlNWNkZTFmMjFjM2EwYTlfMi0zLTEtMS02ODU4NQ_f7553441-8686-405f-b978-fd3ec7ee76f9">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjVjNTBmZTM2ZGNkYTQ1NGY4ZTVjZGUxZjIxYzNhMGE5L3RhYmxlcmFuZ2U6NWM1MGZlMzZkY2RhNDU0ZjhlNWNkZTFmMjFjM2EwYTlfMy0xLTEtMS02ODU4NQ_7223d970-3c89-4f02-a52d-13153a0a44fe">6.0</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjVjNTBmZTM2ZGNkYTQ1NGY4ZTVjZGUxZjIxYzNhMGE5L3RhYmxlcmFuZ2U6NWM1MGZlMzZkY2RhNDU0ZjhlNWNkZTFmMjFjM2EwYTlfMy0zLTEtMS02ODU4NQ_560ffb1c-387b-4bb8-8e3a-9951a617f740">6.1</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjVjNTBmZTM2ZGNkYTQ1NGY4ZTVjZGUxZjIxYzNhMGE5L3RhYmxlcmFuZ2U6NWM1MGZlMzZkY2RhNDU0ZjhlNWNkZTFmMjFjM2EwYTlfNC0xLTEtMS02ODU4NQ_0d1004e3-3ec1-4efc-a59e-8a14ae0c6b85">90.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjVjNTBmZTM2ZGNkYTQ1NGY4ZTVjZGUxZjIxYzNhMGE5L3RhYmxlcmFuZ2U6NWM1MGZlMzZkY2RhNDU0ZjhlNWNkZTFmMjFjM2EwYTlfNC0zLTEtMS02ODU4NQ_e1a052a3-381c-49f2-8a6a-de68cc22bb2e">94.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjVjNTBmZTM2ZGNkYTQ1NGY4ZTVjZGUxZjIxYzNhMGE5L3RhYmxlcmFuZ2U6NWM1MGZlMzZkY2RhNDU0ZjhlNWNkZTFmMjFjM2EwYTlfNS0xLTEtMS02ODU4NQ_0a3d9e95-463c-4a6b-b2cd-a32ddc41eaca">0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjVjNTBmZTM2ZGNkYTQ1NGY4ZTVjZGUxZjIxYzNhMGE5L3RhYmxlcmFuZ2U6NWM1MGZlMzZkY2RhNDU0ZjhlNWNkZTFmMjFjM2EwYTlfNS0zLTEtMS02ODU4NQ_ff1d4101-9d9e-4f00-bd0e-7d5861c786b2">0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMzU5MA_75a9862e-2e74-40a6-9279-3dbbace2c201" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity for the three months ended March&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfMS0xLTEtMS02ODU4NQ_b407aed7-e44c-4e65-ae3b-82e50727d55f">2,021,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfMS0zLTEtMS02ODU4NQ_1ab80626-f11d-4b68-ace0-51d56c88c5a9">6.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4740594349684b0589e4efe56fcf1e5b_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfMS01LTEtMS02ODU4NQ_ef0a8c73-5871-4c6d-a9d4-483ac84e137a">6.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfMS03LTEtMS02ODU4NQ_a1d9ad11-25c7-4884-b458-e7527cfc8970">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfMi0xLTEtMS02ODU4NQ_fee49047-1078-48f9-936b-9d942f0900f8">834,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfMi0zLTEtMS02ODU4NQ_ae8aadd6-0953-46c0-8981-be51318b79a6">0.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNC0xLTEtMS02ODU4NQ_a260a81e-e54c-4a05-aa0f-9b0c4e887ba8">26,080</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNC0zLTEtMS02ODU4NQ_456d1963-01c8-4203-b5a8-1d15b71ed3b3">8.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNS0xLTEtMS02ODU4NQ_881d4e3f-f198-432f-891c-83647db6ca73">2,830,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNS0zLTEtMS02ODU4NQ_c0c890ba-0477-4313-9655-1f27288e91dd">5.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNS01LTEtMS02ODU4NQ_119329d5-3f98-44e2-8194-2759acec7f35">8.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNS03LTEtMS02ODU4NQ_d6b1b3d3-d7f9-4923-995f-59572e49f155">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNi0xLTEtMS02ODU4NQ_a4ccf82e-21ca-4687-b12d-bf6992bbe3a5">1,163,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNi0zLTEtMS02ODU4NQ_881e0e71-741b-4f12-96a4-6182e3f09040">9.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNi01LTEtMS02ODU4NQ_c67370e4-0cac-4da3-80e3-7737c648ce88">6.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNi03LTEtMS02ODU4NQ_16c3e1a4-aa8a-4774-8819-64ae835cb3ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNy0xLTEtMS02ODU4NQ_21e2c1f4-c12f-44e1-86ea-47945b0e2f0b">2,210,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNy0zLTEtMS02ODU4NQ_a37890cd-f2d0-4d87-b598-275f6cef44d1">6.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNy01LTEtMS02ODU4NQ_f77011e6-4f0b-4354-8d29-6edf7dbe5dc5">7.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNy03LTEtMS02ODU4NQ_e24f48ef-11a5-4bef-b5e6-84e09061751a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no stock options exercised in the three months ended March&#160;31, 2023 and 2022. The weighted average grant-date fair value per share of stock options granted during the three months ended March&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="2" name="xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMjY2MA_a479a38a-48b5-4172-86ce-1cc0202c9147">0.69</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="2" name="xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMjY2Nw_b37f4b6f-e887-492c-b86f-2b09a75c2cd2">1.42</ix:nonFraction>, respectively.</span></div><div style="margin-top:6pt"><span><br/></span></div><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMzU5MQ_2a6065b0-aabf-4f3f-96c9-a5ab574dd3b9" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table summarizes the Company's restricted stock unit activity for the three months ended March 31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:78.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f9fb24c8bb04a26883c4eb1d92a0d6b_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjg3YTcwMGM3NDllNzQzYjc5NjU4NWY3NjQzNmE5OTc1L3RhYmxlcmFuZ2U6ODdhNzAwYzc0OWU3NDNiNzk2NTg1Zjc2NDM2YTk5NzVfMS0xLTEtMS02ODU4NQ_b35401ea-0468-4c0c-a379-9fe337a4ae40">1,680,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjg3YTcwMGM3NDllNzQzYjc5NjU4NWY3NjQzNmE5OTc1L3RhYmxlcmFuZ2U6ODdhNzAwYzc0OWU3NDNiNzk2NTg1Zjc2NDM2YTk5NzVfMi0xLTEtMS02ODU4NQ_fe8f5d3c-98ad-4e3c-9057-6ffc45def19a">4,694,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjg3YTcwMGM3NDllNzQzYjc5NjU4NWY3NjQzNmE5OTc1L3RhYmxlcmFuZ2U6ODdhNzAwYzc0OWU3NDNiNzk2NTg1Zjc2NDM2YTk5NzVfMy0xLTEtMS02ODU4NQ_87794431-7e73-45b7-b598-71e2137f2be4">540,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjg3YTcwMGM3NDllNzQzYjc5NjU4NWY3NjQzNmE5OTc1L3RhYmxlcmFuZ2U6ODdhNzAwYzc0OWU3NDNiNzk2NTg1Zjc2NDM2YTk5NzVfNS0xLTEtMS02ODU4NQ_d7b5dbe3-1c73-4549-8510-0282a86c47d4">5,835,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, the Company granted performance-based restricted stock units (&#8220;PRSUs&#8221;) to its employees. The PRSUs vest 50% based on the Company&#8217;s achievement of each of two operational milestones conditioned on the grantee&#8217;s continued employment with the Company. As of March 31, 2023, neither of the two performance criteria had been met. The Company believes that the achievement of these operational milestones is probable and, accordingly, stock-based compensation expense has been recognized for the awards using the accelerated attribution model based on the fair value of the awards as of the date of grant and management&#8217;s best estimate of the date each operational milestone will be achieved. The </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="if79757fcbeca46ebacffdfd09002460a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company will update its estimates related to the probability and timing of achievement of the operational milestones each period until the award either vests or is forfeited.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, total unrecognized compensation expense related to unvested stock options and restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="i86fbb46408bd4a3db8bc2da79cf7f762_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMzM5NQ_dc115244-e818-420f-a731-51abe41f91ae">6.2</ix:nonFraction> million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i21e6f989318241fbbefaf5468e259ca9_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMzQ2OA_2e40350e-0b63-486e-b02c-afc0c496ef6b">1.3</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMzU5Mg_0a2ea8a6-a76c-4813-bc81-79e48db8b5fb" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:56.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.463%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a10edec5d54b3ca68a4c28e1bf34a1_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjE3OTJlMDI2OTBmNTQ4YThhYzU0ZTZkODVmZGFhZGE2L3RhYmxlcmFuZ2U6MTc5MmUwMjY5MGY1NDhhOGFjNTRlNmQ4NWZkYWFkYTZfMi0xLTEtMS02ODU4NQ_63c1abce-bef8-4490-9b48-cfbb4dd43e84">831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e8f73d1083480daefae46435fca891_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjE3OTJlMDI2OTBmNTQ4YThhYzU0ZTZkODVmZGFhZGE2L3RhYmxlcmFuZ2U6MTc5MmUwMjY5MGY1NDhhOGFjNTRlNmQ4NWZkYWFkYTZfMi0zLTEtMS02ODU4NQ_d058b64d-8ddd-4e81-b05c-392c943da09a">704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2770b271c4ae4bbb9a3c41d6903a369a_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjE3OTJlMDI2OTBmNTQ4YThhYzU0ZTZkODVmZGFhZGE2L3RhYmxlcmFuZ2U6MTc5MmUwMjY5MGY1NDhhOGFjNTRlNmQ4NWZkYWFkYTZfMy0xLTEtMS02ODU4NQ_fbcea016-5ca4-4245-8895-fa0bccf0689d">814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e768118a7db47359a07259561180c69_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjE3OTJlMDI2OTBmNTQ4YThhYzU0ZTZkODVmZGFhZGE2L3RhYmxlcmFuZ2U6MTc5MmUwMjY5MGY1NDhhOGFjNTRlNmQ4NWZkYWFkYTZfMy0zLTEtMS02ODU4NQ_90d2dd48-f01f-4586-b2e4-fb67adf08877">755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjE3OTJlMDI2OTBmNTQ4YThhYzU0ZTZkODVmZGFhZGE2L3RhYmxlcmFuZ2U6MTc5MmUwMjY5MGY1NDhhOGFjNTRlNmQ4NWZkYWFkYTZfNC0xLTEtMS02ODU4NQ_6fd5e3ea-7656-4fa0-a625-e26c203f1788">1,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjE3OTJlMDI2OTBmNTQ4YThhYzU0ZTZkODVmZGFhZGE2L3RhYmxlcmFuZ2U6MTc5MmUwMjY5MGY1NDhhOGFjNTRlNmQ4NWZkYWFkYTZfNC0zLTEtMS02ODU4NQ_092bfcdb-28b4-4bd8-bf65-59d8565d4784">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Appreciation Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; On November 7, 2022 (the &#8220;Grant Date&#8221;), the compensation committee of the Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved special retention and recognition grants of stock appreciation rights (&#8220;SARs&#8221;) pursuant to the 2017 Plan to the Company&#8217;s President and Chief Executive Officer, the Company&#8217;s Chief Financial Officer and Treasurer, and certain other executive officers of the Company. The SARs have a measurement price per SAR equal to $1.80, the closing price per share of the Company&#8217;s common stock on the Grant Date, and each grant of SARs will have a maximum term of ten years from the Grant Date. Unless otherwise determined by the Board of Directors, the SARs will be settled in cash upon exercise. The settlement value will be based on the difference between the closing price of the Company&#8217;s common stock on the date of settlement less $1.80 multiplied by the number of SARs exercised. The SARs will vest and become exercisable in equal annual installments on the first, second, and third anniversaries of the Grant Date, subject to the recipient remaining an employee of the Company through and including each applicable vesting date. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfNTQ5NzU1ODIyMTI3_b0ea6d74-6a54-4248-99e4-e5cdba180dec" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of the fair value of the outstanding SARs as of March&#160;31, 2023 includes the closing price of the Company&#8217;s common stock of $0.87 and the following assumptions on a weighted average basis:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:76.959%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4221465155da49fe9746bea8dd9a5099_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOmU1NzMxNzBmMTg3MTRhNzE5ODdlOTFiOTMwZmQ2YWIxL3RhYmxlcmFuZ2U6ZTU3MzE3MGYxODcxNGE3MTk4N2U5MWI5MzBmZDZhYjFfMS0yLTEtMS03MTU4Mw_8dfcd733-9d49-4bf3-9044-027ada92a941">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4221465155da49fe9746bea8dd9a5099_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOmU1NzMxNzBmMTg3MTRhNzE5ODdlOTFiOTMwZmQ2YWIxL3RhYmxlcmFuZ2U6ZTU3MzE3MGYxODcxNGE3MTk4N2U5MWI5MzBmZDZhYjFfMi0yLTEtMS03MTU4Mw_e6a4a930-67a9-4620-b72c-2e8876ead447">5.61</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4221465155da49fe9746bea8dd9a5099_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOmU1NzMxNzBmMTg3MTRhNzE5ODdlOTFiOTMwZmQ2YWIxL3RhYmxlcmFuZ2U6ZTU3MzE3MGYxODcxNGE3MTk4N2U5MWI5MzBmZDZhYjFfMy0yLTEtMS03MTU4Mw_d66b7c8b-6cc6-4c21-99e3-8ba121de2bb5">90.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4221465155da49fe9746bea8dd9a5099_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOmU1NzMxNzBmMTg3MTRhNzE5ODdlOTFiOTMwZmQ2YWIxL3RhYmxlcmFuZ2U6ZTU3MzE3MGYxODcxNGE3MTk4N2U5MWI5MzBmZDZhYjFfNC0yLTEtMS03MTU4Mw_ebd32a32-a5e5-49bc-ba40-d05363a51aa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected forfeiture rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4221465155da49fe9746bea8dd9a5099_D20230101-20230331" decimals="INF" name="xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOmU1NzMxNzBmMTg3MTRhNzE5ODdlOTFiOTMwZmQ2YWIxL3RhYmxlcmFuZ2U6ZTU3MzE3MGYxODcxNGE3MTk4N2U5MWI5MzBmZDZhYjFfNS0yLTEtMS03MTU4Mw_b9bb8eca-26ae-417f-9c66-0fe78668133b">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SARs are accounted for as liability awards as settlement will be in the form of cash unless the Board of Directors authorizes settlement in shares of the Company&#8217;s common stock and such shares are available to be issued from the 2017 Plan. The Company currently intends to settle the SARs in cash if and when exercised. Compensation expense is recorded based the fair value of the SARs, as determined using the Black-Scholes option valuation model, using an accelerated attribution method as the SARs vest. The Company remeasures the fair value of the outstanding SARs each period until settlement and adjusts life-to-date compensation expense to the period end SARs fair value. For the three months ended March&#160;31, 2023, the Company recognized $403&#160;thousand of compensation expense related to the SARs.</span></div><div><span><br/></span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_70"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83MC9mcmFnOjRkYzI3MzBmYjcyMTRmYjVhYzg1NjY1M2RhMTg0NzJjL3RleHRyZWdpb246NGRjMjczMGZiNzIxNGZiNWFjODU2NjUzZGExODQ3MmNfNDU4_1548466a-0a48-4d41-a513-6f539e42c04b" continuedAt="iad8f1cb7d4b84ab19ec05239146c4262" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iad8f1cb7d4b84ab19ec05239146c4262">The Company did <ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83MC9mcmFnOjRkYzI3MzBmYjcyMTRmYjVhYzg1NjY1M2RhMTg0NzJjL3RleHRyZWdpb246NGRjMjczMGZiNzIxNGZiNWFjODU2NjUzZGExODQ3MmNfMzg_621abb15-7a7e-44d3-8d7b-f47e08a056f9"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83MC9mcmFnOjRkYzI3MzBmYjcyMTRmYjVhYzg1NjY1M2RhMTg0NzJjL3RleHRyZWdpb246NGRjMjczMGZiNzIxNGZiNWFjODU2NjUzZGExODQ3MmNfMzg_864049ed-cade-4307-96f7-8afb08a40a3d"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83MC9mcmFnOjRkYzI3MzBmYjcyMTRmYjVhYzg1NjY1M2RhMTg0NzJjL3RleHRyZWdpb246NGRjMjczMGZiNzIxNGZiNWFjODU2NjUzZGExODQ3MmNfMzg_c1ddbde3-2816-4e00-bb0f-96165addcc2b"><ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83MC9mcmFnOjRkYzI3MzBmYjcyMTRmYjVhYzg1NjY1M2RhMTg0NzJjL3RleHRyZWdpb246NGRjMjczMGZiNzIxNGZiNWFjODU2NjUzZGExODQ3MmNfMzg_d53b2202-b921-47fe-9b39-39ef57658d3a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t record a U.S. federal or state income tax benefit for its losses for the three months ended March&#160;31, 2023 and 2022, due to the conclusion that a full valuation allowance is required against the Company&#8217;s U.S. federal and state deferred tax assets. For the three months ended March&#160;31, 2023 and 2022, the Company recorded an immaterial income tax provision related to its Austrian subsidiary.</ix:continuation> </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RleHRyZWdpb246YTBkYTIxOTAxYmRkNDg3YmFkZTg5YmJjYWIzYjQ5YjhfMjA4MQ_c272de64-550e-4760-bd7a-34cd1586d9cc" continuedAt="i25658f79b73c4762954b0c1b453056e7" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i25658f79b73c4762954b0c1b453056e7"><div style="margin-top:6pt"><ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RleHRyZWdpb246YTBkYTIxOTAxYmRkNDg3YmFkZTg5YmJjYWIzYjQ5YjhfMjA4Mg_1c74fb0d-2055-4beb-aadb-b3ee6b934431" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to common stockholders was calculated as follow:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:67.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.977%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfMy0xLTEtMS02ODU4NQ_cd884d86-694a-447b-bda7-f77fbce2b59f">24,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfMy0zLTEtMS02ODU4NQ_c39021b6-ca5f-43ae-a22c-cea2a598407c">21,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend as a result of Class B warrant price reset </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:DividendsPaidinkind" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfNC0xLTEtMS02ODU4NQ_902c30fb-711e-4093-b231-72a98d938999">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:DividendsPaidinkind" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfNC0zLTEtMS02ODU4NQ_241e7ac9-2e31-45b9-9186-566886a14cdd">2,259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfNS0xLTEtMS02ODU4NQ_30889e07-1d03-49c6-8f0e-a12cb122b1cd">24,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfNS0zLTEtMS02ODU4NQ_e104fec7-493f-432c-b8a1-7016b4ed2bb7">24,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding&#8212;basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfNy0xLTEtMS02ODU4NQ_13750b9d-74dc-4173-9521-248a2add23dc"><ix:nonFraction unitRef="shares" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfNy0xLTEtMS02ODU4NQ_a818c49e-7b39-4333-a567-be38fd1f7322">145,967</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfNy0zLTEtMS02ODU4NQ_34840f04-0881-4a5c-96ef-bafa12b5ace8"><ix:nonFraction unitRef="shares" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfNy0zLTEtMS02ODU4NQ_4ae4c26f-1e75-4826-888f-9b3759ceb88d">33,737</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders&#8212; basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfOC0xLTEtMS02ODU4NQ_6cc14dd2-69ef-4f43-a1e6-872e3d89bc18"><ix:nonFraction unitRef="usdPerShare" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfOC0xLTEtMS02ODU4NQ_e0db5504-6f24-47a7-84b6-ef89cbcb544f">0.16</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfOC0zLTEtMS02ODU4NQ_135653fe-9828-4b1e-af2c-5f2a6d22162a"><ix:nonFraction unitRef="usdPerShare" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfOC0zLTEtMS02ODU4NQ_247882aa-4ea2-4a55-bf55-41603c0fadf9">0.72</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted weighted average shares of common stock outstanding for the three months ended March&#160;31, 2023 and March&#160;31, 2022 include the weighted average effect of outstanding pre-funded warrants for the purchase of shares of common stock for which the remaining unfunded exercise price is $<ix:nonFraction unitRef="usdPerShare" contextRef="i543a1b3b9f974153b5b0d78f5aa7e65a_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RleHRyZWdpb246YTBkYTIxOTAxYmRkNDg3YmFkZTg5YmJjYWIzYjQ5YjhfMzk4_0afd1ebe-4127-4ca7-8715-0d59bf516b9e">0.01</ix:nonFraction> or less per share. During the three months ended March 31, 2022, in accordance with the Company&#8217;s Class B Warrant agreement, the exercise price of each outstanding Class B Warrant was adjusted to the price of shares of the Company&#8217;s common stock sold in public or private offerings to the extent such price is lower than the previous Class B warrant price. These price adjustments were accounted for as a deemed dividend that adjusts net loss available to common shareholders for purposes of basic earnings per share. The deemed dividend was calculated using the Black-Scholes pricing model, taking into account historical volatility of the Company&#8217;s common stock and the estimated remaining life of the outstanding Class B Warrants. The Class B Warrants expired in December 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities include outstanding stock options, unvested restricted stock units and warrants to purchase shares of common stock for the three months ended March&#160;31, 2023 and 2022. All potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share, and thus they are considered &#8220;anti-dilutive.&#8221; Therefore, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. <ix:nonNumeric contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RleHRyZWdpb246YTBkYTIxOTAxYmRkNDg3YmFkZTg5YmJjYWIzYjQ5YjhfMjA3OQ_918e3d57-6952-47e8-b1aa-ac7b98ccbc3f" continuedAt="ie2d2914598ed432b9a49a9e66df71125" escape="true">The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</ix:nonNumeric></span></div><div style="margin-top:12pt"><ix:continuation id="ie2d2914598ed432b9a49a9e66df71125"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:65.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.153%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase shares of common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f3437aea96f4fe886c79fb94a8059fe_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjI3MGU5NDkzM2IxMTQ0ZDk5ZjU4YTgxYTQwYzNjOTdjL3RhYmxlcmFuZ2U6MjcwZTk0OTMzYjExNDRkOTlmNThhODFhNDBjM2M5N2NfMi0xLTEtMS02ODU4NQ_0a8bffba-b4db-4169-8594-8f7ac8a41d29">2,830,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcded639cedf4a788b3eecce804bc350_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjI3MGU5NDkzM2IxMTQ0ZDk5ZjU4YTgxYTQwYzNjOTdjL3RhYmxlcmFuZ2U6MjcwZTk0OTMzYjExNDRkOTlmNThhODFhNDBjM2M5N2NfMi0zLTEtMS02ODU4NQ_7c2258e0-9051-48bd-80ff-57cb10528525">2,049,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81603c1b6ca6430691c2b72f0262d107_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjI3MGU5NDkzM2IxMTQ0ZDk5ZjU4YTgxYTQwYzNjOTdjL3RhYmxlcmFuZ2U6MjcwZTk0OTMzYjExNDRkOTlmNThhODFhNDBjM2M5N2NfMy0xLTEtMS02ODU4NQ_d1137586-4d39-4b48-9505-5c5b0c0da7f6">5,835,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c0ed81ded19458591eb27f59b52093f_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjI3MGU5NDkzM2IxMTQ0ZDk5ZjU4YTgxYTQwYzNjOTdjL3RhYmxlcmFuZ2U6MjcwZTk0OTMzYjExNDRkOTlmNThhODFhNDBjM2M5N2NfMy0zLTEtMS02ODU4NQ_d2ef6d92-83ee-43e7-b0a6-9a1f438f2b05">1,940,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase shares of common stock (excluding prefunded warrants, which are included in basic shares outstanding)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac5b1bc09d7c443491ee3a29c39946f6_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjI3MGU5NDkzM2IxMTQ0ZDk5ZjU4YTgxYTQwYzNjOTdjL3RhYmxlcmFuZ2U6MjcwZTk0OTMzYjExNDRkOTlmNThhODFhNDBjM2M5N2NfNC0xLTEtMS02ODU4NQ_e4b40fb9-c759-4328-8f4f-b4e05428d8c4">87,720,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie95358238f73468db9f71aef1ce13baf_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjI3MGU5NDkzM2IxMTQ0ZDk5ZjU4YTgxYTQwYzNjOTdjL3RhYmxlcmFuZ2U6MjcwZTk0OTMzYjExNDRkOTlmNThhODFhNDBjM2M5N2NfNC0zLTEtMS02ODU4NQ_391d3392-213f-4449-b230-39b04636ff11">9,449,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjI3MGU5NDkzM2IxMTQ0ZDk5ZjU4YTgxYTQwYzNjOTdjL3RhYmxlcmFuZ2U6MjcwZTk0OTMzYjExNDRkOTlmNThhODFhNDBjM2M5N2NfNS0xLTEtMS02ODU4NQ_0dd88020-c810-4464-b40d-fd383d82eda5">96,386,089</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjI3MGU5NDkzM2IxMTQ0ZDk5ZjU4YTgxYTQwYzNjOTdjL3RhYmxlcmFuZ2U6MjcwZTk0OTMzYjExNDRkOTlmNThhODFhNDBjM2M5N2NfNS0zLTEtMS02ODU4NQ_625ec855-5b3e-4df6-9d88-97949df0591a">13,438,974</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The following information should be read in conjunction with our unaudited condensed consolidated financial statements and the notes thereto included in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;), on March 21, 2023, the (&#8220;Annual Report&#8221;). This discussion and analysis contains forward-looking statements that involve significant risks and uncertainties. Our actual results, performance or experience could differ materially from what is indicated by any forward-looking statement due to various important factors, risks and uncertainties, including, but not limited to, those set forth under &#8220;Risk Factors&#8221; included elsewhere in this Quarterly Report on Form 10-Q.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are a late clinical-stage biopharmaceutical company discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our lead clinical candidate is mavorixafor, a small molecule antagonist of chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. Due to its ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream, we believe that mavorixafor has the potential to provide therapeutic benefit across a variety of chronic neutropenic disorders, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, primary immunodeficiency. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2022, we announced positive top-line data from our global, pivotal, Phase 3 clinical trial (4WHIM) evaluating the safety and efficacy of mavorixafor in people with WHIM syndrome. While data review and analysis of the secondary and exploratory endpoints of the 4WHIM trial are ongoing, we plan to present additional results at a company event and at several medical meetings during the second quarter of 2023. We are currently preparing a U.S. New Drug Application (&#8220;NDA&#8221;) seeking approval of oral, once-daily mavorixafor in the treatment of people aged 12 years and older with WHIM syndrome. This NDA submission is expected early in the second half of 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are also currently advancing mavorixafor in a Phase 2 clinical trial in people with certain chronic neutropenic disorders following positive results from a Phase 1b clinical trial of mavorixafor in people with idiopathic, cyclic, or congenital neutropenia. Participants are now being enrolled in this Phase 2 clinical trial and we expect to provide an update on clinical results in the second or third quarter of 2023. We also expect to provide clarity on the scope and timing of our planned Phase 3 chronic neutropenia clinical program in the second or third quarter of 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We believe that successfully developing mavorixafor and providing new therapeutic options to individuals diagnosed with certain chronic neutropenic disorders has the potential to revolutionize the treatment landscape, which is principally served by injectable therapies that are frequently associated with treatment-limiting adverse events.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline</span></div><div><img src="xfor-20230331_g1.jpg" alt="Pipeline_03-06-2023.jpg" style="height:294px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To date, we have not generated revenue from product sales and do not expect to generate significant revenue from the sale of our products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Macroeconomic Considerations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Unfavorable conditions in the economy in the United States and abroad may negatively affect the growth of our business and our results of operations. For example, macroeconomic events, including the COVID-19 pandemic, rising inflation, the U.S. Federal Reserve raising interest rates and the Russia-Ukraine war, have led to economic uncertainty globally. The effect of macroeconomic conditions may not be fully reflected in our results of operations until future periods. If, however, economic uncertainty increases or the global economy worsens, our business, financial condition and results of operations may be harmed. For further discussion of the potential impacts of macroeconomic events on our business, financial condition, and operating results, see the section titled &#8220;Risk Factors.&#8221;</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March 31, 2023 and 2022</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the three months ended March&#160;31, 2023 and 2022: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.399%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain of sale of non-financial asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,304)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,268)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,036)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,016)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,942)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,074)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,020)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,965)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,055)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred in connection with the discovery and development of our product candidates, including employee salaries and related expenses, preclinical and clinical development expenses for our product candidates; internal and third-party costs of manufacturing our drug products for use in our preclinical studies and clinical trials; facility, depreciation and other expenses; costs related to compliance with regulatory requirements; and payments made under third-party licensing agreements. We expense research and development costs as incurred. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:62.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.571%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="18" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Direct research and development expenses by product candidate:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mavorixafor </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,272&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X4P-002</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(817)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X4P-003</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Unallocated expense</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,706&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,986&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,063&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,113&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,950&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased $8.0 million in the three months ended March&#160;31, 2023 as compared to the same period in the prior year. Research and development expenses were higher in the current period due to higher accrued in-license fees. During the three month period ended March 31, 2023, we accrued $5.0 million related to a development milestone under </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Genzyme agreement as we believe that it is probable that the milestone will be achieved. Research and development expenses were also higher in the current period due to higher thrid party costs associated with our pivotal Phase 3 clinical trial of mavorixafor for the treatment of people aged 12 years and older with WHIM syndrome.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in sale and marketing, executive, finance and administrative functions. Selling, general and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor and public relations, accounting, and audit services. Selling, general and administrative expenses were generally consistent as compared to the prior year. We expect selling, general and administrative expenses will grow in the future as we continue to build out our selling, general and administrative functions.</span></div><div><span><br/></span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.122%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of Class C warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,288&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(674)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,962&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net, for the three months ended March&#160;31, 2023 increased as compared to the same period in the prior year primarily due to a reduction in the fair value of our Class C warrants, which were issued in the fourth quarter of 2022 and are accounted for as a liability as fair value. We value these Class C warrants using the Black-Scholes option pricing model. A 10% increase (decrease) in the price of our common stock, which is a key input to the valuation model, would result in approximately $2.3 million of expense (income), respectively. Other income (expense), net, also increased in the current period as compared to the same period in the prior year due to an increase in interest income on our money market investments due to a general increase in interest rates and an increase in our invested funds.      </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not record a U.S. federal or state income tax benefit for our losses for the three months ended March&#160;31, 2023 and 2022, respectively, due to our conclusion that a full valuation allowance is required against our U.S. federal and state deferred tax assets. For the three months ended March&#160;31, 2023 and 2022, we recorded an immaterial amount of income tax expense related to our Austrian subsidiary. </span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have funded our operations primarily with proceeds from sales of common stock, warrants and prefunded</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants for the purchase of our preferred stock and our common stock, sales of preferred stock, proceeds from the issuance of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">convertible debt and borrowings under loan and security agreements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Sales Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have entered into a Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales Agreement (&#8220;ATM Sales Agreement&#8221;), with B. Riley Securities, Inc., Cantor Fitzgerald &amp; Co., and Stifel, Nicolaus &amp; Company, Incorporated (collectively the &#8220;Sales Agents&#8221;), pursuant to which we may offer and sell, at our sole discretion through one or more of the Sales Agents, shares of our common stock having an aggregate offering price of up to $50 million. To date, we have sold approximately $14.3 million of our common stock, net of offering costs, under the ATM Sales Agreement.   </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LPC Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In January 2022, we entered into an agreement, (the &#8220;LPC Agreement&#8221;) with Lincoln Park Capital Fund LLC (&#8220;Lincoln Park&#8221;), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pursuant to which we have the right to sell to Lincoln Park shares of our common stock, having an aggregate value of up to $50.0 million, subject to certain limitations and conditions, at our request during a 36-month period. The shares of common stock that we may sell under the LPC Agreement are capped at 5.6&#160;million, which amount may be adjusted under certain conditions as defined in the LPC Agreement. In January 2022, we raised $3.0 million from the sale of shares of our common stock through the LPC Agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Public and Private Equity Offerings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past several years we have funded our operations primarily from sales of common stock, warrants and prefunded warrants through both public offerings and private placements. For example, most recently in December 2022, we sold shares of common stock and, in lieu of common stock, warrant and pre-funded warrants to purchase shares of common stock in a public offering for gross proceeds of $65.1 million, before offering expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Hercules Loan Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2023, we entered into a Second Amended and Restated Loan and Security Agreement (the &#8220;Hercules Loan Agreement&#8221;) with Hercules Capital, Inc., as agent and lender, and Hercules Capital Funding IV LLC and Hercules Capital Funding Trust 2022-1, as lenders (collectively, &#8220;Hercules&#8221;), which agreement amended and restated the Amended and Restated Loan and Security Agreement dated as of June 27, 2019, as subsequently amended from time to time (the &#8220;Previous Loan Agreement&#8221;). The Hercules Loan Agreement provides for a term loan of $32.5&#160;million and an interest-only payment period through October 1, 2024, provided however, if certain conditions are met, then the interest-only payment period will be extended to January 1, 2026. To date, we have borrowed the full $32.5 million under the Hercules Loan Agreement, and such amount remains outstanding as of  March&#160;31, 2023.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any products and we do not expect to generate revenue from sales of any products for several years, if at all. As of March&#160;31, 2023, our cash and cash equivalents were $93.4 million, and our restricted cash balance was $1.0 million. We have a covenant under our Hercules Loan Agreement that currently requires that we maintain a minimum level of cash of $20.0 million, subject to reduction to $10 million upon the achievement of operational milestones. Based on our current financial projections and with no additional funding, we believe we  will not be able to maintain the minimum cash required to satisfy this covenant beginning in the first quarter of 2024. In such event, the lenders could require the repayment of all outstanding debt.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has concluded that substantial doubt exists about our ability to continue as a going concern for the one-year period following the issuance of our condensed consolidated financial statements for the period ended March&#160;31, 2023. To finance our operations, we will need to raise additional capital, which cannot be assured. Unless and until we reach profitability in the future, we will require additional capital to fund our operations, which could be raised through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other collaborations and strategic alliances. If we are unable to obtain funding, we could be forced to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion or commercialization efforts, which would adversely affect our business prospects, or we may be unable to continue operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activities for each of the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.814%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,020)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,965)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,512)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,229)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,595)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,364)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,433&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, net cash used in operating activities was $26.5 million, primarily resulting from our net loss of $24.0 million, adjusted for noncash expenses of $3.1 million and changes in our operating assets and liabilities of $0.6 million. Non-cash expenses primarily includes the change in fair value of our Class C warrant liability, stock-based compensation expense, non-cash lease expense and non-cash interest expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March&#160;31, 2022 was $20.2 million, primarily resulting from our net losses of $22.0 million, adjusted for noncash expenses of $2.0 million and changes in our operating assets and liabilities of $0.3 million. Net cash used in operating activities increased during the three months ended March&#160;31, 2023 as compared to the same period in the prior year primarily due to an increase in our research and development expenses.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, cash used in investing activities were in each period less than $0.1 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, net cash used in financing activities was $2.1 million, consisting primarily of fees paid to Hercules for the amendment and restatement of our Hercules Loan Agreement, including the settlement of a $1.3 million end-of-term payment. During the three months ended March&#160;31, 2022, net cash provided by financing activities was $5.0 million, consisting primarily of $5.9 million of proceeds from a private placement equity offering that closed during the period and the sale of shares of our common stock to Lincoln Park, partially offset by $0.8 million of end-of-term payments made pursuant to our Hercules Loan Agreement. </span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash and cash equivalents will allow us to fund operations into the second quarter of 2024. However, as noted above, based on our current financial projections we believe we would be in violation of a minimum cash covenant of the Hercules Loan Agreement with Hercules in the first quarter of 2024. In order to fund operations and satisfy the minimum cash covenant in the Hercules Loan Agreement, we will be required to raise additional capital, which may be through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other collaborations and strategic alliances. During 2023 and beyond, assuming no changes to our current operational expectations, we expect our expenses to continue to increase in connection with our ongoing activities, particularly as we advance the current and anticipated clinical trials of our product candidates in development. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate the exact amount of our funding requirements. Our short term and long term funding requirements will depend on and could increase significantly as a result of many factors, including:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, number, initiation, progress, timing, costs, design, duration, any potential delays, and results of clinical trials and nonclinical studies for our current or future product candidates, particularly our Phase 2 clinical trial of mavorixafor for the treatment of patients with chronic neutropenic disorders;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of regulatory reviews, approvals or other actions to meet regulatory requirements established by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies for our product candidates than those that we currently expect;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain marketing approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights covering our product candidates, including any such patent claims and intellectual property rights that we have licensed from Genzyme pursuant to the terms of our license agreement with Genzyme;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Hercules Loan Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 7 to the notes to our condensed consolidated financial statements for a full description of our Hercules Loan Agreement.</span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, there were no material changes to our critical accounting policies as reported for the year ended December 31, 2022 as part of our Annual Report.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, see Note 2 of these condensed consolidated financial statements under the heading &#8220;Recently Adopted Accounting Pronouncements&#8221; for new accounting pronouncements or changes to the accounting pronouncements during the three months ended March&#160;31, 2023.</span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Smaller Reporting Company Status</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company (&#8220;SRC&#8221;) as defined by Rule 12b-2 of the Exchange Act and Item 10(f)(1) of Regulation S-K. We may take advantage of certain of the scaled disclosures available to smaller reporting companies for so long as (i) our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_97"></div><div style="margin-top:18pt;padding-left:81pt;text-indent:-81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an SRC, we are not required to provide the information requested by this Item.</span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms and accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March&#160;31, 2023, and have concluded that, based on such evaluation, our disclosure controls and procedures were effective as of March&#160;31, 2023 at the reasonable assurance level. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the three months ended March&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II: OTHER INFORMATION</span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_106"></div><div style="margin-top:18pt;padding-left:81pt;text-indent:-81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition.</span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_109"></div><div style="margin-top:18pt;padding-left:81pt;text-indent:-81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">An investment in our securities involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and related notes hereto, before deciding to invest in our common stock. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. In these circumstances, the market price of our common stock could decline and you may lose all or part of your investment. We cannot assure you that any of the events discussed below will not occur.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses and have not generated revenue from product sales since our inception. We expect to continue to incur losses for the foreseeable future and we may never achieve or maintain profitability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late clinical-stage biopharmaceutical company.</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval or become commercially viable. Since inception, we have incurred significant operating losses. Our net losses were $93.9 million, $88.7 million and $62.1 million for the years ended December 31, 2022, 2021 and 2020 respectively, and were $24.0 million for the quarter ended March&#160;31, 2023. As of March&#160;31, 2023, we had an accumulated deficit of $400.8 million. We have funded our operations to date primarily with proceeds from sales of common stock, warrants and prefunded warrants for the purchase of our preferred stock and our common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements. We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we may never generate product revenue or achieve profitability.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasing operating losses for at least the next several years as we conduct additional clinical trials for our product candidates; continue to discover and develop additional product candidates; acquire or in-license other product candidates and technologies; maintain, expand and protect our intellectual property portfolio; hire additional clinical, scientific and commercial personnel; establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval; seek regulatory approvals for any product candidates that successfully complete clinical trials; establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval; and add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business.  The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. </span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate profits from operations and thereafter to remain profitable depends heavily on:</span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, number, progress, duration, endpoints, cost, results and timing of clinical trials and nonclinical studies of our current or potential future product candidates, including in particular the scope, progress, duration, endpoints, cost, results and timing for completion of our Phase 2 clinical trial of mavorixafor for the treatment of chronic neutropenic disorders;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise sufficient funds to support the development and potential commercialization of our product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes and timing of regulatory reviews, approvals or other actions;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain marketing approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain licensing, collaboration or similar arrangements on favorable terms and whether and to what extent we retain development or commercialization responsibilities under any new licensing, collaboration or similar arrangement;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of any other business, product or technology that we acquire or in which we invest;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture any approved products on commercially reasonable terms;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish a sales and marketing organization or suitable third-party alternatives for any approved product;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of product candidates and programs that we pursue;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, regulatory and scientific personnel; and </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional legal, accounting and other expenses associated with operating as a public company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current plans, we do not expect to generate significant revenue from product sales unless and until we (or a potential future licensee or collaborator) obtain marketing approval for, and commercialize, one or more of our current or potential future product candidates. Neither we nor a licensee may ever succeed in obtaining marketing approval for, or commercializing, our product candidates and, even if we do, we may never generate revenues that are significant enough to generate profits from operations. Even if we do generate profits from operations, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to generate profits from operations and remain profitable would decrease our value and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or continue our operations. A decline in our value could also cause you to lose all or part of your investment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors that may alter or delay our plans. For example, we experienced delays in clinical trial site activation and slower patient enrollment in some of our clinical trials as a result of the COVID-19 pandemic, which delayed our expectations regarding our ability to report data from those trials. Assuming that we complete the development of and obtain marketing approval for any of our product candidates, we will need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays, and may not be successful in such a transition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our liquidity position raises substantial doubt about our ability to continue as a going concern and we will require substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate any product development programs or commercialization efforts.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be forced to delay or reduce the scope of our development programs and/or limit or cease our operations if we are unable to obtain additional funding to support our current operating plan. We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed a large amount of cash since inception. To date, we have funded our operations primarily with proceeds from sales of common stock, warrants and prefunded warrants for the purchase of our preferred stock and our common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements. We expect our research and development expenses to increase in future periods as we continue to advance the clinical development of our product candidates and prepare for the launch and commercialization of any product candidates for which we receive regulatory approval, including potentially building our own commercial organization to address the U.S. and certain other markets. In addition, if we obtain marketing approval for any of our product candidates that are not then subject to licensing, collaboration or similar arrangements with third parties, we expect to incur significant commercialization expenses related to product sales, marketing, distribution and manufacturing. Furthermore, we expect to incur additional costs associated with operating as a public company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we have cash and cash equivalents of $93.4 million. We will require additional capital to sustain our operations, and to carry out our business plans, which may include raising funds through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. While we have successfully raised capital in the past, our ability to raise capital in future periods is not assured. We will also require additional capital to satisfy the covenant under our existing debt facility with Hercules Capital, Inc. and certain affiliated entities (&#8220;Hercules&#8221;) that requires that we maintain a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">minimum level of cash of $20.0 million, subject to reduction to $10.0 million upon the achievement of certain conditions. Based on our current cash flow projections and assuming no additional funding, we will fail to maintain the minimum cash required to satisfy this covenant as soon as the first quarter of 2024. In such event, Hercules could require the repayment of all outstanding debt. Based on the foregoing, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least 12 months from the date of issuance of the financial statements appearing elsewhere in this Quarterly Report. Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainty described above. See also the risk factor titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our term loan contains restrictions that limit our flexibility in operating our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that additional funding will be available on acceptable terms, or at all. If we are unable to raise additional capital when needed or in sufficient amounts or on terms acceptable to us, we could be forced to delay, reduce or eliminate our &#160;&#160;&#160;&#160;research and development programs or any future commercialization efforts of one or more of our product candidates or one or more of our other research and development initiatives. In addition, when we need to secure additional financing, such additional fundraising efforts may divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Any of these events could significantly harm our business, financial condition and prospects, and our stockholders could lose all or part of their investment in our company. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also could be required to:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">seek new or additional collaborators for one or more of our current or future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; or</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">relinquish or license on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the scope, number, initiation, progress, timing, costs, design, duration, any potential delays, and results of clinical trials and nonclinical studies for our current or future product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the clinical development plans that we establish for these product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number and characteristics of product candidates and programs that we develop or may in-license;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the outcome, timing and cost of regulatory reviews, approvals or other actions to meet regulatory requirements established by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies for our product candidates than those that we currently expect;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to obtain marketing approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights covering our product candidates, including any such patent claims and intellectual property rights that we have licensed from Genzyme pursuant to the terms of our license agreement with Genzyme or from other third parties;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost and timing of completion of commercial-scale manufacturing activities with respect to our product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to establish and maintain licensing, collaboration or similar arrangements on favorable terms and whether and to what extent we retain development or commercialization responsibilities under any new licensing, collaboration or similar arrangement;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the success of any other business, product or technology that we acquire or in which we invest;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs of acquiring, licensing or investing in businesses, product candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our need and ability to hire additional management and scientific and medical personnel;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">market acceptance of our product candidates, to the extent any are approved for commercial sale;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the effect of competing technological and market developments;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the costs to operate as a public company; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">business interruptions resulting from pandemics and public health emergencies, including those related to the COVID-19 pandemic, geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods and fires.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our investors, restrict our operations or require us to relinquish rights to our technologies or product candidates. Future debt obligations may expose us to risks that could adversely affect our business, operating results and financial condition and may result in further dilution to our stockholders.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. Other than our common stock purchase agreement with Lincoln Park Capital Fund LLC (&#8220;Lincoln Park&#8221;), pursuant to which Lincoln Park is obligated, subject to certain limitations and conditions, to purchase up to $50.0 million in the aggregate of shares of our common stock, we do not have any committed external sources of funds and may seek to raise additional capital at any time. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends or other distributions, acquiring or licensing intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business and may result in liens being placed on additional assets such as intellectual property. For example, our debt facility with Hercules contains a minimum cash financial covenant that we project we would be in violation of in the first quarter of 2024 based on our current cash flow projections, assuming we do not raise additional funding. If we default on such indebtedness, with Hercules or a future lender, we could be required to pledge additional assets, or the lenders could enforce remedies on the current collateral. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through licensing, collaboration or similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research and development programs or product candidates or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financings or through licensing, collaboration or similar arrangements when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not generated revenues from any product sales since inception and may never become profitable.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated revenues from any product sales. Our ability to generate revenue and become profitable depends upon our ability to successfully obtain marketing approval and commercialize our product candidates, including mavorixafor, or other product candidates that we may develop, in-license or acquire in the future. Even if we are able to successfully achieve regulatory approval for these product candidates, we are unable to predict the extent of any future losses and do not know when any of these product candidates will generate revenue for us, if at all. Our ability to generate revenue from mavorixafor or any of our current or future product candidates also depends on a number of additional factors, including our ability to:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">successfully complete development activities, including all necessary nonclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">complete and submit New Drug Applications to the FDA and obtain regulatory approval for indications for which there is a commercial market;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">complete and submit marketing applications to, and obtain regulatory approval from, foreign regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">set and obtain a commercially viable price for our products;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtain commercial quantities of our products at acceptable cost levels;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">develop a commercial organization capable of sales, marketing and distribution for the products we intend to sell ourselves in the markets in which we have retained commercialization rights;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">find suitable collaborators to help us market, sell and distribute our approved products in other markets; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtain coverage and adequate reimbursement from third-party, including government, payors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because of the numerous risks and uncertainties associated with product development, including the possibility that our product candidates may not advance through development or demonstrate safety and efficacy for their intended uses, the FDA or any other regulatory agency may require additional clinical trials or nonclinical studies. We are unable to predict the timing or amount of increased expenses, or when or if we will be able to achieve or maintain profitability, and such expense could increase beyond our expectations if the FDA or any other regulatory agency requires such additional clinical trials or nonclinical studies as part of the application and approval process or post-approval process if we are successful at achieving regulatory approval. Even if we are able to successfully complete the development and regulatory reviews described above, we anticipate incurring significant costs associated with commercializing these products, if they are approved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to generate revenues from the sale of our product candidates, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our discovery and preclinical development efforts, expand our business or continue our operations and may require us to raise additional capital that may dilute your ownership interest. A decline in our value could also cause you to lose all or part of your investment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in estimates regarding fair value of intangible assets may result in an adverse impact on our results of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test goodwill for impairment annually or more frequently if changes in circumstances or the occurrence of events suggest impairment exists. Any significant change in market conditions, including a sustained decline in our stock price, that indicate a reduction in carrying value may give rise to impairment in the period that the change becomes known. For example, as of December 31, 2021, our market capitalization, measured as the price of our common stock multiplied by shares of common stock outstanding, declined to below the value of our net assets, including goodwill. As a result of the sustained decline in the market price of our common stock, the fair value of our single reporting unit, measured based on our market capitalization as of December 31, 2021, was lower than its carrying value and we concluded that goodwill was impaired. Accordingly, we recorded an impairment charge of $9.8 million to reduce the carrying amount of goodwill to $17.4 million as of December 31, 2021. While we determined that goodwill was not impaired based on its quantitative test as of December 31, 2022, future declines in the market value of our common stock may result in additional impairment charges being recorded.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Development of Our Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend almost entirely on the success of our lead product candidate, mavorixafor, which we are developing for the potential treatment of chronic neutropenic disorders, including WHIM syndrome, and, contingent on a potential strategic partnership, for the treatment of Waldenstr&#246;m&#8217;s. We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, mavorixafor or any other product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends almost entirely on the successful clinical development, regulatory approval and commercialization of mavorixafor. We currently have no products for sale and may never be able to develop marketable drug products. The clinical trials of our product candidates are, and the manufacturing and marketing of our product candidates will be, subject to extensive and rigorous review and regulation by government authorities in the United States and in other countries where we intend to test and, if approved, market any product candidate. Before obtaining regulatory approvals for the commercial sale of any product candidate, we must successfully meet a number of critical developmental milestones, including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">developing dosages that will be well-tolerated, safe and effective;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">completing the development and scale-up to permit manufacture of our product candidates in commercial quantities and at acceptable costs;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">demonstrating through pivotal clinical trials that each product candidate is safe and effective in patients for the intended indication;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time necessary to achieve these developmental milestones for any individual product candidate is long and uncertain, and we may not successfully complete these milestones for mavorixafor or any other product candidates that we may develop. We have not yet completed development of any product candidate. We also may not be able to finalize the design or formulation for our other programs. We may not be able to complete development of any product candidates that demonstrate safety and efficacy and that will have a commercially reasonable treatment and storage period. If we are unable to complete development of mavorixafor or any other product candidates that we may develop, we will not be able to commercialize and earn revenue from them.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may develop mavorixafor, and potentially future product candidates, in combination with other therapies, which could expose us to additional risks.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may develop mavorixafor, and may develop future product candidates, in combination with one or more currently approved therapies. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are commonly used for the treatment of diseases, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs. This could result in our own products being removed from the market or being less successful commercially.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also evaluate mavorixafor or any other future product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States. We will not be able to market and sell mavorixafor or any product candidate we develop in combination with any such unapproved therapies that do not ultimately obtain marketing approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the drugs that we choose to evaluate in combination with mavorixafor or any product candidate we develop, we may be unable to obtain approval of or market mavorixafor or any product candidate we develop.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory review and approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, including mavorixafor, our business will be substantially harmed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not permitted to market mavorixafor or any other product candidate in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until we receive the requisite approval from such countries or jurisdictions, such as the marketing authorization application (&#8220;MAA&#8221;) in the European Union from the European Medicines Agency (&#8220;EMA&#8221;). Prior to submitting an NDA to the FDA for approval of mavorixafor for the treatment of WHIM syndrome, we will need to complete the analysis of the data collected in our Phase 3 pivotal clinical trial of mavorixafor in patients with WHIM syndrome. Our NDA submission may receive a refusal to file response from the FDA, and even if filed by the FDA, we may receive a Complete Response Letter rather than approval for commercial marketing. In addition, we may be required by the FDA to conduct additional clinical trials and/or nonclinical studies to support potential approval. Successfully completing clinical trials and obtaining approval of an NDA is a complex, lengthy, expensive and uncertain process, and the FDA, or a comparable foreign regulatory authority, may delay, limit or deny approval of mavorixafor for the treatment of WHIM syndrome or other indications for many reasons, including, among others:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">disagreement with the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">disagreement with the sufficiency of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure to demonstrate the safety and efficacy of mavorixafor or any other product candidate for its proposed indications;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure to demonstrate that any clinical and other benefits of mavorixafor or any other product candidate outweigh its safety risks;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a negative interpretation of the data from our nonclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">deficiencies in the manufacturing or control processes or failure of third-party manufacturing facilities with which we contract for clinical and commercial supplies to comply with current Good Manufacturing Practice requirements, or cGMPs;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">insufficient data collected from clinical trials of mavorixafor or changes in the approval requirements that render its nonclinical and clinical data insufficient to support the filing of an NDA or to obtain regulatory approval; or</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in clinical practice in or approved products available for the treatment of the target patient population that could have an impact on the indications that we are pursuing for mavorixafor or our other product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or a comparable foreign regulatory authority may also require more information, including additional nonclinical or clinical data to support approval, which may delay or prevent approval of our commercialization plans, or cause us to abandon the development program. Even if we obtain regulatory approval, our product candidates may be approved for fewer or more limited indications than we request, such approval may be contingent on the performance of costly post-marketing clinical trials, or we may not be allowed to include the labeling claims necessary or desirable for the successful commercialization of such product candidate. For instance, it is possible that mavorixafor could be approved for an indication but fail to be used for treating patients in that indication due to the availability of other available treatments or then-accepted clinical practice.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on license agreements with Genzyme, Beth Israel Deaconess Medical Center, Georgetown University and Dana-Farber Cancer Institute to permit us to use patents and patent applications. Termination of these rights or the failure to comply with obligations under these agreements could materially harm our business and prevent us from developing or commercializing our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to license agreements with Genzyme, Beth Israel Deaconess Medical Center, Georgetown University and Dana-Farber Cancer Institute under which we were granted rights to patents and patent applications that are important to our business. We rely on these license agreements in order to be able to use various proprietary technologies that are material to our business, including certain patents and patent applications that cover our product candidates, including mavorixafor. Our rights to use these patents and patent applications and employ the inventions claimed in these licensed patents are subject to the continuation of and our compliance with the terms of our license agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our license agreement with Genzyme imposes upon us various diligence, payment and other obligations, including the following:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our obligation to pay Genzyme milestone payments in the aggregate amount of up to $25.0 million, contingent upon our achievement of certain late-stage regulatory and sales milestones with respect to licensed products.</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our obligation to pay Genzyme tiered royalties based on net sales of licensed products that we commercialize under the agreement.</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our obligation to pay Genzyme a certain percentage of cash payments received by us or our affiliates in consideration for the grant of a sublicense under the license granted to us by Genzyme.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with any of our obligations under the Genzyme license agreement, or we are subject to a bankruptcy, Genzyme may have the right to terminate the license agreement, in which event we would not be able to market any product candidates covered by the license.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to July 2014, we did not control the prosecution, maintenance, or filing of the patents and patent applications that are licensed to us under the Genzyme license agreement, or the enforcement of these patents and patent applications against infringement by third parties. Thus, these patents and patent applications were not drafted by us or our attorneys, and we did not control or have any input into the prosecution of these patents and patent applications prior to our execution of the Genzyme license agreement in July 2014. Under the terms of the license agreement with Genzyme, since July 2014, we have controlled the right to control the prosecution, maintenance, and filing of the patents and patent applications that are licensed to us, and the enforcement of these patents and patent applications against infringement by third parties. However, we cannot be certain that the same level of attention was given to the drafting and prosecution of these patents and patent applications as we may have used if we had control over the drafting and prosecution of such patents and patent applications. We also cannot be certain that drafting or prosecution of the patents and patent applications licensed to us has been conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our license agreement with Beth Israel Deaconess Medical Center, we paid an upfront, one-time fee for the rights granted by the license agreement. This license agreement imposes upon us various obligations, including the requirement to provide Beth Israel Deaconess Medical Center with progress reports at regular intervals and to maintain specified levels of insurance. Beth Israel Deaconess Medical Center may terminate the agreement for our non-payment, insolvency or default of material obligations. We have the right to terminate the agreement for any reason upon 90 days&#8217; advance written notice.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our license agreement with Georgetown imposes upon us various diligence, payment and other obligations, including our obligations to pay Georgetown milestone payments in the aggregate amount of up to $0.8 million, contingent upon our achievement of certain sales milestones with respect to licensed products, to deliver reports upon certain events and at regular intervals and to maintain customary levels of insurance. Georgetown may terminate the agreement for our non-payment, insolvency, failure to maintain insurance or default of material obligations. We have the right to terminate the agreement for any reason upon 60 days advance written notice.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our license agreement with the Dana-Farber Cancer Institute (&#8220;DFCI&#8221;) imposes upon us various diligence, payment and other obligations, including our obligations to pay DFCI milestone payments in the aggregate amount of up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $32 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, contingent upon our achievement of certain regulatory and sales milestones with respect to licensed products, to deliver reports at regular intervals and to maintain certain minimum levels of insurance.  DFCI may terminate the agreement if (i) we cease to carry on our business with respect to the licensed products, (ii) we default on diligence, insurance, payment or any other material obligations, (iii) one of our officers or that of a sublicensee is convicted of a felony relating to the manufacture, use, sale or importation of one or more licensed product, (iv) we become insolvent, (v) we grant a sublicense without notifying DFCI or on terms inconsistent with the terms required of sublicenses under the agreement or (vi) we bring a patent challenge against the licensed products. We have the right to terminate the agreement for any reason upon 90 days advance written notice.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise under any of our license agreements with Genzyme, Beth Israel Deaconess Medical Center, Georgetown University and/or Dana-Farber Cancer Institute regarding the intellectual property that is subject to such license agreement, including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the scope of rights granted under the applicable license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">whether and the extent to which our technology and processes infringe on intellectual property that is not subject to the applicable license agreement;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our diligence obligations with respect to the use of the licensed technology under the applicable license agreement to develop and commercialize products and technologies, including the level of effort and specific activities that will satisfy those diligence obligations; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by us and our collaborators.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain any of our license agreements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates and technologies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of clinical trials may not support our product candidate claims.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our clinical trials are completed as planned, we cannot be certain that their results will support the proposed product candidates, that the FDA or foreign government authorities will agree with our conclusions regarding such results, or that the FDA or foreign governmental authorities will not require additional clinical trials. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful and the results of later clinical trials often do not replicate the results of prior clinical trials and preclinical testing. The clinical trial results may fail to demonstrate that our product candidates are safe for humans and effective for the intended indications. This failure could cause us to abandon a product candidate and may delay development of other product candidates. Any delay in, or termination of, our clinical trials will delay or prevent the submission of our marketing applications (NDA and/or MAA) and, ultimately, our ability to obtain approval and commercialize our product candidates and generate product revenues. Information about certain clinical trials, including results (positive or negative) will be made public according to each country&#8217;s clinical trial register policies. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in our clinical trials may lead to a delay in the submission of our marketing approval application and jeopardize our ability to potentially receive approvals and generate revenues from the sale of our products.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience delays in our current or future clinical trials, including our Phase 2 clinical trial of mavorixafor for the treatment of chronic neutropenic disorders. As a result of the COVID-19 pandemic, we experienced delays in clinical trial site activation and slower patient enrollment in our clinical trials of mavorixafor for the treatment of WHIM syndrome, Waldenstr&#246;m&#8217;s and chronic neutropenia disorders.  Clinical trials may be delayed, suspended or terminated for a variety of reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in reaching agreement with the FDA or a comparable foreign regulatory authority on a trial design that we are able to execute;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in obtaining authorization to commence a trial or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a clinical trial;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">inability, delay or failure in identifying and maintaining a sufficient number of trial sites, many of which may already be engaged in competing clinical trial programs;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in recruiting and enrolling suitable subjects to participate in a trial;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in having subjects complete a trial or return for post-treatment follow-up;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">clinical sites and investigators deviating from trial protocol, failing to conduct the trial in accordance with regulatory requirements, or dropping out of a trial;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delay or failure in obtaining institutional review board (&#8220;IRB&#8221;) approval to conduct a clinical trial at each site;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays resulting from negative or equivocal findings of the Data Safety Monitoring Board (&#8220;DSMB&#8221;) if any;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">ambiguous or negative results;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">decision by the FDA, a comparable foreign regulatory authority, or recommendation by a DSMB to suspend or terminate clinical trials at any time for safety issues or for any other reason;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">inadequate drug product for use in nonclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">lack of adequate funding to continue the product development program; </span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">external business disruptions affecting the initiation, patient enrollment, development and operation of our clinical trials, including a public health emergency, such as the COVID-19 pandemic, and unforeseen events such as the war in Ukraine; or </span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in governmental regulations or requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to enroll a sufficient number of patients in our clinical trials in a timely manner, which could delay or prevent clinical trials of our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on the rate at which we can recruit, enroll and retain patients in testing our product candidates, and we have made certain assumptions about the rate at which we can enroll patients in our clinical trials. The timing of our clinical trials depends in part on the speed at which we can recruit patients to participate in testing mavorixafor and any other current or future product candidates that we may develop as well as completion of required follow-up periods. For example, as a result of the COVID-19 pandemic, we have experienced, and expect to continue to experience, a slower enrollment pace.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot identify patients to participate in our clinical trials or if patients are unwilling to participate in our clinical trials for any reason, including if patients choose to enroll in competitive clinical trials for similar patient populations, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of mavorixafor and any other current or future product candidates that we may develop may be delayed. These delays could result in increased costs, delays in advancing our current or future product candidates, delays in testing the effectiveness of our product candidates or termination of the clinical trials altogether.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a trial, to complete our current and future clinical trials in a timely manner. In particular, we are currently evaluating mavorixafor for the treatment of WHIM syndrome and chronic neutropenic disorders, rare diseases with limited patient pools from which to draw for clinical trials. The eligibility criteria of our clinical trials will further limit the pool of available trial participants. If we experience difficulty enrolling a sufficient number of patients to conduct our clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials as planned, we may be forced to delay, limit or terminate ongoing or planned clinical trials of our product candidates, which would delay our ability to obtain approvals and generate product revenues from any of these product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the commercial opportunity for mavorixafor in chronic neutropenic disorders, including WHIM syndrome, is smaller than we anticipate, our potential future revenue from mavorixafor for the treatment of any of the diseases may be adversely affected and our business may suffer.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the size of the commercial opportunities in any of our target indications is smaller than we anticipate, we may not be able to achieve profitability and growth. Our lead clinical candidate, mavorixafor, is being developed as an oral, once-daily therapy for the potential treatment of a variety of chronic neutropenic disorders, including WHIM syndrome. We have advanced mavorixafor through a pivotal, Phase 3 clinical trial (the &#8220;4WHIM trial) in people with WHIM syndrome, and are currently advancing mavorixafor in a Phase 2 clinical trial in people with certain chronic neutropenic disorders. We are currently aware of only a few small available patient registries for WHIM syndrome, and we rely on various estimates and assumptions to estimate the addressable WHIM syndrome population. Based on a broad online survey of physicians to validate current prevalence estimates and additional research using artificial intelligence, which interrogated a database of more than 300 million anonymized patient records that spanned 10 years of insurance claims, we estimate there are up to 3,700 diagnosed and undiagnosed WHIM patients in the United States, many of whom were previously undiagnosed. If the commercial opportunity in any of our target indications, including WHIM syndrome is smaller than we anticipate, whether because our estimates of the addressable patient population prove to be incorrect or for other reasons, our potential future revenue from mavorixafor may be adversely affected and our business may suffer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is critical to our ability to grow and become profitable that we successfully identify patients with WHIM syndrome and other chronic neutropenic disorders. Our projections of the number of people who have WHIM syndrome (or its other potential primary immunodeficiencies) and chronic neutropenic disorders are based on a variety of sources, including third-party estimates and analyses in the scientific literature, and may prove to be incorrect. Further, new information may emerge that changes our estimate of the prevalence of these diseases or the number of patient candidates for each disease. The effort to identify patients for treatment is at an early stage, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally, the addressable patient population for our indications may be limited or may not be amenable to treatment with mavorixafor, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of pre-clinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Interpretation of results from early, usually smaller, trials that suggest positive trends in some subjects, require caution. Results from later stages of clinical trials enrolling more subjects may fail to show the desired safety and efficacy results or otherwise fail to be consistent with the results of earlier trials of the same product candidate. Inconsistencies may occur for a variety of reasons, including differences in trial design, trial endpoints (or lack of trial endpoints in exploratory studies), subject population, number of subjects, subject selection criteria, trial duration, drug dosage and formulation or due to the lack of statistical power in the earlier trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit, or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including due to changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim top-line or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Preliminary or top-line data may include, for example, data regarding a small percentage of the patients enrolled in a clinical trial, and such preliminary data should not be viewed as an indication, belief or guarantee that other patients enrolled in such clinical trial will achieve similar results or that the preliminary results from such patients will be maintained. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Marketing and Commercialization of Our Product Candidates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties and any approved products will be subject to extensive post-approval regulatory requirements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain regulatory approval for a product candidate, it would be subject to extensive ongoing requirements by the FDA and comparable foreign regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage, distribution, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety and other post-market information. The safety profile and efficacy of any product will continue to be closely monitored by the FDA and comparable foreign regulatory authorities after approval. If the FDA or comparable foreign regulatory authorities become aware of new safety information after approval of any of our product candidates, these regulatory authorities may require labeling changes or the FDA may require establishment of a Risk Evaluation Mitigation Strategy (&#8220;REMS&#8221;), or similar strategy, impose significant restrictions on a product&#8217;s indicated uses or marketing, impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. Progress reports are required at quarterly intervals, every six months and at annual intervals depending upon the country, and more frequently if serious adverse events occur.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, manufacturers of drugs and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations. If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with cGMPs and other applicable regulatory requirements, the FDA may, among other things:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">issue warning letters;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">request modifications to promotional materials or require us to provide corrective information to healthcare practitioners;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">seek an injunction or impose civil or criminal penalties or monetary fines;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspend or withdraw regulatory approval;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspend any ongoing clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">refuse to approve pending applications or supplements to applications filed by us;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our products and generate revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found or alleged to have improperly promoted off-label uses, we may become subject to significant liability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about drug products. These regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and off-label promotion. For example, any regulatory approval that the FDA grants is limited to those indications and patient populations for which a drug is deemed to be safe and effective by the FDA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While physicians in the United States may choose, and are generally permitted, to prescribe products for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, our ability to promote any of our products candidates, if approved, will be narrowly limited to those indications and populations that are specifically approved by the FDA or such other regulatory agencies, and if we are found to have promoted such off-label uses, we may become subject to significant liability. For example, the federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The government has also required companies to enter into consent decrees or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakthrough therapy designation or Fast Track designation by the FDA for our product candidates may not lead to a faster development or regulatory review or approval process, and neither of these designations increases the likelihood that our product candidates will receive marketing approval.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained both breakthrough therapy and Fast Track designations for mavorixafor for the treatment of adult patients with WHIM and we may pursue those designations for other product candidates as well. A breakthrough therapy is defined as a product that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. A breakthrough therapy designation affords the possibility of rolling review, enabling the FDA to review portions of our marketing application before submission of a complete application, and possibly, priority review. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a drug or biologic candidate is intended for the treatment of a serious or life-threatening condition or disease and the drug demonstrates the potential to address unmet medical needs for the condition, the sponsor may apply for Fast Track designation. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designation as a breakthrough therapy and Fast Track designation are within the discretion of the FDA. Accordingly, even if we believe that our product candidates meet the criteria for designation as a breakthrough therapy or Fast Track designation, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of either or both of a breakthrough therapy designation or Fast Track designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies or for Fast Track designation, the FDA may later decide that the products no longer meet the conditions for qualification.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is possible that we may not be able to obtain or maintain orphan drug designation or exclusivity for our drug candidates, which could limit the potential profitability of our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for the treatment or prevention of rare diseases or conditions with relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the (&#8220;Orphan Drug Act&#8221;), the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is defined as a patient population of fewer than 200,000 individuals in the United States. We received orphan drug designation from the FDA for mavorixafor for the treatment of WHIM syndrome in October 2018, and from the EMA in July 2019. We also received orphan drug designation in the U.S. for mavorixafor for the treatment of Waldenstr&#246;m&#8217;s macroglobulinemia in June 2022. If a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for the same indication during that time period with some exceptions. A similar provision in the European Union allows 10 years of exclusivity in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that marketing exclusivity is no longer justified. Orphan drug exclusivity may be lost in both the United States and Europe under certain situations, such as the inability of the holder of the orphan drug designation to produce sufficient quantities of the drug to meet the needs of patients with the rare disease or condition or for certain other reasons.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA has granted rare pediatric disease designation for mavorixafor for the treatment of WHIM syndrome, however, there is no guarantee that FDA approval of mavorixafor for WHIM will result in a priority review voucher.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; that meets certain criteria may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has granted rare pediatric disease designation for mavorixafor for the treatment of WHIM syndrome, however, there is no guarantee that we will be able to obtain a priority review voucher, even if mavorixafor is approved by the FDA. Specifically, FDA may not award the voucher to sponsors of marketing applications unless either (i) the drug has received rare pediatric disease designation as of September 30, 2024 and is then approved by the FDA no later than September 30, 2026; or (ii) Congress reauthorizes the program. Even though we received rare pediatric disease designation by the current statutory deadline of September 30, 2024 we may not receive the voucher if we do not obtain approval by September 2026. Even if legislation is enacted that extends the date by which approval of the rare pediatric disease-designated drug must obtain approval to receive a priority review voucher, we may not obtain approval by that date, and even if we do, we may not obtain a priority review voucher. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish sales and marketing capabilities to market and sell our product candidates, we may be unable to generate any revenue.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are ultimately successful in obtaining regulatory approval of mavorixafor for the treatment of WHIM syndrome or another indication, in order to market and sell mavorixafor and our other product candidates in development, we currently intend to build and develop our own sales, marketing and distribution operations. Although our management team has previous experience with such efforts, there can be no assurance that we will be successful in building these operations. If we are unable to establish adequate sales, marketing and distribution capabilities, we may not be able to generate product revenue and may not become profitable. We will also be competing with many companies that currently have extensive and well-funded sales and marketing operations. If any of our product candidates are approved, we may be unable to compete successfully against these more established companies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among hospitals, physicians, patients and healthcare payors.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for any of our product candidates that we may develop or acquire in the future, the product may not gain market acceptance among hospitals, physicians, health care payors, patients and the medical community. Market acceptance of any of our product candidates for which we receive approval depends on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the efficacy and safety of such product candidates as demonstrated in clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the clinical indications for which the product candidate is approved;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">acceptance by major operators of hospitals, physicians and patients of the product candidate as a safe and effective treatment, particularly the ability of mavorixafor and our other product candidates to establish themselves as a new standard of care in the treatment paradigm for the indications that we are pursuing;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the potential and perceived advantages of our product candidates over alternative treatments as compared to the relative costs of the product candidates and alternative treatments;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the prevalence and severity of any side effects with respect to our product candidates, including mavorixafor;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our ability to offer any approved products for sale at competitive prices;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the timing of market introduction of our products as well as competitive products;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our pricing, and the availability of coverage and adequate reimbursement by third party payors and government authorities;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">relative convenience and ease of administration; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the effectiveness of our sales and marketing efforts and those of our potential future collaborators.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be delays in getting our product candidates, if approved, on hospital or insurance formularies or limitations on coverages that may be available in the early stages of commercialization for newly approved drugs. If any of our product candidates are approved but fail to achieve market acceptance among hospitals, physicians, patients or health care payors, we will not be able to generate significant revenues, which would have a material adverse effect on our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including marketing withdrawal.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by any of our product candidates that we may develop or acquire could cause us or the FDA or other regulatory authorities to interrupt, delay or halt our clinical trials and could result in more restrictive labels or the delay or denial of marketing approval by the FDA or other regulatory authorities of such product candidates. Results of our clinical trials </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. In addition, any drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. If our product candidates receive marketing approval and we or others identify undesirable side effects caused by such product candidates (or any other similar drugs) after such approval, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory authorities may withdraw or limit their approval of such product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory authorities may require the addition of labeling statements, such as a &#8220;boxed&#8221; warning or a contraindication;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be required to change the way such product candidates are distributed or administered, conduct additional clinical trials or change the labeling of the product candidates;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory authorities may require a Risk Evaluation and Mitigation Strategy plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may be subject to regulatory investigations and government enforcement actions;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we may decide to remove such product candidates from the marketplace after they are approved;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we could be sued and held liable for injury caused to individuals exposed to or taking our product candidates; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our reputation may suffer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidates and could substantially increase the costs of commercializing our product candidates, if approved, and significantly impact our ability to successfully commercialize our product candidates and generate revenues.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product candidate for which we obtain marketing approval could be subject to marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate for which we obtain marketing approval will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements, quality assurance and corresponding maintenance of records and documents and requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">restrictions on such products, manufacturers or manufacturing processes;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">restrictions on the labeling, marketing, distribution or use of a product;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">requirements to conduct post-approval clinical trials;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">warning or untitled letters;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">withdrawal of the products from the market;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">recall of products;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">fines, restitution or disgorgement of profits or revenue;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">refusal to permit the import or export of our products;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">product seizure; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">injunctions or the imposition of civil or criminal penalties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If, in the future, we are unable to establish sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to other third parties. In the future, we may choose to build a focused sales and marketing infrastructure to sell some of our product candidates if and when they are approved.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are risks involved both with establishing our own sales and marketing capabilities and with entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the inability of sales personnel to obtain access to physicians or educate adequate numbers of physicians on the benefits of prescribing any future products; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of these product revenue to us may be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition that may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing our lead product candidate, mavorixafor, for the treatment of chronic neutropenic disorders, including WHIM syndrome. We are aware of other companies that are developing CXCR4 inhibitors that are in a similar stage of development as mavorixafor, including BioLineRx, Noxxon, Upsher-Smith, Polyphor and Glycomimetics. To our knowledge, there do not appear to be any competitors with programs in development for WHIM syndrome or chronic neutropenia disorders. With respect to chronic neutropenia, filgrastim injections (human granulocyte colony-stimulating factor (G-CSF)) and two biosimilars (Zarxio and Nivestym) are FDA-approved to reduce the incidence and duration of after affects of severe neutropenia </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e.g.&#8218; fever&#8218; infections&#8218; oropharyngeal ulcers) in symptomatic patients with congenital neutropenia&#8218; cyclic neutropenia&#8218; or idiopathic neutropenia</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many diseases, these drugs are administered in combination to enhance efficacy. Some of the currently approved drug therapies are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well-established therapies and are widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic products. We expect that if any of our product candidates are approved, they will be priced at a significant premium over competitive generic products. This may make it difficult for us to achieve our business strategy of using our product candidates in combination with existing therapies or replacing existing therapies with our product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may develop products that are more effective, have a better safety profile, are more convenient or less costly than any that we are developing or that would render our product candidates obsolete or non-competitive. Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their products sooner than we may obtain approval for our product candidates, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties may compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval for our product candidates outside of the United States, which would limit our market opportunities and could harm our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval of a product candidate in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. If regulatory approval is obtained, sales of any future product candidates outside of the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a product candidate, comparable foreign regulatory authorities also must approve the manufacturing and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for any product candidates, if approved, is also subject to approval. Obtaining approval for any future product candidates in the European Union from the European Commission following the opinion of the European Medicines Agency, if we choose to submit a marketing authorization application there, would be a lengthy and expensive process. Even if a product candidate is approved, the FDA or the European Commission, as the case may be, may limit the indications for which the drug may be marketed, require extensive warnings on the drug labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of any future product candidates in certain countries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for our product candidates may be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects could be harmed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we seek approval to commercialize our product candidates outside of the United States, a variety of risks associated with international operations could harm our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we seek approval of our product candidates outside of the United States, we expect that we will be subject to additional risks in commercialization including:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">different regulatory requirements for approval of therapies in foreign countries;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">reduced protection for intellectual property rights;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">foreign reimbursement, pricing and insurance regimes;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters and public health epidemics, such as the COVID-19 pandemic.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by many of the individual countries in and outside of Europe with which we will need to comply. Many biopharmaceutical companies have found the process of marketing their own products in foreign countries to be very challenging.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize mavorixafor or any other product candidate that we develop, the product may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws and regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted and, in some markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize mavorixafor or any other product candidate successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. and E.U. healthcare industries and elsewhere is cost containment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage and reimbursement will be available for mavorixafor or any other product that we commercialize and, if coverage and reimbursement is available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for mavorixafor may be particularly difficult because of the higher prices typically associated with drugs directed at smaller populations of patients. In addition, third-party payors are likely to impose strict requirements for reimbursement of a higher priced drug, and any launch of a competitive product is likely to create downward pressure on the price initially charged. If reimbursement is not available or is available only to a limited degree, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the applicable regulatory authority. Moreover, eligibility for coverage and reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including research, development, intellectual property, manufacturing, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs, and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. In the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. In the European Union, reference pricing systems and other measures may lead to cost containment and reduced prices. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to develop product candidates and commercialize products and our overall financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit the commercialization of any product candidates we may develop.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk with respect to commercial sales of any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">reduced resources of our management to pursue our business strategy;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">decreased demand for any products that we may develop;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">withdrawal of clinical trial participants; </span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">significant costs to defend any related litigation;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">increased insurance costs; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the inability to commercialize any products that we may develop.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain clinical trial insurance coverage, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we continue clinical trials or begin commercialization of any products. Insurance coverage is increasingly expensive. We may not be able to obtain or maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to significant penalties, including administrative, civil and criminal penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any drugs on the market, we are, and once we begin commercializing our product candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in the jurisdictions in which we conduct our business. Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements and relationships through which we research, as well as market, sell and distribute any products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid; a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the federal false claims laws impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; in addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the federal physician payment transparency requirements, sometimes referred to as the &#8220;Sunshine Act&#8221; under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively the &#8220;ACA&#8221;), require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), information related to payments and other transfers of value to physicians, (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals and the ownership and investment interests of physicians and their immediate family members in such manufacturers;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates and their subcontractors &#160;&#160;&#160;&#160;that perform certain services involving the use or disclosure of individually identifiable health information, and their subcontractors that use, disclose, or otherwise process individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, drug pricing or marketing expenditures;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">state and local laws that require the registration of pharmaceutical sales representatives; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">state and foreign laws also govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to it, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict post-approval activities and affect our ability to sell profitably any product candidates for which we obtain marketing approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Medicare covers certain drug purchases by the elderly and eligible disabled people and introduced a reimbursement methodology based on average sales prices for physician-administered drugs. In addition, Medicare may limit the number of drugs that will be covered in any therapeutic class. Ongoing cost reduction initiatives and future laws could decrease the coverage and price that we will receive for any approved products. While Medicare beneficiaries are limited to most elderly and certain disabled individual, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the ACA became law. The ACA is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Among the provisions of the ACA of importance to our product candidates are the following:</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">extension of manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expansion of eligibility criteria for Medicaid programs;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expansion of the entities eligible for discounts under the Public Health Service Act&#8217;s pharmaceutical pricing program;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">new requirements to report to CMS financial arrangements with physicians, as defined by such law, and teaching hospitals;</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a new requirement to annually report to FDA drug samples that manufacturers and distributors provide to physicians; and</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been challenges to certain aspects of the ACA. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program.It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Presidential executive orders, Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; for such drugs and biologics under the law, and (ii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.HHS has and will continue to issue and update guidance as these programs are implemented. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. Further, in response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, Congress is considering additional health reform measures. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what healthcare reform initiatives may be adopted in the future. However, we expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we will receive for any approved product. These new laws may result in additional reductions in Medicare and other healthcare funding. Any reduction in payments from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals, if any, of our product candidates may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing conditions and other requirements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect its business, results of operations and financial condition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) and other anti-corruption laws that apply in countries where we do business and may do business in the future. The FCPA and these other laws generally prohibit us, our officers and employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential FCPA violations, and may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which its international operations might be subject or the manner in which existing laws might be administered or interpreted.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to other laws and regulations governing our international operations, including regulations administered by the U.S. government and authorities in the European Union or the United Kingdom, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, which we collectively refer to as Trade Control Laws.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA or other legal requirements, including Trade Control Laws. If we are not in compliance with the FCPA and other anti-corruption laws or Trade Control Laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the FCPA, other anti-corruption laws or Trade Control Laws by U.S. or other authorities could also have an adverse impact on our reputation, business, results of operations and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no experience manufacturing our product candidates on a large clinical or commercial scale and have no manufacturing facility. We are currently dependent on a single third party manufacturer for the manufacture of mavorixafor, the active pharmaceutical ingredient (&#8220;API&#8221;), and a single manufacturer of mavorixafor finished drug product capsules. If we experience problems with these third parties, the manufacturing of mavorixafor could be delayed, which could harm our results of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet our projected needs for clinical supplies to support our activities through regulatory approval and commercial manufacturing, the manufacturer with whom we currently work will need to increase its frequency and/or scale of production or we will need to find additional or alternative manufacturers. We have not yet secured alternate suppliers in the event the current manufacturer we utilize is unable to meet demand, or if otherwise we experience any problems with them. If such problems arise and we are unable to arrange for alternative third-party manufacturing sources, we are unable to find an alternative third party capable of reproducing the existing manufacturing method or we are unable to do so on commercially reasonable terms or in a timely manner, we may not be able to complete development of our product candidates, or market or distribute them.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured our product candidates ourselves, including reliance on the third party for regulatory compliance and quality assurance, the possibility of breach of the manufacturing agreement by the third party because of factors beyond our control (including a failure to synthesize and manufacture our product candidates or any products that we may eventually commercialize in accordance with our specifications), and the possibility of termination or nonrenewal of the agreement by the third party, based on its own business priorities, at a time that is costly or damaging to us. In addition, the FDA and other regulatory authorities require that our product candidates and any products that we may eventually commercialize be manufactured according to cGMP and similar foreign standards. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and some state agencies, and are subject to periodic unannounced inspections for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA or other regulatory authority approval before being implemented. FDA requirements also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any third-party manufacturers that we may decide to use. Accordingly, the manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain cGMP compliance. Any failure by our third-party manufacturers to comply with cGMP or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates or products if they are approved in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates. In addition, such failure could be the basis for the FDA to issue a warning letter, withdraw approvals for product candidates previously granted to us, or take other regulatory or legal action, including recall or seizure, total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve pending applications or supplemental applications, detention of product, refusal to permit the import or export of products, injunction, or imposing civil and criminal penalties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current manufacturer and any future manufacturers may not be able to manufacture our product candidates at a cost or in quantities or in a timely manner necessary to make commercially successful products. If we successfully commercialize any of our product candidates, we may be required to establish large-scale commercial manufacturing capabilities. In addition, as our drug development pipeline increases and matures, we will have a greater need for clinical study and commercial manufacturing capacity. We have no experience manufacturing pharmaceutical products on a commercial scale and some of these manufacturers will need to increase their scale of production to meet our projected needs for commercial manufacturing, the satisfaction of which may not be met on a timely basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party CROs to conduct our preclinical studies and clinical trials. If these CROs do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely upon third-party contract research organizations and clinical data management organizations to monitor and manage data for our ongoing preclinical and clinical programs. Although we control only certain aspects of their activities, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We also rely on third parties to conduct our preclinical studies in accordance with Good Laboratory Practice, or GLP, requirements and the Laboratory Animal Welfare Act of 1966 requirements. We, our CROs and our clinical trial sites are required to comply with regulations and current Good Clinical Practices, or GCP, and comparable foreign requirements to ensure that the health, safety and rights of patients are protected in clinical trials, and that data integrity is assured. Regulatory authorities ensure compliance with GCP requirements through periodic inspections of trial sponsors and trial sites. If we, any of our CROs or our clinical trial sites fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials or a specific site may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and preclinical programs. If CROs do not successfully carry out their contractual obligations or meet expected timelines or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions in our supply chain could delay the commercial launch of our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any significant disruption in our supplier relationships could harm our business. We currently rely on a single source supplier of mavorixafor, as well a single supplier for the finished product capsules for mavorixafor. If either of these single source suppliers suffers a major natural or man-made disaster at its manufacturing facility, we would not be able to manufacture mavorixafor on a commercial scale until a qualified alternative supplier is identified. Although alternative sources of supply exist, the number of third party suppliers with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for alternative suppliers. Any significant delay in the supply of a product candidate or its key materials for an ongoing clinical study could considerably delay completion of our clinical studies, product testing and potential regulatory approval of our product candidates. If we or our manufacturers are unable to purchase these key materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed, which would impair our ability to generate revenues from the sale of our product candidates.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, to provide accurate information to the FDA or comparable foreign regulatory authorities, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee or third party misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct and the precautions we take to detect and prevent this activity, such as employee training, may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have established, and may seek to selectively establish in the future, collaborations, and, if we are unable to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may depend on such collaborations for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have, and may selectively seek in the future, third-party collaborators for the development and commercialization of our product candidates. Our likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations involving our product candidates pose many risks to us, including that:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates or products if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators with marketing and distribution rights to one or more product candidates or products may not commit sufficient resources to the marketing and distribution of such drugs;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or products or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may lose certain valuable rights under circumstances identified in our collaborations if we undergo a change of control;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. In addition, if a future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent laws and rulings by U.S. courts make it difficult to predict how patents will be issued or enforced in our industry.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may have a significant impact on our ability to protect our technology and enforce our intellectual property rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been numerous changes over the past ten years to the patent laws and to the rules of the United States Patent and Trademark Office (&#8220;USPTO&#8221;), which may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, the Leahy-Smith America Invents Act (&#8220;AIA&#8221;), which was signed into law in 2011, includes a transition from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system, and changes the way issued patents are challenged. Certain changes, such as the institution of inter partes review proceedings, that allow third parties to challenge newly issued patents, came into effect on September 16, 2012. The burden of proof required for challenging a patent in these proceedings is lower than in district court litigation, and patents in the biologics and pharmaceuticals industry have been successfully challenged using these new post-grant challenges. In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in specified circumstances or weakening the rights of patent owners in specified situations. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, these substantive changes to patent law associated with the AIA may further weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future, all of which could harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the patent positions of companies engaged in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. We cannot assure you that our efforts to seek patent protection for our technology and products will not be negatively impacted by the changes described above, future rulings in district court cases or changes in guidance or procedures issued by the USPTO. We cannot fully predict what impact the Supreme Court&#8217;s decisions may have on the ability of life science companies to obtain or enforce patents relating to their products and technologies in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, although the Supreme Court has held in Myriad that isolated segments of naturally occurring DNA are not patent-eligible subject matter, certain third parties could allege that activities that we may undertake infringe other gene-related patent claims, and we may deem it necessary to defend ourselves against these claims by asserting non-infringement and/or invalidity positions, or pay to obtain a license to these claims. In any of the foregoing or in other situations involving third-party intellectual property rights, if we are unsuccessful in defending against claims of patent infringement, we could be forced to pay damages or be subjected to an injunction that would prevent us from utilizing the patented subject matter. Such outcomes could harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our intellectual property rights, our competitive position could be harmed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on our ability to protect our proprietary technology. We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary technology and products. Where we have the right to do so under our license agreements, we seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and products that are important to our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patents, including those patent rights licensed to us by third parties, are highly uncertain.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The steps we have taken to police and protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both inside and outside the United States. The rights already granted under any of our currently issued patents and those that may be granted under future issued patents may not provide us with the proprietary protection or competitive advantages that we are seeking. If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize technology and products similar or superior to ours, and our ability to successfully commercialize our technology and products may be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to patent rights, we do not know whether any of the pending patent applications for any of our product candidates will result in the issuance of patents that protect our technology or products, or which will effectively prevent others from commercializing competitive technologies and products. Our pending applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Further, the examination process may require us or our licensors to narrow the claims, which may limit the scope of patent protection that may be obtained. Although our license agreement with Genzyme includes a number of issued patents that are exclusively licensed to us, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we own or have licensed from third parties may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in the loss of patent protection, the narrowing of claims in such patents, or the invalidity or unenforceability of such patents, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection for our technology and products. Protecting against the unauthorized use of our patented technology, trademarks and other intellectual property rights is expensive, difficult and may, in some cases, not be possible. In some cases, it may be difficult or impossible to detect third party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be required to incur significant expenses to obtain our intellectual property rights, and we cannot ensure that we will obtain meaningful patent protection for our product candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, it is also possible that we will fail to identify patentable aspects of further inventions made in the course of our development and commercialization activities before they are publicly disclosed, making it too late to obtain patent protection on them. Further, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms where these are available in any countries where we are prosecuting patents. This includes in the United States under the Drug Price Competition and Patent Term Restoration Act of 1984, which permits a patent term extension of up to five years beyond the expiration of a patent that covers an approved product where the permission for the commercial marketing or use of the product is the first permitted commercial marketing or use, and as long as the remaining term of the patent does not exceed 14 years. However, the applicable authorities, including the FDA in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States, and these foreign laws may also be subject to change. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or in some cases </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO, and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other requirements during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the possibility of litigation relating to infringement claims asserted against it, we may become a party to other patent litigation and other proceedings, including inter partes review proceedings, post-grant review proceedings, derivation proceedings declared by the USPTO and similar proceedings in foreign countries, regarding intellectual property rights with respect to our current or future technologies or product candidates or products. The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe or otherwise violate our intellectual property, including patents that may issue to or be licensed by us. As a result, we may be required to file claims in an effort to stop third-party infringement or unauthorized use. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. This can be prohibitively expensive, particularly for a company of our size, and time-consuming, and even if we are successful, any award of monetary damages or other remedy we may receive may not be commercially valuable. In addition, in an infringement proceeding, a court may decide that our asserted intellectual property is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our intellectual property does not cover its technology. An adverse determination in any litigation or defense proceedings could put our intellectual property at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the breadth or strength of our patent or other intellectual property rights is compromised or threatened, it could allow third parties to commercialize our technology or products or result in our inability to commercialize our technology and products without infringing third-party intellectual property rights. Further, third parties may be dissuaded from collaborating with us.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference or derivation proceedings brought by the USPTO or its foreign counterparts may be necessary to determine the priority of inventions with respect to our patent applications, and we may also become involved in other proceedings, such as re-examination proceedings, before the USPTO or its foreign counterparts. Due to the substantial competition in the pharmaceutical space, the number of such proceedings may increase. This could delay the prosecution of our pending patent applications or impact the validity and enforceability of any future patents that we may obtain. In addition, any such litigation, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">submission or proceeding may be resolved adversely to us and, even if successful, may result in substantial costs and distraction to our management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Moreover, intellectual property law relating to the fields in which we operate is still evolving and, consequently, patent and other intellectual property positions in our industry are subject to change and are often uncertain. We may not prevail in any of these suits or other efforts to protect our technology, and the damages or other remedies awarded, if any, may not be commercially valuable. During the course of this type of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, the market price for our common stock could be significantly harmed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to several license agreements and may need to obtain additional licenses from others to advance our research and development activities or allow the commercialization of our current product candidates and any that we may identify and pursue in the future. Our currently license agreements impose, and we expect that future license agreements will impose, various development, diligence, commercialization, and other obligations on us. In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of our product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">From time to time, we may need to rely on licenses to proprietary technologies, which may be difficult or expensive to obtain or we may lose certain licenses which may be difficult to replace.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to obtain licenses to patents and other proprietary rights held by third parties to develop, manufacture and market our product candidates. If we are unable to timely obtain these licenses on commercially reasonable terms and maintain these licenses, our ability to commercially market our product candidates may be inhibited or prevented, which could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates, and to use our proprietary technologies without infringing the proprietary rights of third parties. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference and various post grant proceedings before the USPTO, non-U.S. opposition proceedings, and German nullity proceedings. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of any such infringement claims, or to avoid potential claims, we may choose or be compelled to seek intellectual property licenses from third parties. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us likely would be nonexclusive, which would mean that our competitors also could obtain licenses to the same intellectual property. Ultimately, we could be prevented from commercializing a product candidate or technology or be forced to cease some aspect of our business operations if, as a result of actual or threatened infringement claims, we are unable to enter into licenses of the relevant intellectual property on acceptable terms. Further, if we attempt to modify a product candidate or technology or to develop alternative methods or products in response to infringement claims or to avoid potential claims, we could incur substantial costs, encounter delays in product introductions or interruptions in sales. Ultimately, such efforts could be unsuccessful.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock and negatively impact our ability to raise additional funds. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our trade secrets are difficult to protect and if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technologies and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality, non-competition, non-solicitation, and invention assignment agreements with our employees and consultants that obligate them to assign to us any inventions developed in the course of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their work for us. However, we cannot guarantee that we have executed these agreements with each party that may have or have had access to our trade secrets or that the agreements we have executed will provide adequate protection. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. As a result, we may be forced to bring claims against third parties, or defend claims that they bring against us, to determine ownership of what we regard as our intellectual property. Monitoring unauthorized disclosure is difficult and we do not know whether the procedures that we have followed to prevent such disclosure are or will be adequate. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States may be less willing or unwilling to protect trade secrets. If any of the technology or information that we protect as trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor, our competitive position would be harmed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees, including members of our senior management, were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. All such individuals, including each member of our senior management, executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. We are not aware of any threatened or pending claims related to these matters or concerning the agreements with our senior management, but in the future litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive. In general, we have sought patent protection of our intellectual property in the following jurisdictions: US, Canada, China, Japan and in countries within Europe via the European Patent Office. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As another example, the complexity and uncertainty of European patent laws have increased in recent years. In Europe, a new unitary patent system will likely be introduced by the end of 2023, which would significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications will soon have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (&#8220;UPC&#8221;). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations, Employee Matters and Managing Growth</span></div><div style="margin-top:12pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain executives and to attract, retain and motivate key personnel in a competitive environment for skilled biotechnology personnel.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. We are also highly dependent upon members of our current </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management team, including Paula Ragan, Ph.D., our Chief Executive Officer. The loss of the services provided by these individuals will adversely impact the achievement of our objectives. These individuals could leave our employment at any time, as they are &#8220;at will&#8221; employees. Effective succession planning is also important to our long-term success. Failure to ensure effective transfer of knowledge and smooth transitions involving key employees could hinder our strategic planning and execution. For example, our former Chief Medical Officer resigned in November 2022 and we have engaged an interim Chief Medical Officer while we complete a search for a permanent Chief Medical Officer. While we expect to engage in an orderly transition process if and when we integrate newly appointed officers and managers, we face a variety of risks and uncertainties relating to management transition, including diversion of management attention from business concerns, failure to retain other key personnel, or loss of institutional knowledge. In addition, the loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and an inability to find suitable replacements could result in delays in product development, and harm our business.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend on our ability to retain our management team and other key employees, and to attract and retain qualified personnel in the future. The loss of the services of certain members of our senior management or key employees could prevent or delay the implementation and completion of our strategic objectives, or divert management&#8217;s attention to seeking qualified replacements. The competition for qualified personnel in the pharmaceutical field is intense and we cannot guarantee that we will be able to retain our current personnel or attract and retain new qualified personnel necessary for the development of our business or to recruit suitable replacement personnel.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had 70 full-time employees. Although we announced a reduction in workforce of approximately 20% in July 2022 as part of our streamlining of resources to focus on advancing our lead clinical candidate, mavorixafor, as our development and commercialization plans and strategies develop, or as a result of any future acquisitions, we will need additional managerial, operational, development, sales, marketing, financial and other resources. Our management, personnel and systems currently in place will not be adequate to support this future growth. Future growth would impose significant added responsibilities on our employees, including:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing our clinical trials effectively;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying, recruiting, maintaining, motivating and integrating additional employees;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing our internal development efforts effectively while complying with our contractual obligations to licensors, contractors and other third parties;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improving our managerial, development, operational and finance systems; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanding our facilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our operations expand, we will need to manage additional relationships with various strategic collaborators, suppliers and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate additional management, administrative, research and development, and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing the company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The pharmaceutical industry is highly competitive and is subject to rapid and significant technological change, which could render our technologies and products obsolete or uncompetitive.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is highly competitive and is subject to rapid and significant technological change, which could render certain of our products obsolete or uncompetitive. This is particularly true in the development of therapeutics for oncology indications where new products and combinations of products are rapidly being developed that change the treatment paradigm for patients. There is no assurance that our product candidates will be the best, have the best safety profile, be the first to market, or be the most economical to make or use. The introduction of competitive therapies as alternatives to our product candidates could dramatically reduce the value of those development projects or chances of successfully commercializing those product candidates, which could have a material adverse effect on our long-term financial success.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will compete with companies in the United States and internationally, including major pharmaceutical and chemical companies, specialized CROs, research and development firms, universities and other research institutions. Many of our competitors have greater financial resources and selling and marketing capabilities, greater experience in clinical testing and human clinical trials of pharmaceutical products and greater experience in obtaining FDA and other regulatory approvals than we do. In addition, some of our competitors may have lower development and manufacturing costs.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology or loss of data, including any cyber security incidents, could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability which could harm our ability to operate our business effectively and adversely affect our business and reputation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we, our contract research organizations and other third parties on which we rely collect and store sensitive data, including legally protected patient health information, personally identifiable information about our employees, intellectual property, and proprietary business information. We manage and maintain our applications and data utilizing on-site systems. These applications and data encompass a wide variety of business-critical information including research and development information and business and financial information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy. Additionally, despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, breaches, unauthorized access, interruptions due to employee error or malfeasance or other disruptions, or damage from natural disasters, terrorism, war and telecommunication and electrical failures. &#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have implemented a work model that has enabled substantially all of our employees to periodically work remotely, which may make us more vulnerable to cyberattacks. Any such event could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. We have measures in place that are designed to detect and respond to such security incidents and breaches of privacy and security mandates. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, government enforcement actions and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to conduct research, development and commercialization activities, process and prepare company financial information, manage various selling, general and administrative aspects of our business and damage our reputation, in addition to possibly requiring substantial expenditures of resources to remedy, any of which could adversely affect our business. The loss of clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, there can be no assurance that we will promptly detect any such disruption or security breach, if at all. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our research, development and commercialization efforts could be delayed.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net operating loss (&#8220;NOL&#8221;) carryforwards could expire unused and be unavailable to offset future tax liabilities because of their limited duration or because of restrictions under U.S. tax law. As of December 31, 2022, we had U.S. federal and state NOLs of $342.9 million and $336.5 million, respectively. Our NOLs generated in tax years ending on or prior to December 31, 2017 are only permitted to be carried forward for 20 years under applicable U.S. tax law. Under the Tax Act, as modified by the CARES Act, our federal NOLs generated in tax years ending after December 31, 2017 may be carried forward indefinitely, but the deductibility of federal NOLs, particularly for tax years beginning after December 31, 2020, may be limited. It is uncertain if and to what extent various states will conform to the Tax Act and the CARES Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 382 of the Internal Revenue Code of 1986, as amended, or Section 382, contains rules that limit the ability of a company that undergoes an ownership change to utilize its net operating losses, or NOLs, and tax credits existing as of the date of such ownership change. Under the rules, such an ownership change is generally any change in ownership of more than 50% of a company&#8217;s stock within a rolling three-year period. The rules generally operate by focusing on changes in ownership among stockholders considered by the rules as owning, directly or indirectly, 5% or more of the stock of a company and any change in ownership arising from new issuances of stock by the company. We have experienced multiple ownership changes since our inception and are conducting a study to assess whether an ownership change has occurred and whether these ownership changes will limit the future use of our NOL carryforwards. Future ownership changes as defined by Section 382 may further limit the amount of NOL carryforwards that could be utilized annually to offset future taxable income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our term loan contains restrictions that limit our flexibility in operating our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into a loan and security agreement, as most recently amended and restated in January 2023, with Hercules, secured by a lien on substantially all of our assets, excluding intellectual property. This loan contains various covenants that limit our ability to engage in specified types of transactions. These covenants limit our ability to, among other things:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sell, transfer, lease or dispose of certain assets;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur indebtedness;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">encumber or permit liens on certain assets;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make certain investments;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make certain restricted payments, including paying dividends on, or repurchasing or making distributions with respect to, our common stock; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into certain transactions with affiliates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The covenants also include a requirement that we maintain cash in an aggregate amount greater than or equal to $20 million; provided, however, that following the FDA approval of the sale and marketing of mavorixafor for the treatment to patients with WHIM syndrome, the required level shall be reduced to $10 million. Based on our current cash and cash equivalents and our current operating plan, we believe that if we fail to raise additional capital, we would be in violation of the minimum cash described above in the first quarter of 2024. A breach of any of the covenants under the loan and security agreement could result in a default under the loan. Upon the occurrence of an event of default under the loan, the lenders could elect to declare all amounts outstanding, if any, to be immediately due and payable and terminate all commitments to extend further credit. If there are any amounts outstanding that we are unable to repay, the lenders could proceed against the collateral granted to them to secure such indebtedness.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises such as the COVID-19 pandemic, political crises, geopolitical events, such as the war in Ukraine, or other macroeconomic conditions, which have in the past and may in the future negatively impact our business and financial performance.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates and uncertainty about economic stability. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. The U.S. Federal Reserve recently raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government spending and volatility in financial markets may increase economic uncertainty. If the equity and credit markets deteriorate, including as a result of political unrest or war, such as the war in Ukraine, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been and is likely to continue to be volatile and fluctuate substantially.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has been and could continue to be subject to significant fluctuations. Market prices for securities of pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or the ability of our collaborators to develop product candidates and conduct clinical trials that demonstrate such product candidates are safe and effective;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or the ability of our collaborators to obtain regulatory approvals for product candidates, and delays or failures to obtain such approvals;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any our product candidates to demonstrate safety and efficacy, receive regulatory approval and achieve commercial success;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to maintain our existing third-party license, manufacturing and supply agreements;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by us or our licensors to prosecute, maintain or enforce our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to our current or future product candidates;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any inability to obtain adequate supply of product candidates or the inability to do so at acceptable prices;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse decisions by regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new or competing products by our competitors;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial and development projections that we may provide to the public;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain intellectual property protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including intellectual property or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us of material developments in our business, financial condition and/or operations;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if securities or industry analysts do not publish research or reports about us, or if they issue an adverse or misleading opinions regarding our business and stock;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general macroeconomic, political and market conditions and overall fluctuations in the financial markets in the United States and abroad;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock or our stockholders in the future;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity relating to our markets generally, including with respect to other products and potential products in such markets;</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of health care payment systems; </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial results; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors described in this &#8220;Risk Factors&#8221; section and elsewhere in this Quarterly Report</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, companies trading in the stock market in general have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, including in connection with the COVID-19 pandemic, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Broad market and industry factors, including potentially worsening economic conditions and other adverse effects or developments relating to the COVID-19 pandemic, may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our business, financial condition, results of operations and reputation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8220;Penny stock&#8221; rules may make buying or selling our securities difficult which may make our stock less liquid and make it harder for investors to buy and sell our securities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading in our securities is subject to the SEC&#8217;s &#8220;penny stock&#8221; rules and it is anticipated that trading in our securities will continue to be subject to the penny stock rules for the foreseeable future. The SEC has adopted regulations that generally define a penny stock to be any equity security that has a market price of less than $5.00 per share, subject to certain exceptions. These rules require that any broker-dealer who recommends our securities to persons other than prior customers and accredited investors must, prior to the sale, make a special written suitability determination for the purchaser and receive the purchaser&#8217;s written agreement to execute the transaction. Unless an exception is available, the regulations require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule explaining the penny stock market and the risks associated with trading in the penny stock market. In addition, broker-dealers must disclose commissions payable to both the broker-dealer and the registered representative and current quotations for the securities they offer. The additional burdens imposed upon broker-dealers by these requirements may discourage broker-dealers from recommending transactions in our securities, which could severely limit the liquidity of our securities and consequently adversely affect the market price for our securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced, in part, on the research and reports that industry or financial analysts publish about us or our business. Equity research analysts may elect not to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not anticipate that we will pay any cash dividends in the foreseeable future.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current expectation is that we will retain our future earnings to fund the development and growth of our business. In addition, the terms of our debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain, if any, for the foreseeable future. We are prohibited from declaring or paying any cash dividends under our existing loan and security agreement with Hercules.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to decline.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales, particularly sales by our directors, executive officers, and significant stockholders, may have on the prevailing market price of our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have filed registration statements on Form S-8 registering the issuance of shares of common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. Shares registered under these registration statements are available for sale in the public market subject to vesting arrangements and exercise of options, as well as Rule 144 in the case of our affiliates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), the Sarbanes-Oxley Act of 2002 and the rules and regulations of The Nasdaq Stock Market (&#8220;Nasdaq&#8221;). Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (&#8220;Section 404&#8221;), we are required to perform system and process evaluation and testing of our internal control over financial reporting to allow our management to report on the effectiveness of our internal control over financial reporting in this Quarterly Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us, as and when required, conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, as and when required, may reveal deficiencies in our internal control over financial reporting that are deemed to be significant deficiencies or material weaknesses or that may require prospective or retroactive changes to our consolidated financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404, we are required to furnish a report by our management on our internal control over financial reporting beginning with this Quarterly Report. However, while we remain a non-accelerated filer, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. When we cease to be a smaller reporting company and no longer qualify as a non-accelerated filer, we will be required to incur substantial additional professional fees and internal costs to expand our accounting and finance functions in order to include such attestation report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our consolidated financial statements. Our internal control over financial reporting will not prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. If we identify one or more material weaknesses in our internal controls, investors could lose confidence in the reliability of our consolidated financial statements, the market price of our stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a &#8220;smaller reporting company&#8221; and cannot predict if the reduced reporting requirements applicable to smaller reporting companies will make our securities less attractive to investors.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a &#8220;smaller reporting company&#8221; under the Exchange Act as of June 30, 2022. We may continue to be a smaller reporting company if either (i) the market value of our common stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100.0 million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is less than $700.0 million. As a smaller reporting company, we may rely on exemptions from certain disclosure requirements that are available to smaller reporting companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. For so long as we remain a smaller reporting company, we are permitted and intend to rely on such exemptions from certain disclosure and other requirements that are applicable to other public companies that are not smaller reporting companies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict if investors will find our securities less attractive because we may rely on the exemptions and reduced disclosure obligations applicable to smaller reporting companies. If some investors find our securities less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in securities class action litigation or shareholder derivative litigation that could divert management&#8217;s attention and harm our business and insurance coverage may not be sufficient to cover all costs and damages.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, securities class action or shareholder derivative litigation has often followed certain significant business transactions, such as the sale of a business division or announcement of a merger. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. We may become involved in this type of litigation in the future.The outcome of litigation is necessarily uncertain, and we could be forced to expend significant resources in the defense of such suits, and we may not prevail. Monitoring and defending against legal actions is time-consuming for our management and detracts from management&#8217;s ability to fully focus our internal resources on our business activities. In addition, we may incur substantial legal fees and costs in connection with any such litigation. We have not established any reserves for any potential liability relating to any such potential lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages. We currently maintain insurance coverage for some of these potential liabilities. Other potential liabilities may not be covered by insurance, insurers may dispute coverage or the amount of insurance may not be enough to cover damages awarded. In addition, certain types of damages may not be covered by insurance, and insurance coverage for all or certain forms of liability may become unavailable or prohibitively expensive in the future. A decision adverse to our interests on one or more legal matters or litigation could result in the payment of substantial damages, or possibly fines, and could have a material adverse effect on our reputation, financial condition and results of operations.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and by-laws may discourage, delay or prevent a merger, acquisition or other change in control of our Company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified board of directors such that not all members of the board are elected at one time;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allow the authorized number of our directors to be changed only by resolution of the board of directors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the manner in which stockholders can remove directors from the board;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to the board of directors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call stockholder meetings;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize the board of directors to issue preferred stock without stockholder approval, which could be used to institute a shareholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the board of directors; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or by-laws.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with the Company for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between the Company and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the Company or our directors, officers, employees or stockholders.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on the Company&#8217;s behalf, any action asserting a breach of fiduciary duty owed by our directors, officers, other employees or stockholders to the Company or our stockholders, any action asserting a claim against the Company arising pursuant to the Delaware General Corporation Law or as to which the Delaware General Corporation Law confers jurisdiction on the Court of Chancery of the State of Delaware, or any action asserting a claim arising pursuant to our certificate of incorporation or by-laws or governed by the internal affairs doctrine. This provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company or our directors, officers, employees or stockholders, which may discourage such lawsuits against the Company and our directors, officers, employees or stockholders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alternatively, if a court were to find this provision in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_112"></div><div style="margin-top:18pt;padding-left:81pt;text-indent:-81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_115"></div><div style="margin-top:18pt;padding-left:81pt;text-indent:-81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_118"></div><div style="margin-top:18pt;padding-left:81pt;text-indent:-81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_121"></div><div style="margin-top:18pt;padding-left:81pt;text-indent:-81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;EXHIBITS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Incorporated by Reference to:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit Description</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000162828022024161/x4-ex31to8xkxcharteramen.htm">Restated Certificate of Incorporation, as amended, as of September 1, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/01/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38295</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001501697/000119312517348213/d495338dex32.htm">Amended and Restated By-laws of the Company</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/20/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38295</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1501697/000119312519073465/d702482dex41.htm">Form of Common Stock Certificate</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">3/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">001-38295</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-311q12023.htm">Certification of Principal Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-312q12023.htm">Certification of Principal Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-321q12023.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">* Filed herewith</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">** The certification attached as Exhibit 32.1 accompanying this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i31a6b5aa29ee4f3785de4e1e0f908a81_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.555%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 4, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Paula Ragan, Ph.D.&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paula Ragan, Ph.D.<br/>President and Chief Executive Officer</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.555%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 4, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Adam S. Mostafa&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam S. Mostafa<br/>Chief Financial Officer and Treasurer</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex-311q12023.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iaad49b986e5e41beba113afe9f41bece_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Paula Ragan, Ph.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of X4 Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 4 , 2023</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Paula Ragan, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paula Ragan, Ph.D.<br>President and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex-312q12023.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2ef796c236474b89b739e5b1eed74a64_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Adam S. Mostafa, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of X4 Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 4, 2023</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Adam S. Mostafa</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam S. Mostafa<br>Chief Financial Officer and Treasurer<br>(Principal Financial Officer)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex-321q12023.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0b83e84b5149425caf9b0c1ad384301b_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 32.1</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION</font></div><div style="margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paula Ragan, Ph.D., Chief Executive Officer of X4 Pharmaceuticals, Inc. (the &#8220;Company&#8221;), and Adam S. Mostafa, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge&#58;</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2023, to which this Certification is attached as Exhibit 32.1 (the &#8220;Quarterly Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div><font><br></font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">In Witness Whereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, the undersigned have set their hands hereto as of the 4th day of May, 2023.</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Paula Ragan, Ph.D.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Adam S. Mostafa&#160;&#160;&#160;&#160;</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paula Ragan, Ph.D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Adam S. Mostafa</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chief Financial Officer</font></div><div style="margin-top:3pt;padding-left:288pt;text-align:justify;text-indent:-288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>xfor-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6d137f82-7ad4-4f5a-a1d8-483327cb893c,g:a70c2544-a714-416b-95fa-518d19b53207-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xfor="http://www.x4pharma.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.x4pharma.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.x4pharma.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical">
        <link:definition>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusinessandBasisofPresentation" roleURI="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation">
        <link:definition>0000008 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandFundingAgreements" roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements">
        <link:definition>0000010 - Disclosure - License, Collaboration, and Funding Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilities" roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities">
        <link:definition>0000011 - Disclosure - Fair Value of Financial Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNet">
        <link:definition>0000012 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.x4pharma.com/role/AccruedExpenses">
        <link:definition>0000013 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.x4pharma.com/role/LongTermDebt">
        <link:definition>0000014 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.x4pharma.com/role/Leases">
        <link:definition>0000015 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.x4pharma.com/role/CommitmentandContingencies">
        <link:definition>0000016 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockWarrants" roleURI="http://www.x4pharma.com/role/CommonStockWarrants">
        <link:definition>0000017 - Disclosure - Common Stock Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.x4pharma.com/role/StockBasedCompensation">
        <link:definition>0000018 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.x4pharma.com/role/IncomeTaxes">
        <link:definition>0000019 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://www.x4pharma.com/role/NetLossperShare">
        <link:definition>0000020 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000021 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000022 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilitiesTables" roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables">
        <link:definition>0000023 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetTables">
        <link:definition>0000024 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.x4pharma.com/role/AccruedExpensesTables">
        <link:definition>0000025 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.x4pharma.com/role/LongTermDebtTables">
        <link:definition>0000026 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.x4pharma.com/role/LeasesTables">
        <link:definition>0000027 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockWarrantsTables" roleURI="http://www.x4pharma.com/role/CommonStockWarrantsTables">
        <link:definition>0000028 - Disclosure - Common Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.x4pharma.com/role/StockBasedCompensationTables">
        <link:definition>0000029 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://www.x4pharma.com/role/NetLossperShareTables">
        <link:definition>0000030 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail">
        <link:definition>0000031 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail" roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail">
        <link:definition>0000032 - Disclosure - Summary of Significant Accounting Policies - Schedule of Compensating Balance Arrangements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail">
        <link:definition>0000033 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandFundingAgreementsAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail">
        <link:definition>0000034 - Disclosure - License, Collaboration, and Funding Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail" roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail">
        <link:definition>0000035 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities Measured at Fair Value (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails" roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails">
        <link:definition>0000036 - Disclosure - Fair Value of Financial Assets and Liabilities - Aggregate Fair Values Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails">
        <link:definition>0000037 - Disclosure - Fair Value of Financial Assets and Liabilities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails" roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails">
        <link:definition>0000038 - Disclosure - Fair Value of Financial Assets and Liabilities - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail" roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail">
        <link:definition>0000039 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetAdditionalInformationDetail">
        <link:definition>0000040 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesScheduleofAccruedExpensesDetail" roleURI="http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail">
        <link:definition>0000041 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtSummaryofLongTermDebtDetail" roleURI="http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail">
        <link:definition>0000042 - Disclosure - Long-Term Debt - Summary of Long Term Debt (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtHerculesLoanAgreementAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail">
        <link:definition>0000043 - Disclosure - Long Term Debt - Hercules Loan Agreement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtSummaryofInterestExpenseDetails" roleURI="http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails">
        <link:definition>0000044 - Disclosure - Long-Term Debt - Summary of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail" roleURI="http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail">
        <link:definition>0000045 - Disclosure - Long-Term Debt - Schedule of Future Principal Payments and the Final Payments Due (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/LeasesAdditionalInformationDetail">
        <link:definition>0000046 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofComponentsofLeaseExpenseDetail" roleURI="http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail">
        <link:definition>0000047 - Disclosure - Leases - Schedule of Components of Lease Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail">
        <link:definition>0000048 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1" roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1">
        <link:definition>0000048 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail">
        <link:definition>0000049 - Disclosure - Commitment and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockWarrantsAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail">
        <link:definition>0000050 - Disclosure - Common Stock Warrants - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail" roleURI="http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail">
        <link:definition>0000051 - Disclosure - Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>0000052 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail" roleURI="http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail">
        <link:definition>0000053 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-date Fair Value of Stock Options Granted (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityDetail" roleURI="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail">
        <link:definition>0000054 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationDetails" roleURI="http://www.x4pharma.com/role/StockBasedCompensationDetails">
        <link:definition>0000055 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails" roleURI="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails">
        <link:definition>0000056 - Disclosure - Stock-Based Compensation Summary of Stock-Based Compensation Expense Classification (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>0000057 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail" roleURI="http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail">
        <link:definition>0000058 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareAdditionalInformationDetail" roleURI="http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail">
        <link:definition>0000059 - Disclosure - Net Loss per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail" roleURI="http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail">
        <link:definition>0000060 - Disclosure - Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_IssuanceOnJuly620222Member" abstract="true" name="IssuanceOnJuly620222Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" abstract="true" name="IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_PreFundedWarrantMember" abstract="true" name="PreFundedWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_LineOfCreditCovenantMinimumCash" abstract="false" name="LineOfCreditCovenantMinimumCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xfor_MinCashTestDate1Member" abstract="true" name="MinCashTestDate1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_LongTermDebtNonCurrentIncludingAccretion" abstract="false" name="LongTermDebtNonCurrentIncludingAccretion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_WalthamLeaseMember" abstract="true" name="WalthamLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_CollaborationLicenseAndFundingArrangementsTable" abstract="true" name="CollaborationLicenseAndFundingArrangementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="xfor_LongTermDebtAndEOTPayment" abstract="false" name="LongTermDebtAndEOTPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_AllstonLeaseAgreementMember" abstract="true" name="AllstonLeaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_NonCashInterestExpense" abstract="false" name="NonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_LegacyWarrantsMember" abstract="true" name="LegacyWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" abstract="true" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" abstract="true" name="IssuanceOnAprilSixteenTwoThousandNineteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement" abstract="false" name="IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" abstract="true" name="IssuanceOnOctoberNineteenTwoThousandEighteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" abstract="true" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="xfor_LongTermDebtIncludingAccretion" abstract="false" name="LongTermDebtIncludingAccretion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ContingenciesAndCommitmentsLineItems" abstract="true" name="ContingenciesAndCommitmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" abstract="false" name="ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_IncreaseDecreaseInLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_AccruedExpensesTextBlock" abstract="false" name="AccruedExpensesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="xfor_TwoThousandSeventeenEquityIncentivePlanMember" abstract="true" name="TwoThousandSeventeenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="xfor_CurrentOfficeSpaceUnderLeaseAgreement" abstract="false" name="CurrentOfficeSpaceUnderLeaseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="xfor_AggregateBaseRent" abstract="false" name="AggregateBaseRent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xfor_IssuanceOnDecember920222Member" abstract="true" name="IssuanceOnDecember920222Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_AccruedLeaseConstructionCosts" abstract="false" name="AccruedLeaseConstructionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_CollaborationLicenseAndFundingArrangementsLineItems" abstract="true" name="CollaborationLicenseAndFundingArrangementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_SoftwareMember" abstract="true" name="SoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="xfor_FundedMember" abstract="true" name="FundedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_DebtInstrumentPrepaymentPremiumPercentage" abstract="false" name="DebtInstrumentPrepaymentPremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xfor_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_HerculesSecondAmendedLoanAgreementMember" abstract="true" name="HerculesSecondAmendedLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_Q12022PrivatePlacementMember" abstract="true" name="Q12022PrivatePlacementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" abstract="true" name="IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ViennaAustriaLeaseMember" abstract="true" name="ViennaAustriaLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xfor_MinCashTestDate2Member" abstract="true" name="MinCashTestDate2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_HerculesLoanAgreementMember" abstract="true" name="HerculesLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ViennaLeaseAgreementMember" abstract="true" name="ViennaLeaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_ContingenciesAndCommitmentsTable" abstract="true" name="ContingenciesAndCommitmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="xfor_PrefundedWarrantsAxis" abstract="true" name="PrefundedWarrantsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" abstract="true" name="IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ClassAWarrantMember" abstract="true" name="ClassAWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_PrefundedWarrantsDomain" abstract="true" name="PrefundedWarrantsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ResearchAndDevelopmentIncentiveReceivable" abstract="false" name="ResearchAndDevelopmentIncentiveReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_IssuanceOnJuly20221Member" abstract="true" name="IssuanceOnJuly20221Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_IssuanceOnDecember92022Member" abstract="true" name="IssuanceOnDecember92022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_TwoThousandNineteenEquityIncentivePlanMember" abstract="true" name="TwoThousandNineteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" abstract="true" name="IssuanceOnNovemberNineTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_AccruedExternalResearchAndDevelopmentExpenses" abstract="false" name="AccruedExternalResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_AllstonLeaseMember" abstract="true" name="AllstonLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ScheduleOfAccountingPoliciesTable" abstract="true" name="ScheduleOfAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" abstract="true" name="IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" abstract="false" name="ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="xfor_IndemnificationAgreementsMember" abstract="true" name="IndemnificationAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" abstract="true" name="IssuanceOnMarchThirteenTwoThousandNineteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="xfor_IssuanceOnMarch232021Member" abstract="true" name="IssuanceOnMarch232021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_ResearchAndDevelopmentIncentiveProgramMember" abstract="true" name="ResearchAndDevelopmentIncentiveProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_NonCashLeaseExpense" abstract="false" name="NonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock" abstract="false" name="TemporaryEquityRepurchaseOfConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_IssuanceOnMarch32022Member" abstract="true" name="IssuanceOnMarch32022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xfor_GrantAndIncentiveReceivables" abstract="false" name="GrantAndIncentiveReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xfor_AccretionOnLongTermDebt" abstract="false" name="AccretionOnLongTermDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>xfor-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6d137f82-7ad4-4f5a-a1d8-483327cb893c,g:a70c2544-a714-416b-95fa-518d19b53207-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="xfor-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ea269d25-664c-4266-9507-60bff357031e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c0d8ccc5-87c5-41e5-8716-7227aa9119e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ea269d25-664c-4266-9507-60bff357031e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c0d8ccc5-87c5-41e5-8716-7227aa9119e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveReceivable_edbcc8b2-151e-48d8-a118-955407e354ff" xlink:href="xfor-20230331.xsd#xfor_ResearchAndDevelopmentIncentiveReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ea269d25-664c-4266-9507-60bff357031e" xlink:to="loc_xfor_ResearchAndDevelopmentIncentiveReceivable_edbcc8b2-151e-48d8-a118-955407e354ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cbe1f669-29f0-4f8f-8e9d-86e573168fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ea269d25-664c-4266-9507-60bff357031e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cbe1f669-29f0-4f8f-8e9d-86e573168fc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0545e4b4-49d7-4f82-a531-d410c89ae267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d1548f1f-6d90-40ae-92b7-1e3b117dde5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0545e4b4-49d7-4f82-a531-d410c89ae267" xlink:to="loc_us-gaap_CommonStockValue_d1548f1f-6d90-40ae-92b7-1e3b117dde5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_22d6e7f5-5541-4426-bbcc-9d9bfbd2c0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0545e4b4-49d7-4f82-a531-d410c89ae267" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_22d6e7f5-5541-4426-bbcc-9d9bfbd2c0ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1f10cbfa-8a1d-4ca0-b2b9-1545544d509f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0545e4b4-49d7-4f82-a531-d410c89ae267" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1f10cbfa-8a1d-4ca0-b2b9-1545544d509f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dd023198-be2d-4f22-b660-ab0e92f7062f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0545e4b4-49d7-4f82-a531-d410c89ae267" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dd023198-be2d-4f22-b660-ab0e92f7062f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ddfe0bb1-7853-47fc-b623-807886f74cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0d3a46f3-de5e-4830-b838-3ed47322d91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ddfe0bb1-7853-47fc-b623-807886f74cab" xlink:to="loc_us-gaap_LiabilitiesCurrent_0d3a46f3-de5e-4830-b838-3ed47322d91b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtNonCurrentIncludingAccretion_6374bc22-31a0-45bb-8fd4-06b276cec00a" xlink:href="xfor-20230331.xsd#xfor_LongTermDebtNonCurrentIncludingAccretion"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ddfe0bb1-7853-47fc-b623-807886f74cab" xlink:to="loc_xfor_LongTermDebtNonCurrentIncludingAccretion_6374bc22-31a0-45bb-8fd4-06b276cec00a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8c731cda-518d-4f09-a469-6a4dccae33c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ddfe0bb1-7853-47fc-b623-807886f74cab" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8c731cda-518d-4f09-a469-6a4dccae33c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0d533527-9521-4e82-bbdb-f3c37effe493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ddfe0bb1-7853-47fc-b623-807886f74cab" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0d533527-9521-4e82-bbdb-f3c37effe493" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5c199baa-9395-46b3-8653-57db2ccc9be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ddfe0bb1-7853-47fc-b623-807886f74cab" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5c199baa-9395-46b3-8653-57db2ccc9be6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8d500e00-99f9-4a48-bd26-1f1f309614d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_067cff6a-517e-4f74-9bf2-1e9971821235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8d500e00-99f9-4a48-bd26-1f1f309614d9" xlink:to="loc_us-gaap_AccountsPayableCurrent_067cff6a-517e-4f74-9bf2-1e9971821235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f1ba7bbe-62e3-42a8-9fb7-f4a45ed01cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8d500e00-99f9-4a48-bd26-1f1f309614d9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f1ba7bbe-62e3-42a8-9fb7-f4a45ed01cc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c1cf0bee-ef2a-494f-8dfb-7938eee374d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8d500e00-99f9-4a48-bd26-1f1f309614d9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c1cf0bee-ef2a-494f-8dfb-7938eee374d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_6a2d075a-c508-479c-bda8-423056f82ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8d500e00-99f9-4a48-bd26-1f1f309614d9" xlink:to="loc_us-gaap_LongTermDebtCurrent_6a2d075a-c508-479c-bda8-423056f82ff5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_09239941-59dd-4b9e-909c-ba670574ee4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5d9a5afb-b4f7-4b21-ba05-df5035e42859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_09239941-59dd-4b9e-909c-ba670574ee4c" xlink:to="loc_us-gaap_Liabilities_5d9a5afb-b4f7-4b21-ba05-df5035e42859" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_12b58396-0c95-4bb8-86db-2665658f5e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_09239941-59dd-4b9e-909c-ba670574ee4c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_12b58396-0c95-4bb8-86db-2665658f5e90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2fd6ae53-e567-4863-9a92-b3bf6b32f289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_09239941-59dd-4b9e-909c-ba670574ee4c" xlink:to="loc_us-gaap_StockholdersEquity_2fd6ae53-e567-4863-9a92-b3bf6b32f289" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f0ccbf32-9b7b-40d0-a5e6-aa18283fc3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d2e8304a-1c95-462a-aa1f-7bdc814fad54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f0ccbf32-9b7b-40d0-a5e6-aa18283fc3b9" xlink:to="loc_us-gaap_AssetsCurrent_d2e8304a-1c95-462a-aa1f-7bdc814fad54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0db75926-2799-49b7-bedf-838236328dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f0ccbf32-9b7b-40d0-a5e6-aa18283fc3b9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0db75926-2799-49b7-bedf-838236328dde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_68323bd5-9f21-4c0b-9e79-5238595a1615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f0ccbf32-9b7b-40d0-a5e6-aa18283fc3b9" xlink:to="loc_us-gaap_Goodwill_68323bd5-9f21-4c0b-9e79-5238595a1615" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_90fb31a0-c469-4d4d-91fd-56a53f03480e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f0ccbf32-9b7b-40d0-a5e6-aa18283fc3b9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_90fb31a0-c469-4d4d-91fd-56a53f03480e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2f51849e-f41d-455e-b211-479d423038c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f0ccbf32-9b7b-40d0-a5e6-aa18283fc3b9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2f51849e-f41d-455e-b211-479d423038c6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="xfor-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5b9d9395-984e-4c09-adb7-d9043556f38c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_a8f0fc60-6ab5-4a1b-8e26-fa4f21a45c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5b9d9395-984e-4c09-adb7-d9043556f38c" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_a8f0fc60-6ab5-4a1b-8e26-fa4f21a45c93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_22781cc3-2f7e-4dd3-b168-1addab08d835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5b9d9395-984e-4c09-adb7-d9043556f38c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_22781cc3-2f7e-4dd3-b168-1addab08d835" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_65b007e0-ef6b-4669-a4a0-f2287b76e9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5b9d9395-984e-4c09-adb7-d9043556f38c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_65b007e0-ef6b-4669-a4a0-f2287b76e9ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_89ecf4c6-cdb3-4fdb-879c-7c147304adc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5b9d9395-984e-4c09-adb7-d9043556f38c" xlink:to="loc_us-gaap_InterestExpense_89ecf4c6-cdb3-4fdb-879c-7c147304adc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7d8a58d3-109e-4b87-b3f7-4840c7fbe4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_428d41f8-e5ef-44fc-8f36-dbf7c4005dde" xlink:href="xfor-20230331.xsd#xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7d8a58d3-109e-4b87-b3f7-4840c7fbe4f6" xlink:to="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_428d41f8-e5ef-44fc-8f36-dbf7c4005dde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d7634d6a-dcb7-4a7a-b284-5d9b1e4c4896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7d8a58d3-109e-4b87-b3f7-4840c7fbe4f6" xlink:to="loc_us-gaap_NetIncomeLoss_d7634d6a-dcb7-4a7a-b284-5d9b1e4c4896" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3672ced3-abb7-44dc-b985-fc71c6a4a45e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9184e074-f20e-4be8-8bc7-ec6272b22388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3672ced3-abb7-44dc-b985-fc71c6a4a45e" xlink:to="loc_us-gaap_OperatingExpenses_9184e074-f20e-4be8-8bc7-ec6272b22388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_16d508d9-cabe-45fa-93da-9565a3a32e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d15b5549-575a-452b-b4e5-0a26ed7c33e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_16d508d9-cabe-45fa-93da-9565a3a32e6a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d15b5549-575a-452b-b4e5-0a26ed7c33e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_577666f3-054b-4551-8cb0-65a0a6cf3b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_16d508d9-cabe-45fa-93da-9565a3a32e6a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_577666f3-054b-4551-8cb0-65a0a6cf3b2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f07dc661-ae11-43a8-87f8-d1e517aeb02a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_31070249-360e-44da-831c-56ba9ea44c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f07dc661-ae11-43a8-87f8-d1e517aeb02a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_31070249-360e-44da-831c-56ba9ea44c35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c6813218-0e28-4736-9e23-dda251377023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f07dc661-ae11-43a8-87f8-d1e517aeb02a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c6813218-0e28-4736-9e23-dda251377023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_14bf160b-15e7-4255-ba4c-778da602e29b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f07dc661-ae11-43a8-87f8-d1e517aeb02a" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_14bf160b-15e7-4255-ba4c-778da602e29b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2c757326-e034-4a07-b04e-38ca277eb737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d937e2df-6824-4030-a300-954517e9bb56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2c757326-e034-4a07-b04e-38ca277eb737" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d937e2df-6824-4030-a300-954517e9bb56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e382a2c6-35ce-41f4-b299-daffa1da22f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2c757326-e034-4a07-b04e-38ca277eb737" xlink:to="loc_us-gaap_OperatingIncomeLoss_e382a2c6-35ce-41f4-b299-daffa1da22f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="xfor-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fb5c7d02-86c1-467e-9ae2-8ddfba7e1470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5bd8908-6c75-4562-9aef-320f1ca88e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fb5c7d02-86c1-467e-9ae2-8ddfba7e1470" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5bd8908-6c75-4562-9aef-320f1ca88e2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2cd5b465-95a9-4829-9665-613b5b5893b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fb5c7d02-86c1-467e-9ae2-8ddfba7e1470" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2cd5b465-95a9-4829-9665-613b5b5893b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_335beac7-f842-43fb-9518-664f345a3c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fb5c7d02-86c1-467e-9ae2-8ddfba7e1470" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_335beac7-f842-43fb-9518-664f345a3c0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_97fc683e-f638-41a3-bc9f-bf5d5dfd1e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fb5c7d02-86c1-467e-9ae2-8ddfba7e1470" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_97fc683e-f638-41a3-bc9f-bf5d5dfd1e50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1eaf8e8b-208a-4801-be88-67b1ea592526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement_d43d90a5-fbf2-45b6-8bb4-df20b8bdf694" xlink:href="xfor-20230331.xsd#xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1eaf8e8b-208a-4801-be88-67b1ea592526" xlink:to="loc_xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement_d43d90a5-fbf2-45b6-8bb4-df20b8bdf694" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_31dc0ce0-facc-41ab-868f-7eaada448006" xlink:href="xfor-20230331.xsd#xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1eaf8e8b-208a-4801-be88-67b1ea592526" xlink:to="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_31dc0ce0-facc-41ab-868f-7eaada448006" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_a7aae1a9-567f-41e3-9116-ef0558791aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1eaf8e8b-208a-4801-be88-67b1ea592526" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_a7aae1a9-567f-41e3-9116-ef0558791aee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b42f280f-ccb2-4fbe-ae74-6ff2147e95e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1eaf8e8b-208a-4801-be88-67b1ea592526" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b42f280f-ccb2-4fbe-ae74-6ff2147e95e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_52f7033b-4478-446c-9a38-b1408967ebe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1eaf8e8b-208a-4801-be88-67b1ea592526" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_52f7033b-4478-446c-9a38-b1408967ebe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3f81c527-7d8d-4657-a06c-bdb804e4065e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_8d287284-db30-4fb7-908b-b0a42bbe337e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3f81c527-7d8d-4657-a06c-bdb804e4065e" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_8d287284-db30-4fb7-908b-b0a42bbe337e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_682eea05-0af1-441d-b73f-5c8afd3370b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ce1259b2-0ef4-4eff-928a-a87f9f2f2a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_682eea05-0af1-441d-b73f-5c8afd3370b7" xlink:to="loc_us-gaap_NetIncomeLoss_ce1259b2-0ef4-4eff-928a-a87f9f2f2a3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7c724319-2ae6-4e62-a543-140441d994da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_682eea05-0af1-441d-b73f-5c8afd3370b7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7c724319-2ae6-4e62-a543-140441d994da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashLeaseExpense_2d160dc7-ee49-4582-bd13-1f5ff69f2a76" xlink:href="xfor-20230331.xsd#xfor_NonCashLeaseExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_682eea05-0af1-441d-b73f-5c8afd3370b7" xlink:to="loc_xfor_NonCashLeaseExpense_2d160dc7-ee49-4582-bd13-1f5ff69f2a76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashInterestExpense_a8faf99b-f04f-4e45-9402-6b3c7d85b948" xlink:href="xfor-20230331.xsd#xfor_NonCashInterestExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_682eea05-0af1-441d-b73f-5c8afd3370b7" xlink:to="loc_xfor_NonCashInterestExpense_a8faf99b-f04f-4e45-9402-6b3c7d85b948" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d5eeadd1-fb54-49b5-97df-310e52074cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_682eea05-0af1-441d-b73f-5c8afd3370b7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d5eeadd1-fb54-49b5-97df-310e52074cb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fcfbef70-e0ac-4eed-bc0f-e7ea387b5d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_682eea05-0af1-441d-b73f-5c8afd3370b7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fcfbef70-e0ac-4eed-bc0f-e7ea387b5d82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_5909ab98-b44e-4405-b6ae-3e134ff05195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_682eea05-0af1-441d-b73f-5c8afd3370b7" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_5909ab98-b44e-4405-b6ae-3e134ff05195" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ea337b0e-85dd-4e9d-9ee8-8a88ae839725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_682eea05-0af1-441d-b73f-5c8afd3370b7" xlink:to="loc_us-gaap_ShareBasedCompensation_ea337b0e-85dd-4e9d-9ee8-8a88ae839725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncreaseDecreaseInLeaseLiabilities_436d91ab-c3ef-481b-871d-4c48e90eeb9d" xlink:href="xfor-20230331.xsd#xfor_IncreaseDecreaseInLeaseLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_682eea05-0af1-441d-b73f-5c8afd3370b7" xlink:to="loc_xfor_IncreaseDecreaseInLeaseLiabilities_436d91ab-c3ef-481b-871d-4c48e90eeb9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9baca7b2-c9d0-4fc9-873b-d32fbdf39cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_682eea05-0af1-441d-b73f-5c8afd3370b7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9baca7b2-c9d0-4fc9-873b-d32fbdf39cc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_860d902a-f6d4-44f9-a4eb-cd7e8cd996c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_682eea05-0af1-441d-b73f-5c8afd3370b7" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_860d902a-f6d4-44f9-a4eb-cd7e8cd996c9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2435044d-faee-403f-be44-106cab537d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_ab9b41cf-c4e0-4404-9a26-19c7537fc4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2435044d-faee-403f-be44-106cab537d5f" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_ab9b41cf-c4e0-4404-9a26-19c7537fc4b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_eaaf046c-07f0-4f66-80c6-20d7032712b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2435044d-faee-403f-be44-106cab537d5f" xlink:to="loc_us-gaap_RestrictedCashCurrent_eaaf046c-07f0-4f66-80c6-20d7032712b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_68074671-7913-42da-a9a9-163a245c3be9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2435044d-faee-403f-be44-106cab537d5f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_68074671-7913-42da-a9a9-163a245c3be9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4c4872d2-e35c-498f-b239-c6b57f956a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ef86bb37-7c5a-4d13-a135-5543eb8ea27d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4c4872d2-e35c-498f-b239-c6b57f956a41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ef86bb37-7c5a-4d13-a135-5543eb8ea27d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9c6d271e-80ce-4b57-8542-64fe4c281115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4c4872d2-e35c-498f-b239-c6b57f956a41" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9c6d271e-80ce-4b57-8542-64fe4c281115" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#AccruedExpensesScheduleofAccruedExpensesDetail"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cedcb0bd-ae67-4b2f-9cc3-aa9a1ee22af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_36716406-72c5-43f8-904a-bc18eeba6325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cedcb0bd-ae67-4b2f-9cc3-aa9a1ee22af7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_36716406-72c5-43f8-904a-bc18eeba6325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00ea5820-32eb-492a-98ac-2329fc142e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cedcb0bd-ae67-4b2f-9cc3-aa9a1ee22af7" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00ea5820-32eb-492a-98ac-2329fc142e22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_de9ae5ae-95e4-49b0-8768-16c3ad9c7cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cedcb0bd-ae67-4b2f-9cc3-aa9a1ee22af7" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_de9ae5ae-95e4-49b0-8768-16c3ad9c7cd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedLeaseConstructionCosts_6cf7ab5a-a3c6-4012-bee7-a02e79210283" xlink:href="xfor-20230331.xsd#xfor_AccruedLeaseConstructionCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cedcb0bd-ae67-4b2f-9cc3-aa9a1ee22af7" xlink:to="loc_xfor_AccruedLeaseConstructionCosts_6cf7ab5a-a3c6-4012-bee7-a02e79210283" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses_9755a13b-e07b-4356-82f2-310525a66e6d" xlink:href="xfor-20230331.xsd#xfor_AccruedExternalResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cedcb0bd-ae67-4b2f-9cc3-aa9a1ee22af7" xlink:to="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses_9755a13b-e07b-4356-82f2-310525a66e6d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#LongTermDebtSummaryofLongTermDebtDetail"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtIncludingAccretion_3b923928-fac7-4cdc-a328-97e281c3a686" xlink:href="xfor-20230331.xsd#xfor_LongTermDebtIncludingAccretion"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e4d9a4a0-5a5a-4580-9757-627b666d7b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtIncludingAccretion_3b923928-fac7-4cdc-a328-97e281c3a686" xlink:to="loc_us-gaap_LongTermDebt_e4d9a4a0-5a5a-4580-9757-627b666d7b40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccretionOnLongTermDebt_e4fe4425-3205-4269-97e5-8ab2fdc185e7" xlink:href="xfor-20230331.xsd#xfor_AccretionOnLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtIncludingAccretion_3b923928-fac7-4cdc-a328-97e281c3a686" xlink:to="loc_xfor_AccretionOnLongTermDebt_e4fe4425-3205-4269-97e5-8ab2fdc185e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_01732088-cfd4-4d43-ac86-60ed625e06b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtIncludingAccretion_3b923928-fac7-4cdc-a328-97e281c3a686" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_01732088-cfd4-4d43-ac86-60ed625e06b2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtAndEOTPayment_f85c2960-ad0f-44a1-beeb-5c32cbf2cdad" xlink:href="xfor-20230331.xsd#xfor_LongTermDebtAndEOTPayment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b5f0b268-73d2-4a3a-8fac-39d6c6b3561e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtAndEOTPayment_f85c2960-ad0f-44a1-beeb-5c32cbf2cdad" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b5f0b268-73d2-4a3a-8fac-39d6c6b3561e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_e13757fd-b083-4be5-8474-3ae92baf1c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtAndEOTPayment_f85c2960-ad0f-44a1-beeb-5c32cbf2cdad" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_e13757fd-b083-4be5-8474-3ae92baf1c1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5b27866f-170b-462f-8fbd-1a0bce384a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtAndEOTPayment_f85c2960-ad0f-44a1-beeb-5c32cbf2cdad" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5b27866f-170b-462f-8fbd-1a0bce384a18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_6d7bc366-c049-47d6-8445-61e4057cceb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xfor_LongTermDebtAndEOTPayment_f85c2960-ad0f-44a1-beeb-5c32cbf2cdad" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_6d7bc366-c049-47d6-8445-61e4057cceb3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#LeasesScheduleofComponentsofLeaseExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_6ec764dc-1421-419f-aac4-d52c962bbf47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c585df1b-5141-45e4-b49b-78558d890805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_6ec764dc-1421-419f-aac4-d52c962bbf47" xlink:to="loc_us-gaap_OperatingLeaseCost_c585df1b-5141-45e4-b49b-78558d890805" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9417b08f-3f57-42d9-be64-3b57c7a43acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5371bd35-c7b6-4c08-886e-afba0442f2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9417b08f-3f57-42d9-be64-3b57c7a43acd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5371bd35-c7b6-4c08-886e-afba0442f2ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d559d6af-e1ad-4ce8-abb4-60f077ddae84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9417b08f-3f57-42d9-be64-3b57c7a43acd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d559d6af-e1ad-4ce8-abb4-60f077ddae84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0a68b68c-0cae-466f-a48c-e7f58b62234d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9417b08f-3f57-42d9-be64-3b57c7a43acd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0a68b68c-0cae-466f-a48c-e7f58b62234d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_11290a92-5684-4b98-ad3e-325ab786146a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9417b08f-3f57-42d9-be64-3b57c7a43acd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_11290a92-5684-4b98-ad3e-325ab786146a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_295fa1ef-4879-4432-be63-d73b44492996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9417b08f-3f57-42d9-be64-3b57c7a43acd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_295fa1ef-4879-4432-be63-d73b44492996" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9fad4590-6609-4366-a524-7825493e2597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9417b08f-3f57-42d9-be64-3b57c7a43acd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9fad4590-6609-4366-a524-7825493e2597" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1" xlink:type="simple" xlink:href="xfor-20230331.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cad2633f-25ca-4dd1-ae25-cae1b65d4a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e1cee9d9-4a61-4f58-b8e4-08532eb11936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cad2633f-25ca-4dd1-ae25-cae1b65d4a93" xlink:to="loc_us-gaap_OperatingLeaseLiability_e1cee9d9-4a61-4f58-b8e4-08532eb11936" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ec703606-4187-49bc-aa4c-c8480a63adca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cad2633f-25ca-4dd1-ae25-cae1b65d4a93" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ec703606-4187-49bc-aa4c-c8480a63adca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2e2ba842-9779-47a7-bf07-bc74f2e4f288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_50733c0e-0af2-49cf-afc3-60a18fead8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2e2ba842-9779-47a7-bf07-bc74f2e4f288" xlink:to="loc_us-gaap_NetIncomeLoss_50733c0e-0af2-49cf-afc3-60a18fead8e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPaidinkind_f1dd5d86-6dfe-40b1-bbfb-f86841312133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPaidinkind"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2e2ba842-9779-47a7-bf07-bc74f2e4f288" xlink:to="loc_us-gaap_DividendsPaidinkind_f1dd5d86-6dfe-40b1-bbfb-f86841312133" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>xfor-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6d137f82-7ad4-4f5a-a1d8-483327cb893c,g:a70c2544-a714-416b-95fa-518d19b53207-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="xfor-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended" id="i4ee2606cf0e54f52a3967b68f0729391_CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f8fad25f-ded5-4005-bf54-e25957590f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f8fad25f-ded5-4005-bf54-e25957590f77" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cd4e8946-7ae5-4633-97d0-89b6488a1379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_SharesOutstanding_cd4e8946-7ae5-4633-97d0-89b6488a1379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a627c11e-1c38-411c-a4e0-c1c64691eb29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_StockholdersEquity_a627c11e-1c38-411c-a4e0-c1c64691eb29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_79644e71-45eb-41c9-996e-e1ebc530edb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_79644e71-45eb-41c9-996e-e1ebc530edb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_02ad8628-e121-4356-b582-5faaeea789ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_02ad8628-e121-4356-b582-5faaeea789ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_9ed6af29-3f1c-4767-825e-f33e5f0942a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_9ed6af29-3f1c-4767-825e-f33e5f0942a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_2cf2df78-43d1-4c5e-806f-e792e8ab1079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_2cf2df78-43d1-4c5e-806f-e792e8ab1079" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_35cbc334-0be2-4be6-a717-2202d30ce52f" xlink:href="xfor-20230331.xsd#xfor_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_35cbc334-0be2-4be6-a717-2202d30ce52f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_666ac82f-c5ee-41d1-b9d4-ba14694a6e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_666ac82f-c5ee-41d1-b9d4-ba14694a6e2e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b85d7f07-958c-457e-a10e-a7b7b500d391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_NetIncomeLoss_b85d7f07-958c-457e-a10e-a7b7b500d391" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_04f1de20-d288-4ae8-a4d7-7d0b4f81216d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_87ba9171-6e23-42dd-86e2-94371d194209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1ec5e6d3-5102-434d-b403-6771ba89986d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f8fad25f-ded5-4005-bf54-e25957590f77" xlink:to="loc_us-gaap_StatementTable_1ec5e6d3-5102-434d-b403-6771ba89986d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ce32c42f-9bd0-450f-9f15-9e46310dc217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1ec5e6d3-5102-434d-b403-6771ba89986d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ce32c42f-9bd0-450f-9f15-9e46310dc217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ce32c42f-9bd0-450f-9f15-9e46310dc217_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ce32c42f-9bd0-450f-9f15-9e46310dc217" xlink:to="loc_us-gaap_EquityComponentDomain_ce32c42f-9bd0-450f-9f15-9e46310dc217_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_49f952c5-8149-4472-bebb-b153170dca7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ce32c42f-9bd0-450f-9f15-9e46310dc217" xlink:to="loc_us-gaap_EquityComponentDomain_49f952c5-8149-4472-bebb-b153170dca7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0c6419d1-1967-454b-a194-dd954179c5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_49f952c5-8149-4472-bebb-b153170dca7c" xlink:to="loc_us-gaap_CommonStockMember_0c6419d1-1967-454b-a194-dd954179c5a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_687e64a6-6f4d-4928-a94a-cd4769ad872a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_49f952c5-8149-4472-bebb-b153170dca7c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_687e64a6-6f4d-4928-a94a-cd4769ad872a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6ff2af72-b7f5-4863-8346-a1b0bbd36368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_49f952c5-8149-4472-bebb-b153170dca7c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6ff2af72-b7f5-4863-8346-a1b0bbd36368" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c33ab1d5-3788-4831-bbf3-608f237f170b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_49f952c5-8149-4472-bebb-b153170dca7c" xlink:to="loc_us-gaap_RetainedEarningsMember_c33ab1d5-3788-4831-bbf3-608f237f170b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail" xlink:type="extended" id="i96c4d08bccbd432a800028cb19c82ce0_NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_62c99b1e-c2ee-40bf-8686-57fa74d57473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31815535-09d3-4df2-9dab-2b5114735cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_62c99b1e-c2ee-40bf-8686-57fa74d57473" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31815535-09d3-4df2-9dab-2b5114735cf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d92f76dd-bf16-40e0-9926-40d8ecf33cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_62c99b1e-c2ee-40bf-8686-57fa74d57473" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d92f76dd-bf16-40e0-9926-40d8ecf33cf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb6bce7a-a34d-43c6-97fa-e6dc5e889ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_62c99b1e-c2ee-40bf-8686-57fa74d57473" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb6bce7a-a34d-43c6-97fa-e6dc5e889ae4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfAccountingPoliciesTable_c9b71b59-6bcf-4d67-ba97-bcd72362d4e7" xlink:href="xfor-20230331.xsd#xfor_ScheduleOfAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_62c99b1e-c2ee-40bf-8686-57fa74d57473" xlink:to="loc_xfor_ScheduleOfAccountingPoliciesTable_c9b71b59-6bcf-4d67-ba97-bcd72362d4e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5fe3bb8f-4ee8-414d-b6fb-616e3b40dfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_ScheduleOfAccountingPoliciesTable_c9b71b59-6bcf-4d67-ba97-bcd72362d4e7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5fe3bb8f-4ee8-414d-b6fb-616e3b40dfbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5fe3bb8f-4ee8-414d-b6fb-616e3b40dfbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5fe3bb8f-4ee8-414d-b6fb-616e3b40dfbe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5fe3bb8f-4ee8-414d-b6fb-616e3b40dfbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0abed63-da81-4b6a-9c59-9077da5cf9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5fe3bb8f-4ee8-414d-b6fb-616e3b40dfbe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0abed63-da81-4b6a-9c59-9077da5cf9ef" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail" xlink:type="extended" id="i37145fa703a14c36b97be7c3de0de863_SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_31c6e8fa-897a-4a9d-a8dd-828964dc56eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_baea91fa-9bfe-46da-8715-9b58afa6dea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_31c6e8fa-897a-4a9d-a8dd-828964dc56eb" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_baea91fa-9bfe-46da-8715-9b58afa6dea7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_28f61030-1edf-4c83-be59-a02ad61ae692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_31c6e8fa-897a-4a9d-a8dd-828964dc56eb" xlink:to="loc_us-gaap_RestrictedCash_28f61030-1edf-4c83-be59-a02ad61ae692" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_ea69ef7b-1a4f-406b-86f9-fb74f70ab242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_31c6e8fa-897a-4a9d-a8dd-828964dc56eb" xlink:to="loc_us-gaap_RestrictedCashCurrent_ea69ef7b-1a4f-406b-86f9-fb74f70ab242" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_d20765ae-f77d-4e9c-ad83-b0ec883ce07c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_31c6e8fa-897a-4a9d-a8dd-828964dc56eb" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_d20765ae-f77d-4e9c-ad83-b0ec883ce07c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2edd8255-26be-4fbe-acef-83472df75608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_d20765ae-f77d-4e9c-ad83-b0ec883ce07c" xlink:to="loc_us-gaap_CreditFacilityAxis_2edd8255-26be-4fbe-acef-83472df75608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2edd8255-26be-4fbe-acef-83472df75608_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2edd8255-26be-4fbe-acef-83472df75608" xlink:to="loc_us-gaap_CreditFacilityDomain_2edd8255-26be-4fbe-acef-83472df75608_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_668dbe70-f80a-4fba-8fe9-99810369c1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2edd8255-26be-4fbe-acef-83472df75608" xlink:to="loc_us-gaap_CreditFacilityDomain_668dbe70-f80a-4fba-8fe9-99810369c1b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_c97d8662-ff79-4b8d-a5fd-2c14834061f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_668dbe70-f80a-4fba-8fe9-99810369c1b0" xlink:to="loc_us-gaap_LetterOfCreditMember_c97d8662-ff79-4b8d-a5fd-2c14834061f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_0083d5d1-93a4-4629-a796-1cf55490d432" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_d20765ae-f77d-4e9c-ad83-b0ec883ce07c" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_0083d5d1-93a4-4629-a796-1cf55490d432" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0083d5d1-93a4-4629-a796-1cf55490d432_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_0083d5d1-93a4-4629-a796-1cf55490d432" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_0083d5d1-93a4-4629-a796-1cf55490d432_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9740046a-4fb1-4a4e-8845-ad206c31671b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_0083d5d1-93a4-4629-a796-1cf55490d432" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9740046a-4fb1-4a4e-8845-ad206c31671b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WalthamLeaseMember_da3f534a-9bcb-4cdf-a2f0-486823e44986" xlink:href="xfor-20230331.xsd#xfor_WalthamLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9740046a-4fb1-4a4e-8845-ad206c31671b" xlink:to="loc_xfor_WalthamLeaseMember_da3f534a-9bcb-4cdf-a2f0-486823e44986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ViennaLeaseAgreementMember_11ed0810-82e0-430a-8aaa-cd3a898e5c5b" xlink:href="xfor-20230331.xsd#xfor_ViennaLeaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9740046a-4fb1-4a4e-8845-ad206c31671b" xlink:to="loc_xfor_ViennaLeaseAgreementMember_11ed0810-82e0-430a-8aaa-cd3a898e5c5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AllstonLeaseAgreementMember_becbde97-e81f-4505-a9a4-0e079ab33a4b" xlink:href="xfor-20230331.xsd#xfor_AllstonLeaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9740046a-4fb1-4a4e-8845-ad206c31671b" xlink:to="loc_xfor_AllstonLeaseAgreementMember_becbde97-e81f-4505-a9a4-0e079ab33a4b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail" xlink:type="extended" id="ieb89edcc97ce49c2a2d55e033cf1cdf9_LicenseCollaborationandFundingAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_97601e43-6785-4e94-8c1f-997cce16755e" xlink:href="xfor-20230331.xsd#xfor_CollaborationLicenseAndFundingArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GrantAndIncentiveReceivables_42449547-7cb6-4319-8200-ee1e767abfff" xlink:href="xfor-20230331.xsd#xfor_GrantAndIncentiveReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_97601e43-6785-4e94-8c1f-997cce16755e" xlink:to="loc_xfor_GrantAndIncentiveReceivables_42449547-7cb6-4319-8200-ee1e767abfff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_62d76a59-c463-4e6e-b107-ef6a792268a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_97601e43-6785-4e94-8c1f-997cce16755e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_62d76a59-c463-4e6e-b107-ef6a792268a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_bc91fc33-07a3-4254-8af9-3ef492563e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_97601e43-6785-4e94-8c1f-997cce16755e" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_bc91fc33-07a3-4254-8af9-3ef492563e8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborationLicenseAndFundingArrangementsTable_cb0b8af1-45f7-4561-8c90-dae3372ea553" xlink:href="xfor-20230331.xsd#xfor_CollaborationLicenseAndFundingArrangementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_97601e43-6785-4e94-8c1f-997cce16755e" xlink:to="loc_xfor_CollaborationLicenseAndFundingArrangementsTable_cb0b8af1-45f7-4561-8c90-dae3372ea553" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_69f4ef99-eac7-46b3-bc81-e04e7771959c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsTable_cb0b8af1-45f7-4561-8c90-dae3372ea553" xlink:to="loc_us-gaap_TypeOfArrangementAxis_69f4ef99-eac7-46b3-bc81-e04e7771959c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_69f4ef99-eac7-46b3-bc81-e04e7771959c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_69f4ef99-eac7-46b3-bc81-e04e7771959c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_69f4ef99-eac7-46b3-bc81-e04e7771959c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dcba6be1-4c33-4304-b5b6-1398cccf768f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_69f4ef99-eac7-46b3-bc81-e04e7771959c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dcba6be1-4c33-4304-b5b6-1398cccf768f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember_f4b8c9a0-a931-472d-afb0-7b395ae0c516" xlink:href="xfor-20230331.xsd#xfor_ResearchAndDevelopmentIncentiveProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dcba6be1-4c33-4304-b5b6-1398cccf768f" xlink:to="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember_f4b8c9a0-a931-472d-afb0-7b395ae0c516" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail" xlink:type="extended" id="iefc8d8b35a864df1ad9e40cfb6079cd3_FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail">
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_98608948-1e63-4932-af23-744aa2515118" xlink:href="xfor-20230331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_eded0c27-59b0-4cda-a3d1-3c2a9c6d3c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_98608948-1e63-4932-af23-744aa2515118" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_eded0c27-59b0-4cda-a3d1-3c2a9c6d3c8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_b320fd58-54fd-48f3-b4d7-40c154483891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_98608948-1e63-4932-af23-744aa2515118" xlink:to="loc_us-gaap_DerivativeLiabilities_b320fd58-54fd-48f3-b4d7-40c154483891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_ca80f5d4-17a9-48f7-be5c-3684474fed63" xlink:href="xfor-20230331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_98608948-1e63-4932-af23-744aa2515118" xlink:to="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_ca80f5d4-17a9-48f7-be5c-3684474fed63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b461be5-1039-4223-8b24-30cc8990d354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_ca80f5d4-17a9-48f7-be5c-3684474fed63" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b461be5-1039-4223-8b24-30cc8990d354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3b461be5-1039-4223-8b24-30cc8990d354_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b461be5-1039-4223-8b24-30cc8990d354" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3b461be5-1039-4223-8b24-30cc8990d354_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_266d4dac-be91-4c9f-b47c-9ab5a8224019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b461be5-1039-4223-8b24-30cc8990d354" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_266d4dac-be91-4c9f-b47c-9ab5a8224019" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8eb953c6-f8d5-45be-9b7c-8728616e016d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_266d4dac-be91-4c9f-b47c-9ab5a8224019" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8eb953c6-f8d5-45be-9b7c-8728616e016d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_acdb7c69-5123-4540-9680-a0a5f7875208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_ca80f5d4-17a9-48f7-be5c-3684474fed63" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_acdb7c69-5123-4540-9680-a0a5f7875208" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_acdb7c69-5123-4540-9680-a0a5f7875208_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_acdb7c69-5123-4540-9680-a0a5f7875208" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_acdb7c69-5123-4540-9680-a0a5f7875208_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49356b77-83b3-4c49-a825-8946f93ec6af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_acdb7c69-5123-4540-9680-a0a5f7875208" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49356b77-83b3-4c49-a825-8946f93ec6af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ced7ae29-ad6f-4221-be0a-8f4c726f7fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49356b77-83b3-4c49-a825-8946f93ec6af" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ced7ae29-ad6f-4221-be0a-8f4c726f7fff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e7476d53-7457-49e2-807f-6b387131ac59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49356b77-83b3-4c49-a825-8946f93ec6af" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e7476d53-7457-49e2-807f-6b387131ac59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e2f100ca-c2bb-4b88-9cd8-62f75069c4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49356b77-83b3-4c49-a825-8946f93ec6af" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e2f100ca-c2bb-4b88-9cd8-62f75069c4ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_c022fd1d-cf3f-49e8-8181-893523cde05b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_ca80f5d4-17a9-48f7-be5c-3684474fed63" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_c022fd1d-cf3f-49e8-8181-893523cde05b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c022fd1d-cf3f-49e8-8181-893523cde05b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_c022fd1d-cf3f-49e8-8181-893523cde05b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c022fd1d-cf3f-49e8-8181-893523cde05b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fc073ba9-656f-49d1-8b8b-f4b0382af8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_c022fd1d-cf3f-49e8-8181-893523cde05b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fc073ba9-656f-49d1-8b8b-f4b0382af8ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_8f6b40f8-4a61-4849-8fd7-7259de2935c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fc073ba9-656f-49d1-8b8b-f4b0382af8ae" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_8f6b40f8-4a61-4849-8fd7-7259de2935c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c3e2bf8c-b843-4d89-b0a8-d18fc0587b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fc073ba9-656f-49d1-8b8b-f4b0382af8ae" xlink:to="loc_us-gaap_WarrantMember_c3e2bf8c-b843-4d89-b0a8-d18fc0587b75" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails" xlink:type="simple" xlink:href="xfor-20230331.xsd#FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails" xlink:type="extended" id="i4cfe2879e5e84c8caf3ca4de97af41e9_FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_3007c150-6731-4f47-9825-167bdc35900a" xlink:href="xfor-20230331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7ae3eb29-9997-4be9-b588-51068e713910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_3007c150-6731-4f47-9825-167bdc35900a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7ae3eb29-9997-4be9-b588-51068e713910" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_dcae25bc-4997-4144-9337-892d9f3f7a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7ae3eb29-9997-4be9-b588-51068e713910" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_dcae25bc-4997-4144-9337-892d9f3f7a48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2ae68b32-90ce-4ba3-a86b-7e09dfdaa6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7ae3eb29-9997-4be9-b588-51068e713910" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2ae68b32-90ce-4ba3-a86b-7e09dfdaa6e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a5b86e6d-d84b-4ace-a007-3ce0e4dd9081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_4ed4a547-1296-45d4-9ff7-cb37208cedb3" xlink:href="xfor-20230331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_3007c150-6731-4f47-9825-167bdc35900a" xlink:to="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_4ed4a547-1296-45d4-9ff7-cb37208cedb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8c2fe628-038c-4316-828a-4b99bff1370d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_4ed4a547-1296-45d4-9ff7-cb37208cedb3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8c2fe628-038c-4316-828a-4b99bff1370d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8c2fe628-038c-4316-828a-4b99bff1370d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8c2fe628-038c-4316-828a-4b99bff1370d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8c2fe628-038c-4316-828a-4b99bff1370d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c9f0491-f761-41f3-bfbe-d05855a3b5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8c2fe628-038c-4316-828a-4b99bff1370d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c9f0491-f761-41f3-bfbe-d05855a3b5ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_c53d49cb-6774-4e11-9e52-fb714c303415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c9f0491-f761-41f3-bfbe-d05855a3b5ef" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_c53d49cb-6774-4e11-9e52-fb714c303415" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b3f3375f-e1eb-435a-9bf4-f1305248bb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c9f0491-f761-41f3-bfbe-d05855a3b5ef" xlink:to="loc_us-gaap_WarrantMember_b3f3375f-e1eb-435a-9bf4-f1305248bb9f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="xfor-20230331.xsd#FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" xlink:type="extended" id="if01ec64cc43a49d3a375459a2498102a_FairValueofFinancialAssetsandLiabilitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_af947ec0-4c74-464d-acb7-52e4b7e6ccab" xlink:href="xfor-20230331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_9b7f15c0-62c2-4142-afda-b1ca0323f4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_af947ec0-4c74-464d-acb7-52e4b7e6ccab" xlink:to="loc_us-gaap_DerivativeLiabilities_9b7f15c0-62c2-4142-afda-b1ca0323f4e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_851b0a32-0a88-4ef8-ad65-1db72decdcb7" xlink:href="xfor-20230331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_af947ec0-4c74-464d-acb7-52e4b7e6ccab" xlink:to="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_851b0a32-0a88-4ef8-ad65-1db72decdcb7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_27c3c528-6095-4372-8fd1-4c6b4a7f51c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_851b0a32-0a88-4ef8-ad65-1db72decdcb7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_27c3c528-6095-4372-8fd1-4c6b4a7f51c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_27c3c528-6095-4372-8fd1-4c6b4a7f51c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_27c3c528-6095-4372-8fd1-4c6b4a7f51c1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_27c3c528-6095-4372-8fd1-4c6b4a7f51c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_09d54a94-3a60-4a93-8944-d80d7d47918c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_27c3c528-6095-4372-8fd1-4c6b4a7f51c1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_09d54a94-3a60-4a93-8944-d80d7d47918c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_bcb824d3-cc22-4bcc-9d36-a3e0dd890d91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_09d54a94-3a60-4a93-8944-d80d7d47918c" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_bcb824d3-cc22-4bcc-9d36-a3e0dd890d91" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails" xlink:type="simple" xlink:href="xfor-20230331.xsd#FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails" xlink:type="extended" id="i1d9d796ff6db4da8906f1902f4ea259e_FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb63995f-d224-4af5-a26b-46308400def0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_bd13c6c2-7842-49cc-bbae-15b5a24b3899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb63995f-d224-4af5-a26b-46308400def0" xlink:to="loc_us-gaap_SharePrice_bd13c6c2-7842-49cc-bbae-15b5a24b3899" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_628e9f4f-35d8-41fd-86d8-67132d0f3df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb63995f-d224-4af5-a26b-46308400def0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_628e9f4f-35d8-41fd-86d8-67132d0f3df9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e543ea76-b388-4ecb-b79c-29d397d7bc94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb63995f-d224-4af5-a26b-46308400def0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e543ea76-b388-4ecb-b79c-29d397d7bc94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_702c3448-2d25-4663-9cf1-fd53e24b32aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb63995f-d224-4af5-a26b-46308400def0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_702c3448-2d25-4663-9cf1-fd53e24b32aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9edd68a0-4274-43fd-87cc-45adcb0ded3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb63995f-d224-4af5-a26b-46308400def0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9edd68a0-4274-43fd-87cc-45adcb0ded3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e6c59905-26d4-425e-b47a-bc61682c53f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb63995f-d224-4af5-a26b-46308400def0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e6c59905-26d4-425e-b47a-bc61682c53f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_778cd2ae-6650-4121-99c1-ce6c9c97d596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb63995f-d224-4af5-a26b-46308400def0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_778cd2ae-6650-4121-99c1-ce6c9c97d596" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_76dd0d72-2c7e-419a-8031-8ba14db70e59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_778cd2ae-6650-4121-99c1-ce6c9c97d596" xlink:to="loc_us-gaap_AwardTypeAxis_76dd0d72-2c7e-419a-8031-8ba14db70e59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76dd0d72-2c7e-419a-8031-8ba14db70e59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_76dd0d72-2c7e-419a-8031-8ba14db70e59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76dd0d72-2c7e-419a-8031-8ba14db70e59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a19c79ce-e47d-4f08-81af-f5cafff3e1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_76dd0d72-2c7e-419a-8031-8ba14db70e59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a19c79ce-e47d-4f08-81af-f5cafff3e1e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_7dce4e79-3287-4c1b-86f0-949ab5caf806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a19c79ce-e47d-4f08-81af-f5cafff3e1e6" xlink:to="loc_us-gaap_WarrantMember_7dce4e79-3287-4c1b-86f0-949ab5caf806" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail" xlink:type="extended" id="i84be9d35b86b4614a138c1a662452108_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_19901095-5a56-4d17-a1ba-6e9a7611c21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6410fd85-f387-4607-b312-c1696d1aca64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_19901095-5a56-4d17-a1ba-6e9a7611c21c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6410fd85-f387-4607-b312-c1696d1aca64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_12408728-e68e-4453-94c9-b7f77b997034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_19901095-5a56-4d17-a1ba-6e9a7611c21c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_12408728-e68e-4453-94c9-b7f77b997034" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f6f3a0fa-04ae-439a-8152-0d6612772134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_19901095-5a56-4d17-a1ba-6e9a7611c21c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f6f3a0fa-04ae-439a-8152-0d6612772134" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_147ed715-12df-4a3b-ab52-b97cfa3da49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_19901095-5a56-4d17-a1ba-6e9a7611c21c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_147ed715-12df-4a3b-ab52-b97cfa3da49c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93196610-9de8-469f-a29b-fbdd8a50960d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_147ed715-12df-4a3b-ab52-b97cfa3da49c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93196610-9de8-469f-a29b-fbdd8a50960d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_93196610-9de8-469f-a29b-fbdd8a50960d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93196610-9de8-469f-a29b-fbdd8a50960d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_93196610-9de8-469f-a29b-fbdd8a50960d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01330cfe-bc0e-4269-9d75-4d4389f8d6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93196610-9de8-469f-a29b-fbdd8a50960d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01330cfe-bc0e-4269-9d75-4d4389f8d6e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1d180e12-2098-41ed-9a73-81641c4cd23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01330cfe-bc0e-4269-9d75-4d4389f8d6e9" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1d180e12-2098-41ed-9a73-81641c4cd23e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f8233f87-a453-4f92-9eb9-d78ba5b2d9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01330cfe-bc0e-4269-9d75-4d4389f8d6e9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f8233f87-a453-4f92-9eb9-d78ba5b2d9f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_0571a0d5-0b1e-4479-ae18-ff2ce794cf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01330cfe-bc0e-4269-9d75-4d4389f8d6e9" xlink:to="loc_us-gaap_ComputerEquipmentMember_0571a0d5-0b1e-4479-ae18-ff2ce794cf9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SoftwareMember_bdae57dc-2aab-4012-8b1b-c79fffc74bc2" xlink:href="xfor-20230331.xsd#xfor_SoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01330cfe-bc0e-4269-9d75-4d4389f8d6e9" xlink:to="loc_xfor_SoftwareMember_bdae57dc-2aab-4012-8b1b-c79fffc74bc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LabEquipmentMember_8a342c3e-6aba-42d5-b2f7-76e5f2acafbe" xlink:href="xfor-20230331.xsd#xfor_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01330cfe-bc0e-4269-9d75-4d4389f8d6e9" xlink:to="loc_xfor_LabEquipmentMember_8a342c3e-6aba-42d5-b2f7-76e5f2acafbe" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail" xlink:type="extended" id="ib141e16524774ce9879b5d3730624016_LongTermDebtHerculesLoanAgreementAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_0aa89a5f-1fed-4879-b270-a34eb367fc32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_0aa89a5f-1fed-4879-b270-a34eb367fc32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_afcfa348-907e-447c-b150-5984b074780e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_afcfa348-907e-447c-b150-5984b074780e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_2098a439-8c2f-4d21-a5a7-bdcd208f72ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_2098a439-8c2f-4d21-a5a7-bdcd208f72ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DebtInstrumentPrepaymentPremiumPercentage_492d4154-ae2b-4c04-b0d2-c03c97fc1bcc" xlink:href="xfor-20230331.xsd#xfor_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:to="loc_xfor_DebtInstrumentPrepaymentPremiumPercentage_492d4154-ae2b-4c04-b0d2-c03c97fc1bcc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_67902c45-2eec-4832-aa61-0fa9c2e831a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_67902c45-2eec-4832-aa61-0fa9c2e831a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditCovenantMinimumCash_824e50ee-cff0-4f2d-80c0-5750987e7e29" xlink:href="xfor-20230331.xsd#xfor_LineOfCreditCovenantMinimumCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:to="loc_xfor_LineOfCreditCovenantMinimumCash_824e50ee-cff0-4f2d-80c0-5750987e7e29" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_790e710d-af72-4fec-9bd8-11d8dffb1018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_790e710d-af72-4fec-9bd8-11d8dffb1018" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_a5fde19c-a3b5-4f44-9ca6-1aca7ea071a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_a5fde19c-a3b5-4f44-9ca6-1aca7ea071a3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5e58e6ab-ed0f-4911-9cb8-0c75189f2cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:to="loc_us-gaap_DebtInstrumentTable_5e58e6ab-ed0f-4911-9cb8-0c75189f2cef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f23a68a7-0f4c-4c03-944c-707b4b52d5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5e58e6ab-ed0f-4911-9cb8-0c75189f2cef" xlink:to="loc_us-gaap_DebtInstrumentAxis_f23a68a7-0f4c-4c03-944c-707b4b52d5eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f23a68a7-0f4c-4c03-944c-707b4b52d5eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f23a68a7-0f4c-4c03-944c-707b4b52d5eb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f23a68a7-0f4c-4c03-944c-707b4b52d5eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4924a6c4-f802-4460-abb6-2911edeadf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f23a68a7-0f4c-4c03-944c-707b4b52d5eb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4924a6c4-f802-4460-abb6-2911edeadf6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesLoanAgreementMember_9181a0fb-160a-43b8-ac3f-144f2a7ea899" xlink:href="xfor-20230331.xsd#xfor_HerculesLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4924a6c4-f802-4460-abb6-2911edeadf6c" xlink:to="loc_xfor_HerculesLoanAgreementMember_9181a0fb-160a-43b8-ac3f-144f2a7ea899" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesSecondAmendedLoanAgreementMember_a1d5fe53-2b52-4439-b922-9623c9fb90b3" xlink:href="xfor-20230331.xsd#xfor_HerculesSecondAmendedLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4924a6c4-f802-4460-abb6-2911edeadf6c" xlink:to="loc_xfor_HerculesSecondAmendedLoanAgreementMember_a1d5fe53-2b52-4439-b922-9623c9fb90b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_91c89374-4efe-4b1b-a5ef-f2d970d159f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5e58e6ab-ed0f-4911-9cb8-0c75189f2cef" xlink:to="loc_us-gaap_VariableRateAxis_91c89374-4efe-4b1b-a5ef-f2d970d159f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_91c89374-4efe-4b1b-a5ef-f2d970d159f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_91c89374-4efe-4b1b-a5ef-f2d970d159f1" xlink:to="loc_us-gaap_VariableRateDomain_91c89374-4efe-4b1b-a5ef-f2d970d159f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8318023b-fbce-4726-b14d-3cde5e827c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_91c89374-4efe-4b1b-a5ef-f2d970d159f1" xlink:to="loc_us-gaap_VariableRateDomain_8318023b-fbce-4726-b14d-3cde5e827c2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_0fb4356a-19e1-4ff2-b7c6-3379604ea059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_8318023b-fbce-4726-b14d-3cde5e827c2b" xlink:to="loc_us-gaap_PrimeRateMember_0fb4356a-19e1-4ff2-b7c6-3379604ea059" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f9a0ab0c-8906-4f81-b58c-91e9100d3a79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5e58e6ab-ed0f-4911-9cb8-0c75189f2cef" xlink:to="loc_srt_RangeAxis_f9a0ab0c-8906-4f81-b58c-91e9100d3a79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f9a0ab0c-8906-4f81-b58c-91e9100d3a79_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f9a0ab0c-8906-4f81-b58c-91e9100d3a79" xlink:to="loc_srt_RangeMember_f9a0ab0c-8906-4f81-b58c-91e9100d3a79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9628a3ca-2051-4c1a-8835-7213f5c5b2b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f9a0ab0c-8906-4f81-b58c-91e9100d3a79" xlink:to="loc_srt_RangeMember_9628a3ca-2051-4c1a-8835-7213f5c5b2b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_29ad107a-3907-44bd-869c-bbfcca67635c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9628a3ca-2051-4c1a-8835-7213f5c5b2b1" xlink:to="loc_srt_MaximumMember_29ad107a-3907-44bd-869c-bbfcca67635c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3f0dbb71-11b5-4c7a-83ed-2df59261c6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5e58e6ab-ed0f-4911-9cb8-0c75189f2cef" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3f0dbb71-11b5-4c7a-83ed-2df59261c6f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_3f0dbb71-11b5-4c7a-83ed-2df59261c6f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3f0dbb71-11b5-4c7a-83ed-2df59261c6f6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_3f0dbb71-11b5-4c7a-83ed-2df59261c6f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_cb16b299-eaee-47ea-85c7-d20b089263fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3f0dbb71-11b5-4c7a-83ed-2df59261c6f6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_cb16b299-eaee-47ea-85c7-d20b089263fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_fb5deb5e-a414-4d54-be8e-c7f5cfc90eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_cb16b299-eaee-47ea-85c7-d20b089263fc" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_fb5deb5e-a414-4d54-be8e-c7f5cfc90eee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1e336b04-f005-4156-b880-ccb7930a48ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5e58e6ab-ed0f-4911-9cb8-0c75189f2cef" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1e336b04-f005-4156-b880-ccb7930a48ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1e336b04-f005-4156-b880-ccb7930a48ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1e336b04-f005-4156-b880-ccb7930a48ab" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1e336b04-f005-4156-b880-ccb7930a48ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f1a57516-ed85-4af5-a28e-038add75636e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1e336b04-f005-4156-b880-ccb7930a48ab" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f1a57516-ed85-4af5-a28e-038add75636e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_82437120-f081-4c22-9774-1f88772728b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f1a57516-ed85-4af5-a28e-038add75636e" xlink:to="loc_us-gaap_SubsequentEventMember_82437120-f081-4c22-9774-1f88772728b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_08ee129a-d2d2-4a31-a363-483d7a61dcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5e58e6ab-ed0f-4911-9cb8-0c75189f2cef" xlink:to="loc_us-gaap_CreditFacilityAxis_08ee129a-d2d2-4a31-a363-483d7a61dcb4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_08ee129a-d2d2-4a31-a363-483d7a61dcb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_08ee129a-d2d2-4a31-a363-483d7a61dcb4" xlink:to="loc_us-gaap_CreditFacilityDomain_08ee129a-d2d2-4a31-a363-483d7a61dcb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9374af7c-004d-4088-8c09-5f134fa97ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_08ee129a-d2d2-4a31-a363-483d7a61dcb4" xlink:to="loc_us-gaap_CreditFacilityDomain_9374af7c-004d-4088-8c09-5f134fa97ef5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate1Member_bffb52b6-5fd8-4480-be0b-8c2481c7d9c1" xlink:href="xfor-20230331.xsd#xfor_MinCashTestDate1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_9374af7c-004d-4088-8c09-5f134fa97ef5" xlink:to="loc_xfor_MinCashTestDate1Member_bffb52b6-5fd8-4480-be0b-8c2481c7d9c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate2Member_fa6a13a8-c45f-438b-8ae7-5d5097ee0aed" xlink:href="xfor-20230331.xsd#xfor_MinCashTestDate2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_9374af7c-004d-4088-8c09-5f134fa97ef5" xlink:to="loc_xfor_MinCashTestDate2Member_fa6a13a8-c45f-438b-8ae7-5d5097ee0aed" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails" xlink:type="simple" xlink:href="xfor-20230331.xsd#LongTermDebtSummaryofInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails" xlink:type="extended" id="idea2ea749d5a4668b3dbd5d86113909a_LongTermDebtSummaryofInterestExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cfde9957-2230-4737-a5d0-005d0d37d495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_e16d0dd2-c367-49ed-ac14-bb97fdc1db2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cfde9957-2230-4737-a5d0-005d0d37d495" xlink:to="loc_us-gaap_InterestExpenseDebt_e16d0dd2-c367-49ed-ac14-bb97fdc1db2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_9854e900-dd1f-4d0d-bad3-b882b4447ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cfde9957-2230-4737-a5d0-005d0d37d495" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_9854e900-dd1f-4d0d-bad3-b882b4447ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6601da3a-d72f-4793-b326-c4bc92f46440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cfde9957-2230-4737-a5d0-005d0d37d495" xlink:to="loc_us-gaap_DebtInstrumentTable_6601da3a-d72f-4793-b326-c4bc92f46440" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_494c4827-cfce-4757-96d1-a8ebc146294a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6601da3a-d72f-4793-b326-c4bc92f46440" xlink:to="loc_us-gaap_DebtInstrumentAxis_494c4827-cfce-4757-96d1-a8ebc146294a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_494c4827-cfce-4757-96d1-a8ebc146294a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_494c4827-cfce-4757-96d1-a8ebc146294a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_494c4827-cfce-4757-96d1-a8ebc146294a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_785aa300-0fe7-4043-9edd-1b92c927878f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_494c4827-cfce-4757-96d1-a8ebc146294a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_785aa300-0fe7-4043-9edd-1b92c927878f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesLoanAgreementMember_37f9be9e-2e9d-4582-b310-cec7861f6626" xlink:href="xfor-20230331.xsd#xfor_HerculesLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_785aa300-0fe7-4043-9edd-1b92c927878f" xlink:to="loc_xfor_HerculesLoanAgreementMember_37f9be9e-2e9d-4582-b310-cec7861f6626" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7e7f5caa-1cf6-4880-ab9a-c5f2f92e6dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6601da3a-d72f-4793-b326-c4bc92f46440" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7e7f5caa-1cf6-4880-ab9a-c5f2f92e6dd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7e7f5caa-1cf6-4880-ab9a-c5f2f92e6dd9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7e7f5caa-1cf6-4880-ab9a-c5f2f92e6dd9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7e7f5caa-1cf6-4880-ab9a-c5f2f92e6dd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_aed56d1a-8b0b-4c31-993e-58776875b9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7e7f5caa-1cf6-4880-ab9a-c5f2f92e6dd9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_aed56d1a-8b0b-4c31-993e-58776875b9f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_5997e5e7-6095-4ea9-b136-bfd9dee6413b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6601da3a-d72f-4793-b326-c4bc92f46440" xlink:to="loc_us-gaap_VariableRateAxis_5997e5e7-6095-4ea9-b136-bfd9dee6413b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_5997e5e7-6095-4ea9-b136-bfd9dee6413b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_5997e5e7-6095-4ea9-b136-bfd9dee6413b" xlink:to="loc_us-gaap_VariableRateDomain_5997e5e7-6095-4ea9-b136-bfd9dee6413b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_96297996-27c6-431c-af76-426090e6f9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_5997e5e7-6095-4ea9-b136-bfd9dee6413b" xlink:to="loc_us-gaap_VariableRateDomain_96297996-27c6-431c-af76-426090e6f9e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2aa4b3c3-864f-4f27-a58b-4a9cdc4240e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6601da3a-d72f-4793-b326-c4bc92f46440" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2aa4b3c3-864f-4f27-a58b-4a9cdc4240e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2aa4b3c3-864f-4f27-a58b-4a9cdc4240e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2aa4b3c3-864f-4f27-a58b-4a9cdc4240e7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2aa4b3c3-864f-4f27-a58b-4a9cdc4240e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2333510b-e1b0-434a-b819-556aeb6ff169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2aa4b3c3-864f-4f27-a58b-4a9cdc4240e7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2333510b-e1b0-434a-b819-556aeb6ff169" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ddaedfc9-ad19-4269-ad17-ac2916c28ee1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6601da3a-d72f-4793-b326-c4bc92f46440" xlink:to="loc_srt_RangeAxis_ddaedfc9-ad19-4269-ad17-ac2916c28ee1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ddaedfc9-ad19-4269-ad17-ac2916c28ee1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ddaedfc9-ad19-4269-ad17-ac2916c28ee1" xlink:to="loc_srt_RangeMember_ddaedfc9-ad19-4269-ad17-ac2916c28ee1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_01addccb-37e2-4914-a23c-640e23106990" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ddaedfc9-ad19-4269-ad17-ac2916c28ee1" xlink:to="loc_srt_RangeMember_01addccb-37e2-4914-a23c-640e23106990" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#LeasesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/LeasesAdditionalInformationDetail" xlink:type="extended" id="i928f308380424379b2f68afd0d6bed70_LeasesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement_ee10d983-802a-477b-b563-4c77e27824e5" xlink:href="xfor-20230331.xsd#xfor_CurrentOfficeSpaceUnderLeaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement_ee10d983-802a-477b-b563-4c77e27824e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AggregateBaseRent_a3030543-53ce-403a-916e-3fef6839dedf" xlink:href="xfor-20230331.xsd#xfor_AggregateBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_xfor_AggregateBaseRent_a3030543-53ce-403a-916e-3fef6839dedf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9b73b8bd-38af-440f-8496-c1d028fcde47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9b73b8bd-38af-440f-8496-c1d028fcde47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_c4f03bd7-2489-495b-8da6-3372c34d1e8d" xlink:href="xfor-20230331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_c4f03bd7-2489-495b-8da6-3372c34d1e8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_f74ad5d1-9081-4b61-8337-5d5a7e348be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_f74ad5d1-9081-4b61-8337-5d5a7e348be1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent_a3d10a22-3929-40dd-8ce6-543aa39fc195" xlink:href="xfor-20230331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent_a3d10a22-3929-40dd-8ce6-543aa39fc195" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_5d0ee844-c86f-49a3-a968-9436c15eaea3" xlink:href="xfor-20230331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_5d0ee844-c86f-49a3-a968-9436c15eaea3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_58def249-9405-4666-ac83-4ddd6d97e2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_58def249-9405-4666-ac83-4ddd6d97e2a1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d811482e-aaa2-4904-b216-49b19cb688c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_us-gaap_OperatingLeaseLiability_d811482e-aaa2-4904-b216-49b19cb688c7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_82f34258-bcb6-4302-9525-3af5b4faf9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_82f34258-bcb6-4302-9525-3af5b4faf9ea" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ac3cad04-c91b-4bfc-b77c-296f02264a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ac3cad04-c91b-4bfc-b77c-296f02264a1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9f9f41c7-2c1e-4155-9b45-36563417f09f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ac3cad04-c91b-4bfc-b77c-296f02264a1c" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9f9f41c7-2c1e-4155-9b45-36563417f09f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9f9f41c7-2c1e-4155-9b45-36563417f09f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9f9f41c7-2c1e-4155-9b45-36563417f09f" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9f9f41c7-2c1e-4155-9b45-36563417f09f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_140c71cf-2ae9-48c2-b3ee-2e159e6b8cd4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9f9f41c7-2c1e-4155-9b45-36563417f09f" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_140c71cf-2ae9-48c2-b3ee-2e159e6b8cd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WalthamLeaseMember_b159d44d-9a8f-4620-8182-11886aef6d4b" xlink:href="xfor-20230331.xsd#xfor_WalthamLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_140c71cf-2ae9-48c2-b3ee-2e159e6b8cd4" xlink:to="loc_xfor_WalthamLeaseMember_b159d44d-9a8f-4620-8182-11886aef6d4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ViennaAustriaLeaseMember_58d069cf-cd04-4ed1-804d-72fd42b1264e" xlink:href="xfor-20230331.xsd#xfor_ViennaAustriaLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_140c71cf-2ae9-48c2-b3ee-2e159e6b8cd4" xlink:to="loc_xfor_ViennaAustriaLeaseMember_58d069cf-cd04-4ed1-804d-72fd42b1264e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AllstonLeaseMember_f69ab18f-29e7-45f2-bfb7-b7f72866c505" xlink:href="xfor-20230331.xsd#xfor_AllstonLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_140c71cf-2ae9-48c2-b3ee-2e159e6b8cd4" xlink:to="loc_xfor_AllstonLeaseMember_f69ab18f-29e7-45f2-bfb7-b7f72866c505" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#CommitmentandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail" xlink:type="extended" id="icd43cabbf48b45b99b0add8de4ea7408_CommitmentandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ContingenciesAndCommitmentsLineItems_20837380-10c3-41e3-89b8-8509ad00d057" xlink:href="xfor-20230331.xsd#xfor_ContingenciesAndCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_8fb319af-8533-4d92-96fa-1278479f5785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_ContingenciesAndCommitmentsLineItems_20837380-10c3-41e3-89b8-8509ad00d057" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_8fb319af-8533-4d92-96fa-1278479f5785" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ContingenciesAndCommitmentsTable_595e3295-6e61-4ebc-926b-22bd7cfe6d8f" xlink:href="xfor-20230331.xsd#xfor_ContingenciesAndCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_xfor_ContingenciesAndCommitmentsLineItems_20837380-10c3-41e3-89b8-8509ad00d057" xlink:to="loc_xfor_ContingenciesAndCommitmentsTable_595e3295-6e61-4ebc-926b-22bd7cfe6d8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_29056540-bc69-4e44-8352-dc5249163897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_xfor_ContingenciesAndCommitmentsTable_595e3295-6e61-4ebc-926b-22bd7cfe6d8f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_29056540-bc69-4e44-8352-dc5249163897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_29056540-bc69-4e44-8352-dc5249163897_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_29056540-bc69-4e44-8352-dc5249163897" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_29056540-bc69-4e44-8352-dc5249163897_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e2c659b1-37c3-4ea1-9355-ddc426e3ae26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_29056540-bc69-4e44-8352-dc5249163897" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e2c659b1-37c3-4ea1-9355-ddc426e3ae26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IndemnificationAgreementsMember_e9dcc421-1119-4dcc-82df-4fa8bd20dfe6" xlink:href="xfor-20230331.xsd#xfor_IndemnificationAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e2c659b1-37c3-4ea1-9355-ddc426e3ae26" xlink:to="loc_xfor_IndemnificationAgreementsMember_e9dcc421-1119-4dcc-82df-4fa8bd20dfe6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#CommonStockWarrantsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail" xlink:type="extended" id="id750b8e62cb24694b99fce7462fddfb3_CommonStockWarrantsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_6839ede4-e1a4-4b16-a089-77dc75d117a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fa49b5ad-0ca6-4e5a-a4b3-61196909f2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6839ede4-e1a4-4b16-a089-77dc75d117a5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fa49b5ad-0ca6-4e5a-a4b3-61196909f2c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_18a81237-0258-47c1-a3bd-a7054d2a7cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6839ede4-e1a4-4b16-a089-77dc75d117a5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_18a81237-0258-47c1-a3bd-a7054d2a7cfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_7b6e3369-0a50-44b3-ad06-48cf56a49945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6839ede4-e1a4-4b16-a089-77dc75d117a5" xlink:to="loc_us-gaap_DividendsCommonStock_7b6e3369-0a50-44b3-ad06-48cf56a49945" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_e4923b43-cc8d-4fd5-bb45-453fdb92eb74" xlink:href="xfor-20230331.xsd#xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6839ede4-e1a4-4b16-a089-77dc75d117a5" xlink:to="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_e4923b43-cc8d-4fd5-bb45-453fdb92eb74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_715c6056-0a50-4667-906c-97d4476ebcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6839ede4-e1a4-4b16-a089-77dc75d117a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_715c6056-0a50-4667-906c-97d4476ebcc6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_59efe203-2ed9-49f0-88f2-7502ed50c57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_715c6056-0a50-4667-906c-97d4476ebcc6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_59efe203-2ed9-49f0-88f2-7502ed50c57b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_59efe203-2ed9-49f0-88f2-7502ed50c57b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_59efe203-2ed9-49f0-88f2-7502ed50c57b" xlink:to="loc_us-gaap_EquityComponentDomain_59efe203-2ed9-49f0-88f2-7502ed50c57b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9adb96bd-4fbf-42a8-9e3d-77b0e8901893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_59efe203-2ed9-49f0-88f2-7502ed50c57b" xlink:to="loc_us-gaap_EquityComponentDomain_9adb96bd-4fbf-42a8-9e3d-77b0e8901893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_Q12022PrivatePlacementMember_7a3432ce-e2d0-455f-b943-b2b8a1418ad8" xlink:href="xfor-20230331.xsd#xfor_Q12022PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9adb96bd-4fbf-42a8-9e3d-77b0e8901893" xlink:to="loc_xfor_Q12022PrivatePlacementMember_7a3432ce-e2d0-455f-b943-b2b8a1418ad8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail" xlink:type="extended" id="i938aa950841c46f2a4a482ac6fa72a5a_CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_358dbc55-a100-4498-8b0d-003cc6f126e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f801aad9-4019-49e3-aaa4-a2133046d3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_358dbc55-a100-4498-8b0d-003cc6f126e2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f801aad9-4019-49e3-aaa4-a2133046d3b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9b828e68-3ef9-4ee6-a9a4-15c635c91342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_358dbc55-a100-4498-8b0d-003cc6f126e2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9b828e68-3ef9-4ee6-a9a4-15c635c91342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_32e3c4ed-28cd-4a9c-8fdd-0cc2fdca27be" xlink:href="xfor-20230331.xsd#xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_358dbc55-a100-4498-8b0d-003cc6f126e2" xlink:to="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_32e3c4ed-28cd-4a9c-8fdd-0cc2fdca27be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_a2768c5f-fa50-45b5-a94e-72d3e2fbf338" xlink:href="xfor-20230331.xsd#xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_358dbc55-a100-4498-8b0d-003cc6f126e2" xlink:to="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_a2768c5f-fa50-45b5-a94e-72d3e2fbf338" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_a9b7d0e4-cfe6-40f4-b74b-184b848550ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_358dbc55-a100-4498-8b0d-003cc6f126e2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_a9b7d0e4-cfe6-40f4-b74b-184b848550ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4050e8e8-4c58-4449-83df-6a5d12179f44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_a9b7d0e4-cfe6-40f4-b74b-184b848550ef" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4050e8e8-4c58-4449-83df-6a5d12179f44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4050e8e8-4c58-4449-83df-6a5d12179f44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4050e8e8-4c58-4449-83df-6a5d12179f44" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4050e8e8-4c58-4449-83df-6a5d12179f44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4050e8e8-4c58-4449-83df-6a5d12179f44" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_7510ece9-2d9f-4d6a-a62e-8110433feef8" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_7510ece9-2d9f-4d6a-a62e-8110433feef8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_950fc939-f162-4362-af0e-5a9e9ada6b5a" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_950fc939-f162-4362-af0e-5a9e9ada6b5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_3c6783fb-275a-4244-ba01-1f50976ba442" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_3c6783fb-275a-4244-ba01-1f50976ba442" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_0aa9583b-4d45-4b55-b94f-41248b073525" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_0aa9583b-4d45-4b55-b94f-41248b073525" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_2a59d9a3-2fb6-4c69-9639-9e365659f18b" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_2a59d9a3-2fb6-4c69-9639-9e365659f18b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_0a05639d-4ae9-41f7-8884-efc8c927fb57" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_0a05639d-4ae9-41f7-8884-efc8c927fb57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_5ccc2ba5-6b24-41db-8566-092783d0c1df" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_5ccc2ba5-6b24-41db-8566-092783d0c1df" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarch232021Member_02be387a-184a-4e9e-af16-074dfaba4702" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnMarch232021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnMarch232021Member_02be387a-184a-4e9e-af16-074dfaba4702" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_f6cd6246-bbef-4220-8e48-9dfb0aacc64f" xlink:href="xfor-20230331.xsd#xfor_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_PreFundedWarrantMember_f6cd6246-bbef-4220-8e48-9dfb0aacc64f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_de6c686a-8de1-401d-a945-7dea750bb2dd" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_de6c686a-8de1-401d-a945-7dea750bb2dd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarch32022Member_59258470-ffa9-49c2-9358-7de7e895a811" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnMarch32022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnMarch32022Member_59258470-ffa9-49c2-9358-7de7e895a811" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnJuly20221Member_2c506fb3-9d52-4991-be65-e3aa8e538ff0" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnJuly20221Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnJuly20221Member_2c506fb3-9d52-4991-be65-e3aa8e538ff0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnJuly620222Member_d0d42c0f-9b34-4a8b-a7f1-173bfdcfb5ca" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnJuly620222Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnJuly620222Member_d0d42c0f-9b34-4a8b-a7f1-173bfdcfb5ca" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnDecember92022Member_95dc0a74-1877-404e-bc2d-ace3c23497d2" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnDecember92022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnDecember92022Member_95dc0a74-1877-404e-bc2d-ace3c23497d2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnDecember920222Member_0d2b7f7d-16e7-4741-8953-a499ab5b06ef" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnDecember920222Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnDecember920222Member_0d2b7f7d-16e7-4741-8953-a499ab5b06ef" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9087f739-cf77-4dca-b8c4-98699fa46653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_a9b7d0e4-cfe6-40f4-b74b-184b848550ef" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9087f739-cf77-4dca-b8c4-98699fa46653" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9087f739-cf77-4dca-b8c4-98699fa46653_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9087f739-cf77-4dca-b8c4-98699fa46653" xlink:to="loc_us-gaap_EquityComponentDomain_9087f739-cf77-4dca-b8c4-98699fa46653_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_26c4b626-fd29-46c4-a95a-5e75f3980457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9087f739-cf77-4dca-b8c4-98699fa46653" xlink:to="loc_us-gaap_EquityComponentDomain_26c4b626-fd29-46c4-a95a-5e75f3980457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_72680a92-f557-4b27-80f2-7b0e75b08226" xlink:href="xfor-20230331.xsd#xfor_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_26c4b626-fd29-46c4-a95a-5e75f3980457" xlink:to="loc_xfor_PreFundedWarrantMember_72680a92-f557-4b27-80f2-7b0e75b08226" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassAWarrantMember_89ae126e-6ebe-487d-ab63-fe428cb97417" xlink:href="xfor-20230331.xsd#xfor_ClassAWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_26c4b626-fd29-46c4-a95a-5e75f3980457" xlink:to="loc_xfor_ClassAWarrantMember_89ae126e-6ebe-487d-ab63-fe428cb97417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LegacyWarrantsMember_218248b5-7a17-4034-83e1-858f07d83cf3" xlink:href="xfor-20230331.xsd#xfor_LegacyWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_26c4b626-fd29-46c4-a95a-5e75f3980457" xlink:to="loc_xfor_LegacyWarrantsMember_218248b5-7a17-4034-83e1-858f07d83cf3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsAxis_2c56323d-06ac-4d68-acc2-0a24488fd80f" xlink:href="xfor-20230331.xsd#xfor_PrefundedWarrantsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_a9b7d0e4-cfe6-40f4-b74b-184b848550ef" xlink:to="loc_xfor_PrefundedWarrantsAxis_2c56323d-06ac-4d68-acc2-0a24488fd80f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsDomain_2c56323d-06ac-4d68-acc2-0a24488fd80f_default" xlink:href="xfor-20230331.xsd#xfor_PrefundedWarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_xfor_PrefundedWarrantsAxis_2c56323d-06ac-4d68-acc2-0a24488fd80f" xlink:to="loc_xfor_PrefundedWarrantsDomain_2c56323d-06ac-4d68-acc2-0a24488fd80f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsDomain_a546e4df-fc35-4edc-b839-1e07cbe074c4" xlink:href="xfor-20230331.xsd#xfor_PrefundedWarrantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_xfor_PrefundedWarrantsAxis_2c56323d-06ac-4d68-acc2-0a24488fd80f" xlink:to="loc_xfor_PrefundedWarrantsDomain_a546e4df-fc35-4edc-b839-1e07cbe074c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FundedMember_1a506398-54c7-4cfb-91f2-0f4086522f8f" xlink:href="xfor-20230331.xsd#xfor_FundedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xfor_PrefundedWarrantsDomain_a546e4df-fc35-4edc-b839-1e07cbe074c4" xlink:to="loc_xfor_FundedMember_1a506398-54c7-4cfb-91f2-0f4086522f8f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="i9b142cfab93a46b483ff134ef443280a_StockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7f7cfccd-260a-4fb4-b8d5-8e4f9fa64a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_baff7047-73b7-491a-84b0-98b23867518e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7f7cfccd-260a-4fb4-b8d5-8e4f9fa64a3c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_baff7047-73b7-491a-84b0-98b23867518e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_07404bb1-db83-4245-b5f7-2dd1f7a9dd6b" xlink:href="xfor-20230331.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7f7cfccd-260a-4fb4-b8d5-8e4f9fa64a3c" xlink:to="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_07404bb1-db83-4245-b5f7-2dd1f7a9dd6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c4fe1471-3b8c-4df0-936e-6df9a22a6b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7f7cfccd-260a-4fb4-b8d5-8e4f9fa64a3c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c4fe1471-3b8c-4df0-936e-6df9a22a6b18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a8656201-2482-4094-8268-bb76f29c457c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7f7cfccd-260a-4fb4-b8d5-8e4f9fa64a3c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a8656201-2482-4094-8268-bb76f29c457c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc565799-a48e-4431-bfb4-a2d95adfc53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7f7cfccd-260a-4fb4-b8d5-8e4f9fa64a3c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc565799-a48e-4431-bfb4-a2d95adfc53f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9075203a-f8ae-4532-b511-bedb894ac410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc565799-a48e-4431-bfb4-a2d95adfc53f" xlink:to="loc_us-gaap_PlanNameAxis_9075203a-f8ae-4532-b511-bedb894ac410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9075203a-f8ae-4532-b511-bedb894ac410_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9075203a-f8ae-4532-b511-bedb894ac410" xlink:to="loc_us-gaap_PlanNameDomain_9075203a-f8ae-4532-b511-bedb894ac410_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_76d7e4e1-5dad-4b72-9e73-6a33ebf495a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9075203a-f8ae-4532-b511-bedb894ac410" xlink:to="loc_us-gaap_PlanNameDomain_76d7e4e1-5dad-4b72-9e73-6a33ebf495a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember_b74c292c-7eec-4123-85e8-d91d8a15ba17" xlink:href="xfor-20230331.xsd#xfor_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_76d7e4e1-5dad-4b72-9e73-6a33ebf495a4" xlink:to="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember_b74c292c-7eec-4123-85e8-d91d8a15ba17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember_32e17f13-64aa-4acd-9b11-c00d69a84bda" xlink:href="xfor-20230331.xsd#xfor_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_76d7e4e1-5dad-4b72-9e73-6a33ebf495a4" xlink:to="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember_32e17f13-64aa-4acd-9b11-c00d69a84bda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e0d31442-59a0-4669-8e56-7ae9582933f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc565799-a48e-4431-bfb4-a2d95adfc53f" xlink:to="loc_us-gaap_AwardTypeAxis_e0d31442-59a0-4669-8e56-7ae9582933f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0d31442-59a0-4669-8e56-7ae9582933f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e0d31442-59a0-4669-8e56-7ae9582933f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0d31442-59a0-4669-8e56-7ae9582933f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3605921c-528f-475b-adaf-dba249b5687c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e0d31442-59a0-4669-8e56-7ae9582933f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3605921c-528f-475b-adaf-dba249b5687c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3a4bb07f-cc8e-47d8-900b-c3dd3756ff70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3605921c-528f-475b-adaf-dba249b5687c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3a4bb07f-cc8e-47d8-900b-c3dd3756ff70" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail" xlink:type="extended" id="i2612505b6d5548db9a3263b4fe592988_StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4592202-e29d-4214-8adf-26ffa131008f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_62b8e341-1d7e-439e-b319-ee138ea9c0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4592202-e29d-4214-8adf-26ffa131008f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_62b8e341-1d7e-439e-b319-ee138ea9c0f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_faee6964-de70-43f1-b4aa-121d3d1dec70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4592202-e29d-4214-8adf-26ffa131008f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_faee6964-de70-43f1-b4aa-121d3d1dec70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3cae4725-c020-4b1e-b64e-637e23dd8b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4592202-e29d-4214-8adf-26ffa131008f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3cae4725-c020-4b1e-b64e-637e23dd8b3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_681e5ed1-5c15-4c2c-8fc2-4e12223637ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4592202-e29d-4214-8adf-26ffa131008f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_681e5ed1-5c15-4c2c-8fc2-4e12223637ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_5e9e8afb-bf7e-49c7-8a4e-1629d7eed46c" xlink:href="xfor-20230331.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4592202-e29d-4214-8adf-26ffa131008f" xlink:to="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_5e9e8afb-bf7e-49c7-8a4e-1629d7eed46c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a01bcf38-0753-470e-b537-dd216e6106f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4592202-e29d-4214-8adf-26ffa131008f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a01bcf38-0753-470e-b537-dd216e6106f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dc142c17-baf5-4968-b2c5-cde86ff65366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a01bcf38-0753-470e-b537-dd216e6106f6" xlink:to="loc_us-gaap_AwardTypeAxis_dc142c17-baf5-4968-b2c5-cde86ff65366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc142c17-baf5-4968-b2c5-cde86ff65366_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_dc142c17-baf5-4968-b2c5-cde86ff65366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc142c17-baf5-4968-b2c5-cde86ff65366_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b601665-5fae-4b54-8740-09e1cca77a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_dc142c17-baf5-4968-b2c5-cde86ff65366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b601665-5fae-4b54-8740-09e1cca77a4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a7b08880-fc1b-4512-8d96-ac7aab4dae9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b601665-5fae-4b54-8740-09e1cca77a4c" xlink:to="loc_us-gaap_WarrantMember_a7b08880-fc1b-4512-8d96-ac7aab4dae9a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="xfor-20230331.xsd#StockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationDetails" xlink:type="extended" id="i01409cb380584d41967cc900cbbefc48_StockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09eebb2b-d809-459c-ae74-c9b967df709d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2c370ff8-5f42-4b46-94ee-112a90ef3bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09eebb2b-d809-459c-ae74-c9b967df709d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2c370ff8-5f42-4b46-94ee-112a90ef3bee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_512c35ac-9a31-45a4-bf09-a3706e3ecce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2c370ff8-5f42-4b46-94ee-112a90ef3bee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_512c35ac-9a31-45a4-bf09-a3706e3ecce5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4bd1a983-e4e2-463d-b7ec-792a6a0aa3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2c370ff8-5f42-4b46-94ee-112a90ef3bee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4bd1a983-e4e2-463d-b7ec-792a6a0aa3a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f2aec776-88f1-4a33-bd01-94c9b48a1673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2c370ff8-5f42-4b46-94ee-112a90ef3bee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f2aec776-88f1-4a33-bd01-94c9b48a1673" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a7f685c2-de65-4253-ad6e-e43fe0ccb298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3f25bb74-7de1-432c-8f43-75c65dec9afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09eebb2b-d809-459c-ae74-c9b967df709d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3f25bb74-7de1-432c-8f43-75c65dec9afb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a5be851c-90a9-4778-b9a7-31e326a2d3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3f25bb74-7de1-432c-8f43-75c65dec9afb" xlink:to="loc_us-gaap_AwardTypeAxis_a5be851c-90a9-4778-b9a7-31e326a2d3cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5be851c-90a9-4778-b9a7-31e326a2d3cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a5be851c-90a9-4778-b9a7-31e326a2d3cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5be851c-90a9-4778-b9a7-31e326a2d3cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_188bd2dd-c7ec-475e-a0f6-00a821dc6d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a5be851c-90a9-4778-b9a7-31e326a2d3cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_188bd2dd-c7ec-475e-a0f6-00a821dc6d36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1084c55f-538d-4a13-962a-c8db131f1ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_188bd2dd-c7ec-475e-a0f6-00a821dc6d36" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1084c55f-538d-4a13-962a-c8db131f1ce9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails" xlink:type="simple" xlink:href="xfor-20230331.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails" xlink:type="extended" id="i0904403510b945099412e0eaab5cbb73_StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e85dbee0-5df2-4387-9bd7-5628d9d7b118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4ea4b378-7eeb-4265-9f9d-d243b299d3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e85dbee0-5df2-4387-9bd7-5628d9d7b118" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4ea4b378-7eeb-4265-9f9d-d243b299d3af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9bd3b74-840d-4cbe-bf73-f665e138912f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e85dbee0-5df2-4387-9bd7-5628d9d7b118" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9bd3b74-840d-4cbe-bf73-f665e138912f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_223cfe22-3814-44b4-bfe8-281a5a962ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9bd3b74-840d-4cbe-bf73-f665e138912f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_223cfe22-3814-44b4-bfe8-281a5a962ec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_223cfe22-3814-44b4-bfe8-281a5a962ec0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_223cfe22-3814-44b4-bfe8-281a5a962ec0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_223cfe22-3814-44b4-bfe8-281a5a962ec0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0b5d390c-a989-4a74-81ed-126ce77feb21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_223cfe22-3814-44b4-bfe8-281a5a962ec0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0b5d390c-a989-4a74-81ed-126ce77feb21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_84a697c3-f828-413a-91b2-703892fbeff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0b5d390c-a989-4a74-81ed-126ce77feb21" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_84a697c3-f828-413a-91b2-703892fbeff2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_43bd72dc-eece-4c57-accc-746c7e3dcc27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0b5d390c-a989-4a74-81ed-126ce77feb21" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_43bd72dc-eece-4c57-accc-746c7e3dcc27" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#NetLossperShareAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail" xlink:type="extended" id="ife037491e7e049df88988ea7fefb1669_NetLossperShareAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_811339e8-fea1-4010-b7a9-17c40493eaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4cd19e8e-cac2-44bb-aac9-af2fb254a6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_811339e8-fea1-4010-b7a9-17c40493eaa4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4cd19e8e-cac2-44bb-aac9-af2fb254a6cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_aa7abce4-79ff-47e3-bf0b-abdc88006c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_811339e8-fea1-4010-b7a9-17c40493eaa4" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_aa7abce4-79ff-47e3-bf0b-abdc88006c59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a925a091-d481-4e5b-806e-5b784a67e6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_aa7abce4-79ff-47e3-bf0b-abdc88006c59" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a925a091-d481-4e5b-806e-5b784a67e6cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a925a091-d481-4e5b-806e-5b784a67e6cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a925a091-d481-4e5b-806e-5b784a67e6cf" xlink:to="loc_us-gaap_EquityComponentDomain_a925a091-d481-4e5b-806e-5b784a67e6cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ca306499-449e-4405-9965-2640c74f5808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a925a091-d481-4e5b-806e-5b784a67e6cf" xlink:to="loc_us-gaap_EquityComponentDomain_ca306499-449e-4405-9965-2640c74f5808" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_d530e733-505b-400f-9225-a4f53c92e9fb" xlink:href="xfor-20230331.xsd#xfor_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ca306499-449e-4405-9965-2640c74f5808" xlink:to="loc_xfor_PreFundedWarrantMember_d530e733-505b-400f-9225-a4f53c92e9fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6f4fa4fe-c954-4704-b33b-9a207501c74c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_aa7abce4-79ff-47e3-bf0b-abdc88006c59" xlink:to="loc_srt_RangeAxis_6f4fa4fe-c954-4704-b33b-9a207501c74c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f4fa4fe-c954-4704-b33b-9a207501c74c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6f4fa4fe-c954-4704-b33b-9a207501c74c" xlink:to="loc_srt_RangeMember_6f4fa4fe-c954-4704-b33b-9a207501c74c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_58f5d6fe-5829-4ef4-b047-1141561d8eff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6f4fa4fe-c954-4704-b33b-9a207501c74c" xlink:to="loc_srt_RangeMember_58f5d6fe-5829-4ef4-b047-1141561d8eff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c13e686e-2feb-499a-bbb6-4e0b5abf0fb8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_58f5d6fe-5829-4ef4-b047-1141561d8eff" xlink:to="loc_srt_MaximumMember_c13e686e-2feb-499a-bbb6-4e0b5abf0fb8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail" xlink:type="extended" id="ie3bb2ee41361417ea42d64f28aac7877_NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0f037f32-8ce9-4a88-9a21-4b66d023c9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_052ac467-eec9-4081-a0e4-a8d056b602c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0f037f32-8ce9-4a88-9a21-4b66d023c9fe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_052ac467-eec9-4081-a0e4-a8d056b602c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8d16c64-b8c2-42e5-8774-844d508b5987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0f037f32-8ce9-4a88-9a21-4b66d023c9fe" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8d16c64-b8c2-42e5-8774-844d508b5987" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_26225235-0fcd-4aa2-8ba8-c019c8cb7658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8d16c64-b8c2-42e5-8774-844d508b5987" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_26225235-0fcd-4aa2-8ba8-c019c8cb7658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_26225235-0fcd-4aa2-8ba8-c019c8cb7658_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_26225235-0fcd-4aa2-8ba8-c019c8cb7658" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_26225235-0fcd-4aa2-8ba8-c019c8cb7658_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_946a56d5-034b-4ced-b77c-5d23928df8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_26225235-0fcd-4aa2-8ba8-c019c8cb7658" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_946a56d5-034b-4ced-b77c-5d23928df8d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7df6947c-09f7-4fcc-bd54-3b20bd5cee98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_946a56d5-034b-4ced-b77c-5d23928df8d1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7df6947c-09f7-4fcc-bd54-3b20bd5cee98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3a3acf50-519e-4cb9-abf2-fc0a1d4d18e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_946a56d5-034b-4ced-b77c-5d23928df8d1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3a3acf50-519e-4cb9-abf2-fc0a1d4d18e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e7382fdf-d5eb-482e-af42-5da444c0d415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_946a56d5-034b-4ced-b77c-5d23928df8d1" xlink:to="loc_us-gaap_WarrantMember_e7382fdf-d5eb-482e-af42-5da444c0d415" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>xfor-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6d137f82-7ad4-4f5a-a1d8-483327cb893c,g:a70c2544-a714-416b-95fa-518d19b53207-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_c5a96dc8-f5cd-4c40-9d6d-2fbc704a5f7f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LongTermDebtIncludingAccretion_708f4ba1-6408-4543-a668-44d1580e5a45_totalLabel_en-US" xlink:label="lab_xfor_LongTermDebtIncludingAccretion" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_xfor_LongTermDebtIncludingAccretion_label_en-US" xlink:label="lab_xfor_LongTermDebtIncludingAccretion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Including Accretion</link:label>
    <link:label id="lab_xfor_LongTermDebtIncludingAccretion_documentation_en-US" xlink:label="lab_xfor_LongTermDebtIncludingAccretion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Including Accretion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtIncludingAccretion" xlink:href="xfor-20230331.xsd#xfor_LongTermDebtIncludingAccretion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LongTermDebtIncludingAccretion" xlink:to="lab_xfor_LongTermDebtIncludingAccretion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86bfc0f5-0d42-43b9-a060-105f0aa994ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8fb3fe3a-e54c-4424-a7f3-d363243e62e8_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_54f58f73-cab7-4264-87e9-35f2b6c45eae_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_74b9459f-f2d2-4710-b113-9a68214c2933_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_138c41f6-be9f-4924-9c12-315d9383eab5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AccruedExpensesTextBlock_3c658840-e9ec-4111-9705-1814a3f6a7ea_terseLabel_en-US" xlink:label="lab_xfor_AccruedExpensesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_xfor_AccruedExpensesTextBlock_label_en-US" xlink:label="lab_xfor_AccruedExpensesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses [Text Block]</link:label>
    <link:label id="lab_xfor_AccruedExpensesTextBlock_documentation_en-US" xlink:label="lab_xfor_AccruedExpensesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedExpensesTextBlock" xlink:href="xfor-20230331.xsd#xfor_AccruedExpensesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AccruedExpensesTextBlock" xlink:to="lab_xfor_AccruedExpensesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_e259a7b4-1385-48e2-b5b4-f14b1666a3b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_ce56f2c3-0438-4505-846a-8d406cd1fc9b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_f0009922-c803-497b-af7e-8e2a6e292c55_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent_e19beeb8-acbf-42ca-b21d-6cb8d2cc2ee4_terseLabel_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual base rent</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent_label_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Annual Base Rent</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent_documentation_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Annual Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" xlink:href="xfor-20230331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" xlink:to="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2147ee86-b8d2-47bf-8213-518b34a1ddbd_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_790b9468-34d8-4f58-a894-7e0fda470440_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument variable percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_78e8f7e4-a77a-4a1a-a375-c4a1df58eb2c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_67c52a58-6604-483b-9ae8-0fb4bdd3737b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate-operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6612413-9a06-4271-8c2c-8c60275cdb17_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_DebtInstrumentPrepaymentPremiumPercentage_058087a3-ab5a-4b96-a3fb-681d28070b6d_terseLabel_en-US" xlink:label="lab_xfor_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument prepayment premium, percentage</link:label>
    <link:label id="lab_xfor_DebtInstrumentPrepaymentPremiumPercentage_label_en-US" xlink:label="lab_xfor_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Premium, Percentage</link:label>
    <link:label id="lab_xfor_DebtInstrumentPrepaymentPremiumPercentage_documentation_en-US" xlink:label="lab_xfor_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Premium, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DebtInstrumentPrepaymentPremiumPercentage" xlink:href="xfor-20230331.xsd#xfor_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_DebtInstrumentPrepaymentPremiumPercentage" xlink:to="lab_xfor_DebtInstrumentPrepaymentPremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0be018f6-4f02-470b-bb5a-650cde52cc58_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_bea15fa7-50df-44ff-aae2-66e430d112e4_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5b22ec35-f4d8-4466-8ec1-cd5e3102daac_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax benefit</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_d22a107d-74a7-456f-8647-97d0528fdb25_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On October 25, 2016</link:label>
    <link:label id="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_label_en-US" xlink:label="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On October Twenty Five Two Thousand Sixteen [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on october twenty five two thousand sixteen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:to="lab_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LabEquipmentMember_7a03b3dd-2e35-4cb1-9138-b6fab8856dcf_terseLabel_en-US" xlink:label="lab_xfor_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_xfor_LabEquipmentMember_label_en-US" xlink:label="lab_xfor_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_xfor_LabEquipmentMember_documentation_en-US" xlink:label="lab_xfor_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LabEquipmentMember" xlink:href="xfor-20230331.xsd#xfor_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LabEquipmentMember" xlink:to="lab_xfor_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_91ce2138-9888-433f-93d4-096e2b87a22a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_634cd033-a2f1-425d-9b74-f3ee614a3968_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_97b26c68-c6f2-4f01-a9b2-699f17a33e53_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_ac3d6cd1-93e7-4efa-8990-43dbdc3e3f7a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2751eb1b-0bba-46f5-a69c-7781d5a8c8b2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_ab284ea0-a929-4c4f-868f-6dbe0cdaf813_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Valuation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_432e234c-d9c1-4b11-98e2-02d05710778a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from computation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_99fd36b8-76af-4f34-9a77-45766d440718_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Principal Payments and the Final Payments Due</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_bc4b5711-6fbb-4bb4-81eb-59fcb1bd7291_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember_cc0afb46-1d5c-4801-a2ca-560799e82435_terseLabel_en-US" xlink:label="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan</link:label>
    <link:label id="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember_label_en-US" xlink:label="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:href="xfor-20230331.xsd#xfor_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="lab_xfor_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ca744951-13d6-4c06-b600-f652ec9d15b0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_2a7c9380-f387-446c-81d6-0a803da2cf82_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_4c68096a-cc78-45c2-b40c-09c0519577bd_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_75eb63f3-4746-4383-9b96-fe351c2bbde4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_37e569c5-6615-45c8-85a1-a05a900ff152_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_97b5c81e-10f2-4837-be27-c97e0575457f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease not yet commenced, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_798aacb3-58e5-4e63-bf3b-e880eb122cff_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_8b680ac4-3a5b-45eb-bee5-a292accab0cf_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_a607ad0b-47c1-4ffa-975c-528ab186e007_terseLabel_en-US" xlink:label="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label id="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_label_en-US" xlink:label="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label id="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_documentation_en-US" xlink:label="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:href="xfor-20230331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_29d617c9-ffa4-48ad-a7c4-da9642503584_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Including Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8c1333e6-da18-4e4d-930b-8094cd68a027_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_c7622da8-d185-4266-9c45-fac13e18e025_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a3c25202-a071-4644-a73d-2e885350024e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5a24ac64-6384-4e09-959f-c33d8e175c1e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f8ef1232-0d79-4f68-ab55-b26e1dd65b35_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_35878ad9-dda8-49ab-b1f9-802eabfe15a2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average contractual term outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_1428d345-fa50-4af2-a500-9dfe5cd21226_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate increase percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_406cdea2-f3f2-4656-ba6b-59020b6fbd1d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_55997048-d1f3-4c21-baad-180fe520c247_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_85ce389b-5f1f-4071-bcb8-87c1996a0ea1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ad395e01-6fbd-4219-84ff-39e86e9e52fa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_409c65f8-39ae-4f18-b5b0-b84862c0eb2d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_f62ac697-721d-479e-8713-df1238f0bcfb_terseLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:href="xfor-20230331.xsd#xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:to="lab_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LegacyWarrantsMember_d14a08f4-6409-4810-b6c5-7112586ac3c8_terseLabel_en-US" xlink:label="lab_xfor_LegacyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Warrants</link:label>
    <link:label id="lab_xfor_LegacyWarrantsMember_label_en-US" xlink:label="lab_xfor_LegacyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Warrants [Member]</link:label>
    <link:label id="lab_xfor_LegacyWarrantsMember_documentation_en-US" xlink:label="lab_xfor_LegacyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LegacyWarrantsMember" xlink:href="xfor-20230331.xsd#xfor_LegacyWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LegacyWarrantsMember" xlink:to="lab_xfor_LegacyWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_90591d22-04d0-424d-8141-dd6cf5a2ab99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0feb754b-592b-4e55-8de4-e3d4f8448396_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_43468a2b-c55b-43e5-99d4-d62ada61f80b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1228083f-f5d2-422c-98cd-78d0980aafc9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_229987ef-eb8b-453b-9787-150308df4216_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e304d6b1-b385-4dcc-87e1-8d1c49cfb4a3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term-operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aaa0b208-1e1f-48bc-b1a6-1fa5cec33497_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_MinCashTestDate1Member_824cf6ff-0e3f-4855-8aaf-6fd37ed5c0c4_terseLabel_en-US" xlink:label="lab_xfor_MinCashTestDate1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 1</link:label>
    <link:label id="lab_xfor_MinCashTestDate1Member_label_en-US" xlink:label="lab_xfor_MinCashTestDate1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 1 [Member]</link:label>
    <link:label id="lab_xfor_MinCashTestDate1Member_documentation_en-US" xlink:label="lab_xfor_MinCashTestDate1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate1Member" xlink:href="xfor-20230331.xsd#xfor_MinCashTestDate1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_MinCashTestDate1Member" xlink:to="lab_xfor_MinCashTestDate1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_dde03bf1-8ba9-4cb6-9762-b51268b8a011_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_a99746e4-1fa4-4675-8c0e-228cffd39ef2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_fc968e83-f84c-49c9-81f9-61feb832dd8b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2537f900-7bff-4372-85d6-a711e162a012_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_67ad07a9-0dee-473b-8660-d5a6ad01bac2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AllstonLeaseMember_64db2b28-d73b-49ad-8e17-0846c46f869a_terseLabel_en-US" xlink:label="lab_xfor_AllstonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allston Lease</link:label>
    <link:label id="lab_xfor_AllstonLeaseMember_label_en-US" xlink:label="lab_xfor_AllstonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allston Lease [Member]</link:label>
    <link:label id="lab_xfor_AllstonLeaseMember_documentation_en-US" xlink:label="lab_xfor_AllstonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allston Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AllstonLeaseMember" xlink:href="xfor-20230331.xsd#xfor_AllstonLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AllstonLeaseMember" xlink:to="lab_xfor_AllstonLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_970ff93b-34d4-4c96-9ab3-6d0200bef5e5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7871f59b-bd9b-4e8e-890e-13519a8d08eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_6a852d8e-8faa-48ee-92f1-684272d41597_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2e45170a-443b-4d78-9881-74b5fd5863cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_155bea65-35ec-4a6b-b41a-7d747e871203_terseLabel_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_label_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Office Space</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_documentation_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Office Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:href="xfor-20230331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:to="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2a67fbed-cb6e-4e91-92ed-49c4d661975f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_54f252d6-bf57-432b-95a4-f645a61083fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cf930e8d-0e71-45a8-bbc2-7732ba77ee16_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement_1e547d40-bdca-4000-97ae-f9ca7cacbe71_terseLabel_en-US" xlink:label="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current office space under lease agreement</link:label>
    <link:label id="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement_label_en-US" xlink:label="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Office Space Under Lease Agreement</link:label>
    <link:label id="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement_documentation_en-US" xlink:label="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current office space under lease agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:href="xfor-20230331.xsd#xfor_CurrentOfficeSpaceUnderLeaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:to="lab_xfor_CurrentOfficeSpaceUnderLeaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_19583a9c-9270-45e5-b878-3ab366c441c3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_5dbbfff0-e9b3-4c3d-bf6e-8a6df17557e4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_c13d8308-656a-4c19-8991-23d3f3b9abdf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3a0870fb-3a8e-4969-b5ee-4e1ffbeea503_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_4cc85414-7e3d-43b1-bf3a-9319f712952f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_7809fc56-6513-417f-b23d-82d0726694bb_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_HerculesSecondAmendedLoanAgreementMember_f56a00ea-5814-4177-8031-5fb4c9f544d6_terseLabel_en-US" xlink:label="lab_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Second Amended Loan Agreement</link:label>
    <link:label id="lab_xfor_HerculesSecondAmendedLoanAgreementMember_label_en-US" xlink:label="lab_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Second Amended Loan Agreement [Member]</link:label>
    <link:label id="lab_xfor_HerculesSecondAmendedLoanAgreementMember_documentation_en-US" xlink:label="lab_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Second Amended Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:href="xfor-20230331.xsd#xfor_HerculesSecondAmendedLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:to="lab_xfor_HerculesSecondAmendedLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_4b677e93-7f86-48bf-96c0-4fa5696f6fcf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_70746dc4-0c40-4e35-b07f-0edbb0f762f0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_bf14a907-1103-4f2a-b77c-9bcae5e77e0a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4b5503eb-e191-45d9-8e57-c84caaec3473_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f9e8bade-e754-4d3e-bc12-f354ac566dfa_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0fb131c9-edfe-48ab-b761-af5197971ed2_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ViennaLeaseAgreementMember_9a97c734-b956-44ab-aa8f-0ecc5979d9b8_terseLabel_en-US" xlink:label="lab_xfor_ViennaLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vienna Austria Lease</link:label>
    <link:label id="lab_xfor_ViennaLeaseAgreementMember_label_en-US" xlink:label="lab_xfor_ViennaLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vienna Lease Agreement [Member]</link:label>
    <link:label id="lab_xfor_ViennaLeaseAgreementMember_documentation_en-US" xlink:label="lab_xfor_ViennaLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vienna lease agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ViennaLeaseAgreementMember" xlink:href="xfor-20230331.xsd#xfor_ViennaLeaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ViennaLeaseAgreementMember" xlink:to="lab_xfor_ViennaLeaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_6d69c0d3-02e7-4a76-8aa8-1351554f03c9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_de406e18-b4d3-4ff2-bb47-8d1e83b4dcea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_bc695847-f4eb-42e6-a420-7e4b033f6e05_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1be30c61-0dae-4aab-b012-7270a49bbf8c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_9d82c1d8-6d2b-434d-9459-2cc451557206_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnJuly620222Member_dc9e672f-ab7e-4a7b-a7a4-45dfa03e964d_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnJuly620222Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on July 6 2022 Two</link:label>
    <link:label id="lab_xfor_IssuanceOnJuly620222Member_label_en-US" xlink:label="lab_xfor_IssuanceOnJuly620222Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on July 6 2022 2 [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnJuly620222Member_documentation_en-US" xlink:label="lab_xfor_IssuanceOnJuly620222Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on July 6 2022 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnJuly620222Member" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnJuly620222Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnJuly620222Member" xlink:to="lab_xfor_IssuanceOnJuly620222Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_1f7c8faf-b923-423b-89a3-ff33ae8775f6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_e9db44e2-f89c-4160-b2fd-13770504af59_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_99ac6327-3115-4231-9c9d-6a48e77d026d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_edfdb9b6-fe77-4d31-8e1f-2a1c2ecb9508_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fdf10dbe-16a4-44b0-9507-132489fbaa03_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_19b84892-8bac-4180-a132-f73ba340714a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3c6d86ab-5fe9-4ae7-8148-f4a1e23deba2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_HerculesLoanAgreementMember_7b40f110-772a-4cc1-b0c5-79137d4d5f98_terseLabel_en-US" xlink:label="lab_xfor_HerculesLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Loan Agreement</link:label>
    <link:label id="lab_xfor_HerculesLoanAgreementMember_label_en-US" xlink:label="lab_xfor_HerculesLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Loan Agreement [Member]</link:label>
    <link:label id="lab_xfor_HerculesLoanAgreementMember_documentation_en-US" xlink:label="lab_xfor_HerculesLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesLoanAgreementMember" xlink:href="xfor-20230331.xsd#xfor_HerculesLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_HerculesLoanAgreementMember" xlink:to="lab_xfor_HerculesLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b7c9486f-480d-4813-bb5b-790948d2af49_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ec9c5df-35ee-4722-a94e-765f1200b053_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5234475c-17ca-48ea-8375-4f4dadfddb1e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost of stock based awards, recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_765bc7e4-9e93-4b15-a8f0-724725ca7a7c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average contractual term outstanding, Exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_23d3aad9-6ec0-4d1b-8917-5c6725e35100_terseLabel_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, weighted average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Awards Grant In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Awards Grant in Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:href="xfor-20230331.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnMarch32022Member_862bb5f6-5a07-4f3f-a3a5-da8e7b689274_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnMarch32022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on March 3 2022</link:label>
    <link:label id="lab_xfor_IssuanceOnMarch32022Member_label_en-US" xlink:label="lab_xfor_IssuanceOnMarch32022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on March 3 2022 [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnMarch32022Member_documentation_en-US" xlink:label="lab_xfor_IssuanceOnMarch32022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on March 3 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarch32022Member" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnMarch32022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnMarch32022Member" xlink:to="lab_xfor_IssuanceOnMarch32022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_f93e94b1-283c-464e-9a4f-3dbaf3f97eff_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e37a944f-1103-416d-8b13-479f5831abab_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4343c2ff-7c21-4d09-afd9-44345f8883e4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPayment_f6392862-374e-4625-8a31-0e1105ce34e5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility periodic payment</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPayment_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Periodic Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:to="lab_us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_a9ab9ac1-a6ca-457f-b9e9-d7c6d8d0a4e3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses_0864a1bf-8712-486f-8023-d52172fd1fc3_terseLabel_en-US" xlink:label="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued external research and development expenses</link:label>
    <link:label id="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued External Research And Development Expenses</link:label>
    <link:label id="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued external research and development expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:href="xfor-20230331.xsd#xfor_AccruedExternalResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:to="lab_xfor_AccruedExternalResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9fd76cb3-a9da-4e7d-996c-733157ad8729_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield (in percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d87cc30d-bb75-41db-b609-51c98d7ca7ab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveReceivable_0995d47c-d662-429f-8832-1cef57a82d2d_terseLabel_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development incentive receivable</link:label>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveReceivable_label_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Incentive Receivable</link:label>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveReceivable_documentation_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development incentive receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:href="xfor-20230331.xsd#xfor_ResearchAndDevelopmentIncentiveReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:to="lab_xfor_ResearchAndDevelopmentIncentiveReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ScheduleOfAccountingPoliciesTable_e97b9dd6-d221-40ad-aae2-80591884fdf4_terseLabel_en-US" xlink:label="lab_xfor_ScheduleOfAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounting Policies [Table]</link:label>
    <link:label id="lab_xfor_ScheduleOfAccountingPoliciesTable_label_en-US" xlink:label="lab_xfor_ScheduleOfAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounting Policies [Table]</link:label>
    <link:label id="lab_xfor_ScheduleOfAccountingPoliciesTable_documentation_en-US" xlink:label="lab_xfor_ScheduleOfAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfAccountingPoliciesTable" xlink:href="xfor-20230331.xsd#xfor_ScheduleOfAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ScheduleOfAccountingPoliciesTable" xlink:to="lab_xfor_ScheduleOfAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_cfc23c81-23a2-40a3-aac9-4493efe5941c_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_dfe61639-c3f3-4dba-a620-6a73f0d377e3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_b75b2ca7-1d6f-48c3-8606-e2a44a748742_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_6b4e5500-8a8e-441d-82c7-424aeb3fb639_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_dd49d47c-b880-4374-8f86-602082ec9f01_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_DenominatorAbstract_f8003fce-6761-4afb-9161-2c5a2a27f099_terseLabel_en-US" xlink:label="lab_xfor_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_xfor_DenominatorAbstract_label_en-US" xlink:label="lab_xfor_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_xfor_DenominatorAbstract_documentation_en-US" xlink:label="lab_xfor_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DenominatorAbstract" xlink:href="xfor-20230331.xsd#xfor_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_DenominatorAbstract" xlink:to="lab_xfor_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0d20e06c-f12f-4943-9ce7-e1ae14d09d6a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AggregateBaseRent_71054ab6-f2fe-409e-ac70-690775eae021_terseLabel_en-US" xlink:label="lab_xfor_AggregateBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current base rent</link:label>
    <link:label id="lab_xfor_AggregateBaseRent_label_en-US" xlink:label="lab_xfor_AggregateBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Base Rent</link:label>
    <link:label id="lab_xfor_AggregateBaseRent_documentation_en-US" xlink:label="lab_xfor_AggregateBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate base rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AggregateBaseRent" xlink:href="xfor-20230331.xsd#xfor_AggregateBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AggregateBaseRent" xlink:to="lab_xfor_AggregateBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_02c3b6b1-9846-447f-a258-cbf5e2d51051_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_13d4b530-b362-4816-957f-2a8710b53ff9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_a7127744-087f-43d3-a111-d05da561f57d_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_231307e3-74e0-431b-b654-0a087bdba423_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d9abc3db-5475-41c7-8e94-66d22c08e67e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_2f591627-849e-496b-ba65-d257bafeb3ce_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_3e5c78b7-d7b9-41a0-b019-4091b96e07c2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_81854137-3153-4544-9fb2-951e280d37b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5af1106a-3dd5-4d9d-9307-6d2a6c0d50bf_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_77d09431-b39b-4133-8fd6-1383833a6309_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_a005b72b-b580-4db7-ad9e-ade23fa6311a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from lines of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_53737305-3f17-43b5-934d-a034bc269920_terseLabel_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease not yet commenced</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_label_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Amount</link:label>
    <link:label id="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_documentation_en-US" xlink:label="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:href="xfor-20230331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:to="lab_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember_09da8285-57e2-40c8-9767-8684ec2fbefc_terseLabel_en-US" xlink:label="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Equity Incentive Plan</link:label>
    <link:label id="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:href="xfor-20230331.xsd#xfor_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="lab_xfor_TwoThousandNineteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_940f0480-3c21-48ef-abf6-cf875ef7abee_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares Options, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_9dfe5c58-344c-4b63-9149-c5dc8a93b5e8_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9967b909-92ca-4f1b-86b0-1359e7e33d48_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_19dae3f8-45a8-4f91-a1e9-e01b2ccfdf23_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On December 28, 2017 One</link:label>
    <link:label id="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_label_en-US" xlink:label="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On December Twenty Eight Two Thousand Seventeen One [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on december twenty eight two thousand seventeen one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:to="lab_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_9603a45c-3cd8-4548-9255-a8aafbbbf6be_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On March 13, 2019</link:label>
    <link:label id="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_label_en-US" xlink:label="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On March Thirteen Two Thousand Nineteen [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on march thirteen two thousand nineteen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:to="lab_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_fc89f0aa-766a-470e-b6db-2276dbaa5802_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d7e01e95-4f6a-45f9-a457-1498147433db_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fb8457ae-136c-4554-9ddb-093fbd5e1caa_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cdbb3446-32ca-4920-bf55-c0e55eed6b9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_7da906df-e2ae-45d9-990d-692d0385f357_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember_88742c0e-af87-454b-81c6-469e76b13f6e_terseLabel_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Incentive</link:label>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember_label_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Incentive Program [Member]</link:label>
    <link:label id="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember_documentation_en-US" xlink:label="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development incentive program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:href="xfor-20230331.xsd#xfor_ResearchAndDevelopmentIncentiveProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:to="lab_xfor_ResearchAndDevelopmentIncentiveProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_6544f47a-9719-4755-927f-9546294da94a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_be191258-a558-4ebb-addb-f2f194ca4240_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_d6c671bf-5739-4eb2-a171-189a117dc7e8_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_102dd32a-bd55-41bb-879b-2fba69f0638d_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9a4a9fdd-21d0-4949-9985-9a86d3c13195_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders&#8212;basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_74bfb63f-cf5c-471f-b64d-abe76d70fcef_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnDecember920222Member_226bb37c-5d78-4c08-bfeb-9429d6a5e87b_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnDecember920222Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on December 9 2022 2</link:label>
    <link:label id="lab_xfor_IssuanceOnDecember920222Member_label_en-US" xlink:label="lab_xfor_IssuanceOnDecember920222Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on December 9 2022 2 [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnDecember920222Member_documentation_en-US" xlink:label="lab_xfor_IssuanceOnDecember920222Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on December 9 2022 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnDecember920222Member" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnDecember920222Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnDecember920222Member" xlink:to="lab_xfor_IssuanceOnDecember920222Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6081433a-c499-4a7c-a637-d2de2c141248_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_13d65db0-b24c-434a-bd15-b81d0d17e8b8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3c28937e-516d-4498-bddb-1e9031a3916b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_24ed2a8d-a19f-43ce-a718-06ff7731127e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock_c521504d-d10f-41ae-9cdc-e11d395a4e57_terseLabel_en-US" xlink:label="lab_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock_label_en-US" xlink:label="lab_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Reconciliation Of Cash And Cash Equivalents And Restricted Cash To Cash Flows [Table Text Block]</link:label>
    <link:label id="lab_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock_documentation_en-US" xlink:label="lab_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of cash and cash equivalents and restricted cash to cashflows.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:href="xfor-20230331.xsd#xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:to="lab_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStock_40c9d444-45f5-4624-b92d-fba31471aaf8_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends on common stock declared or paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e0f97560-2ed5-476a-907d-32dc75df4b04_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_8c8c0b21-9942-46d3-acf5-bf5d5b8409c9_terseLabel_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:label id="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:label id="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="xfor-20230331.xsd#xfor_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_xfor_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_6caae188-d3f0-430f-9432-532385a58fbb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, Value, Shares Issued Net of Tax Withholdings</link:label>
    <link:label id="lab_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_label_en-US" xlink:label="lab_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, Value, Shares Issued Net of Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="lab_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aebe9841-4d6e-4f6b-8f0a-200ea9375cfc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a17519f5-39bb-4cfe-aa38-c6d692363354_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_455abfd8-7188-48a3-959f-b5c94420ecf2_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative Liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative Financial Instruments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:to="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2991d168-67b9-42cd-b8d4-0ffe4e1e4968_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Aggregate Fair Values of Warrant Liability and Derivative Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2c015c6b-930b-4198-81a1-45d52bf7577e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_2b920cf9-3e3e-4160-bd57-b93ef82858b4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_badea2a9-c238-47da-8d06-9c901bf64a84_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On April 16, 2019</link:label>
    <link:label id="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_label_en-US" xlink:label="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On April Sixteen Two Thousand Nineteen [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on april sixteen two thousand nineteen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:to="lab_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_97183ea4-94d5-4653-97f0-db2ea87a34bc_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_70711c2e-8bc9-496e-abf8-d372cc1aca7c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_04849aef-5a64-4899-8fdb-445413662301_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_befd2894-a6e3-423f-a011-49f96097ce18_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_9a2c8457-877e-4454-99d7-56b08da15143_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0b861ebb-ba39-44b9-9201-6f9bc410c31c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate of loan</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_7711d2cb-e4e7-4733-b6f5-6eea438ec771_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, renewal term of contract (years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_df82ff42-340c-4672-adac-826ac15c7044_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_29ef9c56-1e2e-483d-99a9-e2e48747b003_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_f717a136-9873-49d4-aba9-7ad57ae90feb_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f62163d2-54d6-4b3c-a52e-ca8d2555844b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4ec29f69-77ab-464d-bc1c-96e4af9fb5e3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_df65e27e-6fe0-46a6-be81-2652f8c22181_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_32960559-a52d-4cd1-a118-df220938cec9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5ebf9e17-416f-4709-9526-16f379abf140_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9ce51a74-e9e6-44d6-8246-9d99fec82f92_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d8edf478-1a37-4236-9b25-bd334e254fcf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_fed647bd-db64-42ef-a63a-831512fae34c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ea95fcdd-f654-4c5e-8e1f-f66e3e314b29_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, Exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_GrantAndIncentiveReceivables_e3cd5e23-e4bc-4f4b-b9c2-cdb8400ebfff_terseLabel_en-US" xlink:label="lab_xfor_GrantAndIncentiveReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant receivable</link:label>
    <link:label id="lab_xfor_GrantAndIncentiveReceivables_label_en-US" xlink:label="lab_xfor_GrantAndIncentiveReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant And Incentive Receivables</link:label>
    <link:label id="lab_xfor_GrantAndIncentiveReceivables_documentation_en-US" xlink:label="lab_xfor_GrantAndIncentiveReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant and incentive receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GrantAndIncentiveReceivables" xlink:href="xfor-20230331.xsd#xfor_GrantAndIncentiveReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_GrantAndIncentiveReceivables" xlink:to="lab_xfor_GrantAndIncentiveReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9b89619b-1a85-4686-8dc5-1a26e15e5b73_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8d4c2981-7b96-46ba-864d-ed1a05319553_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_beae03c0-effb-4299-aac3-89ba58071a33_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_81f86207-7779-47b5-a7de-64d786e288cb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4c9a997c-78a7-4c57-bb57-6ace2947a0c2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5a43fe55-b8cf-4d20-bd32-1df421d7aa4f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_3862fd02-c8a6-486f-81d9-244ac8f93ed6_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_9838d956-aec1-407a-907d-0854c1c6075a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_22210d79-e359-43c8-b7af-d5d555385990_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnDecember92022Member_582d4acc-c63a-4a6a-ba1b-95c41e91c757_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnDecember92022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on December 9 2022</link:label>
    <link:label id="lab_xfor_IssuanceOnDecember92022Member_label_en-US" xlink:label="lab_xfor_IssuanceOnDecember92022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on December 9 2022 [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnDecember92022Member_documentation_en-US" xlink:label="lab_xfor_IssuanceOnDecember92022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on December 9 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnDecember92022Member" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnDecember92022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnDecember92022Member" xlink:to="lab_xfor_IssuanceOnDecember92022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_Q12022PrivatePlacementMember_8cda87b6-ec89-4873-b913-cb636aa1ec45_terseLabel_en-US" xlink:label="lab_xfor_Q12022PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Q1 2022 Private Placement</link:label>
    <link:label id="lab_xfor_Q12022PrivatePlacementMember_label_en-US" xlink:label="lab_xfor_Q12022PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Q1 2022 Private Placement [Member]</link:label>
    <link:label id="lab_xfor_Q12022PrivatePlacementMember_documentation_en-US" xlink:label="lab_xfor_Q12022PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Q1 2022 Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_Q12022PrivatePlacementMember" xlink:href="xfor-20230331.xsd#xfor_Q12022PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_Q12022PrivatePlacementMember" xlink:to="lab_xfor_Q12022PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_48847981-bdc0-4c75-9364-80593cb922e9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9f04e853-0a1b-4726-a438-e01f1a33a26f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_21879a4c-2a3c-4e44-a76c-615a9aefa9b7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d9bf0070-a6ee-4011-bb47-a879283fe261_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8ca7cfbc-c900-415e-8cc9-b4cf695a1f98_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_cb9eea87-fe45-49e8-a481-d2ea3afc6cc5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_602bc76f-2c60-4cce-94fd-f1b4036d92cf_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnMarch232021Member_0f8d9d32-41fa-4ce3-a343-56a4009bd9b8_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnMarch232021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On March 23, 2021</link:label>
    <link:label id="lab_xfor_IssuanceOnMarch232021Member_label_en-US" xlink:label="lab_xfor_IssuanceOnMarch232021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On March 23, 2021 [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnMarch232021Member_documentation_en-US" xlink:label="lab_xfor_IssuanceOnMarch232021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On March 23, 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarch232021Member" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnMarch232021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnMarch232021Member" xlink:to="lab_xfor_IssuanceOnMarch232021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1563b7eb-19f5-490d-97f0-8a621cda62a8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_37324fcd-54d0-44ba-b37c-3664f9f53415_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount, net of accretion</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_24eb6328-85fd-49d2-8a26-49dd73998074_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses, other current assets and research and development incentive receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3baf5934-dacc-4568-a25d-2431b1bdd4b2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_36720b71-2384-435d-b96e-abfdfcfb73cd_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_0ae78d24-6942-4d69-845e-7c4364b1063c_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On October 19, 2018</link:label>
    <link:label id="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_label_en-US" xlink:label="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On October Nineteen Two Thousand Eighteen [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on october nineteen two thousand eighteen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:to="lab_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_83502715-6e4c-46fe-96b4-2775175108a5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3bde06b9-03af-4d3a-95b9-cafe04936e24_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7a72a1d3-9bcc-4255-b8c0-8f3922765c43_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1fbfaffa-fd94-4bf9-890a-34f8c3ff2099_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_00db72d4-7ac8-4bad-8290-9fe66a519f68_terseLabel_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_label_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</link:label>
    <link:label id="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_documentation_en-US" xlink:label="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:href="xfor-20230331.xsd#xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:to="lab_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_84cc1590-ccbe-410d-8c9a-3b3a8cd72595_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f3c81123-c0bc-43ee-8377-a467d41a5d5f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1a702325-83fd-4b79-bc0e-cea786f57eed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_a1515dd4-9fd9-4376-ba6e-527cbdbfd432_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_3917a026-036e-41e4-bdba-2c8f7e83f620_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_20e74fb8-5770-4f50-9e14-00c1d90e6d94_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_daddca9e-4cf3-433a-a9ca-3340b3624874_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_4b0e133e-fc6f-40c2-95e6-0ab130a395b4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IncreaseDecreaseInLeaseLiabilities_151f11ee-7887-4cd3-92a4-c81b629b2148_terseLabel_en-US" xlink:label="lab_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_xfor_IncreaseDecreaseInLeaseLiabilities_label_en-US" xlink:label="lab_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Lease Liabilities</link:label>
    <link:label id="lab_xfor_IncreaseDecreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:href="xfor-20230331.xsd#xfor_IncreaseDecreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_xfor_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ed2a8580-2324-4a4e-b30a-011ea84afd76_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding&#8212;diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_924885c6-9a1e-4a24-aa99-5682352fee53_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_5b3a17c1-92db-475a-a3c2-229def002807_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_67d4eb59-15b8-4171-a689-c7bf96a864bf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c94012ad-1c0d-4336-80fa-dff888f17dd6_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_687b141f-f1a1-4b4f-a7b9-97dd02480c46_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 500,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively; 122,207,488 and 121,667,250 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_98822a77-6e4c-4c44-8e26-a7c1b447b6ab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_8bded1e3-e762-4dcb-936b-3a15f62666e8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_b6fd514b-0042-416f-9f53-00e73bc0b04b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</link:label>
    <link:label id="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_label_en-US" xlink:label="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_19106782-2ef9-4336-8a5d-0f41ce26ff3c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_6bf3d3a0-d418-4a3b-bbba-3ec472371d7d_terseLabel_en-US" xlink:label="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of shares of common stock, and pre-funded warrants, net of issuance costs (1)</link:label>
    <link:label id="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_label_en-US" xlink:label="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Net of Issuance Costs</link:label>
    <link:label id="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:href="xfor-20230331.xsd#xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:to="lab_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b8926469-04e7-43fd-8a8d-d3c995eb06aa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_f370f621-f7ae-4726-9016-d37755541793_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ee683ed-d40d-4da2-b649-ac27be5eeafd_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65a85193-f338-4628-a474-6107675bb92f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2bfc3a50-bbfe-483b-9ae2-60fe836b549e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_3980ac74-3d1a-4b54-8617-8ee42c6009fa_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On November 29, 2019 One</link:label>
    <link:label id="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_label_en-US" xlink:label="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Twenty Nine Two Thousand Nineteen One [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Twenty Nine Two Thousand Nineteen One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:to="lab_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2bc02c5a-e69c-48e1-b687-11181f7dfe59_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_43b4f78a-6a06-4a40-a41b-e9b13e321305_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_cccbaa83-db4f-4e7f-999e-acf0d989dc2c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d2a09224-3c57-45c6-bde3-d4980bbd3a5d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dc244bbe-1f02-4a63-9a1d-e3aa6b80948f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average contractual term outstanding, Vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_946991de-2de1-4e35-815c-40599a60fae7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_b8805e5a-4c83-4b22-a6c0-48490d5b4332_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_880f3fcb-ab29-4fb0-bb57-874d85ed92dd_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_080acb88-562a-4694-9075-38d9d5ed9d93_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_6c9b3e54-3a9d-4adc-9e46-9e84a93d097f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement_dfb158c4-80ef-479d-9ed9-c44d36b6c693_negatedTerseLabel_en-US" xlink:label="lab_xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees paid to amendment loan and security agreement and issuance costs related to the sale of warrants</link:label>
    <link:label id="lab_xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement_label_en-US" xlink:label="lab_xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs Related To Sale Of Warrants And Fees Paid For Amendments To Loan And Security Agreement</link:label>
    <link:label id="lab_xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement_documentation_en-US" xlink:label="lab_xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs Related To Sale Of Warrants And Fees Paid For Amendments To Loan And Security Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement" xlink:href="xfor-20230331.xsd#xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement" xlink:to="lab_xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_fa9b86ca-2535-4c5a-8903-5c851773aa02_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_7b13ccc9-d80c-4102-98a1-2519ccad7c8b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_49bd6a15-6542-48a2-a952-fe05761e1abd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_PrefundedWarrantsAxis_7c1cdfe6-b208-4cb4-9123-cab514aa8c80_terseLabel_en-US" xlink:label="lab_xfor_PrefundedWarrantsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants [Axis]</link:label>
    <link:label id="lab_xfor_PrefundedWarrantsAxis_label_en-US" xlink:label="lab_xfor_PrefundedWarrantsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants [Axis]</link:label>
    <link:label id="lab_xfor_PrefundedWarrantsAxis_documentation_en-US" xlink:label="lab_xfor_PrefundedWarrantsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsAxis" xlink:href="xfor-20230331.xsd#xfor_PrefundedWarrantsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_PrefundedWarrantsAxis" xlink:to="lab_xfor_PrefundedWarrantsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a4d48823-189f-4a07-9259-2247c8cf657c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares Options, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_dda37102-6f24-41d5-b69b-db97c1993e77_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_a86dd0d5-68e0-46a5-b16e-5b303b1ccc6a_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ViennaAustriaLeaseMember_6b719572-7e18-4715-8e1d-12c592e18d2f_terseLabel_en-US" xlink:label="lab_xfor_ViennaAustriaLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vienna Lease</link:label>
    <link:label id="lab_xfor_ViennaAustriaLeaseMember_label_en-US" xlink:label="lab_xfor_ViennaAustriaLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vienna Austria Lease [Member]</link:label>
    <link:label id="lab_xfor_ViennaAustriaLeaseMember_documentation_en-US" xlink:label="lab_xfor_ViennaAustriaLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vienna Austria Lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ViennaAustriaLeaseMember" xlink:href="xfor-20230331.xsd#xfor_ViennaAustriaLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ViennaAustriaLeaseMember" xlink:to="lab_xfor_ViennaAustriaLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_a0802b0d-4f42-4ec1-b9b1-39170a3dc5c7_terseLabel_en-US" xlink:label="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label id="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_label_en-US" xlink:label="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label id="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_documentation_en-US" xlink:label="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:href="xfor-20230331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="lab_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_2b78e2b2-72bd-46da-8f86-2bfa9e2f9a78_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, term of contract (years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dd82da68-2f24-48a0-8c5b-f10008baf0a7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_407b8bf2-f82b-4fc0-8901-5b40694d2b1c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_cc5b043a-16d1-4b20-a81b-ca512e69f9a6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_CollaborationLicenseAndFundingArrangementsTable_d18bf2ef-fbd2-4d2b-83e9-c7efb906b452_terseLabel_en-US" xlink:label="lab_xfor_CollaborationLicenseAndFundingArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration License And Funding Arrangements [Table]</link:label>
    <link:label id="lab_xfor_CollaborationLicenseAndFundingArrangementsTable_label_en-US" xlink:label="lab_xfor_CollaborationLicenseAndFundingArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration License And Funding Arrangements [Table]</link:label>
    <link:label id="lab_xfor_CollaborationLicenseAndFundingArrangementsTable_documentation_en-US" xlink:label="lab_xfor_CollaborationLicenseAndFundingArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration, license and funding arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborationLicenseAndFundingArrangementsTable" xlink:href="xfor-20230331.xsd#xfor_CollaborationLicenseAndFundingArrangementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsTable" xlink:to="lab_xfor_CollaborationLicenseAndFundingArrangementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IndemnificationAgreementsMember_0092c33b-9a80-439f-aa27-2f9be3a2cd66_terseLabel_en-US" xlink:label="lab_xfor_IndemnificationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreements</link:label>
    <link:label id="lab_xfor_IndemnificationAgreementsMember_label_en-US" xlink:label="lab_xfor_IndemnificationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreements [Member]</link:label>
    <link:label id="lab_xfor_IndemnificationAgreementsMember_documentation_en-US" xlink:label="lab_xfor_IndemnificationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreements Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IndemnificationAgreementsMember" xlink:href="xfor-20230331.xsd#xfor_IndemnificationAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IndemnificationAgreementsMember" xlink:to="lab_xfor_IndemnificationAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnJuly20221Member_167b4d9c-56ca-4bf4-8a5d-c7ec3af7eff0_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnJuly20221Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on July 2022 1</link:label>
    <link:label id="lab_xfor_IssuanceOnJuly20221Member_label_en-US" xlink:label="lab_xfor_IssuanceOnJuly20221Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on July 2022 1 [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnJuly20221Member_documentation_en-US" xlink:label="lab_xfor_IssuanceOnJuly20221Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on July 2022 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnJuly20221Member" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnJuly20221Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnJuly20221Member" xlink:to="lab_xfor_IssuanceOnJuly20221Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_be66a0c3-74c2-42fb-9777-c18e053bf761_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cc2e4635-f1be-41db-beca-c4ab1f0fe265_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_234a1350-167b-4ed3-98f2-46351648aa08_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_19de9e77-6593-4d40-8922-dd4a7847e5f7_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_3159d4e9-4ade-4833-b917-b379aa614c6d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c0f78049-446b-4813-aca7-c138bf8b395a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e36e1c08-eb2e-4d8a-a980-2a9d617ea507_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_0bc5cace-d62a-4435-bb29-b9966ab8c2c0_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Nine Two Thousand Twenty One</link:label>
    <link:label id="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_label_en-US" xlink:label="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Nine Two Thousand Twenty One [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on November Nine Two Thousand Twenty One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:to="lab_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bf92bf4f-9eac-4063-b80c-f53cc5c381b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (in percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_ece60d1d-9eee-419e-aff5-8160d160275a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_59446608-a2c6-417f-b11d-6ac8cb8c7819_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_2b43a3bd-92f3-46a4-9c9c-06a3ac786441_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_CollaborationLicenseAndFundingArrangementsLineItems_5f09388c-ba43-43a7-a361-96db015c6565_terseLabel_en-US" xlink:label="lab_xfor_CollaborationLicenseAndFundingArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration License And Funding Arrangements [Line Items]</link:label>
    <link:label id="lab_xfor_CollaborationLicenseAndFundingArrangementsLineItems_label_en-US" xlink:label="lab_xfor_CollaborationLicenseAndFundingArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration License And Funding Arrangements [Line Items]</link:label>
    <link:label id="lab_xfor_CollaborationLicenseAndFundingArrangementsLineItems_documentation_en-US" xlink:label="lab_xfor_CollaborationLicenseAndFundingArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration, license and funding arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems" xlink:href="xfor-20230331.xsd#xfor_CollaborationLicenseAndFundingArrangementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="lab_xfor_CollaborationLicenseAndFundingArrangementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8f6939c3-9aad-4eec-bceb-9442e3b2ba8e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_f5fd450a-8304-4779-a7c4-6599928939d3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensatingBalancesTextBlock_24002545-5e4b-4c1f-9180-e6f19e70c4a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensatingBalancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensatingBalancesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensatingBalancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Compensating Balances [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensatingBalancesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensatingBalancesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensatingBalancesTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensatingBalancesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_844b58c3-7eab-430a-85cb-1205b93ae1ba_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_26fec574-4885-4a46-9efd-171703161db0_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_eb9b14cc-a209-44c3-9620-1f1e82003969_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_86fc4297-7242-45e3-9699-fbebda61259e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_bcac033d-0267-466b-ac42-a1329a051f30_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_8fc5c29f-7f32-4c75-9fa5-a66e9df91f2c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_63fe9d27-311e-4d52-b9d1-b131d8a625a1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_e9519453-73e7-4bdf-9a67-49c076dd938b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_3a39dca6-5457-4e67-adfe-2d9ed73add16_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_68ef9c38-fe5b-4d5e-abec-f8610b001e13_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_8ad9969d-1fae-4f38-aa9d-5589dfbec403_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AllstonLeaseAgreementMember_3c1cc924-ca57-480d-beab-c47e85e73d6d_terseLabel_en-US" xlink:label="lab_xfor_AllstonLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allston Lease Agreement</link:label>
    <link:label id="lab_xfor_AllstonLeaseAgreementMember_label_en-US" xlink:label="lab_xfor_AllstonLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allston Lease Agreement [Member]</link:label>
    <link:label id="lab_xfor_AllstonLeaseAgreementMember_documentation_en-US" xlink:label="lab_xfor_AllstonLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allston Lease Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AllstonLeaseAgreementMember" xlink:href="xfor-20230331.xsd#xfor_AllstonLeaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AllstonLeaseAgreementMember" xlink:to="lab_xfor_AllstonLeaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_2ea2d3a2-9406-4cbb-a972-eceded89fb9f_terseLabel_en-US" xlink:label="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On September 12, 2018 One</link:label>
    <link:label id="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_label_en-US" xlink:label="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance On September Twelve Two Thousand Eighteen One [Member]</link:label>
    <link:label id="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_documentation_en-US" xlink:label="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance on september twelve two thousand eighteen one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:to="lab_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_476d3ef5-a320-4695-854f-6bdbd91cd26b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4033e395-61eb-4fd8-9285-ec2753ec8378_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_60deb735-fc86-46a4-b5a8-b17116163077_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bfbb4567-ed52-4a84-bc18-8437ffd1d484_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost of stock based awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c67bdc36-2036-444f-8b81-5cc125326b93_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8dad8500-9e15-4df2-a64b-0edf42e7ad61_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_MinCashTestDate2Member_7f14e12f-267c-45fd-bc12-4c8a3556ff1f_terseLabel_en-US" xlink:label="lab_xfor_MinCashTestDate2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 2</link:label>
    <link:label id="lab_xfor_MinCashTestDate2Member_label_en-US" xlink:label="lab_xfor_MinCashTestDate2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 2 [Member]</link:label>
    <link:label id="lab_xfor_MinCashTestDate2Member_documentation_en-US" xlink:label="lab_xfor_MinCashTestDate2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Min Cash Test Date 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate2Member" xlink:href="xfor-20230331.xsd#xfor_MinCashTestDate2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_MinCashTestDate2Member" xlink:to="lab_xfor_MinCashTestDate2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_f8952383-4231-4742-aa50-de6f171925f0_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_92c66cda-10b7-4651-a358-cc47f7477806_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a52118f3-6c7a-434b-8c7d-582c2575bcc9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_855fe91a-fc5f-47b1-bff3-f30418c941cd_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_172fa3fe-e4ad-4833-a276-fb0de17426a8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c7135627-0d46-4b1b-b56a-2e52e6a90159_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ContingenciesAndCommitmentsTable_06f97159-fed0-493b-9590-a579470ed735_terseLabel_en-US" xlink:label="lab_xfor_ContingenciesAndCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies And Commitments [Table]</link:label>
    <link:label id="lab_xfor_ContingenciesAndCommitmentsTable_label_en-US" xlink:label="lab_xfor_ContingenciesAndCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies And Commitments [Table]</link:label>
    <link:label id="lab_xfor_ContingenciesAndCommitmentsTable_documentation_en-US" xlink:label="lab_xfor_ContingenciesAndCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies And Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ContingenciesAndCommitmentsTable" xlink:href="xfor-20230331.xsd#xfor_ContingenciesAndCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ContingenciesAndCommitmentsTable" xlink:to="lab_xfor_ContingenciesAndCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_b9856f97-20bc-4fa9-bb71-3bfa6e70d6f4_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_d6415155-8378-42e3-a248-ae5bd287dd19_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_NonCashInterestExpense_4c6fd506-5ad0-4122-a8e8-e480fd77a93c_terseLabel_en-US" xlink:label="lab_xfor_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of debt discount</link:label>
    <link:label id="lab_xfor_NonCashInterestExpense_label_en-US" xlink:label="lab_xfor_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense</link:label>
    <link:label id="lab_xfor_NonCashInterestExpense_documentation_en-US" xlink:label="lab_xfor_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashInterestExpense" xlink:href="xfor-20230331.xsd#xfor_NonCashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_NonCashInterestExpense" xlink:to="lab_xfor_NonCashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_2a8f13ab-d00c-441f-8703-ecf3c9e16c42_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6c40c35b-5844-4320-bb3d-e98feda97317_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_879cd526-7f9d-4833-b505-4c302acd8c7b_terseLabel_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected forfeiture rate (in percentage)</link:label>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_label_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Forfeiture Rate</link:label>
    <link:label id="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_documentation_en-US" xlink:label="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Forfeiture Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:href="xfor-20230331.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:to="lab_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AccruedLeaseConstructionCosts_0e373d87-bf7b-4356-a981-03d727b46573_terseLabel_en-US" xlink:label="lab_xfor_AccruedLeaseConstructionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued deferred financing fees</link:label>
    <link:label id="lab_xfor_AccruedLeaseConstructionCosts_label_en-US" xlink:label="lab_xfor_AccruedLeaseConstructionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Lease Construction Costs</link:label>
    <link:label id="lab_xfor_AccruedLeaseConstructionCosts_documentation_en-US" xlink:label="lab_xfor_AccruedLeaseConstructionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Lease Construction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedLeaseConstructionCosts" xlink:href="xfor-20230331.xsd#xfor_AccruedLeaseConstructionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AccruedLeaseConstructionCosts" xlink:to="lab_xfor_AccruedLeaseConstructionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_71acc8ba-e168-417e-86e8-8e738c39ad7d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_728ca387-fc4e-4d82-be51-37931ae75217_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dc4cb20a-4d5f-44e6-bc02-20fcd8b1d8b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_70f42bff-50bd-42fa-8e89-42e4a99b243c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_49d5798b-e4eb-4ef7-a11a-fa1c0de50de2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b150834d-341a-4914-9fa1-0723a1b386ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPaidinkind_79edfa2e-9733-4632-b2d0-c9602ee6a522_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsPaidinkind" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Paid-in-kind</link:label>
    <link:label id="lab_us-gaap_DividendsPaidinkind_label_en-US" xlink:label="lab_us-gaap_DividendsPaidinkind" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Paid-in-kind</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPaidinkind" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPaidinkind"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPaidinkind" xlink:to="lab_us-gaap_DividendsPaidinkind" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_NonCashLeaseExpense_b847ff4a-978e-498c-bfcb-2377b3e54082_terseLabel_en-US" xlink:label="lab_xfor_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_xfor_NonCashLeaseExpense_label_en-US" xlink:label="lab_xfor_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Lease Expense</link:label>
    <link:label id="lab_xfor_NonCashLeaseExpense_documentation_en-US" xlink:label="lab_xfor_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashLeaseExpense" xlink:href="xfor-20230331.xsd#xfor_NonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_NonCashLeaseExpense" xlink:to="lab_xfor_NonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_52e3d6d5-d2dd-459d-a64c-e5a0e2b0b6da_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class C Warrant Liability</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ccab2872-8cad-446b-ac5b-fe71de45bbc6_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_533ff0b1-83aa-4b81-86b1-8abc9a3b1c82_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding&#8212;basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_456cb7e1-c737-4ca1-91e7-368875feae9f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax benefit</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_d1e9b827-bcf1-4c7b-8a6a-5cd6f90ec891_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, Vested and expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_758e2dd8-b93f-472d-bd96-ea2d0eb8b30a_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_af16c494-c363-4e23-994e-ca1c474cc2f0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f19869af-92ac-4c86-b21b-19a8485ef5ce_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2e8869ec-0f48-4532-9080-87a92b6e3396_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5b6ca0b7-04c4-4057-b4b0-200158b1a418_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_4bb12893-862c-450d-ab9e-5dad05f3dfb1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_38d51f3d-bc78-4007-ad3f-8d4a0d54bb38_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ClassAWarrantMember_89cc0146-e72e-4548-aa02-eb220f6f0ee9_terseLabel_en-US" xlink:label="lab_xfor_ClassAWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Warrant</link:label>
    <link:label id="lab_xfor_ClassAWarrantMember_label_en-US" xlink:label="lab_xfor_ClassAWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Warrant [Member]</link:label>
    <link:label id="lab_xfor_ClassAWarrantMember_documentation_en-US" xlink:label="lab_xfor_ClassAWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassAWarrantMember" xlink:href="xfor-20230331.xsd#xfor_ClassAWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ClassAWarrantMember" xlink:to="lab_xfor_ClassAWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_ade8dfd5-0306-4d05-8fdd-18d9c95fb598_negatedTerseLabel_en-US" xlink:label="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend on Class B Warrant price reset</link:label>
    <link:label id="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_label_en-US" xlink:label="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Repurchase Of Convertible Preferred Stock</link:label>
    <link:label id="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_documentation_en-US" xlink:label="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Repurchase Of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock" xlink:href="xfor-20230331.xsd#xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock" xlink:to="lab_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_2260b529-5c1c-4741-927d-3321d16a39ff_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, current portion</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6736026d-c303-49a9-a54a-12a46becbc96_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_86cb9b69-dab2-4e43-a16a-af8a98761b38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Long Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_b94f3070-0538-4916-836a-a3b4916a708c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0cf6a332-d4b4-4a09-a092-ae0bd155464f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_656eb3dd-850d-4645-9758-cfe4318a3fb7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_SoftwareMember_6cf91546-d5d2-4c0b-adda-9d9faa7ed2f1_terseLabel_en-US" xlink:label="lab_xfor_SoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_xfor_SoftwareMember_label_en-US" xlink:label="lab_xfor_SoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software [Member]</link:label>
    <link:label id="lab_xfor_SoftwareMember_documentation_en-US" xlink:label="lab_xfor_SoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SoftwareMember" xlink:href="xfor-20230331.xsd#xfor_SoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_SoftwareMember" xlink:to="lab_xfor_SoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_d397cc89-f8fd-4ae0-bc2e-3db18b47c529_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e5d7f1d9-33a1-4289-bea1-133c0fc56f20_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_475af697-cfb3-4e7e-871e-c33844842ef8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-Based Compensation Expense Classification</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_70d576ab-56c4-4a1f-951d-961be4f91167_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7ad03971-a5f7-4a3f-b451-2c0903d3fd73_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (in percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_556e3d09-5031-4f93-923d-2c2195ea03b2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee taxes paid related to net share settlement of vested restricted stock units</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6fa1f803-cf30-4e55-adbe-295acdfa5532_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_ab40de0b-6113-4586-a689-95cf7c3af785_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_567c28da-ee2e-4eeb-a5b5-0f8681e0b06f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5b8c1bbc-df39-4145-bb4e-efc065f4c578_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_faf5bcfc-3970-4b28-a911-b66380fc25f3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7b5703d5-684d-499e-a199-22c827cb75d8_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b32159a5-9560-4ca2-a300-af37f202bace_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_NumeratorAbstract_3f84fe20-fe8e-4393-b601-7a349409ae8d_terseLabel_en-US" xlink:label="lab_xfor_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_xfor_NumeratorAbstract_label_en-US" xlink:label="lab_xfor_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_xfor_NumeratorAbstract_documentation_en-US" xlink:label="lab_xfor_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NumeratorAbstract" xlink:href="xfor-20230331.xsd#xfor_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_NumeratorAbstract" xlink:to="lab_xfor_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_PrefundedWarrantsDomain_a7fb516e-d03b-4d98-8834-ff78b512fbda_terseLabel_en-US" xlink:label="lab_xfor_PrefundedWarrantsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants [Domain]</link:label>
    <link:label id="lab_xfor_PrefundedWarrantsDomain_label_en-US" xlink:label="lab_xfor_PrefundedWarrantsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants [Domain]</link:label>
    <link:label id="lab_xfor_PrefundedWarrantsDomain_documentation_en-US" xlink:label="lab_xfor_PrefundedWarrantsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prefunded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsDomain" xlink:href="xfor-20230331.xsd#xfor_PrefundedWarrantsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_PrefundedWarrantsDomain" xlink:to="lab_xfor_PrefundedWarrantsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d316139f-3ad6-4100-b866-0e6e4622e814_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders&#8212;diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b2e6c22b-8c56-4445-bc08-80800986e32c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_099add57-244f-48ad-a1a7-5de7359dd26c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_4cc55ab2-557b-4602-bd14-aa98d88b3819_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_ContingenciesAndCommitmentsLineItems_f1e35936-54f2-4b9c-9058-d0b11b8e8b95_terseLabel_en-US" xlink:label="lab_xfor_ContingenciesAndCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies And Commitments [Line Items]</link:label>
    <link:label id="lab_xfor_ContingenciesAndCommitmentsLineItems_label_en-US" xlink:label="lab_xfor_ContingenciesAndCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies And Commitments [Line Items]</link:label>
    <link:label id="lab_xfor_ContingenciesAndCommitmentsLineItems_documentation_en-US" xlink:label="lab_xfor_ContingenciesAndCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies And Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ContingenciesAndCommitmentsLineItems" xlink:href="xfor-20230331.xsd#xfor_ContingenciesAndCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_ContingenciesAndCommitmentsLineItems" xlink:to="lab_xfor_ContingenciesAndCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a25e21e9-a3ef-438a-9b1a-806c96c0e42e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_f5b2acd9-c17e-44d8-97de-b714ddd74edd_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8e575f31-c656-4b67-a461-0a6f276487dd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_96c18887-3b6b-47c1-8662-c9067869c243_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d4c9d1b5-dc85-4c0c-b690-e1fcad6b993d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LongTermDebtAndEOTPayment_cf7a10eb-0464-4ac8-ae6a-0bd72ead4cb0_totalLabel_en-US" xlink:label="lab_xfor_LongTermDebtAndEOTPayment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of long-term debt</link:label>
    <link:label id="lab_xfor_LongTermDebtAndEOTPayment_label_en-US" xlink:label="lab_xfor_LongTermDebtAndEOTPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt and EOT payment</link:label>
    <link:label id="lab_xfor_LongTermDebtAndEOTPayment_documentation_en-US" xlink:label="lab_xfor_LongTermDebtAndEOTPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt and end of term payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtAndEOTPayment" xlink:href="xfor-20230331.xsd#xfor_LongTermDebtAndEOTPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LongTermDebtAndEOTPayment" xlink:to="lab_xfor_LongTermDebtAndEOTPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_b1f37de0-62ea-42ed-be2c-9fdd11913080_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_7acff00f-1e93-431d-8e41-ce3f77039006_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_FundedMember_ac6ae0e1-5039-4a1e-a8bd-e09bb70bb35d_terseLabel_en-US" xlink:label="lab_xfor_FundedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded</link:label>
    <link:label id="lab_xfor_FundedMember_label_en-US" xlink:label="lab_xfor_FundedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded [Member]</link:label>
    <link:label id="lab_xfor_FundedMember_documentation_en-US" xlink:label="lab_xfor_FundedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FundedMember" xlink:href="xfor-20230331.xsd#xfor_FundedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_FundedMember" xlink:to="lab_xfor_FundedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_cca785f2-fc74-4fc7-b140-d4e8970d2684_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_757bb6f7-2c27-4d19-b572-d4fbbfbd7e53_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_30b1f71d-5689-4fb5-87a7-b796373fad16_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_99c98efc-0bb6-4eff-93a3-65908d715b43_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5bab88e8-e0b0-434d-a63e-501bb62cf90b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_AccretionOnLongTermDebt_23541cd3-752c-4db3-97ee-06684c525112_negatedLabel_en-US" xlink:label="lab_xfor_AccretionOnLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative accretion of end of term payments</link:label>
    <link:label id="lab_xfor_AccretionOnLongTermDebt_label_en-US" xlink:label="lab_xfor_AccretionOnLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion On Long Term Debt</link:label>
    <link:label id="lab_xfor_AccretionOnLongTermDebt_documentation_en-US" xlink:label="lab_xfor_AccretionOnLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion on long term debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccretionOnLongTermDebt" xlink:href="xfor-20230331.xsd#xfor_AccretionOnLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_AccretionOnLongTermDebt" xlink:to="lab_xfor_AccretionOnLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_131ccec8-8ffd-40fb-8c18-2dd3104c7ef4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_645a8ae9-52b9-4a74-bfda-33025705f9a7_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_PreFundedWarrantMember_548489e6-fbe1-4da7-9a7b-8b5c14a2ba12_terseLabel_en-US" xlink:label="lab_xfor_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrant</link:label>
    <link:label id="lab_xfor_PreFundedWarrantMember_label_en-US" xlink:label="lab_xfor_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrant [Member]</link:label>
    <link:label id="lab_xfor_PreFundedWarrantMember_documentation_en-US" xlink:label="lab_xfor_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember" xlink:href="xfor-20230331.xsd#xfor_PreFundedWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_PreFundedWarrantMember" xlink:to="lab_xfor_PreFundedWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c3351569-a332-4d23-b568-aeeec9526e86_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_b06f0b28-c5d5-4313-a3c3-d32ade331b0e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_13f27829-c2ee-44cf-909a-77a119a145d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_fa6c1556-93b4-490d-9e1c-8445d876c6cb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6228e311-c648-4fdb-95d0-d0849963e4c2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_15baef32-f75d-475c-8cfe-ff15c4f61e08_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_eacf4b2d-5b51-4cfe-aa56-8181d2264979_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_156a3ba9-3149-4ab2-ba5e-02498a787780_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2754a5be-42c9-4f66-99a9-c28bfd34a74e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Collaboration, and Funding Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_d8d3424f-7746-4ba5-b7cd-70eb48d64ece_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_e1a1360d-8785-4d54-a942-600a1a7dcb8a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_caaddf3b-ad6d-4fbb-8c7f-6fb8f26c36b4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_1d100d95-1111-4c50-8582-575eb4f439af_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_324a345c-d13d-4a4b-8cf1-1e078e12e44c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_880c1b18-7269-4c97-823e-86dbe6084443_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_890c8534-9fd6-4678-bd41-a5eb254d2a70_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_a893a853-567e-4667-880a-49fb47273e4b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_eb5a220f-c25f-4ffa-b6db-91c178a4df63_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b80d0cea-232f-475e-bc42-8e7ec6709aaa_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LongTermDebtNonCurrentIncludingAccretion_aa22810b-d075-4cbd-a53e-84be91b632da_terseLabel_en-US" xlink:label="lab_xfor_LongTermDebtNonCurrentIncludingAccretion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of discount and current portion</link:label>
    <link:label id="lab_xfor_LongTermDebtNonCurrentIncludingAccretion_label_en-US" xlink:label="lab_xfor_LongTermDebtNonCurrentIncludingAccretion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Non Current Including Accretion</link:label>
    <link:label id="lab_xfor_LongTermDebtNonCurrentIncludingAccretion_documentation_en-US" xlink:label="lab_xfor_LongTermDebtNonCurrentIncludingAccretion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt non current including accretion.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtNonCurrentIncludingAccretion" xlink:href="xfor-20230331.xsd#xfor_LongTermDebtNonCurrentIncludingAccretion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LongTermDebtNonCurrentIncludingAccretion" xlink:to="lab_xfor_LongTermDebtNonCurrentIncludingAccretion" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_WalthamLeaseMember_c5875eb3-ce96-4e2b-a65d-b92ee0d84e27_terseLabel_en-US" xlink:label="lab_xfor_WalthamLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waltham Lease</link:label>
    <link:label id="lab_xfor_WalthamLeaseMember_label_en-US" xlink:label="lab_xfor_WalthamLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waltham Lease [Member]</link:label>
    <link:label id="lab_xfor_WalthamLeaseMember_documentation_en-US" xlink:label="lab_xfor_WalthamLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waltham Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WalthamLeaseMember" xlink:href="xfor-20230331.xsd#xfor_WalthamLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_WalthamLeaseMember" xlink:to="lab_xfor_WalthamLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6989aaf2-1ba5-4b10-8149-1c4c83e7417a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5569abd1-b91f-41aa-8178-f78f65eb99eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_46c011bc-0a3f-4f75-aa9b-0680ced89c59_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_93008875-ca28-4f23-a829-3a8178395a00_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares of Common Stock Issuable (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4131df76-b047-493e-9c0c-e39557c22f3f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7a936763-ddec-48ba-840e-e3954d5051e9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_417d957b-28c2-4762-ae3c-98953276cc04_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_0feea4c4-2508-48bb-b8ec-9229be7d6e44_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of the Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xfor_LineOfCreditCovenantMinimumCash_f8538d84-540d-47c3-9a20-ab0e5cd6ae5f_terseLabel_en-US" xlink:label="lab_xfor_LineOfCreditCovenantMinimumCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Covenant, Minimum Cash</link:label>
    <link:label id="lab_xfor_LineOfCreditCovenantMinimumCash_label_en-US" xlink:label="lab_xfor_LineOfCreditCovenantMinimumCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Covenant, Minimum Cash</link:label>
    <link:label id="lab_xfor_LineOfCreditCovenantMinimumCash_documentation_en-US" xlink:label="lab_xfor_LineOfCreditCovenantMinimumCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Covenant, Minimum Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditCovenantMinimumCash" xlink:href="xfor-20230331.xsd#xfor_LineOfCreditCovenantMinimumCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xfor_LineOfCreditCovenantMinimumCash" xlink:to="lab_xfor_LineOfCreditCovenantMinimumCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_e45a8ba3-a6c3-43f8-911e-3e875d70d717_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability (Note 4)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>xfor-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6d137f82-7ad4-4f5a-a1d8-483327cb893c,g:a70c2544-a714-416b-95fa-518d19b53207-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.x4pharma.com/role/CoverPage" xlink:type="simple" xlink:href="xfor-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f63d6efd-bd63-40ae-92ad-9dcd9366be26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_DocumentType_f63d6efd-bd63-40ae-92ad-9dcd9366be26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_269d752e-3b51-4ab7-ae20-911d8cf600b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_DocumentQuarterlyReport_269d752e-3b51-4ab7-ae20-911d8cf600b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6dab35b4-4322-4084-9ccd-1e4aa5d2d0b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_DocumentPeriodEndDate_6dab35b4-4322-4084-9ccd-1e4aa5d2d0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9f2aa2a7-0ead-4474-aa3c-b7bf39f1058b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_DocumentTransitionReport_9f2aa2a7-0ead-4474-aa3c-b7bf39f1058b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f3de63eb-997c-4b4d-923b-486c19a46207" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_EntityFileNumber_f3de63eb-997c-4b4d-923b-486c19a46207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1cf4d60c-b353-4f3e-a946-6a74e397f7df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_EntityRegistrantName_1cf4d60c-b353-4f3e-a946-6a74e397f7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_fb19c16e-4ee0-4c27-9bd4-b49b939bf9b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_fb19c16e-4ee0-4c27-9bd4-b49b939bf9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_190b710d-a755-410b-94fa-815fdbe3561d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_EntityTaxIdentificationNumber_190b710d-a755-410b-94fa-815fdbe3561d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_bf62e612-a921-4935-aa93-0c8cd7284618" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_EntityAddressAddressLine1_bf62e612-a921-4935-aa93-0c8cd7284618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_28e7b90f-7ed8-4497-b853-f10ea0895ae4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_EntityAddressAddressLine2_28e7b90f-7ed8-4497-b853-f10ea0895ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c1b9d43b-21fd-4fcc-86f2-c3fb60ec87e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_EntityAddressCityOrTown_c1b9d43b-21fd-4fcc-86f2-c3fb60ec87e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_bf2782c3-9d1c-4242-a827-7bce272cb25b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_EntityAddressStateOrProvince_bf2782c3-9d1c-4242-a827-7bce272cb25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8e12f1b1-9a69-4cb8-8d00-8ad0215f62f3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_EntityAddressPostalZipCode_8e12f1b1-9a69-4cb8-8d00-8ad0215f62f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_70f4f04f-1bc8-47c4-a957-9793907a9ce3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_CityAreaCode_70f4f04f-1bc8-47c4-a957-9793907a9ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6288aeb9-430b-4524-82b3-2ed587500828" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_LocalPhoneNumber_6288aeb9-430b-4524-82b3-2ed587500828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_00d35123-8e61-4b04-a338-384a82a8513f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_Security12bTitle_00d35123-8e61-4b04-a338-384a82a8513f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1f747e9b-e801-447f-a047-537332d649ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_TradingSymbol_1f747e9b-e801-447f-a047-537332d649ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a4dcb3a3-3b63-49f9-b4d3-2554d230d434" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_SecurityExchangeName_a4dcb3a3-3b63-49f9-b4d3-2554d230d434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_0052e334-b9ab-4b31-b9e4-652104e12e36" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_EntityCurrentReportingStatus_0052e334-b9ab-4b31-b9e4-652104e12e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7dc9522b-03db-40a8-b2cc-7d2401e86b40" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_EntityInteractiveDataCurrent_7dc9522b-03db-40a8-b2cc-7d2401e86b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_64955f59-7a9e-44c8-bc49-df0f840f2777" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_EntityFilerCategory_64955f59-7a9e-44c8-bc49-df0f840f2777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d04e9e0e-a725-4576-8e8e-91f9a7478050" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_EntitySmallBusiness_d04e9e0e-a725-4576-8e8e-91f9a7478050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0c2cb8af-8918-4448-a9ac-fb9179f14ad5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_EntityEmergingGrowthCompany_0c2cb8af-8918-4448-a9ac-fb9179f14ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_221a37ce-e27a-4a26-a9a5-823bee10c750" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_EntityShellCompany_221a37ce-e27a-4a26-a9a5-823bee10c750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7f739ec5-d23a-4958-a254-b8d2ef843bc8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7f739ec5-d23a-4958-a254-b8d2ef843bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d7c52da1-16ab-47ca-b088-b5d36afdd92b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_AmendmentFlag_d7c52da1-16ab-47ca-b088-b5d36afdd92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_cc03e6c1-624c-417d-af6a-0f0887852352" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_DocumentFiscalYearFocus_cc03e6c1-624c-417d-af6a-0f0887852352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_43eadd7c-38e3-4f7f-82f5-888ef456bfd8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_43eadd7c-38e3-4f7f-82f5-888ef456bfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c1d2461a-a677-40c2-9683-c0687e00ea39" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_EntityCentralIndexKey_c1d2461a-a677-40c2-9683-c0687e00ea39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d89cbd9f-6a8d-48b1-9334-2fb27f55feca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_711118ff-e5db-415e-aaa1-045581e7a4c2" xlink:to="loc_dei_CurrentFiscalYearEndDate_d89cbd9f-6a8d-48b1-9334-2fb27f55feca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="xfor-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2d9d785b-5820-41fe-9129-4371a07eed16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_04339bee-ec5b-49b9-acba-64ae67395f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2d9d785b-5820-41fe-9129-4371a07eed16" xlink:to="loc_us-gaap_AssetsAbstract_04339bee-ec5b-49b9-acba-64ae67395f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7431c1c2-5011-4045-8848-95f6836383c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_04339bee-ec5b-49b9-acba-64ae67395f54" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7431c1c2-5011-4045-8848-95f6836383c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0e676e01-0b3e-41ff-9bba-11265ae182eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7431c1c2-5011-4045-8848-95f6836383c3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0e676e01-0b3e-41ff-9bba-11265ae182eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveReceivable_e938681e-7bef-470f-aefb-a675249ec570" xlink:href="xfor-20230331.xsd#xfor_ResearchAndDevelopmentIncentiveReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7431c1c2-5011-4045-8848-95f6836383c3" xlink:to="loc_xfor_ResearchAndDevelopmentIncentiveReceivable_e938681e-7bef-470f-aefb-a675249ec570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_de9ed91b-5abf-4261-996f-b48a7f9cf01c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7431c1c2-5011-4045-8848-95f6836383c3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_de9ed91b-5abf-4261-996f-b48a7f9cf01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d1e12889-7bf7-49ce-b99a-b90cb75fb05c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7431c1c2-5011-4045-8848-95f6836383c3" xlink:to="loc_us-gaap_AssetsCurrent_d1e12889-7bf7-49ce-b99a-b90cb75fb05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_64f38804-d25d-4d20-a929-e9e7d652f78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_04339bee-ec5b-49b9-acba-64ae67395f54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_64f38804-d25d-4d20-a929-e9e7d652f78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_10c7b8ae-a8e9-49a8-a151-4c67d6327b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_04339bee-ec5b-49b9-acba-64ae67395f54" xlink:to="loc_us-gaap_Goodwill_10c7b8ae-a8e9-49a8-a151-4c67d6327b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9e1aa579-3d1e-4812-9c33-2a5bc4ed70e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_04339bee-ec5b-49b9-acba-64ae67395f54" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9e1aa579-3d1e-4812-9c33-2a5bc4ed70e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_77da991f-3e1c-4908-99cb-32c621951711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_04339bee-ec5b-49b9-acba-64ae67395f54" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_77da991f-3e1c-4908-99cb-32c621951711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f338c33c-46e5-4e78-8947-f20a1ee34197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_04339bee-ec5b-49b9-acba-64ae67395f54" xlink:to="loc_us-gaap_Assets_f338c33c-46e5-4e78-8947-f20a1ee34197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e855e4d-f31e-456e-b4a2-e0548238dd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2d9d785b-5820-41fe-9129-4371a07eed16" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e855e4d-f31e-456e-b4a2-e0548238dd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5c3a6eda-391d-434f-ba7b-59af82faba9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e855e4d-f31e-456e-b4a2-e0548238dd0f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5c3a6eda-391d-434f-ba7b-59af82faba9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5b52dd9b-c7ef-462d-a527-8fd05bf46467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5c3a6eda-391d-434f-ba7b-59af82faba9f" xlink:to="loc_us-gaap_AccountsPayableCurrent_5b52dd9b-c7ef-462d-a527-8fd05bf46467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ad69fedf-814c-44af-a99f-bdca24f467b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5c3a6eda-391d-434f-ba7b-59af82faba9f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ad69fedf-814c-44af-a99f-bdca24f467b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_00e6523a-0075-4ab3-ba8f-e24e20613288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5c3a6eda-391d-434f-ba7b-59af82faba9f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_00e6523a-0075-4ab3-ba8f-e24e20613288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_57ffd4a3-719d-4239-ac70-c3472bfa280f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5c3a6eda-391d-434f-ba7b-59af82faba9f" xlink:to="loc_us-gaap_LongTermDebtCurrent_57ffd4a3-719d-4239-ac70-c3472bfa280f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_71bee3ab-713a-42e5-bcd6-dc0671d2a67f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5c3a6eda-391d-434f-ba7b-59af82faba9f" xlink:to="loc_us-gaap_LiabilitiesCurrent_71bee3ab-713a-42e5-bcd6-dc0671d2a67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtNonCurrentIncludingAccretion_f60c9364-678d-4d45-9a21-7bf3c98b9d91" xlink:href="xfor-20230331.xsd#xfor_LongTermDebtNonCurrentIncludingAccretion"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e855e4d-f31e-456e-b4a2-e0548238dd0f" xlink:to="loc_xfor_LongTermDebtNonCurrentIncludingAccretion_f60c9364-678d-4d45-9a21-7bf3c98b9d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22786ad3-e959-4f3f-9575-b6f46118da6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e855e4d-f31e-456e-b4a2-e0548238dd0f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22786ad3-e959-4f3f-9575-b6f46118da6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_ab0304da-10c5-4fa9-96cd-6e581e58653f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e855e4d-f31e-456e-b4a2-e0548238dd0f" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_ab0304da-10c5-4fa9-96cd-6e581e58653f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9aa9ec9d-54e7-43c1-9f45-2fc9e73e5ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e855e4d-f31e-456e-b4a2-e0548238dd0f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9aa9ec9d-54e7-43c1-9f45-2fc9e73e5ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2a6a3258-f945-4461-9bd5-e69d5e837f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e855e4d-f31e-456e-b4a2-e0548238dd0f" xlink:to="loc_us-gaap_Liabilities_2a6a3258-f945-4461-9bd5-e69d5e837f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e354c9b3-e2da-45f8-9db2-573ee4eed957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e855e4d-f31e-456e-b4a2-e0548238dd0f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e354c9b3-e2da-45f8-9db2-573ee4eed957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_247d2692-d07b-49a9-b28f-decb852bd162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e855e4d-f31e-456e-b4a2-e0548238dd0f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_247d2692-d07b-49a9-b28f-decb852bd162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_62cd21f8-af30-4b91-b474-eff0bb0cfbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_247d2692-d07b-49a9-b28f-decb852bd162" xlink:to="loc_us-gaap_CommonStockValue_62cd21f8-af30-4b91-b474-eff0bb0cfbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6d37e25b-6060-46bd-aa16-8c0424457abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_247d2692-d07b-49a9-b28f-decb852bd162" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6d37e25b-6060-46bd-aa16-8c0424457abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aaf3ee7f-2bf9-4415-b0b5-84414e3ee227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_247d2692-d07b-49a9-b28f-decb852bd162" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aaf3ee7f-2bf9-4415-b0b5-84414e3ee227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_519b9a74-428d-494c-a068-ab926c666eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_247d2692-d07b-49a9-b28f-decb852bd162" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_519b9a74-428d-494c-a068-ab926c666eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4a6bac58-919b-4180-bac9-998f8136fd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_247d2692-d07b-49a9-b28f-decb852bd162" xlink:to="loc_us-gaap_StockholdersEquity_4a6bac58-919b-4180-bac9-998f8136fd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ff5cf7cb-4998-4fd8-b04c-bd0f0d94e88d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e855e4d-f31e-456e-b4a2-e0548238dd0f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ff5cf7cb-4998-4fd8-b04c-bd0f0d94e88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="xfor-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_14bc5c66-bb05-4c6b-b363-d80915bb823d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_01916d9b-a486-4897-ab65-432d7b1bc0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_14bc5c66-bb05-4c6b-b363-d80915bb823d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_01916d9b-a486-4897-ab65-432d7b1bc0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8bad8757-16a3-4128-9876-8e98d173d63a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_14bc5c66-bb05-4c6b-b363-d80915bb823d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8bad8757-16a3-4128-9876-8e98d173d63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_9685f0e2-6e41-474d-9e07-3fe5ef994b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_14bc5c66-bb05-4c6b-b363-d80915bb823d" xlink:to="loc_us-gaap_CommonStockSharesIssued_9685f0e2-6e41-474d-9e07-3fe5ef994b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_995aeecf-0047-43f7-a6a7-d77be65bf4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_14bc5c66-bb05-4c6b-b363-d80915bb823d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_995aeecf-0047-43f7-a6a7-d77be65bf4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="xfor-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_43ab7cdc-ca69-4f28-97ee-aa3a04bcc1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3ac472b7-c048-4594-bb72-175520473855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43ab7cdc-ca69-4f28-97ee-aa3a04bcc1a3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3ac472b7-c048-4594-bb72-175520473855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8870f0dd-79bc-4bdb-b45b-03be5810e738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ac472b7-c048-4594-bb72-175520473855" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8870f0dd-79bc-4bdb-b45b-03be5810e738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_584e2c4f-9d13-4312-901f-872aa85ceee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ac472b7-c048-4594-bb72-175520473855" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_584e2c4f-9d13-4312-901f-872aa85ceee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_52df38fc-7096-4f85-8061-e000e91833d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ac472b7-c048-4594-bb72-175520473855" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_52df38fc-7096-4f85-8061-e000e91833d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ada3d081-9a99-45cd-8bef-36d9dc97638a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ac472b7-c048-4594-bb72-175520473855" xlink:to="loc_us-gaap_OperatingExpenses_ada3d081-9a99-45cd-8bef-36d9dc97638a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f46256f3-d9d8-4830-a7b3-a6f5aeb0fb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ac472b7-c048-4594-bb72-175520473855" xlink:to="loc_us-gaap_OperatingIncomeLoss_f46256f3-d9d8-4830-a7b3-a6f5aeb0fb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_956afde0-ff39-400a-9cda-b1ec341a756f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ac472b7-c048-4594-bb72-175520473855" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_956afde0-ff39-400a-9cda-b1ec341a756f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_645e32cf-a327-4703-9d34-8819dcc6060d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_956afde0-ff39-400a-9cda-b1ec341a756f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_645e32cf-a327-4703-9d34-8819dcc6060d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9689b483-18ec-4421-804e-05923e143346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_956afde0-ff39-400a-9cda-b1ec341a756f" xlink:to="loc_us-gaap_InterestExpense_9689b483-18ec-4421-804e-05923e143346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c3e9d9cc-4383-4aad-93d7-b575631e7325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_956afde0-ff39-400a-9cda-b1ec341a756f" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c3e9d9cc-4383-4aad-93d7-b575631e7325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8cffffe2-f910-47d0-be30-ff044c3c23b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_956afde0-ff39-400a-9cda-b1ec341a756f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8cffffe2-f910-47d0-be30-ff044c3c23b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_91a5fb50-b6c4-42b5-b0c7-592f243289d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_956afde0-ff39-400a-9cda-b1ec341a756f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_91a5fb50-b6c4-42b5-b0c7-592f243289d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_383b8236-58a0-443f-9f8f-14914e6d88e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ac472b7-c048-4594-bb72-175520473855" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_383b8236-58a0-443f-9f8f-14914e6d88e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_eb44fb71-d19c-4de3-8b44-2e4153331d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ac472b7-c048-4594-bb72-175520473855" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_eb44fb71-d19c-4de3-8b44-2e4153331d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d938fdcf-f4cb-4ab3-9d89-570022083e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ac472b7-c048-4594-bb72-175520473855" xlink:to="loc_us-gaap_NetIncomeLoss_d938fdcf-f4cb-4ab3-9d89-570022083e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_f312703f-8c26-4a0a-920c-9a14099cf951" xlink:href="xfor-20230331.xsd#xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ac472b7-c048-4594-bb72-175520473855" xlink:to="loc_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock_f312703f-8c26-4a0a-920c-9a14099cf951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_77b57967-9414-44db-8897-a7a5798075f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ac472b7-c048-4594-bb72-175520473855" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_77b57967-9414-44db-8897-a7a5798075f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_34f43153-eacc-43c0-8b16-d513ff4ba768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ac472b7-c048-4594-bb72-175520473855" xlink:to="loc_us-gaap_EarningsPerShareBasic_34f43153-eacc-43c0-8b16-d513ff4ba768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0d35544d-22d7-4863-b535-cabce7d7af6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ac472b7-c048-4594-bb72-175520473855" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0d35544d-22d7-4863-b535-cabce7d7af6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a0958cc9-86a1-4c6a-88ac-5faf48741c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ac472b7-c048-4594-bb72-175520473855" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a0958cc9-86a1-4c6a-88ac-5faf48741c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_70c3a252-491e-41b7-948f-cf1bbd14ae9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ac472b7-c048-4594-bb72-175520473855" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_70c3a252-491e-41b7-948f-cf1bbd14ae9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="xfor-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_cf10a97c-5f06-4f70-b793-83f9573586e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1ec5e6d3-5102-434d-b403-6771ba89986d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_cf10a97c-5f06-4f70-b793-83f9573586e5" xlink:to="loc_us-gaap_StatementTable_1ec5e6d3-5102-434d-b403-6771ba89986d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ce32c42f-9bd0-450f-9f15-9e46310dc217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1ec5e6d3-5102-434d-b403-6771ba89986d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ce32c42f-9bd0-450f-9f15-9e46310dc217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_49f952c5-8149-4472-bebb-b153170dca7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ce32c42f-9bd0-450f-9f15-9e46310dc217" xlink:to="loc_us-gaap_EquityComponentDomain_49f952c5-8149-4472-bebb-b153170dca7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0c6419d1-1967-454b-a194-dd954179c5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_49f952c5-8149-4472-bebb-b153170dca7c" xlink:to="loc_us-gaap_CommonStockMember_0c6419d1-1967-454b-a194-dd954179c5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_687e64a6-6f4d-4928-a94a-cd4769ad872a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_49f952c5-8149-4472-bebb-b153170dca7c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_687e64a6-6f4d-4928-a94a-cd4769ad872a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6ff2af72-b7f5-4863-8346-a1b0bbd36368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_49f952c5-8149-4472-bebb-b153170dca7c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6ff2af72-b7f5-4863-8346-a1b0bbd36368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c33ab1d5-3788-4831-bbf3-608f237f170b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_49f952c5-8149-4472-bebb-b153170dca7c" xlink:to="loc_us-gaap_RetainedEarningsMember_c33ab1d5-3788-4831-bbf3-608f237f170b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f8fad25f-ded5-4005-bf54-e25957590f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1ec5e6d3-5102-434d-b403-6771ba89986d" xlink:to="loc_us-gaap_StatementLineItems_f8fad25f-ded5-4005-bf54-e25957590f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f8fad25f-ded5-4005-bf54-e25957590f77" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cd4e8946-7ae5-4633-97d0-89b6488a1379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_SharesOutstanding_cd4e8946-7ae5-4633-97d0-89b6488a1379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a627c11e-1c38-411c-a4e0-c1c64691eb29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_StockholdersEquity_a627c11e-1c38-411c-a4e0-c1c64691eb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_79644e71-45eb-41c9-996e-e1ebc530edb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_79644e71-45eb-41c9-996e-e1ebc530edb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_02ad8628-e121-4356-b582-5faaeea789ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_02ad8628-e121-4356-b582-5faaeea789ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_9ed6af29-3f1c-4767-825e-f33e5f0942a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_9ed6af29-3f1c-4767-825e-f33e5f0942a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_2cf2df78-43d1-4c5e-806f-e792e8ab1079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_2cf2df78-43d1-4c5e-806f-e792e8ab1079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_35cbc334-0be2-4be6-a717-2202d30ce52f" xlink:href="xfor-20230331.xsd#xfor_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_xfor_StockIssuedDuringPeriodSharesWarrantsExercised_35cbc334-0be2-4be6-a717-2202d30ce52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_666ac82f-c5ee-41d1-b9d4-ba14694a6e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_666ac82f-c5ee-41d1-b9d4-ba14694a6e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b85d7f07-958c-457e-a10e-a7b7b500d391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_NetIncomeLoss_b85d7f07-958c-457e-a10e-a7b7b500d391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_04f1de20-d288-4ae8-a4d7-7d0b4f81216d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_SharesOutstanding_04f1de20-d288-4ae8-a4d7-7d0b4f81216d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_87ba9171-6e23-42dd-86e2-94371d194209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b477687d-1335-4dc2-9b0b-d9ec9b9ee91d" xlink:to="loc_us-gaap_StockholdersEquity_87ba9171-6e23-42dd-86e2-94371d194209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="xfor-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a5d65e2b-c694-469e-be85-c5fdeab9c0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6ccdb706-66ba-43fa-94f7-01c18e54fef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5d65e2b-c694-469e-be85-c5fdeab9c0cc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6ccdb706-66ba-43fa-94f7-01c18e54fef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_528403b6-a55c-4432-a32d-19b3e5ba9aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6ccdb706-66ba-43fa-94f7-01c18e54fef4" xlink:to="loc_us-gaap_NetIncomeLoss_528403b6-a55c-4432-a32d-19b3e5ba9aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1995aad-d532-43a2-8bcd-ffe26a23c0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6ccdb706-66ba-43fa-94f7-01c18e54fef4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1995aad-d532-43a2-8bcd-ffe26a23c0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_33ca4243-cb63-4d1d-abd2-92bdd682bf10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1995aad-d532-43a2-8bcd-ffe26a23c0b1" xlink:to="loc_us-gaap_ShareBasedCompensation_33ca4243-cb63-4d1d-abd2-92bdd682bf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_31eced79-cba7-4eec-8a43-7cda15e1f295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1995aad-d532-43a2-8bcd-ffe26a23c0b1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_31eced79-cba7-4eec-8a43-7cda15e1f295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashLeaseExpense_acc93c74-09e3-4830-81d2-eab2c02a8116" xlink:href="xfor-20230331.xsd#xfor_NonCashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1995aad-d532-43a2-8bcd-ffe26a23c0b1" xlink:to="loc_xfor_NonCashLeaseExpense_acc93c74-09e3-4830-81d2-eab2c02a8116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NonCashInterestExpense_c092f677-3fff-469b-ae37-f6cf9c34b2cc" xlink:href="xfor-20230331.xsd#xfor_NonCashInterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1995aad-d532-43a2-8bcd-ffe26a23c0b1" xlink:to="loc_xfor_NonCashInterestExpense_c092f677-3fff-469b-ae37-f6cf9c34b2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_86d4a3b5-c417-485c-9337-0e494cba49ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1995aad-d532-43a2-8bcd-ffe26a23c0b1" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_86d4a3b5-c417-485c-9337-0e494cba49ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_276c55a3-511c-4d7f-b9ab-d3cd8e6eb819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1995aad-d532-43a2-8bcd-ffe26a23c0b1" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_276c55a3-511c-4d7f-b9ab-d3cd8e6eb819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_340826c5-d216-4847-8e7d-29c7969d1c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1995aad-d532-43a2-8bcd-ffe26a23c0b1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_340826c5-d216-4847-8e7d-29c7969d1c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_86158ca2-6e5f-48fc-8015-dc7a9b2ddf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_340826c5-d216-4847-8e7d-29c7969d1c24" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_86158ca2-6e5f-48fc-8015-dc7a9b2ddf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_331e94c8-0391-4d77-845a-652ec3cb7932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_340826c5-d216-4847-8e7d-29c7969d1c24" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_331e94c8-0391-4d77-845a-652ec3cb7932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_915836e4-80a9-4beb-bdba-7ff2a8b1f72f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_340826c5-d216-4847-8e7d-29c7969d1c24" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_915836e4-80a9-4beb-bdba-7ff2a8b1f72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IncreaseDecreaseInLeaseLiabilities_114fb69f-5798-4575-b26e-9f1f2647f5c1" xlink:href="xfor-20230331.xsd#xfor_IncreaseDecreaseInLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_340826c5-d216-4847-8e7d-29c7969d1c24" xlink:to="loc_xfor_IncreaseDecreaseInLeaseLiabilities_114fb69f-5798-4575-b26e-9f1f2647f5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7f668b1-a141-403e-a4aa-e6833e59ec44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6ccdb706-66ba-43fa-94f7-01c18e54fef4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7f668b1-a141-403e-a4aa-e6833e59ec44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_180fc39b-8f0e-4442-9be6-60bc128773bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5d65e2b-c694-469e-be85-c5fdeab9c0cc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_180fc39b-8f0e-4442-9be6-60bc128773bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_1491f27f-56e9-4a2f-9e38-55b74d31fb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_180fc39b-8f0e-4442-9be6-60bc128773bd" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_1491f27f-56e9-4a2f-9e38-55b74d31fb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a675d460-1913-4349-9792-780c049472ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_180fc39b-8f0e-4442-9be6-60bc128773bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a675d460-1913-4349-9792-780c049472ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec4b9e2f-ac0c-4fb0-8d98-95063e1c45b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5d65e2b-c694-469e-be85-c5fdeab9c0cc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec4b9e2f-ac0c-4fb0-8d98-95063e1c45b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a06613af-6e8d-4892-88b9-89c5b50f84a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec4b9e2f-ac0c-4fb0-8d98-95063e1c45b6" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a06613af-6e8d-4892-88b9-89c5b50f84a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement_f86ff4a8-b0d2-4672-ace4-d27dd3d0159b" xlink:href="xfor-20230331.xsd#xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec4b9e2f-ac0c-4fb0-8d98-95063e1c45b6" xlink:to="loc_xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement_f86ff4a8-b0d2-4672-ace4-d27dd3d0159b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_f82d8cfd-03ee-48b6-9862-f6958f6e0c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec4b9e2f-ac0c-4fb0-8d98-95063e1c45b6" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_f82d8cfd-03ee-48b6-9862-f6958f6e0c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_103f2e10-541b-437e-be52-e1d69d2541c5" xlink:href="xfor-20230331.xsd#xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec4b9e2f-ac0c-4fb0-8d98-95063e1c45b6" xlink:to="loc_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts_103f2e10-541b-437e-be52-e1d69d2541c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1f486776-0ce9-451e-87ae-ec730fb73a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec4b9e2f-ac0c-4fb0-8d98-95063e1c45b6" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1f486776-0ce9-451e-87ae-ec730fb73a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01427723-46fb-477f-bafa-46a0779419c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec4b9e2f-ac0c-4fb0-8d98-95063e1c45b6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01427723-46fb-477f-bafa-46a0779419c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18b6c287-f89d-4290-8a89-2aaf04a086d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5d65e2b-c694-469e-be85-c5fdeab9c0cc" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18b6c287-f89d-4290-8a89-2aaf04a086d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1639f4a2-7498-4055-8f6f-a6f6c9f4b9db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5d65e2b-c694-469e-be85-c5fdeab9c0cc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1639f4a2-7498-4055-8f6f-a6f6c9f4b9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0f52acc7-aaee-4a76-8158-6b8835b5f3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5d65e2b-c694-469e-be85-c5fdeab9c0cc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0f52acc7-aaee-4a76-8158-6b8835b5f3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4f96de40-8ebf-479b-906e-eedf4fe76d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5d65e2b-c694-469e-be85-c5fdeab9c0cc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4f96de40-8ebf-479b-906e-eedf4fe76d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="simple" xlink:href="xfor-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_af06ad4b-f2c3-415d-b4af-d63faef8dd52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3faf7a39-92ea-45e6-9c62-7c164cb0ffa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_af06ad4b-f2c3-415d-b4af-d63faef8dd52" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3faf7a39-92ea-45e6-9c62-7c164cb0ffa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9b291b4b-c531-45c3-adff-c5a88166e494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_af06ad4b-f2c3-415d-b4af-d63faef8dd52" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9b291b4b-c531-45c3-adff-c5a88166e494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="simple" xlink:href="xfor-20230331.xsd#NatureoftheBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b17ff546-6882-4944-8fd3-b86832f4c987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_93cfc1f2-fb46-4b31-940c-eee012c95d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b17ff546-6882-4944-8fd3-b86832f4c987" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_93cfc1f2-fb46-4b31-940c-eee012c95d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="xfor-20230331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7f570f85-1711-44fc-af13-c607c6710a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_64a8da9c-ff0e-45b9-af92-f0c46cb84445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f570f85-1711-44fc-af13-c607c6710a42" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_64a8da9c-ff0e-45b9-af92-f0c46cb84445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements" xlink:type="simple" xlink:href="xfor-20230331.xsd#LicenseCollaborationandFundingAgreements"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_43a781fe-51e6-408b-ad27-a3ba6e9c2da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8f1d0c1f-2f21-4086-be6d-6ef7937e8431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_43a781fe-51e6-408b-ad27-a3ba6e9c2da9" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8f1d0c1f-2f21-4086-be6d-6ef7937e8431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities" xlink:type="simple" xlink:href="xfor-20230331.xsd#FairValueofFinancialAssetsandLiabilities"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6d8520dc-ac2a-48d6-8451-f6446b92a340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_dd24beea-90d7-443f-b310-10cf7f283d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6d8520dc-ac2a-48d6-8451-f6446b92a340" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_dd24beea-90d7-443f-b310-10cf7f283d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="xfor-20230331.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c58e65c8-24a8-43ea-9512-99c417dfe056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4a60f8e6-f5a7-49dd-b155-2b2fde203b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c58e65c8-24a8-43ea-9512-99c417dfe056" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4a60f8e6-f5a7-49dd-b155-2b2fde203b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/AccruedExpenses" xlink:type="simple" xlink:href="xfor-20230331.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_46caee66-414e-488a-8c6c-440ea442cd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedExpensesTextBlock_fd7f1b92-7b9a-43b9-bd62-c34882b2168d" xlink:href="xfor-20230331.xsd#xfor_AccruedExpensesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_46caee66-414e-488a-8c6c-440ea442cd9e" xlink:to="loc_xfor_AccruedExpensesTextBlock_fd7f1b92-7b9a-43b9-bd62-c34882b2168d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebt" xlink:type="simple" xlink:href="xfor-20230331.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_10d9de37-a9e7-436d-9651-466823c4b04a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_3d6768c9-175d-4bf5-8775-2c130ac92f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_10d9de37-a9e7-436d-9651-466823c4b04a" xlink:to="loc_us-gaap_LongTermDebtTextBlock_3d6768c9-175d-4bf5-8775-2c130ac92f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/Leases" xlink:type="simple" xlink:href="xfor-20230331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d9305115-614b-434c-a1b4-6b9a84e00d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_7884710c-057e-49d0-8bae-6020c2577cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d9305115-614b-434c-a1b4-6b9a84e00d46" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_7884710c-057e-49d0-8bae-6020c2577cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="xfor-20230331.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_62ad1e5f-a110-433c-babb-ba91790120e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7918bd6e-27b3-42b7-8157-6ee97d56fd86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_62ad1e5f-a110-433c-babb-ba91790120e7" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7918bd6e-27b3-42b7-8157-6ee97d56fd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommonStockWarrants" xlink:type="simple" xlink:href="xfor-20230331.xsd#CommonStockWarrants"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CommonStockWarrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_455d1829-e321-4bf7-a79b-b3aff29edc07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_f8bbff96-b95e-43d1-b0b5-322c410adcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_455d1829-e321-4bf7-a79b-b3aff29edc07" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_f8bbff96-b95e-43d1-b0b5-322c410adcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="xfor-20230331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38fa8c8e-f4e0-4ed3-aede-5edf2500fcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5a86a530-68bf-4b79-a9e2-2319d3b7b228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38fa8c8e-f4e0-4ed3-aede-5edf2500fcf5" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5a86a530-68bf-4b79-a9e2-2319d3b7b228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="xfor-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ce86464a-6eef-4a91-b889-e0e6d89ff433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_92ef9484-2929-43ce-9e02-69b89cd93fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce86464a-6eef-4a91-b889-e0e6d89ff433" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_92ef9484-2929-43ce-9e02-69b89cd93fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShare" xlink:type="simple" xlink:href="xfor-20230331.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fa6c23f6-d9da-4ba9-b267-dc6349797c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_d402252e-e845-4af0-b539-60874def27ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fa6c23f6-d9da-4ba9-b267-dc6349797c2c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_d402252e-e845-4af0-b539-60874def27ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="xfor-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aa047914-3cfc-4aa3-96ee-157af508dfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_da343791-8c9d-4dc8-8602-ec78b384c29e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa047914-3cfc-4aa3-96ee-157af508dfa1" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_da343791-8c9d-4dc8-8602-ec78b384c29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_ea5df50f-0025-4416-ae10-fb28db443423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa047914-3cfc-4aa3-96ee-157af508dfa1" xlink:to="loc_us-gaap_UseOfEstimates_ea5df50f-0025-4416-ae10-fb28db443423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0333edb7-f94c-4ab7-8810-09457b18c477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa047914-3cfc-4aa3-96ee-157af508dfa1" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0333edb7-f94c-4ab7-8810-09457b18c477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_fdcf2656-7324-4e06-a094-db488a35b4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa047914-3cfc-4aa3-96ee-157af508dfa1" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_fdcf2656-7324-4e06-a094-db488a35b4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fd898e5f-8555-4449-aed0-4294806696e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa047914-3cfc-4aa3-96ee-157af508dfa1" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fd898e5f-8555-4449-aed0-4294806696e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_d6287684-c1f4-41a7-babb-ac918c533a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa047914-3cfc-4aa3-96ee-157af508dfa1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_d6287684-c1f4-41a7-babb-ac918c533a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="xfor-20230331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aa3fef2f-08d8-41cb-ad3c-8f6bc0c4a998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensatingBalancesTextBlock_a13e6864-8ef0-4281-b870-da79536487c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensatingBalancesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa3fef2f-08d8-41cb-ad3c-8f6bc0c4a998" xlink:to="loc_us-gaap_ScheduleOfCompensatingBalancesTextBlock_a13e6864-8ef0-4281-b870-da79536487c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock_c017b11c-52ed-489c-a10f-275be9bbea59" xlink:href="xfor-20230331.xsd#xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa3fef2f-08d8-41cb-ad3c-8f6bc0c4a998" xlink:to="loc_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock_c017b11c-52ed-489c-a10f-275be9bbea59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" xlink:type="simple" xlink:href="xfor-20230331.xsd#FairValueofFinancialAssetsandLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bc0e16dc-ac33-44f3-9d58-40d107c76d63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_fef15775-fee7-4a28-990b-fdc08eff4982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bc0e16dc-ac33-44f3-9d58-40d107c76d63" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_fef15775-fee7-4a28-990b-fdc08eff4982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_0d621353-32a0-4261-aeb6-8fb0f0543e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bc0e16dc-ac33-44f3-9d58-40d107c76d63" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_0d621353-32a0-4261-aeb6-8fb0f0543e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_606a3d18-cf39-49d3-9a3c-1d7e50db9dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bc0e16dc-ac33-44f3-9d58-40d107c76d63" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_606a3d18-cf39-49d3-9a3c-1d7e50db9dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="xfor-20230331.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b6123f0d-915d-4bf9-b26e-fa465a12e855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_19a1ba41-df06-47bd-a00e-d4e4aeaf3395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b6123f0d-915d-4bf9-b26e-fa465a12e855" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_19a1ba41-df06-47bd-a00e-d4e4aeaf3395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="xfor-20230331.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5e611db1-0aeb-4c85-8ed4-fdab90985ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d88c4734-7fe0-4196-a1f8-e5f68e2e9aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5e611db1-0aeb-4c85-8ed4-fdab90985ab2" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d88c4734-7fe0-4196-a1f8-e5f68e2e9aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="xfor-20230331.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_00d6b6d6-7581-4547-9979-430c5ee54d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_333be8ce-07f2-4310-8af5-d3e5b0a95fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_00d6b6d6-7581-4547-9979-430c5ee54d80" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_333be8ce-07f2-4310-8af5-d3e5b0a95fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_e5ef52f9-f71d-4935-a7ff-baf67eb2b9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_00d6b6d6-7581-4547-9979-430c5ee54d80" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_e5ef52f9-f71d-4935-a7ff-baf67eb2b9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_759ae18f-94d4-4c8e-9432-59873f37efc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_00d6b6d6-7581-4547-9979-430c5ee54d80" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_759ae18f-94d4-4c8e-9432-59873f37efc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesTables" xlink:type="simple" xlink:href="xfor-20230331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d0308034-4242-4084-ab72-4db8706f0a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_01c93d4e-096f-4226-8028-2f91d625f201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d0308034-4242-4084-ab72-4db8706f0a08" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_01c93d4e-096f-4226-8028-2f91d625f201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_77ea04ac-97a4-428c-985e-1ae9ff4e6e28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d0308034-4242-4084-ab72-4db8706f0a08" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_77ea04ac-97a4-428c-985e-1ae9ff4e6e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommonStockWarrantsTables" xlink:type="simple" xlink:href="xfor-20230331.xsd#CommonStockWarrantsTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CommonStockWarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9d041bb0-bbc9-4204-badb-26e713e639aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_78334ba5-6762-43c0-b4a7-422a4780bab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9d041bb0-bbc9-4204-badb-26e713e639aa" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_78334ba5-6762-43c0-b4a7-422a4780bab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="xfor-20230331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_921bbb53-71bc-4cd5-a701-3565873ecc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_1c1c7d92-1edf-4e28-8792-ab99a9148683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_921bbb53-71bc-4cd5-a701-3565873ecc2c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_1c1c7d92-1edf-4e28-8792-ab99a9148683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_728c74d4-4ed7-4729-811b-552033728e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_921bbb53-71bc-4cd5-a701-3565873ecc2c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_728c74d4-4ed7-4729-811b-552033728e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_f2726eab-e13f-4190-be27-6a29411e3c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_921bbb53-71bc-4cd5-a701-3565873ecc2c" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_f2726eab-e13f-4190-be27-6a29411e3c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8c8aaf75-fb1d-48cc-b1b4-b967737b339f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_921bbb53-71bc-4cd5-a701-3565873ecc2c" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8c8aaf75-fb1d-48cc-b1b4-b967737b339f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_1b6213ac-bc0e-4bda-954c-92a4c8a41f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_921bbb53-71bc-4cd5-a701-3565873ecc2c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_1b6213ac-bc0e-4bda-954c-92a4c8a41f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="xfor-20230331.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_00b12676-544f-4178-9945-8750d99d9d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f427f992-f9ff-41b4-9251-938d4f338d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_00b12676-544f-4178-9945-8750d99d9d1f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f427f992-f9ff-41b4-9251-938d4f338d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ff8dcd2f-21d4-46da-97aa-c484fbd5d07d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_00b12676-544f-4178-9945-8750d99d9d1f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ff8dcd2f-21d4-46da-97aa-c484fbd5d07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3bf8ddd0-4828-4238-941d-c066376c17a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ScheduleOfAccountingPoliciesTable_c9b71b59-6bcf-4d67-ba97-bcd72362d4e7" xlink:href="xfor-20230331.xsd#xfor_ScheduleOfAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3bf8ddd0-4828-4238-941d-c066376c17a1" xlink:to="loc_xfor_ScheduleOfAccountingPoliciesTable_c9b71b59-6bcf-4d67-ba97-bcd72362d4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5fe3bb8f-4ee8-414d-b6fb-616e3b40dfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfAccountingPoliciesTable_c9b71b59-6bcf-4d67-ba97-bcd72362d4e7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5fe3bb8f-4ee8-414d-b6fb-616e3b40dfbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0abed63-da81-4b6a-9c59-9077da5cf9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5fe3bb8f-4ee8-414d-b6fb-616e3b40dfbe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0abed63-da81-4b6a-9c59-9077da5cf9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_62c99b1e-c2ee-40bf-8686-57fa74d57473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ScheduleOfAccountingPoliciesTable_c9b71b59-6bcf-4d67-ba97-bcd72362d4e7" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_62c99b1e-c2ee-40bf-8686-57fa74d57473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31815535-09d3-4df2-9dab-2b5114735cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_62c99b1e-c2ee-40bf-8686-57fa74d57473" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31815535-09d3-4df2-9dab-2b5114735cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d92f76dd-bf16-40e0-9926-40d8ecf33cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_62c99b1e-c2ee-40bf-8686-57fa74d57473" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d92f76dd-bf16-40e0-9926-40d8ecf33cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb6bce7a-a34d-43c6-97fa-e6dc5e889ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_62c99b1e-c2ee-40bf-8686-57fa74d57473" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb6bce7a-a34d-43c6-97fa-e6dc5e889ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_195bc643-fce7-4f03-9c9d-8a56ee14d4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_d20765ae-f77d-4e9c-ad83-b0ec883ce07c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_195bc643-fce7-4f03-9c9d-8a56ee14d4dd" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_d20765ae-f77d-4e9c-ad83-b0ec883ce07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2edd8255-26be-4fbe-acef-83472df75608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_d20765ae-f77d-4e9c-ad83-b0ec883ce07c" xlink:to="loc_us-gaap_CreditFacilityAxis_2edd8255-26be-4fbe-acef-83472df75608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_668dbe70-f80a-4fba-8fe9-99810369c1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2edd8255-26be-4fbe-acef-83472df75608" xlink:to="loc_us-gaap_CreditFacilityDomain_668dbe70-f80a-4fba-8fe9-99810369c1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_c97d8662-ff79-4b8d-a5fd-2c14834061f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_668dbe70-f80a-4fba-8fe9-99810369c1b0" xlink:to="loc_us-gaap_LetterOfCreditMember_c97d8662-ff79-4b8d-a5fd-2c14834061f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_0083d5d1-93a4-4629-a796-1cf55490d432" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_d20765ae-f77d-4e9c-ad83-b0ec883ce07c" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_0083d5d1-93a4-4629-a796-1cf55490d432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9740046a-4fb1-4a4e-8845-ad206c31671b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_0083d5d1-93a4-4629-a796-1cf55490d432" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9740046a-4fb1-4a4e-8845-ad206c31671b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WalthamLeaseMember_da3f534a-9bcb-4cdf-a2f0-486823e44986" xlink:href="xfor-20230331.xsd#xfor_WalthamLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9740046a-4fb1-4a4e-8845-ad206c31671b" xlink:to="loc_xfor_WalthamLeaseMember_da3f534a-9bcb-4cdf-a2f0-486823e44986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ViennaLeaseAgreementMember_11ed0810-82e0-430a-8aaa-cd3a898e5c5b" xlink:href="xfor-20230331.xsd#xfor_ViennaLeaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9740046a-4fb1-4a4e-8845-ad206c31671b" xlink:to="loc_xfor_ViennaLeaseAgreementMember_11ed0810-82e0-430a-8aaa-cd3a898e5c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AllstonLeaseAgreementMember_becbde97-e81f-4505-a9a4-0e079ab33a4b" xlink:href="xfor-20230331.xsd#xfor_AllstonLeaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9740046a-4fb1-4a4e-8845-ad206c31671b" xlink:to="loc_xfor_AllstonLeaseAgreementMember_becbde97-e81f-4505-a9a4-0e079ab33a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_31c6e8fa-897a-4a9d-a8dd-828964dc56eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_d20765ae-f77d-4e9c-ad83-b0ec883ce07c" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_31c6e8fa-897a-4a9d-a8dd-828964dc56eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_baea91fa-9bfe-46da-8715-9b58afa6dea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_31c6e8fa-897a-4a9d-a8dd-828964dc56eb" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_baea91fa-9bfe-46da-8715-9b58afa6dea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_28f61030-1edf-4c83-be59-a02ad61ae692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_31c6e8fa-897a-4a9d-a8dd-828964dc56eb" xlink:to="loc_us-gaap_RestrictedCash_28f61030-1edf-4c83-be59-a02ad61ae692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_ea69ef7b-1a4f-406b-86f9-fb74f70ab242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_31c6e8fa-897a-4a9d-a8dd-828964dc56eb" xlink:to="loc_us-gaap_RestrictedCashCurrent_ea69ef7b-1a4f-406b-86f9-fb74f70ab242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fb39a311-4802-47c5-ab76-9d6118b643d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44871f20-9bb9-4733-b3bb-c41f3f816e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fb39a311-4802-47c5-ab76-9d6118b643d9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44871f20-9bb9-4733-b3bb-c41f3f816e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_b0ec4cb9-82dd-4429-a22d-cf2b713a9cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fb39a311-4802-47c5-ab76-9d6118b643d9" xlink:to="loc_us-gaap_RestrictedCashCurrent_b0ec4cb9-82dd-4429-a22d-cf2b713a9cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_fbba76ff-c264-45d7-a8d6-f66066b8d521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fb39a311-4802-47c5-ab76-9d6118b643d9" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_fbba76ff-c264-45d7-a8d6-f66066b8d521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_67517a78-842d-474c-ae53-413dbc00b9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fb39a311-4802-47c5-ab76-9d6118b643d9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_67517a78-842d-474c-ae53-413dbc00b9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_025a845e-f4dd-43a9-82ec-9e5fe5ac863e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborationLicenseAndFundingArrangementsTable_cb0b8af1-45f7-4561-8c90-dae3372ea553" xlink:href="xfor-20230331.xsd#xfor_CollaborationLicenseAndFundingArrangementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_025a845e-f4dd-43a9-82ec-9e5fe5ac863e" xlink:to="loc_xfor_CollaborationLicenseAndFundingArrangementsTable_cb0b8af1-45f7-4561-8c90-dae3372ea553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_69f4ef99-eac7-46b3-bc81-e04e7771959c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsTable_cb0b8af1-45f7-4561-8c90-dae3372ea553" xlink:to="loc_us-gaap_TypeOfArrangementAxis_69f4ef99-eac7-46b3-bc81-e04e7771959c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dcba6be1-4c33-4304-b5b6-1398cccf768f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_69f4ef99-eac7-46b3-bc81-e04e7771959c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dcba6be1-4c33-4304-b5b6-1398cccf768f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember_f4b8c9a0-a931-472d-afb0-7b395ae0c516" xlink:href="xfor-20230331.xsd#xfor_ResearchAndDevelopmentIncentiveProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dcba6be1-4c33-4304-b5b6-1398cccf768f" xlink:to="loc_xfor_ResearchAndDevelopmentIncentiveProgramMember_f4b8c9a0-a931-472d-afb0-7b395ae0c516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_97601e43-6785-4e94-8c1f-997cce16755e" xlink:href="xfor-20230331.xsd#xfor_CollaborationLicenseAndFundingArrangementsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsTable_cb0b8af1-45f7-4561-8c90-dae3372ea553" xlink:to="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_97601e43-6785-4e94-8c1f-997cce16755e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_GrantAndIncentiveReceivables_42449547-7cb6-4319-8200-ee1e767abfff" xlink:href="xfor-20230331.xsd#xfor_GrantAndIncentiveReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_97601e43-6785-4e94-8c1f-997cce16755e" xlink:to="loc_xfor_GrantAndIncentiveReceivables_42449547-7cb6-4319-8200-ee1e767abfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_62d76a59-c463-4e6e-b107-ef6a792268a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_97601e43-6785-4e94-8c1f-997cce16755e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_62d76a59-c463-4e6e-b107-ef6a792268a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_bc91fc33-07a3-4254-8af9-3ef492563e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_CollaborationLicenseAndFundingArrangementsLineItems_97601e43-6785-4e94-8c1f-997cce16755e" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_bc91fc33-07a3-4254-8af9-3ef492563e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a1c48d96-645d-452a-a266-5f2cf43fc449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_ca80f5d4-17a9-48f7-be5c-3684474fed63" xlink:href="xfor-20230331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a1c48d96-645d-452a-a266-5f2cf43fc449" xlink:to="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_ca80f5d4-17a9-48f7-be5c-3684474fed63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b461be5-1039-4223-8b24-30cc8990d354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_ca80f5d4-17a9-48f7-be5c-3684474fed63" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b461be5-1039-4223-8b24-30cc8990d354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_266d4dac-be91-4c9f-b47c-9ab5a8224019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b461be5-1039-4223-8b24-30cc8990d354" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_266d4dac-be91-4c9f-b47c-9ab5a8224019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8eb953c6-f8d5-45be-9b7c-8728616e016d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_266d4dac-be91-4c9f-b47c-9ab5a8224019" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8eb953c6-f8d5-45be-9b7c-8728616e016d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_acdb7c69-5123-4540-9680-a0a5f7875208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_ca80f5d4-17a9-48f7-be5c-3684474fed63" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_acdb7c69-5123-4540-9680-a0a5f7875208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49356b77-83b3-4c49-a825-8946f93ec6af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_acdb7c69-5123-4540-9680-a0a5f7875208" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49356b77-83b3-4c49-a825-8946f93ec6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ced7ae29-ad6f-4221-be0a-8f4c726f7fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49356b77-83b3-4c49-a825-8946f93ec6af" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ced7ae29-ad6f-4221-be0a-8f4c726f7fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e7476d53-7457-49e2-807f-6b387131ac59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49356b77-83b3-4c49-a825-8946f93ec6af" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e7476d53-7457-49e2-807f-6b387131ac59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e2f100ca-c2bb-4b88-9cd8-62f75069c4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49356b77-83b3-4c49-a825-8946f93ec6af" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e2f100ca-c2bb-4b88-9cd8-62f75069c4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_c022fd1d-cf3f-49e8-8181-893523cde05b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_ca80f5d4-17a9-48f7-be5c-3684474fed63" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_c022fd1d-cf3f-49e8-8181-893523cde05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fc073ba9-656f-49d1-8b8b-f4b0382af8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_c022fd1d-cf3f-49e8-8181-893523cde05b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fc073ba9-656f-49d1-8b8b-f4b0382af8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_8f6b40f8-4a61-4849-8fd7-7259de2935c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fc073ba9-656f-49d1-8b8b-f4b0382af8ae" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_8f6b40f8-4a61-4849-8fd7-7259de2935c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c3e2bf8c-b843-4d89-b0a8-d18fc0587b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fc073ba9-656f-49d1-8b8b-f4b0382af8ae" xlink:to="loc_us-gaap_WarrantMember_c3e2bf8c-b843-4d89-b0a8-d18fc0587b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_98608948-1e63-4932-af23-744aa2515118" xlink:href="xfor-20230331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_ca80f5d4-17a9-48f7-be5c-3684474fed63" xlink:to="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_98608948-1e63-4932-af23-744aa2515118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_eded0c27-59b0-4cda-a3d1-3c2a9c6d3c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_98608948-1e63-4932-af23-744aa2515118" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_eded0c27-59b0-4cda-a3d1-3c2a9c6d3c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_b320fd58-54fd-48f3-b4d7-40c154483891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_98608948-1e63-4932-af23-744aa2515118" xlink:to="loc_us-gaap_DerivativeLiabilities_b320fd58-54fd-48f3-b4d7-40c154483891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails" xlink:type="simple" xlink:href="xfor-20230331.xsd#FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9847bbd2-2d7a-4902-a117-212dea301c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_4ed4a547-1296-45d4-9ff7-cb37208cedb3" xlink:href="xfor-20230331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9847bbd2-2d7a-4902-a117-212dea301c95" xlink:to="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_4ed4a547-1296-45d4-9ff7-cb37208cedb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8c2fe628-038c-4316-828a-4b99bff1370d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_4ed4a547-1296-45d4-9ff7-cb37208cedb3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8c2fe628-038c-4316-828a-4b99bff1370d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c9f0491-f761-41f3-bfbe-d05855a3b5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8c2fe628-038c-4316-828a-4b99bff1370d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c9f0491-f761-41f3-bfbe-d05855a3b5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_c53d49cb-6774-4e11-9e52-fb714c303415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c9f0491-f761-41f3-bfbe-d05855a3b5ef" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_c53d49cb-6774-4e11-9e52-fb714c303415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b3f3375f-e1eb-435a-9bf4-f1305248bb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c9f0491-f761-41f3-bfbe-d05855a3b5ef" xlink:to="loc_us-gaap_WarrantMember_b3f3375f-e1eb-435a-9bf4-f1305248bb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_3007c150-6731-4f47-9825-167bdc35900a" xlink:href="xfor-20230331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_4ed4a547-1296-45d4-9ff7-cb37208cedb3" xlink:to="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_3007c150-6731-4f47-9825-167bdc35900a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7ae3eb29-9997-4be9-b588-51068e713910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_3007c150-6731-4f47-9825-167bdc35900a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7ae3eb29-9997-4be9-b588-51068e713910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_dcae25bc-4997-4144-9337-892d9f3f7a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7ae3eb29-9997-4be9-b588-51068e713910" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_dcae25bc-4997-4144-9337-892d9f3f7a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2ae68b32-90ce-4ba3-a86b-7e09dfdaa6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7ae3eb29-9997-4be9-b588-51068e713910" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2ae68b32-90ce-4ba3-a86b-7e09dfdaa6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a5b86e6d-d84b-4ace-a007-3ce0e4dd9081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7ae3eb29-9997-4be9-b588-51068e713910" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a5b86e6d-d84b-4ace-a007-3ce0e4dd9081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="xfor-20230331.xsd#FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b359b69d-b381-407d-8646-c9629bf99741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_851b0a32-0a88-4ef8-ad65-1db72decdcb7" xlink:href="xfor-20230331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b359b69d-b381-407d-8646-c9629bf99741" xlink:to="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_851b0a32-0a88-4ef8-ad65-1db72decdcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_27c3c528-6095-4372-8fd1-4c6b4a7f51c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_851b0a32-0a88-4ef8-ad65-1db72decdcb7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_27c3c528-6095-4372-8fd1-4c6b4a7f51c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_09d54a94-3a60-4a93-8944-d80d7d47918c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_27c3c528-6095-4372-8fd1-4c6b4a7f51c1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_09d54a94-3a60-4a93-8944-d80d7d47918c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_bcb824d3-cc22-4bcc-9d36-a3e0dd890d91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_09d54a94-3a60-4a93-8944-d80d7d47918c" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_bcb824d3-cc22-4bcc-9d36-a3e0dd890d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_af947ec0-4c74-464d-acb7-52e4b7e6ccab" xlink:href="xfor-20230331.xsd#xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_851b0a32-0a88-4ef8-ad65-1db72decdcb7" xlink:to="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_af947ec0-4c74-464d-acb7-52e4b7e6ccab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_9b7f15c0-62c2-4142-afda-b1ca0323f4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_af947ec0-4c74-464d-acb7-52e4b7e6ccab" xlink:to="loc_us-gaap_DerivativeLiabilities_9b7f15c0-62c2-4142-afda-b1ca0323f4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails" xlink:type="simple" xlink:href="xfor-20230331.xsd#FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c4c6e82d-ed78-4c0c-b6ec-6636faf710d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_778cd2ae-6650-4121-99c1-ce6c9c97d596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c4c6e82d-ed78-4c0c-b6ec-6636faf710d7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_778cd2ae-6650-4121-99c1-ce6c9c97d596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_76dd0d72-2c7e-419a-8031-8ba14db70e59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_778cd2ae-6650-4121-99c1-ce6c9c97d596" xlink:to="loc_us-gaap_AwardTypeAxis_76dd0d72-2c7e-419a-8031-8ba14db70e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a19c79ce-e47d-4f08-81af-f5cafff3e1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_76dd0d72-2c7e-419a-8031-8ba14db70e59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a19c79ce-e47d-4f08-81af-f5cafff3e1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_7dce4e79-3287-4c1b-86f0-949ab5caf806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a19c79ce-e47d-4f08-81af-f5cafff3e1e6" xlink:to="loc_us-gaap_WarrantMember_7dce4e79-3287-4c1b-86f0-949ab5caf806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb63995f-d224-4af5-a26b-46308400def0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_778cd2ae-6650-4121-99c1-ce6c9c97d596" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb63995f-d224-4af5-a26b-46308400def0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_bd13c6c2-7842-49cc-bbae-15b5a24b3899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb63995f-d224-4af5-a26b-46308400def0" xlink:to="loc_us-gaap_SharePrice_bd13c6c2-7842-49cc-bbae-15b5a24b3899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_628e9f4f-35d8-41fd-86d8-67132d0f3df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb63995f-d224-4af5-a26b-46308400def0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_628e9f4f-35d8-41fd-86d8-67132d0f3df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e543ea76-b388-4ecb-b79c-29d397d7bc94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb63995f-d224-4af5-a26b-46308400def0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e543ea76-b388-4ecb-b79c-29d397d7bc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_702c3448-2d25-4663-9cf1-fd53e24b32aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb63995f-d224-4af5-a26b-46308400def0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_702c3448-2d25-4663-9cf1-fd53e24b32aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9edd68a0-4274-43fd-87cc-45adcb0ded3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb63995f-d224-4af5-a26b-46308400def0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9edd68a0-4274-43fd-87cc-45adcb0ded3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e6c59905-26d4-425e-b47a-bc61682c53f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb63995f-d224-4af5-a26b-46308400def0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e6c59905-26d4-425e-b47a-bc61682c53f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c740f01f-f669-4ead-94f6-70843cb356be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_147ed715-12df-4a3b-ab52-b97cfa3da49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c740f01f-f669-4ead-94f6-70843cb356be" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_147ed715-12df-4a3b-ab52-b97cfa3da49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93196610-9de8-469f-a29b-fbdd8a50960d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_147ed715-12df-4a3b-ab52-b97cfa3da49c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93196610-9de8-469f-a29b-fbdd8a50960d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01330cfe-bc0e-4269-9d75-4d4389f8d6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93196610-9de8-469f-a29b-fbdd8a50960d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01330cfe-bc0e-4269-9d75-4d4389f8d6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1d180e12-2098-41ed-9a73-81641c4cd23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01330cfe-bc0e-4269-9d75-4d4389f8d6e9" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1d180e12-2098-41ed-9a73-81641c4cd23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f8233f87-a453-4f92-9eb9-d78ba5b2d9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01330cfe-bc0e-4269-9d75-4d4389f8d6e9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f8233f87-a453-4f92-9eb9-d78ba5b2d9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_0571a0d5-0b1e-4479-ae18-ff2ce794cf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01330cfe-bc0e-4269-9d75-4d4389f8d6e9" xlink:to="loc_us-gaap_ComputerEquipmentMember_0571a0d5-0b1e-4479-ae18-ff2ce794cf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_SoftwareMember_bdae57dc-2aab-4012-8b1b-c79fffc74bc2" xlink:href="xfor-20230331.xsd#xfor_SoftwareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01330cfe-bc0e-4269-9d75-4d4389f8d6e9" xlink:to="loc_xfor_SoftwareMember_bdae57dc-2aab-4012-8b1b-c79fffc74bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LabEquipmentMember_8a342c3e-6aba-42d5-b2f7-76e5f2acafbe" xlink:href="xfor-20230331.xsd#xfor_LabEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01330cfe-bc0e-4269-9d75-4d4389f8d6e9" xlink:to="loc_xfor_LabEquipmentMember_8a342c3e-6aba-42d5-b2f7-76e5f2acafbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_19901095-5a56-4d17-a1ba-6e9a7611c21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_147ed715-12df-4a3b-ab52-b97cfa3da49c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_19901095-5a56-4d17-a1ba-6e9a7611c21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6410fd85-f387-4607-b312-c1696d1aca64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_19901095-5a56-4d17-a1ba-6e9a7611c21c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6410fd85-f387-4607-b312-c1696d1aca64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_12408728-e68e-4453-94c9-b7f77b997034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_19901095-5a56-4d17-a1ba-6e9a7611c21c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_12408728-e68e-4453-94c9-b7f77b997034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f6f3a0fa-04ae-439a-8152-0d6612772134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_19901095-5a56-4d17-a1ba-6e9a7611c21c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f6f3a0fa-04ae-439a-8152-0d6612772134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/PropertyandEquipmentNetAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#PropertyandEquipmentNetAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/PropertyandEquipmentNetAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_20f0ef6c-a038-4f4e-a4cf-74d3e3984d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2c5ce06e-9392-4699-bba5-8859e5258239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_20f0ef6c-a038-4f4e-a4cf-74d3e3984d81" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2c5ce06e-9392-4699-bba5-8859e5258239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#AccruedExpensesScheduleofAccruedExpensesDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5cc7fc31-42d4-47db-9b3c-2d65942708ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_48b4820d-f971-46d3-98e7-7752b4103395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5cc7fc31-42d4-47db-9b3c-2d65942708ec" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_48b4820d-f971-46d3-98e7-7752b4103395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses_f8c270f2-57f9-490e-a91c-ebc416671250" xlink:href="xfor-20230331.xsd#xfor_AccruedExternalResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5cc7fc31-42d4-47db-9b3c-2d65942708ec" xlink:to="loc_xfor_AccruedExternalResearchAndDevelopmentExpenses_f8c270f2-57f9-490e-a91c-ebc416671250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a960d37a-7d3c-462f-a3da-bb888f048b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5cc7fc31-42d4-47db-9b3c-2d65942708ec" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a960d37a-7d3c-462f-a3da-bb888f048b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccruedLeaseConstructionCosts_65cf7a45-3f62-4e70-b444-42ddfd1a42a8" xlink:href="xfor-20230331.xsd#xfor_AccruedLeaseConstructionCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5cc7fc31-42d4-47db-9b3c-2d65942708ec" xlink:to="loc_xfor_AccruedLeaseConstructionCosts_65cf7a45-3f62-4e70-b444-42ddfd1a42a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ebaedb5a-0f09-4b0c-908b-be4fa0f04d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5cc7fc31-42d4-47db-9b3c-2d65942708ec" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ebaedb5a-0f09-4b0c-908b-be4fa0f04d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f6c7655b-777c-4177-95f0-bdf04ad3b80b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5cc7fc31-42d4-47db-9b3c-2d65942708ec" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f6c7655b-777c-4177-95f0-bdf04ad3b80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#LongTermDebtSummaryofLongTermDebtDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_480bf776-3743-44dd-ae4d-5335ad2d133c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9afd125c-0651-45fb-a707-53583760894e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_480bf776-3743-44dd-ae4d-5335ad2d133c" xlink:to="loc_us-gaap_LongTermDebt_9afd125c-0651-45fb-a707-53583760894e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_6713f6a9-67fe-451d-8e75-39f7aa37c307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_480bf776-3743-44dd-ae4d-5335ad2d133c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_6713f6a9-67fe-451d-8e75-39f7aa37c307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AccretionOnLongTermDebt_8ad16edb-39aa-4e72-ac41-769c2fe1398f" xlink:href="xfor-20230331.xsd#xfor_AccretionOnLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_480bf776-3743-44dd-ae4d-5335ad2d133c" xlink:to="loc_xfor_AccretionOnLongTermDebt_8ad16edb-39aa-4e72-ac41-769c2fe1398f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtIncludingAccretion_e5579df0-7282-463c-ad53-8e70e27ac32e" xlink:href="xfor-20230331.xsd#xfor_LongTermDebtIncludingAccretion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_480bf776-3743-44dd-ae4d-5335ad2d133c" xlink:to="loc_xfor_LongTermDebtIncludingAccretion_e5579df0-7282-463c-ad53-8e70e27ac32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_894d5dab-da5c-4398-9ccc-4d6965697d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_480bf776-3743-44dd-ae4d-5335ad2d133c" xlink:to="loc_us-gaap_LongTermDebtCurrent_894d5dab-da5c-4398-9ccc-4d6965697d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_bb449094-5648-41c5-8e18-700137278ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_480bf776-3743-44dd-ae4d-5335ad2d133c" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_bb449094-5648-41c5-8e18-700137278ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditCovenantMinimumCash_70706a2d-445c-4c55-b98d-b4f1b3bea57b" xlink:href="xfor-20230331.xsd#xfor_LineOfCreditCovenantMinimumCash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_480bf776-3743-44dd-ae4d-5335ad2d133c" xlink:to="loc_xfor_LineOfCreditCovenantMinimumCash_70706a2d-445c-4c55-b98d-b4f1b3bea57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f6bea54b-421d-47ac-b902-7fe925037779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5e58e6ab-ed0f-4911-9cb8-0c75189f2cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f6bea54b-421d-47ac-b902-7fe925037779" xlink:to="loc_us-gaap_DebtInstrumentTable_5e58e6ab-ed0f-4911-9cb8-0c75189f2cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f23a68a7-0f4c-4c03-944c-707b4b52d5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5e58e6ab-ed0f-4911-9cb8-0c75189f2cef" xlink:to="loc_us-gaap_DebtInstrumentAxis_f23a68a7-0f4c-4c03-944c-707b4b52d5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4924a6c4-f802-4460-abb6-2911edeadf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f23a68a7-0f4c-4c03-944c-707b4b52d5eb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4924a6c4-f802-4460-abb6-2911edeadf6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesLoanAgreementMember_9181a0fb-160a-43b8-ac3f-144f2a7ea899" xlink:href="xfor-20230331.xsd#xfor_HerculesLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4924a6c4-f802-4460-abb6-2911edeadf6c" xlink:to="loc_xfor_HerculesLoanAgreementMember_9181a0fb-160a-43b8-ac3f-144f2a7ea899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesSecondAmendedLoanAgreementMember_a1d5fe53-2b52-4439-b922-9623c9fb90b3" xlink:href="xfor-20230331.xsd#xfor_HerculesSecondAmendedLoanAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4924a6c4-f802-4460-abb6-2911edeadf6c" xlink:to="loc_xfor_HerculesSecondAmendedLoanAgreementMember_a1d5fe53-2b52-4439-b922-9623c9fb90b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_91c89374-4efe-4b1b-a5ef-f2d970d159f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5e58e6ab-ed0f-4911-9cb8-0c75189f2cef" xlink:to="loc_us-gaap_VariableRateAxis_91c89374-4efe-4b1b-a5ef-f2d970d159f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8318023b-fbce-4726-b14d-3cde5e827c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_91c89374-4efe-4b1b-a5ef-f2d970d159f1" xlink:to="loc_us-gaap_VariableRateDomain_8318023b-fbce-4726-b14d-3cde5e827c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_0fb4356a-19e1-4ff2-b7c6-3379604ea059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_8318023b-fbce-4726-b14d-3cde5e827c2b" xlink:to="loc_us-gaap_PrimeRateMember_0fb4356a-19e1-4ff2-b7c6-3379604ea059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f9a0ab0c-8906-4f81-b58c-91e9100d3a79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5e58e6ab-ed0f-4911-9cb8-0c75189f2cef" xlink:to="loc_srt_RangeAxis_f9a0ab0c-8906-4f81-b58c-91e9100d3a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9628a3ca-2051-4c1a-8835-7213f5c5b2b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f9a0ab0c-8906-4f81-b58c-91e9100d3a79" xlink:to="loc_srt_RangeMember_9628a3ca-2051-4c1a-8835-7213f5c5b2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_29ad107a-3907-44bd-869c-bbfcca67635c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9628a3ca-2051-4c1a-8835-7213f5c5b2b1" xlink:to="loc_srt_MaximumMember_29ad107a-3907-44bd-869c-bbfcca67635c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3f0dbb71-11b5-4c7a-83ed-2df59261c6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5e58e6ab-ed0f-4911-9cb8-0c75189f2cef" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3f0dbb71-11b5-4c7a-83ed-2df59261c6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_cb16b299-eaee-47ea-85c7-d20b089263fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3f0dbb71-11b5-4c7a-83ed-2df59261c6f6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_cb16b299-eaee-47ea-85c7-d20b089263fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_fb5deb5e-a414-4d54-be8e-c7f5cfc90eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_cb16b299-eaee-47ea-85c7-d20b089263fc" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_fb5deb5e-a414-4d54-be8e-c7f5cfc90eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1e336b04-f005-4156-b880-ccb7930a48ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5e58e6ab-ed0f-4911-9cb8-0c75189f2cef" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1e336b04-f005-4156-b880-ccb7930a48ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f1a57516-ed85-4af5-a28e-038add75636e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1e336b04-f005-4156-b880-ccb7930a48ab" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f1a57516-ed85-4af5-a28e-038add75636e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_82437120-f081-4c22-9774-1f88772728b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f1a57516-ed85-4af5-a28e-038add75636e" xlink:to="loc_us-gaap_SubsequentEventMember_82437120-f081-4c22-9774-1f88772728b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_08ee129a-d2d2-4a31-a363-483d7a61dcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5e58e6ab-ed0f-4911-9cb8-0c75189f2cef" xlink:to="loc_us-gaap_CreditFacilityAxis_08ee129a-d2d2-4a31-a363-483d7a61dcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9374af7c-004d-4088-8c09-5f134fa97ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_08ee129a-d2d2-4a31-a363-483d7a61dcb4" xlink:to="loc_us-gaap_CreditFacilityDomain_9374af7c-004d-4088-8c09-5f134fa97ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate1Member_bffb52b6-5fd8-4480-be0b-8c2481c7d9c1" xlink:href="xfor-20230331.xsd#xfor_MinCashTestDate1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_9374af7c-004d-4088-8c09-5f134fa97ef5" xlink:to="loc_xfor_MinCashTestDate1Member_bffb52b6-5fd8-4480-be0b-8c2481c7d9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_MinCashTestDate2Member_fa6a13a8-c45f-438b-8ae7-5d5097ee0aed" xlink:href="xfor-20230331.xsd#xfor_MinCashTestDate2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_9374af7c-004d-4088-8c09-5f134fa97ef5" xlink:to="loc_xfor_MinCashTestDate2Member_fa6a13a8-c45f-438b-8ae7-5d5097ee0aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5e58e6ab-ed0f-4911-9cb8-0c75189f2cef" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_0aa89a5f-1fed-4879-b270-a34eb367fc32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_0aa89a5f-1fed-4879-b270-a34eb367fc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_afcfa348-907e-447c-b150-5984b074780e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_afcfa348-907e-447c-b150-5984b074780e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_2098a439-8c2f-4d21-a5a7-bdcd208f72ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_2098a439-8c2f-4d21-a5a7-bdcd208f72ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DebtInstrumentPrepaymentPremiumPercentage_492d4154-ae2b-4c04-b0d2-c03c97fc1bcc" xlink:href="xfor-20230331.xsd#xfor_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:to="loc_xfor_DebtInstrumentPrepaymentPremiumPercentage_492d4154-ae2b-4c04-b0d2-c03c97fc1bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_67902c45-2eec-4832-aa61-0fa9c2e831a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_67902c45-2eec-4832-aa61-0fa9c2e831a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LineOfCreditCovenantMinimumCash_824e50ee-cff0-4f2d-80c0-5750987e7e29" xlink:href="xfor-20230331.xsd#xfor_LineOfCreditCovenantMinimumCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:to="loc_xfor_LineOfCreditCovenantMinimumCash_824e50ee-cff0-4f2d-80c0-5750987e7e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_790e710d-af72-4fec-9bd8-11d8dffb1018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_790e710d-af72-4fec-9bd8-11d8dffb1018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_a5fde19c-a3b5-4f44-9ca6-1aca7ea071a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1482304b-bb02-4866-8b2d-33be5cee6524" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_a5fde19c-a3b5-4f44-9ca6-1aca7ea071a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails" xlink:type="simple" xlink:href="xfor-20230331.xsd#LongTermDebtSummaryofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b7a618a7-cd50-43f1-a145-fa38a20b2965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6601da3a-d72f-4793-b326-c4bc92f46440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b7a618a7-cd50-43f1-a145-fa38a20b2965" xlink:to="loc_us-gaap_DebtInstrumentTable_6601da3a-d72f-4793-b326-c4bc92f46440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_494c4827-cfce-4757-96d1-a8ebc146294a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6601da3a-d72f-4793-b326-c4bc92f46440" xlink:to="loc_us-gaap_DebtInstrumentAxis_494c4827-cfce-4757-96d1-a8ebc146294a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_785aa300-0fe7-4043-9edd-1b92c927878f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_494c4827-cfce-4757-96d1-a8ebc146294a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_785aa300-0fe7-4043-9edd-1b92c927878f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_HerculesLoanAgreementMember_37f9be9e-2e9d-4582-b310-cec7861f6626" xlink:href="xfor-20230331.xsd#xfor_HerculesLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_785aa300-0fe7-4043-9edd-1b92c927878f" xlink:to="loc_xfor_HerculesLoanAgreementMember_37f9be9e-2e9d-4582-b310-cec7861f6626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7e7f5caa-1cf6-4880-ab9a-c5f2f92e6dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6601da3a-d72f-4793-b326-c4bc92f46440" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7e7f5caa-1cf6-4880-ab9a-c5f2f92e6dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_aed56d1a-8b0b-4c31-993e-58776875b9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7e7f5caa-1cf6-4880-ab9a-c5f2f92e6dd9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_aed56d1a-8b0b-4c31-993e-58776875b9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_5997e5e7-6095-4ea9-b136-bfd9dee6413b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6601da3a-d72f-4793-b326-c4bc92f46440" xlink:to="loc_us-gaap_VariableRateAxis_5997e5e7-6095-4ea9-b136-bfd9dee6413b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_96297996-27c6-431c-af76-426090e6f9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_5997e5e7-6095-4ea9-b136-bfd9dee6413b" xlink:to="loc_us-gaap_VariableRateDomain_96297996-27c6-431c-af76-426090e6f9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2aa4b3c3-864f-4f27-a58b-4a9cdc4240e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6601da3a-d72f-4793-b326-c4bc92f46440" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2aa4b3c3-864f-4f27-a58b-4a9cdc4240e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2333510b-e1b0-434a-b819-556aeb6ff169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2aa4b3c3-864f-4f27-a58b-4a9cdc4240e7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2333510b-e1b0-434a-b819-556aeb6ff169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ddaedfc9-ad19-4269-ad17-ac2916c28ee1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6601da3a-d72f-4793-b326-c4bc92f46440" xlink:to="loc_srt_RangeAxis_ddaedfc9-ad19-4269-ad17-ac2916c28ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_01addccb-37e2-4914-a23c-640e23106990" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ddaedfc9-ad19-4269-ad17-ac2916c28ee1" xlink:to="loc_srt_RangeMember_01addccb-37e2-4914-a23c-640e23106990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cfde9957-2230-4737-a5d0-005d0d37d495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6601da3a-d72f-4793-b326-c4bc92f46440" xlink:to="loc_us-gaap_DebtInstrumentLineItems_cfde9957-2230-4737-a5d0-005d0d37d495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_e16d0dd2-c367-49ed-ac14-bb97fdc1db2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cfde9957-2230-4737-a5d0-005d0d37d495" xlink:to="loc_us-gaap_InterestExpenseDebt_e16d0dd2-c367-49ed-ac14-bb97fdc1db2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_9854e900-dd1f-4d0d-bad3-b882b4447ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cfde9957-2230-4737-a5d0-005d0d37d495" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_9854e900-dd1f-4d0d-bad3-b882b4447ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2d5e4419-5cd5-488a-97dd-252bcdec3063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_f17a4c79-e443-459a-a67f-06e23c1e3f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2d5e4419-5cd5-488a-97dd-252bcdec3063" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_f17a4c79-e443-459a-a67f-06e23c1e3f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_8cbf127f-9d2c-42ba-982f-098b70e1d991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2d5e4419-5cd5-488a-97dd-252bcdec3063" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_8cbf127f-9d2c-42ba-982f-098b70e1d991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9a3bdc5a-28c7-4c4d-9053-572645730108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2d5e4419-5cd5-488a-97dd-252bcdec3063" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9a3bdc5a-28c7-4c4d-9053-572645730108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f80cdd72-9670-4cb8-ba01-7da0ec4fcb22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2d5e4419-5cd5-488a-97dd-252bcdec3063" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f80cdd72-9670-4cb8-ba01-7da0ec4fcb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LongTermDebtAndEOTPayment_73fe86a6-1cf7-4fe6-aa81-853a25314092" xlink:href="xfor-20230331.xsd#xfor_LongTermDebtAndEOTPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2d5e4419-5cd5-488a-97dd-252bcdec3063" xlink:to="loc_xfor_LongTermDebtAndEOTPayment_73fe86a6-1cf7-4fe6-aa81-853a25314092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#LeasesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LeasesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0b3c3a35-873b-40f1-8ef2-411a70c94b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ac3cad04-c91b-4bfc-b77c-296f02264a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0b3c3a35-873b-40f1-8ef2-411a70c94b12" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ac3cad04-c91b-4bfc-b77c-296f02264a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9f9f41c7-2c1e-4155-9b45-36563417f09f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ac3cad04-c91b-4bfc-b77c-296f02264a1c" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9f9f41c7-2c1e-4155-9b45-36563417f09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_140c71cf-2ae9-48c2-b3ee-2e159e6b8cd4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9f9f41c7-2c1e-4155-9b45-36563417f09f" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_140c71cf-2ae9-48c2-b3ee-2e159e6b8cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_WalthamLeaseMember_b159d44d-9a8f-4620-8182-11886aef6d4b" xlink:href="xfor-20230331.xsd#xfor_WalthamLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_140c71cf-2ae9-48c2-b3ee-2e159e6b8cd4" xlink:to="loc_xfor_WalthamLeaseMember_b159d44d-9a8f-4620-8182-11886aef6d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ViennaAustriaLeaseMember_58d069cf-cd04-4ed1-804d-72fd42b1264e" xlink:href="xfor-20230331.xsd#xfor_ViennaAustriaLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_140c71cf-2ae9-48c2-b3ee-2e159e6b8cd4" xlink:to="loc_xfor_ViennaAustriaLeaseMember_58d069cf-cd04-4ed1-804d-72fd42b1264e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AllstonLeaseMember_f69ab18f-29e7-45f2-bfb7-b7f72866c505" xlink:href="xfor-20230331.xsd#xfor_AllstonLeaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_140c71cf-2ae9-48c2-b3ee-2e159e6b8cd4" xlink:to="loc_xfor_AllstonLeaseMember_f69ab18f-29e7-45f2-bfb7-b7f72866c505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ac3cad04-c91b-4bfc-b77c-296f02264a1c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement_ee10d983-802a-477b-b563-4c77e27824e5" xlink:href="xfor-20230331.xsd#xfor_CurrentOfficeSpaceUnderLeaseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_xfor_CurrentOfficeSpaceUnderLeaseAgreement_ee10d983-802a-477b-b563-4c77e27824e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_AggregateBaseRent_a3030543-53ce-403a-916e-3fef6839dedf" xlink:href="xfor-20230331.xsd#xfor_AggregateBaseRent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_xfor_AggregateBaseRent_a3030543-53ce-403a-916e-3fef6839dedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9b73b8bd-38af-440f-8496-c1d028fcde47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9b73b8bd-38af-440f-8496-c1d028fcde47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_c4f03bd7-2489-495b-8da6-3372c34d1e8d" xlink:href="xfor-20230331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace_c4f03bd7-2489-495b-8da6-3372c34d1e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_f74ad5d1-9081-4b61-8337-5d5a7e348be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_f74ad5d1-9081-4b61-8337-5d5a7e348be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent_a3d10a22-3929-40dd-8ce6-543aa39fc195" xlink:href="xfor-20230331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent_a3d10a22-3929-40dd-8ce6-543aa39fc195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_5d0ee844-c86f-49a3-a968-9436c15eaea3" xlink:href="xfor-20230331.xsd#xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount_5d0ee844-c86f-49a3-a968-9436c15eaea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_58def249-9405-4666-ac83-4ddd6d97e2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_58def249-9405-4666-ac83-4ddd6d97e2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d811482e-aaa2-4904-b216-49b19cb688c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_us-gaap_OperatingLeaseLiability_d811482e-aaa2-4904-b216-49b19cb688c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_82f34258-bcb6-4302-9525-3af5b4faf9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0647da1b-450f-4b7c-8216-83cd3e3c2d05" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_82f34258-bcb6-4302-9525-3af5b4faf9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#LeasesScheduleofComponentsofLeaseExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2c577564-52f7-4728-b79f-e1cae0fc7c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_6c24e5bc-36eb-4bc4-879e-7472584a0dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2c577564-52f7-4728-b79f-e1cae0fc7c5d" xlink:to="loc_us-gaap_OperatingLeaseCost_6c24e5bc-36eb-4bc4-879e-7472584a0dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_14d3a338-4f32-46c2-bcce-41f59ec4285e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2c577564-52f7-4728-b79f-e1cae0fc7c5d" xlink:to="loc_us-gaap_LeaseCost_14d3a338-4f32-46c2-bcce-41f59ec4285e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_cfc64749-ce1a-41a9-8105-601c18e8ddcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2c577564-52f7-4728-b79f-e1cae0fc7c5d" xlink:to="loc_us-gaap_OperatingLeasePayments_cfc64749-ce1a-41a9-8105-601c18e8ddcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_b1ad9ab4-f43f-4383-b286-042daadac2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2c577564-52f7-4728-b79f-e1cae0fc7c5d" xlink:to="loc_us-gaap_SubleaseIncome_b1ad9ab4-f43f-4383-b286-042daadac2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_67f665ac-28a4-4c85-8663-316944268c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2c577564-52f7-4728-b79f-e1cae0fc7c5d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_67f665ac-28a4-4c85-8663-316944268c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_23eac073-e153-421b-9334-778b9570cfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2c577564-52f7-4728-b79f-e1cae0fc7c5d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_23eac073-e153-421b-9334-778b9570cfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_27f2a7fc-c4ee-43c3-ad5d-68c60bf8f5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_484c1fa6-5c28-4814-a4fc-f54fe5413987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27f2a7fc-c4ee-43c3-ad5d-68c60bf8f5ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_484c1fa6-5c28-4814-a4fc-f54fe5413987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7bc37fc5-91b0-446e-ae6c-d8ceedfa005a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27f2a7fc-c4ee-43c3-ad5d-68c60bf8f5ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7bc37fc5-91b0-446e-ae6c-d8ceedfa005a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_24a117af-c519-43c5-b3c4-27c8cf70264c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27f2a7fc-c4ee-43c3-ad5d-68c60bf8f5ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_24a117af-c519-43c5-b3c4-27c8cf70264c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0c3afce2-4479-4dd1-8c95-e252eee29adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27f2a7fc-c4ee-43c3-ad5d-68c60bf8f5ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0c3afce2-4479-4dd1-8c95-e252eee29adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b478ba63-5a9a-4603-92df-3aa122903446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27f2a7fc-c4ee-43c3-ad5d-68c60bf8f5ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b478ba63-5a9a-4603-92df-3aa122903446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e80779c6-4b3b-43c5-b41e-f1a268a6113d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27f2a7fc-c4ee-43c3-ad5d-68c60bf8f5ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e80779c6-4b3b-43c5-b41e-f1a268a6113d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ed3a2fd5-1e1d-47fc-b5f6-459f095ada51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27f2a7fc-c4ee-43c3-ad5d-68c60bf8f5ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ed3a2fd5-1e1d-47fc-b5f6-459f095ada51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cf6ee1e7-5198-468e-a947-5e6695927f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27f2a7fc-c4ee-43c3-ad5d-68c60bf8f5ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cf6ee1e7-5198-468e-a947-5e6695927f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ea7a3684-e0ef-458f-b15a-9bd9bd747791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27f2a7fc-c4ee-43c3-ad5d-68c60bf8f5ed" xlink:to="loc_us-gaap_OperatingLeaseLiability_ea7a3684-e0ef-458f-b15a-9bd9bd747791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1" xlink:type="simple" xlink:href="xfor-20230331.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#CommitmentandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_297ee38a-c0c1-42bb-8116-d94a48e8fe2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ContingenciesAndCommitmentsTable_595e3295-6e61-4ebc-926b-22bd7cfe6d8f" xlink:href="xfor-20230331.xsd#xfor_ContingenciesAndCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_297ee38a-c0c1-42bb-8116-d94a48e8fe2f" xlink:to="loc_xfor_ContingenciesAndCommitmentsTable_595e3295-6e61-4ebc-926b-22bd7cfe6d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_29056540-bc69-4e44-8352-dc5249163897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ContingenciesAndCommitmentsTable_595e3295-6e61-4ebc-926b-22bd7cfe6d8f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_29056540-bc69-4e44-8352-dc5249163897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e2c659b1-37c3-4ea1-9355-ddc426e3ae26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_29056540-bc69-4e44-8352-dc5249163897" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e2c659b1-37c3-4ea1-9355-ddc426e3ae26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IndemnificationAgreementsMember_e9dcc421-1119-4dcc-82df-4fa8bd20dfe6" xlink:href="xfor-20230331.xsd#xfor_IndemnificationAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e2c659b1-37c3-4ea1-9355-ddc426e3ae26" xlink:to="loc_xfor_IndemnificationAgreementsMember_e9dcc421-1119-4dcc-82df-4fa8bd20dfe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ContingenciesAndCommitmentsLineItems_20837380-10c3-41e3-89b8-8509ad00d057" xlink:href="xfor-20230331.xsd#xfor_ContingenciesAndCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ContingenciesAndCommitmentsTable_595e3295-6e61-4ebc-926b-22bd7cfe6d8f" xlink:to="loc_xfor_ContingenciesAndCommitmentsLineItems_20837380-10c3-41e3-89b8-8509ad00d057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_8fb319af-8533-4d92-96fa-1278479f5785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_ContingenciesAndCommitmentsLineItems_20837380-10c3-41e3-89b8-8509ad00d057" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_8fb319af-8533-4d92-96fa-1278479f5785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#CommonStockWarrantsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6e121910-3aa5-47f2-af27-03b9b8a9297f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_715c6056-0a50-4667-906c-97d4476ebcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6e121910-3aa5-47f2-af27-03b9b8a9297f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_715c6056-0a50-4667-906c-97d4476ebcc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_59efe203-2ed9-49f0-88f2-7502ed50c57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_715c6056-0a50-4667-906c-97d4476ebcc6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_59efe203-2ed9-49f0-88f2-7502ed50c57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9adb96bd-4fbf-42a8-9e3d-77b0e8901893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_59efe203-2ed9-49f0-88f2-7502ed50c57b" xlink:to="loc_us-gaap_EquityComponentDomain_9adb96bd-4fbf-42a8-9e3d-77b0e8901893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_Q12022PrivatePlacementMember_7a3432ce-e2d0-455f-b943-b2b8a1418ad8" xlink:href="xfor-20230331.xsd#xfor_Q12022PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9adb96bd-4fbf-42a8-9e3d-77b0e8901893" xlink:to="loc_xfor_Q12022PrivatePlacementMember_7a3432ce-e2d0-455f-b943-b2b8a1418ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_6839ede4-e1a4-4b16-a089-77dc75d117a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_715c6056-0a50-4667-906c-97d4476ebcc6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_6839ede4-e1a4-4b16-a089-77dc75d117a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fa49b5ad-0ca6-4e5a-a4b3-61196909f2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6839ede4-e1a4-4b16-a089-77dc75d117a5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fa49b5ad-0ca6-4e5a-a4b3-61196909f2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_18a81237-0258-47c1-a3bd-a7054d2a7cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6839ede4-e1a4-4b16-a089-77dc75d117a5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_18a81237-0258-47c1-a3bd-a7054d2a7cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_7b6e3369-0a50-44b3-ad06-48cf56a49945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6839ede4-e1a4-4b16-a089-77dc75d117a5" xlink:to="loc_us-gaap_DividendsCommonStock_7b6e3369-0a50-44b3-ad06-48cf56a49945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_e4923b43-cc8d-4fd5-bb45-453fdb92eb74" xlink:href="xfor-20230331.xsd#xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6839ede4-e1a4-4b16-a089-77dc75d117a5" xlink:to="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_e4923b43-cc8d-4fd5-bb45-453fdb92eb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_baebc32c-df9f-4df4-829d-1396efd2c958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_a9b7d0e4-cfe6-40f4-b74b-184b848550ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_baebc32c-df9f-4df4-829d-1396efd2c958" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_a9b7d0e4-cfe6-40f4-b74b-184b848550ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4050e8e8-4c58-4449-83df-6a5d12179f44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_a9b7d0e4-cfe6-40f4-b74b-184b848550ef" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4050e8e8-4c58-4449-83df-6a5d12179f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4050e8e8-4c58-4449-83df-6a5d12179f44" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_7510ece9-2d9f-4d6a-a62e-8110433feef8" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember_7510ece9-2d9f-4d6a-a62e-8110433feef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_950fc939-f162-4362-af0e-5a9e9ada6b5a" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember_950fc939-f162-4362-af0e-5a9e9ada6b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_3c6783fb-275a-4244-ba01-1f50976ba442" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember_3c6783fb-275a-4244-ba01-1f50976ba442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_0aa9583b-4d45-4b55-b94f-41248b073525" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember_0aa9583b-4d45-4b55-b94f-41248b073525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_2a59d9a3-2fb6-4c69-9639-9e365659f18b" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember_2a59d9a3-2fb6-4c69-9639-9e365659f18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_0a05639d-4ae9-41f7-8884-efc8c927fb57" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember_0a05639d-4ae9-41f7-8884-efc8c927fb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_5ccc2ba5-6b24-41db-8566-092783d0c1df" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember_5ccc2ba5-6b24-41db-8566-092783d0c1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarch232021Member_02be387a-184a-4e9e-af16-074dfaba4702" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnMarch232021Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnMarch232021Member_02be387a-184a-4e9e-af16-074dfaba4702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_f6cd6246-bbef-4220-8e48-9dfb0aacc64f" xlink:href="xfor-20230331.xsd#xfor_PreFundedWarrantMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_PreFundedWarrantMember_f6cd6246-bbef-4220-8e48-9dfb0aacc64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_de6c686a-8de1-401d-a945-7dea750bb2dd" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember_de6c686a-8de1-401d-a945-7dea750bb2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnMarch32022Member_59258470-ffa9-49c2-9358-7de7e895a811" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnMarch32022Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnMarch32022Member_59258470-ffa9-49c2-9358-7de7e895a811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnJuly20221Member_2c506fb3-9d52-4991-be65-e3aa8e538ff0" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnJuly20221Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnJuly20221Member_2c506fb3-9d52-4991-be65-e3aa8e538ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnJuly620222Member_d0d42c0f-9b34-4a8b-a7f1-173bfdcfb5ca" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnJuly620222Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnJuly620222Member_d0d42c0f-9b34-4a8b-a7f1-173bfdcfb5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnDecember92022Member_95dc0a74-1877-404e-bc2d-ace3c23497d2" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnDecember92022Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnDecember92022Member_95dc0a74-1877-404e-bc2d-ace3c23497d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_IssuanceOnDecember920222Member_0d2b7f7d-16e7-4741-8953-a499ab5b06ef" xlink:href="xfor-20230331.xsd#xfor_IssuanceOnDecember920222Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_57667a2d-7158-4c9f-93e9-d06f738768c9" xlink:to="loc_xfor_IssuanceOnDecember920222Member_0d2b7f7d-16e7-4741-8953-a499ab5b06ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9087f739-cf77-4dca-b8c4-98699fa46653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_a9b7d0e4-cfe6-40f4-b74b-184b848550ef" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9087f739-cf77-4dca-b8c4-98699fa46653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_26c4b626-fd29-46c4-a95a-5e75f3980457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9087f739-cf77-4dca-b8c4-98699fa46653" xlink:to="loc_us-gaap_EquityComponentDomain_26c4b626-fd29-46c4-a95a-5e75f3980457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_72680a92-f557-4b27-80f2-7b0e75b08226" xlink:href="xfor-20230331.xsd#xfor_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_26c4b626-fd29-46c4-a95a-5e75f3980457" xlink:to="loc_xfor_PreFundedWarrantMember_72680a92-f557-4b27-80f2-7b0e75b08226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassAWarrantMember_89ae126e-6ebe-487d-ab63-fe428cb97417" xlink:href="xfor-20230331.xsd#xfor_ClassAWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_26c4b626-fd29-46c4-a95a-5e75f3980457" xlink:to="loc_xfor_ClassAWarrantMember_89ae126e-6ebe-487d-ab63-fe428cb97417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_LegacyWarrantsMember_218248b5-7a17-4034-83e1-858f07d83cf3" xlink:href="xfor-20230331.xsd#xfor_LegacyWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_26c4b626-fd29-46c4-a95a-5e75f3980457" xlink:to="loc_xfor_LegacyWarrantsMember_218248b5-7a17-4034-83e1-858f07d83cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsAxis_2c56323d-06ac-4d68-acc2-0a24488fd80f" xlink:href="xfor-20230331.xsd#xfor_PrefundedWarrantsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_a9b7d0e4-cfe6-40f4-b74b-184b848550ef" xlink:to="loc_xfor_PrefundedWarrantsAxis_2c56323d-06ac-4d68-acc2-0a24488fd80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PrefundedWarrantsDomain_a546e4df-fc35-4edc-b839-1e07cbe074c4" xlink:href="xfor-20230331.xsd#xfor_PrefundedWarrantsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_PrefundedWarrantsAxis_2c56323d-06ac-4d68-acc2-0a24488fd80f" xlink:to="loc_xfor_PrefundedWarrantsDomain_a546e4df-fc35-4edc-b839-1e07cbe074c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_FundedMember_1a506398-54c7-4cfb-91f2-0f4086522f8f" xlink:href="xfor-20230331.xsd#xfor_FundedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_PrefundedWarrantsDomain_a546e4df-fc35-4edc-b839-1e07cbe074c4" xlink:to="loc_xfor_FundedMember_1a506398-54c7-4cfb-91f2-0f4086522f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_358dbc55-a100-4498-8b0d-003cc6f126e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_a9b7d0e4-cfe6-40f4-b74b-184b848550ef" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_358dbc55-a100-4498-8b0d-003cc6f126e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f801aad9-4019-49e3-aaa4-a2133046d3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_358dbc55-a100-4498-8b0d-003cc6f126e2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f801aad9-4019-49e3-aaa4-a2133046d3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9b828e68-3ef9-4ee6-a9a4-15c635c91342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_358dbc55-a100-4498-8b0d-003cc6f126e2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9b828e68-3ef9-4ee6-a9a4-15c635c91342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_32e3c4ed-28cd-4a9c-8fdd-0cc2fdca27be" xlink:href="xfor-20230331.xsd#xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_358dbc55-a100-4498-8b0d-003cc6f126e2" xlink:to="loc_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued_32e3c4ed-28cd-4a9c-8fdd-0cc2fdca27be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_a2768c5f-fa50-45b5-a94e-72d3e2fbf338" xlink:href="xfor-20230331.xsd#xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_358dbc55-a100-4498-8b0d-003cc6f126e2" xlink:to="loc_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights_a2768c5f-fa50-45b5-a94e-72d3e2fbf338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1fc6c187-66dc-4726-a863-903b786c2ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc565799-a48e-4431-bfb4-a2d95adfc53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1fc6c187-66dc-4726-a863-903b786c2ff0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc565799-a48e-4431-bfb4-a2d95adfc53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9075203a-f8ae-4532-b511-bedb894ac410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc565799-a48e-4431-bfb4-a2d95adfc53f" xlink:to="loc_us-gaap_PlanNameAxis_9075203a-f8ae-4532-b511-bedb894ac410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_76d7e4e1-5dad-4b72-9e73-6a33ebf495a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9075203a-f8ae-4532-b511-bedb894ac410" xlink:to="loc_us-gaap_PlanNameDomain_76d7e4e1-5dad-4b72-9e73-6a33ebf495a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember_b74c292c-7eec-4123-85e8-d91d8a15ba17" xlink:href="xfor-20230331.xsd#xfor_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_76d7e4e1-5dad-4b72-9e73-6a33ebf495a4" xlink:to="loc_xfor_TwoThousandNineteenEquityIncentivePlanMember_b74c292c-7eec-4123-85e8-d91d8a15ba17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember_32e17f13-64aa-4acd-9b11-c00d69a84bda" xlink:href="xfor-20230331.xsd#xfor_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_76d7e4e1-5dad-4b72-9e73-6a33ebf495a4" xlink:to="loc_xfor_TwoThousandSeventeenEquityIncentivePlanMember_32e17f13-64aa-4acd-9b11-c00d69a84bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e0d31442-59a0-4669-8e56-7ae9582933f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc565799-a48e-4431-bfb4-a2d95adfc53f" xlink:to="loc_us-gaap_AwardTypeAxis_e0d31442-59a0-4669-8e56-7ae9582933f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3605921c-528f-475b-adaf-dba249b5687c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e0d31442-59a0-4669-8e56-7ae9582933f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3605921c-528f-475b-adaf-dba249b5687c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3a4bb07f-cc8e-47d8-900b-c3dd3756ff70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3605921c-528f-475b-adaf-dba249b5687c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3a4bb07f-cc8e-47d8-900b-c3dd3756ff70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7f7cfccd-260a-4fb4-b8d5-8e4f9fa64a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bc565799-a48e-4431-bfb4-a2d95adfc53f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7f7cfccd-260a-4fb4-b8d5-8e4f9fa64a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_baff7047-73b7-491a-84b0-98b23867518e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7f7cfccd-260a-4fb4-b8d5-8e4f9fa64a3c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_baff7047-73b7-491a-84b0-98b23867518e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_07404bb1-db83-4245-b5f7-2dd1f7a9dd6b" xlink:href="xfor-20230331.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7f7cfccd-260a-4fb4-b8d5-8e4f9fa64a3c" xlink:to="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue_07404bb1-db83-4245-b5f7-2dd1f7a9dd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c4fe1471-3b8c-4df0-936e-6df9a22a6b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7f7cfccd-260a-4fb4-b8d5-8e4f9fa64a3c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c4fe1471-3b8c-4df0-936e-6df9a22a6b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a8656201-2482-4094-8268-bb76f29c457c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7f7cfccd-260a-4fb4-b8d5-8e4f9fa64a3c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a8656201-2482-4094-8268-bb76f29c457c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5c520c3f-23c9-45d9-98fd-552434d4a7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a01bcf38-0753-470e-b537-dd216e6106f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5c520c3f-23c9-45d9-98fd-552434d4a7b3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a01bcf38-0753-470e-b537-dd216e6106f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dc142c17-baf5-4968-b2c5-cde86ff65366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a01bcf38-0753-470e-b537-dd216e6106f6" xlink:to="loc_us-gaap_AwardTypeAxis_dc142c17-baf5-4968-b2c5-cde86ff65366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b601665-5fae-4b54-8740-09e1cca77a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_dc142c17-baf5-4968-b2c5-cde86ff65366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b601665-5fae-4b54-8740-09e1cca77a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a7b08880-fc1b-4512-8d96-ac7aab4dae9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b601665-5fae-4b54-8740-09e1cca77a4c" xlink:to="loc_us-gaap_WarrantMember_a7b08880-fc1b-4512-8d96-ac7aab4dae9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4592202-e29d-4214-8adf-26ffa131008f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a01bcf38-0753-470e-b537-dd216e6106f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4592202-e29d-4214-8adf-26ffa131008f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_62b8e341-1d7e-439e-b319-ee138ea9c0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4592202-e29d-4214-8adf-26ffa131008f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_62b8e341-1d7e-439e-b319-ee138ea9c0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_faee6964-de70-43f1-b4aa-121d3d1dec70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4592202-e29d-4214-8adf-26ffa131008f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_faee6964-de70-43f1-b4aa-121d3d1dec70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3cae4725-c020-4b1e-b64e-637e23dd8b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4592202-e29d-4214-8adf-26ffa131008f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3cae4725-c020-4b1e-b64e-637e23dd8b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_681e5ed1-5c15-4c2c-8fc2-4e12223637ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4592202-e29d-4214-8adf-26ffa131008f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_681e5ed1-5c15-4c2c-8fc2-4e12223637ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_5e9e8afb-bf7e-49c7-8a4e-1629d7eed46c" xlink:href="xfor-20230331.xsd#xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d4592202-e29d-4214-8adf-26ffa131008f" xlink:to="loc_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_5e9e8afb-bf7e-49c7-8a4e-1629d7eed46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#StockBasedCompensationSummaryofStockOptionActivityDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b890681d-bbc9-42bf-8e50-0e4adfed064f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b06123de-4566-4cda-a87c-ed9d4360dff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b890681d-bbc9-42bf-8e50-0e4adfed064f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b06123de-4566-4cda-a87c-ed9d4360dff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a070160f-afae-4553-973c-ec9e09ad6570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b06123de-4566-4cda-a87c-ed9d4360dff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a070160f-afae-4553-973c-ec9e09ad6570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8de537a8-ced6-4cfc-8124-0907551154be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b06123de-4566-4cda-a87c-ed9d4360dff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8de537a8-ced6-4cfc-8124-0907551154be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8b5885b7-f0a0-4f58-a6ac-42d928184ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b06123de-4566-4cda-a87c-ed9d4360dff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8b5885b7-f0a0-4f58-a6ac-42d928184ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f3c016af-e31a-4d8a-ade3-cc793216a2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b06123de-4566-4cda-a87c-ed9d4360dff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f3c016af-e31a-4d8a-ade3-cc793216a2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_745ea443-10c0-4d81-9efe-372ab6344f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b890681d-bbc9-42bf-8e50-0e4adfed064f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_745ea443-10c0-4d81-9efe-372ab6344f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1f2d9956-3af6-4f8a-a748-f39b38efd088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b890681d-bbc9-42bf-8e50-0e4adfed064f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1f2d9956-3af6-4f8a-a748-f39b38efd088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7dfdcdf2-692e-4e68-8507-2e85af7244f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b890681d-bbc9-42bf-8e50-0e4adfed064f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7dfdcdf2-692e-4e68-8507-2e85af7244f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_03a1ab35-e2e5-42b8-a489-bef46628f6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7dfdcdf2-692e-4e68-8507-2e85af7244f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_03a1ab35-e2e5-42b8-a489-bef46628f6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_08837039-9a68-45a9-af0b-750dc357493b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7dfdcdf2-692e-4e68-8507-2e85af7244f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_08837039-9a68-45a9-af0b-750dc357493b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_08b4194d-6ed4-4c91-b6a3-a6e04bc706f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7dfdcdf2-692e-4e68-8507-2e85af7244f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_08b4194d-6ed4-4c91-b6a3-a6e04bc706f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f1cf79b8-5bb6-4aee-909e-1a3d61a8f98b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7dfdcdf2-692e-4e68-8507-2e85af7244f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f1cf79b8-5bb6-4aee-909e-1a3d61a8f98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_bfd62630-32f1-4179-b451-f11076673be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b890681d-bbc9-42bf-8e50-0e4adfed064f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_bfd62630-32f1-4179-b451-f11076673be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_48dfb4f4-4348-49a1-8dd4-69dddb34a30b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b890681d-bbc9-42bf-8e50-0e4adfed064f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_48dfb4f4-4348-49a1-8dd4-69dddb34a30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dab63314-9829-4924-ace8-e154786572a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b890681d-bbc9-42bf-8e50-0e4adfed064f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dab63314-9829-4924-ace8-e154786572a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_37ab3be1-6445-45db-81e1-9b842b490cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b890681d-bbc9-42bf-8e50-0e4adfed064f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_37ab3be1-6445-45db-81e1-9b842b490cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b21fe96f-c523-47fc-b772-2337ea27ccfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b890681d-bbc9-42bf-8e50-0e4adfed064f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b21fe96f-c523-47fc-b772-2337ea27ccfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d9c76097-3b10-4049-98bf-a0d1fa1fec1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b890681d-bbc9-42bf-8e50-0e4adfed064f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d9c76097-3b10-4049-98bf-a0d1fa1fec1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1c1b60e2-80da-4127-886a-b62af6afdb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b890681d-bbc9-42bf-8e50-0e4adfed064f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1c1b60e2-80da-4127-886a-b62af6afdb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_330ba309-dcc1-41fb-aca4-b390b6a4e351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b890681d-bbc9-42bf-8e50-0e4adfed064f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_330ba309-dcc1-41fb-aca4-b390b6a4e351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_352082bc-91fe-412e-8072-5d63da78a49f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b890681d-bbc9-42bf-8e50-0e4adfed064f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_352082bc-91fe-412e-8072-5d63da78a49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="xfor-20230331.xsd#StockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c867b6b3-f19b-431c-9385-804a2dacd406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3f25bb74-7de1-432c-8f43-75c65dec9afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c867b6b3-f19b-431c-9385-804a2dacd406" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3f25bb74-7de1-432c-8f43-75c65dec9afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a5be851c-90a9-4778-b9a7-31e326a2d3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3f25bb74-7de1-432c-8f43-75c65dec9afb" xlink:to="loc_us-gaap_AwardTypeAxis_a5be851c-90a9-4778-b9a7-31e326a2d3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_188bd2dd-c7ec-475e-a0f6-00a821dc6d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a5be851c-90a9-4778-b9a7-31e326a2d3cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_188bd2dd-c7ec-475e-a0f6-00a821dc6d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1084c55f-538d-4a13-962a-c8db131f1ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_188bd2dd-c7ec-475e-a0f6-00a821dc6d36" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1084c55f-538d-4a13-962a-c8db131f1ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09eebb2b-d809-459c-ae74-c9b967df709d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3f25bb74-7de1-432c-8f43-75c65dec9afb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09eebb2b-d809-459c-ae74-c9b967df709d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2c370ff8-5f42-4b46-94ee-112a90ef3bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09eebb2b-d809-459c-ae74-c9b967df709d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2c370ff8-5f42-4b46-94ee-112a90ef3bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_512c35ac-9a31-45a4-bf09-a3706e3ecce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2c370ff8-5f42-4b46-94ee-112a90ef3bee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_512c35ac-9a31-45a4-bf09-a3706e3ecce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4bd1a983-e4e2-463d-b7ec-792a6a0aa3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2c370ff8-5f42-4b46-94ee-112a90ef3bee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4bd1a983-e4e2-463d-b7ec-792a6a0aa3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f2aec776-88f1-4a33-bd01-94c9b48a1673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2c370ff8-5f42-4b46-94ee-112a90ef3bee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f2aec776-88f1-4a33-bd01-94c9b48a1673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a7f685c2-de65-4253-ad6e-e43fe0ccb298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2c370ff8-5f42-4b46-94ee-112a90ef3bee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a7f685c2-de65-4253-ad6e-e43fe0ccb298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails" xlink:type="simple" xlink:href="xfor-20230331.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d01c5490-9c24-4537-9524-3cc252a012bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9bd3b74-840d-4cbe-bf73-f665e138912f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d01c5490-9c24-4537-9524-3cc252a012bb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9bd3b74-840d-4cbe-bf73-f665e138912f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_223cfe22-3814-44b4-bfe8-281a5a962ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9bd3b74-840d-4cbe-bf73-f665e138912f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_223cfe22-3814-44b4-bfe8-281a5a962ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0b5d390c-a989-4a74-81ed-126ce77feb21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_223cfe22-3814-44b4-bfe8-281a5a962ec0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0b5d390c-a989-4a74-81ed-126ce77feb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_84a697c3-f828-413a-91b2-703892fbeff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0b5d390c-a989-4a74-81ed-126ce77feb21" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_84a697c3-f828-413a-91b2-703892fbeff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_43bd72dc-eece-4c57-accc-746c7e3dcc27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0b5d390c-a989-4a74-81ed-126ce77feb21" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_43bd72dc-eece-4c57-accc-746c7e3dcc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e85dbee0-5df2-4387-9bd7-5628d9d7b118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9bd3b74-840d-4cbe-bf73-f665e138912f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e85dbee0-5df2-4387-9bd7-5628d9d7b118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4ea4b378-7eeb-4265-9f9d-d243b299d3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e85dbee0-5df2-4387-9bd7-5628d9d7b118" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4ea4b378-7eeb-4265-9f9d-d243b299d3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cf119604-6c0f-40f1-961a-47757718e81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_836b880a-6d5b-4287-9601-0c0d5affcd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cf119604-6c0f-40f1-961a-47757718e81f" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_836b880a-6d5b-4287-9601-0c0d5affcd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_91d39575-e284-45c3-9a2a-ad9bce3b2df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cf119604-6c0f-40f1-961a-47757718e81f" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_91d39575-e284-45c3-9a2a-ad9bce3b2df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3987a8e0-9788-4121-8ffb-3743c8f72bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cf119604-6c0f-40f1-961a-47757718e81f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3987a8e0-9788-4121-8ffb-3743c8f72bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a5753896-794d-4746-b8d4-fa3fe90fe315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_NumeratorAbstract_dfa7f772-26d3-48d1-9e80-9d064a006d9f" xlink:href="xfor-20230331.xsd#xfor_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a5753896-794d-4746-b8d4-fa3fe90fe315" xlink:to="loc_xfor_NumeratorAbstract_dfa7f772-26d3-48d1-9e80-9d064a006d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3b9e5b07-adf7-4498-8754-2dad0d8f107a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_NumeratorAbstract_dfa7f772-26d3-48d1-9e80-9d064a006d9f" xlink:to="loc_us-gaap_NetIncomeLoss_3b9e5b07-adf7-4498-8754-2dad0d8f107a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPaidinkind_8b4fea2c-647e-4ee0-bf8d-90db870d9551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPaidinkind"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_NumeratorAbstract_dfa7f772-26d3-48d1-9e80-9d064a006d9f" xlink:to="loc_us-gaap_DividendsPaidinkind_8b4fea2c-647e-4ee0-bf8d-90db870d9551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f13d4dfd-7ef4-404d-8386-fe8364b0b233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_NumeratorAbstract_dfa7f772-26d3-48d1-9e80-9d064a006d9f" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f13d4dfd-7ef4-404d-8386-fe8364b0b233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_DenominatorAbstract_f0854109-a46d-41ae-a671-10da6636bc30" xlink:href="xfor-20230331.xsd#xfor_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a5753896-794d-4746-b8d4-fa3fe90fe315" xlink:to="loc_xfor_DenominatorAbstract_f0854109-a46d-41ae-a671-10da6636bc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_52023cb8-9dfa-4e5b-a620-91398911d50e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_DenominatorAbstract_f0854109-a46d-41ae-a671-10da6636bc30" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_52023cb8-9dfa-4e5b-a620-91398911d50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fe8b3da1-c0eb-4511-97b6-374b5dda651c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_DenominatorAbstract_f0854109-a46d-41ae-a671-10da6636bc30" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fe8b3da1-c0eb-4511-97b6-374b5dda651c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_543281ef-f753-4734-a839-c09efb1c94ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_DenominatorAbstract_f0854109-a46d-41ae-a671-10da6636bc30" xlink:to="loc_us-gaap_EarningsPerShareBasic_543281ef-f753-4734-a839-c09efb1c94ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5182469d-8eb4-46b0-9870-5ae285dc9001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xfor_DenominatorAbstract_f0854109-a46d-41ae-a671-10da6636bc30" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5182469d-8eb4-46b0-9870-5ae285dc9001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#NetLossperShareAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4c9d0287-c7c9-40e1-a162-0c1de5de6b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_aa7abce4-79ff-47e3-bf0b-abdc88006c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4c9d0287-c7c9-40e1-a162-0c1de5de6b7a" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_aa7abce4-79ff-47e3-bf0b-abdc88006c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a925a091-d481-4e5b-806e-5b784a67e6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_aa7abce4-79ff-47e3-bf0b-abdc88006c59" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a925a091-d481-4e5b-806e-5b784a67e6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ca306499-449e-4405-9965-2640c74f5808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a925a091-d481-4e5b-806e-5b784a67e6cf" xlink:to="loc_us-gaap_EquityComponentDomain_ca306499-449e-4405-9965-2640c74f5808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xfor_PreFundedWarrantMember_d530e733-505b-400f-9225-a4f53c92e9fb" xlink:href="xfor-20230331.xsd#xfor_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ca306499-449e-4405-9965-2640c74f5808" xlink:to="loc_xfor_PreFundedWarrantMember_d530e733-505b-400f-9225-a4f53c92e9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6f4fa4fe-c954-4704-b33b-9a207501c74c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_aa7abce4-79ff-47e3-bf0b-abdc88006c59" xlink:to="loc_srt_RangeAxis_6f4fa4fe-c954-4704-b33b-9a207501c74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_58f5d6fe-5829-4ef4-b047-1141561d8eff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6f4fa4fe-c954-4704-b33b-9a207501c74c" xlink:to="loc_srt_RangeMember_58f5d6fe-5829-4ef4-b047-1141561d8eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c13e686e-2feb-499a-bbb6-4e0b5abf0fb8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_58f5d6fe-5829-4ef4-b047-1141561d8eff" xlink:to="loc_srt_MaximumMember_c13e686e-2feb-499a-bbb6-4e0b5abf0fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_811339e8-fea1-4010-b7a9-17c40493eaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_aa7abce4-79ff-47e3-bf0b-abdc88006c59" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_811339e8-fea1-4010-b7a9-17c40493eaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4cd19e8e-cac2-44bb-aac9-af2fb254a6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_811339e8-fea1-4010-b7a9-17c40493eaa4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4cd19e8e-cac2-44bb-aac9-af2fb254a6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail" xlink:type="simple" xlink:href="xfor-20230331.xsd#NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_836227ff-8630-4991-9fc5-7e8991d3e201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8d16c64-b8c2-42e5-8774-844d508b5987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_836227ff-8630-4991-9fc5-7e8991d3e201" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8d16c64-b8c2-42e5-8774-844d508b5987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_26225235-0fcd-4aa2-8ba8-c019c8cb7658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8d16c64-b8c2-42e5-8774-844d508b5987" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_26225235-0fcd-4aa2-8ba8-c019c8cb7658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_946a56d5-034b-4ced-b77c-5d23928df8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_26225235-0fcd-4aa2-8ba8-c019c8cb7658" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_946a56d5-034b-4ced-b77c-5d23928df8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7df6947c-09f7-4fcc-bd54-3b20bd5cee98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_946a56d5-034b-4ced-b77c-5d23928df8d1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7df6947c-09f7-4fcc-bd54-3b20bd5cee98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3a3acf50-519e-4cb9-abf2-fc0a1d4d18e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_946a56d5-034b-4ced-b77c-5d23928df8d1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3a3acf50-519e-4cb9-abf2-fc0a1d4d18e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e7382fdf-d5eb-482e-af42-5da444c0d415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_946a56d5-034b-4ced-b77c-5d23928df8d1" xlink:to="loc_us-gaap_WarrantMember_e7382fdf-d5eb-482e-af42-5da444c0d415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0f037f32-8ce9-4a88-9a21-4b66d023c9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8d16c64-b8c2-42e5-8774-844d508b5987" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0f037f32-8ce9-4a88-9a21-4b66d023c9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_052ac467-eec9-4081-a0e4-a8d056b602c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0f037f32-8ce9-4a88-9a21-4b66d023c9fe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_052ac467-eec9-4081-a0e4-a8d056b602c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>xfor-20230331_g1.jpg
<TEXT>
begin 644 xfor-20230331_g1.jpg
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M @(" @(" @(" O_  !$( ^H)& ,!$0 "$0$#$0'_Q  ?  $  @,! 0$! 0$
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M"3=VPO E0[5CX>)$X_$F.&3D\F7_V@ , P$  A$#$0 _ ._@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M>
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M8!4:W:*=IMH[/T>!"A/EJLMT1SVO5[<_#F*U[6I^LUWM%R(%T
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M731.:4N=W=[=0E7Z-:(1K8W(T][CE_I;*!&KT>3B/M#)P9&=;$5&,@NO8L+
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MP4Y!/V2M2VT<.:@S$JLC4Z>[#&A9UW/;B;B1%3.1R.8N5CN>Z\MW N(
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MO<]VWMK?A5KV.3;+R@+\
M                ! ':FY6G\*;/'5UD6UGBL9<<9ARX(2$E$-\KJ+D;X49V
M*VE69DS<*3YJI<I5T%/M)K-B'K2I2UH!7K5S<22L[6)F"N&+#@/1J])7I@1R
M>R;BO0K]]#=8-M/&^SGMK+,;%()WCJ%OJ_KINJ=K4BCY[&6%>EQ8QMB'JK2F
M\E%M"6Q,.$4*UKN.+@>+?_**E**WH92$"6LQ!FV-NC5&)$B/=SUTM[X34]IN
M!51.FY7=$=  &Q3YVS9NR;H-&B"+5HU12;-FS9(B#=NW0(5)%!!%(M"I(D3*
M4I2EI0I2EI2E*4H!\1$:ER9$0Y>]*K@NTYVUV;]5[K=G=.&@:#KB/")E*<I@
M9R^G"UP0+.?9IG^PR2+B0/DRX4G!"\>@GWLT5IZQ ]!JNE+LHMS4*N[S2F6=
M;J>7ZET5;TQMYRY=-?B_)>L?KL]'AMF[M:]46SEF3UB,'ZFSGS]I>17-1"+9
M2:[.0FD;>ARGW2E2/:[*Z(%98]:G7>8<8(I%,9P6I@LXNQFV%6LT_P SD*M_
M*93J47"JX$_4:]G]BWIEL^U]]C+UH?R)S_\ :X\"X6Q\Z]<_-W_Y'+7B;2YE
MO2]H6T/;8G16U6+DO%]J7BCJGQXUHZ4BLEXN997OJ(?71*QS6M3/(U.W&32/
MN$B9:F18L6%PMN2.X5R\.-52=*FZ50*#;.A)_*I.&[5D)-S&@Z8]'/5&])$N
MB^LC8B7.8Y5Z3LO:K,6:T]CWJLU!XAD>4VW>.C'4C22A7*Z)YNRKJ8X;NU.X
MK)N1!&O VG(]Z>J9_4HFY04;OFU56;MNLH-E3M6E*W8RK5&2=B@S$C-WMY['
MZ0_&Q_LF+[^VW(Y#0FP:]ASQU_\ 7U%_.1?H&!H=^<J2]N9^>BD3_0JW[T[4
ME_.':_-M:0^NVU]LA]"3^9:E^=?4PCIBORQ[2R=95V8ZON#8W-95\V[,6I==
MO2:7',)JWY]@O&2L<Y)2M*\4JS=+$X2U*<N_O$,4]"FI\-H1X$&:@QI:8AI&
M@3#58]CMIS7)<K5]M#E9]#BRT[B'4;M'M&9Y)Y(6;C'(:DI -';GCR1TY8]]
MW=BRXI!+BBT2.\DXMC:)7*E*4W^]E#<+0M##ZM^;?MW&IM#1SY.I6HHF)7R\
MG&O9ZRLB1(*N_6:UE_M(>WLM?9]MJM]Z<P_/OC8?$W*>VIW64_YA6O\ :B_/
M0A(_^E4P'\D*W_"7-!T/ZW_:<7?\VV?F_P#I5.KH#;AQ_:[K<8:/O1"^B',.
M*6I;:2U12N*V.3&<<K5!C-W!DO(,]@G(+Y>.0IN51=VN]ME^L6I*\?+-UY$W
M"[/56GW]&4TW7X;:-HCT&>E6X$JRPFQ4;T3XD1TN]RI[)CF.=U3VXMT=.VK7
M45:VDO3=F/47>-458?%=DREP-X]5;DW=^XCT3CK0M9!:M?L3J6NM]"QR1OM%
M4DRU-P%I6H^&TJQ4H-(ID]4H^6')PU?=U3MIC/;>]6L3UU.=39Q;-^1U7;,'
M5UDG.Q4GV?-I3+73DZ+NV;;[CR&<6Q.RT_B"X%*J4,HQ9NLIUFIQ>B!R%>0T
MPR1-ZPM -;69LTZKV5J\S4,ZH6H5\;&O.N5SH#O<Z;?$]=BM0G'L!M54UFS1
MXXP%DM1VSS?HPN0^#;UA98U:3B%HQYWJ&.7$@W,:M4*M&,5,6Y4M?7<9C\YS
M^JJ6M1.Z'M6B3U%UOFE5L_0W:GBH[=8$O2$J^TUJPO=0U+C,Q_X(LJ?R<7Q_
MNQ* 76=_$YO\E$_A4YV?0L'[Q_.W\ZNX?FBQ /KMM?;-:Z$O\PU'\]?\S +3
M=K[[&7K0_D3G_P"UQX^%NMCYUZY^;O\ \BAK99[<70UI&T&X$T\9>>992R)C
MIMD5*XT[;QZ6:A"FN;+=^WG&<BDZSB/*Z=Q;BC:J?8R[BM3D]7<X:_;EZ2FO
MK)V\L_2+/T^FSL2*V9E4BX\,)RMSHT1Z877Y<BH77:.=L=HVUT9?-A#!+K)J
MU\$M2;O,Q;ML:EOQ7<6WW$<WD#<OI,./V5166:[B>YZZE3>NI6@^7*FVEQ>:
M+;.B5^<U#3W171VL<_/AX$PMN1<M_LDYQ:N!;0
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M.VUGGXL9[I/G3J#'TVD
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M=M['E>?HE3_#-LI/Y7LN?[U:8P7<O]K["NZ)WX]8[\YB?QRIU= ;;
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M3$>,Q,#,>5([W950N3_Z2YLUO_G<^_BI:]K1\N?Z6OOM^TNO-0LMZ9'[E_\
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MKGIOK*J']<!I[1.DY2GV?I,M(R[)27AS.1C&HU/P3\N3GNY[ERNZ(ZOK1_\
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M]H$\E]143=DZ1%*90N"W9"2N7!+M^_.4O$-I:X%IR6<N$S4XR+RHX2,7=X2
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M:4X3N7:BG%HMFZ13N'3APDW;I*+JID,,6:FI>1EHTU-1$@R\LU7O>NY:C?\
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MU:B.^&U];B+@A0WH_2VXU>NF87+A?>K41KKGIA57M3$=+8&SP
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M:K$<-735PF55!PW72,8BR!TCE,0Y:U*8IJ5I7@J!M1%1R(J944^D#Z
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M8Y@ZJBI4M3I<>T;$/Q=:D+PEX>"N[3_(!<FPH</*R$UJ^Q:B&1 =H
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MJ;)R=6@NAU6BQM(C*O1X7YKW>RP[IVY?NVK<_-_Z @'H8
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M1JTH50AJU^U2ARUK7U.'[5*_Y +L<I&RU]GVVJWWIS#\^^-@3<I[:FI;*?\
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MG+>20]$J?X9ME)_*]ES_ 'JTR#XNY?[7V$IHG?CUCOSF)_'*G5MQR7_SJ?\
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M'U9=5*##EYARK/4E=3Q6NW5R?@G.OR[C,=BVWL<7@ 7L
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MG2+"4RC5&7J4O4)R-&EL=S(T6$Z&N-CV+B1(+'.PH]5;G)ENZ1=8!>
M
M *]]-.S<P;I6U,ZE-5>/;JRO,9#U23UTW#D"'O*=M"1LR'>W;?CW(4BE9\=!
MV-'/H]J29?K)(E>R,@8C4I"'.HMPK&%<IEF9"DU2J5:6CQGS-6<YT5'N8K$<
M^(L1<"-AM<F5>B<[)M],]5ML\\+M->DCM$$[GR@;-,E8Y+!7M@\U:9L7DAT[
M58VERE&%+9-)8LI6.CT3U/6;,CQYCFXG<K1*@Y)9R12T"VCTV+JYT/2L&)FD
MX<*,VL&+%<WJ_P!4GF!82N=79>Z8T]>]N[1>#)>]IYTA&,ZC)P%LRMML\7WG
M,7'8MRXZE+MNRW75I+/U;G5MNYE**+,)9@BNYBFKMRW67.].\%96RM*V0LM+
M#TR#4&(Y'-8K$A/5T-\)7O9@5<>!^VCVWJC7.15OQ87M =DCIQVD%VXZO+-]
M[YOM.5QE;\O;<"CB>Y+%@F3IE,R:$JY7E4[NQO.*KO".FZ=$S(JMR%)PT,0]
M?74'1:*QU,M-&E(L_,1X+Y-'-;I+X;=TJ+EQPXF7)MMN(.0/H8;9Y14@D]F+
M\U67HV2__=%S9+QZC'GIPTJ;>6M7$$8[+PTI2E=QT7U/\_J@04/0LLXQV*+,
M3<PG4OC,P_$@L=^TN!TIZ(],&BFT7%FZ;\30-@-I&I3W!/EJ[FKUNE4BAE$S
M7->LXNO)3*"1U%*MVRKBK1KQABM$$2&J6HN=)H=*HD#2*9)MEFKNEVWO]V]U
M[W>LBNN3G(AAVO703A_:)X=M_".:[DR3:]J6WD:&R>Q?XNF+8A;B5GX.V[NM
M=HS=O+LLZ<;*0YH^\Y0ZB9&B:U5FZ!BN"$(JFJ,>T%GY.T<C#D)Z+%@P8<5L
M1%@N8CL36O8F[8]MUSUVFW[5RDLK%M&-Q]9%FV%"KOW,19%JV]:,4YDU6ZTD
MXC+;B&4,Q6?K-6J*2KTS5FB94R:**9E#&,1,A> M!,0(+8$O!@,O5D%C6-OV
M\+6X4OVLN0J,U=[!S0+J]O67R;+6U>V&,CW$^5E+GN?!T_$6TUNJ56+7CI&>
MM2Y+<EX?ERJYC+.G+!BP>/5U#KNW*ZQSJ&^HJIM%/K6A_9ZM1W342"^2FHBW
MO?+JUF->FYCV/9>O/<C6N7GJIJK!/H<;9[8ANN'O6\BY:U"2\2\(_I$9CNJ!
M>60\>HTX&QI&UK2M2*I-,R&*F8[21<OFB]2;CE%9"M41\,.0T-;.2<9D>/IU
M2B-6^Z8>U6+[IC&,Q)TT=B1>?>F0G!>VS*T_9#UF8>UL77-Y*?WG@.W(2U<3
M8G1DK(98)LN-MIA-MK>/$V<QL).1;N64M..)5M4LU0B4@U:F*GR1LBS()Z/9
M>G3-;D:[%B171Z>Q&08-[$EV-1'786)#Q7M<N-,_=(G0M1I8J!92.VJO3'C'
M6+@3(&G7,",O6Q<B,6#:0>VVYCV5S0CZ(EV,]"SUMOY2+>MV$VTEXUFLBHLT
M<)&XLR2R*J*BB9A%U:ERM:ITS39V_4\TB(JMN1[51R.:YBN:Y&N:Y$5+T=[1
M_>EK3K;FDS V/=/-F7CD*^K0QE&NX2UYS)\I;\S>*<$K*/9-A#/)*V+8B&KB
M/8)/N1L2E8IF19-&Z!CJ\50]1]I--A4BGRU-@QHD>#*IA8Z,YJOPWJK6JK&,
M;<W<MR;E$0T!I5V;^#](6>]2VHK&MU96G+UU3W++73D&+OB<M"2M:'D)F\[@
MOETC9K* L:,=Q[,LO<CY),KY]('HV11(94ZI3K'$=2+,R%'J%5J,K&C18U7>
MY\5L16*QKE>^(N!&PV.:F)Z[ISLEW/)YRT<WF(N3B7)U2-I2/>Q[D[<Q"KD0
M?-E&JIT3*$,4JM$U35+4Q34I6E.$IJ>H!87M1[7-=M.2[W\A!C0!L[<*;./'
MM[8VPA=&4KI@;]O).^)AWE2;M.<EVTLG"1T 5O&N+0L>#11CJLXQL:I%4%E>
M-.<W&[M2D+]555<I 6=LY(69E8TI3XT6,R9B:8YT9S'+BN:W)@APTNN3I+[9
MDVLG9_:6->=J1]LZB\=)7"_M\KKO0OF">N;;R#9BCRE2N>X%SL. YF*AMTZD
M>]3>1BRJ*:R[)59%(Y/AW5NSM)M!!;"J4JD96;A[5P1&7]2]N6[IM6]CN>U2
MH:%]"_:%V,VR<3>8-5%TVM&.Z.V%FR=ZXZ9L5*'4*=VTD)&(Q:@O5JXW"T5,
MP[GN*T+O%<%-P5H*;#T*J U[5B3DY&@L7-8L6$B>RQ7047.]C<OLB^# .G?"
MVEO&<)B# >/8/&V/H$RJ[6"@TW*JKM\YW*.YB=F)%PL]N.>6*BE1=\_<.7:I
M44R'5J1,A2B_T^G2-*E8<E3Y=LK+0MIK>GT2JYU[G.7+>YSE5W3([95V>.%L
MOZVL'Z\[EN?*+'+^ [.;V19UN04W:;;&TE%-W>0GB;FY8=_9+F3>2'&Y)G:5
M.UF&:>ZU:<"-*D6,N(V;LY(SE=I]?BQHK)VFLP,8US-*<GFF[16.>KO-7;E[
M>A]?%/4"PE<^;-E_IDSIJ^PQK>G27O:><\+RMN2Z#JQ)2VXJW<BN;/?(/+7I
MDV,EK2?K3:C%!$S1)PQ=QKP[$Q&JSE5)JQHU%9GK+4N?K4C7HFF0I^05%16*
MQ&Q,.XTQJL<JX=I%:K'79%5;FHEC %F
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M%5M6],-7!9< ZFT8"X4[EMQM>"%WX_G23+5C(J2I$2)4;46:SSQJ\Y2@9!-
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MB6$I5!J$.I2DW-1H\-KVHD5\)8>>ERY&06+M;6<71 7@
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M,\7.V9HG<+F4%PHEGZ79^7=+TR7TM(ESGO55<][DVE>J_L1,+6\Y$)E 38
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MF]78\36Z6UZ.Q8E3/6[&_)ER6& 60
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MB9=SM]/G>!Z:'I@?^0W?AWA=W.]2]_\ SL[B]\7<KN9WM<L_<?[-Q_)^3?\
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M>3OR1\;&KI3TY/>=]A8?B'&67\Q::DKIQI:I[HQ;DB^H2Z+7N,T[;4.FY>6
M7*-ASA2P]P3+5^R/W5=O$3<>U2HK2)*HGOHU2.?!?8*VLNDY0XE'PS4.)!C.
M9I\KFW0GIBQ),8,YL9FY<OZ,*ESD:569RSFG2TGIU,J$Q#B0GZ9#;B6"V:@O
MS'/:]N<Y6Y4;BP9,W"?[S0M1/1W7K;8O:<=',VMKP+\JE>7,/8W6MY>$A<H.
M:%J)Z.Z];;%[3AS-K:\"_*I7EQL;K6\O"0N4'-"U$]'=>MMB]IPYFUM>!?E4
MKRXV-UK>7A(7*#FA:B>CNO6VQ>TX<S:VO ORJ5Y<;&ZUO+PD+E!S0M1/1W7K
M;8O:<.9M;7@7Y5*\N-C=:WEX2%R@YH6HGH[KUML7M.',VMKP+\JE>7&QNM;R
M\)"Y0<T+43T=UZVV+VG#F;6UX%^52O+C8W6MY>$A<H.:%J)Z.Z];;%[3AS-K
M:\"_*I7EQL;K6\O"0N4'-"U$]'=>MMB]IPYFUM>!?E4KRXV-UK>7A(7*#FA:
MB>CNO6VQ>TX<S:VO ORJ5Y<;&ZUO+PD+E!S0M1/1W7K;8O:<.9M;7@7Y5*\N
M-C=:WEX2%R@YH6HGH[KUML7M.',VMKP+\JE>7&QNM;R\)"Y0<T+43T=UZVV+
MVG#F;6UX%^52O+C8W6MY>$A<H.:%J)Z.Z];;%[3AS-K:\"_*I7EQL;K6\O"0
MN4'-"U$]'=>MMB]IPYFUM>!?E4KRXV-UK>7A(7*#FA:B>CNO6VQ>TX<S:VO
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MYH6HGH[KUML7M.(CF;6UX%^52O+E5V-UK>7A(7*#FA:B>CNO6VQ>TX<S:VO
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M>U5SKL.;=?N39FAQ)U.FS-2E9R7TN#,,8]%QL=GL7#T#E7.:_G]26F"W&V
M                                   *Q=LG[&[J-_H@^?C%XM%C//+3
M?[;Z/%*'HF^<>M]C?3)<X41Z /)8
M                      !9UJG]C=V57]>3Y^+>%2I/GFM9[5/^84OEH/./
MH??WM],85BBVE#
M
M                                    [;]EG[&#IG^^N6/GMR\-/U+S
MYUK\E#^;ECTM9/\ Y=6?_*Q_I,V31&090
M                 !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                                 !E7M(^%7T0(OT:[%^M);T&[)^H,
M5$H1(                                            !E7M(^%7T0(
MOT:[%^M);T&[)^H,5$H1(
M     !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                     !GV-_W;=_>MQ_;60@[1_B,'\JWYMQ/V>_'8GY%W
M\;#=0I9<0                                    *Q=LG[&[J-_H@^?
MC%XM%C//+3?[;Z/%*'HF^<>M]C?3)<X41Z /)8
M                                !9UJG]C=V57]>3Y^+>%2I/GFM9[5
M/^84OEH/./H??WM],85BBVE#
M
M                                              [;]EG[&#IG^^N6
M/GMR\-/U+SYUK\E#^;ECTM9/_EU9_P#*Q_I,V31&090
M                           !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                                           !E7M(^%7T0(OT:[%^
MM);T&[)^H,5$H1(                                            !
ME7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M               !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                               !GV-_W;=_>MQ_;60@[1_B,'\JWYMQ
M/V>_'8GY%W\;#=0I9<0                                    *Q=LG
M[&[J-_H@^?C%XM%C//+3?[;Z/%*'HF^<>M]C?3)<X41Z /)8
M                                          !9UJG]C=V57]>3Y^+>
M%2I/GFM9[5/^84OEH/./H??WM],85BBVE#
M
M                                                        [;]E
MG[&#IG^^N6/GMR\-/U+SYUK\E#^;ECTM9/\ Y=6?_*Q_I,V31&090
M                                     !E7M(^%7T0(OT:[%^M);T&[
M)^H,5$H1(                                            !E7M(^%
M7T0(OT:[%^M);T&[)^H,5$H1(
M         !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                         !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                                         !GV-_W;=_>MQ_;60@[1
M_B,'\JWYMQ/V>_'8GY%W\;#=0I9<0
M     *Q=LG[&[J-_H@^?C%XM%C//+3?[;Z/%*'HF^<>M]C?3)<X41Z /)8
M                                                    !9UJG]C=
MV57]>3Y^+>%2I/GFM9[5/^84OEH/./H??WM],85BBVE#
M
M
M      [;]EG[&#IG^^N6/GMR\-/U+SYUK\E#^;ECTM9/_EU9_P#*Q_I,V31&
M090                                            !E7M(^%7T0(OT
M:[%^M);T&[)^H,5$H1(
M   !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                   !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                                   !E7M(^%7T0(OT:[%^M);T&[)^
MH,5$H1(                                            !GV-_W;=_
M>MQ_;60@[1_B,'\JWYMQ/V>_'8GY%W\;#=0I9<0
M               *Q=LG[&[J-_H@^?C%XM%C//+3?[;Z/%*'HF^<>M]C?3)<
MX41Z /)8
M  !9UJG]C=V57]>3Y^+>%2I/GFM9[5/^84OEH/./H??WM],85BBVE#
M
M
M                [;]EG[&#IG^^N6/GMR\-/U+SYUK\E#^;ECTM9/\ Y=6?
M_*Q_I,V31&090                                            !E7
MM(^%7T0(OT:[%^M);T&[)^H,5$H1(
M             !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                             !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1
M(                                            !E7M(^%7T0(OT:[
M%^M);T&[)^H,5$H1(
M !GV-_W;=_>MQ_;60@[1_B,'\JWYMQ/V>_'8GY%W\;#=0I9<0
M                         *Q=LG[&[J-_H@^?C%XM%C//+3?[;Z/%*'HF
M^<>M]C?3)<X41Z /)8
M            !9UJG]C=V57]>3Y^+>%2I/GFM9[5/^84OEH/./H??WM],85B
MBVE#
M         %*&J:E*4K6M:TI2E*<->&OJ4I2E/5K7AX!C@_1=NY:JU1=(+-E:
M%H:J2Z1T52T-3A+6I%"TK2E:?M?4]4<VJBMO3/3_  _Q.;FN:MSFJQ5Z9^8[
M3@
M             !VW[+/V,'3/]]<L?/;EX:?J7GSK7Y*'\W+'I:R?_+JS_P"5
MC_29LFB,@R@                                            #*O:1
M\*OH@1?HUV+]:2WH-V3]08J)0B0
M           #*O:1\*OH@1?HUV+]:2WH-V3]08J)0B0
M                           #*O:1\*OH@1?HUV+]:2WH-V3]08J)0B0
M                                           #*O:1\*OH@1?HUV+]
M:2WH-V3]08J)0B0                                            #
M/L;_ +MN_O6X_MK(0=H_Q&#^5;\VXG[/?CL3\B[^-ANH4LN(
M                        %8NV3]C=U&_T0?/QB\6BQGGEIO\ ;?1XI0]$
MWSCUOL;Z9+G"B/0!Y+
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M!7$W*).3/SSS<&S>;H.]=>EULZ01<MULL0)%D7"9%D54ZE<[Q%$E"UH<M?\
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MX*\/!7@]2O!]O@K_  \ QP!D
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M+]&NQ?K26]!NR?J#%1*$2
M      9]C?\ =MW]ZW']M9"#M'^(P?RK?FW$_9[\=B?D7?QL-U"EEQ
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M/1-\X];[&^F2YPHCT >2P
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M<^;CEJKG_)Z!^94[YZ6(\>AQO\<C^KS_ ,\1)Z)7H-[<U_IR&T$MJTWMR?\
MJC>DBK&[6K0CE[&3NK)QJ>TUWU<+6%44J@D^?W';#N;2LF3-6G!Q4;=5H-I"
M)=&.8J-)=BY>&2W&B%!'-1UD*_)S+;V4JJ0TQ=)K'W8V^Z@OPO3GX%1.B4EH
MJP]$6R53D77+7:)%>C.FY\-7Z4[VH\*^$[G::BKT+2!NQ0TL1??KD76AFIL2
MW<=:;FD^S@W5QMSM&;:_&$.N]NVX7Z+E.M2(6U:QUCG*<E#)OYQLLF8J[ ]"
MV"W-6<L"5HDB[39FIJUSL&WI3G9C4_*O^*BIN7%1T+;/P]53MIZHW29*BH]K
M%?D:D9$Q17NO](A]J]Z.3.86TV;J8E]6^S9UXYKD$EF43.6OJ[B;)AUN+*I"
M6) 8F>1UK1R]"5K3N@9@GREY6E:E,^D')R;I#%+2H1Z6RCVFH$BW.?#=)J]W
M51'1KWK[G%FM]BU#8LM78EH[$6LJCT5L.-#J383.>R"R K8;>EBPYS_9N<<4
M WL>63:>#<K2^"\R8PS'!-$9"4QG?%N7FUC'"RC=M+%@I1N^=0[I=*E3HM7;
M1)9LH<M*F*1T8U/5&!/RC)^2FI*(["R:AOAXNEB3#B_1NB2I-1B4FIT^I0FZ
M9$D8K(F'<HN!UZL5>DJ9%]T=:^2X_9Q;8:T;"E5\Q'LS*=N1KM&"C$KGMZS\
ML6Z25406D;;GK,N9-PC=4021;HGHLR(NE0]358R29'*O&Z?E76FL7&F&-DM.
ME'JF)V!SX+L.Y>U[,+F+=SG8?9,7#D]%3S;%:)4M*1%J.I9^"U<#<;(<S#Q;
MICX;\2/;>W;;B3J'IB6^O?-'H>S+=O,7TI@O-EI9).@FLY0M6^()UCZ;<%3+
M4R4?'3;.1E6$C(*5I0I#N^Y;?A-Z]1(I=X6*2T1I.(YK)^1?*^S8[36^VJ86
M.:GM8W%-JF@U48+%B4FJ0YY6K?I<9BP7^TUZ.B,<[W6EI[)#0&R<NY735KEE
M-.&H2Q(^*]- ]<7SEO7S!1CQQ:^3HM121L1<O+T5J4Y:LY?1B!F]3(N^^YHX
M(H=$J1Q)6N@I4Z VJ4V85VI?-&K#<N?"7)%W/2S7K?M8%;MD/H=S"T.U<2B5
MF52'KAY@]D9B.5D=N6#MWY'Y6-PY%TUKMHP+;,Z9FVGW6#-W#;<0A%6!G&+3
MR1;B#!JFUC(^X#J]S;\A6R:)"$35+<"/=*J9"T(DC=;8A?VH[K$U37&C0X<1
M^.9D%TIV)<Y4W4)>US/;8N0P]$ZA)1[1Q(\"&D.3JS=.9<ER(_<QF)^OG^Q2
M*F4M/QW:5F;.C9#N,I7?:-KN\X9:B#7';YKC@(F2EF^0<N,4FF/XUOW5:'41
MI!V0T8RKME4Q*%6@Y+@I114V]59J-&M);)LI C/;(2;L#L*JU-+@NOBKF]6^
M]C7<]%8;!DI>7L5H<NGYF7ANJM0;C9C8U7)&F4N@MRM_]N$C7N9TV/YZFP]E
M'BW$N0-F#<C;)\+!HPT^XSS#79>1X>)4N*%MIVU>LI>6CYEW%N56KUG%KNEF
MZE"*U140*>B9^#=KBVMG)V6M5#64B.5\+4[F,Q.P*],*HBMO3(YV1?\ $S-#
MV0ITY82,V?A,2%'6;9%B8$QHQ<37.17(Y;VMO<FWAZ1IW2KM8M+JN7\=:2\9
MZ08O'F"[RNN"Q;:=U*3,,\FG[Z<D&\#;4W>EGJ6H:CTS^5<1Y7RKF;?.TZN#
MO'#ETI0Z8S:M8^JZAFJO-5A9B?@L=&>RYUR(U,3VL?CR86XL.%C4Z%&H1EG]
M$2@K4I.SLC9MLC29J(R7A1<;%<Y7JC&/B0M+RXW*W&YT5[LN-SG$&]M]I5QY
M@#4%8%X8HMIA:-O9NMB8E)&TX)@1C!M+UMB6:M)M[!L&W E'MWC*=@5#M$$B
M))N2K+$I^R=PD]82K3-0ILQ!G(BQXDB]&M>JWNP/;D:J\_"Y'9R]#DYQ5-%6
MS\E1ZQ)3-/ETEX-4AO<L)C;F-BPW-1[F(W(W&CV9J)AQ8G=$6S1EE:;-C-HW
MMC*%VXPBLB9YN*L'#2DBHA%%NR[<FSL8XFGML1MSR#-V>S[#BT(U\6IFJ)R5
M3BR.%&KF1=_9*BZ/5+;5N)*09I9:0AXE1,N!D-JX4>K&JF.(^]-OIW7M:AL2
M'*T/0QLS!GYF0;.56-@8YV33(LP]'/<QKW(NEP6(UVY;N6WJUSW9<*T&:UM.
M&N_51:]PW)I]B\(ZF\9PEYW!8=VVM.LY5CD.V92WWMK73:]T.R6W'KOGK2+G
M2OFB3A-S4G<MPX;/&B?*6;SOM!0JG9^DQH<*HK/4J:<QL5CT5JPGM<CV/8V]
M6M:Y4PN<V[=-:K5R.3%LC:FB6OK\"-'HS:779%D1\&*QZ.2,QS'0HC'K@8YR
MHC\2-<U=RJH]N<Q8 ;6U%%SM6,7MW"22Z"[+3VBN@LF55%9%2[%DU$E4CTK1
M5(R9C4,6M*TK0W!46&QZJEDIQS<U6K,_P%/T0T1VB%3T7.1R2?SA=/M"*:(-
M.<;BO45J!Q+"7@O84A>%LXQQ9!VA:CAC>=XWNS@7*LM,PSYLDT?)Q$7:;@Z+
MA\91JQ-,'6306DC1U"TBSB5ZI.G*;3IQT%)A&/BQG/?>QC%=D:Y+W)C<_.:V
MY7777X+S9]LDLK1(=/K59I[)I9-8C($NR'#5(L2(C%O<QR-:[2FPEPN?FLQ*
MZY7X"EY[?EL[:/61I[QM#8G=8+QQBZTKJ6O8T9<["=>NL<Q<@QEE4(MDRM:.
M;VTZ6DE6,6AN<M(@I<E'? 8K:J2UU;+Q;$46I33YQ*A,S3V8+V*B::Y'-SE5
M[G/R8GNVL6"[GFL73DOHHVFHLC#IZTF1I\.*Z+AB(]5@M<UV:C8;&L<KL+$W
M>''BZ&YT]-4VT&TV[,>^(_2_IZTL69<$O;,%!O+[,RDF%F,88LU'-7\9$R4N
M2VI.2O*['5NN&;MV\?J<)$Y1H<ZSY519)"!I-G:I:F ZJU*KOA,C.<D.]JO<
M["ZY7(W$QC&-=>B-;U+MKGVZT%LZ'82:AT&CV?A1GR[6+&PJV$UF-$5J.=@>
M^)%<RYSGOYSFYSW*J-^+,."M,FU5T23VJ7".,8K%V>K6B[J=U3AV$6QF'%YV
M2Q3E)W&MZ.(5!LVO!O(17(31,FX3(Z;DF(]S7DA#/8X_V2GZI9*NPZ5/3:S5
M/C*S;5SDP/=<V(S%B5F%;\;$S7*BIES7G"ITFA:(-EXU?I<DV1J\NV*N:UK7
MZ;":KGP(N!&MBH]MVEO5,28V.S<]A'KT/+:=JW0XU<]\ULV_<7(4<#\B[NPT
M=+\CY2?,G*:-N7ME.3<95NWW]S@W^()O;W!3@D=$>-%A-H^E1'0[]/OPN<WT
MGI$-H,R\O'6TFGP61L*2>'&QJW7ZIQ78F_\ G[#9B.T@TF:+M35TZ9\4:9&L
MG:Y,P3EN9DS<O/1+&ZW]ZS=V.6UZNFT+6T%C3=OPTN[?-&[4\BS0JA&F;LV[
M9$A%7.*MFJQ6Z7!JDW5%2-I+7P9?"Y6-8C,S+C;<YZ-17.PJM[KW*Y=K/2V]
MG;,5Z8H5.H*.@+,O9,S6-K8BQ7Q5;%5&:6N-D)RN:B8V)A;<QJ-PWR1U]XOT
M.Z,;J9Z\KRP7%WSD!^JTL&S\/1[>$A<?7;DA\24EZ9"N&,4A735I-M;>CY J
MCXS-RG15-!SR-:5,W>)1MGINO5R"^ST"H++R[?-'QEQ+%9";<FE-7$CE:KG)
MDQ)FWIB1EZ$W:^0LI9B8;:Z:I+9J<==!A2R(QD&+'=B73GI@<B/:QKL_ [G.
MP.?A5N6Z=\E8#VQ.F+*$'?\ @V!L&:MQ^YLE5$AXZZ)"S)"0@ZOK1OJQ[H)!
MQKADX266=&HVXI(N_&K-EZN6;@Y5.FI2M0L9592) GG3$.(F/HF(]$=A?#>W
M$Y%]OUT<ERH9%%GJ/HE4&>ASE)9)Q8+G0>A>Z$YS+X<:#%P,<U4O=DN2Y45J
MXFNR\[FS/T.,]7.J&1L#(G+FV-L3L7]S9008+JLW4S2,F$8.,LQM((*%4CE)
M"644JLLGNJD8Q;[B547)D5"[&M37EHU*;,2USIJ<5&0K^AQ-Q.?=S\+>=TW)
M?DO-,6$LHVT=?BR<[>V1IJ.?,8<US\+\#86+;3&NVY,N!K\+FKA<6>:B]K-B
M[23E2ZM-&F32CA]YC;%DR[L:[G3]FG L;BGH->L?=$;%Q4)%E+1-M+MG#920
M?G?JOG#55P='=,156K4RR$W6)2#5*K5X[9F;1'LN=>K47.8Y7.7GMRX6X;DN
M2\O=:T0Z?9RHS%#H=GY9TC3W.@Q55,"/>S-BM1&-Z%;T<]^-7NO7#SW:6VD6
MGW F;-(&+-I-IOL:,Q:2[G4<SRM942BDSB5UI:6=6BY>D81S=-DWGHJ_HIU'
M.'#9LU3E4Y#EJQ"N$BE5SK,5&H2-9FK,5.86:TE%TE[MUFICNQ+G87PG8T1R
MNP784S2,MO1Z/5;-T^W%$E6T_5"HV8AMS6KC582KA;F(^'&1S'.:U-,:[&[*
MF=S\C9)IH                                      +L]4GL &A_P#G
M4W1_MW6"//MN//+4_;@_1X1^Q'_#&\\DS_TW5?\ YZGG/8*B?M
M
M
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MB9REP(G3Q695[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
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M3?./6^QOIDN<*(] 'DL
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M'GVW'GEJ?MP?H\(_8C_AC>>29_Z;JO\ \]3SGL%1/V@
M
M
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M;^>D)6Y\LYV;@:Z%?>RXN4]I'PJ^B!W>C78OUIY.]!NR?J#%1*$2
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M?3)<X41Z /)8
M      !9UJG]C=V57]>3Y^+>%2I/GFM9[5/^84OEH/./H??WM],85BBVE#
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M!CG)M.5SE>]UW.O?<FZ1+R  LQ30
M      NSU2>P :'_ .=3='^W=8(\^VX\\M3]N#]'A'[$?\,;SR3/_3=5_P#G
MJ><]@J)^T
M
M
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MBRW+=B8[HFN:O1'TB6*>
M     9]C?]VW?WK<?VUD(.T?XC!_*M^;<3]GOQV)^1=_&PW4*67$
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MBE#T3?./6^QOIDN<*(] 'DL
M                  LZU3^QN[*K^O)\_%O"I4GSS6L]JG_,*7RT'G'T/O[V
M^F,*Q1;2A@
M                   $K\HZY=569L6QN$\CY:?SV*XBL 6.LMM;5DV[%-T;
M6;4:6ZTJ:V+:9K+,&B)4^*;G5,A0S=%0R1E$4SDA)2@4B2FG3TM)I#FW7XGX
MWJ[/V]V]V<Z_=;99)^UMH:I3H=*G:DL:GP\&&$V'!8GF61B>9,8["G0MQ8<U
M'="TB@)LK8
M                  79ZI/8 -#_ /.INC_;NL$>?;<>>6I^W!^CPC]B/^&-
MYY)G_INJ_P#SU/.>P5$_:
M
M
M                                [(=AOFQQD+1'.8PE'2SF5PCEM:*:
M&7<57,2T;QAG$];Z12FIPHHIR:-S(IEX:EH1J6A>#=X!9K-Q7Q)QS'?^S 5K
M?:6*B_XN<?C?Y/>Q4"SVB/(VDE(;8<O;B##F(ES<.*<E&++1W+TW/AI+/<NZ
MO<MY;^+D>!P                                            #/L;_
M +MN_O6X_MK(0=H_Q&#^5;\VXG[/?CL3\B[^-ANH4LN(
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M]C=U&_T0?/QB\6BQGGEIO]M]'BE#T3?./6^QOIDN<*(] 'DL
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MV7ZWUFJ?9F=ILO3G170YF7;$?ICD<N/&YN2YC,VYI62+:4$
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M.:W*[HL71.]LA)M)=DU-ME%6)*MB/TISMTZ%B=@<[$UKL2MP]"WVFF,#*,8
M                 +,=;&C[%FG?35H1R]8LC>3RZ-2F+%+VR WN26BG\,RE
MBV7BVX*)VPT8P356-8\NO.7IN.%W9^+31+QO"0YU:E0ZS-U*J5Z3F&L;"I47
M!#P(YJN;CBMS\2KB=A8W::WGE]M59JGT6A61J4HZ*^8KDOIL;&K5:UVDP'YB
M(QJHV^([;<[)<5G"VE"+L]4GL &A_P#G4W1_MW6"//MN//+4_;@_1X1^Q'_#
M&\\DS_TW5?\ YZGG/8*B?M
M
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M>:2-9BRV+UIN2C1'-_6=)M]XZF1=C\B@
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MRTW^V^CQ2AZ)OG'K?8WTR7.%$>@#R6
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MD;>6JZ,H5!1%8Y:$W3D:-B&*V)T1:357N=$J-KG2<5RNPL@X8;&MZ'-QLO\
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MIYSV"HG[0
M
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MDZ-+2\-VFPE9@C>:8DB-TJ'"5Z7X&L62&C%O;>.M?%KV?<6U[R?J:S7W8O\
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M]ZW']M9"#M'^(P?RK?FW$_9[\=B?D7?QL-U"EEQ
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MXM%C//+3?[;Z/%*'HF^<>M]C?3)<X41Z /)8
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M1TVU8DJV6ANBMZ<-ND8V_I;>3.UE6_KUR'<=A77H&S/8UGZ(CV%;9H&X<<Y
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MQZAG,)8<M-W-%VO82>1K3D6.<;G>VA<JT='6G8%AJT+&6Y'H(NIAPX?L(Y)
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M>P5$_:
M
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M)FE[W1'Q;M9-XN2U"M;:C5X1\A(MF;AHM605:E68HG5C5>*(0OQ;NH3]KO\
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M<?VUD(.T?XC!_*M^;<3]GOQV)^1=_&PW4*67$
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M,7BT6,\\M-_MOH\4H>B;YQZWV-],ESA1'H \E@
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MRRAS;QSJJJ5K50]35I6M:UK6M1S:B(VY,Q/\?\#FJXEQ/<KG./X':<
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M^T8IS%-ZT=*HFTN??_YZYS1[F+>URM=_Y_YM'YCN.!O>Y<_7%/Z?\;Z<6<%
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M?_G4W1_MW6"//MN//+4_;@_1X1^Q'_#&\\DS_P!-U7_YZGG/8*B?M
M
M
M                                          &S,99IS!A60DY;#N5<
MC8JE)IDE'3$ECF];CLI]*L$5Z.464B[MR2;'?-"N*$4*FH8Q"G]4M.$"N6@L
MG9>UD&7EK4V;D;22TH]SX4.?E)>:9">K<+GL9,,>C'N;D<K4:Z[(:T,:IS&.
M<U3*'K4QSFK4QS'-7A,8QJ\-3&J:O#6M?M@3Z(B)A;F(T_P#L
M    /U116<K)-VZ2BZZZA$4$$2&56665-0B:::9*5JHH8YBT*6E*UK4W!0#K
M>]D-CGO<D-D-'.<YSL+4:W*KG*N:C4;NG'??L]]/JNFK0OBS'4DWY/=+N7/>
M=[DWJFJ2[+NB4Y60:&K5(E:U:-3L6/JTX>"-^V+I2)59.>@PW?A'2F-_MNC?
MY)A3]4_ 7R26B.S11T2;5VDE8NF4B7GTD)!>G)R<%83'[IWX9^FQ]O\ ]TE8
M+(>=0                                            #/L;_NV[^];
MC^VLA!VC_$8/Y5OS;B?L]^.Q/R+OXV&ZA2RX@                      !
MQ!^B8;QMS'>TUV7^0+QD>X]HV*WM&\KIEN1OI#N9;EL:@(F;FY&C"+:KNGO$
M1C%TKQ+=%9=3B]Q%(ZABDKMBP,)T>@6@@PFXXL;$QJ;6)SH+D:F7-V^GM&HK
M?Q8<O7[-QHSL$* K7O=G+<UL9JN6Y+W+A:G0I>:+]$>;470KKVT_:>K(TGYQ
MKE6Z+&S%,W5=$97&>8+%[EP+NRI&(;ON6Y)Q_#MWN](.$4^*;JK+4W]\R="%
M,89EA;.UBBSL]&J4GJ>'&A-:U=,A/O7&U>@>]=KIF%;RT='K,A(P:9.ZJBPH
MRO<FEQ67-P.;?BB,8FWTB5NT>VQ^S@SWL;[[TIXGU%UNO/<UAG3S:<;8GI19
MV@:.9^QKVQ++W2P[Z+DQ@SAD>2QUL3BG&J2)$5^0[C918ZJ)%(V@V5KLE:B#
M49F0TN29%C.5^FP79'LB-:N%L17Y5<G0^V2=?M70)VRTQ3I:H8YV)"@L:S2H
MR96/AN<W$L-&9$1>B]HN)]#D>PSZ./ZPO_%3G$5FW/GIJG]A]'@EHL'YU*5[
M<Q]*C%W0J9;P    "L7;)^QNZC?Z(/GXQ>+18SSRTW^V^CQ2AZ)OG'K?8WTR
M7.%$>@#R6
M    6=:I_8W=E5_7D^?BWA4J3YYK6>U3_F%+Y:#SCZ'W][?3&%8HMI0P
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M9MV[8]VZ*:1>S5X
M   79ZI/8 -#_P#.INC_ &[K!'GVW'GEJ?MP?H\(_8C_ (8WGDF?^FZK_P#/
M4\Y[!43]H
M
M
M                  N8V/VB1YGK,#3.-]0RM<18@E6TBQH]01Y#>=_MN%Q#
MQ2!'"9^61\>X*W>/*E+0G&)H-^,*8YR"=H5.6;F-/B-_D\NN+W3^A3_N=[W1
M'A_R:&CQ!T.[%1K!V?G4;;2VD%\-^!SL<E3WYL:,Y6.;@BS*8H,O>M]RQ(N#
M"UJG9E[2/A5]$"S^C78OUI^-OH-V3]08J)0B0
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M:+&>>6F_VWT>*4/1-\X];[&^F2YPHCT >2P
M                             "SK5/[&[LJOZ\GS\6\*E2?/-:SVJ?\
M,*7RT'G'T/O[V^F,*Q1;2A@
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M^)5]\L]=NFM":S,P]OFDO,8$]RBS<*[]+6M7]!S\#9!IL
M                                 +L]4GL &A_^=3='^W=8(\^VX\\M
M3]N#]'A'[$?\,;SR3/\ TW5?_GJ><]@J)^T
M
M
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M_6D;Z#=D_4&*B4(D
M S[&_P"[;O[UN/[:R$':/\1@_E6_-N)^SWX[$_(N_C8;J%++B
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M\6BQGGEIO]M]'BE#T3?./6^QOIDN<*(] 'DL
M                               LZU3^QN[*K^O)\_%O"I4GSS6L]JG_
M #"E\M!YQ]#[^]OIC"L46TH8
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M_P"=3='^W=8(\^VX\\M3]N#]'A'[$?\ #&\\DS_TW5?_ )ZGG/8*B?M
M
M
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MCZ1!E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
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M7;)^QNZC?Z(/GXQ>+18SSRTW^V^CQ2AZ)OG'K?8WTR7.%$>@#R6
M                                              6=:I_8W=E5_7D^
M?BWA4J3YYK6>U3_F%+Y:#SCZ'W][?3&%8HMI0P
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MT]3=49N$D'"QD-D-CE5D-C$RHV_JGJY[O=7="14$V5P
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M?=0\$)L[?%Z\K.<?.8&L%*WLO;1>./+G^23]4C]T4+[J'@A-G;XO7E9SCYS
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M8<3"   #*O:1\*OH@1?HUV+]:2WH-V3]08J)0B0
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M6J?V-W95?UY/GXMX5*D^>:UGM4_YA2^6@\X^A]_>WTQA6*+:4,
M
M
M           #MOV6?L8.F?[ZY8^>W+PT_4O/G6OR4/YN6/2UD_\ EU9_\K'^
MDS9-$9!E                                             &5>TCX5
M?1 B_1KL7ZTEO0;LGZ@Q42A$@
M         &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M                         &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M                                         &5>TCX5?1 B_1KL7ZTE
MO0;LGZ@Q42A$@                                            &?8
MW_=MW]ZW']M9"#M'^(P?RK?FW$_9[\=B?D7?QL-U"EEQ
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MJ?V-W95?UY/GXMX5*D^>:UGM4_YA2^6@\X^A]_>WTQA6*+:4,
M
M
M          #MOV6?L8.F?[ZY8^>W+PT_4O/G6OR4/YN6/2UD_P#EU9_\K'^D
MS9-$9!E                                             &5>TCX5?
M1 B_1KL7ZTEO0;LGZ@Q42A$@
M        &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M                        &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M                                        &5>TCX5?1 B_1KL7ZTEO
M0;LGZ@Q42A$@                                            &?8W
M_=MW]ZW']M9"#M'^(P?RK?FW$_9[\=B?D7?QL-U"EEQ
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M.M4_L;NRJ_KR?/Q;PJ5)\\UK/:I_S"E\M!YQ]#[^]OIC"L46TH8
M
M
M            ';?LL_8P=,_WURQ\]N7AI^I>?.M?DH?S<L>EK)_\NK/_ )6/
M])FR:(R#*                                             ,J]I'P
MJ^B!%^C78OUI+>@W9/U!BHE")
M          ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                          ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
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M)V(TE5+1URL1(SZE58TPR,M[H6FO;!;G7X6PFK@:UJ[36M_:1X$L08
M%G6J?V-W95?UY/GXMX5*D^>:UGM4_P"84OEH/./H??WM],85BBVE#
M
M
M               [;]EG[&#IG^^N6/GMR\-/U+SYUK\E#^;ECTM9/_EU9_\
M*Q_I,V31&090                                            !E7M
M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M            !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                            !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                                            !E7M(^%7T0(OT:[%
M^M);T&[)^H,5$H1(
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M.$EY5&6F[)M%>UTKGB)&&LZ6:*1LE%.G!W<4\;-%R.C519J'XMLY5PG42T-
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M=:I_8W=E5_7D^?BWA4J3YYK6>U3_ )A2^6@\X^A]_>WTQA6*+:4,
M
M
M             #MOV6?L8.F?[ZY8^>W+PT_4O/G6OR4/YN6/2UD_^75G_P K
M'^DS9-$9!E                                             &5>TC
MX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M           &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M                           &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
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M)OG'K?8WTR7.%$>@#R6
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MRF3\8'@;=I%XN7E>P/YT V:68X1\#,<F.9E;?@3Y3)^,#P-NTB\7+RO8'\Z
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M+Q!K/4][IV[>..\FY_<SX['_ %L->J;OSXD7B#6>I[W3MV\<=Y-S^YGQV/\
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MS\8O&;8SSRTW^V^CQ2#T3?./6^QOIDN<*(] 'DL
M                                  LZU3^QN[*K^O)\_%O"I4GSS6L]
MJG_,*7RT'G'T/O[V^F,*Q1;2A@
M
M                                               =M^RS]C!TS_?7
M+'SVY>&GZEY\ZU^2A_-RQZ6LG_RZL_\ E8_TF;)HC(,H
M                             RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M                                             RKVD?"KZ($7Z-=B
M_6DMZ#=D_4&*B4(D
M RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M                 RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
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M%XZ[&>>6F_VWT>*86B;YQZWV-],ESA1'H \E@
M                               %G6J?V-W95?UY/GXMX5*D^>:UGM4_
MYA2^6@\X^A]_>WTQA6*+:4,
M
M                                            #MOV6?L8.F?[ZY8^
M>W+PT_4O/G6OR4/YN6/2UD_^75G_ ,K'^DS9-$9!E
M                          &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M                                          &5>TCX5?1 B_1KL7ZT
MEO0;LGZ@Q42A$@                                            &5
M>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M              &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
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MVWT>*5+1-\X];[&^F2YPHCT >2P
M                     "SK5/[&[LJOZ\GS\6\*E2?/-:SVJ?\ ,*7RT'G'
MT/O[V^F,*Q1;2A@
M
M                                    =M^RS]C!TS_?7+'SVY>&GZEY
M\ZU^2A_-RQZ6LG_RZL_^5C_29LFB,@R@
M                #*O:1\*OH@1?HUV+]:2WH-V3]08J)0B0
M                                #*O:1\*OH@1?HUV+]:2WH-V3]08J
M)0B0                                            #*O:1\*OH@1?
MHUV+]:2WH-V3]08J)0B0
M    #*O:1\*OH@1?HUV+]:2WH-V3]08J)0B0
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MC=V57]>3Y^+>%2I/GFM9[5/^84OEH/./H??WM],85BBVE#
M
M
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M6^5[6+Q!Y3#R2?J;_O>A?>H\+WL[?&%\DV<?-F&O]*WRO:Q>(/*8>23]3?\
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M-C(G25J_PFD:[9:TUEYC4EI;.SUGYF]6X)Z5F)9;TW5R1F,O_5,W'(KX
M                                   !E7M(^%7T0(OT:[%^M);T&[)^
MH,5$H1(                                            !E7M(^%7T
M0(OT:[%^M);T&[)^H,5$H1(
M       !GV-_W;=_>MQ_;60@[1_B,'\JWYMQ/V>_'8GY%W\;#=0I9<0
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M[V]%B4O-A;1SE8@SDC5$5:A35:BN<W"Y['*J9Z=6Q6W.7-OQ)DO15)^BY%_
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M?3)<X41Z /)8
M      !9UJG]C=V57]>3Y^+>%2I/GFM9[5/^84OEH/./H??WM],85BBVE#
M
M
M                    NSU2>P :'_YU-T?[=U@CS[;CSRU/VX/T>$?L1_PQ
MO/),_P#3=5_^>IYSV"HG[0
M
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MT*K<:$];=0;;45]-F'9T&,F)\K,LO<W39:81$9%;B1<3<U[.C8TW\,@UR
M                                 !E7M(^%7T0(OT:[%^M);T&[)^H,
M5$H1(                                            !E7M(^%7T0(
MOT:[%^M);T&[)^H,5$H1(
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MH\4@=$WSCUOL;Z9+G"B/0!Y+
M                   +.M4_L;NRJ_KR?/Q;PJ5)\\UK/:I_S"E\M!YQ]#[^
M]OIC"L46TH8
M
M                                %V>J3V #0_\ SJ;H_P!NZP1Y]MQY
MY:G[<'Z/"/V(_P"&-YY)G_INJ_\ SU/.>P5$_:
M
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M.+<16MR0YF%M1H6+"N[9F.S9J#/-$@
M    &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M                    &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
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MN8GS#C4MN_//9;W3/GVFX_1?O[U72;_."N'YN9@8NAG_ #C4OR#?G$,W1/\
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MBE:T3?./6^QOIDN<*(] 'DL
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MIU5G0ZKM)DHE2A1(%6D(*.<]\L]SU8QK<3GO143(WHL"OPMRKA;E*O1;C7X
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ME<W.PN5.AZHC*U2X]#J<Y2IF(R-'DW-:Y68L"XD1<W$B.Z+GM--"2(D
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M .=3='^W=8(\^VX\\M3]N#]'A'[$?\,;SR3/_3=5_P#GJ><]@J)^T
M
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M8BRT>$N+)$AN5JW8FM5S%VV.N2]CD7HC,A]((
M          ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                          ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
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M_AC>>29_Z;JO_P ]3SGL%1/V@
M
M          .J;81:B'=WXMR!IWGWJCF0Q>_1NVSN..<YZ6;=#I1*3CR**+UK
MQ+.XTZG*4I2E(6>*3^*47*S,XKX4:3=D6'GM]R[;3]5?\3\C?^()H:P:-:NS
M>B738*0Y>U4-9*>PX6MU;*,1T&)<C6YT:6R*KE<KG2V(OZ%F/SI
M                        #*O:1\*OH@1?HUV+]:2WH-V3]08J)0B0
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MQZWV-],ESA1'H \E@
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M]-U7_P">IYSV"HG[0
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M($7Z-=B_6DMZ#=D_4&*B4(D
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M$>@#R6
M 6=:I_8W=E5_7D^?BWA4J3YYK6>U3_F%+Y:#SCZ'W][?3&%8HMI0P
M    -\Y\U/9RU/R]L3N<[W[^):S;=3M.VW?>W:%M=S;?2=*O",.(M" CTGG
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M^BX><6J=T0K7S\JZ4CU=S8+TPOTJ'!A/>GKOAL:]OKX53%T17@+04D
M     "[/5)[ !H?_ )U-T?[=U@CS[;CSRU/VX/T>$?L1_P ,;SR3/_3=5_\
MGJ><]@J)^T
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MPJ^B!%^C78OUI+>@W9/U!BHE")
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MQNZC?Z(/GXQ>,BQGGEIO]M]'BD-HF^<>M]C?3)<X41Z /)8
M                                         !9UJG]C=V57]>3Y^+>%
M2I/GFM9[5/\ F%+Y:#SCZ'W][?3&%8HMI0P
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M)[DU4) C
M   "[/5)[ !H?_G4W1_MW6"//MN//+4_;@_1X1^Q'_#&\\DS_P!-U7_YZGG/
M8*B?M
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M5H+5@162<.-*R4&4@PY2!$F'-<Z#4)B)>YD-^=I3W/BNQ1'7N5Y3$.)ZQ
M  )K[.2V5;LUR:98M%,RIFF48:YC%*6IMU.S$7=WJJ5W:^H4J<&8U:_P;HS:
M4Q8E0DVIMI$1W:NQ?Y&B?),52'1] 314FXCL*1J1,2OZ9W!)M3]9T=J'>2-E
MG\]H                                 95[2/A5]$"+]&NQ?K26]!NR
M?J#%1*$2                                             95[2/A5
M]$"+]&NQ?K26]!NR?J#%1*$2
M         9]C?]VW?WK<?VUD(.T?XC!_*M^;<3]GOQV)^1=_&PW4*67$
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M1'H \E@
M %G6J?V-W95?UY/GXMX5*D^>:UGM4_YA2^6@\X^A]_>WTQA6*+:4,
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MA_\ G4W1_MW6"//MN//+4_;@_1X1^Q'_  QO/),_]-U7_P">IYSV"HG[0
M
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MKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M               RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
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MTW^V^CQ2*T3?./6^QOIDN<*(] 'DL
M                        LZU3^QN[*K^O)\_%O"I4GSS6L]JG_,*7RT'G
M'T/O[V^F,*Q1;2A@
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MY[;0?G43_$A>+"58
M       "[/5)[ !H?_G4W1_MW6"//MN//+4_;@_1X1^Q'_#&\\DS_P!-U7_Y
MZGG/8*B?M
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ML4=J7JUNJ8ROC9NVQ6=23R$B>>0
MRKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M                RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
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M[&[LJOZ\GS\6\*E2?/-:SVJ?\PI?+0><?0^_O;Z8PK%%M*&
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MB?M
M                                               '0]L>MG@]N*:@
M]669X%5O;,,K5[AZV99%1+OAEB4.F2^'K-2E*K0S8U35844IQ:[@G**%.1(A
MA9J#2EBO;.3#;H3=PB]$[I^Y;T/5./S8\FGY).!2Y"H:#]B*@D2KSS<%9FH+
MD=J:"N<L@Q[=J/&;AT_#G0X2X+VJ]QU!"Y'Y/
M            &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
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MRN;DR>Z+)96S=IZ=5X,Y5)A8DHUL1'-='6+E<RYN;?U1:@-@FTP
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M/V-W4;_1!\_&+Q)6,\\M-_MOH\4KNB;YQZWV-],ESA1'H \E@
M                                           %G6J?V-W95?UY/GXM
MX5*D^>:UGM4_YA2^6@\X^A]_>WTQA6*+:4,
M
M                                                        "[/5
M)[ !H?\ YU-T?[=U@CS[;CSRU/VX/T>$?L1_PQO/),_]-U7_ .>IYSV"HG[0
M
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MZXGO>]U[G*KE57.<N)SLY3ZQQ.@
M  RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M                  RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
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M;)^QNZC?Z(/GXQ>++8SSRTW^V^CQ2DZ)OG'K?8WTR7.%$>@#R6
M                                             6=:I_8W=E5_7D^?
MBWA4J3YYK6>U3_F%+Y:#SCZ'W][?3&%8HMI0P
M
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MIO7X\/CCRZ'D;/5(7X'KWW4/!";1+Q>O*S@[SF!K'5-Z_'A\<>70\C9ZI"_
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MG<RT+->N3=QEB/Q=&2S&8:<
M #*O:1\*OH@1?HUV+]:2WH-V3]08J)0B0
M                 #*O:1\*OH@1?HUV+]:2WH-V3]08J)0B0
M                                 #/L;_NV[^];C^VLA!VC_$8/Y5OS
M;B?L]^.Q/R+OXV&ZA2RX@                      !SO;9W;>7ILK,K8;Q
MQ:^G^V,Q-\HX]F+V=2L]?DK:*\.M&7(K!%CT&L?;;XKM(Y$J*54,<E:5-NTI
M6GJBZV6LE"M%+34>)..E5EWHS"UB/OO2^_*Y"C6KM?%LW,2L"'(MFDFF*^]7
MJR["N'J5*9O^F'9<\1W'/XZKF[ BU<S&6X7B=R;QRJ\U./P,SNSN2'_3#LN>
M([CG\=5S=@0YF,MPO$[DWCCFIQ^!F=V=R1UI;-C5Q<6NW11A'5==6/6V*YO+
M;>_':]BLI5]-LXEI:F4;VL.)=-)60C6:SUL_B+68R)#F;D+4LM2B9E$J$5/K
M6O4UE'JLW3H<?5#)7!GW8<6*$QZYJ*[<N=ANO7:-E4&IQ*S29.I1)?4KII'K
M@OQ8;HCV-SE:V_$UJ.W/1'/#Z+6U(9!M_%>EG1Y84BJC%ZA+INZ],DQ3 QB2
M%Q,\;2%C,L;VTO6A^!:%=7==,B_41,7USZS8U2AZ<2:AKOH;2$!\Q4*K&;G2
M+6,8Y>ATQ'J]WND8V[VGN*/HES\PR6IM*@.R5![G/3JM*5F!GKHKWXO=,0F#
MH_\ 0R>SOQ'B&T66I7&LAJ-S>[@6#K(-USN0\AV_:D?<KV.;]W(2Q;:L.XH9
MN2V&KZJZ;-S))/)-6A>4G<H[Y&[>-J=OJY,S419"921E&N=@1&,5RMOR.>L1
MKUQ.3;:F%O.PDI2]#ZARDM#2?EUJ$YASWN>]K;UW2,8QS6W)T*NQ*G5%,NWK
MV'N"="V(+<UL:(CW=C"!L^_K4@;^QNYO2X[E:6NK-NZHV?D''UT7&[=S<9((
M78C&MW:#N4=TWY9JY8G9\D62<6BQMKIRL3,2DU;#,OB,>YC\")BNW;'M;A8Y
M,-]V%K=I46_$52V=D)*C2L.L4=72K8+V->S&Y;KUS'L<[$]KD?AOO<[;16W8
M<O7KLS-1UQ:MM ^EC4+>+EH^O3(F*8=>]W[% C1I(WO;KE[9]XR"+1.M2,Z.
M+FM^46JB3UB)EJI$I0I2T&L[02+*;6JC)0D5L*#$=@OYS'7/8G:N;^@V?0)Y
M]3HM.GHMSHDQ":Y]W5IFON_6135^V3]C=U&_T0?/QB\25C//+3?[;Z/%*YHF
M^<>M]C?3)<X41Z /)8
M            !9UJG]C=V57]>3Y^+>%2I/GFM9[5/^84OEH/./H??WM],85B
MBVE#
M
M                          [;]EG[&#IG^^N6/GMR\-/U+SYUK\E#^;EC
MTM9/_EU9_P#*Q_I,V31&090
M       !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                       !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                                       !E7M(^%7T0(OT:[%^M);T
M&[)^H,5$H1(                                            !E7M(
M^%7T0(OT:[%^M);T&[)^H,5$H1(
M           !GV-_W;=_>MQ_;60@[1_B,'\JWYMQ/V>_'8GY%W\;#=0I9<0
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M;)^QNZC?Z(/GXQ>.NQGGEIO]M]'BF%HF^<>M]C?3)<X41Z /)8
M                                            !9UJG]C=V57]>3Y^
M+>%2I/GFM9[5/^84OEH/./H??WM],85BBVE#
M
M                                                          [;
M]EG[&#IG^^N6/GMR\-/U+SYUK\E#^;ECTM9/_EU9_P#*Q_I,V31&090
M                                       !E7M(^%7T0(OT:[%^M);T
M&[)^H,5$H1(                                            !E7M(
M^%7T0(OT:[%^M);T&[)^H,5$H1(
M           !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                           !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
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MK?8WTR7.%$>@#R6
M          6=:I_8W=E5_7D^?BWA4J3YYK6>U3_F%+Y:#SCZ'W][?3&%8HMI
M0P
M
M                       .V_99^Q@Z9_OKECY[<O#3]2\^=:_)0_FY8]+6
M3_Y=6?\ RL?Z3-DT1D&4
M     95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
M                     95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
M                                     95[2/A5]$"+]&NQ?K26]!NR
M?J#%1*$2                                             95[2/A5
M]$"+]&NQ?K26]!NR?J#%1*$2
M         9]C?]VW?WK<?VUD(.T?XC!_*M^;<3]GOQV)^1=_&PW4*67$
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M^,7BT6,\\M-_MOH\4H>B;YQZWV-],ESA1'H \E@
M                                 %G6J?V-W95?UY/GXMX5*D^>:UGM
M4_YA2^6@\X^A]_>WTQA6*+:4,
M
M                                              #MOV6?L8.F?[ZY
M8^>W+PT_4O/G6OR4/YN6/2UD_P#EU9_\K'^DS9-$9!E
M                            &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M                                            &5>TCX5?1 B_1KL7
MZTEO0;LGZ@Q42A$@
M&5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M                &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
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M4M1,B4+^B3]F7I/1T07YK+QQBRQ,09JPM<&.E)&8Q]!0UEL\E6Q>]^VWC=]
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MC?3)<X41Z /)8
M       !9UJG]C=V57]>3Y^+>%2I/GFM9[5/^84OEH/./H??WM],85BBVE#
M
M
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M6DMZ#=D_4&*B4(D
MRKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M                RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
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M*4/1-\X];[&^F2YPHCT >2P
M                 "SK5/[&[LJOZ\GS\6\*E2?/-:SVJ?\ ,*7RT'G'T/O[
MV^F,*Q1;2A@
M
M                                79ZI/8 -#_\ .INC_;NL$>?;<>>6
MI^W!^CPC]B/^&-YY)G_INJ__ #U/.>P5$_:
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M>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M              &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
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M7;)^QNZC?Z(/GXQ>+18SSRTW^V^CQ2AZ)OG'K?8WTR7.%$>@#R6
M                                              6=:I_8W=E5_7D^
M?BWA4J3YYK6>U3_F%+Y:#SCZ'W][?3&%8HMI0P
M
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M5]$"+]&NQ?K26]!NR?J#%1*$2
M          95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
M                          95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
M                                          95[2/A5]$"+]&NQ?K2
M6]!NR?J#%1*$2                                             9]
MC?\ =MW]ZW']M9"#M'^(P?RK?FW$_9[\=B?D7?QL-U"EEQ
M         #C2]$JZ5-;.9]6>CW+>D; ^7\H/L28Z=R:5W8SL=[=S:T+VALE4
MN>W:O:I,5VY)!-=JU=)HKIG(<J=-\AR&,6NT+!U&DRM-JDM4YR%+MFGX<#WX
M,;%9A7V7K9.>:JM]3:O-U*DS5+DXLPZ48JXV,Q8'M?>WV/KY?T%.>HF-]$H:
MLL6R^%=0V)-8>2\7SC^&E)>TI+3U;L2T>/[>D4):'<'>6WCYD[3,A(MD%2T(
MX*4U4^ Y3DX2BT2+K!TV8;-R4U*R\PB.1%2,Y<CDN=NGJFU[$JT\VW]3EGR<
M]*S4Q+1%:KF.@L;?A7$F<UB.W7LC-,67AZ*"PICBR<1XNQ_K+M+'6.;:BK0L
MJV&FG*T'S6"MN$:D9146@\EL:N'3E)%JFF2AUUU534+Z\YJ^J.J8A:'TW'C3
M,S&E7QX[E>]VJ'YSG;:Y'M0[9:+HBRD"#+2\&:AR\NU&,34[,C6Y&IE8Y>V.
MW+90W!JPNK0'@.>UPM[U::HW_II>F<AD2V8^S[P)5KFC([.RJ3%N1<4R0CN'
M';>TZM^+:I<<U,BN??.J90^I;1PZ;#K,ZRD8-;VZ7I>!SGL_!,QX7.557/Q7
MYRYQMJS;ZG$HLFZL8TJ+M,TS&U&/_#/P7M:UK6YF"ZYNY+$Q#$^     5B[9
M/V-W4;_1!\_&+Q:+&>>6F_VWT>*4/1-\X];[&^F2YPHCT >2P
M                                           "SK5/[&[LJOZ\GS\6
M\*E2?/-:SVJ?\PI?+0><?0^_O;Z8PK%%M*&
M
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MK51S7-5O0N/L' QP         #*O:1\*OH@1?HUV+]:2WH-V3]08J)0B0
M                                         #*O:1\*OH@1?HUV+]:2
MWH-V3]08J)0B0                                            #*O
M:1\*OH@1?HUV+]:2WH-V3]08J)0B0
M             #*O:1\*OH@1?HUV+]:2WH-V3]08J)0B0
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M>M]C?3)<X41Z /)8
M          !9UJG]C=V57]>3Y^+>%2I/GFM9[5/^84OEH/./H??WM],85BBV
ME#
M
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MVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M              RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
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M1+,REFJY#@T]%;(ST)(S&.5SM+7$YCV8E<KG-;A1R.=G87X<N&]:OA;B@
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M[/1W/1#8^AI1*57*O4):JRJ3D&#*/BL:KGMN>V+#;BS'([<N7ULXJ3%T-<
M        'J0#9%Y.PK1RGQK=U+QS9PG4QBT417>HHJDJ8E:5+O$,:G#2M*TX
M/4'1$5S8;W)ML1?X3N@M:Z-!:Y,USFM=VQ:%MAM/.'--.J>W,?8.LIO8=GO<
M,6G=+J%:RMP3*:L[(W5?<>]D*N[DEGK@IU&<1&$J0JM$J<EX:$*8QZUJEC*E
M.U6D1)B?C+,1FQWLOPM;FM9"5K<QJ-W3G%]T2J-3:'7X,I2I5).6=*PGJQKG
MNSW18S5=B>YSMRB<^[-*J1<C7@
M          !=GJD]@ T/_P ZFZ/]NZP1Y]MQYY:G[<'Z/"/V(_X8WGDF?^FZ
MK_\ /4\Y[!43]H                                +SM@SD=:W]3&1<
M;JG/W/R+BY>22)QO 2LY8\RP=LC52K3UYNX\U<'JTX*TW?\ NBPV:BX)V)"Y
MT9B^^W._AQ'@/_B$6894M"NS=IX;$U19FK,A.6[.U//P8D-^=SO-H,L=:0NY
M^.8         !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                            !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                                            !E7M(^%7T0(OT:[%
M^M);T&[)^H,5$H1(
M!E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
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MR?L;NHW^B#Y^,7BT6,\\M-_MOH\4H>B;YQZWV-],ESA1'H \E@
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MS7>B;$K<2TCUK,NV7:D-&RR0GJ^$Z CG94>K6*KL:NQXF,<BY+KL!4^+F:Y
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M]\G#CH>_S'%_.G_-PQHP^>J7_,H/SL<H_%_-5
M                      %V>J3V #0__.INC_;NL$>?;<>>6I^W!^CPC]B/
M^&-YY)G_ *;JO_SU/.>P5$_:                                "SG8
M[R"[+:#X3;(UK1.6C<J1[K@^U5!/$M[RI:&I_#3E,8WK_P"O@$O0ENJLJON_
MFWGE+R:LNR/Y'"WD5^ZE(M)BL]TZL2$&_M(KSMG&P3\)          #*O:1\
M*OH@1?HUV+]:2WH-V3]08J)0B0
M          #*O:1\*OH@1?HUV+]:2WH-V3]08J)0B0
M                          #*O:1\*OH@1?HUV+]:2WH-V3]08J)0B0
M                                          #*O:1\*OH@1?HUV+]:
M2WH-V3]08J)0B0                                            #/
ML;_NV[^];C^VLA!VC_$8/Y5OS;B?L]^.Q/R+OXV&ZA2RX@
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MY^+>%2I/GFM9[5/^84OEH/./H??WM],85BBVE#
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MV:N4Z=%2?D:C:.#'I\W"GH#92&W'!B,BLQ-B1E<F)CG)B1')DW65"GD7@UF
M                                            79ZI/8 -#_\ .INC
M_;NL$>?;<>>6I^W!^CPC]B/^&-YY)G_INJ__ #U/.>P5$_:
M                   "VK8HVPM/:[+6E2)'.G9>/LC7*L>A:UHB1Y!TLXIS
M5IZA>%6ZTBTX?M\8)F@,5U4A.3_VVO=\54_[CQQY.FJLI_D?ZQ)N=A=7*C3)
M1&]4YDSJV[M9-SOU3LV%_/P^          ,J]I'PJ^B!%^C78OUI+>@W9/U!
MBHE")                                             ,J]I'PJ^B!
M%^C78OUI+>@W9/U!BHE")
M      ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                      ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
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M)\\UK/:I_P PI?+0><?0^_O;Z8PK%%M*&
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MVG6U-3AS;)=9.3E83(<&#>BX&MRKN41,3GN=M)N&L3H2#(L940
M
M         "[/5)[ !H?_ )U-T?[=U@CS[;CSRU/VX/T>$?L1_P ,;SR3/_3=
M5_\ GJ><]@J)^T                                '33L!<,NV4)FW/
MLBV720G',1C"UU3H5(1RVBC4N&ZET%S5^RH\M7MU*N[3@H=B<M3;Q=TMMLO+
MJNJ)I=J]K&_XN_[3\KO^(G;>#'G;!Z'4M$:Z)(MC5:;1KLYBQ6ZFDT<WH5P)
M-/SN<].J.C<6L_,@          RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M                                          RKVD?"KZ($7Z-=B_6D
MMZ#=D_4&*B4(D                                             RK
MVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M              RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
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M"B/0!Y+
M  +.M4_L;NRJ_KR?/Q;PJ5)\\UK/:I_S"E\M!YQ]#[^]OIC"L46TH8
M
M
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M:1\*OH@1?HUV+]:2WH-V3]08J)0B0
M             #*O:1\*OH@1?HUV+]:2WH-V3]08J)0B0
M                             #*O:1\*OH@1?HUV+]:2WH-V3]08J)0B
M0                                            #*O:1\*OH@1?HUV
M+]:2WH-V3]08J)0B0
M #/L;_NV[^];C^VLA!VC_$8/Y5OS;B?L]^.Q/R+OXV&ZA2RX@
M                         5B[9/V-W4;_ $0?/QB\6BQGGEIO]M]'BE#T
M3?./6^QOIDN<*(] 'DL
M              LZU3^QN[*K^O)\_%O"I4GSS6L]JG_,*7RT'G'T/O[V^F,*
MQ1;2A@
M
M                           79ZI/8 -#_P#.INC_ &[K!'GVW'GEJ?MP
M?H\(_8C_ (8WGDF?^FZK_P#/4\Y[!43]H
M  _VE*FK0I:5,8U:4*6E*UK6M:\%*4I3[?J@<5<U&XEVCJNV0&SQ=XFC&NIW
M,\$HTR)<L28F-K7ED3$=6=;DD0AU;C?,E.#D]P/FNZ5 JA>,;-%J^H15:IA<
MJ!2EA-U;--SW)YDU><G5^Z=SO8GY%>31\DG M?,QM"JP]02-9REQKZK-P7(Y
MD],PU=AE83TVY: _+%<QUT2,U$Q.:S"7XBS'YW            95[2/A5]$"
M+]&NQ?K26]!NR?J#%1*$2
M      95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
M                      95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
M                                      95[2/A5]$"+]&NQ?K26]!N
MR?J#%1*$2                                             9]C?\
M=MW]ZW']M9"#M'^(P?RK?FW$_9[\=B?D7?QL-U"EEQ
M                   K%VR?L;NHW^B#Y^,7BT6,\\M-_MOH\4H>B;YQZWV-
M],ESA1'H \E@
M      %G6J?V-W95?UY/GXMX5*D^>:UGM4_YA2^6@\X^A]_>WTQA6*+:4,
M
M
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M^ LQ^=P             95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
M                                    95[2/A5]$"+]&NQ?K26]!NR?
MJ#%1*$2                                             95[2/A5]
M$"+]&NQ?K26]!NR?J#%1*$2
M        95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
M                        9]C?]VW?WK<?VUD(.T?XC!_*M^;<3]GOQV)^
M1=_&PW4*67$                                    "L7;)^QNZC?Z(
M/GXQ>+18SSRTW^V^CQ2AZ)OG'K?8WTR7.%$>@#R6
M                                   6=:I_8W=E5_7D^?BWA4J3YYK6
M>U3_ )A2^6@\X^A]_>WTQA6*+:4,
M
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M^B!%^C78OUI+>@W9/U!BHE")
M         ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                         ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                                         ,J]I'PJ^B!%^C78OUI+
M>@W9/U!BHE")                                             ,^Q
MO^[;O[UN/[:R$':/\1@_E6_-N)^SWX[$_(N_C8;J%++B
M                    !6+MD_8W=1O]$'S\8O%HL9YY:;_;?1XI0]$WSCUO
ML;Z9+G"B/0!Y+
M        +.M4_L;NRJ_KR?/Q;PJ5)\\UK/:I_P PI?+0><?0^_O;Z8PK%%M*
M&
M
M                      !VW[+/V,'3/]]<L?/;EX:?J7GSK7Y*'\W+'I:R
M?_+JS_Y6/])FR:(R#*
M   ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                   ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                                   ,J]I'PJ^B!%^C78OUI+>@W9/U
M!BHE")                                             ,J]I'PJ^B
M!%^C78OUI+>@W9/U!BHE")
M       ,^QO^[;O[UN/[:R$':/\ $8/Y5OS;B?L]^.Q/R+OXV$2]J!_@!M+^
M5Z!_W+R -)V__F:7_.6?-1B(T4/Y@D_SR'\Q,%$HU.:'
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M$](E>J5B]F YI-M>&ODLKR V25K?O@X7)CG>ZB>D2O5*Q>S <TFVO#7R65Y
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M)Z1*]4K%[,!S2;:\-?)97D!LDK6_?!PN3'.]U$](E>J5B]F YI-M>&ODLKR
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MOY7H'_<O( ^V_P#YFE_SEGS48G]%#^8)/\\A_,3!1*-3FAP
M                     "7F&_WJ&L_^KE\Y<J+'3?.[:?VY'Z0XN%%\Z=M/
M[N^DO(ABN%/
M      )&9 =\JTT:<4>'AY!=V?6F[_W=]WC)]ZG_ +'O#_[PEYQ^*A4-.E%G
M$^-+N_S+)4'X[,V;3TN-4&_&EE_[B.8B"M@
M
M                                                        3KN9
MWRK9V8\1]6O(=1[UI6G_ '.,M:^7W!\=X?\ WA:X[L5BY-.IGG-\'&7_ #+[
M-/Q:'5-3TNI.3P4=W^9!050H0
M         !+S_$&_K@?\FQ8OZ&_WC_I2X?T _OC_ $1$,5TIX
M                                 !+S_$&_K@?\FQ8OZ&_WC_I2X?T
M_OC_ $1$,5TIX                                            !+S
M_$&_K@?\FQ8OZ&_WC_I2X?T _OC_ $1$,5TIX
M                     !+S_$&_K@?\FQ8OZ&_WC_I2X?T _OC_ $1$,5TI
MX                                            !8WLO\ _#[=_P#)
M!/\ ^^MA"ZV!_G:8_-7_ #L$V1H7_P _SGYG$^?ER7^U _P VE_*] _[EY %
MCM__ #-+_G+/FHQ<-%#^8)/\\A_,3!1*-3FAP
M           "7F&_WJ&L_P#JY?.7*BQTWSNVG]N1^D.+A1?.G;3^[OI+R(8K
MA3P                                                      #<M
MQ.^4Z?L3(</!5CE3.3>E.'UVXM;6"7=*_P#JWW*G_P!R)".[%1J:B]#,32?$
MDG?]Q-S+\5GJ0WTN;GT\%(._[C30CR$
M
M                                                     F*X=\IT
M!,4*UX*L=6=6]"T_;4(MB5\[I7_-Z]RI_P#<"R.=BL>U.>VHX?DSG?YES<_%
MH?PV^EU:[Y(YW_<0Z%;*8
M      2\_P 0;^N!_P FQ8OZ&_WC_I2X?T _OC_1$0Q72G@
M                               $O/\ $&_K@?\ )L6+^AO]X_Z4N']
M/[X_T1$,5TIX                                            !+S_
M !!OZX'_ ";%B_H;_>/^E+A_0#^^/]$1#%=*>
M                      2\_P 0;^N!_P FQ8OZ&_WC_I2X?T _OC_1$0Q7
M2G@                                            %C>R__P /MW_R
M03_^^MA"ZV!_G:8_-7_.P39&A?\ S_.?F<3Y^7)?[4#_   VE_*] _[EY %C
MM_\ S-+_ )RSYJ,7#10_F"3_ #R'\Q,%$HU.:'
M             )>8;_>H:S_ZN7SERHL=-\[MI_;D?I#BX47SIVT_N[Z2\B&*
MX4\                                                       V#
M)/*'Q193'AK^Q\AY/=[O#P5IRVV\1(</!_DKR#_^T941U].E6]3&F'=LR6XI
M(Q7WTF1A=3,33O?AR:?Y&OABD<
M
M                                               !*!N[W]%<JQX?
M[VU0VZ[W>#[57N)[H1X>#_[ _P#[!.-??9=[.IJ#%[:6B?86EK[[%1H:\ZJ0
MU]^4B\4B^(,JP                                            !+S
M_$&_K@?\FQ8OZ&_WC_I2X?T _OC_ $1$,5TIX
M                     !+S_$&_K@?\FQ8OZ&_WC_I2X?T _OC_ $1$,5TI
MX                                            !+S_$&_K@?\FQ8O
MZ&_WC_I2X?T _OC_ $1$,5TIX
M         !+S_$&_K@?\FQ8OZ&_WC_I2X?T _OC_ $1$,5TIX
M                                 !8WLO\ _#[=_P#)!/\ ^^MA"ZV!
M_G:8_-7_ #L$V1H7_P _SGYG$^?ER7^U _P VE_*] _[EY %CM__ #-+_G+/
MFHQ<-%#^8)/\\A_,3!1*-3FAP                                  "
M7F&_WJ&L_P#JY?.7*BQTWSNVG]N1^D.+A1?.G;3^[OI+R(8KA3P
M                                             #VG#S?MB(8_:Y+.
MW$[W?\G+8^UT>'=_^P.'_P!T<W.18$-M^Y>]?T*V%Q3(<^^4@P^IB1%]]L'B
MGBC@8X
M
M                           &^HUW0^EV]&/#P4;9\QB[W>#[7+<>9=1X
M>#_[ X?_ '1+0W7T":9TIR7=[\&9XI8(;[[+3D/J:A+.[:6FOL-"B)*^
M                                         2\_Q!OZX'_)L6+^AO\
M>/\ I2X?T _OC_1$0Q72G@
M      $O/\0;^N!_R;%B_H;_ 'C_ *4N'] /[X_T1$,5TIX
M                               !+S_$&_K@?\FQ8OZ&_P!X_P"E+A_0
M#^^/]$1#%=*>                                             2\_
MQ!OZX'_)L6+^AO\ >/\ I2X?T _OC_1$0Q72G@
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MD=LS^]?L/^7JU_F]RB+UH??SQ-_FK_GH!JO1>\[4C^?0OH\R<SHW,><P
M                                                  ">.N_[>C+^
M85IV_P!5Y"J68VJ__6DW_C"+Q;?^B']1T_ZX@<+64<
M
M
M   #L6P[^]#TS?R,X9^;&+&D);ST5S\M,_2$/4\#SG69_-9/Z(>D)\B
M                                        #*O:1\*OH@1?HUV+]:2W
MH-V3]08J)0B0                                            #*O:
M1\*OH@1?HUV+]:2WH-V3]08J)0B0
M            #*O:1\*OH@1?HUV+]:2WH-V3]08J)0B0
M                            #*O:1\*OH@1?HUV+]:2WH-V3]08J)0B0
M                                            #/L;_NV[^];C^VLA
M!VC_ !&#^5;\VXG[/?CL3\B[^-ANH4LN(
M         %2.V9_>OV'_ "]6O\WN41>M#[^>)O\ -7_/0#5>B]YVI'\^A?1Y
MDYG1N8\Y@
M   $\==_V]&7\PK3M_JO(52S&U7_ .M)O_&$7BV_]$/ZCI_UQ X6LHX
M
M
M                '8MAW]Z'IF_D9PS\V,6-(2WGHKGY:9^D(>IX'G.LS^:R
M?T0](3Y$                                             &5>TCX5
M?1 B_1KL7ZTEO0;LGZ@Q42A$@
M         &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M                         &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M                                         &5>TCX5?1 B_1KL7ZTE
MO0;LGZ@Q42A$@                                            &?8
MW_=MW]ZW']M9"#M'^(P?RK?FW$_9[\=B?D7?QL-U"EEQ
M                     J1VS/[U^P_Y>K7^;W*(O6A]_/$W^:O^>@&J]%[S
MM2/Y]"^CS)S.C<QYS
M            )XZ[_MZ,OYA6G;_5>0JEF-JO_P!:3?\ C"+Q;?\ HA_4=/\
MKB!PM91P
M
M                             .Q;#O[T/3-_(SAGYL8L:0EO/17/RTS]
M(0]3P/.=9G\UD_HAZ0GR(
M      ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                      ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                                      ,J]I'PJ^B!%^C78OUI+>@W
M9/U!BHE")                                             ,J]I'P
MJ^B!%^C78OUI+>@W9/U!BHE")
M          ,^QO\ NV[^];C^VLA!VC_$8/Y5OS;B?L]^.Q/R+OXV&ZA2RX@
M                                   5([9G]Z_8?\O5K_-[E$7K0^_G
MB;_-7_/0#5>B]YVI'\^A?1YDYG1N8\Y@
M                          $\==_V]&7\PK3M_JO(52S&U7_ZTF_\81>+
M;_T0_J.G_7$#A:RC@
M
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M6ALK3@].W7DQY0%/5:7X!_WH>&?IXM]/QQ4\UH;*TX/3MUY,>4!3U6E^ ?\
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MC^Y=E][;/,5K+ 6UL-,ZDM=9F<H,5VY='@N;#?\ DXS<4&)N>@>XV<.XIP
M  !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                  !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                                  !E7M(^%7T0(OT:[%^M);T&[)^H
M,5$H1(                                            !GV-_W;=_>
MMQ_;60@[1_B,'\JWYMQ/V>_'8GY%W\;#=0I9<0
M              *D=LS^]?L/^7JU_F]RB+UH??SQ-_FK_GH!JO1>\[4C^?0O
MH\R<SHW,><P
M     ">.N_[>C+^85IV_U7D*I9C:K_\ 6DW_ (PB\6W_ *(?U'3_ *X@<+64
M<
M
M                      "[_:.^Q7:+?]-TZ?\ #E?0\VV@_G>K?G4Q\Y$/
MUY\@=YZX7_2;?I-'.=@1)^HX
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MPJ^B!%^C78OUI+>@W9/U!BHE")
M           ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                           ,^QO^[;O[UN/[:R$':/\ $8/Y5OS;B?L]
M^.Q/R+OXV&ZA2RX@                                    5([9G]Z_
M8?\ +U:_S>Y1%ZT/OYXF_P U?\] -5Z+WG:D?SZ%]'F3F=&YCSF
M                                              3QUW_;T9?S"M.W
M^J\A5+,;5?\ ZTF_\81>+;_T0_J.G_7$#A:RC@  ![5K3*%NW-;L^ZB8Z?:P
M<Y$R[B"EVR3R)FFT:_;O%HF3:+IF(YCW*:)D5DSE,4Z:QBFH:E1C1H:Q8,:"
MV(L-T1KFXTS7)B3#B:O5)MM.R5C-EYF7CN@MF&P7L>K'MQ,>U%148]JY'-=N
M53I%Y.T?TW886TR8YU#8$L&T[1B6CZ EI1>T()A!H2UCY(C67<B2E"QJ1:.5
M6\R:WTD:'X>+[N+[IB\)J&UM9"L5%*S-4FJ33YAZH]&XWJZZ)!5UZ)?U3<:K
M[E#=6B%9ZCK9RGU^A2,*5A-<Q[W06-9C@S+6X'.P[:H_2T3+DQNN**H:(D;@
MEXJ!AFJKZ7FY)E$1;%&G"N\D9)TDR8M4J5X*554<K)D+3_*8;+B1&0H<2+$=
MAAPT5SG=)J954TI!A1(\6'+P6K%BQG-8QO5.<N%J?K*=)&J'0-BBW=%<VPL>
MP+6;Y3Q;8T#<:U\1<&T0N2ZG5E,V[B]5I"111HX?\OBD9Y:B)JUI5Q5OND^Q
MD*745%M1/Q;10W3,T]TC/17LTMRYC$BKYE<FY3 [ E_2Q'H:TMAZ5+V.C0Y*
M1A-J=-@,B:<QC4BQ'0418RJ[#>N-F-UW58<F1#FI&Y#SL7RJX,PQIUV:2>2L
MA8NL6X,P7G9U'D--W-;<7)3[2Y,IN#4M-!DO(-SJ-UXBV7S5Z9"M> JL*Y-N
M<)JD&K4J50JUL=12LY%@R$O$N5K'N:QS(.[ONRY[T5N+J7(;O6BT>S^ARM0G
MZ; F*M.0;V/B0V*]L297S+"KFWMTF$Y'X;]TQ2AH;2-(  6![,G']D9*U0QU
ML9!M2 O.W5+(N]ZI"7)&-)>,.\:(,S-7)F;U,Y*K)F.:I#<'"7>]:*A;*:F9
M.B.C2L=TO&TR$F)CE1;G8K\J%[T.9&2J-I8<M/2L.<E])C.P16->W$U$N6Y<
MV]#']HY9%GX[U9W[:MB6S"6A;3"(L==E V]'-HJ):JO;.A7KM1!DT2(1(ZCI
M=90]:4IO'4J:OJF'=9*9F9RA2L>9C.F(SG1,3WKB<N&(YK<Y?6,?1"DI2GVI
MGI61EV2LM#9!PLAM1C&WP6*ZYJ9,JY7$'!:2F$J]#EJVW>VJW#-K7?!1=RVW
M,7%(MY6"FF2$C%R*"5M3;DB+QBY(9-PF5PW1/2AJ5I0R9:_Q17[21XTM0ZA,
M2\1T"-#8VY[5N<W/:F1Q9[&2LO.VGI$K-0&S$"-$<U['M1S'-TMZYS5R.SF^
MN21VKN,\>XLSY8T%C:RK:L6%?8?AYAY%6M$,H5@YE%KTOEFK(+MF*)"*.S-&
M#-.JE:;U2-2%X> M!$6&G9N>I<W%G)A\U$;,.:CGN<YV'2X;KLO.O<Y2P:*-
M-D*979&!3Y.'(P8DHQZLAL:QJOTZ,V]4:FZPM:E_K(5AB[FN          #<
MFG?$J>=LTV!B1:=/;1+WEEXP\ZG&EESQM$8M_(\=2-,^;4=UJ9EN;M5T^#C-
M[A];P&BJK/ZV4Z:GDAZ<LLW%@ONQ9R-V[EP[KI$M0*4E;K$C2EC:G2<>Y,>'
M'AN8Y=SB3%M=-#;FM;2HAI&R3;>/V][K7Z2X+(9WA657M\EMF:G=SUP0M8XK
M,DT^XXI:095.-XTO#RK<W"[F\;!L[6UKLG&FG2^I=+B+#PX\=]S&+BON9U>U
MA)6V%F6V5J,O(-G%GDF(*1L:P]+PWO>S#=C?U%]^+G[DA^+&50 "7.BG)N"<
M3Y>D;FU#6:TOFQ7%CS,.UAGMFP=\HI7&[EH!RP?TAI^O$)G(Q92A*+T^R$HX
M,2GJ*'%<M%)U.>D&P:5,++3*1$5SDBK#S&H^],3,[;<F0M=C:E1*75(DS7Y-
M)Z3= >QK%@LC>:N?"5JX'Y-IKVXMUE]<E)AS4?HDM?4/J)O>_<114UBN^'%N
MGQ5;BV(K-FT+;28IN"2Q6]MOC<EMNBICH\-&O#13=]?]H0M0I%I(U*I,M*SS
MH<[+H_3WZHB-QW[G/3.?^L62D6@L9+5^OSD]26QJ9.+#U+#U)!>D+#BQW0G9
ML/%[#;*S\ARD#.7_ 'S-6LR)&VQ+WC<TI;D<FR0C4V$#(33UY$,B1[7[&P(E
M'JMR413]8E1/<)ZVA1<95D6%*R\.,[%&APV->M^*][41KEQ=%>[HN>:ZJ$6!
M&GYZ-*MTN6C1HKX286MN8Y[G,3"F:VY+FW)FMW)B0S#%          -R:;X:
M)N+41@6WY^.9S$'.9HQ;#S43(MTW4?*1,I?$$QD8Y\U6+4KEHNS76253-2I3
MD4K0Q> PBJO$?"I%4BP7+"BPY>,YJIFJCDA/<U6NZ;7$K9Z#"F*]1)>/#2+
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M)>KNDUK6E4M])RLA:NK2LE+,E9:'I%S&-1C&WRT%SKD3(E[G*Y?7<0R%F*B
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MN%_TFWZ31SG8$2?J.
M                                             %BVA+6W-Z>KF:6+
M>\@YD\-7"^33=MW"AUE+)D')Z$[OP^_6M4F-3U+RUO3@3.0G'$*54F\:8H]6
M?(Q&P8KL<K$7.]A[)O\ FT\K^20\CS3M%*D1K16>E62=OJ7#<L)[41&U"&Q+
M]2Q^J?O>+NV+F.O8MR=-K%\SDV3.2CW*+QA(-6[YB\;'*JW=,W:1%VSE!0M:
MT51.BHF8IJ>I4IBF&PFN:YK7-?B:Y,2?Y'Y 3,M,24S,2DU!=+S4J]\.*Q[<
M+V/8JL>Q6]"YJM5'-Z%6GVCB8QE7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                                         !E7M(^%7T0(OT:[%^M)
M;T&[)^H,5$H1(                                            !E7
MM(^%7T0(OT:[%^M);T&[)^H,5$H1(
M             !GV-_W;=_>MQ_;60@[1_B,'\JWYMQ/V>_'8GY%W\;#=0I9<
M0                                    *D=LS^]?L/^7JU_F]RB+UH?
M?SQ-_FK_ )Z :KT7O.U(_GT+Z/,G,Z-S'G,
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M?]-TZ?\ #E?0\VV@_G>K?G4Q\Y$/UY\@=YZX7_2;?I-'.=@1)^HX
M
M                     !?_ +*;4LXNJVI+3W=C^BTQ9C,TQ8*[A2G'/+4X
MQ--_!DJ=6M5#,'2B:B5"EIP-WE2^N*B+C9R?6(QTC%=G0TO9[GHD_0?F/Y-3
M0CAT6K2>BC1)?2Y&NQ$EZHQC<UDY<Y8<SD;DU2QKF/5SG8HK&KT9<B+.>!S*
MO:1\*OH@1?HUV+]:2WH-V3]08J)0B0
M              #*O:1\*OH@1?HUV+]:2WH-V3]08J)0B0
M                              #*O:1\*OH@1?HUV+]:2WH-V3]08J)0
MB0                                            #/L;_NV[^];C^V
MLA!VC_$8/Y5OS;B?L]^.Q/R+OXV&ZA2RX@
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MY#$,8BA#$.F:I5$S4J4Q3%KP&*8M>"I34K3@K2OV@5,5[FID"I<MR[9_0[@
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M.^Q7:+?]-TZ?\.5]#S;:#^=ZM^=3'SD0_7GR!WGKA?\ 2;?I-'.=@1)^HX
M
M                           !N#3YE1]A7,V/,E,EE$D[;N-BO+)D.J4K
MNWWA^0S[-4J)J5524B7+RF[ZM-[@-N\)2CNDIATI-09AO_MN;?[7/3M2BZ)]
MC9;1!L#:BR4Q#1SJO*14@N<UN9,L;ILM$3%N7,CL8[%U-Z<\[)6CIL^:MGK1
M8CAH\;HNVJZ=>%-=NY3*LBLG7^$ADSE-2O\ D,-J)<Y&N3:>?@A'@19:-&EH
M\-8,>7<K'L=MH]CL+FN]DCDPJ9K[2/A5]$")]&NQ?K3/]!NR?J#%1*$2
M                                         95[2/A5]$"+]&NQ?K26
M]!NR?J#%1*$2                                             95[
M2/A5]$"+]&NQ?K26]!NR?J#%1*$2
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MS2L>+2UQ;O3&[KW.3UR<H-O=8[/S5!UJU5JC3O--/P8=.9@W&DOOP[K=MO\
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M>K?G4Q\Y$/UY\@=YZX7_ $FWZ31SG8$2?J.
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M Z/1KL7ZTUSZ#=D_4&*B4(D
M        RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M                        RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
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MO1E_,*T[?ZKR%4LQM5_^M)O_ !A%XMO_ $0_J.G_ %Q X6LHX
M
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M.:C6M3J3!!(&$
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M7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M              !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
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MW["ZV0LY7J14XTS59A(TO$@.8B)&?$SUB0G(ZYR9,UCLNW[YU7C7AL@
M "I';,_O7[#_ )>K7^;W*(O6A]_/$W^:O^>@&J]%[SM2/Y]"^CS)S.C<QYS
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MK[V*]RY&/B)=G<]WZ"&HLI40         ">.N_[>C+^85IV_U7D*I9C:K_\
M6DW_ (PB\6W_ *(?U'3_ *X@<+64<
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M;:#^=ZM^=3'SD0_7GR!WGKA?])M^DT<YV!$GZC@
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MTR!%JD>"QW39*N248YOL7)!1R>L2]]I'PJ^B!T>C78OUIKGT&[)^H,5$H1(
M                                           !E7M(^%7T0(OT:[%^
MM);T&[)^H,5$H1(                                            !
ME7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
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M:O\ GH!JO1>\[4C^?0OH\R<SHW,><P
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M075ZH]->A?2C<UESMZP^1[EC[KM%E6#Q#:5RJD>/)9C(/5;AO"ZKIE7E%XZ
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MP
M          "6&9M9&2\Y83PS@BZ[?L:-M+!\9"15JR5O1T^UN&1;P-KM[39F
MN!U(W([;.53QR"9U*MFC4M5C&J2A"?8J?%O5&)U)K&R.A-9ZQML+7VVID].S
M%4ME$C1)F%,1)=T"&L:969?I#(<O"BHU'NN;IL6+F9'.5<XB>/ILX
M         #<&GS%;[-69L>8U9(J*IW)<;%"64(14Q6EOLS\NGWBID2UJDDG$
MMGE=[U*;W 7>X3%'=)2[IN:@R[?_ ''-O]KGKVI1=$^V4MH?6!M1:V8B(UU(
ME(JP6N<W/F7MTJ6AIBW3GQWL;AZF]><=DK1JV8M6S)HB1NT9MT6C5!.G F@W
M;)E1113I_ 0J9"EI3_(4;42YJ-:FTP_!"/'BS,:-,QXBQH\PY7O>[;5[W8G.
M=[)7+B4S7VD?"KZ($3Z-=B_6F?Z#=D_4&*B4(D
M                       RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
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MB)D1&IM)SN=D+K#9#@PV084-(<*$B-:UK;FM:B7-1J)D1&ID1&Y$0] =AV
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MWG:D?SZ%]'F3F=&YCSF
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MWV*[1;_ING3_ (<KZ'FVT'\[U;\ZF/G(A^O/D#O/7"_Z3;])HYSL")/U'
M
M                           +_P#93::5[5MJ2U!W8PHC,7FS-#V"@X3^
MS,[4HHFH_G"4.E3BC/W2:::52FKPMV9C>M*L+C9R06&QT]%;G1$N9[GHE_2?
MF/Y-31<AUFJR6A=1)C3)"@Q$F*F]BYKYS"K8<LMSLNIF*KWM<UN&(]K>@+D1
M9SP.95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
M                    95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
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M]A_R]6O\WN41>M#[^>)O\U?\] -5Z+WG:D?SZ%]'F3F=&YCSF
M                                            3QUW_;T9?S"M.W^J
M\A5+,;5?_K2;_P 81>+;_P!$/ZCI_P!<0.%K*.
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MKB9C8U^!>J;>U<+O7:8$K/STEIR2<Y%E$F&X(FE1'LQMZE^!4QIG+FK>T\B
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MYK$]V_G?J)<S]!GVUKK;06AG)V"[')P;H,&_TJ'?G)ZSWN?$3I(^XB*+&54
M                              "[_:.^Q7:+?]-TZ?\ #E?0\VV@_G>K
M?G4Q\Y$/UY\@=YZX7_2;?I-'.=@1)^HX
M
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M"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M           RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
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M/,G,Z-S'G,
M     GCKO^WHR_F%:=O]5Y"J68VJ_P#UI-_XPB\6W_HA_4=/^N('"UE'
M
M
M                  N_VCOL5VBW_3=.G_#E?0\VV@_G>K?G4Q\Y$/UY\@=Y
MZX7_ $FWZ31SG8$2?J.
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M?1 B_1KL7ZTEO0;LGZ@Q42A$@
M         &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M                         &?8W_=MW]ZW']M9"#M'^(P?RK?FW$_9[\=B
M?D7?QL-U"EEQ     (K:O,*WIGG&,99EBR\)"S+.\XNX57<_(2L<Q/'L8B?8
M+H46AXMXJ9<RTHW,4E4J$K1.M3'H8I2FKMI*7-5>0ARLG$9"BMBM?>]SFI<C
M7IML1R]$G.*K:ZB3M>I<.2D([(,=D9D2^(Y[&X6L>BI>QCW7JYZ79MV3UBMF
MNS)SZXIP.[[Q>>E:4I6AIV]'%/4]6GJ*V87A]7_**3L$K#MW.0$_7BN_QA&M
M>9C7EW=0E>WCK]2A^#O9F91C$>53&3,3Q37?(E5P[D;B01XQ2M:$3JLZM],M
M5#5X."G#PU'!UA)^&U71:A+PV]-7/N_:Q#B_0RJD)N*-5)2&WIN6(B?M8TL$
MT;:;+ETYPEZL;BN2WKC[[9"#D6"L!R^J*"4>T?H*<:=ZV3WZ'Y6E4E24K3@)
M7AKP< N=F:''HD*:9&BLC:H<Q6X+^A1>J1O3-A6-LU,6<@3T.8F(<QJUS'HL
M/%<ER*G1-3;OR7$TA:"Z        !$O7;J70T=:/=1.IDT>A+/<0XQN"Y+?B
M'=%*L9:\54TX>QXJ1JDLF=.+<WA*0:#HR9J*$;N%3I\)REI61I$@M4JDC(([
M"DU$1KEZ3-T]4]=&(Y4]<C*Q/MIE+GJA=B=*PW.:G5/VF-7UG/5$4X.-F3L>
MLW;;>X,M:W-66H.ZK9L.<R/,1,I=S5@RN;)65;W2:-Y&>9V\65<E86/9\.WE
M(5LW4JT=-2%+W)C8Y%!F<[;<-H+3R=DV2U*IDBR)':QKFIN60F;EN*[*][[E
M<N5KNB5V7.TU9^R\Y:Y\U6*I/.A08D1R8DRQ(C^BNOR,8S$B-S7)SFHB-+5<
M_P#H0O":E@3+G3!J>RU'9.8QJCJ$B\WLK+N>S;CDV[=0Q(AY)61:T&[M5!TX
MH0I7M$93DE*\)FCG]L6N2FB;-:<U*C3H2R[ERK!QM>B=.Y[GM=AZG-Q=-"QS
MNAA)+ <M/J$5LPB9-.P/8Y>EF,8K;^JSL/4KE/@]"ZZR<VQ>0]0NS!S^^F73
MW!<1<%XXTC+A>4D)'&KBPKYC\=Y<Q621Y6J56&1N*X(%W&LT3509J-)DR)SH
MN$B(\M$*E2CX$C:"1:B).*C(CDVGXV8X42[IX6N:YW19A\T.ZK-MC3UG9YRN
M=(HKH:.RJS _2XL*_J6N5JM3G9]V;M=FHU<;6       J1VS/[U^P_Y>K7^;
MW*(O6A]_/$W^:O\ GH!JO1>\[4C^?0OH\R<SHW,><P
M                                    ">.N_P"WHR_F%:=O]5Y"J68V
MJ_\ UI-_XPB\6W_HA_4=/^N('"UE'
M
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M8HG""=HO*#R_R>I*OP]_LH\#!3QD*?B=IYT@V*)P@G:+R@\O\GJ2K\/?[*/
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M>ZZ!C39P[2G     &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M                                &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q4
M2A$@                                            &5>TCX5?1 B_
M1KL7ZTEO0;LGZ@Q42A$@
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M]CB9B:GLE);0[F9F&E:HDQ$6,VD1FM8NW=B=%8]$Z3,4*]K>=B<67B]FS
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MG:D?SZ%]'F3F=&YCSF
M             3QUW_;T9?S"M.W^J\A5+,;5?_K2;_QA%XMO_1#^HZ?]<0.%
MK*.
M
M                        !V+8=_>AZ9OY&<,_-C%C2$MYZ*Y^6F?I"'J>
M!YSK,_FLG]$/2$^1
M !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                 !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                                 !E7M(^%7T0(OT:[%^M);T&[)^H,
M5$H1(                                            !E7M(^%7T0(
MOT:[%^M);T&[)^H,5$H1(
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MZT/OYXF_S5_ST U7HO>=J1_/H7T>9.9T;F/.8
M                               !/'7?]O1E_,*T[?ZKR%4LQM5_^M)O
M_&$7BV_]$/ZCI_UQ X6LHX
M
M                                           '8MAW]Z'IF_D9PS\V
M,6-(2WGHKGY:9^D(>IX'G.LS^:R?T0](3Y$
M                    &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M                                    &5>TCX5?1 B_1KL7ZTEO0;LG
MZ@Q42A$@                                            &5>TCX5?
M1 B_1KL7ZTEO0;LGZ@Q42A$@
M        &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
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M7O.U(_GT+Z/,G,Z-S'G,
M               GCKO^WHR_F%:=O]5Y"J68VJ__ %I-_P",(O%M_P"B']1T
M_P"N('"UE'
M
M                                [%L._O0],W\C.&?FQBQI"6\]%<_+
M3/TA#U/ \YUF?S63^B'I"?(@
M         RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M                         RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M                                         RKVD?"KZ($7Z-=B_6DM
MZ#=D_4&*B4(D                                             RKV
MD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
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M^ZYOCCF_:'ONA7YI>7_UT&O%I.M5._H'%&L-B^OW]US?''-^T/?="OS2\O\
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M<WQQS?M#WW0K\TO+_P"N@UXM)UJIW] XHUAL7U^_NN;XXYOVA[[H5^:7E_\
M70:\6DZU4[^@<4:PV+Z_?W7-\<<W[0]]T*_-+R_^N@UXM)UJIW] XHUAL7U^
M_NN;XXYOVA[[H5^:7E_]=!KQ:3K53OZ!Q1K#8OK]_=<WQQS?M#WW0K\TO+_Z
MZ#7BTG6JG?T#BC6&Q?7[^ZYOCCF_:'ONA7YI>7_UT&O%I.M5._H'%&L-B^OW
M]US?''-^T/?="OS2\O\ ZZ#7BTG6JG?T#BC6&Q?7[^ZYOCCF_:'ONA7YI>7_
M -=!KQ:3K53OZ!Q1K#8OK]_=<WQQS?M#WW0K\TO+_P"N@UXM)UJIW] XHUAL
M7U^_NN;XXYOVA[[H5^:7E_\ 70:\6DZU4[^@<4:PV+Z_?W7-\<<W[0]]T*_-
M+R_^N@UXM)UJIW] XHUAL7U^_NN;XXYOVA[[H5^:7E_]=!KQ:3K53OZ!Q1K#
M8OK]_=<WQQS?M#WW0K\TO+_ZZ#7BTG6JG?T#BC6&Q?7[^ZYOCCF_:'ONA7YI
M>7_UT&O%I.M5._H'%&L-B^OW]US?''-^T/?="OS2\O\ ZZ#7BTG6JG?T#BC6
M&Q?7[^ZYOCCF_:'ONA7YI>7_ -=!KQ:3K53OZ!Q1K#8OK]_=<WQQS?M#WW0K
M\TO+_P"N@UXM)UJIW] XHUAL7U^_NN;XXYOVA[[H5^:7E_\ 70:\6DZU4[^@
M<4:PV+Z_?W7-\<<W[0]]T*_-+R_^N@UXM)UJIW] XHUAL7U^_NN;XXYOVA[[
MH5^:7E_]=!KQ:3K53OZ!Q1K#8OK]_=<WQQS?M#WW0K\TO+_ZZ#7BTG6JG?T#
MBC6&Q?7[^ZYOCCF_:'ONA7YI>7_UT&O%I.M5._H'%&L-B^OW]US?''-^T/?=
M"OS2\O\ ZZ#7BTG6JG?T#BC6&Q?7[^ZYOCCF_:'ONA7YI>7_ -=!KQ:3K53O
MZ!Q1K#8OK]_=<WQQS?M#WW0K\TO+_P"N@UXM)UJIW] XHUAL7U^_NN;XXYOV
MA[[H5^:7E_\ 70:\6DZU4[^@<4:PV+Z_?W7-\<<W[0]]T*_-+R_^N@UXM)UJ
MIW] XHUAL7U^_NN;XXYOVA[[H5^:7E_]=!KQ:3K53OZ!Q1K#8OK]_=<WQQS?
MM#WW0K\TO+_ZZ#7BTG6JG?T#BC6&Q?7[^ZYOCCF_:'ONA7YI>7_UT&O%I.M5
M._H'%&L-B^OW]US?''-^T/?="OS2\O\ ZZ#7BTG6JG?T#BC6&Q?7[^ZYOCCF
M_:'ONA7YI>7_ -=!KQ:3K53OZ!Q1K#8OK]_=<WQQS?M#WW0K\TO+_P"N@UXM
M)UJIW] XHUAL7U^_NN;XXYOVA[[H5^:7E_\ 70:\6DZU4[^@<4:PV+Z_?W7-
M\<<W[0]]T*_-+R_^N@UXM)UJIW] XHUAL7U^_NN;XXYOVA[[H5^:7E_]=!KQ
M:3K53OZ!Q1K#8OK]_=<WQQS?M#WW0K\TO+_ZZ#7BTG6JG?T#BC6&Q?7[^ZYO
MCCF_:'ONA7YI>7_UT&O%I.M5._H'%&L-B^OW]US?''-^T/?="OS2\O\ ZZ#7
MBTG6JG?T#BC6&Q?7[^ZYOCCF_:'ONA7YI>7_ -=!KQ:3K53OZ!Q1K#8OK]_=
M<WQQS?M#WW0K\TO+_P"N@UXM)UJIW] XHUAL7U^_NN;XXYOVA[[H5^:7E_\
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M(_IAJRI<$>'A<4:EIO"R=[O^T=R;9]]M/P%(_IAJRI<$>'A<4:EIO"R=[O\
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M1_3#5E2X(\/"XHU+3>%D[W?]H[DVS[[:?@*1_3#5E2X(\/"XHU+3>%D[W?\
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M_GB;_-7_ #T U7HO>=J1_/H7T>9.9T;F/.8
M                             !/'7?\ ;T9?S"M.W^J\A5+,;5?_ *TF
M_P#&$7BV_P#1#^HZ?]<0.%K*.
M
M                                              !V+8=_>AZ9OY&<
M,_-C%C2$MYZ*Y^6F?I"'J>!YSK,_FLG]$/2$^1
M                       !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                                       !E7M(^%7T0(OT:[%^M);T
M&[)^H,5$H1(                                            !E7M(
M^%7T0(OT:[%^M);T&[)^H,5$H1(
M           !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
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M9T;F/.8
M !/'7?\ ;T9?S"M.W^J\A5+,;5?_ *TF_P#&$7BV_P#1#^HZ?]<0.%K*.
M
M
M                  !V+8=_>AZ9OY&<,_-C%C2$MYZ*Y^6F?I"'J>!YSK,_
MFLG]$/2$^1                                             !E7M(
M^%7T0(OT:[%^M);T&[)^H,5$H1(
M           !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                           !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
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MF]RB+UH??SQ-_FK_ )Z :KT7O.U(_GT+Z/,G,Z-S'G,
M                                      GCKO\ MZ,OYA6G;_5>0JEF
M-JO_ -:3?^,(O%M_Z(?U'3_KB!PM91P
M
M                                                    .Q;#O[T/
M3-_(SAGYL8L:0EO/17/RTS](0]3P/.=9G\UD_HAZ0GR(
M                             ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                                             ,J]I'PJ^B!%^C78
MOUI+>@W9/U!BHE")
M ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                 ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
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M1CL^]+\C57G%YL= M9"G)M;0NC.EW0LS38K'ICQMW*,>[H;\XL1%U-A@
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M]RB+UH??SQ-_FK_GH!JO1>\[4C^?0OH\R<SHW,><P
M                                   ">.N_[>C+^85IV_U7D*I9C:K_
M /6DW_C"+Q;?^B']1T_ZX@<+64<
M
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M7-_60],?#$     ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                               ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE
M")                                             ,J]I'PJ^B!%^C
M78OUI+>@W9/U!BHE")
M   ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
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M_GH!JO1>\[4C^?0OH\R<SHW,><P
M                     ">.N_[>C+^85IV_U7D*I9C:K_\ 6DW_ (PB\6W_
M *(?U'3_ *X@<+64<
M
M                                      "[_:.^Q7:+?]-TZ?\ #E?0
M\VV@_G>K?G4Q\Y$/UY\@=YZX7_2;?I-'.=@1)^HX
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MJ]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M               ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                               ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE
M")                                             ,J]I'PJ^B!%^C
M78OUI+>@W9/U!BHE")
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MS/[U^P_Y>K7^;W*(O6A]_/$W^:O^>@&J]%[SM2/Y]"^CS)S.C<QYS
M                                                )XZ[_MZ,OYA6
MG;_5>0JEF-JO_P!:3?\ C"+Q;?\ HA_4=/\ KB!PM91P
M
M
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M]$"+]&NQ?K26]!NR?J#%1*$2
M         95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
M                         95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
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MU_F]RB+UH??SQ-_FK_GH!JO1>\[4C^?0OH\R<SHW,><P
M                                      ">.N_[>C+^85IV_P!5Y"J6
M8VJ__6DW_C"+Q;?^B']1T_ZX@<+64<
M
M                                                   "[_:.^Q7:
M+?\ 3=.G_#E?0\VV@_G>K?G4Q\Y$/UY\@=YZX7_2;?I-'.=@1)^HX
M                                  %FVS6U4N<09*;8HNV34IC;),@@
MR:U=*I\DM>\%^%&,DD#K'+R9D\6.BU=4*;=WE$5MSA(>HG*#4EE)C4\5W\GF
M%]Y_0N_3N7'D+R6N@O!MY9&-;.B2:.M;9&$Z*[ UV.<D&Y8T%S6H['$@)?&@
MWMOPH]F*YS6G2T+X?D895[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
M                                   95[2/A5]$"+]&NQ?K26]!NR?J
M#%1*$2                                             95[2/A5]$
M"+]&NQ?K26]!NR?J#%1*$2
M       95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
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MN_[>C+^85IV_U7D*I9C:K_\ 6DW_ (PB\6W_ *(?U'3_ *X@<+64<
M
M
M              "[_:.^Q7:+?]-TZ?\ #E?0\VV@_G>K?G4Q\Y$/UY\@=YZX
M7_2;?I-'.=@1)^HX                                         '^)
MJJ(J)K(J'251.51)5,QB*)J$/0Q%$CT-2J9RFH6M*TK2M*T /8U[7,>U',<F
M%S796N:NZ:YO/13KIT89D4SGIUQ_>CY;CK@:L3VM=9ZTK0Q[BMNI8]VY-2JA
MJ[SE K)WZM>']GC9-(FM62$&*[=M3 [VV_;D4_#CR0%@6Z'.BK::@2T/2Z7,
M1$GI).IE)J^*QFY;^!?ID'^S)I>TCX5?1 ZO1KL7ZTU9Z#=D_4&*B4(D
M                                         RKVD?"KZ($7Z-=B_6DM
MZ#=D_4&*B4(D                                             RKV
MD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M             RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M                             S[&_P"[;O[UN/[:R$':/\1@_E6_-N)^
MSWX[$_(N_C8;J%++B      !!C:)'DRZ9)^C#?Y*I<]HDF-RIREK&]U"G2XW
M=]2J7=8L9ZAO4WMW^-P"I6UQZPQL.YTR'C]SB^W"471%6)L8F%9>C=-@X_<X
M\GQ\!!ZYL:X,LB T)7J[MR(3L^]$J^F[*R)W#IM+/I6*L^KQ>=65<FXEJSDW
M-P&W$]TC=-%0I2[I!5)B0I$I!LE-.@MU+-I_*56]V-5;"O5^7:8N/:R-*/-4
MRAR,O82==+LU'.I_+'NQ.1ZO9!Q+$O7:8]8FUD8F+J3;>FU_BZUM;%^65AEI
M 3V.YBU'3R,G(])I+GMZ30CX5]+-X*[3U.Y=6PH\HLW.CQZJ%5U$N*]:COGD
MJ&^GRUJ9R5I;61I*)#54>W"[ MS'.1D7=.A7Y,-[DONNVLLQ9N)2I6VU0DJ*
MV',4Z-!5R/;<_2WM1CGI"C97.A*N2[$K;[L.YSK;1L8VT        $<M6NFV
MU-8&G#+>FB^9VX;9M+,%KGM6<G;3/&IW'&,32#*1JXB33+!TV(ZXU@D7[,W5
M)NF-ZWAX*ES:9/1*9/2L_!:V)$E78D1V+"[)=EPJCOVF!4I"%5)":I\5[H<*
M:;@<K+KT]K$CDZ70G,U>'H439V8]@G-T7_K U"V/;3(R:;RXKONS!MM030ZQ
MMU$CJ8F\=H-VYCF+P%H=2E35IZT7Z#HC5N._2X-*@1HCNA8V,Y?>:^\U]%T-
M*%!9ID6J3$*&WGN?!:GOK#-:X\]#6[(G+DO6W\4;1J^,GSU.4<,)CS-&F2]9
M>G)"U,ZJ:-MNT'*U.**4U5/6>LH7UW .^-;RTLLU'S-"9+LZI\*88GOJ]#I@
M:'UF9EV"7KD28?TF19=Z^\C%_P "WS9J["G3GLQ,Z77GO$.7,UW[<MW8GG<0
MOH?)#BQ%H-K!SUX6)>;F3;%MBSHYQ25)(6!&I$J=8R/$O%]Y*I^+.2LU^U\]
M:"3AR<U*PH$.%$;%O9CQ7M8]EV<]4NN>I9:!8Z0L_.1)R5FHT>)$A.A71,&'
M"Y['WYK&KBO8G/Z9> *F7$      "I';,_O7[#_EZM?YO<HB]:'W\\3?YJ_Y
MZ :KT7O.U(_GT+Z/,G,Z-S'G,             +%-$EAZ<=0<1>>GG)-OLK6
MS1<C!^_PSEY*6GTE5)9N@5U6VI&&[L%CWJZ9VIEDBU:T.\9K/&Q5$7:3,YZ=
M:2;J]*B2]5DXRQJ=!5K9B7PLVMSC:[#C;?BN7+FKA=<K7.+_ &-D;/5Z#.4"
MHR[96L3#7+)S6-]^-J7Z6YF/ [#=>F;YHS&W$CT8I'BU-*N7KGU#TTT5@5(S
M(+6X%HB?JY354C(&+9U(XD+L=.2%I1:W"11TW:"Y?[\2=($;;ZKE$AY6/6Y"
M#2=>%B8I5S,3.J>KMIC?9WY%3H7-6_-1Q 2MEZM,U_8YI*PY]D3 ^_<L8W.=
M$5WI>#/:[HT5N'.5IN37-#Z:L:7/!X-P%:C5Q,8W;(QN4LJKS4Y)25U7>U:E
M9O8=%JO+J1[0K=>BRL@9JV3I1^I5FB5NFR5HXP+-1*Q.0HE3JD960YQ;X,'"
MUK60E6]KL5V-U_08E7,SEQ7Y)>VL&SE.F8%$H<JCHU/3#,S*O>YT2,U+E9<Y
MZL;<[$Z)@:W/S&X6L7%H#3A@2Z-1^6+=QE;53-$GISR5T7 HGOLK4M&/.F><
MN%]6IJ%H5)!0J:!#F)1=VZ0;;Y#+4-24J]3@TB1C3D;.5N:QG1/>[<L;[?/Z
M2(YW.(*SU#F;0U27ILNF%'9T2+T,*"F[BN]IN:FYQ/5K<6<3%VF6G[#FG^YL
M,1&&K>3AHB?L%_(R;\LS*S:EQ.6L@V:,YE=U(OUR<:JU-OUJU*B@>JV\1.A=
MVA:]8VJ5"J0:A$J,;3(D&*UJ)<UN#$BWIFM3:]>]2V:(]"I%"F*/"I$ND&%,
M0'*Y<;WZ:YJHUKW*KG-RITKF^QN-LV58&DC%.@C"FHS+>GNN5[GO6\+@L^67
M9WO=MMNUUZ77DTL<_5*SFBM2)(1-GMF^XFW)4^\4]3&/OU/@S,U79VT]1I,C
M5=0P9>&R*V^'#>B7L@7IG-ORNB*[*XE9.1LK2[#4>T%5H6NDS.17P7X8T6$Y
M7:9,X79K\.:R"B9J>N>'BMQLXM3EY1.'F^ +]P-=]Z'5A[0O.$R'-W&T2G#I
M'68-'C>9EG#=-5=9.B255(YP0ZBI$CJHT/14G=.I:ZC2T2H.JL*J0)?.?#=!
M:Q;NB<F%K5S=M<]OZVT=5+70]M).0Z2E!CT.;G,R'&9,/BICZ%JM>]R9VTE\
M)S<615;ME;.;,62V$LL7[BF;=HOY"R;@=PQI)LF=%&3:4H1S&2::*E:F0*YC
M'#-?BZU-5/E&YO&W=XUOITZRHR$I/PVX6S#&KAZ2\]/T.Q-__B:ZK-,BT6J3
MU,C.2)$DXCF7MZ)NZ1WL<2*UV'G8C6(D2.+7[6PIIETLZ>\9YKU16-/9>R5F
MU$\YC_%;69D;9BH.W&J"#U*1DW,>^2JYXR-E(-=R9T5>A#S;9HC'F,@Y<UH4
M>HUFM5:<IU$FF2,G35NB1L+7N<]V;<W$B\]%:VZ[:<JOSFH;0EJ-9RS%!IM9
MM-)OJU1K"8Y>5:]T-C(;4Q7O5%3%FO8Y^/%G/:QK,CG'E94P5ISSQIING4YI
M5M6?QK,XJDB-<K8CDI1_<;<D:Y5;'4GHA](OUSHI(,G5'>^F<K91JQ=DY*V6
M;?9.4E4ZO3*Q!HU<C,G(<\F*!':UK,J="J(U-M4PYV=B<F54<=53HEGJW9R:
MM)9B5B4V-2W734HKW14N6[/8Y7.=FM=CQ-=A<QKVX$<F7 ]'^FW%%P8SREJC
MU)&FU,)8G51B&MKPBKF/?7]=3LC1.D6629NT'""";J8MYND5!9#CW<P3C'C9
MNT7*IE5^KS\*<D:+2,*5*>SE>[.;"8W%EPN14VFO5;VNPM;D1SE;=A64L]2X
M]-J5IK18]9J6N!(3+VK,1'79F)KFNPHY[&MPN;B>_*]K6.Q;\QO8VB#7#6ZL
M6XHQ).Z<,SQ]NO)O'TN:ZY>YX.Y48;@HI'R[-[(G1JM5-1N=R6B)77%&573>
MK<F.DI%SLS:6S>DSL]/-JU.<Y&QFX&L<S%M*U42_VN=T*M3%DG*=)6+MIJJF
M4NEOL_6(<-SY=^FOB,B8.<]'*YO2OS<=V)6O6Y46!. ;2P2UR9<T?JNF[OM"
MVK%C)IRZMNVXTZTY<]V0<JVCCV(=TCO'BG"ISN]X]"IEK1FJ0[YAZBXL]4CU
M1TG!=0H4.8C33FMQO=D8QR.=IMW/NS??W#]HHM"E**VHS4*U$:+*2\BUZK#A
MMSXD9CT32;\N!5SNIVG9[-T3HQ??NS7S#?ELX4II3NVQ&E\3+*T[6OZM_3[Z
M>:7%/N$8V&4DTRW&J9L1226;IE,9:0;IJ+4JJVY/QABUN<E;84Z6C5+7R'-.
ME6N>^'I3$8YC,KKLQO0^Q8[G-7%<7:FSVAW5IZ7HVQ>+(LG'MAPX^GO<](CU
MPLQ^:.PXG7)NGM:[=-NO*_\ 5)A/F[YYR'B%.27F&%K23)2%E'1$TW3V!G8B
M/N.$.\*F0J9WZ<;*MT7)DRD3,X;JU(0A. A;11:CKO3)2?5J0G1T=>U-IKV*
MYBW>MB3$WUKBBVEHVL%<GZ2D18T.5<F!Z[I6/8D1F+G7M1[6NNS<35N:TT&)
MH@P             GCKO^WHR_F%:=O\ 5>0JEF-JO_UI-_XPB\6W_HA_4=/^
MN('"UE'                                      "9FBO28OJEOF=+.
MSBEGXIQW&HW#DF[D^3%<,X]>KH[.(CE7G"DUD73>/E%.4K$.@T;QJZZA%3$2
M;K5FT5>2BRT/28>J)V;7!!9TW9MZNPYRHV],B95<K6YNZ;;K'65=::=C:?&U
M+2J>UKYF)DQ-;G7,3%FHYZ(]<3L2,:URJU<U'27D\V[+JSY-:SH#2S>>1;99
M*G8NLA/;KFV,O.<1]C-+13)]="*Y453<88E#5BJ[M2_L9']H2&93;:3#-41:
MW#E8SLY(36-<UOK*Y&*F3]?W2ECBUG0TE(CI2!9F-4):&N%T=T1[7ONZ-C71
M6NSO;A>TW:,!U6Z2L6Q&(K;U6Z69^6N'!ERO$XZ?M^<.LM-6!)N'JD8D15RZ
MX%SQ])@E&"Z+GC7#=TH@<CIZV>$51RJ)7IV)/Q:)6H;8-2@IB8]FYBIAO]J^
M[/:J86JF+(BMN=@6HLK3(5)E[469F'3%$F%N>Q^5\![G7;I<[#CS%1]ZM=<K
M7O1^)*VA=37H        6-1.$,6N-FI<V<UK30/E9AEEO;K2[JR4U1=&$/-6
M^U.QI&4DJ,3%XAZZ+OF:U4^R;V_PT*:E,B5*=2V$&FI,+J%T#&YES=NYZXK\
M.+H4Z(V!"HU,=H=S5:66372%-I#;&Q/Q8,<)N'#BP;3EZ&\KE%S-?@
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MLA,3'&;.4Z-F]0L*9@9?UYG-+Z?:1\*OH@3'HUV+]:> ?0;LGZ@Q42A$@
M                                         &5>TCX5?1 B_1KL7ZTE
MO0;LGZ@Q42A$@                                            &5>
MTCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M             &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
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M)BSED:=9Q8L6!$?-34=+EB/PY&WWJUB(F:CG7*Z]55<*9<A*T6,M8
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MO/6[+=BZG$XHL5[7Q(CF-5L.]V!JNQJU,6:F+"E^%O186XMUA:?".\X@
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ML7ZTEO0;LGZ@Q42A$@
M  &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M                  &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
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M-_XPB\6W_HA_4=/^N('"UE'
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MT:[%^M);T&[)^H,5$H1(
M    !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                    !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
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MR%WLS5[;3=;DX-8@S#:=$2+C5\FD-F2&]67Q-)9AST;=ESG9N6\MA&Q3;
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M]YVI'\^A?1YDYG1N8\Y@
M              $\==_V]&7\PK3M_JO(52S&U7_ZTF_\81>+;_T0_J.G_7$#
MA:RC@
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M^5=(TVCP\.!SD58D3"U,:W(UN*Z]WMO>O/(7"S%/
M                                                       +O]H[
M[%=HM_TW3I_PY7T/-MH/YWJWYU,?.1#]>?('>>N%_P!)M^DT<YV!$GZC@
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M$"+]&NQ?K26]!NR?J#%1*$2
M        95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
M                        95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
M                                        9]C?]VW?WK<?VUD(.T?X
MC!_*M^;<3]GOQV)^1=_&PW4*67$
M   "I';,_O7[#_EZM?YO<HB]:'W\\3?YJ_YZ :KT7O.U(_GT+Z/,G,Z-S'G,
M                                                       GCKO^
MWHR_F%:=O]5Y"J68VJ__ %I-_P",(O%M_P"B']1T_P"N('"UE'
M
M
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M+]&NQ?K26]!NR?J#%1*$2
M      95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
M                      95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
M                                      9]C?\ =MW]ZW']M9"#M'^(
MP?RK?FW$_9[\=B?D7?QL-U"EEQ
M   J1VS/[U^P_P"7JU_F]RB+UH??SQ-_FK_GH!JO1>\[4C^?0OH\R<SHW,><
MP                                                      ">.N_
M[>C+^85IV_U7D*I9C:K_ /6DW_C"+Q;?^B']1T_ZX@<+64<
M
M
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MLCLW"KHF'$]KBQD39Y0,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                                   ,J]I'PJ^B!%^C78OUI+>@W9/U
M!BHE")                                             ,J]I'PJ^B
M!%^C78OUI+>@W9/U!BHE")
M       ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                       ,^QO^[;O[UN/[:R$':/\ $8/Y5OS;B?L]^.Q/
MR+OXV&ZA2RX@                                    5([9G]Z_8?\
M+U:_S>Y1%ZT/OYXF_P U?\] -5Z+WG:D?SZ%]'F3F=&YCSF
M                                          3QUW_;T9?S"M.W^J\A
M5+,;5?\ ZTF_\81>+;_T0_J.G_7$#A:RC@
M
M                                                       7?[1W
MV*[1;_ING3_AROH>;;0?SO5OSJ8^<B'Z\^0.\]<+_I-OTFCG.P(D_4<
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M%^M);T&[)^H,5$H1(
M !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                 !E7M(^%7T0(OT:[%^M);T&[)^H,5$H1(
M                                 !GV-_W;=_>MQ_;60@[1_B,'\JWY
MMQ/V>_'8GY%W\;#=0I9<0                                    *D=
MLS^]?L/^7JU_F]RB+UH??SQ-_FK_ )Z :KT7O.U(_GT+Z/,G,Z-S'G,
M                                                  GCKO\ MZ,O
MYA6G;_5>0JEF-JO_ -:3?^,(O%M_Z(?U'3_KB!PM91P
M
M
M    .A/5YA'*&>MFIH\L_$]L4NNXHV/T^W*]CJ3-O07$PK/ =RQ;E[5Y<LLS
M04W7\Q&DXLBIE:\HWRD,1,YB^=JM*3$[7*Q!E8>FQ&S,PZ[$B9-/<WHG-ZI#
M]0_(D:(=CM#.J2E=MK5]9:5-6<A2D*+J>:F;YA\2FQF0L$I!CQ&XH4O&=C<Q
MK&X,+G7N:UU,O@V]:G0M7\8^*.W8Q-8JMO?X\+CGO+RV7D?^OY?@JM_=H\&W
MK4Z%J_C'Q1V[#6*K;W^/"XX\MEY'_K^7X*K?W:/!MZU.A:OXQ\4=NPUBJV]_
MCPN./+9>1_Z_E^"JW]VCP;>M3H6K^,?%';L-8JMO?X\+CCRV7D?^OY?@JM_=
MH\&WK4Z%J_C'Q1V[#6*K;W^/"XX\MEY'_K^7X*K?W:/!MZU.A:OXQ\4=NPUB
MJV]_CPN./+9>1_Z_E^"JW]VCP;>M3H6K^,?%';L-8JMO?X\+CCRV7D?^OY?@
MJM_=H\&WK4Z%J_C'Q1V[#6*K;W^/"XX\MEY'_K^7X*K?W:/!MZU.A:OXQ\4=
MNPUBJV]_CPN./+9>1_Z_E^"JW]VCP;>M3H6K^,?%';L-8JMO?X\+CCRV7D?^
MOY?@JM_=H\&WK4Z%J_C'Q1V[#6*K;W^/"XX\MEY'_K^7X*K?W:/!MZU.A:OX
MQ\4=NPUBJV]_CPN./+9>1_Z_E^"JW]VCP;>M3H6K^,?%';L-8JMO?X\+CCRV
M7D?^OY?@JM_=H\&WK4Z%J_C'Q1V[#6*K;W^/"XX\MEY'_K^7X*K?W:/!MZU.
MA:OXQ\4=NPUBJV]_CPN./+9>1_Z_E^"JW]VCP;>M3H6K^,?%';L-8JMO?X\+
MCCRV7D?^OY?@JM_=H\&WK4Z%J_C'Q1V[#6*K;W^/"XX\MEY'_K^7X*K?W:/!
MMZU.A:OXQ\4=NPUBJV]_CPN./+9>1_Z_E^"JW]VCP;>M3H6K^,?%';L-8JMO
M?X\+CCRV7D?^OY?@JM_=H\&WK4Z%J_C'Q1V[#6*K;W^/"XX\MEY'_K^7X*K?
MW:/!MZU.A:OXQ\4=NPUBJV]_CPN./+9>1_Z_E^"JW]VG^EV;.M(YJ4KALI*5
MKNU,;(F*3%+_ )Z[E\&K2G_JI4-8JMO?X\+CA?):>1^1%5+?XE_JJM?]U--@
MVSLI]5DVNB2996)9S<YR%67F[O;OS(IUK3?-1&V&K_C3TI3U"T-2E?\ O%'=
M#L[4GKG-9#3UW\7$5BK^31T%:?"B.D)JI5Z(U,UDM(/AWNZ5\X^6P^W\4FOB
MK9 V-$+-Y#,&19:\5$S5,I;]I-.]J'/2A:4*FXEG*J[QRGO[U:U2*S-6F[ZX
MHEY:R\)JM=-S"ONYS,C>VV_\#SY;7R==HIYD25L)96#0VN3-FI]^JIAOKL@,
M;"@,=AZM8S?6+4<<8HQQB*#3MS&]G0=HQ). RB,2S(DN[4IPUX^0?'WEY!?A
MK6M3KJ*&X3?;%CEY:7E&:7+P$AM];_N7GGC"UEM[66ZJ+JK:VO3%<GG;E8SU
M<QB=3#AMNAPF^QAL:AL4=A4P   RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M                                           RKVD?"KZ($7Z-=B_6
MDMZ#=D_4&*B4(D                                             R
MKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M               RKVD?"KZ($7Z-=B_6DMZ#=D_4&*B4(D
M                               S[&_[MN_O6X_MK(0=H_Q&#^5;\VXG
M[/?CL3\B[^-ANH4LN(                                    %2.V9_
M>OV'_+U:_P WN41>M#[^>)O\U?\ /0#5>B]YVI'\^A?1YDYG1N8\Y@
M                                                $\==_P!O1E_,
M*T[?ZKR%4LQM5_\ K2;_ ,81>+;_ -$/ZCI_UQ X6LHX
M
M
M     '8MAW]Z'IF_D9PS\V,6-(2WGHKGY:9^D(>IX'G.LS^:R?T0](3Y$
M                                          &5>TCX5?1 B_1KL7ZT
MEO0;LGZ@Q42A$@                                            &5
M>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M              &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A$@
M                              &5>TCX5?1 B_1KL7ZTEO0;LGZ@Q42A
M$@                                            &?8W_=MW]ZW']M
M9"#M'^(P?RK?FW$_9[\=B?D7?QL-U"EEQ
M          J1VS/[U^P_Y>K7^;W*(O6A]_/$W^:O^>@&J]%[SM2/Y]"^CS)S
M.C<QYS
M )XZ[_MZ,OYA6G;_ %7D*I9C:K_]:3?^,(O%M_Z(?U'3_KB!PM91P
M
M
M              .Q;#O[T/3-_(SAGYL8L:0EO/17/RTS](0]3P/.=9G\UD_H
MAZ0GR(                                             ,J]I'PJ^B
M!%^C78OUI+>@W9/U!BHE")
M       ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                       ,J]I'PJ^B!%^C78OUI+>@W9/U!BHE")
M                                       ,J]I'PJ^B!%^C78OUI+>@
MW9/U!BHE")                                             ,^QO^
M[;O[UN/[:R$':/\ $8/Y5OS;B?L]^.Q/R+OXV&ZA2RX@
M                    5([9G]Z_8?\ +U:_S>Y1%ZT/OYXF_P U?\] -5Z+
MWG:D?SZ%]'F3F=&YCSF
M              3QUW_;T9?S"M.W^J\A5+,;5?\ ZTF_\81>+;_T0_J.G_7$
M#A:RC@
M
M                           =BV'?WH>F;^1G#/S8Q8TA+>>BN?EIGZ0A
MZG@><ZS/YK)_1#TA/D0
M    95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
M                    95[2/A5]$"+]&NQ?K26]!NR?J#%1*$2
M                                    95[2/A5]$"+]&NQ?K26]!NR?
MJ#%1*$2                                             95[2/A5]
M$"+]&NQ?K26]!NR?J#%1*$2
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MAS8=#CK@7O.?\6&I8_I?[6_:/2[O/W)_*$1]?#FPZ''7 O><_P"+#4L?TO\
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M?M'I=WG[D_E"(^OAS8=#CK@7O.?\6&I8_I?[6_:/2[O/W)_*$1]?#FPZ''7
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M^T[G&X@YW^G;I"KU1OKLP'-)L9PRG>TUXN-DM%WVG<XW$'._T[=(5>J-]=F
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M?:=SC<0<[_3MTA5ZHWUV8#FDV,X93O::\7&R6B[[3N<;B#G?Z=ND*O5&^NS
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M2_E>@?\ <O( UO;_ /F:7_.6?-1CIT4/Y@D_SR'\Q,%$HU.:'
M                        )>?X@W]<#_DV+%_0W^\?]*7#^@']\?Z(B&*Z
M4\                                                       E!J
M:=T>L=-"W#P[FEW'C3A_T"Y;\8<'_LY/P?\ M$Y7E5T.@K?M4^"WWGQD_P B
MTVG?CAV9<FUK5+)VL6.G^1%\095@
M
M                                                 +7M33OENSVT
MT+\/[6<QXTWO\G(,>WXQX/\ V5;\ V#77WV-H*\['!;[T&,G^1MFU#T?H>V8
M=[.63M9:.W_(JA&OC4P
M   !+S_$&_K@?\FQ8OZ&_P!X_P"E+A_0#^^/]$1#%=*>
M                             2\_Q!OZX'_)L6+^AO\ >/\ I2X?T _O
MC_1$0Q72G@                                            $O/\0;
M^N!_R;%B_H;_ 'C_ *4N'] /[X_T1$,5TIX
M                   !+S_$&_K@?\FQ8OZ&_P!X_P"E+A_0#^^/]$1#%=*>
M                                             6-[+_\ P^W?_)!/
M_P"^MA"ZV!_G:8_-7_.P39&A?_/\Y^9Q/GY<E_M0/\ -I?RO0/\ N7D 6.W_
M /,TO^<L^:C%PT4/Y@D_SR'\Q,%$HU.:'
M        )>?X@W]<#_DV+%_0W^\?]*7#^@']\?Z(B&*Z4\
M                                         WUFUWRVV].:W#^TP(Q:
M;WJ>IR#*^6F/!]K^#DW!_P"T2M5=? HBIO-J=K,S#2P5Q^.6LVO2I[4]Z;FT
M_P"TT*(HKX
M
M                               %G&;7=7NSCTYK</#N9#8M.'_)R!AE
MICP?%J4%ZJJHZQ%$5>=&:WWFS+39]=?CT.+-NZ4PUO:LFT_[2L<44U@
M                                        2\_Q!OZX'_)L6+^AO]X_
MZ4N'] /[X_T1$,5TIX
M  !+S_$&_K@?\FQ8OZ&_WC_I2X?T _OC_1$0Q72G@
M                         $O/\0;^N!_R;%B_H;_>/^E+A_0#^^/]$1#%
M=*>                                             2\_Q!OZX'_)L
M6+^AO]X_Z4N'] /[X_T1$,5TIX
M          !8WLO_ /#[=_\ )!/_ .^MA"ZV!_G:8_-7_.P39&A?_/\ .?F<
M3Y^7)?[4#_ #:7\KT#_N7D 6.W_\S2_YRSYJ,7#10_F"3_/(?S$P42C4YH<
M                                  EY_B#?UP/^38L7]#?[Q_TI</Z
M?WQ_HB(8KI3P
M      #:61'?*;2P2G6O#5EBF6:5]3UU>#-N8W1>'U/MT(Z)3_U#-G78Y:E)
MU,NJ?*YEW_<2U1?BE*$G42CT^73B_P"9JT81$@
M
M                                                           6
M(Y$=T<;-C!)*UX:LLTRS2M:_;X>.S&Y+2O\ GH1R6G_JH+C-N1UAJ2G/;-.;
M])7_ #-C5%^+0UH*=1.O3]LZO^97<*<:Y
M                  )>?X@W]<#_ )-BQ?T-_O'_ $I</Z ?WQ_HB(8KI3P
M                                           "7G^(-_7 _P"38L7]
M#?[Q_P!*7#^@']\?Z(B&*Z4\
M         EY_B#?UP/\ DV+%_0W^\?\ 2EP_H!_?'^B(ABNE/
M                                  )>?X@W]<#_ )-BQ?T-_O'_ $I<
M/Z ?WQ_HB(8KI3P                                            "
MQO9?_P"'V[_Y()__ 'UL(76P/\[3'YJ_YV";(T+_ .?YS\SB?/RY+_:@?X ;
M2_E>@?\ <O( L=O_ .9I?\Y9\U&+AHH?S!)_GD/YB8*)1J<T.
M                        2\_Q!OZX'_)L6+^AO]X_Z4N'] /[X_T1$,5T
MIX                                                      !EUS
M/.4PN/$:UX>06>]:;M?XN_?][ON#X[P_^\.^.['"E$ZF$YOAHR_YF;-/QP:<
MGI<%6_*(Z_YF(CH,(
M
M                                      "==S.^5;.S'B/JUY#J/>M*
MT_[G&6M?+[@^.\/_ +PM<=V*Q<FG4SSF^#C+_F7V:?BT.J:GI=2<G@H[O\R"
M@JA0@                                            "7G^(-_7 _Y
M-BQ?T-_O'_2EP_H!_?'^B(ABNE/
M            )>?X@W]<#_DV+%_0W^\?]*7#^@']\?Z(B&*Z4\
M                                   EY_B#?UP/^38L7]#?[Q_TI</Z
M ?WQ_HB(8KI3P                                            "7G
M^(-_7 _Y-BQ?T-_O'_2EP_H!_?'^B(ABNE/
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MFG7G'';(-B%HMX+W67Y0; ;6<$^'EN6',)U7]%-.O...V0;$+1;P7NLOR@V
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MFG7G'';(-B%HMX+W67Y0; ;6<$^'EN6',)U7]%-.O...V0;$+1;P7NLOR@V
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M8QML
M
M
M
M
M
M
M
(       /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780630069312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">X4 PHARMACEUTICALS, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3181608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">61 North Beacon Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">529-8300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XFOR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,207,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780630571008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 93,406<span></span>
</td>
<td class="nump">$ 121,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_ResearchAndDevelopmentIncentiveReceivable', window );">Research and development incentive receivable</a></td>
<td class="nump">658<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,158<span></span>
</td>
<td class="nump">5,807<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">98,222<span></span>
</td>
<td class="nump">128,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">986<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">17,351<span></span>
</td>
<td class="nump">17,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">6,844<span></span>
</td>
<td class="nump">7,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">124,405<span></span>
</td>
<td class="nump">155,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,992<span></span>
</td>
<td class="nump">7,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">11,762<span></span>
</td>
<td class="nump">12,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">1,315<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">19,483<span></span>
</td>
<td class="nump">22,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_LongTermDebtNonCurrentIncludingAccretion', window );">Long-term debt, net of discount and current portion</a></td>
<td class="nump">31,827<span></span>
</td>
<td class="nump">32,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">3,377<span></span>
</td>
<td class="nump">3,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liability (Note 4)</a></td>
<td class="nump">17,692<span></span>
</td>
<td class="nump">23,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">72,729<span></span>
</td>
<td class="nump">81,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 500,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively; 122,207,488 and 121,667,250 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">452,431<span></span>
</td>
<td class="nump">450,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(400,758)<span></span>
</td>
<td class="num">(376,738)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">51,676<span></span>
</td>
<td class="nump">74,051<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 124,405<span></span>
</td>
<td class="nump">$ 155,586<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LongTermDebtNonCurrentIncludingAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt non current including accretion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LongTermDebtNonCurrentIncludingAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ResearchAndDevelopmentIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development incentive receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ResearchAndDevelopmentIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780629901952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">122,207,488<span></span>
</td>
<td class="nump">121,667,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">122,207,488<span></span>
</td>
<td class="nump">121,667,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780630184576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 22,063<span></span>
</td>
<td class="nump">$ 14,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">7,241<span></span>
</td>
<td class="nump">7,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (Loss) on Disposition of Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(509)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">29,304<span></span>
</td>
<td class="nump">21,268<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(29,304)<span></span>
</td>
<td class="num">(21,268)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">835<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,109)<span></span>
</td>
<td class="num">(913)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="nump">5,439<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">5,288<span></span>
</td>
<td class="num">(674)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(24,016)<span></span>
</td>
<td class="num">(21,942)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(24,020)<span></span>
</td>
<td class="num">(21,965)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock', window );">Deemed dividend on Class B Warrant price reset</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,259)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (24,020)<span></span>
</td>
<td class="num">$ (24,224)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders&#8212;basic</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders&#8212;diluted</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding&#8212;diluted</a></td>
<td class="nump">145,967,000<span></span>
</td>
<td class="nump">33,737,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding&#8212;basic</a></td>
<td class="nump">145,967,000<span></span>
</td>
<td class="nump">33,737,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Repurchase Of Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780630663904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,127,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 64,412<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 347,374<span></span>
</td>
<td class="num">$ (119)<span></span>
</td>
<td class="num">$ (282,871)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,512,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">5,820<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">5,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">Restricted Stock, Value, Shares Issued Net of Tax Withholdings</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock Issued During Period Shares Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</a></td>
<td class="nump">1,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,965)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,965)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,809,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">49,714<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">354,638<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="num">(304,836)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,667,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">74,051<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">450,786<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="num">(376,738)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</a></td>
<td class="nump">1,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(24,020)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,020)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,207,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 51,676<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 452,431<span></span>
</td>
<td class="num">$ (119)<span></span>
</td>
<td class="num">$ (400,758)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780630074304">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (24,020)<span></span>
</td>
<td class="num">$ (21,965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,645<span></span>
</td>
<td class="nump">1,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">385<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_NonCashInterestExpense', window );">Accretion of debt discount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">225<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,439)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets and research and development incentive receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,084<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,714)<span></span>
</td>
<td class="num">(713)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">496<span></span>
</td>
<td class="num">(984)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(250)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(26,512)<span></span>
</td>
<td class="num">(20,229)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Acquisition of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee taxes paid related to net share settlement of vested restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement', window );">Fees paid to amendment loan and security agreement and issuance costs related to the sale of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(381)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayments of Secured Debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,300)<span></span>
</td>
<td class="num">(795)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts', window );">Proceeds from sale of shares of common stock, and pre-funded warrants, net of issuance costs (1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,124)<span></span>
</td>
<td class="nump">4,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(28,595)<span></span>
</td>
<td class="num">(15,364)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">123,028<span></span>
</td>
<td class="nump">83,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 94,433<span></span>
</td>
<td class="nump">$ 67,744<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1) For the three month period ended March 31, 2023, includes payment of issuance costs related to December 2022 public sale of shares of common stock and pre-funded warrants</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance costs Related To Sale Of Warrants And Fees Paid For Amendments To Loan And Security Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance or Sale of Equity, Net of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780632190944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780713794528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text">NATURE OF THE BUSINESS AND BASIS OF PRESENTATION<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X4 Pharmaceuticals, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) is a late-stage clinical biopharmaceutical company focused on the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company&#8217;s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. Due to its ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream, the Company believes that mavorixafor has the potential to provide therapeutic benefit across a variety of chronic neutropenic disorders, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (&#8220;WHIM&#8221;)) syndrome, a rare, primary immunodeficiency, and certain cancers. Following announcement of positive top-line data from the Company&#8217;s global, pivotal, Phase 3 clinical trial in November 2022, the Company is preparing a United States regulatory submission seeking approval of oral, once-daily mavorixafor in the treatment of people aged 12 years and older with WHIM syndrome. The Company is also currently enrolling participants in a Phase 2 clinical trial in people with certain chronic neutropenic disorders following positive results from a Phase 1b clinical trial evaluating mavorixafor in people with idiopathic, cyclic, or congenital neutropenia that were presented in the third quarter of 2022. The Company also conducted a proof-of-concept Phase 1b clinical trial of mavorixafor in combination with ibrutinib in people with Waldenstr&#246;m&#8217;s macroglobulinemia (&#8220;Waldenstr&#246;m&#8217;s&#8221;), a rare form of lymphoma. The Company reported positive results from the Waldenstr&#246;m&#8217;s Phase 1b trial in the third quarter of 2022 and concluded the trial in December 2022. Any further studies of mavorixafor in Waldenstr&#246;m&#8217;s or other oncology indication will be subject to completing a strategic partnership. The Company is headquartered in Boston, Massachusetts and has an additional facility in Vienna, Austria. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern Assessment&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2014-15,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2014-15&#8221;), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. Since inception, the Company has incurred significant operating losses and negative cash flows from operations. As of March&#160;31, 2023, the Company had $93.4 million of cash and cash equivalents, an accumulated deficit of $400.8 million  and net cash used in operating activities of $26.5 million.  The Company has a covenant under its Second Amended and Restated Loan and Security Agreement with Hercules Capital Inc. (&#8220;Hercules&#8221;) that requires that the Company maintain a minimum level of cash of $20 million, subject to reduction to $10 million upon the achievement of operational milestones. Based on its current cash flow projections and with no additional funding, the Company believes it will not be able to maintain the minimum cash required to satisfy this covenant beginning in the first quarter of 2024. In such event, the lender could require the repayment of all outstanding debt.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has assessed the Company&#8217;s ability to continue as a going concern in accordance with the requirements of ASC 205-40 and determined that the Company&#8217;s accumulated deficit, history of losses and future expected losses met the ASC 205-40 standard for raising substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company does not have adequate financial resources to fund its forecasted operating costs for at least one year after the date that these condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To finance its operations, the Company will need to raise additional capital, which cannot be assured. Unless and until the Company reach&#8217;s profitability in the future, it will require additional capital to fund our operations, which could be raised through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other collaborations and strategic alliances. If the Company is unable to obtain funding, it could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which would adversely affect its business prospects, or it may be unable to continue operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including X4 Pharmaceuticals (Austria) GmbH, which is incorporated in Vienna, Austria (&#8220;X4 Austria&#8221;), and X4 Therapeutics, Inc. All significant intercompany accounts and transactions have been eliminated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet at December 31, 2022 that is presented in these interim condensed consolidated financial statements was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying condensed consolidated financial statements are unaudited. The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial statements. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s&#160;audited financial statements and the notes thereto for the year ended December&#160;31, 2022 included in the 2022 Annual Report filed with the SEC on March 21, 2023. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&#8217;s condensed financial position, condensed results of its operations and cash flows have been made. The results of operations for the three months ended March&#160;31, 2023 are not necessarily indicative of the results of operations that may be expected for the year ending December&#160;31, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the impairment or lack of impairment of long-lived assets including operating lease right-of-use assets and goodwill, and assumptions underlying the fair value of warrant liabilities. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780631312624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 21, 2023. Since the date of those consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:60.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.726%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Waltham lease</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Vienna Austria lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Boston lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s lease agreements for its facilities in Massachusetts and Austria, the Company maintains letters of credit, which are secured by restricted cash, for the benefit of the respective landlord. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the sum of the total of amounts shown in the Company&#8217;s condensed consolidated statements of cash flows as of March&#160;31, 2023 and December&#160;31, 2022:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:62.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.758%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,433&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,028&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then the Company would perform an interim quantitative impairment test, whereby the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than its carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no triggering events during the three months ended March&#160;31, 2023 that necessitated an interim impairment test of goodwill.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recently Adopted Accounting Standards</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments</span> (&#8220;ASU 2016-13&#8221;), as amended. ASU 2016-13 requires that financial assets measured at amortized cost, such as trade receivables, be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. The Company adopted ASU 2016-13 on January 1, 2023. As the Company did not have accounts receivable on its consolidated balance sheet as of the date of adoption, there was no impact to the adoption of ASU 2016-13.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780631382720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Funding Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License, Collaboration, and Funding Agreements</a></td>
<td class="text">LICENSE, COLLABORATION AND FUNDING AGREEMENTS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Incentive Program</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in a research and development incentive program provided by the Austrian government whereby the Company is entitled to reimbursement by the Austrian government for a percentage of qualifying research and development expenses and capital expenditures incurred by the Company&#8217;s subsidiary in Austria. As of March&#160;31, 2023, the amount due under the program is $0.7 million, which amount is included in research and development incentive receivable in the condensed consolidated balance sheet. During the three months ended March&#160;31, 2023 and 2022, the Company recorded $121.0 thousand and $135.3 thousand, respectively, of income related to the program within the condensed consolidated statements of operations as other income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, the Company entered into a license agreement with Genzyme (the &#8220;Genzyme Agreement&#8221;) pursuant to which the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company was granted an exclusive license to certain patents and intellectual property owned or controlled by Genzyme related to the CXCR4 receptor to develop and commercialize products containing licensed compounds (including but not limited to</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mavorixafor) for all therapeutic, prophylactic and diagnostic uses, with the exception of autologous and allogenic human stem cell therapy. Under the terms of the Genzyme Agreement, the Company is obligated to use commercially reasonable efforts to develop and commercialize licensed products for use in the field in the United States and at least one other major market country.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to pay Genzyme milestone payments in the aggregate amount of up to $25.0 million, contingent upon the achievement by the Company of certain clinical-stage regulatory and sales milestones with respect to licensed products. During three months ended March&#160;31, 2023, the Company accrued $5.0 million related to a development milestone under the Genzyme Agreement as the Company believes that it is probable under ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that the milestone will be achieved. The $5.0 million accrued payment has been recorded within research and development expense on the condensed consolidated statements of operations. An additional $7.0 million of regulatory milestone payments are not yet probable but are reasonably possible of becoming payable with the next twelve to eighteen month period under the Genzyme Agreement. The Company is also obligated to pay Genzyme tiered royalties based on net sales of licensed products that the Company commercializes under the agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain on Sale of Non-Financial Asset</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, a third party, who had previously acquired rights to certain intellectual property from the Company, terminated the arrangement and transferred these rights back to the Company. Also during the three months ended March 31, 2022, the Company transferred these rights to another third party in return for $0.5 million. The Company has no continuing involvement in any ongoing research and development activities associated with the intellectual property. The Company concluded that these third parties are "non-customers" as the underlying intellectual property transferred to and from these third parties supports potential drug candidates that are not aligned with the Company's strategic focus and, therefore, are not an output of the Company's ordinary activities. Accordingly, the Company accounted for the sale of the intellectual property as the sale of a non-financial asset under ASC Topic 610-20,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Gains and Losses from the Derecognition of Nonfinancial Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 610-20"), and included the gain in gain on sale of non-financial asset for the three months ended March 31, 2022. </span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material modifications of the Company&#8217;s license or collaboration agreements during the three months ended March&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780722646112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets and Liabilities</a></td>
<td class="text">FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of March 31, 2023 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class C warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2022 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities: </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class C warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,141&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,141&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash equivalents consisted of money market funds invested primarily in short term commercial paper, asset- backed securities, certificate of deposits and repurchase agreements. The money market funds were valued based on reported market pricing for the identical assets, which represents a Level 1 measurement, or by using inputs observable in active markets for similar securities, which represents a Level&#160;2 measurement.</span></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll-forward of the aggregate fair values financial instruments for which fair values are determined using Level 3 inputs:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:38.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.006%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.006%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.009%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Embedded Derivative Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class C Warrant Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,439)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,439)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31,  2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,692&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Embedded Derivative Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of the embedded derivative liability recognized in connection with the Company&#8217;s loan agreement with Hercules (see Note 7), which is associated with additional fees due to Hercules upon events of default, was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of this embedded derivative liability, which is reported within other non-current liabilities on the condensed consolidated balance sheets, is estimated by the Company at each reporting date based, in part, on the results of third party valuations, which are prepared based on a discounted cash flow model that considers the timing and probability of occurrence of a redemption upon an event of default, the potential amount of prepayment fees or contingent interest upon an event of default and the Company&#8217;s risk-adjusted discount rate of 14%. </span></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class C Warrant Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company issued Class C Warrants for the purchase of shares of its common stock in a public offering of common stock. The Class C Warrants are accounted for as a liability on the condensed consolidated balance sheet and are adjusted to fair value at period end through &#8220;other income (expense)&#8221; in the condensed, consolidated statements of operations and comprehensive loss. </span></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculated the fair value of the Class C Warrants using the Black-Scholes option pricing model, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which represents a Level 3 measurement within the fair value hierarchy, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the following inputs:</span></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:54.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.99</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780631398656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">PROPERTY AND EQUIPMENT, NET<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:58.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.635%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,332&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense related to property and equipment was $127 thousand and $133 thousand for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780632055280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_AccruedExpensesTextBlock', window );">Accrued Expenses</a></td>
<td class="text">ACCRUED EXPENSES<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued deferred financing fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,762&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,034&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_AccruedExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_AccruedExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780631403136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:58.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.635%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount, net of accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(767)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative accretion of end of term payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,381&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,619&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(554)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,315)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,304&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hercules Loan Agreement, As Amended</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into a Loan and Security Agreement (the &#8220;Hercules Loan Agreement&#8221;), as amended most recently in January 2023, with Hercules, under which the Company has borrowed an aggregate of $32.5 million of term loans to date representing the maximum borrowings. Borrowings under the Hercules Loan Agreement accrues interest at a variable rate equal to the greater of (i)&#160;10.15% or (ii)&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;prime rate plus 3.15%.&#160;In an event of default and until such event is no longer continuing, the interest rate applicable to borrowings would be increased by 4.0%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Hercules Loan Agreement are repayable in monthly interest-only payments through September 2024, and in equal monthly payments of principal and accrued interest from October&#160;1, 2024 until the maturity date of the loan on April 1, 2026; provided, however, if certain conditions are met and the Company achieves certain operational and financial milestones, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the maturity date will be extended to July 1, 2027. The Company may prepay all, but not less than all, of the outstanding borrowings, subject to a prepayment premium of 3.0% of the principal amount outstanding as of the date of repayment. In addition, the Hercules Loan Agreement provides for payments of $0.8 million and $1.3 million payable on July 1, 2023 and April 1, 2026, respectively, which payments are accelerated upon the prepayment of the borrowings upon the Company&#8217;s election or upon default of the loan. Borrowings under the Hercules Loan Agreement are collateralized by substantially all of the Company&#8217;s personal property and other assets except for its intellectual property (but including rights to payment and proceeds from the sale, licensing or disposition of the intellectual property). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Hercules Loan Agreement, the Company has agreed to affirmative and negative covenants. Pursuant to the Hercules Loan Agreement, the Company is required to maintain cash in an account or accounts in which Hercules has a first priority security interest, in an aggregate amount greater than $20.0 million. Upon the FDA&#8217;s approval of the sale and marketing of mavorixafor for the treatment to patients with WHIM syndrome with a label claim that is generally consistent with that sought in the Company&#8217;s New Drug Application filing, the required level shall be reduced to $10.0 million. A breach of any of the covenants under the Hercules Loan Agreement could result in a default under the loan. Upon the occurrence of an event of default under the loan facility with Hercules, the lender could elect to declare all amounts outstanding, if any, to be immediately due and payable and terminate all commitments to extend further credit. If there are any amounts outstanding that the Company is unable to repay, Hercules could proceed against the collateral to secure such indebtedness.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hercules Loan Agreement also restricts the Company&#8217;s ability to incur additional indebtedness, pay dividends, encumber its intellectual property, or engage in certain fundamental business transactions, such as mergers or acquisitions of other businesses, with certain exceptions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized interest expense under the Hercules Loan Agreement as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual effective interest rate of the Hercules Loan Agreement as of March&#160;31, 2023 is 13.8%. There were no principal payments due or paid under the Hercules Loan Agreement during the three months ended March&#160;31, 2023. An end-of-term payment of $1.3 million was paid during the three months ended March 31, 2023 in conjunction with the second amendment and restatement of the Hercules Loan Agreement, which was entered into on January 6, 2023. The Company concluded that the amendment and restatement represented a modification to the debt. Accordingly, fees paid to third parties directly related to the amended and restated debt were expensed as incurred and fees paid to Hercules in conjunction with the amendment and restatement were deferred and are being amortized to interest expense over the life of the debt arrangement using the effective interest method. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, future principal and accrued end-of-term payments due under the Hercules Loan Agreement were as follows (in thousands): </span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780631346976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements for its facilities in Boston, Massachusetts, which is the Company&#8217;s principal executive office; Vienna, Austria, which is the Company&#8217;s research and development center; and Waltham, Massachusetts, which the Company has sublet to a third party. There are no restrictions or financial covenants associated with any of the lease agreements. </span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Vienna Austria Leases&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for approximately 1,200 square meters of laboratory and office space in Vienna, Austria (&#8220;Vienna Lease&#8221;), which commenced in February 2021 for a term of 7 years. The annual base rent for the Vienna Lease is approximately $285 thousand.</span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Boston Lease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company leases approximately 28,000 square feet of office space in Boston, Massachusetts (&#8220;Boston Lease&#8221;), which serves as the Company&#8217;s headquarters. Base rental payments are approximately $1.1 million  annually, plus certain operating expenses. The term of the Boston Lease will continue until November 2026, unless earlier terminated. The Company has the right to sublease the premises, subject to landlord consent and also has the right to renew the Boston Lease for an additional five years at the then prevailing effective market rental rate. The Company is required to maintain a security deposit in the form of a letter of credit for $0.6&#160;million for the benefit of the landlord. </span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Waltham Lease&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately 6,000 square feet of office space in Waltham, Massachusetts (&#8220;Waltham Lease&#8221;). The Waltham Lease, as amended, commenced on January&#160;1, 2019, and expires on December 31, 2023. The base rent is approximately $0.3 million annually. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, which costs are not included in the determination of the leases&#8217; right-of-use assets or lease liabilities. The Company is subleasing the space to a third party for the duration of the lease. The right-of-use asset is being amortized to rent expense over the five-year term of the lease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As the Company&#8217;s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three months ended March&#160;31, 2023 and 2022 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.182%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8212;operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities due under lease agreements that have commenced as of March&#160;31, 2023 are as follows (in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:78.220%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder of the year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities as of March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,552&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780631343744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitment and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with contract manufacturing organizations (&#8220;CMOs&#8221;) for the production of mavorixafor for use in clinical trials. The Company&#8217;s agreement with the CMO who produces batches of drug substance for use in the Company&#8217;s clinical drug supply contains cancellation provisions that would require the Company to pay up to the full contract value upon cancellation. As of March&#160;31, 2023, the Company has approximately $0.8 million of such commitments in place subject to cancellation provisions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company to, among other things, indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification obligations. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of March&#160;31, 2023 or December&#160;31, 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to any legal proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780633406960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Common Stock Warrants</a></td>
<td class="text">COMMON STOCK AND COMMON STOCK WARRANTS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company&#8217;s Restated Certificate of Incorporation authorized the Company to issue 500 million shares of common stock, par value $0.001 per share. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of the holders of any preferred stock that may be issued. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. No cash dividends have been declared or paid to date. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with previous public and private sales of shares of its common stock, the Company has issued warrants and pre-funded warrants, which are exercisable for the purchase shares of the Company&#8217;s common stock. All outstanding warrants and pre-funded warrants are currently exercisable and do not have price reset provisions. Upon the closing of these public and </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">private offerings, the Company received approximately 99% of the exercise price for the pre-funded warrants, for which the remaining exercise price is equal to or less than $0.01 per share.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the Company&#8217;s outstanding warrants and pre-funded warrants to purchase shares of common stock consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares of<br/>Common<br/>Stock Issuable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 25, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 24, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 28, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 28, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 12, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 12, 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 19, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 19, 2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 13, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 12, 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 16, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,866,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 15, 2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 23, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 9, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,008,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">766,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 6, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,276,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 6, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,925,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 6, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 9, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,762,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 9, 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 9, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,800,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(f)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,871,750&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) In November 2019, the Company received $11.999 per pre-funded warrant, or $21.0 million in aggregate proceeds. Each pre-funded</span></div>warrant may be exercised for an additional $0.001 per pre-funded warrant. (b) In March 2021, the Company received $8.69 per pre-funded warrant, or $435 thousand in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant. (c) In November 2021, the Company received $4.97 per pre-funded warrant, or $10.0&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant. (d) In March 2022, the Company received $1.79 per pre-funded warrant, or $1.4&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant. (e) In July 2022, the Company received $1.094 per pre-funded warrant, or $14.5 million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.001  per pre-funded warrant.  (f) In December 2022, the Company received $1.099 per pre-funded warrant, or $7.5&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.001 per pre-funded warrant.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780631436784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Plans&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the following equity incentive plans:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The X4 Pharmaceuticals Inc. 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (the &#8220;2015 Plan&#8221;);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The X4 Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;); and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The X4 Pharmaceuticals Inc. 2019 Inducement Equity Incentive Plan (the &#8220;2019 Plan&#8221;)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company also has the following employee stock purchase plan:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The X4 Pharmaceutical Inc. 2017 Employee Stock Purchase Plan (the &#8220;2017 ESPP&#8221;)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These plans are administered by the Board of Directors or by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the term of the stock option may not be greater than ten years. Incentive stock options granted to employees and restricted stock awards granted to employees, officers, members of the board of directors, advisors, and consultants of the Company typically vest over four years. Non-statutory options granted to employees, officers, members of the board of directors, advisors, and consultants of the Company typically vest over three or four years. Shares that are expired, terminated, surrendered or canceled under the Plans without having been fully exercised will be available for future awards. In </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, there are an aggregate of approximately 1.0&#160;million shares of common stock available for issuance under the Company&#8217;s equity incentive plans. Approximately 150,000 shares of common stock remain available for issuance under the 2017 ESPP.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Valuation&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees, directors and non-employees.</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.961%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity for the three months ended March&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,021,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,080)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830,300&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163,500&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,210,011&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no stock options exercised in the three months ended March&#160;31, 2023 and 2022. The weighted average grant-date fair value per share of stock options granted during the three months ended March&#160;31, 2023 and 2022 was $0.69 and $1.42, respectively.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table summarizes the Company's restricted stock unit activity for the three months ended March 31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:78.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,680,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(540,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,835,016&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, the Company granted performance-based restricted stock units (&#8220;PRSUs&#8221;) to its employees. The PRSUs vest 50% based on the Company&#8217;s achievement of each of two operational milestones conditioned on the grantee&#8217;s continued employment with the Company. As of March 31, 2023, neither of the two performance criteria had been met. The Company believes that the achievement of these operational milestones is probable and, accordingly, stock-based compensation expense has been recognized for the awards using the accelerated attribution model based on the fair value of the awards as of the date of grant and management&#8217;s best estimate of the date each operational milestone will be achieved. The </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company will update its estimates related to the probability and timing of achievement of the operational milestones each period until the award either vests or is forfeited.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, total unrecognized compensation expense related to unvested stock options and restricted stock units was $6.2 million, which is expected to be recognized over a weighted average period of 1.3 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:56.148%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.463%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780631428464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXESThe Company did not record a U.S. federal or state income tax benefit for its losses for the three months ended March&#160;31, 2023 and 2022, due to the conclusion that a full valuation allowance is required against the Company&#8217;s U.S. federal and state deferred tax assets. For the three months ended March&#160;31, 2023 and 2022, the Company recorded an immaterial income tax provision related to its Austrian subsidiary.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780632063376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">NET LOSS PER SHARE<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to common stockholders was calculated as follow:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:67.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.977%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,965)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend as a result of Class B warrant price reset </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,259)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,020)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,224)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding&#8212;basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders&#8212; basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.72)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted weighted average shares of common stock outstanding for the three months ended March&#160;31, 2023 and March&#160;31, 2022 include the weighted average effect of outstanding pre-funded warrants for the purchase of shares of common stock for which the remaining unfunded exercise price is $0.01 or less per share. During the three months ended March 31, 2022, in accordance with the Company&#8217;s Class B Warrant agreement, the exercise price of each outstanding Class B Warrant was adjusted to the price of shares of the Company&#8217;s common stock sold in public or private offerings to the extent such price is lower than the previous Class B warrant price. These price adjustments were accounted for as a deemed dividend that adjusts net loss available to common shareholders for purposes of basic earnings per share. The deemed dividend was calculated using the Black-Scholes pricing model, taking into account historical volatility of the Company&#8217;s common stock and the estimated remaining life of the outstanding Class B Warrants. The Class B Warrants expired in December 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities include outstanding stock options, unvested restricted stock units and warrants to purchase shares of common stock for the three months ended March&#160;31, 2023 and 2022. All potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share, and thus they are considered &#8220;anti-dilutive.&#8221; Therefore, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:65.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.153%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase shares of common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,835,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,940,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase shares of common stock (excluding prefunded warrants, which are included in basic shares outstanding)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,720,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,449,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,386,089&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,438,974&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780630658192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including X4 Pharmaceuticals (Austria) GmbH, which is incorporated in Vienna, Austria (&#8220;X4 Austria&#8221;), and X4 Therapeutics, Inc. All significant intercompany accounts and transactions have been eliminated.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the impairment or lack of impairment of long-lived assets including operating lease right-of-use assets and goodwill, and assumptions underlying the fair value of warrant liabilities. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#8217;s consolidated financial statements.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents&#8212;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of March&#160;31, 2023 and December&#160;31, 2022.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then the Company would perform an interim quantitative impairment test, whereby the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than its carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no triggering events during the three months ended March&#160;31, 2023 that necessitated an interim impairment test of goodwill.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text">Recently Adopted Accounting Standards<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments</span> (&#8220;ASU 2016-13&#8221;), as amended. ASU 2016-13 requires that financial assets measured at amortized cost, such as trade receivables, be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. The Company adopted ASU 2016-13 on January 1, 2023. As the Company did not have accounts receivable on its consolidated balance sheet as of the date of adoption, there was no impact to the adoption of ASU 2016-13.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780631295856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensatingBalancesTextBlock', window );">Schedule of Restricted Cash</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:60.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.726%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Waltham lease</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Vienna Austria lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter of credit security: Boston lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the sum of the total of amounts shown in the Company&#8217;s condensed consolidated statements of cash flows as of March&#160;31, 2023 and December&#160;31, 2022:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:62.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.758%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,433&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,028&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensatingBalancesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes disclosure of these arrangements and the amount involved, if determinable, for the most recent audited balance sheet required and for any subsequent unaudited balance sheet required in the notes to the financial statements. Compensating balances that are maintained under an agreement to assure future credit availability are generally disclosed in the notes to the financial statements along with the amount and terms of such agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 6.H.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13728-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensatingBalancesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of reconciliation of cash and cash equivalents and restricted cash to cashflows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780633388128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of March 31, 2023 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class C warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2022 Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#8212;money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities: </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class C warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,141&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,141&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Aggregate Fair Values of Warrant Liability and Derivative Liability</a></td>
<td class="text"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll-forward of the aggregate fair values financial instruments for which fair values are determined using Level 3 inputs:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:38.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.006%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.006%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.009%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Embedded Derivative Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class C Warrant Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,439)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,439)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31,  2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,692&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:54.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.99</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780631353152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:58.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.635%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,332&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780631428464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued deferred financing fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,762&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,034&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780633102144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Long Term Debt</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:58.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.635%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount, net of accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(767)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative accretion of end of term payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,381&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,619&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(554)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,315)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,304&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Interest Income and Interest Expense Disclosure</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized interest expense under the Hercules Loan Agreement as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Principal Payments and the Final Payments Due</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, future principal and accrued end-of-term payments due under the Hercules Loan Agreement were as follows (in thousands): </span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780630158224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three months ended March&#160;31, 2023 and 2022 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.182%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8212;operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities due under lease agreements that have commenced as of March&#160;31, 2023 are as follows (in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:78.220%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remainder of the year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities as of March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,552&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780631416544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the Company&#8217;s outstanding warrants and pre-funded warrants to purchase shares of common stock consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares of<br/>Common<br/>Stock Issuable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 25, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 24, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 28, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 28, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 12, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 12, 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 19, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 19, 2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 13, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 12, 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 16, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,866,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 15, 2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 23, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 9, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,008,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">766,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 6, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,276,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 6, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,925,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 6, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 9, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,762,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 9, 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 9, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,800,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(f)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,871,750&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) In November 2019, the Company received $11.999 per pre-funded warrant, or $21.0 million in aggregate proceeds. Each pre-funded</span></div>warrant may be exercised for an additional $0.001 per pre-funded warrant. (b) In March 2021, the Company received $8.69 per pre-funded warrant, or $435 thousand in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant. (c) In November 2021, the Company received $4.97 per pre-funded warrant, or $10.0&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant. (d) In March 2022, the Company received $1.79 per pre-funded warrant, or $1.4&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant. (e) In July 2022, the Company received $1.094 per pre-funded warrant, or $14.5 million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.001  per pre-funded warrant.  (f) In December 2022, the Company received $1.099 per pre-funded warrant, or $7.5&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.001 per pre-funded warrant.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780630024928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Stock Option Valuation</a></td>
<td class="text">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees, directors and non-employees.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.961%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity for the three months ended March&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,021,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,080)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830,300&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163,500&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,210,011&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table summarizes the Company's restricted stock unit activity for the three months ended March 31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:78.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,680,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(540,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,835,016&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-Based Compensation Expense Classification</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:56.148%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.463%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of the fair value of the outstanding SARs as of March&#160;31, 2023 includes the closing price of the Company&#8217;s common stock of $0.87 and the following assumptions on a weighted average basis:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:76.959%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.200%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.61</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected forfeiture rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780633123984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to common stockholders was calculated as follow:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:67.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.977%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,965)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend as a result of Class B warrant price reset </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,259)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,020)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,224)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding&#8212;basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders&#8212; basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.72)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text">The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:65.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.153%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase shares of common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,835,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,940,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase shares of common stock (excluding prefunded warrants, which are included in basic shares outstanding)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,720,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,449,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,386,089&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,438,974&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780630241312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 93,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(400,758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (376,738)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">$ (26,512)<span></span>
</td>
<td class="num">$ (20,229)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780628284112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Compensating Balance Arrangements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Total restricted cash</a></td>
<td class="nump">$ 777<span></span>
</td>
<td class="nump">$ 1,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash, current portion</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Vienna Austria Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Allston Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">$ 571<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_WalthamLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_WalthamLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_ViennaLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_ViennaLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_AllstonLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_AllstonLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780628374288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 93,406<span></span>
</td>
<td class="nump">$ 121,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash, current portion</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 94,433<span></span>
</td>
<td class="nump">$ 123,028<span></span>
</td>
<td class="nump">$ 67,744<span></span>
</td>
<td class="nump">$ 83,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780627784960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Funding Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">$ 123,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain (Loss) on Disposition of Other Assets</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xfor_ResearchAndDevelopmentIncentiveProgramMember', window );">Research and Development Incentive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_GrantAndIncentiveReceivables', window );">Grant receivable</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">$ 121,000<span></span>
</td>
<td class="nump">$ 135,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_CollaborationLicenseAndFundingArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration, license and funding arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_CollaborationLicenseAndFundingArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_GrantAndIncentiveReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant and incentive receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_GrantAndIncentiveReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xfor_ResearchAndDevelopmentIncentiveProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xfor_ResearchAndDevelopmentIncentiveProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780628016656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities Measured at Fair Value (Detail) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 70,973<span></span>
</td>
<td class="nump">$ 73,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">17,702<span></span>
</td>
<td class="nump">23,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Class C Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">17,692<span></span>
</td>
<td class="nump">23,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">70,959<span></span>
</td>
<td class="nump">70,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">2,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">17,702<span></span>
</td>
<td class="nump">23,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Class C Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">$ 17,692<span></span>
</td>
<td class="nump">$ 23,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780628496544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Aggregate Fair Values Financial Instruments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 23,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(5,439)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">17,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember', window );">Embedded Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Class C Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">23,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(5,439)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 17,692<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780633123984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780625847632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Fair Value Assumptions (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.80%<span></span>
</td>
<td class="nump">94.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of warrant liability</a></td>
<td class="nump">$ 17,702<span></span>
</td>
<td class="nump">$ 23,141<span></span>
</td>
<td class="nump">$ 17,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Class C Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share)</a></td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (in percentage)</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 7 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (in percentage)</a></td>
<td class="nump">91.90%<span></span>
</td>
<td class="nump">101.70%<span></span>
</td>
<td class="nump">90.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (in percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780628286848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,341<span></span>
</td>
<td class="nump">$ 2,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(1,355)<span></span>
</td>
<td class="num">(1,228)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">986<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,274<span></span>
</td>
<td class="nump">1,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_SoftwareMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 642<span></span>
</td>
<td class="nump">$ 639<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_SoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_SoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xfor_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780630663120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780630262000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee compensation and benefits</a></td>
<td class="nump">$ 2,742<span></span>
</td>
<td class="nump">$ 6,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_AccruedExternalResearchAndDevelopmentExpenses', window );">Accrued external research and development expenses</a></td>
<td class="nump">7,721<span></span>
</td>
<td class="nump">3,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">924<span></span>
</td>
<td class="nump">571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_AccruedLeaseConstructionCosts', window );">Accrued deferred financing fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 11,762<span></span>
</td>
<td class="nump">$ 12,034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_AccruedExternalResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued external research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_AccruedExternalResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_AccruedLeaseConstructionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Lease Construction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_AccruedLeaseConstructionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780625820208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Summary of Long Term Debt (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount of long-term debt</a></td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="nump">$ 32,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Debt discount, net of accretion</a></td>
<td class="num">(767)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_AccretionOnLongTermDebt', window );">Cumulative accretion of end of term payments</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">1,315<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_LongTermDebtIncludingAccretion', window );">Long-term debt</a></td>
<td class="nump">32,381<span></span>
</td>
<td class="nump">33,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="num">(554)<span></span>
</td>
<td class="num">(1,315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Long-term debt, net of current portion</a></td>
<td class="nump">$ 31,827<span></span>
</td>
<td class="nump">$ 32,304<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, including portion classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_AccretionOnLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion on long term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_AccretionOnLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LongTermDebtIncludingAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Including Accretion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LongTermDebtIncludingAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780625710496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt - Hercules Loan Agreement - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2024</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember', window );">Hercules Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument variable percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate increase percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPayment', window );">Line of credit facility periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember', window );">Hercules Loan Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPayment', window );">Line of credit facility periodic payment</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember', window );">Hercules Loan Agreement | Maximum | Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_DebtInstrumentPrepaymentPremiumPercentage', window );">Debt instrument prepayment premium, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember', window );">Hercules Loan Agreement | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument variable percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesSecondAmendedLoanAgreementMember', window );">Hercules Second Amended Loan Agreement | Min Cash Test Date 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_LineOfCreditCovenantMinimumCash', window );">Line of Credit, Covenant, Minimum Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xfor_HerculesSecondAmendedLoanAgreementMember', window );">Hercules Second Amended Loan Agreement | Min Cash Test Date 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_LineOfCreditCovenantMinimumCash', window );">Line of Credit, Covenant, Minimum Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments of both interest and principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_DebtInstrumentPrepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Prepayment Premium, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_DebtInstrumentPrepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LineOfCreditCovenantMinimumCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit, Covenant, Minimum Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LineOfCreditCovenantMinimumCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xfor_HerculesSecondAmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xfor_HerculesSecondAmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=xfor_MinCashTestDate1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=xfor_MinCashTestDate1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=xfor_MinCashTestDate2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=xfor_MinCashTestDate2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780633427008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Summary of Interest Expense (Details) - Hercules Loan Agreement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="nump">$ 884<span></span>
</td>
<td class="nump">$ 909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xfor_HerculesLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780630201584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Future Principal Payments and the Final Payments Due (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">4,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">20,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">7,458<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_LongTermDebtAndEOTPayment', window );">Principal amount of long-term debt</a></td>
<td class="nump">$ 33,148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LongTermDebtAndEOTPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term debt and end of term payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LongTermDebtAndEOTPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780625681024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 11, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>m&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,844<span></span>
</td>
<td class="nump">$ 7,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_WalthamLeaseMember', window );">Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_CurrentOfficeSpaceUnderLeaseAgreement', window );">Current office space under lease agreement | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_AggregateBaseRent', window );">Current base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease, term of contract (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_ViennaAustriaLeaseMember', window );">Vienna Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace', window );">Office space | m&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease not yet commenced, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent', window );">Annual base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_AllstonLeaseMember', window );">Allston Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_CurrentOfficeSpaceUnderLeaseAgreement', window );">Current office space under lease agreement | ft&#178;</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount', window );">Lease not yet commenced</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease, renewal term of contract (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_AggregateBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_AggregateBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_CurrentOfficeSpaceUnderLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current office space under lease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_CurrentOfficeSpaceUnderLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Annual Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Office Space</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_WalthamLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_WalthamLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_ViennaAustriaLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_ViennaAustriaLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_AllstonLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=xfor_AllstonLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780628475616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed operating lease cost</a></td>
<td class="nump">$ 522<span></span>
</td>
<td class="nump">$ 530<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">522<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term-operating leases (in years)</a></td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate-operating leases</a></td>
<td class="nump">11.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780628179744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 1,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">1,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">1,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">5,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(1,112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">$ 4,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780631282320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xfor_IndemnificationAgreementsMember', window );">Indemnification Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_ContingenciesAndCommitmentsLineItems', window );"><strong>Contingencies And Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ContingenciesAndCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingencies And Commitments [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ContingenciesAndCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xfor_IndemnificationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xfor_IndemnificationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780628270848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 06, 2022</div></th>
<th class="th"><div>Mar. 03, 2022</div></th>
<th class="th"><div>Mar. 23, 2021</div></th>
<th class="th"><div>Nov. 02, 2020</div></th>
<th class="th"><div>Nov. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends on common stock declared or paid</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights', window );">Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_Q12022PrivatePlacementMember', window );">Q1 2022 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights', window );">Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_Q12022PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_Q12022PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780623074784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 09, 2022</div></th>
<th class="th"><div>Jul. 06, 2022</div></th>
<th class="th"><div>Mar. 03, 2022</div></th>
<th class="th"><div>Nov. 09, 2021</div></th>
<th class="th"><div>Mar. 23, 2021</div></th>
<th class="th"><div>Nov. 02, 2020</div></th>
<th class="th"><div>Nov. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">111,871,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued', window );">Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights', window );">Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_PrefundedWarrantsAxis=xfor_FundedMember', window );">Funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.094<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="nump">$ 4.97<span></span>
</td>
<td class="nump">$ 8.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember', window );">Issuance On October 25, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 19.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember', window );">Issuance On October 25, 2016 | Legacy Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">5,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember', window );">Issuance On December 28, 2017 One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 19.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember', window );">Issuance On December 28, 2017 One | Legacy Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">115,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember', window );">Issuance On September 12, 2018 One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 19.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember', window );">Issuance On September 12, 2018 One | Legacy Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">20,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember', window );">Issuance On October 19, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 19.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember', window );">Issuance On October 19, 2018 | Legacy Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">20,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember', window );">Issuance On March 13, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 19.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember', window );">Issuance On March 13, 2019 | Legacy Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember', window );">Issuance On April 16, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember', window );">Issuance On April 16, 2019 | Class A Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">3,866,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember', window );">Issuance On November 29, 2019 One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember', window );">Issuance On November 29, 2019 One | Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch232021Member', window );">Issuance On March 23, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 8.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch232021Member', window );">Issuance On March 23, 2021 | Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember', window );">Issuance on November Nine Two Thousand Twenty One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">2,008,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 4.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch32022Member', window );">Issuance on March 3 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">766,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnJuly20221Member', window );">Issuance on July 2022 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">13,276,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 1.095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnJuly620222Member', window );">Issuance on July 6 2022 Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">50,925,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 1.095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnDecember92022Member', window );">Issuance on December 9 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">32,762,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnDecember920222Member', window );">Issuance on December 9 2022 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable (in shares)</a></td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Additional Exercise Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_PrefundedWarrantsAxis=xfor_FundedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_PrefundedWarrantsAxis=xfor_FundedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_LegacyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_LegacyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_ClassAWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_ClassAWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch232021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch232021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch32022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnMarch32022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnJuly20221Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnJuly20221Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnJuly620222Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnJuly620222Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnDecember92022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnDecember92022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnDecember920222Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xfor_IssuanceOnDecember920222Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780625676624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue', window );">Options granted, weighted average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 1.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost of stock based awards</a></td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost of stock based awards, recognition period</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xfor_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xfor_TwoThousandSeventeenEquityIncentivePlanMember', window );">Two Thousand Seventeen Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Awards Grant in Period Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xfor_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xfor_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xfor_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xfor_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780628451904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-date Fair Value of Stock Options Granted (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.80%<span></span>
</td>
<td class="nump">94.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Class C Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (in percentage)</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 7 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (in percentage)</a></td>
<td class="nump">91.90%<span></span>
</td>
<td class="nump">101.70%<span></span>
</td>
<td class="nump">90.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (in percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate', window );">Expected forfeiture rate (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Forfeiture Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780629975344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,021,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">834,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(26,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">2,830,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares Options, Exercisable (in shares)</a></td>
<td class="nump">1,163,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares Options, Vested and expected to vest (in shares)</a></td>
<td class="nump">2,210,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in usd per share)</a></td>
<td class="nump">$ 6.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in usd per share)</a></td>
<td class="nump">8.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in usd per share)</a></td>
<td class="nump">5.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable (in usd per share)</a></td>
<td class="nump">9.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested and expected to vest (in usd per share)</a></td>
<td class="nump">$ 6.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual term outstanding (in years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual term outstanding, Exercisable (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual term outstanding, Vested and expected to vest (in years)</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Beginning balance</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780628201136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">4,694,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(540,238)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested ending balance (in shares)</a></td>
<td class="nump">5,835,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested beginning balance (in shares)</a></td>
<td class="nump">1,680,563<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780627951472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Summary of Stock-Based Compensation Expense Classification (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 1,645<span></span>
</td>
<td class="nump">$ 1,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">831<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 814<span></span>
</td>
<td class="nump">$ 755<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780628218608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780628362336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,020)<span></span>
</td>
<td class="num">$ (21,965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPaidinkind', window );">Dividends, Paid-in-kind</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,259)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (24,020)<span></span>
</td>
<td class="num">$ (24,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xfor_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding&#8212;basic</a></td>
<td class="nump">145,967,000<span></span>
</td>
<td class="nump">33,737,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding&#8212;diluted</a></td>
<td class="nump">145,967,000<span></span>
</td>
<td class="nump">33,737,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders&#8212;basic</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders&#8212;diluted</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPaidinkind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid paid-in-kind dividends (PIK) declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPaidinkind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Denominator</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xfor_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Numerator</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xfor_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xfor_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780627999472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net Loss per Share - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember', window );">Pre Funded Warrant | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xfor_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139780632421552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share (in shares)</a></td>
<td class="nump">96,386,089<span></span>
</td>
<td class="nump">13,438,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share (in shares)</a></td>
<td class="nump">2,830,300<span></span>
</td>
<td class="nump">2,049,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share (in shares)</a></td>
<td class="nump">5,835,016<span></span>
</td>
<td class="nump">1,940,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Class C Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share (in shares)</a></td>
<td class="nump">87,720,773<span></span>
</td>
<td class="nump">9,449,028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>xfor-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xfor="http://www.x4pharma.com/20230331"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="xfor-20230331.xsd" xlink:type="simple"/>
    <context id="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia80ce664878241a6a1f41c82e266dff4_I20230501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="i8402c14812aa4792af598dc3f27820a4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1ca029d12cad45af98e015984da7cdeb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i553e6350cf6c429980b87aeb902c6c55_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i148ac761490846059a641c4096bff174_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2b29c1af764d49dd8a2b25cd40f9c5e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idd2737e0aa5e4ceda68812a691c9447b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if43cc4ccf2b647bfba5772dafdf4d1df_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3bcc5907b6014b9d93c0ce335d74d143_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id687fd50375c4b9289fc38f39c37c931_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7da3eb074b8d4cb09f155d7cbd131475_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3c39f890c41047c9a65d791fe89d7f5c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2699357e209d4ca393deb31d5b50ef76_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id4f97645aff94169b01a7e55e7ad5b86_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib174ac43e0694fac9a20163af9e3c6c1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id108597db204485299a9f94cb8127d3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51c1bc362afa49eeb95ed63f82caa21b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4fed87c65647480c8d625fffe1b0ea5c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b481bc1391f4635a7c7fc91a64f1e08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i127a474f92264d58b7e85a4321f95964_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06ba2f0164234d80aef6eb30ab849e77_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id4b750c506b44cbda93e01a7505ed761_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iec90ace9f4384f59bd0e68d11db46c7a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia32dbc78288b4274b74a087a419e35ff_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5cb4dfe1750c4c539b0698f339b61a94_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i83228390dcb849b29ea600f914617cc1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3f2a6bfe01ec46bc85d75976e40b1ab0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4a25074b350146a4adca9401db84ac82_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic5139ec8cd3c4c57a78f7ac8c654556a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic7ba5290654141e4b61b83ad34d08c17_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i810c7142f18049f48bf12b8c5fed906f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaLeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ied52c772cd6240a0a1fae6e51f2ddfb4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaLeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i654563320ef74399a7b67534f01c3d1f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i57677a75b59a47908ea0dc176c8f9bcd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide51a96471e14846b0eafc7204f8f180_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i65095af2a0774d4ca62250a84f77486a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia0808869d78f44fcb077f2e781a826d0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4569714abef741429d743af4a4bf2be0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8c1816e489194f42bdd5f5bf10009b9c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if2ab8413e7e84528b4f5fdcb13e35002_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifeef5c014ddc40deb4afa45ea2116298_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i381526f76190408a9511bfe7c72a7ff0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i135f5bb1ba83401da08651bc765c88e9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icfb4d92d12744b63a445624d8eac9b0c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i73a291db2a214ab8bd5e5491ada2141b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie5dd8502aef84153bdcb16bdbd51c805_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia57db8f000ee4e0db6a8ea78cb129405_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia4afbc3f95ef42a4b901ae73cd5145db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia3668be13a034a95babcca27311d8576_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5e321b38d9d409c9c0f8404d848b3dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d6a3b6f090b4a87bcfb08e640d71bba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1b09f270112741469f241038cd756330_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib3b2a90a4f734a278a5d983fe879b015_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e93d6b488d5402094357867417eaf30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia6a0892801fe4d00ba9b8e44831c13dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i416807bcc91c4426b94694508810dfe8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib7ba75f2aa194fdfa790914ca3e5f732_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d93fbb6a1a344a8b945a2a6d090a483_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i81add40f359a4d498e9c203424802dfe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i64eed22c85fc47188e427943319310db_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id13c30409f644883bc0984bf6cca3669_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id99d965540fb4a3d8b3bf165eb026ad5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idf55d74b96f44b02b711f225b809780f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i600de8e95d2f4f32915317e0807fd211_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4adf5f56124545d5a93d3519e1e8f047_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i08cceb6ad460483886bad3c9fcd6710e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6fbe040e10eb4417b2f7665f9b30f4e7_D20230331-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8067028e2bde498d90d62f8632965d93_D20221231-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i833765a4f0bd42efb5804d15e1b6865f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i64189e1012e04d2a966fd7a2f71a3db9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i13aa4785edcb43ea8c372564342c427b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3e5c556c18904363b107b9fc923ba681_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7410737db5a84986b20145230e3dfa68_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie6c7932d5157432c9771d0031da998c3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i94a2b42432f045c69a6a314871000d9c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i121a3bffe8da40d3bfa57370f4d064ce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i17c81259a02f42f0875544b1198e4095_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i06a2ca03978148dc9bd965d74ecd6189_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xfor:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4e9d1a47182c4c47854e138d3c2b5d17_D20181001-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie15dfe94dd9d4fe39d6d8e1f3b74ce9a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic8e87f99c10e4fb881a7bed5735567ff_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i28f0cf51fe7e42fbb78f10ac69a552e6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia310f627aef34b0faca97728c514f3c1_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i792dfc869c4b408e892ad399f14978bb_D20240701-20240701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-01</endDate>
        </period>
    </context>
    <context id="ia4e98937b5cb4858b0ac41a2a5352c45_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">xfor:MinCashTestDate1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie2d3052cd5e24327abde1e8113a23cd2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">xfor:MinCashTestDate2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesSecondAmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i758d637f0af747e88e3b2ef6d3eae458_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib8529518add445d8a6792e09b74e9bf9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xfor:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if95bc8592c8940cab11430e303f438e5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaAustriaLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i44b39b28bc5548a2886646bbc220829d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:ViennaAustriaLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i25a8d7091c814a1188d29fe34e7e629d_D20191111-20191111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-11</startDate>
            <endDate>2019-11-11</endDate>
        </period>
    </context>
    <context id="i23498fecf6314534a7194a398e3e01ba_I20191111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:AllstonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-11</instant>
        </period>
    </context>
    <context id="i25e5f6ca21c44724bd4163d8dc79dbe2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i02b354bcacc54b7baa76c20057184051_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">xfor:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9d0d898499ff4bda99b5eb41e4b472d0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:IndemnificationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib84837e886bd42e9be166c81d4c7ebdf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xfor:IndemnificationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c446d1ebf6c4761a059bfe41f76a3e8_I20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:Q12022PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-23</instant>
        </period>
    </context>
    <context id="i59fa5f3cd8cf463cb6ab5a26e83105b0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iade75dd12e4e4311828ad8732615848a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic7ff88f12eeb444480a302991cd38a77_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ica711cd3944d444d8e90591b4f36f165_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i659abfcb1f9b4bab9b076ba940943d85_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8f782c581af34e0bbaf1f1c156ed8abd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id50d3ea6ecda45bb92708c1a5fcceadc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberNineteenTwoThousandEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i831b8fe131874b52b6235c73b19040d9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnOctoberNineteenTwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i44c6c0606f1e473a95f0fd0e8f1f0ceb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarchThirteenTwoThousandNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:LegacyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie46fdfe3fed3486d838e54a83d18ef93_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarchThirteenTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i61d35b6a71594a80acb565c214ebd4d8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnAprilSixteenTwoThousandNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:ClassAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i57d428ba32094371b2dd937c8006e5f0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnAprilSixteenTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6e73b6bdb52e4b4289aa86a4856b47d5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7df7eb9e7da8482fafec0c3a38337782_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idb769b89cd694464bdd20ebea31ac73d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarch232021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i721101088e744db48fa346c2c77fd85b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarch232021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic3c41890d3204b10bab8bd252409ac92_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnNovemberNineTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id9018c6d85d24e0dba02aaac05afaddb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnMarch32022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5011564a8640482d8512bf19c9642f10_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnJuly20221Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7edde0006e1e454d8fea426452b3b54e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnJuly620222Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i818c42fab04d4637b93d77e2ac2f2974_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnDecember92022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i21bf4eefdb5f491ca5fc00294f5db16a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xfor:IssuanceOnDecember920222Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib89426f0e382467982b04ef21eb04de6_I20191129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-29</instant>
        </period>
    </context>
    <context id="i7b8255b9ad4e4346b4353461add65217_I20191129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2019-11-29</instant>
        </period>
    </context>
    <context id="i4a0759706aef4898bfd9353dc9c1c0cf_I20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-23</instant>
        </period>
    </context>
    <context id="ibd18ae94cc92493599001fb5cde340a6_I20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2021-03-23</instant>
        </period>
    </context>
    <context id="i7b76566d4b4d440f9b96f6bd007aea3e_I20211109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-09</instant>
        </period>
    </context>
    <context id="i0fe40bc1e0fd489aa6756bc0c4fcb174_I20211109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2021-11-09</instant>
        </period>
    </context>
    <context id="i3f7f41a7ee2c446eb9fdb515a92b8d90_I20201102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2020-11-02</instant>
        </period>
    </context>
    <context id="i4705077c59e44584ac747abb1c31531c_I20220303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-03</instant>
        </period>
    </context>
    <context id="ie54bb572558c468f842e439ada8634bb_I20220303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2022-03-03</instant>
        </period>
    </context>
    <context id="iac8921647cac40fbafd7ae760b99dccc_I20220706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xfor:PrefundedWarrantsAxis">xfor:FundedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-06</instant>
        </period>
    </context>
    <context id="i057e951826ef4df4b14c1200eeac39f1_I20220706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2022-07-06</instant>
        </period>
    </context>
    <context id="i9bda35ba3715478cb44dadfb584bfff4_I20221209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <instant>2022-12-09</instant>
        </period>
    </context>
    <context id="i9c915254cae9474f9c1872cf496e414a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if3afe5f2291441f68f12e2ab64cf0818_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xfor:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4740594349684b0589e4efe56fcf1e5b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9f9fb24c8bb04a26883c4eb1d92a0d6b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86fbb46408bd4a3db8bc2da79cf7f762_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i21e6f989318241fbbefaf5468e259ca9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i19a10edec5d54b3ca68a4c28e1bf34a1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i15e8f73d1083480daefae46435fca891_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2770b271c4ae4bbb9a3c41d6903a369a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8e768118a7db47359a07259561180c69_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4221465155da49fe9746bea8dd9a5099_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i543a1b3b9f974153b5b0d78f5aa7e65a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xfor:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1f3437aea96f4fe886c79fb94a8059fe_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idcded639cedf4a788b3eecce804bc350_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i81603c1b6ca6430691c2b72f0262d107_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4c0ed81ded19458591eb27f59b52093f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iac5b1bc09d7c443491ee3a29c39946f6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie95358238f73468db9f71aef1ce13baf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqm">
        <measure>utr:sqm</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80L2ZyYWc6ZjZhNzE2OTM1NjBlNDBhMmI1YzY3MDdjZDY1N2Q1MDUvdGFibGU6Y2U0MjVjMWM1ZjRhNGE5YWE5YWQ4MjQ4OWY1MDMzNWYvdGFibGVyYW5nZTpjZTQyNWMxYzVmNGE0YTlhYTlhZDgyNDg5ZjUwMzM1Zl8wLTEtMS0xLTY4NTg1_68177959-6286-4b21-9986-c6beec79801a">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80L2ZyYWc6ZjZhNzE2OTM1NjBlNDBhMmI1YzY3MDdjZDY1N2Q1MDUvdGFibGU6Y2U0MjVjMWM1ZjRhNGE5YWE5YWQ4MjQ4OWY1MDMzNWYvdGFibGVyYW5nZTpjZTQyNWMxYzVmNGE0YTlhYTlhZDgyNDg5ZjUwMzM1Zl8xLTEtMS0xLTY4NTg1_678f4766-ea67-4219-9ec2-4a0dc069621f">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80L2ZyYWc6ZjZhNzE2OTM1NjBlNDBhMmI1YzY3MDdjZDY1N2Q1MDUvdGFibGU6Y2U0MjVjMWM1ZjRhNGE5YWE5YWQ4MjQ4OWY1MDMzNWYvdGFibGVyYW5nZTpjZTQyNWMxYzVmNGE0YTlhYTlhZDgyNDg5ZjUwMzM1Zl8yLTEtMS0xLTY4NTg1_bedf9fbd-4a01-4434-a286-78939292545d">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80L2ZyYWc6ZjZhNzE2OTM1NjBlNDBhMmI1YzY3MDdjZDY1N2Q1MDUvdGFibGU6Y2U0MjVjMWM1ZjRhNGE5YWE5YWQ4MjQ4OWY1MDMzNWYvdGFibGVyYW5nZTpjZTQyNWMxYzVmNGE0YTlhYTlhZDgyNDg5ZjUwMzM1Zl8zLTEtMS0xLTY4NTg1_1fc6ed3e-70c2-479f-ad8e-befaa21bb094">0001501697</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80L2ZyYWc6ZjZhNzE2OTM1NjBlNDBhMmI1YzY3MDdjZDY1N2Q1MDUvdGFibGU6Y2U0MjVjMWM1ZjRhNGE5YWE5YWQ4MjQ4OWY1MDMzNWYvdGFibGVyYW5nZTpjZTQyNWMxYzVmNGE0YTlhYTlhZDgyNDg5ZjUwMzM1Zl80LTEtMS0xLTY4NTg1_886c9b5f-209a-4ec8-946c-dbc13bf487ac">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8yMzU1_0204fd1b-0b94-41e9-837e-e174980513bf">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6MmVhNWY1YTI5N2FlNGQ5MzgxY2EyMzEwYTE5MTU1ZDkvdGFibGVyYW5nZToyZWE1ZjVhMjk3YWU0ZDkzODFjYTIzMTBhMTkxNTVkOV8wLTAtMS0xLTY4NTg1_9d3a41a6-f75d-4082-b10e-f3e8b6c1584f">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8zMDQ_b553e18a-5ec3-4216-a389-b7edecd5ff36">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6YWMyZWYyOTA2ZTEyNDhmNDhmMTJmMGU5OTUzZmE2MDIvdGFibGVyYW5nZTphYzJlZjI5MDZlMTI0OGY0OGYxMmYwZTk5NTNmYTYwMl8wLTAtMS0xLTY4NTg1_81883e9b-2ad4-4ccf-a9f9-eb4fd8acbdb6">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8zOTI_260061d6-15f0-45c1-9933-c02f2a22ee80">001-38295</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8yMzU2_b005df42-f686-4d6f-b037-4bb9535f0ff8">X4 PHARMACEUTICALS, INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6MTA3YzM1MGU3ZTAzNDgxNmI4MDY3YWIyYTdjNjQ3YTAvdGFibGVyYW5nZToxMDdjMzUwZTdlMDM0ODE2YjgwNjdhYjJhN2M2NDdhMF8wLTAtMS0xLTY4NTg1L3RleHRyZWdpb246NzZlMTQ1NWM0ZGRkNDJhMDk4Zjc0ZjY0Yzg3ODgwOGNfNQ_ed9c57d6-ccac-451e-82fb-04689c70708d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6MTA3YzM1MGU3ZTAzNDgxNmI4MDY3YWIyYTdjNjQ3YTAvdGFibGVyYW5nZToxMDdjMzUwZTdlMDM0ODE2YjgwNjdhYjJhN2M2NDdhMF8wLTEtMS0xLTY4NTg1L3RleHRyZWdpb246MzdkMWM3YThiZmEwNGE5YjkzY2RiNmZkZDk1ZDU0YjVfNQ_3944cd9a-731d-4786-af36-d01bf7b3e3f6">27-3181608</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6MTA3YzM1MGU3ZTAzNDgxNmI4MDY3YWIyYTdjNjQ3YTAvdGFibGVyYW5nZToxMDdjMzUwZTdlMDM0ODE2YjgwNjdhYjJhN2M2NDdhMF8yLTAtMS0xLTY4NTg1L3RleHRyZWdpb246MWM3YWRkZTE0MGMyNGUyODljNDAzMzA2MmNmMDJhYmVfNQ_918b7f33-b45d-4012-a53f-b0d0a0957973">61 North Beacon Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6MTA3YzM1MGU3ZTAzNDgxNmI4MDY3YWIyYTdjNjQ3YTAvdGFibGVyYW5nZToxMDdjMzUwZTdlMDM0ODE2YjgwNjdhYjJhN2M2NDdhMF8yLTAtMS0xLTY4NTg1L3RleHRyZWdpb246MWM3YWRkZTE0MGMyNGUyODljNDAzMzA2MmNmMDJhYmVfOQ_a5234ff6-8531-4a2e-8df7-a9f3b5bbd053">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6MTA3YzM1MGU3ZTAzNDgxNmI4MDY3YWIyYTdjNjQ3YTAvdGFibGVyYW5nZToxMDdjMzUwZTdlMDM0ODE2YjgwNjdhYjJhN2M2NDdhMF8yLTAtMS0xLTY4NTg1L3RleHRyZWdpb246MWM3YWRkZTE0MGMyNGUyODljNDAzMzA2MmNmMDJhYmVfMTI_32640648-0e97-4e17-b5fd-4152a997fade">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6MTA3YzM1MGU3ZTAzNDgxNmI4MDY3YWIyYTdjNjQ3YTAvdGFibGVyYW5nZToxMDdjMzUwZTdlMDM0ODE2YjgwNjdhYjJhN2M2NDdhMF8yLTAtMS0xLTY4NTg1L3RleHRyZWdpb246MWM3YWRkZTE0MGMyNGUyODljNDAzMzA2MmNmMDJhYmVfMTY_90b71b49-579f-402d-8743-d00baf62564c">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6MTA3YzM1MGU3ZTAzNDgxNmI4MDY3YWIyYTdjNjQ3YTAvdGFibGVyYW5nZToxMDdjMzUwZTdlMDM0ODE2YjgwNjdhYjJhN2M2NDdhMF8yLTEtMS0xLTY4NTg1L3RleHRyZWdpb246YjgzM2U2NzM1ODJjNGRmMDgyNzJhNGFhYzIyYTNiN2RfNQ_29527345-06d5-44aa-90a3-0ccc587e6fa1">02134</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8yMzU3_c405cf2a-3158-4f64-9840-5b0f78226e09">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8yMzU4_820c362d-c4e1-4231-8b8b-f577a6cd07fc">529-8300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6NzRmMWM2ZGNkYTIzNGQzNTkxYWQzY2RiYTYzYmM5OTcvdGFibGVyYW5nZTo3NGYxYzZkY2RhMjM0ZDM1OTFhZDNjZGJhNjNiYzk5N18xLTAtMS0xLTY4NTg1_347e4462-4894-4ebb-bfa8-826ba6f90f59">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6NzRmMWM2ZGNkYTIzNGQzNTkxYWQzY2RiYTYzYmM5OTcvdGFibGVyYW5nZTo3NGYxYzZkY2RhMjM0ZDM1OTFhZDNjZGJhNjNiYzk5N18xLTItMS0xLTY4NTg1_f68b217b-a8a3-4386-b043-c705af2186e7">XFOR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6NzRmMWM2ZGNkYTIzNGQzNTkxYWQzY2RiYTYzYmM5OTcvdGFibGVyYW5nZTo3NGYxYzZkY2RhMjM0ZDM1OTFhZDNjZGJhNjNiYzk5N18xLTQtMS0xLTY4NTg1_309d842f-99c9-4516-a5f7-d2c20c853004">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8yMzU5_4aba160b-26ca-475d-a70b-52cee664d229">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8yMzYw_c2325269-33be-4297-b99c-0969e8a9a46e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6ZDE5N2Y5NTA5ZGZlNDBjOThkOTQ5NmM0MWRlZDdkNDkvdGFibGVyYW5nZTpkMTk3Zjk1MDlkZmU0MGM5OGQ5NDk2YzQxZGVkN2Q0OV8xLTAtMS0xLTY4NTg1_9dab57ca-fbc3-4d4f-b123-79a4b0f2a08c">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6ZDE5N2Y5NTA5ZGZlNDBjOThkOTQ5NmM0MWRlZDdkNDkvdGFibGVyYW5nZTpkMTk3Zjk1MDlkZmU0MGM5OGQ5NDk2YzQxZGVkN2Q0OV8xLTQtMS0xLTY4NTg1_ab24df31-3c04-4a30-82f1-f4268930daf8">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGFibGU6ZDE5N2Y5NTA5ZGZlNDBjOThkOTQ5NmM0MWRlZDdkNDkvdGFibGVyYW5nZTpkMTk3Zjk1MDlkZmU0MGM5OGQ5NDk2YzQxZGVkN2Q0OV8yLTQtMS0xLTY4NTg1_eeac65c6-71a1-463e-90bd-2991ed5b98f1">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8yMzYy_f48133af-5b75-4bbf-b930-c968b53f12d8">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia80ce664878241a6a1f41c82e266dff4_I20230501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8xL2ZyYWc6NDBmZGU4YmQyM2E3NGEwZTlhNWQxNGFiMzUxYjBmMmYvdGV4dHJlZ2lvbjo0MGZkZThiZDIzYTc0YTBlOWE1ZDE0YWIzNTFiMGYyZl8yMzE3_5cef4be6-3464-4105-ab36-1b821c85531b"
      unitRef="shares">122207488</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMy0xLTEtMS02ODU4NQ_d42e01e3-dae2-4eb9-844c-d087438d36c5"
      unitRef="usd">93406000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMy0zLTEtMS02ODU4NQ_8aa33a30-e97f-4264-9dd0-f9dbbec5ce10"
      unitRef="usd">121718000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <xfor:ResearchAndDevelopmentIncentiveReceivable
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfNC0xLTEtMS02ODU4NQ_eb2bed05-8463-4034-bb6e-7a2b53bd424e"
      unitRef="usd">658000</xfor:ResearchAndDevelopmentIncentiveReceivable>
    <xfor:ResearchAndDevelopmentIncentiveReceivable
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfNC0zLTEtMS02ODU4NQ_1082ce18-6b00-45f1-b6fd-5e7217b36ba6"
      unitRef="usd">1152000</xfor:ResearchAndDevelopmentIncentiveReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfNS0xLTEtMS02ODU4NQ_edb2b047-6dd3-4a1a-85c0-67333f3923ee"
      unitRef="usd">4158000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfNS0zLTEtMS02ODU4NQ_2387f451-3dcf-40f3-a112-e958eae95b97"
      unitRef="usd">5807000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfNi0xLTEtMS02ODU4NQ_a1cc5308-4e63-43d0-a206-ad84e6ec0d0c"
      unitRef="usd">98222000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfNi0zLTEtMS02ODU4NQ_a57e00a9-c913-4acb-9495-d8e2953bd067"
      unitRef="usd">128677000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfNy0xLTEtMS02ODU4NQ_52739be3-a351-472a-b9fa-0ed547b32c4a"
      unitRef="usd">986000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfNy0zLTEtMS02ODU4NQ_38b11f8a-4b22-4e52-85c5-fc0e016c8933"
      unitRef="usd">1104000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfOC0xLTEtMS02ODU4NQ_b90b7eba-5315-43d4-ac7a-ac6d923e93b0"
      unitRef="usd">17351000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfOC0zLTEtMS02ODU4NQ_57b394bd-e732-4b63-be46-0ab65111a044"
      unitRef="usd">17351000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfOS0xLTEtMS02ODU4NQ_37bc5acc-f3a4-4f6b-964a-cde742614111"
      unitRef="usd">6844000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfOS0zLTEtMS02ODU4NQ_948b07d9-4cbd-483f-89f7-2c220043b252"
      unitRef="usd">7229000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTAtMS0xLTEtNjg1ODU_6e715919-8615-4685-9285-d8e6128cca89"
      unitRef="usd">1002000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTAtMy0xLTEtNjg1ODU_d98d732d-1500-40d4-8ef6-3dbd9f1ba0ac"
      unitRef="usd">1225000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTEtMS0xLTEtNjg1ODU_fb630e2d-7bd8-4eea-b117-0958a229f0be"
      unitRef="usd">124405000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTEtMy0xLTEtNjg1ODU_71f0a39b-e581-478a-959b-08a562ccafea"
      unitRef="usd">155586000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTQtMS0xLTEtNjg1ODU_4cad02d7-4ab8-4084-a0a7-2adbc6e4dcb7"
      unitRef="usd">5992000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTQtMy0xLTEtNjg1ODU_7b2eb224-98a8-4f70-99cb-1dc8ade8adb1"
      unitRef="usd">7777000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTUtMS0xLTEtNjg1ODU_5ebfbe01-6946-4df4-8211-8350f9c42b8e"
      unitRef="usd">11762000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTUtMy0xLTEtNjg1ODU_ff0e236e-6625-496b-9d41-260046b5c1c7"
      unitRef="usd">12034000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTYtMS0xLTEtNjg1ODU_578cbafa-d783-4693-b449-a4561c6533c2"
      unitRef="usd">1175000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTYtMy0xLTEtNjg1ODU_c5ca83d0-0b56-4157-a15c-fb9a6e9c90e0"
      unitRef="usd">1198000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTctMS0xLTEtNjg1ODU_86125327-6edf-45ea-8052-ccfabf5a8576"
      unitRef="usd">554000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTctMy0xLTEtNjg1ODU_041840ec-5ed4-475a-ba4b-a1eb7211a4ae"
      unitRef="usd">1315000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTgtMS0xLTEtNjg1ODU_73e68121-600c-4705-92d8-50875df7f5ee"
      unitRef="usd">19483000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTgtMy0xLTEtNjg1ODU_c607b88e-426f-4c35-87c7-0d05bfff5872"
      unitRef="usd">22324000</us-gaap:LiabilitiesCurrent>
    <xfor:LongTermDebtNonCurrentIncludingAccretion
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTktMS0xLTEtNjg1ODU_fdfbfa75-8b80-4a90-a8c9-70fc24a2c781"
      unitRef="usd">31827000</xfor:LongTermDebtNonCurrentIncludingAccretion>
    <xfor:LongTermDebtNonCurrentIncludingAccretion
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMTktMy0xLTEtNjg1ODU_15208393-af03-4c26-8a74-bdec975ae52c"
      unitRef="usd">32304000</xfor:LongTermDebtNonCurrentIncludingAccretion>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjAtMS0xLTEtNjg1ODU_eba3ce5f-e380-41b0-b083-ceae71ee3efc"
      unitRef="usd">3377000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjAtMy0xLTEtNjg1ODU_1c26d77b-77f6-41e2-8067-8de794058c35"
      unitRef="usd">3603000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjEtMS0xLTEtNjg4NTA_39de351c-fecc-405c-a64f-805e7fdfe0a0"
      unitRef="usd">17692000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjEtMy0xLTEtNjg4NDI_a4dc0d21-cb3e-447d-8864-23659223860f"
      unitRef="usd">23131000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjEtMS0xLTEtNjg1ODU_c9164059-0f5c-4699-9708-a2b276a5c806"
      unitRef="usd">350000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjEtMy0xLTEtNjg1ODU_151c96d1-9e43-4a4d-b826-492a2b5e6551"
      unitRef="usd">173000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjItMS0xLTEtNjg1ODU_a917e22a-4ad3-4acc-923b-3fe48e0eed12"
      unitRef="usd">72729000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjItMy0xLTEtNjg1ODU_e008032d-0504-4555-b49a-7cdc7ee9345c"
      unitRef="usd">81535000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjMtMS0xLTEtNjg1ODU_d4e9954f-4305-4ae1-a39a-66e3fc16b7c7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjMtMy0xLTEtNjg1ODU_1fc0f2e7-8084-4fa6-b51f-42f48610b00e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMC0xLTEtNjg1ODUvdGV4dHJlZ2lvbjo3N2Q1OTMwNWQwNWM0NThmOTkxOGEwNmEwYTY5YTZiOV8xOQ_0fcacf9e-5d77-4fb9-b368-0f547a21a1aa"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMC0xLTEtNjg1ODUvdGV4dHJlZ2lvbjo3N2Q1OTMwNWQwNWM0NThmOTkxOGEwNmEwYTY5YTZiOV8xOQ_d26dced0-d313-4551-a42d-990bab881426"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMC0xLTEtNjg1ODUvdGV4dHJlZ2lvbjo3N2Q1OTMwNWQwNWM0NThmOTkxOGEwNmEwYTY5YTZiOV8zMw_e046814b-63df-4c47-8fe4-b3575a337bef"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMC0xLTEtNjg1ODUvdGV4dHJlZ2lvbjo3N2Q1OTMwNWQwNWM0NThmOTkxOGEwNmEwYTY5YTZiOV8xMjM_544e4f42-555c-4f7a-985b-0784ab1f85f9"
      unitRef="shares">122207488</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMC0xLTEtNjg1ODUvdGV4dHJlZ2lvbjo3N2Q1OTMwNWQwNWM0NThmOTkxOGEwNmEwYTY5YTZiOV8xMjM_cad2b812-71be-4cd9-a555-297768f312da"
      unitRef="shares">122207488</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMC0xLTEtNjg1ODUvdGV4dHJlZ2lvbjo3N2Q1OTMwNWQwNWM0NThmOTkxOGEwNmEwYTY5YTZiOV8xMzA_079accea-89cd-44b7-a5c3-1ebbf3302745"
      unitRef="shares">121667250</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMC0xLTEtNjg1ODUvdGV4dHJlZ2lvbjo3N2Q1OTMwNWQwNWM0NThmOTkxOGEwNmEwYTY5YTZiOV8xMzA_c7b74d24-96df-4745-84d3-3dcd94bcd11b"
      unitRef="shares">121667250</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMS0xLTEtNjg1ODU_19c8d478-660f-4f0f-b9f6-8acab4e57f81"
      unitRef="usd">122000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjUtMy0xLTEtNjg1ODU_b8118228-23ce-48dd-bc38-5b6cad7a9eb8"
      unitRef="usd">122000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjYtMS0xLTEtNjg1ODU_bf0f9e77-f12b-413b-a7f2-5f9c6d45353c"
      unitRef="usd">452431000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjYtMy0xLTEtNjg1ODU_4d2ec06c-5924-4556-9446-e7fbdc74b91d"
      unitRef="usd">450786000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjctMS0xLTEtNjg1ODU_442471c3-d906-476d-a8da-1b824c44d364"
      unitRef="usd">-119000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjctMy0xLTEtNjg1ODU_ed8aa81e-2170-4fb3-b155-7529d750d09a"
      unitRef="usd">-119000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjgtMS0xLTEtNjg1ODU_0fb5cc31-5148-4910-b439-ae677bf59011"
      unitRef="usd">-400758000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjgtMy0xLTEtNjg1ODU_70fc51c8-6d81-48fd-9b52-76b8c6e43eb8"
      unitRef="usd">-376738000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjktMS0xLTEtNjg1ODU_97bc3817-0766-42e3-8244-ef57cc188251"
      unitRef="usd">51676000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMjktMy0xLTEtNjg1ODU_c7b1f5a5-6328-42be-a28d-1c28f040912f"
      unitRef="usd">74051000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMzAtMS0xLTEtNjg1ODU_ff90d5d3-535f-44eb-9ef9-4a8de312d95c"
      unitRef="usd">124405000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yMi9mcmFnOmVmMDU2M2M2YmZkOTRlODVhYzI4ZmQ0MWE4ZDE0NTg1L3RhYmxlOmMzMDNkZGJmMGI3MzQ5NDc5MGJmNjRiMDk1YTQ5OGEzL3RhYmxlcmFuZ2U6YzMwM2RkYmYwYjczNDk0NzkwYmY2NGIwOTVhNDk4YTNfMzAtMy0xLTEtNjg1ODU_004d514d-166e-4dcd-9dda-4a099d488ded"
      unitRef="usd">155586000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfNC0xLTEtMS02ODU4NQ_82813d04-f3b9-4eb9-b6de-b22cda0ac5e6"
      unitRef="usd">22063000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfNC0zLTEtMS02ODU4NQ_d09ae21e-71b7-435f-8aec-e1c7c3770922"
      unitRef="usd">14113000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfNS0xLTEtMS02ODU4NQ_78ffe44c-697a-42fc-b8ba-f9f1c5139683"
      unitRef="usd">7241000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfNS0zLTEtMS02ODU4NQ_8b89d77a-e5bb-4981-a277-98816c037fdf"
      unitRef="usd">7664000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfNi0xLTEtMS02ODU4NQ_b15a49a1-b8cd-45b1-a345-e030bbdcf7f2"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfNi0zLTEtMS02ODU4NQ_f24331f8-3e7e-497e-ba44-f2999e24caa4"
      unitRef="usd">509000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:OperatingExpenses
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfNy0xLTEtMS02ODU4NQ_9e87c4be-3324-4786-b063-4f497ba6d145"
      unitRef="usd">29304000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfNy0zLTEtMS02ODU4NQ_a841f7bd-c551-4eee-bf6f-0b3c168c386a"
      unitRef="usd">21268000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfOC0xLTEtMS02ODU4NQ_2f8b0404-d5ac-4ab5-8107-f7ecc4697428"
      unitRef="usd">-29304000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfOC0zLTEtMS02ODU4NQ_ab45bf31-89a8-4e63-a12e-6ab2e91f157a"
      unitRef="usd">-21268000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTAtMS0xLTEtNjg1ODU_87100774-1066-4e22-8a38-cab9d68f071f"
      unitRef="usd">835000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTAtMy0xLTEtNjg1ODU_7dedd71b-2742-4698-83e8-e771b1dec00b"
      unitRef="usd">3000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTEtMS0xLTEtNjg1ODU_c42ab8bd-62a5-40c7-b44a-2afd49deca6d"
      unitRef="usd">1109000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTEtMy0xLTEtNjg1ODU_eff25d84-37bd-4318-bf9b-df496a8ec8cc"
      unitRef="usd">913000</us-gaap:InterestExpense>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTItMy0xLTEtNjg1ODU_a61858f7-16e1-468b-b1e3-6d2dcdc63c1a"
      unitRef="usd">176000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTMtMS0xLTEtNjg4NzA_484acca6-d286-4e62-8379-24c6529144a8"
      unitRef="usd">5439000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTMtMS0xLTEtNjg1ODU_ff7c7667-1040-4537-9561-96e8075058c1"
      unitRef="usd">123000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTMtMy0xLTEtNjg1ODU_1b4ffb5d-c5e4-4c24-be4c-52974c821ba5"
      unitRef="usd">60000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTQtMS0xLTEtNjg1ODU_365d4fd5-7a29-48d9-8416-b36c7b168f7c"
      unitRef="usd">5288000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTQtMy0xLTEtNjg1ODU_b8ad88f6-387f-43cb-a194-8d8e0b2afc4e"
      unitRef="usd">-674000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTUtMS0xLTEtNjg1ODU_dedc3bf5-1245-4436-be7f-4d50273be918"
      unitRef="usd">-24016000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTUtMy0xLTEtNjg1ODU_033e60b2-bf4c-4d84-ad52-d0a268cee8ab"
      unitRef="usd">-21942000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTYtMS0xLTEtNjg1ODU_f28fc1a9-0c28-4f17-9653-3598424b8742"
      unitRef="usd">4000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTYtMy0xLTEtNjg1ODU_a9b6bf82-785d-4fc7-8936-6f03970e72a6"
      unitRef="usd">23000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTctMS0xLTEtNjg1ODU_9c6eb2f1-78bb-4ee6-b0c0-79cacba35364"
      unitRef="usd">-24020000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i553e6350cf6c429980b87aeb902c6c55_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTctMy0xLTEtNjg1ODU_23e06e56-16fc-48cc-9c84-833776fa5ef2"
      unitRef="usd">-21965000</us-gaap:NetIncomeLoss>
    <xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTgtMS0xLTEtNjg1ODU_399e9f08-e684-41a8-95af-7524fcccfca1"
      unitRef="usd">0</xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock>
    <xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTgtMy0xLTEtNjg1ODU_bb192a03-7773-4298-bf68-a9a3843b124e"
      unitRef="usd">2259000</xfor:TemporaryEquityRepurchaseOfConvertiblePreferredStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTktMS0xLTEtNjg1ODU_cef952ec-768a-42d8-86ca-9bde04ceeeb6"
      unitRef="usd">-24020000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMTktMy0xLTEtNjg1ODU_f3af3137-5a86-452d-a4ff-56e2cebd3835"
      unitRef="usd">-24224000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMjAtMS0xLTEtNjg1ODU_87694fac-5dc2-496d-afd5-5522a909e40f"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMjAtMS0xLTEtNjg1ODU_ed33fe2e-291f-434f-ba52-2eb441d83fad"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMjAtMy0xLTEtNjg1ODU_0ca1e1ee-2900-40c8-8c39-24473c5cd995"
      unitRef="usdPerShare">-0.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMjAtMy0xLTEtNjg1ODU_99257dc1-51aa-40bf-a68a-e1f292a3f5fb"
      unitRef="usdPerShare">-0.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMjEtMS0xLTEtNjg1ODU_9913c6b1-740a-49a0-9d66-02b450e87cf7"
      unitRef="shares">145967000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMjEtMS0xLTEtNjg1ODU_efcdb0fc-e665-4c87-a4d4-d62fe2084fea"
      unitRef="shares">145967000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMjEtMy0xLTEtNjg1ODU_18e87532-38cc-40b7-a47f-72aac1a93af7"
      unitRef="shares">33737000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yNS9mcmFnOjI1ZDgxNzRjYWU2YTRlNTg5ZDhjZDQxY2UzNDJkY2ViL3RhYmxlOjAzMmY0MjRlMzBmOTQxYjM5YTY0ZjE2ZTM5OTA1OWZhL3RhYmxlcmFuZ2U6MDMyZjQyNGUzMGY5NDFiMzlhNjRmMTZlMzk5MDU5ZmFfMjEtMy0xLTEtNjg1ODU_a8cfc3d8-5785-48f9-a3ba-6b2a1ed1cbbe"
      unitRef="shares">33737000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i148ac761490846059a641c4096bff174_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfMi0xLTEtMS02ODk0Mg_abc37aec-23c5-43e8-bf46-d977e636a6a4"
      unitRef="shares">121667250</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i148ac761490846059a641c4096bff174_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfMi0zLTEtMS02ODk0Mg_368b9b1f-a600-4b82-9b8e-f3b1aeffac28"
      unitRef="usd">122000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2b29c1af764d49dd8a2b25cd40f9c5e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfMi01LTEtMS02ODk0Mg_4f3e754d-82cc-4c8a-948b-0b3856637f3b"
      unitRef="usd">450786000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idd2737e0aa5e4ceda68812a691c9447b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfMi03LTEtMS02ODk0Mg_0c8f6f2e-e8f7-4ed3-8375-32d214ffeb5c"
      unitRef="usd">-119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if43cc4ccf2b647bfba5772dafdf4d1df_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfMi05LTEtMS02ODk0Mg_77dbf774-2cfb-46b3-8ceb-17c70da57822"
      unitRef="usd">-376738000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfMi0xMS0xLTEtNjg5NDI_40b7be14-8ffe-41b9-83f5-d88bc053dc0d"
      unitRef="usd">74051000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i3bcc5907b6014b9d93c0ce335d74d143_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfNC0xLTEtMS02ODk0Nw_805b8eee-30f0-4438-9ff0-caf188ae40e2"
      unitRef="shares">540238</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id687fd50375c4b9289fc38f39c37c931_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfNi01LTEtMS02ODk0Nw_5dc7a418-0311-40c2-ad4a-dd5c8b8139e5"
      unitRef="usd">1645000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfNi0xMS0xLTEtNjg5NDc_a9532f32-7e82-4931-8d90-8119411958e5"
      unitRef="usd">1645000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i7da3eb074b8d4cb09f155d7cbd131475_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfNy05LTEtMS02ODk0Nw_4c227654-e7fc-466e-be43-e0c2b6fc366e"
      unitRef="usd">-24020000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfNy0xMS0xLTEtNjg5NDc_770e063e-df2a-4ef9-bd96-f6eb3413e509"
      unitRef="usd">-24020000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i3c39f890c41047c9a65d791fe89d7f5c_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfOC0xLTEtMS02ODk1NA_b5ef5e8a-324e-4803-989a-8111ffade192"
      unitRef="shares">122207488</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3c39f890c41047c9a65d791fe89d7f5c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfOC0zLTEtMS02ODk1NA_d3bb44b6-da0e-426f-b8ed-217cc116aadc"
      unitRef="usd">122000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2699357e209d4ca393deb31d5b50ef76_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfOC01LTEtMS02ODk1NA_eaad301d-5a1c-4a4f-a279-c20ef3f4128b"
      unitRef="usd">452431000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id4f97645aff94169b01a7e55e7ad5b86_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfOC03LTEtMS02ODk1NA_41591d85-7368-4137-95d5-b59e2e8cde6e"
      unitRef="usd">-119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib174ac43e0694fac9a20163af9e3c6c1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfOC05LTEtMS02ODk1NA_3b7a1300-3262-4c3d-a92c-f1f48bad8bd4"
      unitRef="usd">-400758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOmQwYzJhYzYxMmMzNzQxMTViNDFkYzdmNDI4Y2RhZDkzL3RhYmxlcmFuZ2U6ZDBjMmFjNjEyYzM3NDExNWI0MWRjN2Y0MjhjZGFkOTNfOC0xMS0xLTEtNjg5NTQ_328435e5-1e62-49ad-8de1-1bd05d4c387c"
      unitRef="usd">51676000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="id108597db204485299a9f94cb8127d3a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMi0xLTEtMS02OTAzMw_8e8bdd1e-a0f0-4a44-bb70-b9b7665ef72f"
      unitRef="shares">28127657</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id108597db204485299a9f94cb8127d3a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMi0zLTEtMS02OTAzMw_91ff242e-0935-4d85-b8c0-e3284b1ed67f"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i51c1bc362afa49eeb95ed63f82caa21b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMi01LTEtMS02OTAzMw_e294687a-96ae-49c1-86f6-515d9df18be8"
      unitRef="usd">347374000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4fed87c65647480c8d625fffe1b0ea5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMi03LTEtMS02OTAzMw_8c34483d-0b32-4280-830e-a14b54cd2285"
      unitRef="usd">-119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5b481bc1391f4635a7c7fc91a64f1e08_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMi05LTEtMS02OTAzMw_af05e438-c38c-407a-850a-4b0cb079b793"
      unitRef="usd">-282871000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i127a474f92264d58b7e85a4321f95964_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMi0xMS0xLTEtNjkwMzM_9a8fe18a-0833-4e0f-a2b2-45ae36dd3379"
      unitRef="usd">64412000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i06ba2f0164234d80aef6eb30ab849e77_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMy0wLTEtMS02ODkyMC90ZXh0cmVnaW9uOmI1YmRlYWNjNWEzZTQwM2FhMjM5NmE2MzEyNjU1NzNkXzEzNQ_850c7d02-1bce-4d8d-b378-1e61e986acb2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id4b750c506b44cbda93e01a7505ed761_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMy0xLTEtMS02OTAyNA_8e806444-7567-4e97-a98e-940d3924d48a"
      unitRef="shares">2512902</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id4b750c506b44cbda93e01a7505ed761_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMy0zLTEtMS02OTAyNA_2165d0f5-5d49-4a0e-adb4-5128aa4e7176"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iec90ace9f4384f59bd0e68d11db46c7a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMy01LTEtMS02OTAyNA_216e4981-e1f8-4803-9255-e41211768158"
      unitRef="usd">5817000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfMy0xMS0xLTEtNjkwMjQ_8a637e30-b0f1-4dae-9fae-2421d948fe32"
      unitRef="usd">5820000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <xfor:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="id4b750c506b44cbda93e01a7505ed761_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNC0xLTEtMS02OTAyNA_9249f0ee-6a21-44dd-8856-3e8a34f9066f"
      unitRef="shares">100</xfor:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="id4b750c506b44cbda93e01a7505ed761_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNS0xLTEtMS02OTA0OQ_e97ab6cb-3081-479b-ab3f-32ff4f4a40c6"
      unitRef="shares">168817</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="iec90ace9f4384f59bd0e68d11db46c7a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNS01LTEtMS02OTA0OQ_df82d842-fe61-48c8-9c6b-07d9fdd2452f"
      unitRef="usd">-12000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNS0xMS0xLTEtNjkwNDk_a0d218fd-9df2-48a1-b13d-f64845ace8e2"
      unitRef="usd">-12000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iec90ace9f4384f59bd0e68d11db46c7a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNS01LTEtMS02OTAyNA_b97c3e8c-1687-42b0-83b1-da31a2d3529b"
      unitRef="usd">1459000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNS0xMS0xLTEtNjkwMjQ_129e164b-79e9-4a60-8ee9-44c65140bd41"
      unitRef="usd">1459000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i553e6350cf6c429980b87aeb902c6c55_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNy05LTEtMS02OTA1Mg_563704b7-717f-49bd-9db2-101538caf1f9"
      unitRef="usd">-21965000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNi0xMS0xLTEtNjkwMjQ_560edaee-d690-41f5-bb15-3ae59c9828cf"
      unitRef="usd">-21965000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ia32dbc78288b4274b74a087a419e35ff_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfOC0xLTEtMS02OTA1NQ_d551c92d-cbb2-47dd-ba6b-48b4511e890b"
      unitRef="shares">30809476</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia32dbc78288b4274b74a087a419e35ff_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfOC0zLTEtMS02OTA1NQ_8b5df98e-f73a-480f-9e79-049773876a16"
      unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5cb4dfe1750c4c539b0698f339b61a94_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfOC01LTEtMS02OTA1NQ_2670ec27-d7f2-426f-aedb-cb11a12c8039"
      unitRef="usd">354638000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i83228390dcb849b29ea600f914617cc1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfOC03LTEtMS02OTA1NQ_49566e19-caa4-44d8-8a4e-93cff5ada169"
      unitRef="usd">-119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f2a6bfe01ec46bc85d75976e40b1ab0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNy05LTEtMS02OTAyNA_e8e7de2d-397a-45b5-b5c3-9c7442087160"
      unitRef="usd">-304836000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a25074b350146a4adca9401db84ac82_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8yOC9mcmFnOjBjZTJiNmNmNDNhZjQ4YThiYjIxZjI4YzQzZTMyNjc5L3RhYmxlOjlkNGQxNjk1MzYyOTQ0YmI4OTkwNTY2NWQwMTY4MjBhL3RhYmxlcmFuZ2U6OWQ0ZDE2OTUzNjI5NDRiYjg5OTA1NjY1ZDAxNjgyMGFfNy0xMS0xLTEtNjkwMjQ_d167db52-b7aa-4c23-8200-19a39a6e59fd"
      unitRef="usd">49714000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMy0xLTEtMS02ODU4NQ_3ab1216e-3869-42e4-93f3-07a7e7f6e777"
      unitRef="usd">-24020000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMy0zLTEtMS02ODU4NQ_23507738-f924-47e4-8a29-974174707882"
      unitRef="usd">-21965000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfNS0xLTEtMS02ODU4NQ_d9450cca-d352-4100-911a-e3ce23f2e78c"
      unitRef="usd">1645000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfNS0zLTEtMS02ODU4NQ_306609ce-aa68-41dd-97bb-2824fb80614c"
      unitRef="usd">1459000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfNi0xLTEtMS02ODU4NQ_e17e6b68-b961-4e0c-8e86-04073b0cb7e4"
      unitRef="usd">127000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfNi0zLTEtMS02ODU4NQ_af48f850-ad7e-4b88-b512-8fbca15c37c2"
      unitRef="usd">133000</us-gaap:DepreciationDepletionAndAmortization>
    <xfor:NonCashLeaseExpense
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfNy0xLTEtMS02ODU4NQ_4426a5c0-be57-46c1-a600-697d486ded40"
      unitRef="usd">385000</xfor:NonCashLeaseExpense>
    <xfor:NonCashLeaseExpense
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfNy0zLTEtMS02ODU4NQ_82e6cebf-bb88-4a1b-8dc0-83d3c74621f6"
      unitRef="usd">366000</xfor:NonCashLeaseExpense>
    <xfor:NonCashInterestExpense
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfOC0xLTEtMS02ODU4NQ_1e45b321-682c-44e1-bf87-f80355a23e21"
      unitRef="usd">225000</xfor:NonCashInterestExpense>
    <xfor:NonCashInterestExpense
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfOC0zLTEtMS02ODU4NQ_d2494531-6aab-4991-8046-ce912d3c0a94"
      unitRef="usd">198000</xfor:NonCashInterestExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfOS0xLTEtMS02ODU4NQ_9677dacc-32d0-4e70-8bcd-5ef56d7d06be"
      unitRef="usd">-5439000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfOS0zLTEtMS02ODU4NQ_074e7637-3871-4dde-9689-e4872d00a0bc"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTAtMS0xLTEtNjg1ODU_2614c90b-9271-4cca-a7c4-35b4b8f485d6"
      unitRef="usd">51000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTAtMy0xLTEtNjg1ODU_afe39ab5-2a37-4d2c-bd45-af2f07d40f92"
      unitRef="usd">120000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTItMS0xLTEtNjg1ODU_d16032ea-5070-4c50-a880-c4ef9907c6cb"
      unitRef="usd">-2084000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTItMy0xLTEtNjg1ODU_4f0315c2-9e73-4c65-809e-4f017cc37da1"
      unitRef="usd">-1633000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTMtMS0xLTEtNjg1ODU_e9c80d56-1863-4370-94a5-9ff44266a06f"
      unitRef="usd">-1714000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTMtMy0xLTEtNjg1ODU_3bc1d2d8-b38f-46a8-9678-ef971abbf97d"
      unitRef="usd">-713000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTQtMS0xLTEtNjg1ODU_428844e7-aef7-4ce5-86bd-a7e4c0c846bf"
      unitRef="usd">496000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTQtMy0xLTEtNjg1ODU_1d142526-404a-4a76-8cb9-7d9af3d7735d"
      unitRef="usd">-984000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <xfor:IncreaseDecreaseInLeaseLiabilities
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTUtMS0xLTEtNjg1ODU_b99affbb-631b-4868-8516-f37ae0f7c13d"
      unitRef="usd">-250000</xfor:IncreaseDecreaseInLeaseLiabilities>
    <xfor:IncreaseDecreaseInLeaseLiabilities
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTUtMy0xLTEtNjg1ODU_7336896c-8ffe-4585-b257-920490384073"
      unitRef="usd">-236000</xfor:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTctMS0xLTEtNjg1ODU_288a7a1c-3d53-4db1-b7e4-99774dc8f063"
      unitRef="usd">-26512000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTctMy0xLTEtNjg1ODU_6603e921-2da2-44e3-b495-a8514b97574f"
      unitRef="usd">-20229000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTktMS0xLTEtNjg1ODU_fb2434f3-e2d1-4765-b1d6-612a2022478d"
      unitRef="usd">9000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMTktMy0xLTEtNjg1ODU_331493f2-0a18-4e83-be0c-80ac274c376e"
      unitRef="usd">22000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjAtMS0xLTEtNjg1ODU_d79f7cde-faa8-4ade-af9b-f40c3ee17442"
      unitRef="usd">-9000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjAtMy0xLTEtNjg1ODU_c2560fb0-2146-45b9-8778-2cd8d5c65eed"
      unitRef="usd">-22000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjMtMS0xLTEtNjg1ODU_f2cf11d4-e289-4621-993c-f25bb694dc8a"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjMtMy0xLTEtNjg1ODU_60ab4cb7-7b27-42e7-99d8-30ea0f96d200"
      unitRef="usd">12000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <xfor:IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjQtMS0xLTEtNjg1ODU_23a0a4d3-2b53-4574-8ad0-d682de458d89"
      unitRef="usd">381000</xfor:IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement>
    <xfor:IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjQtMy0xLTEtNjg1ODU_9b0101e3-a527-44fd-90c9-30485e059a3b"
      unitRef="usd">114000</xfor:IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjUtMS0xLTEtNjg1ODU_16b2c633-de66-4321-9bb7-489a996e060e"
      unitRef="usd">1300000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjUtMy0xLTEtNjg1ODU_3506fab8-62da-4d22-8e9f-c501960f99a8"
      unitRef="usd">795000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjYtMS0xLTEtNjg1ODU_af199409-8a84-4abd-a25e-eefab0bb9286"
      unitRef="usd">443000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjYtMy0xLTEtNjg1ODU_78ba9af6-ba6b-4906-bb66-1087f9aac6b1"
      unitRef="usd">5877000</xfor:ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjgtMS0xLTEtNjg1ODU_398586e7-6775-4356-831d-3df4facf359e"
      unitRef="usd">-2124000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjgtMy0xLTEtNjg1ODU_19a51e16-685a-4bc5-a61c-eba0f52cde34"
      unitRef="usd">4956000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjktMS0xLTEtNjg1ODU_7377b561-aa6f-4003-b704-ce64caf6fad7"
      unitRef="usd">50000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjktMy0xLTEtNjg1ODU_7521ac3e-9a36-4ae8-97d1-d25e848a6874"
      unitRef="usd">-69000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzAtMS0xLTEtNjg1ODU_c53aef03-7b5b-4399-a1b0-7413db6dce7a"
      unitRef="usd">-28595000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzAtMy0xLTEtNjg1ODU_21177061-60e2-499f-bd91-0841e29c3ea9"
      unitRef="usd">-15364000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzEtMS0xLTEtNjg1ODU_c64be81f-5466-4d65-bf8a-0c2df322bfe6"
      unitRef="usd">123028000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i127a474f92264d58b7e85a4321f95964_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzEtMy0xLTEtNjg1ODU_714f2950-73ac-4d08-b6ba-1dae0d22fa5d"
      unitRef="usd">83108000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzItMS0xLTEtNjg1ODU_904f6440-4c7e-49bd-be3f-39eab78453c1"
      unitRef="usd">94433000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4a25074b350146a4adca9401db84ac82_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzItMy0xLTEtNjg1ODU_d38f8ff4-47eb-460a-ba9a-bb3e65aa9eda"
      unitRef="usd">67744000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zNy9mcmFnOjQ2MzdiMGI1ZjBiYTQ1Yjk5MTdmMDdkODdiMmJmNWNkL3RleHRyZWdpb246NDYzN2IwYjVmMGJhNDViOTkxN2YwN2Q4N2IyYmY1Y2RfNTk4Mw_77c974dd-389f-4e68-aca9-4024807809e5">NATURE OF THE BUSINESS AND BASIS OF PRESENTATION&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;X4 Pharmaceuticals, Inc. (together with its subsidiaries, the &#x201c;Company&#x201d;) is a late-stage clinical biopharmaceutical company focused on the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company&#x2019;s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. Due to its ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream, the Company believes that mavorixafor has the potential to provide therapeutic benefit across a variety of chronic neutropenic disorders, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (&#x201c;WHIM&#x201d;)) syndrome, a rare, primary immunodeficiency, and certain cancers. Following announcement of positive top-line data from the Company&#x2019;s global, pivotal, Phase 3 clinical trial in November 2022, the Company is preparing a United States regulatory submission seeking approval of oral, once-daily mavorixafor in the treatment of people aged 12 years and older with WHIM syndrome. The Company is also currently enrolling participants in a Phase 2 clinical trial in people with certain chronic neutropenic disorders following positive results from a Phase 1b clinical trial evaluating mavorixafor in people with idiopathic, cyclic, or congenital neutropenia that were presented in the third quarter of 2022. The Company also conducted a proof-of-concept Phase 1b clinical trial of mavorixafor in combination with ibrutinib in people with Waldenstr&#xf6;m&#x2019;s macroglobulinemia (&#x201c;Waldenstr&#xf6;m&#x2019;s&#x201d;), a rare form of lymphoma. The Company reported positive results from the Waldenstr&#xf6;m&#x2019;s Phase 1b trial in the third quarter of 2022 and concluded the trial in December 2022. Any further studies of mavorixafor in Waldenstr&#xf6;m&#x2019;s or other oncology indication will be subject to completing a strategic partnership. The Company is headquartered in Boston, Massachusetts and has an additional facility in Vienna, Austria. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern Assessment&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No.&#160;2014-15,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern (Subtopic 205-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2014-15&#x201d;), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. Since inception, the Company has incurred significant operating losses and negative cash flows from operations. As of March&#160;31, 2023, the Company had $93.4 million of cash and cash equivalents, an accumulated deficit of $400.8 million  and net cash used in operating activities of $26.5 million.  The Company has a covenant under its Second Amended and Restated Loan and Security Agreement with Hercules Capital Inc. (&#x201c;Hercules&#x201d;) that requires that the Company maintain a minimum level of cash of $20 million, subject to reduction to $10 million upon the achievement of operational milestones. Based on its current cash flow projections and with no additional funding, the Company believes it will not be able to maintain the minimum cash required to satisfy this covenant beginning in the first quarter of 2024. In such event, the lender could require the repayment of all outstanding debt.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management has assessed the Company&#x2019;s ability to continue as a going concern in accordance with the requirements of ASC 205-40 and determined that the Company&#x2019;s accumulated deficit, history of losses and future expected losses met the ASC 205-40 standard for raising substantial doubt about the Company&#x2019;s ability to continue as a going concern. The Company does not have adequate financial resources to fund its forecasted operating costs for at least one year after the date that these condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To finance its operations, the Company will need to raise additional capital, which cannot be assured. Unless and until the Company reach&#x2019;s profitability in the future, it will require additional capital to fund our operations, which could be raised through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other collaborations and strategic alliances. If the Company is unable to obtain funding, it could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which would adversely affect its business prospects, or it may be unable to continue operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including X4 Pharmaceuticals (Austria) GmbH, which is incorporated in Vienna, Austria (&#x201c;X4 Austria&#x201d;), and X4 Therapeutics, Inc. All significant intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Condensed Consolidated Financial Statements&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated balance sheet at December 31, 2022 that is presented in these interim condensed consolidated financial statements was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying condensed consolidated financial statements are unaudited. The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial statements. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s&#160;audited financial statements and the notes thereto for the year ended December&#160;31, 2022 included in the 2022 Annual Report filed with the SEC on March 21, 2023. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&#x2019;s condensed financial position, condensed results of its operations and cash flows have been made. The results of operations for the three months ended March&#160;31, 2023 are not necessarily indicative of the results of operations that may be expected for the year ending December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of Estimates&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the impairment or lack of impairment of long-lived assets including operating lease right-of-use assets and goodwill, and assumptions underlying the fair value of warrant liabilities. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zNy9mcmFnOjQ2MzdiMGI1ZjBiYTQ1Yjk5MTdmMDdkODdiMmJmNWNkL3RleHRyZWdpb246NDYzN2IwYjVmMGJhNDViOTkxN2YwN2Q4N2IyYmY1Y2RfMjEyMA_35910066-59ee-4ccd-8e7a-5bc63a7ffc4f"
      unitRef="usd">93400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zNy9mcmFnOjQ2MzdiMGI1ZjBiYTQ1Yjk5MTdmMDdkODdiMmJmNWNkL3RleHRyZWdpb246NDYzN2IwYjVmMGJhNDViOTkxN2YwN2Q4N2IyYmY1Y2RfNTQ5NzU1ODMxMDMy_dcd4cca0-f8f6-4188-9e45-d599ddf96e61"
      unitRef="usd">-400800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zNy9mcmFnOjQ2MzdiMGI1ZjBiYTQ1Yjk5MTdmMDdkODdiMmJmNWNkL3RleHRyZWdpb246NDYzN2IwYjVmMGJhNDViOTkxN2YwN2Q4N2IyYmY1Y2RfNTQ5NzU1ODMxMDM5_33a3668e-7387-4b96-b770-e74abc165367"
      unitRef="usd">-26500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zNy9mcmFnOjQ2MzdiMGI1ZjBiYTQ1Yjk5MTdmMDdkODdiMmJmNWNkL3RleHRyZWdpb246NDYzN2IwYjVmMGJhNDViOTkxN2YwN2Q4N2IyYmY1Y2RfMjE5OTAyMzI3Nzc0NQ_ee07d4b9-d35d-4737-9a26-56a1d8de623b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including X4 Pharmaceuticals (Austria) GmbH, which is incorporated in Vienna, Austria (&#x201c;X4 Austria&#x201d;), and X4 Therapeutics, Inc. All significant intercompany accounts and transactions have been eliminated.&lt;/span&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zNy9mcmFnOjQ2MzdiMGI1ZjBiYTQ1Yjk5MTdmMDdkODdiMmJmNWNkL3RleHRyZWdpb246NDYzN2IwYjVmMGJhNDViOTkxN2YwN2Q4N2IyYmY1Y2RfMjE5OTAyMzI3Nzc0Ng_bff93c5e-8eae-4d30-8af2-878e57165cf5">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of Estimates&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the impairment or lack of impairment of long-lived assets including operating lease right-of-use assets and goodwill, and assumptions underlying the fair value of warrant liabilities. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#x2019;s consolidated financial statements.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RleHRyZWdpb246MmQ5NTYzN2ViYTIyNDAxZGJkYmNlZTg5YTQxZTU4NTNfMTA1OTk_1ce2fc95-d277-44b8-b149-ef2b8d4da914">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 21, 2023. Since the date of those consolidated financial statements, there have been no material changes to the Company&#x2019;s significant accounting policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letter of credit security: Waltham lease&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letter of credit security: Vienna Austria lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letter of credit security: Boston lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Company&#x2019;s lease agreements for its facilities in Massachusetts and Austria, the Company maintains letters of credit, which are secured by restricted cash, for the benefit of the respective landlord. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the sum of the total of amounts shown in the Company&#x2019;s condensed consolidated statements of cash flows as of March&#160;31, 2023 and December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then the Company would perform an interim quantitative impairment test, whereby the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than its carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no triggering events during the three months ended March&#160;31, 2023 that necessitated an interim impairment test of goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments&lt;/span&gt; (&#x201c;ASU 2016-13&#x201d;), as amended. ASU 2016-13 requires that financial assets measured at amortized cost, such as trade receivables, be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. The Company adopted ASU 2016-13 on January 1, 2023. As the Company did not have accounts receivable on its consolidated balance sheet as of the date of adoption, there was no impact to the adoption of ASU 2016-13.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RleHRyZWdpb246MmQ5NTYzN2ViYTIyNDAxZGJkYmNlZTg5YTQxZTU4NTNfMTA1OTU_515c0efe-cf2f-4002-87d1-ae35019685d7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&#x2014;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCompensatingBalancesTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RleHRyZWdpb246MmQ5NTYzN2ViYTIyNDAxZGJkYmNlZTg5YTQxZTU4NTNfMTA1OTY_c4d6d973-9ef5-4a05-9667-28e5bcd3e190">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letter of credit security: Waltham lease&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letter of credit security: Vienna Austria lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letter of credit security: Boston lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensatingBalancesTextBlock>
    <us-gaap:RestrictedCash
      contextRef="ic5139ec8cd3c4c57a78f7ac8c654556a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfMi0xLTEtMS02ODU4NQ_67036e94-eeb4-4cca-badc-1d0876aacb51"
      unitRef="usd">250000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ic7ba5290654141e4b61b83ad34d08c17_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfMi0zLTEtMS02ODU4NQ_1bb04740-fc8c-4c40-8d3f-2dcc92166f51"
      unitRef="usd">250000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i810c7142f18049f48bf12b8c5fed906f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfMy0xLTEtMS02ODU4NQ_cf926557-e6e5-48ba-a3a2-a27e5ab36fd5"
      unitRef="usd">206000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ied52c772cd6240a0a1fae6e51f2ddfb4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfMy0zLTEtMS02ODU4NQ_213d8acc-6bf7-44fb-a33a-08694ff24737"
      unitRef="usd">205000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i654563320ef74399a7b67534f01c3d1f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfNC0xLTEtMS02ODU4NQ_0a0fed6b-bafc-4d69-9e55-e2a14cafb5dd"
      unitRef="usd">571000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i57677a75b59a47908ea0dc176c8f9bcd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfNC0zLTEtMS02ODU4NQ_cbe3d856-6f6b-4af7-a8bd-f931bae1ae45"
      unitRef="usd">855000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfNS0xLTEtMS02ODU4NQ_fb0777b4-bae5-4093-aa99-898953367967"
      unitRef="usd">1027000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfNS0zLTEtMS02ODU4NQ_014e3c16-71f1-41b6-8258-f97eb4b3f4d8"
      unitRef="usd">1310000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashCurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfNi0xLTEtMS02ODU4NQ_602261e6-3a0b-4cdb-a6c1-fa3838b59ae3"
      unitRef="usd">250000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfNi0zLTEtMS02ODU4NQ_bc6d9016-785f-4b5e-a097-99240adc264e"
      unitRef="usd">285000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfNy0xLTEtMS02ODU4NQ_33f649da-4002-4777-8a8a-d9e15395a34f"
      unitRef="usd">777000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOmFhZmJiN2E4ZTYxODQ0ZGFiMWZlYTQzMzUxMTFlYmY4L3RhYmxlcmFuZ2U6YWFmYmI3YThlNjE4NDRkYWIxZmVhNDMzNTExMWViZjhfNy0zLTEtMS02ODU4NQ_6da2deb8-7f98-45af-a0b5-2c088a88b782"
      unitRef="usd">1025000</us-gaap:RestrictedCashNoncurrent>
    <xfor:ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RleHRyZWdpb246MmQ5NTYzN2ViYTIyNDAxZGJkYmNlZTg5YTQxZTU4NTNfMTA1OTc_b173c0d2-8519-4f0d-8491-ecd0de467eba">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the sum of the total of amounts shown in the Company&#x2019;s condensed consolidated statements of cash flows as of March&#160;31, 2023 and December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</xfor:ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOjNmOGY2ZGVmYjYxZDRiNGJhMWQ1OWYyMGIxYTRjNWQ0L3RhYmxlcmFuZ2U6M2Y4ZjZkZWZiNjFkNGI0YmExZDU5ZjIwYjFhNGM1ZDRfMS0xLTEtMS02ODU4NQ_2f66ba1b-4fdc-4d8d-8e58-41c4cbf1c5b2"
      unitRef="usd">93406000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOjNmOGY2ZGVmYjYxZDRiNGJhMWQ1OWYyMGIxYTRjNWQ0L3RhYmxlcmFuZ2U6M2Y4ZjZkZWZiNjFkNGI0YmExZDU5ZjIwYjFhNGM1ZDRfMS0zLTEtMS02ODU4NQ_015c077f-1fc9-44f7-9411-a04fe6b1e566"
      unitRef="usd">121718000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOjNmOGY2ZGVmYjYxZDRiNGJhMWQ1OWYyMGIxYTRjNWQ0L3RhYmxlcmFuZ2U6M2Y4ZjZkZWZiNjFkNGI0YmExZDU5ZjIwYjFhNGM1ZDRfMi0xLTEtMS02ODU4NQ_84ac6458-2362-4ba7-aa3d-98ee08f6e29c"
      unitRef="usd">250000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOjNmOGY2ZGVmYjYxZDRiNGJhMWQ1OWYyMGIxYTRjNWQ0L3RhYmxlcmFuZ2U6M2Y4ZjZkZWZiNjFkNGI0YmExZDU5ZjIwYjFhNGM1ZDRfMi0zLTEtMS02ODU4NQ_9c8ba91d-7aef-4c65-823f-a4534ddb379c"
      unitRef="usd">285000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOjNmOGY2ZGVmYjYxZDRiNGJhMWQ1OWYyMGIxYTRjNWQ0L3RhYmxlcmFuZ2U6M2Y4ZjZkZWZiNjFkNGI0YmExZDU5ZjIwYjFhNGM1ZDRfMy0xLTEtMS02ODU4NQ_402247cc-5b7d-4ddc-afb0-669d6617e020"
      unitRef="usd">777000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOjNmOGY2ZGVmYjYxZDRiNGJhMWQ1OWYyMGIxYTRjNWQ0L3RhYmxlcmFuZ2U6M2Y4ZjZkZWZiNjFkNGI0YmExZDU5ZjIwYjFhNGM1ZDRfMy0zLTEtMS02ODU4NQ_d295e415-616e-4f5a-aacb-2afdb47723d4"
      unitRef="usd">1025000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOjNmOGY2ZGVmYjYxZDRiNGJhMWQ1OWYyMGIxYTRjNWQ0L3RhYmxlcmFuZ2U6M2Y4ZjZkZWZiNjFkNGI0YmExZDU5ZjIwYjFhNGM1ZDRfNC0xLTEtMS02ODU4NQ_07200cc9-2e4a-4835-8352-d628eb0d36b9"
      unitRef="usd">94433000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RhYmxlOjNmOGY2ZGVmYjYxZDRiNGJhMWQ1OWYyMGIxYTRjNWQ0L3RhYmxlcmFuZ2U6M2Y4ZjZkZWZiNjFkNGI0YmExZDU5ZjIwYjFhNGM1ZDRfNC0zLTEtMS02ODU4NQ_07471363-63f7-4bbd-9191-f183c345cff4"
      unitRef="usd">123028000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RleHRyZWdpb246MmQ5NTYzN2ViYTIyNDAxZGJkYmNlZTg5YTQxZTU4NTNfMTA1OTg_2ca8d9dc-59ee-4b63-a4bd-fae3656f2ad5">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then the Company would perform an interim quantitative impairment test, whereby the Company compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of its net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than its carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no triggering events during the three months ended March&#160;31, 2023 that necessitated an interim impairment test of goodwill.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RleHRyZWdpb246MmQ5NTYzN2ViYTIyNDAxZGJkYmNlZTg5YTQxZTU4NTNfMTA2MDM_8cf4db74-cf51-4092-8057-492df4c337e7"
      xsi:nil="true"/>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80MC9mcmFnOjJkOTU2MzdlYmEyMjQwMWRiZGJjZWU4OWE0MWU1ODUzL3RleHRyZWdpb246MmQ5NTYzN2ViYTIyNDAxZGJkYmNlZTg5YTQxZTU4NTNfMTA2MDQ_ab13cdc8-30b4-4b2e-a481-baba0ac713bb">Recently Adopted Accounting Standards&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments&lt;/span&gt; (&#x201c;ASU 2016-13&#x201d;), as amended. ASU 2016-13 requires that financial assets measured at amortized cost, such as trade receivables, be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. The Company adopted ASU 2016-13 on January 1, 2023. As the Company did not have accounts receivable on its consolidated balance sheet as of the date of adoption, there was no impact to the adoption of ASU 2016-13.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80My9mcmFnOmVlNGVhODkyNTQ1ZjQ5NzNiZDhhMTA5N2RkNmYxZmU5L3RleHRyZWdpb246ZWU0ZWE4OTI1NDVmNDk3M2JkOGExMDk3ZGQ2ZjFmZTlfMjEwMQ_0145665f-1508-4aeb-8dd8-86816cd515c7">LICENSE, COLLABORATION AND FUNDING AGREEMENTS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Incentive Program&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company participates in a research and development incentive program provided by the Austrian government whereby the Company is entitled to reimbursement by the Austrian government for a percentage of qualifying research and development expenses and capital expenditures incurred by the Company&#x2019;s subsidiary in Austria. As of March&#160;31, 2023, the amount due under the program is $0.7 million, which amount is included in research and development incentive receivable in the condensed consolidated balance sheet. During the three months ended March&#160;31, 2023 and 2022, the Company recorded $121.0 thousand and $135.3 thousand, respectively, of income related to the program within the condensed consolidated statements of operations as other income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License and Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2014, the Company entered into a license agreement with Genzyme (the &#x201c;Genzyme Agreement&#x201d;) pursuant to which the&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company was granted an exclusive license to certain patents and intellectual property owned or controlled by Genzyme related to the CXCR4 receptor to develop and commercialize products containing licensed compounds (including but not limited to&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;mavorixafor) for all therapeutic, prophylactic and diagnostic uses, with the exception of autologous and allogenic human stem cell therapy. Under the terms of the Genzyme Agreement, the Company is obligated to use commercially reasonable efforts to develop and commercialize licensed products for use in the field in the United States and at least one other major market country.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is obligated to pay Genzyme milestone payments in the aggregate amount of up to $25.0 million, contingent upon the achievement by the Company of certain clinical-stage regulatory and sales milestones with respect to licensed products. During three months ended March&#160;31, 2023, the Company accrued $5.0 million related to a development milestone under the Genzyme Agreement as the Company believes that it is probable under ASC Topic 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, that the milestone will be achieved. The $5.0 million accrued payment has been recorded within research and development expense on the condensed consolidated statements of operations. An additional $7.0 million of regulatory milestone payments are not yet probable but are reasonably possible of becoming payable with the next twelve to eighteen month period under the Genzyme Agreement. The Company is also obligated to pay Genzyme tiered royalties based on net sales of licensed products that the Company commercializes under the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gain on Sale of Non-Financial Asset&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, a third party, who had previously acquired rights to certain intellectual property from the Company, terminated the arrangement and transferred these rights back to the Company. Also during the three months ended March 31, 2022, the Company transferred these rights to another third party in return for $0.5 million. The Company has no continuing involvement in any ongoing research and development activities associated with the intellectual property. The Company concluded that these third parties are "non-customers" as the underlying intellectual property transferred to and from these third parties supports potential drug candidates that are not aligned with the Company's strategic focus and, therefore, are not an output of the Company's ordinary activities. Accordingly, the Company accounted for the sale of the intellectual property as the sale of a non-financial asset under ASC Topic 610-20,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Gains and Losses from the Derecognition of Nonfinancial Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 610-20"), and included the gain in gain on sale of non-financial asset for the three months ended March 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no material modifications of the Company&#x2019;s license or collaboration agreements during the three months ended March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <xfor:GrantAndIncentiveReceivables
      contextRef="ide51a96471e14846b0eafc7204f8f180_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80My9mcmFnOmVlNGVhODkyNTQ1ZjQ5NzNiZDhhMTA5N2RkNmYxZmU5L3RleHRyZWdpb246ZWU0ZWE4OTI1NDVmNDk3M2JkOGExMDk3ZGQ2ZjFmZTlfNDY4_e5ed1e7f-9a68-489b-9260-7cc0eccb1f87"
      unitRef="usd">700000</xfor:GrantAndIncentiveReceivables>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i65095af2a0774d4ca62250a84f77486a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80My9mcmFnOmVlNGVhODkyNTQ1ZjQ5NzNiZDhhMTA5N2RkNmYxZmU5L3RleHRyZWdpb246ZWU0ZWE4OTI1NDVmNDk3M2JkOGExMDk3ZGQ2ZjFmZTlfNjU0_103f6c49-fea0-46b3-a59e-cffdb0ea30d7"
      unitRef="usd">121000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i65095af2a0774d4ca62250a84f77486a_D20230101-20230331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80My9mcmFnOmVlNGVhODkyNTQ1ZjQ5NzNiZDhhMTA5N2RkNmYxZmU5L3RleHRyZWdpb246ZWU0ZWE4OTI1NDVmNDk3M2JkOGExMDk3ZGQ2ZjFmZTlfNjU0_f5bf99d7-7183-4a98-9d45-dce3bdb83e99"
      unitRef="usd">121000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia0808869d78f44fcb077f2e781a826d0_D20220101-20220331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80My9mcmFnOmVlNGVhODkyNTQ1ZjQ5NzNiZDhhMTA5N2RkNmYxZmU5L3RleHRyZWdpb246ZWU0ZWE4OTI1NDVmNDk3M2JkOGExMDk3ZGQ2ZjFmZTlfNjYx_53d8bc39-cf35-4228-af36-625a2e0312b4"
      unitRef="usd">135300</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia0808869d78f44fcb077f2e781a826d0_D20220101-20220331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80My9mcmFnOmVlNGVhODkyNTQ1ZjQ5NzNiZDhhMTA5N2RkNmYxZmU5L3RleHRyZWdpb246ZWU0ZWE4OTI1NDVmNDk3M2JkOGExMDk3ZGQ2ZjFmZTlfNjYx_d94c87f9-2e32-4717-a630-4f9c96d03e68"
      unitRef="usd">135300</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80My9mcmFnOmVlNGVhODkyNTQ1ZjQ5NzNiZDhhMTA5N2RkNmYxZmU5L3RleHRyZWdpb246ZWU0ZWE4OTI1NDVmNDk3M2JkOGExMDk3ZGQ2ZjFmZTlfMTE4Mg_a696082e-c0ee-4d0e-91d7-5428a9a081f7"
      unitRef="usd">500000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RleHRyZWdpb246NjFiYjk2ODAyZGQ4NGI0ZWJjYmQwOWFjZTRlNGI2OTNfMzA1NQ_189a4b36-f5a2-48f0-923c-cfc1f239040e">FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of March 31, 2023 Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&#x2014;money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Embedded derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class C warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2022 Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&#x2014;money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Embedded derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class C warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash equivalents consisted of money market funds invested primarily in short term commercial paper, asset- backed securities, certificate of deposits and repurchase agreements. The money market funds were valued based on reported market pricing for the identical assets, which represents a Level 1 measurement, or by using inputs observable in active markets for similar securities, which represents a Level&#160;2 measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll-forward of the aggregate fair values financial instruments for which fair values are determined using Level 3 inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.009%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Embedded Derivative Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class C Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31,  2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Embedded Derivative Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The fair value of the embedded derivative liability recognized in connection with the Company&#x2019;s loan agreement with Hercules (see Note 7), which is associated with additional fees due to Hercules upon events of default, was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of this embedded derivative liability, which is reported within other non-current liabilities on the condensed consolidated balance sheets, is estimated by the Company at each reporting date based, in part, on the results of third party valuations, which are prepared based on a discounted cash flow model that considers the timing and probability of occurrence of a redemption upon an event of default, the potential amount of prepayment fees or contingent interest upon an event of default and the Company&#x2019;s risk-adjusted discount rate of 14%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Class C Warrant Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the Company issued Class C Warrants for the purchase of shares of its common stock in a public offering of common stock. The Class C Warrants are accounted for as a liability on the condensed consolidated balance sheet and are adjusted to fair value at period end through &#x201c;other income (expense)&#x201d; in the condensed, consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculated the fair value of the Class C Warrants using the Black-Scholes option pricing model, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which represents a Level 3 measurement within the fair value hierarchy, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with the following inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.99&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RleHRyZWdpb246NjFiYjk2ODAyZGQ4NGI0ZWJjYmQwOWFjZTRlNGI2OTNfMzA1MQ_2170683d-c213-4347-90ba-bef8d0a5e95d">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of March 31, 2023 Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&#x2014;money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Embedded derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class C warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2022 Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&#x2014;money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Embedded derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class C warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4569714abef741429d743af4a4bf2be0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfMy0xLTEtMS02ODU4NQ_0b1364d0-b457-4bb9-9c3a-0b3ebb7ea96e"
      unitRef="usd">70959000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8c1816e489194f42bdd5f5bf10009b9c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfMy0zLTEtMS02ODU4NQ_56a19e95-ac48-4cac-b08f-892f95e4f5c6"
      unitRef="usd">14000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if2ab8413e7e84528b4f5fdcb13e35002_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfMy01LTEtMS02ODU4NQ_9a34103c-8afb-481f-8038-6087a354a4f8"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifeef5c014ddc40deb4afa45ea2116298_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfMy03LTEtMS02ODU4NQ_55a21b49-75e9-432f-af28-11b465696829"
      unitRef="usd">70973000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4569714abef741429d743af4a4bf2be0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNC0xLTEtMS02ODU4NQ_96f87efb-d7d8-4780-92ed-138e7b8a7358"
      unitRef="usd">70959000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8c1816e489194f42bdd5f5bf10009b9c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNC0zLTEtMS02ODU4NQ_109b7fa0-6dec-472b-899a-e4c60bca8794"
      unitRef="usd">14000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if2ab8413e7e84528b4f5fdcb13e35002_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNC01LTEtMS02ODU4NQ_e9eb1633-320d-480c-9039-5e2342b6f03c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifeef5c014ddc40deb4afa45ea2116298_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNC03LTEtMS02ODU4NQ_34fd92c7-ecc4-4afa-9d65-7dc0c94bb7dc"
      unitRef="usd">70973000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i381526f76190408a9511bfe7c72a7ff0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNi0xLTEtMS02ODU4NQ_b94240e9-19a3-4976-bc5d-623c134b2ddf"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i135f5bb1ba83401da08651bc765c88e9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNi0zLTEtMS02ODU4NQ_a20438ff-fc90-483f-b2dd-41aba5bddf59"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="icfb4d92d12744b63a445624d8eac9b0c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNi01LTEtMS02ODU4NQ_baa2017e-7692-4990-98a3-08f67ac7b4f2"
      unitRef="usd">10000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i73a291db2a214ab8bd5e5491ada2141b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNi03LTEtMS02ODU4NQ_1e863789-4dbe-4b11-a736-d586a1cb725e"
      unitRef="usd">10000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie5dd8502aef84153bdcb16bdbd51c805_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNy01LTEtMS02OTQwNA_6cc4ef01-5371-4e51-9b94-82fcef39f3d4"
      unitRef="usd">17692000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia57db8f000ee4e0db6a8ea78cb129405_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNy03LTEtMS02OTQwNA_37a567b7-d42d-4bd9-bcee-277f031f7abf"
      unitRef="usd">17692000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i4569714abef741429d743af4a4bf2be0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNy0xLTEtMS02ODU4NQ_30adc716-125d-41a2-9b9d-c7b8e481364e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i8c1816e489194f42bdd5f5bf10009b9c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNy0zLTEtMS02ODU4NQ_71b2ee5a-3ad3-4a0b-9d71-ff6566a296db"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if2ab8413e7e84528b4f5fdcb13e35002_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNy01LTEtMS02ODU4NQ_aa1fb4b5-eee0-4e2c-8010-e9b4e3cef6a4"
      unitRef="usd">17702000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ifeef5c014ddc40deb4afa45ea2116298_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjJhOTI4OWE1NGFkNjRmMDZhYWEzMzJmZjBiODY3ZjIyL3RhYmxlcmFuZ2U6MmE5Mjg5YTU0YWQ2NGYwNmFhYTMzMmZmMGI4NjdmMjJfNy03LTEtMS02ODU4NQ_d807f519-b7b1-49de-af03-b42e8ee2d1ce"
      unitRef="usd">17702000</us-gaap:DerivativeLiabilities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia4afbc3f95ef42a4b901ae73cd5145db_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfMy0xLTEtMS02ODU4NQ_21f89fa7-8351-478e-8bc3-c8d56390325e"
      unitRef="usd">70170000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia3668be13a034a95babcca27311d8576_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfMy0zLTEtMS02ODU4NQ_94e5bb1c-82cb-4cf5-a4ec-3383ef908317"
      unitRef="usd">2858000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib5e321b38d9d409c9c0f8404d848b3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfMy01LTEtMS02ODU4NQ_186598ce-d536-4338-b3e7-466dc4313976"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8d6a3b6f090b4a87bcfb08e640d71bba_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfMy03LTEtMS02ODU4NQ_eff07696-e653-4bca-852a-31be473b9f89"
      unitRef="usd">73028000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia4afbc3f95ef42a4b901ae73cd5145db_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNC0xLTEtMS02ODU4NQ_77a67c25-f3ee-4257-a6ef-f9bf71aa8b87"
      unitRef="usd">70170000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia3668be13a034a95babcca27311d8576_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNC0zLTEtMS02ODU4NQ_a30f6e3b-1dc2-4355-9abf-1e2d6e056488"
      unitRef="usd">2858000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib5e321b38d9d409c9c0f8404d848b3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNC01LTEtMS02ODU4NQ_b99932d6-c2ac-4585-8a76-41256c372149"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8d6a3b6f090b4a87bcfb08e640d71bba_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNC03LTEtMS02ODU4NQ_22104a9e-a337-4f63-b445-fce46f15dd51"
      unitRef="usd">73028000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i1b09f270112741469f241038cd756330_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNi0xLTEtMS02ODU4NQ_ba713139-a35c-4756-baef-ffdfd0247abc"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ib3b2a90a4f734a278a5d983fe879b015_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNi0zLTEtMS02ODU4NQ_6b151348-f03c-4eaa-a19d-fd4c55fd43bd"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i1e93d6b488d5402094357867417eaf30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNi01LTEtMS02ODU4NQ_f612f288-bb7d-403c-b22f-2127546b99e8"
      unitRef="usd">10000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia6a0892801fe4d00ba9b8e44831c13dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNi03LTEtMS02ODU4NQ_4f187d2b-109d-4025-984a-62ece51bc098"
      unitRef="usd">10000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i416807bcc91c4426b94694508810dfe8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNy01LTEtMS02OTQ2MQ_43acd8d5-83cb-47fc-af51-8492ccf5e3a0"
      unitRef="usd">23131000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ib7ba75f2aa194fdfa790914ca3e5f732_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNy03LTEtMS02OTQ2MQ_1461fb47-3bd0-4aee-9c5f-e5d18412d74a"
      unitRef="usd">23131000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia4afbc3f95ef42a4b901ae73cd5145db_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNy0xLTEtMS02ODU4NQ_7ba8fce2-14b8-41ce-b432-95d98ff3e613"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia3668be13a034a95babcca27311d8576_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNy0zLTEtMS02ODU4NQ_320bb405-993c-4a66-adb7-8085b4ede6cd"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ib5e321b38d9d409c9c0f8404d848b3dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNy01LTEtMS02ODU4NQ_021add62-c5a4-4d4f-a38b-4a8560f4253a"
      unitRef="usd">23141000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i8d6a3b6f090b4a87bcfb08e640d71bba_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjMxZDZjM2YwOTEwMTRmNzVhZTQyODZiODY2ZjE3ZjkyL3RhYmxlcmFuZ2U6MzFkNmMzZjA5MTAxNGY3NWFlNDI4NmI4NjZmMTdmOTJfNy03LTEtMS02ODU4NQ_495d10ff-629c-4ae4-add4-66161d00eb54"
      unitRef="usd">23141000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RleHRyZWdpb246NjFiYjk2ODAyZGQ4NGI0ZWJjYmQwOWFjZTRlNGI2OTNfMzA1Mg_5a382f8f-2ae2-43da-81b0-e0f1d43400f6">&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll-forward of the aggregate fair values financial instruments for which fair values are determined using Level 3 inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.009%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Embedded Derivative Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class C Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31,  2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i2d93fbb6a1a344a8b945a2a6d090a483_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfMS0xLTEtMS02ODU4NQ_277bc9e7-d515-4f18-b65c-e6376b453273"
      unitRef="usd">10000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i81add40f359a4d498e9c203424802dfe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfMS0zLTEtMS02ODU4NQ_419b93d2-89ee-44d8-a26a-5f5807c9745b"
      unitRef="usd">23131000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfMS01LTEtMS02ODU4NQ_ad9688e1-43a4-4a42-8cc8-9149e7fdf87f"
      unitRef="usd">23141000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i64eed22c85fc47188e427943319310db_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfMy0xLTEtMS02ODU4NQ_a6983062-2931-49a6-8cca-9ccc7587fd10"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="id13c30409f644883bc0984bf6cca3669_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfMy0zLTEtMS02ODU4NQ_c27f5dfc-7515-4f4d-bc86-424b227d4803"
      unitRef="usd">-5439000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfMy01LTEtMS02ODU4NQ_c689ca10-5ac2-4dd6-be82-78e653de20ee"
      unitRef="usd">-5439000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id99d965540fb4a3d8b3bf165eb026ad5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfNS0xLTEtMS02ODU4NQ_b0bc3be5-dd3b-49f9-b928-c306741eeead"
      unitRef="usd">10000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="idf55d74b96f44b02b711f225b809780f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfNS0zLTEtMS02ODU4NQ_af973faf-ac3b-4a5a-8fc6-6cebb284d15a"
      unitRef="usd">17692000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjg5Y2IyYjg0ZWMwMzRkOWZiNDAzYmViYWVkMGVmZDI1L3RhYmxlcmFuZ2U6ODljYjJiODRlYzAzNGQ5ZmI0MDNiZWJhZWQwZWZkMjVfNS01LTEtMS02ODU4NQ_9d4800bc-0bc8-437e-8d31-997e12d48abe"
      unitRef="usd">17702000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DerivativeLiabilities
      contextRef="i600de8e95d2f4f32915317e0807fd211_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RleHRyZWdpb246NjFiYjk2ODAyZGQ4NGI0ZWJjYmQwOWFjZTRlNGI2OTNfMTc0OQ_f120b11a-7714-439e-a8df-dbbba8a518d7"
      unitRef="usd">0.14</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RleHRyZWdpb246NjFiYjk2ODAyZGQ4NGI0ZWJjYmQwOWFjZTRlNGI2OTNfMzA1Mw_9431074a-6252-4a1f-baf9-192bb01a3b0a">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.99&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="i4adf5f56124545d5a93d3519e1e8f047_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfMS0yLTEtMS02OTU0Mg_34c562db-b046-4a51-8c5e-dc3859e5027a"
      unitRef="usdPerShare">0.87</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i08cceb6ad460483886bad3c9fcd6710e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfMS00LTEtMS03MDY0NA_41160f81-3cb7-40a2-b2a3-3f1b46d04906"
      unitRef="usdPerShare">0.99</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6fbe040e10eb4417b2f7665f9b30f4e7_D20230331-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfMS0yLTEtMS02ODU4NQ_de1f8499-c647-4b0a-b261-1ba51b87e3d9"
      unitRef="number">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8067028e2bde498d90d62f8632965d93_D20221231-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfMS00LTEtMS02ODU4NQ_4101f2ed-e98f-4194-b367-7ba7d5778682"
      unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6fbe040e10eb4417b2f7665f9b30f4e7_D20230331-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfMi0yLTEtMS02ODU4NQ_277c54b3-1868-46e9-bd8a-594c8f92b2ac">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8067028e2bde498d90d62f8632965d93_D20221231-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfMi00LTEtMS02ODU4NQ_41d69478-d1c8-448e-8b43-b4d5784dfabe">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6fbe040e10eb4417b2f7665f9b30f4e7_D20230331-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfMy0yLTEtMS02ODU4NQ_ec802efa-e42a-4dde-9718-59a3175ad158"
      unitRef="number">0.919</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8067028e2bde498d90d62f8632965d93_D20221231-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfMy00LTEtMS02ODU4NQ_87a4ad97-b17d-412d-b304-461695a7667b"
      unitRef="number">1.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6fbe040e10eb4417b2f7665f9b30f4e7_D20230331-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfNC0yLTEtMS02ODU4NQ_b5ce9be3-7afb-4f09-aa4e-ec3d08a826fc"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8067028e2bde498d90d62f8632965d93_D20221231-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80Ni9mcmFnOjYxYmI5NjgwMmRkODRiNGViY2JkMDlhY2U0ZTRiNjkzL3RhYmxlOjkxNTIxZjQwZDNjODQzMDhiNjRlYTJiOWRhYTBlYTdhL3RhYmxlcmFuZ2U6OTE1MjFmNDBkM2M4NDMwOGI2NGVhMmI5ZGFhMGVhN2FfNC00LTEtMS02ODU4NQ_fd25c4e6-ee24-4bc1-bbd4-50b459be8229"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RleHRyZWdpb246Y2E1MDlhZWY4ZTVmNDdkOTllYWNkZjVmZjI2MGZlOGVfMjMy_216223d9-97e7-4637-9e7e-44e071b36cfe">PROPERTY AND EQUIPMENT, NET&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense related to property and equipment was $127 thousand and $133 thousand for the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RleHRyZWdpb246Y2E1MDlhZWY4ZTVmNDdkOTllYWNkZjVmZjI2MGZlOGVfMjMz_0cf2333c-0d5f-4525-bbf4-4b0ae5df236a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i833765a4f0bd42efb5804d15e1b6865f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfMS0xLTEtMS02ODU4NQ_6929bcf2-c02c-468f-b40d-3483f4260635"
      unitRef="usd">228000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i64189e1012e04d2a966fd7a2f71a3db9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfMS0zLTEtMS02ODU4NQ_722bbf83-02fb-44cd-b732-fafb16c3532b"
      unitRef="usd">228000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i13aa4785edcb43ea8c372564342c427b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfMi0xLTEtMS02ODU4NQ_bfc999e4-d69a-49ff-bdb0-60907388202b"
      unitRef="usd">1274000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3e5c556c18904363b107b9fc923ba681_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfMi0zLTEtMS02ODU4NQ_d088a5b6-9632-4bfd-a5ed-cb8caf90bf2f"
      unitRef="usd">1268000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7410737db5a84986b20145230e3dfa68_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfMy0xLTEtMS02ODU4NQ_e3035add-127d-4608-905f-4bdb8de8c366"
      unitRef="usd">173000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie6c7932d5157432c9771d0031da998c3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfMy0zLTEtMS02ODU4NQ_7d4e78fe-e57d-43c4-88bb-1af6245435c9"
      unitRef="usd">173000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i94a2b42432f045c69a6a314871000d9c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfNC0xLTEtMS02ODU4NQ_f83615cb-55dd-4c0c-b1fb-fb854d626ea8"
      unitRef="usd">24000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i121a3bffe8da40d3bfa57370f4d064ce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfNC0zLTEtMS02ODU4NQ_835c1dbc-b6c5-475a-bd0c-ffcc604c235d"
      unitRef="usd">24000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i17c81259a02f42f0875544b1198e4095_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfNS0xLTEtMS02ODU4NQ_a0bd4b54-957c-4bbe-bcf0-3ded2df55dff"
      unitRef="usd">642000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i06a2ca03978148dc9bd965d74ecd6189_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfNS0zLTEtMS02ODU4NQ_0ba7afa1-f8f3-4b9a-a2f9-5788b4cdeabc"
      unitRef="usd">639000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfNi0xLTEtMS02ODU4NQ_fd02e17b-0c2f-41d0-b406-e20b8a7e0ad3"
      unitRef="usd">2341000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfNi0zLTEtMS02ODU4NQ_afa0f6c9-3db2-41bf-8236-afaab94acee3"
      unitRef="usd">2332000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfNy0xLTEtMS02ODU4NQ_631c2086-a271-4ede-baaf-f571d980970f"
      unitRef="usd">1355000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfNy0zLTEtMS02ODU4NQ_1fcde24a-16d3-4337-82f8-eed4f698e8dd"
      unitRef="usd">1228000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfOC0xLTEtMS02ODU4NQ_c25d49b3-f8c5-4206-aeb9-1880491caf68"
      unitRef="usd">986000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RhYmxlOmNkMjgzMzJmYWMwYzRjNzA5MTExMzI4OGI4MjVmNGJkL3RhYmxlcmFuZ2U6Y2QyODMzMmZhYzBjNGM3MDkxMTEzMjg4YjgyNWY0YmRfOC0zLTEtMS02ODU4NQ_b480a93d-99ca-4deb-abe0-1174552d8ea8"
      unitRef="usd">1104000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RleHRyZWdpb246Y2E1MDlhZWY4ZTVmNDdkOTllYWNkZjVmZjI2MGZlOGVfMTcw_4bf7cfb5-627f-4159-88ec-1a77d3c03845"
      unitRef="usd">127000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV80OS9mcmFnOmNhNTA5YWVmOGU1ZjQ3ZDk5ZWFjZGY1ZmYyNjBmZThlL3RleHRyZWdpb246Y2E1MDlhZWY4ZTVmNDdkOTllYWNkZjVmZjI2MGZlOGVfMTc3_f1f34756-f723-458b-b02d-afe9905cfe4c"
      unitRef="usd">133000</us-gaap:DepreciationDepletionAndAmortization>
    <xfor:AccruedExpensesTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RleHRyZWdpb246ZTNmYzAzNWI3ZjAxNDY2N2IzYTM3Yzg2ODk3ZmIwMTBfNzI_20a67432-18e8-4376-ba8b-9ee71b2c920a">ACCRUED EXPENSES&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued external research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued deferred financing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</xfor:AccruedExpensesTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RleHRyZWdpb246ZTNmYzAzNWI3ZjAxNDY2N2IzYTM3Yzg2ODk3ZmIwMTBfNzA_92c4dce7-00af-4d59-b961-9c305c99eda4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued external research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued deferred financing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfMS0xLTEtMS02ODU4NQ_94f5b9dc-79bd-4f71-9d43-89346fcd86ce"
      unitRef="usd">2742000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfMS0zLTEtMS02ODU4NQ_9d48b830-3379-44f2-8153-9bedc0224697"
      unitRef="usd">6592000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <xfor:AccruedExternalResearchAndDevelopmentExpenses
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfMi0xLTEtMS02ODU4NQ_7d17c530-441b-4d26-8529-fae791d2a468"
      unitRef="usd">7721000</xfor:AccruedExternalResearchAndDevelopmentExpenses>
    <xfor:AccruedExternalResearchAndDevelopmentExpenses
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfMi0zLTEtMS02ODU4NQ_3b8fa3c7-447d-4c9e-9f56-876e4269ec77"
      unitRef="usd">3906000</xfor:AccruedExternalResearchAndDevelopmentExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfMy0xLTEtMS02ODU4NQ_f586f5c1-2a96-4096-a815-42b5798d7596"
      unitRef="usd">924000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfMy0zLTEtMS02ODU4NQ_ad48ea7d-211e-4451-9b4d-fc096c0b5cb4"
      unitRef="usd">571000</us-gaap:AccruedProfessionalFeesCurrent>
    <xfor:AccruedLeaseConstructionCosts
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfNC0xLTEtMS02ODU4NQ_5c78058f-fc31-49bf-b67d-e56b895ff169"
      unitRef="usd">0</xfor:AccruedLeaseConstructionCosts>
    <xfor:AccruedLeaseConstructionCosts
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfNC0zLTEtMS02ODU4NQ_4fd76fc7-f4d9-48e7-ab45-3f96a2004c5b"
      unitRef="usd">591000</xfor:AccruedLeaseConstructionCosts>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfNS0xLTEtMS02ODU4NQ_f6c35983-d095-48fe-8f45-66d4ab54ee21"
      unitRef="usd">375000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfNS0zLTEtMS02ODU4NQ_ab8c9da2-5e46-4584-88f3-42ea00d227bc"
      unitRef="usd">374000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfNi0xLTEtMS02ODU4NQ_eb0bffdc-b710-4caa-9d53-20a006347e01"
      unitRef="usd">11762000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81Mi9mcmFnOmUzZmMwMzViN2YwMTQ2NjdiM2EzN2M4Njg5N2ZiMDEwL3RhYmxlOmQ1OWUwOTQyOGQ3NjQ3NjQ4ZmI4MWNiNzFiMTBhMzEzL3RhYmxlcmFuZ2U6ZDU5ZTA5NDI4ZDc2NDc2NDhmYjgxY2I3MWIxMGEzMTNfNi0zLTEtMS02ODU4NQ_135cba7a-5bd1-471a-878d-c00ae932774a"
      unitRef="usd">12034000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNjAzOA_75bbb41f-f9e4-4015-9c02-be14b2021418">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt discount, net of accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative accretion of end of term payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Hercules Loan Agreement, As Amended&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into a Loan and Security Agreement (the &#x201c;Hercules Loan Agreement&#x201d;), as amended most recently in January 2023, with Hercules, under which the Company has borrowed an aggregate of $32.5 million of term loans to date representing the maximum borrowings. Borrowings under the Hercules Loan Agreement accrues interest at a variable rate equal to the greater of (i)&#160;10.15% or (ii)&#160; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wall Street Journal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;prime rate plus 3.15%.&#160;In an event of default and until such event is no longer continuing, the interest rate applicable to borrowings would be increased by 4.0%. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the Hercules Loan Agreement are repayable in monthly interest-only payments through September 2024, and in equal monthly payments of principal and accrued interest from October&#160;1, 2024 until the maturity date of the loan on April 1, 2026; provided, however, if certain conditions are met and the Company achieves certain operational and financial milestones, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the maturity date will be extended to July 1, 2027. The Company may prepay all, but not less than all, of the outstanding borrowings, subject to a prepayment premium of 3.0% of the principal amount outstanding as of the date of repayment. In addition, the Hercules Loan Agreement provides for payments of $0.8 million and $1.3 million payable on July 1, 2023 and April 1, 2026, respectively, which payments are accelerated upon the prepayment of the borrowings upon the Company&#x2019;s election or upon default of the loan. Borrowings under the Hercules Loan Agreement are collateralized by substantially all of the Company&#x2019;s personal property and other assets except for its intellectual property (but including rights to payment and proceeds from the sale, licensing or disposition of the intellectual property). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under the Hercules Loan Agreement, the Company has agreed to affirmative and negative covenants. Pursuant to the Hercules Loan Agreement, the Company is required to maintain cash in an account or accounts in which Hercules has a first priority security interest, in an aggregate amount greater than $20.0 million. Upon the FDA&#x2019;s approval of the sale and marketing of mavorixafor for the treatment to patients with WHIM syndrome with a label claim that is generally consistent with that sought in the Company&#x2019;s New Drug Application filing, the required level shall be reduced to $10.0 million. A breach of any of the covenants under the Hercules Loan Agreement could result in a default under the loan. Upon the occurrence of an event of default under the loan facility with Hercules, the lender could elect to declare all amounts outstanding, if any, to be immediately due and payable and terminate all commitments to extend further credit. If there are any amounts outstanding that the Company is unable to repay, Hercules could proceed against the collateral to secure such indebtedness.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Hercules Loan Agreement also restricts the Company&#x2019;s ability to incur additional indebtedness, pay dividends, encumber its intellectual property, or engage in certain fundamental business transactions, such as mergers or acquisitions of other businesses, with certain exceptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized interest expense under the Hercules Loan Agreement as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The annual effective interest rate of the Hercules Loan Agreement as of March&#160;31, 2023 is 13.8%. There were no principal payments due or paid under the Hercules Loan Agreement during the three months ended March&#160;31, 2023. An end-of-term payment of $1.3 million was paid during the three months ended March 31, 2023 in conjunction with the second amendment and restatement of the Hercules Loan Agreement, which was entered into on January 6, 2023. The Company concluded that the amendment and restatement represented a modification to the debt. Accordingly, fees paid to third parties directly related to the amended and restated debt were expensed as incurred and fees paid to Hercules in conjunction with the amendment and restatement were deferred and are being amortized to interest expense over the life of the debt arrangement using the effective interest method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, future principal and accrued end-of-term payments due under the Hercules Loan Agreement were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNjAzNA_e8d90bb4-8373-4ef5-a5f6-0a58d5a263f9">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt discount, net of accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative accretion of end of term payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfMS0xLTEtMS02ODU4NQ_0c644e88-6023-4efc-b9e5-e557b6a8864d"
      unitRef="usd">32500000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfMS0zLTEtMS02ODU4NQ_b409eb84-aa89-4b6e-a99c-085638ae99c0"
      unitRef="usd">32500000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfMi0xLTEtMS02ODU4NQ_926a408d-38ed-45db-80f2-df5832767abd"
      unitRef="usd">767000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfMi0zLTEtMS02ODU4NQ_be252114-349f-4705-94cd-42e1a8ccc6e3"
      unitRef="usd">196000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <xfor:AccretionOnLongTermDebt
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfMy0xLTEtMS02ODU4NQ_bb44f6d3-3c48-4db0-9050-aa5b7711cc5b"
      unitRef="usd">-648000</xfor:AccretionOnLongTermDebt>
    <xfor:AccretionOnLongTermDebt
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfMy0zLTEtMS02ODU4NQ_f669cc31-8ac3-4a83-8f6b-dd61c4a7a3d2"
      unitRef="usd">-1315000</xfor:AccretionOnLongTermDebt>
    <xfor:LongTermDebtIncludingAccretion
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfNC0xLTEtMS02ODU4NQ_cef1fa2f-4c81-4e11-9fb2-a6462a5fea41"
      unitRef="usd">32381000</xfor:LongTermDebtIncludingAccretion>
    <xfor:LongTermDebtIncludingAccretion
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfNC0zLTEtMS02ODU4NQ_e00b53b2-e5f9-484c-b007-531e504217a5"
      unitRef="usd">33619000</xfor:LongTermDebtIncludingAccretion>
    <us-gaap:LongTermDebtCurrent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfNS0xLTEtMS02ODU4NQ_e6ed6e69-ef53-46db-8395-c5a08b54cd65"
      unitRef="usd">554000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfNS0zLTEtMS02ODU4NQ_7c7bf469-48ab-477c-902d-6b5ad428d94a"
      unitRef="usd">1315000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfNi0xLTEtMS02ODU4NQ_bc60142f-e5ab-4abd-b247-12b3009742e7"
      unitRef="usd">31827000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOmIwNzkzNWFjMjNkZDQwZWE5MTJkZDNiNjRjZDQ1YWE1L3RhYmxlcmFuZ2U6YjA3OTM1YWMyM2RkNDBlYTkxMmRkM2I2NGNkNDVhYTVfNi0zLTEtMS02ODU4NQ_e42a349e-ba8b-4a43-a3c8-93d412244f83"
      unitRef="usd">32304000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i4e9d1a47182c4c47854e138d3c2b5d17_D20181001-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfMzcy_a52aa468-fabf-4d3d-b2c5-f2952f0a4df9"
      unitRef="usd">32500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie15dfe94dd9d4fe39d6d8e1f3b74ce9a_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfODAx_641693d2-f832-4a49-8d7c-d1be9629c339"
      unitRef="number">0.1015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic8e87f99c10e4fb881a7bed5735567ff_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfODUz_64e525a8-ae54-49ee-a181-005fa6dc2dc3"
      unitRef="number">0.0315</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="ie15dfe94dd9d4fe39d6d8e1f3b74ce9a_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfOTkx_4e7ff89d-8e46-4b8c-8ca2-a38464c64bac"
      unitRef="number">0.040</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <xfor:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="i28f0cf51fe7e42fbb78f10ac69a552e6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfMTM4NA_ef4e5a4b-2c06-4ce4-a219-7d5dfc1555f6"
      unitRef="number">0.030</xfor:DebtInstrumentPrepaymentPremiumPercentage>
    <us-gaap:LineOfCreditFacilityPeriodicPayment
      contextRef="ia310f627aef34b0faca97728c514f3c1_D20220701-20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfMTUxOA_ddcf39a1-4dc9-4105-b558-5f35e6bba767"
      unitRef="usd">800000</us-gaap:LineOfCreditFacilityPeriodicPayment>
    <us-gaap:LineOfCreditFacilityPeriodicPayment
      contextRef="i792dfc869c4b408e892ad399f14978bb_D20240701-20240701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfMTUyNQ_bb3e064d-4c05-4851-9f43-99d0f336dc31"
      unitRef="usd">1300000</us-gaap:LineOfCreditFacilityPeriodicPayment>
    <xfor:LineOfCreditCovenantMinimumCash
      contextRef="ia4e98937b5cb4858b0ac41a2a5352c45_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNTQ5NzU1ODIxOTg5_333d46e5-ce4c-404c-9e2b-61a0d0a69d76"
      unitRef="usd">20000000</xfor:LineOfCreditCovenantMinimumCash>
    <xfor:LineOfCreditCovenantMinimumCash
      contextRef="ie2d3052cd5e24327abde1e8113a23cd2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNTQ5NzU1ODIyMjM5_de65f9ab-1367-4446-9086-fbe133bb36e1"
      unitRef="usd">10000000</xfor:LineOfCreditCovenantMinimumCash>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNjAzNQ_4a17feed-4266-469b-b79f-39bcdd4597e6">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized interest expense under the Hercules Loan Agreement as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebt
      contextRef="ie15dfe94dd9d4fe39d6d8e1f3b74ce9a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjJiYWJkNzIxNjMwYTQ4M2FiYmYxNjhmYWE5YjA1M2FhL3RhYmxlcmFuZ2U6MmJhYmQ3MjE2MzBhNDgzYWJiZjE2OGZhYTliMDUzYWFfMi0xLTEtMS02ODU4NQ_4852daaf-02a7-40a5-bda3-6f5218d8764b"
      unitRef="usd">884000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i758d637f0af747e88e3b2ef6d3eae458_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjJiYWJkNzIxNjMwYTQ4M2FiYmYxNjhmYWE5YjA1M2FhL3RhYmxlcmFuZ2U6MmJhYmQ3MjE2MzBhNDgzYWJiZjE2OGZhYTliMDUzYWFfMi0zLTEtMS02ODU4NQ_2392068c-ee8b-4528-b256-54769287b50d"
      unitRef="usd">909000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ie15dfe94dd9d4fe39d6d8e1f3b74ce9a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjJiYWJkNzIxNjMwYTQ4M2FiYmYxNjhmYWE5YjA1M2FhL3RhYmxlcmFuZ2U6MmJhYmQ3MjE2MzBhNDgzYWJiZjE2OGZhYTliMDUzYWFfMy0xLTEtMS02ODU4NQ_5544b2f7-98f6-403c-b2a6-3262d8c4233a"
      unitRef="usd">225000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i758d637f0af747e88e3b2ef6d3eae458_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjJiYWJkNzIxNjMwYTQ4M2FiYmYxNjhmYWE5YjA1M2FhL3RhYmxlcmFuZ2U6MmJhYmQ3MjE2MzBhNDgzYWJiZjE2OGZhYTliMDUzYWFfMy0zLTEtMS02ODU4NQ_98f3cfc6-c114-4406-b0c5-9bfdf6059c3a"
      unitRef="usd">198000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib8529518add445d8a6792e09b74e9bf9_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNTY1MQ_becb6abe-2bab-4fbe-80f5-2100126653c3"
      unitRef="number">0.138</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="ie15dfe94dd9d4fe39d6d8e1f3b74ce9a_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNTY2Ng_e1769699-20d8-47fe-afa3-ff55a76086fc"
      unitRef="usd">0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNTc5Mw_b2900d44-225b-4805-9440-1551633fbb01"
      unitRef="usd">1300000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RleHRyZWdpb246ZmIwMzU1M2JhOTEzNDI1ODg1OTdkMjIxMmJkZGZlYmRfNjAzNg_5952d25b-bea1-477c-bd51-fefce14b313f">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, future principal and accrued end-of-term payments due under the Hercules Loan Agreement were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjI1YjYzZDc5MTM4ZTQwNjU4MmRiNmMwNzYyOGI0MTA3L3RhYmxlcmFuZ2U6MjViNjNkNzkxMzhlNDA2NTgyZGI2YzA3NjI4YjQxMDdfMS0xLTEtMS02ODU4NQ_34319520-cacc-481f-b220-804792608666"
      unitRef="usd">554000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjI1YjYzZDc5MTM4ZTQwNjU4MmRiNmMwNzYyOGI0MTA3L3RhYmxlcmFuZ2U6MjViNjNkNzkxMzhlNDA2NTgyZGI2YzA3NjI4YjQxMDdfMi0xLTEtMS02ODU4NQ_fab7f6e5-5b5b-4840-b572-1c21f2376e87"
      unitRef="usd">4750000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjI1YjYzZDc5MTM4ZTQwNjU4MmRiNmMwNzYyOGI0MTA3L3RhYmxlcmFuZ2U6MjViNjNkNzkxMzhlNDA2NTgyZGI2YzA3NjI4YjQxMDdfMy0xLTEtMS02ODU4NQ_ae20536d-dd59-47e7-9667-d5c3a1dd0554"
      unitRef="usd">20386000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjI1YjYzZDc5MTM4ZTQwNjU4MmRiNmMwNzYyOGI0MTA3L3RhYmxlcmFuZ2U6MjViNjNkNzkxMzhlNDA2NTgyZGI2YzA3NjI4YjQxMDdfNC0xLTEtMS02OTgxNA_fbb41347-adc5-4cf1-ae52-d03d830c8a89"
      unitRef="usd">7458000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <xfor:LongTermDebtAndEOTPayment
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81NS9mcmFnOmZiMDM1NTNiYTkxMzQyNTg4NTk3ZDIyMTJiZGRmZWJkL3RhYmxlOjI1YjYzZDc5MTM4ZTQwNjU4MmRiNmMwNzYyOGI0MTA3L3RhYmxlcmFuZ2U6MjViNjNkNzkxMzhlNDA2NTgyZGI2YzA3NjI4YjQxMDdfNC0xLTEtMS02ODU4NQ_ab28f4f3-d59a-4b45-aab0-033a8eda4010"
      unitRef="usd">33148000</xfor:LongTermDebtAndEOTPayment>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfMjYxOQ_c7e36a33-2f16-4412-970a-c2808b7b6783">LEASES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has lease agreements for its facilities in Boston, Massachusetts, which is the Company&#x2019;s principal executive office; Vienna, Austria, which is the Company&#x2019;s research and development center; and Waltham, Massachusetts, which the Company has sublet to a third party. There are no restrictions or financial covenants associated with any of the lease agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Vienna Austria Leases&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an operating lease for approximately 1,200 square meters of laboratory and office space in Vienna, Austria (&#x201c;Vienna Lease&#x201d;), which commenced in February 2021 for a term of 7 years. The annual base rent for the Vienna Lease is approximately $285 thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Boston Lease&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company leases approximately 28,000 square feet of office space in Boston, Massachusetts (&#x201c;Boston Lease&#x201d;), which serves as the Company&#x2019;s headquarters. Base rental payments are approximately $1.1 million  annually, plus certain operating expenses. The term of the Boston Lease will continue until November 2026, unless earlier terminated. The Company has the right to sublease the premises, subject to landlord consent and also has the right to renew the Boston Lease for an additional five years at the then prevailing effective market rental rate. The Company is required to maintain a security deposit in the form of a letter of credit for $0.6&#160;million for the benefit of the landlord. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Waltham Lease&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases approximately 6,000 square feet of office space in Waltham, Massachusetts (&#x201c;Waltham Lease&#x201d;). The Waltham Lease, as amended, commenced on January&#160;1, 2019, and expires on December 31, 2023. The base rent is approximately $0.3 million annually. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, which costs are not included in the determination of the leases&#x2019; right-of-use assets or lease liabilities. The Company is subleasing the space to a third party for the duration of the lease. The right-of-use asset is being amortized to rent expense over the five-year term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As the Company&#x2019;s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense for the three months ended March&#160;31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(dollars in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities due under lease agreements that have commenced as of March&#160;31, 2023 are as follows (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.220%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remainder of the year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace
      contextRef="if95bc8592c8940cab11430e303f438e5_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfNDYz_b0830f8e-8b00-4ceb-8aee-d67ff6d02f55"
      unitRef="sqm">1200</xfor:LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="i44b39b28bc5548a2886646bbc220829d_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfNTk1_1cf4b6e0-0f6a-4698-aabb-8e0e1e8bb8f6">P7Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <xfor:LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent
      contextRef="i44b39b28bc5548a2886646bbc220829d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfNjU4_f21293cf-9b68-4166-8c9f-3874bc8016fd"
      unitRef="usd">285000</xfor:LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent>
    <xfor:CurrentOfficeSpaceUnderLeaseAgreement
      contextRef="i25a8d7091c814a1188d29fe34e7e629d_D20191111-20191111"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfNzA5_992940c5-37f0-46ee-be7a-93e56c3e333a"
      unitRef="sqft">28000</xfor:CurrentOfficeSpaceUnderLeaseAgreement>
    <xfor:LesseeOperatingLeaseLeaseNotYetCommencedAmount
      contextRef="i25a8d7091c814a1188d29fe34e7e629d_D20191111-20191111"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfNTQ5NzU1ODE2NTE0_f96539e2-0d6f-4747-81da-d5d6736de2bd"
      unitRef="usd">1100000</xfor:LesseeOperatingLeaseLeaseNotYetCommencedAmount>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i23498fecf6314534a7194a398e3e01ba_I20191111"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfMTE1MA_6decf1bf-7b78-4ddd-ae83-d7d8be0f8a1d">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <xfor:CurrentOfficeSpaceUnderLeaseAgreement
      contextRef="i25e5f6ca21c44724bd4163d8dc79dbe2_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfMTM4NQ_e166d456-e8c0-4380-a7a2-1f595a940e87"
      unitRef="sqft">6000</xfor:CurrentOfficeSpaceUnderLeaseAgreement>
    <xfor:AggregateBaseRent
      contextRef="i25e5f6ca21c44724bd4163d8dc79dbe2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfMTU5Nw_888c79e1-2dcc-42c2-871d-081f9d3342d6"
      unitRef="usd">300000</xfor:AggregateBaseRent>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i02b354bcacc54b7baa76c20057184051_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfMjYyMA_f011fcf1-d8c9-428c-979f-26fa73ff7171">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfMjYyMg_2990020b-f36d-437a-884f-c6a56b1b67a3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense for the three months ended March&#160;31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(dollars in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfMi0xLTEtMS02ODU4NQ_21fa4d33-8ca9-4545-9e29-f2fa29e12a1f"
      unitRef="usd">522000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfMi0zLTEtMS02ODU4NQ_8f1972a3-7ad2-42b6-bd4a-7c8ff20d3f8c"
      unitRef="usd">530000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfNC0xLTEtMS02ODU4NQ_b6a0f8d6-4701-458b-8a99-95bf2aa63481"
      unitRef="usd">522000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfNC0zLTEtMS02ODU4NQ_588bfafc-c1fb-4fe9-b555-8e75ae2941d1"
      unitRef="usd">530000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfNy0xLTEtMS02ODU4NQ_05df67a3-1893-45db-9b8f-09fc61a85a8e"
      unitRef="usd">346000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfNy0zLTEtMS02ODU4NQ_75214acd-c05d-4c43-9d13-c9072e267f2f"
      unitRef="usd">342000</us-gaap:OperatingLeasePayments>
    <us-gaap:SubleaseIncome
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfOC0xLTEtMS02ODU4NQ_c1f5d757-12d7-48fc-8d1c-1a9ac7e7648b"
      unitRef="usd">49000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfOC0zLTEtMS02ODU4NQ_4334ae6b-c386-4263-8d0f-82752705c258"
      unitRef="usd">49000</us-gaap:SubleaseIncome>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfOS0xLTEtMS02ODU4NQ_6fe68743-0a5c-4089-be36-e76295e8c8c4">P3Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjFlOGJkMGY5MGVhNTQyNGRiZTA5NTU0MGI1ZDE5MDhhL3RhYmxlcmFuZ2U6MWU4YmQwZjkwZWE1NDI0ZGJlMDk1NTQwYjVkMTkwOGFfMTAtMS0xLTEtNjg1ODU_a35234b7-8d3f-4872-969f-0d415503910d"
      unitRef="number">0.113</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RleHRyZWdpb246NzI2NmVkZjZiNjY3NDQzNWE3OTAzMjAzYjJjN2FhNDFfMjYyMw_0c89f34e-b618-4623-8c08-eb8c52be3d79">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities due under lease agreements that have commenced as of March&#160;31, 2023 are as follows (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.220%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remainder of the year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfMS0xLTEtMS02ODU4NQ_773137f9-338a-4c09-b3a8-124e168d3618"
      unitRef="usd">1210000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfMi0xLTEtMS02ODU4NQ_60fa5684-8ce8-4970-ad67-64bbfbd1436b"
      unitRef="usd">1378000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfMy0xLTEtMS02ODU4NQ_8d19d5e8-7144-4b92-b425-5a8947af7415"
      unitRef="usd">1406000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfNC0xLTEtMS02ODU4NQ_d692d9a9-fc0e-4b10-831b-2163781adb77"
      unitRef="usd">1337000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfNS0xLTEtMS02ODU4NQ_c703e3da-066a-476e-8326-33d7580dfa59"
      unitRef="usd">285000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfNi0xLTEtMS02ODU4NQ_712e8191-d6f0-4b19-8834-1ab87b6edab7"
      unitRef="usd">48000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfNy0xLTEtMS02ODU4NQ_3fe5e108-10ea-4a5b-8e4e-f3b2f97468c5"
      unitRef="usd">5664000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfOC0xLTEtMS02ODU4NQ_3f224605-25cb-48b5-a2db-7c23c05fd5a6"
      unitRef="usd">1112000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV81OC9mcmFnOjcyNjZlZGY2YjY2NzQ0MzVhNzkwMzIwM2IyYzdhYTQxL3RhYmxlOjgyY2QyNmQzNWZkNDQxM2FhZjYzNTE1NmJjOThiMmE3L3RhYmxlcmFuZ2U6ODJjZDI2ZDM1ZmQ0NDEzYWFmNjM1MTU2YmM5OGIyYTdfOS0xLTEtMS02ODU4NQ_e5335ce5-953c-46fd-9a6e-bb716a60f530"
      unitRef="usd">4552000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82MS9mcmFnOjg4ZTBiNWEwZGNmMzQ2ZDg4MzZiM2Y5Mjk3N2ViOWM0L3RleHRyZWdpb246ODhlMGI1YTBkY2YzNDZkODgzNmIzZjkyOTc3ZWI5YzRfMjIwMQ_796cdfe6-825e-4ca1-906a-1023299937b4">COMMITMENTS AND CONTINGENCIES &lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with contract manufacturing organizations (&#x201c;CMOs&#x201d;) for the production of mavorixafor for use in clinical trials. The Company&#x2019;s agreement with the CMO who produces batches of drug substance for use in the Company&#x2019;s clinical drug supply contains cancellation provisions that would require the Company to pay up to the full contract value upon cancellation. As of March&#160;31, 2023, the Company has approximately $0.8 million of such commitments in place subject to cancellation provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification Agreements&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company to, among other things, indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification obligations. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of March&#160;31, 2023 or December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to any legal proceedings.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i9d0d898499ff4bda99b5eb41e4b472d0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82MS9mcmFnOjg4ZTBiNWEwZGNmMzQ2ZDg4MzZiM2Y5Mjk3N2ViOWM0L3RleHRyZWdpb246ODhlMGI1YTBkY2YzNDZkODgzNmIzZjkyOTc3ZWI5YzRfMTYwOA_67aed9c5-e9d9-4c7d-876d-a8d2879ffa4b"
      unitRef="usd">0</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="ib84837e886bd42e9be166c81d4c7ebdf_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82MS9mcmFnOjg4ZTBiNWEwZGNmMzQ2ZDg4MzZiM2Y5Mjk3N2ViOWM0L3RleHRyZWdpb246ODhlMGI1YTBkY2YzNDZkODgzNmIzZjkyOTc3ZWI5YzRfMTYwOA_d12539ca-6bd4-4165-bbab-23d8178fedc4"
      unitRef="usd">0</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzk5MA_cef644ef-2410-4d9b-b60d-fe300943553e">COMMON STOCK AND COMMON STOCK WARRANTS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the Company&#x2019;s Restated Certificate of Incorporation authorized the Company to issue 500 million shares of common stock, par value $0.001 per share. The voting, dividend and liquidation rights of the holders of the Company&#x2019;s common stock are subject to and qualified by the rights, powers and preferences of the holders of any preferred stock that may be issued. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. No cash dividends have been declared or paid to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with previous public and private sales of shares of its common stock, the Company has issued warrants and pre-funded warrants, which are exercisable for the purchase shares of the Company&#x2019;s common stock. All outstanding warrants and pre-funded warrants are currently exercisable and do not have price reset provisions. Upon the closing of these public and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;private offerings, the Company received approximately 99% of the exercise price for the pre-funded warrants, for which the remaining exercise price is equal to or less than $0.01 per share.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023, the Company&#x2019;s outstanding warrants and pre-funded warrants to purchase shares of common stock consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares of&lt;br/&gt;Common&lt;br/&gt;Stock Issuable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 25, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 24, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 28, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 28, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 12, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 12, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 19, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 19, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 13, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 12, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 16, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,866,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 15, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 23, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 9, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,008,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;766,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 6, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,276,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(e)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 6, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,925,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 6, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 9, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,762,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 9, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 9, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(f)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111,871,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(a) In November 2019, the Company received $11.999 per pre-funded warrant, or $21.0 million in aggregate proceeds. Each pre-funded&lt;/span&gt;&lt;/div&gt;warrant may be exercised for an additional $0.001 per pre-funded warrant. (b) In March 2021, the Company received $8.69 per pre-funded warrant, or $435 thousand in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant. (c) In November 2021, the Company received $4.97 per pre-funded warrant, or $10.0&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant. (d) In March 2022, the Company received $1.79 per pre-funded warrant, or $1.4&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant. (e) In July 2022, the Company received $1.094 per pre-funded warrant, or $14.5 million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.001  per pre-funded warrant.  (f) In December 2022, the Company received $1.099 per pre-funded warrant, or $7.5&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.001 per pre-funded warrant.</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfMTU3_cfcb2bf7-d196-4504-af36-54bf6cc240f2"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfMTk0_5c9dd5d7-9e36-4bcb-9b67-0236fcb656ae"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfMTk0_8dc105a5-7631-4180-84a4-bfdf7d06af1b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DividendsCommonStock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNjQ2_78c2fa1c-57bd-4fd6-9ef8-19431769bd0e"
      unitRef="usd">0</us-gaap:DividendsCommonStock>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="i0c446d1ebf6c4761a059bfe41f76a3e8_I20210323"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNjgyMg_03c7ffbf-b73b-423f-9681-55e3178c2c1b"
      unitRef="usdPerShare">0.01</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzk5NA_7c4a949b-4c57-402f-80df-6e15a9b65ec4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023, the Company&#x2019;s outstanding warrants and pre-funded warrants to purchase shares of common stock consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares of&lt;br/&gt;Common&lt;br/&gt;Stock Issuable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 25, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 24, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 28, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 28, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 12, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 12, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 19, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 19, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 13, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 12, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 16, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,866,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 15, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 23, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 9, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,008,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;766,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 6, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,276,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(e)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 6, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,925,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 6, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 9, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,762,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 9, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 9, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(f)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111,871,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(a) In November 2019, the Company received $11.999 per pre-funded warrant, or $21.0 million in aggregate proceeds. Each pre-funded&lt;/span&gt;&lt;/div&gt;warrant may be exercised for an additional $0.001 per pre-funded warrant. (b) In March 2021, the Company received $8.69 per pre-funded warrant, or $435 thousand in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant. (c) In November 2021, the Company received $4.97 per pre-funded warrant, or $10.0&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant. (d) In March 2022, the Company received $1.79 per pre-funded warrant, or $1.4&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.01 per pre-funded warrant. (e) In July 2022, the Company received $1.094 per pre-funded warrant, or $14.5 million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.001  per pre-funded warrant.  (f) In December 2022, the Company received $1.099 per pre-funded warrant, or $7.5&#160;million in aggregate proceeds. Each pre-funded warrant may be exercised for an additional $0.001 per pre-funded warrant.</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i59fa5f3cd8cf463cb6ab5a26e83105b0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMS0yLTEtMS02ODU4NQ_c926c199-f307-4baf-b1ba-3b388ba3627f"
      unitRef="shares">5155</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iade75dd12e4e4311828ad8732615848a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMS00LTEtMS02ODU4NQ_d64e5687-1047-4cee-9a73-48b6770d062b"
      unitRef="usdPerShare">19.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic7ff88f12eeb444480a302991cd38a77_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMi0yLTEtMS02ODU4NQ_1cc2c5bc-b92f-4a03-ba43-8e68a028b63d"
      unitRef="shares">115916</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ica711cd3944d444d8e90591b4f36f165_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMi00LTEtMS02ODU4NQ_91967fad-8038-4c0a-8ad4-9f8c98b58f49"
      unitRef="usdPerShare">19.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i659abfcb1f9b4bab9b076ba940943d85_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMy0yLTEtMS02ODU4NQ_f5d6d3d6-3cac-4106-a57c-7b1c20c5e9a2"
      unitRef="shares">20220</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i8f782c581af34e0bbaf1f1c156ed8abd_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMy00LTEtMS02ODU4NQ_d9011a9c-53f8-45d0-8b9d-06f53baa840e"
      unitRef="usdPerShare">19.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id50d3ea6ecda45bb92708c1a5fcceadc_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfNC0yLTEtMS02ODU4NQ_8181b7de-0ece-4c99-9db6-7992e5930116"
      unitRef="shares">20016</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i831b8fe131874b52b6235c73b19040d9_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfNC00LTEtMS02ODU4NQ_06b68b16-53d8-46ab-bf35-c223b8ddda77"
      unitRef="usdPerShare">19.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i44c6c0606f1e473a95f0fd0e8f1f0ceb_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfNS0yLTEtMS02ODU4NQ_37552924-d9a6-4ff5-984a-3456a6e74301"
      unitRef="shares">5000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie46fdfe3fed3486d838e54a83d18ef93_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfNS00LTEtMS02ODU4NQ_38a838d8-1e66-42e7-b583-dd3df9e88d11"
      unitRef="usdPerShare">19.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i61d35b6a71594a80acb565c214ebd4d8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfNi0yLTEtMS02ODU4NQ_29525a69-780f-4a5d-bda5-ee2b23c87e37"
      unitRef="shares">3866154</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i57d428ba32094371b2dd937c8006e5f0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfNi00LTEtMS02ODU4NQ_a074ed4a-9d3c-4978-bd0c-3a0cb90aadd6"
      unitRef="usdPerShare">13.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i6e73b6bdb52e4b4289aa86a4856b47d5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfOC0yLTEtMS02ODU4NQ_f060fce5-aaae-460c-a211-9602900bada7"
      unitRef="shares">1250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7df7eb9e7da8482fafec0c3a38337782_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfOC00LTEtMS02ODU4NQ_7299721c-b80e-45e7-a455-609fc39e2ffe"
      unitRef="usdPerShare">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="idb769b89cd694464bdd20ebea31ac73d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfOS0yLTEtMS02ODU4NQ_47dff035-edf8-46cd-b48f-dbca2503ab02"
      unitRef="shares">50000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i721101088e744db48fa346c2c77fd85b_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfOS00LTEtMS02ODU4NQ_01111638-18ef-43dd-9f65-f7c310d0e2e8"
      unitRef="usdPerShare">8.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic3c41890d3204b10bab8bd252409ac92_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTAtMi0xLTEtNjg1ODU_50deb184-c797-4dae-8d12-84f224e2a320"
      unitRef="shares">2008032</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic3c41890d3204b10bab8bd252409ac92_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTAtNC0xLTEtNjg1ODU_d60a60d1-444a-4562-857c-99c52ef289a5"
      unitRef="usdPerShare">4.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id9018c6d85d24e0dba02aaac05afaddb_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTEtMi0xLTEtNjg1ODU_5df655b4-36d0-45a3-86c8-a63287aa1403"
      unitRef="shares">766666</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id9018c6d85d24e0dba02aaac05afaddb_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTEtNC0xLTEtNjg1ODU_ab441db3-679a-4272-a998-6a18196eb0e9"
      unitRef="usdPerShare">1.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i5011564a8640482d8512bf19c9642f10_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTItMi0xLTEtNjg1ODU_68d7f37c-8687-42c4-af7d-a28ffce23aab"
      unitRef="shares">13276279</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i5011564a8640482d8512bf19c9642f10_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTItNC0xLTEtNjg1ODU_7da6608a-17ac-4ebb-ae53-783548a76771"
      unitRef="usdPerShare">1.095</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i7edde0006e1e454d8fea426452b3b54e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTMtMi0xLTEtNjg1ODU_4eb0c453-843a-4986-bde1-8242c5a314bf"
      unitRef="shares">50925365</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7edde0006e1e454d8fea426452b3b54e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTMtNC0xLTEtNjg1ODU_38e66f27-74e0-4288-b3f5-08e133c28e22"
      unitRef="usdPerShare">1.095</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i818c42fab04d4637b93d77e2ac2f2974_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTQtMi0xLTEtNzA5OTc_1cc38552-f085-4947-9b4b-90a7af0715d0"
      unitRef="shares">32762947</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i818c42fab04d4637b93d77e2ac2f2974_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTQtNC0xLTEtNzEwMDY_904a2ef3-a932-4ce4-8f91-4290e729593b"
      unitRef="usdPerShare">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i21bf4eefdb5f491ca5fc00294f5db16a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTUtMi0xLTEtNzA5OTc_902c6281-b07f-4f55-aeae-11cd43e4ba1c"
      unitRef="shares">6800000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i21bf4eefdb5f491ca5fc00294f5db16a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTUtNC0xLTEtNzEwMDY_e6e3d200-844a-4c59-bf82-65eaac672a5c"
      unitRef="usdPerShare">1.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RhYmxlOjA1Yzk0OTQyNmYyNzQ1OWFhYWYxMGRlZDZiN2FkYzZhL3RhYmxlcmFuZ2U6MDVjOTQ5NDI2ZjI3NDU5YWFhZjEwZGVkNmI3YWRjNmFfMTQtMi0xLTEtNjg1ODU_ceafe3a7-73b6-413d-ad5f-8a259a1ca83b"
      unitRef="shares">111871750</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ib89426f0e382467982b04ef21eb04de6_I20191129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzExMQ_8c63d58a-4f82-4a67-bc10-7566830ac14f"
      unitRef="usdPerShare">11.999</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued
      contextRef="i7b8255b9ad4e4346b4353461add65217_I20191129"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzE0MQ_ad918977-6842-4627-a54b-9aea38691fb2"
      unitRef="usd">21000000</xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="i7b8255b9ad4e4346b4353461add65217_I20191129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzIyNg_b090b716-72fe-4794-98d5-3372b8365aa9"
      unitRef="usdPerShare">0.001</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i4a0759706aef4898bfd9353dc9c1c0cf_I20210323"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzI5NA_237e0fbb-00f9-4a35-99bf-61ee262c8cee"
      unitRef="usdPerShare">8.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued
      contextRef="ibd18ae94cc92493599001fb5cde340a6_I20210323"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzMyNA_e856a27b-5123-46a3-ad7f-a1d62ce415f5"
      unitRef="usd">435000</xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="i0c446d1ebf6c4761a059bfe41f76a3e8_I20210323"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzQwOQ_03c7ffbf-b73b-423f-9681-55e3178c2c1b"
      unitRef="usdPerShare">0.01</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7b76566d4b4d440f9b96f6bd007aea3e_I20211109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzQ4MQ_28fe951e-40fc-4e1f-aef3-d27f231e93e3"
      unitRef="usdPerShare">4.97</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued
      contextRef="i0fe40bc1e0fd489aa6756bc0c4fcb174_I20211109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzUxMQ_bb19a800-cd9d-4046-a90b-d2083fc676ad"
      unitRef="usd">10000000</xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="i3f7f41a7ee2c446eb9fdb515a92b8d90_I20201102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzU5Ng_4729ab44-1784-41ea-9df1-7d3e1983b395"
      unitRef="usdPerShare">0.01</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i4705077c59e44584ac747abb1c31531c_I20220303"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzY2NA_67e804b1-c839-40dd-9ef0-e90029cd4e25"
      unitRef="usdPerShare">1.79</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued
      contextRef="ie54bb572558c468f842e439ada8634bb_I20220303"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzY5NA_004e14f1-d628-4339-99c2-5c138e4697af"
      unitRef="usd">1400000</xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="ie54bb572558c468f842e439ada8634bb_I20220303"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzc3OQ_98947300-20d9-4b6d-84d0-2e9048dfdb93"
      unitRef="usdPerShare">0.01</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iac8921647cac40fbafd7ae760b99dccc_I20220706"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzg0Ng_b181785a-e40a-45d7-b271-4e95d94a5a78"
      unitRef="usdPerShare">1.094</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued
      contextRef="i057e951826ef4df4b14c1200eeac39f1_I20220706"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzg3Ng_85c51af8-3faa-439a-b630-dfd224066006"
      unitRef="usd">14500000</xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="i057e951826ef4df4b14c1200eeac39f1_I20220706"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNzk2MQ_4c34e3b0-29ba-4ef5-8fb3-4950e30b7f8d"
      unitRef="usdPerShare">0.001</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued
      contextRef="i9bda35ba3715478cb44dadfb584bfff4_I20221209"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNTQ5NzU1ODI5Mjc4_887e4e8d-407e-487a-8459-23e7ec4b8c4b"
      unitRef="usd">7500000</xfor:ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued>
    <xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights
      contextRef="i057e951826ef4df4b14c1200eeac39f1_I20220706"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82NC9mcmFnOjY3NDE1ODBmZjIwMTRiMjU5ZjJlNGJmNzc2Yzc1NTk1L3RleHRyZWdpb246Njc0MTU4MGZmMjAxNGIyNTlmMmU0YmY3NzZjNzU1OTVfNTQ5NzU1ODI5MjA1_4c34e3b0-29ba-4ef5-8fb3-4950e30b7f8d"
      unitRef="usdPerShare">0.001</xfor:ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMzU4OA_40a4488d-bdfc-4674-82ed-8d997b3d8f4a">STOCK-BASED COMPENSATION&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Plans&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has the following equity incentive plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The X4 Pharmaceuticals Inc. 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (the &#x201c;2015 Plan&#x201d;);&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The X4 Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;); and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The X4 Pharmaceuticals Inc. 2019 Inducement Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company also has the following employee stock purchase plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt"&gt;The X4 Pharmaceutical Inc. 2017 Employee Stock Purchase Plan (the &#x201c;2017 ESPP&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These plans are administered by the Board of Directors or by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the term of the stock option may not be greater than ten years. Incentive stock options granted to employees and restricted stock awards granted to employees, officers, members of the board of directors, advisors, and consultants of the Company typically vest over four years. Non-statutory options granted to employees, officers, members of the board of directors, advisors, and consultants of the Company typically vest over three or four years. Shares that are expired, terminated, surrendered or canceled under the Plans without having been fully exercised will be available for future awards. In &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, there are an aggregate of approximately 1.0&#160;million shares of common stock available for issuance under the Company&#x2019;s equity incentive plans. Approximately 150,000 shares of common stock remain available for issuance under the 2017 ESPP.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Valuation&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees, directors and non-employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,021,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,210,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no stock options exercised in the three months ended March&#160;31, 2023 and 2022. The weighted average grant-date fair value per share of stock options granted during the three months ended March&#160;31, 2023 and 2022 was $0.69 and $1.42, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The following table summarizes the Company's restricted stock unit activity for the three months ended March 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,680,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,694,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(540,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,835,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, the Company granted performance-based restricted stock units (&#x201c;PRSUs&#x201d;) to its employees. The PRSUs vest 50% based on the Company&#x2019;s achievement of each of two operational milestones conditioned on the grantee&#x2019;s continued employment with the Company. As of March 31, 2023, neither of the two performance criteria had been met. The Company believes that the achievement of these operational milestones is probable and, accordingly, stock-based compensation expense has been recognized for the awards using the accelerated attribution model based on the fair value of the awards as of the date of grant and management&#x2019;s best estimate of the date each operational milestone will be achieved. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company will update its estimates related to the probability and timing of achievement of the operational milestones each period until the award either vests or is forfeited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, total unrecognized compensation expense related to unvested stock options and restricted stock units was $6.2 million, which is expected to be recognized over a weighted average period of 1.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.148%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9c915254cae9474f9c1872cf496e414a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMTc4NA_6314dbc1-653f-4f4f-8176-bc8a50406f54"
      unitRef="shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="if3afe5f2291441f68f12e2ab64cf0818_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMTg5MQ_70286dd4-a640-46fe-a1af-e79cef363d63"
      unitRef="shares">150000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMzU4OQ_ff5cc5d8-b956-4f18-8993-0341ff169b5d">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees, directors and non-employees.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjVjNTBmZTM2ZGNkYTQ1NGY4ZTVjZGUxZjIxYzNhMGE5L3RhYmxlcmFuZ2U6NWM1MGZlMzZkY2RhNDU0ZjhlNWNkZTFmMjFjM2EwYTlfMi0xLTEtMS02ODU4NQ_370de8b6-673e-405a-8b41-7d2841d4597a"
      unitRef="number">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjVjNTBmZTM2ZGNkYTQ1NGY4ZTVjZGUxZjIxYzNhMGE5L3RhYmxlcmFuZ2U6NWM1MGZlMzZkY2RhNDU0ZjhlNWNkZTFmMjFjM2EwYTlfMi0zLTEtMS02ODU4NQ_f7553441-8686-405f-b978-fd3ec7ee76f9"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjVjNTBmZTM2ZGNkYTQ1NGY4ZTVjZGUxZjIxYzNhMGE5L3RhYmxlcmFuZ2U6NWM1MGZlMzZkY2RhNDU0ZjhlNWNkZTFmMjFjM2EwYTlfMy0xLTEtMS02ODU4NQ_7223d970-3c89-4f02-a52d-13153a0a44fe">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjVjNTBmZTM2ZGNkYTQ1NGY4ZTVjZGUxZjIxYzNhMGE5L3RhYmxlcmFuZ2U6NWM1MGZlMzZkY2RhNDU0ZjhlNWNkZTFmMjFjM2EwYTlfMy0zLTEtMS02ODU4NQ_560ffb1c-387b-4bb8-8e3a-9951a617f740">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjVjNTBmZTM2ZGNkYTQ1NGY4ZTVjZGUxZjIxYzNhMGE5L3RhYmxlcmFuZ2U6NWM1MGZlMzZkY2RhNDU0ZjhlNWNkZTFmMjFjM2EwYTlfNC0xLTEtMS02ODU4NQ_0d1004e3-3ec1-4efc-a59e-8a14ae0c6b85"
      unitRef="number">0.908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjVjNTBmZTM2ZGNkYTQ1NGY4ZTVjZGUxZjIxYzNhMGE5L3RhYmxlcmFuZ2U6NWM1MGZlMzZkY2RhNDU0ZjhlNWNkZTFmMjFjM2EwYTlfNC0zLTEtMS02ODU4NQ_e1a052a3-381c-49f2-8a6a-de68cc22bb2e"
      unitRef="number">0.945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjVjNTBmZTM2ZGNkYTQ1NGY4ZTVjZGUxZjIxYzNhMGE5L3RhYmxlcmFuZ2U6NWM1MGZlMzZkY2RhNDU0ZjhlNWNkZTFmMjFjM2EwYTlfNS0xLTEtMS02ODU4NQ_0a3d9e95-463c-4a6b-b2cd-a32ddc41eaca"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjVjNTBmZTM2ZGNkYTQ1NGY4ZTVjZGUxZjIxYzNhMGE5L3RhYmxlcmFuZ2U6NWM1MGZlMzZkY2RhNDU0ZjhlNWNkZTFmMjFjM2EwYTlfNS0zLTEtMS02ODU4NQ_ff1d4101-9d9e-4f00-bd0e-7d5861c786b2"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMzU5MA_75a9862e-2e74-40a6-9279-3dbbace2c201">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,021,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,210,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfMS0xLTEtMS02ODU4NQ_b407aed7-e44c-4e65-ae3b-82e50727d55f"
      unitRef="shares">2021480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfMS0zLTEtMS02ODU4NQ_1ab80626-f11d-4b68-ace0-51d56c88c5a9"
      unitRef="usdPerShare">6.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4740594349684b0589e4efe56fcf1e5b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfMS01LTEtMS02ODU4NQ_ef0a8c73-5871-4c6d-a9d4-483ac84e137a">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i1ca029d12cad45af98e015984da7cdeb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfMS03LTEtMS02ODU4NQ_a1d9ad11-25c7-4884-b458-e7527cfc8970"
      unitRef="usd">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfMi0xLTEtMS02ODU4NQ_fee49047-1078-48f9-936b-9d942f0900f8"
      unitRef="shares">834900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfMi0zLTEtMS02ODU4NQ_ae8aadd6-0953-46c0-8981-be51318b79a6"
      unitRef="usdPerShare">0.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNC0xLTEtMS02ODU4NQ_a260a81e-e54c-4a05-aa0f-9b0c4e887ba8"
      unitRef="shares">26080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNC0zLTEtMS02ODU4NQ_456d1963-01c8-4203-b5a8-1d15b71ed3b3"
      unitRef="usdPerShare">8.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNS0xLTEtMS02ODU4NQ_881d4e3f-f198-432f-891c-83647db6ca73"
      unitRef="shares">2830300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNS0zLTEtMS02ODU4NQ_c0c890ba-0477-4313-9655-1f27288e91dd"
      unitRef="usdPerShare">5.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNS01LTEtMS02ODU4NQ_119329d5-3f98-44e2-8194-2759acec7f35">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNS03LTEtMS02ODU4NQ_d6b1b3d3-d7f9-4923-995f-59572e49f155"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNi0xLTEtMS02ODU4NQ_a4ccf82e-21ca-4687-b12d-bf6992bbe3a5"
      unitRef="shares">1163500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNi0zLTEtMS02ODU4NQ_881e0e71-741b-4f12-96a4-6182e3f09040"
      unitRef="usdPerShare">9.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNi01LTEtMS02ODU4NQ_c67370e4-0cac-4da3-80e3-7737c648ce88">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNi03LTEtMS02ODU4NQ_16c3e1a4-aa8a-4774-8819-64ae835cb3ca"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNy0xLTEtMS02ODU4NQ_21e2c1f4-c12f-44e1-86ea-47945b0e2f0b"
      unitRef="shares">2210011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNy0zLTEtMS02ODU4NQ_a37890cd-f2d0-4d87-b598-275f6cef44d1"
      unitRef="usdPerShare">6.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNy01LTEtMS02ODU4NQ_f77011e6-4f0b-4354-8d29-6edf7dbe5dc5">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjkwMjcwZmZkN2M1YzQzOWNhNGZmNjM0OTk5OTAyYThjL3RhYmxlcmFuZ2U6OTAyNzBmZmQ3YzVjNDM5Y2E0ZmY2MzQ5OTk5MDJhOGNfNy03LTEtMS02ODU4NQ_e24f48ef-11a5-4bef-b5e6-84e09061751a"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMjY2MA_a479a38a-48b5-4172-86ce-1cc0202c9147"
      unitRef="usdPerShare">0.69</xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue>
    <xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMjY2Nw_b37f4b6f-e887-492c-b86f-2b09a75c2cd2"
      unitRef="usdPerShare">1.42</xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMzU5MQ_2a6065b0-aabf-4f3f-96c9-a5ab574dd3b9">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The following table summarizes the Company's restricted stock unit activity for the three months ended March 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,680,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,694,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(540,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,835,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9f9fb24c8bb04a26883c4eb1d92a0d6b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjg3YTcwMGM3NDllNzQzYjc5NjU4NWY3NjQzNmE5OTc1L3RhYmxlcmFuZ2U6ODdhNzAwYzc0OWU3NDNiNzk2NTg1Zjc2NDM2YTk5NzVfMS0xLTEtMS02ODU4NQ_b35401ea-0468-4c0c-a379-9fe337a4ae40"
      unitRef="shares">1680563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjg3YTcwMGM3NDllNzQzYjc5NjU4NWY3NjQzNmE5OTc1L3RhYmxlcmFuZ2U6ODdhNzAwYzc0OWU3NDNiNzk2NTg1Zjc2NDM2YTk5NzVfMi0xLTEtMS02ODU4NQ_fe8f5d3c-98ad-4e3c-9057-6ffc45def19a"
      unitRef="shares">4694691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjg3YTcwMGM3NDllNzQzYjc5NjU4NWY3NjQzNmE5OTc1L3RhYmxlcmFuZ2U6ODdhNzAwYzc0OWU3NDNiNzk2NTg1Zjc2NDM2YTk5NzVfMy0xLTEtMS02ODU4NQ_87794431-7e73-45b7-b598-71e2137f2be4"
      unitRef="shares">540238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i8402c14812aa4792af598dc3f27820a4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjg3YTcwMGM3NDllNzQzYjc5NjU4NWY3NjQzNmE5OTc1L3RhYmxlcmFuZ2U6ODdhNzAwYzc0OWU3NDNiNzk2NTg1Zjc2NDM2YTk5NzVfNS0xLTEtMS02ODU4NQ_d7b5dbe3-1c73-4549-8510-0282a86c47d4"
      unitRef="shares">5835016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i86fbb46408bd4a3db8bc2da79cf7f762_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMzM5NQ_dc115244-e818-420f-a731-51abe41f91ae"
      unitRef="usd">6200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i21e6f989318241fbbefaf5468e259ca9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMzQ2OA_2e40350e-0b63-486e-b02c-afc0c496ef6b">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfMzU5Mg_0a2ea8a6-a76c-4813-bc81-79e48db8b5fb">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.148%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i19a10edec5d54b3ca68a4c28e1bf34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjE3OTJlMDI2OTBmNTQ4YThhYzU0ZTZkODVmZGFhZGE2L3RhYmxlcmFuZ2U6MTc5MmUwMjY5MGY1NDhhOGFjNTRlNmQ4NWZkYWFkYTZfMi0xLTEtMS02ODU4NQ_63c1abce-bef8-4490-9b48-cfbb4dd43e84"
      unitRef="usd">831000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i15e8f73d1083480daefae46435fca891_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjE3OTJlMDI2OTBmNTQ4YThhYzU0ZTZkODVmZGFhZGE2L3RhYmxlcmFuZ2U6MTc5MmUwMjY5MGY1NDhhOGFjNTRlNmQ4NWZkYWFkYTZfMi0zLTEtMS02ODU4NQ_d058b64d-8ddd-4e81-b05c-392c943da09a"
      unitRef="usd">704000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2770b271c4ae4bbb9a3c41d6903a369a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjE3OTJlMDI2OTBmNTQ4YThhYzU0ZTZkODVmZGFhZGE2L3RhYmxlcmFuZ2U6MTc5MmUwMjY5MGY1NDhhOGFjNTRlNmQ4NWZkYWFkYTZfMy0xLTEtMS02ODU4NQ_fbcea016-5ca4-4245-8895-fa0bccf0689d"
      unitRef="usd">814000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8e768118a7db47359a07259561180c69_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjE3OTJlMDI2OTBmNTQ4YThhYzU0ZTZkODVmZGFhZGE2L3RhYmxlcmFuZ2U6MTc5MmUwMjY5MGY1NDhhOGFjNTRlNmQ4NWZkYWFkYTZfMy0zLTEtMS02ODU4NQ_90d2dd48-f01f-4586-b2e4-fb67adf08877"
      unitRef="usd">755000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjE3OTJlMDI2OTBmNTQ4YThhYzU0ZTZkODVmZGFhZGE2L3RhYmxlcmFuZ2U6MTc5MmUwMjY5MGY1NDhhOGFjNTRlNmQ4NWZkYWFkYTZfNC0xLTEtMS02ODU4NQ_6fd5e3ea-7656-4fa0-a625-e26c203f1788"
      unitRef="usd">1645000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOjE3OTJlMDI2OTBmNTQ4YThhYzU0ZTZkODVmZGFhZGE2L3RhYmxlcmFuZ2U6MTc5MmUwMjY5MGY1NDhhOGFjNTRlNmQ4NWZkYWFkYTZfNC0zLTEtMS02ODU4NQ_092bfcdb-28b4-4bd8-bf65-59d8565d4784"
      unitRef="usd">1459000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RleHRyZWdpb246ZmU0NGM0YTc4ZDkxNDYxYTk5YjVhZjM0MzE0NDU4YTZfNTQ5NzU1ODIyMTI3_b0ea6d74-6a54-4248-99e4-e5cdba180dec">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of the fair value of the outstanding SARs as of March&#160;31, 2023 includes the closing price of the Company&#x2019;s common stock of $0.87 and the following assumptions on a weighted average basis:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.959%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4221465155da49fe9746bea8dd9a5099_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOmU1NzMxNzBmMTg3MTRhNzE5ODdlOTFiOTMwZmQ2YWIxL3RhYmxlcmFuZ2U6ZTU3MzE3MGYxODcxNGE3MTk4N2U5MWI5MzBmZDZhYjFfMS0yLTEtMS03MTU4Mw_8dfcd733-9d49-4bf3-9044-027ada92a941"
      unitRef="number">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4221465155da49fe9746bea8dd9a5099_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOmU1NzMxNzBmMTg3MTRhNzE5ODdlOTFiOTMwZmQ2YWIxL3RhYmxlcmFuZ2U6ZTU3MzE3MGYxODcxNGE3MTk4N2U5MWI5MzBmZDZhYjFfMi0yLTEtMS03MTU4Mw_e6a4a930-67a9-4620-b72c-2e8876ead447">P5Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4221465155da49fe9746bea8dd9a5099_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOmU1NzMxNzBmMTg3MTRhNzE5ODdlOTFiOTMwZmQ2YWIxL3RhYmxlcmFuZ2U6ZTU3MzE3MGYxODcxNGE3MTk4N2U5MWI5MzBmZDZhYjFfMy0yLTEtMS03MTU4Mw_d66b7c8b-6cc6-4c21-99e3-8ba121de2bb5"
      unitRef="number">0.908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4221465155da49fe9746bea8dd9a5099_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOmU1NzMxNzBmMTg3MTRhNzE5ODdlOTFiOTMwZmQ2YWIxL3RhYmxlcmFuZ2U6ZTU3MzE3MGYxODcxNGE3MTk4N2U5MWI5MzBmZDZhYjFfNC0yLTEtMS03MTU4Mw_ebd32a32-a5e5-49bc-ba40-d05363a51aa4"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="i4221465155da49fe9746bea8dd9a5099_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV82Ny9mcmFnOmZlNDRjNGE3OGQ5MTQ2MWE5OWI1YWYzNDMxNDQ1OGE2L3RhYmxlOmU1NzMxNzBmMTg3MTRhNzE5ODdlOTFiOTMwZmQ2YWIxL3RhYmxlcmFuZ2U6ZTU3MzE3MGYxODcxNGE3MTk4N2U5MWI5MzBmZDZhYjFfNS0yLTEtMS03MTU4Mw_b9bb8eca-26ae-417f-9c66-0fe78668133b"
      unitRef="number">0.22</xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83MC9mcmFnOjRkYzI3MzBmYjcyMTRmYjVhYzg1NjY1M2RhMTg0NzJjL3RleHRyZWdpb246NGRjMjczMGZiNzIxNGZiNWFjODU2NjUzZGExODQ3MmNfNDU4_1548466a-0a48-4d41-a513-6f539e42c04b">INCOME TAXESThe Company did not record a U.S. federal or state income tax benefit for its losses for the three months ended March&#160;31, 2023 and 2022, due to the conclusion that a full valuation allowance is required against the Company&#x2019;s U.S. federal and state deferred tax assets. For the three months ended March&#160;31, 2023 and 2022, the Company recorded an immaterial income tax provision related to its Austrian subsidiary.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83MC9mcmFnOjRkYzI3MzBmYjcyMTRmYjVhYzg1NjY1M2RhMTg0NzJjL3RleHRyZWdpb246NGRjMjczMGZiNzIxNGZiNWFjODU2NjUzZGExODQ3MmNfMzg_621abb15-7a7e-44d3-8d7b-f47e08a056f9"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83MC9mcmFnOjRkYzI3MzBmYjcyMTRmYjVhYzg1NjY1M2RhMTg0NzJjL3RleHRyZWdpb246NGRjMjczMGZiNzIxNGZiNWFjODU2NjUzZGExODQ3MmNfMzg_864049ed-cade-4307-96f7-8afb08a40a3d"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83MC9mcmFnOjRkYzI3MzBmYjcyMTRmYjVhYzg1NjY1M2RhMTg0NzJjL3RleHRyZWdpb246NGRjMjczMGZiNzIxNGZiNWFjODU2NjUzZGExODQ3MmNfMzg_c1ddbde3-2816-4e00-bb0f-96165addcc2b"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83MC9mcmFnOjRkYzI3MzBmYjcyMTRmYjVhYzg1NjY1M2RhMTg0NzJjL3RleHRyZWdpb246NGRjMjczMGZiNzIxNGZiNWFjODU2NjUzZGExODQ3MmNfMzg_d53b2202-b921-47fe-9b39-39ef57658d3a"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RleHRyZWdpb246YTBkYTIxOTAxYmRkNDg3YmFkZTg5YmJjYWIzYjQ5YjhfMjA4MQ_c272de64-550e-4760-bd7a-34cd1586d9cc">NET LOSS PER SHARE&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follow:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deemed dividend as a result of Class B warrant price reset &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding&#x2014;basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to common stockholders&#x2014; basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted weighted average shares of common stock outstanding for the three months ended March&#160;31, 2023 and March&#160;31, 2022 include the weighted average effect of outstanding pre-funded warrants for the purchase of shares of common stock for which the remaining unfunded exercise price is $0.01 or less per share. During the three months ended March 31, 2022, in accordance with the Company&#x2019;s Class B Warrant agreement, the exercise price of each outstanding Class B Warrant was adjusted to the price of shares of the Company&#x2019;s common stock sold in public or private offerings to the extent such price is lower than the previous Class B warrant price. These price adjustments were accounted for as a deemed dividend that adjusts net loss available to common shareholders for purposes of basic earnings per share. The deemed dividend was calculated using the Black-Scholes pricing model, taking into account historical volatility of the Company&#x2019;s common stock and the estimated remaining life of the outstanding Class B Warrants. The Class B Warrants expired in December 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s potentially dilutive securities include outstanding stock options, unvested restricted stock units and warrants to purchase shares of common stock for the three months ended March&#160;31, 2023 and 2022. All potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share, and thus they are considered &#x201c;anti-dilutive.&#x201d; Therefore, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase shares of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,049,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,835,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,940,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase shares of common stock (excluding prefunded warrants, which are included in basic shares outstanding)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,720,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,449,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,386,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,438,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RleHRyZWdpb246YTBkYTIxOTAxYmRkNDg3YmFkZTg5YmJjYWIzYjQ5YjhfMjA4Mg_1c74fb0d-2055-4beb-aadb-b3ee6b934431">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follow:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deemed dividend as a result of Class B warrant price reset &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding&#x2014;basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to common stockholders&#x2014; basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfMy0xLTEtMS02ODU4NQ_cd884d86-694a-447b-bda7-f77fbce2b59f"
      unitRef="usd">-24020000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfMy0zLTEtMS02ODU4NQ_c39021b6-ca5f-43ae-a22c-cea2a598407c"
      unitRef="usd">-21965000</us-gaap:NetIncomeLoss>
    <us-gaap:DividendsPaidinkind
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfNC0xLTEtMS02ODU4NQ_902c30fb-711e-4093-b231-72a98d938999"
      unitRef="usd">0</us-gaap:DividendsPaidinkind>
    <us-gaap:DividendsPaidinkind
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfNC0zLTEtMS02ODU4NQ_241e7ac9-2e31-45b9-9186-566886a14cdd"
      unitRef="usd">2259000</us-gaap:DividendsPaidinkind>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfNS0xLTEtMS02ODU4NQ_30889e07-1d03-49c6-8f0e-a12cb122b1cd"
      unitRef="usd">-24020000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfNS0zLTEtMS02ODU4NQ_e104fec7-493f-432c-b8a1-7016b4ed2bb7"
      unitRef="usd">-24224000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfNy0xLTEtMS02ODU4NQ_13750b9d-74dc-4173-9521-248a2add23dc"
      unitRef="shares">145967000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfNy0xLTEtMS02ODU4NQ_a818c49e-7b39-4333-a567-be38fd1f7322"
      unitRef="shares">145967000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfNy0zLTEtMS02ODU4NQ_34840f04-0881-4a5c-96ef-bafa12b5ace8"
      unitRef="shares">33737000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfNy0zLTEtMS02ODU4NQ_4ae4c26f-1e75-4826-888f-9b3759ceb88d"
      unitRef="shares">33737000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfOC0xLTEtMS02ODU4NQ_6cc14dd2-69ef-4f43-a1e6-872e3d89bc18"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfOC0xLTEtMS02ODU4NQ_e0db5504-6f24-47a7-84b6-ef89cbcb544f"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfOC0zLTEtMS02ODU4NQ_135653fe-9828-4b1e-af2c-5f2a6d22162a"
      unitRef="usdPerShare">-0.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjY2MzNkM2JhZDgwOTQyZWE5YjY0YjRjYmY5NTBlMDIzL3RhYmxlcmFuZ2U6NjYzM2QzYmFkODA5NDJlYTliNjRiNGNiZjk1MGUwMjNfOC0zLTEtMS02ODU4NQ_247882aa-4ea2-4a55-bf55-41603c0fadf9"
      unitRef="usdPerShare">-0.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i543a1b3b9f974153b5b0d78f5aa7e65a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RleHRyZWdpb246YTBkYTIxOTAxYmRkNDg3YmFkZTg5YmJjYWIzYjQ5YjhfMzk4_0afd1ebe-4127-4ca7-8715-0d59bf516b9e"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RleHRyZWdpb246YTBkYTIxOTAxYmRkNDg3YmFkZTg5YmJjYWIzYjQ5YjhfMjA3OQ_918e3d57-6952-47e8-b1aa-ac7b98ccbc3f">The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase shares of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,049,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,835,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,940,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase shares of common stock (excluding prefunded warrants, which are included in basic shares outstanding)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,720,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,449,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,386,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,438,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1f3437aea96f4fe886c79fb94a8059fe_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjI3MGU5NDkzM2IxMTQ0ZDk5ZjU4YTgxYTQwYzNjOTdjL3RhYmxlcmFuZ2U6MjcwZTk0OTMzYjExNDRkOTlmNThhODFhNDBjM2M5N2NfMi0xLTEtMS02ODU4NQ_0a8bffba-b4db-4169-8594-8f7ac8a41d29"
      unitRef="shares">2830300</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idcded639cedf4a788b3eecce804bc350_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjI3MGU5NDkzM2IxMTQ0ZDk5ZjU4YTgxYTQwYzNjOTdjL3RhYmxlcmFuZ2U6MjcwZTk0OTMzYjExNDRkOTlmNThhODFhNDBjM2M5N2NfMi0zLTEtMS02ODU4NQ_7c2258e0-9051-48bd-80ff-57cb10528525"
      unitRef="shares">2049158</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i81603c1b6ca6430691c2b72f0262d107_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjI3MGU5NDkzM2IxMTQ0ZDk5ZjU4YTgxYTQwYzNjOTdjL3RhYmxlcmFuZ2U6MjcwZTk0OTMzYjExNDRkOTlmNThhODFhNDBjM2M5N2NfMy0xLTEtMS02ODU4NQ_d1137586-4d39-4b48-9505-5c5b0c0da7f6"
      unitRef="shares">5835016</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4c0ed81ded19458591eb27f59b52093f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjI3MGU5NDkzM2IxMTQ0ZDk5ZjU4YTgxYTQwYzNjOTdjL3RhYmxlcmFuZ2U6MjcwZTk0OTMzYjExNDRkOTlmNThhODFhNDBjM2M5N2NfMy0zLTEtMS02ODU4NQ_d2ef6d92-83ee-43e7-b0a6-9a1f438f2b05"
      unitRef="shares">1940788</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iac5b1bc09d7c443491ee3a29c39946f6_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjI3MGU5NDkzM2IxMTQ0ZDk5ZjU4YTgxYTQwYzNjOTdjL3RhYmxlcmFuZ2U6MjcwZTk0OTMzYjExNDRkOTlmNThhODFhNDBjM2M5N2NfNC0xLTEtMS02ODU4NQ_e4b40fb9-c759-4328-8f4f-b4e05428d8c4"
      unitRef="shares">87720773</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie95358238f73468db9f71aef1ce13baf_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjI3MGU5NDkzM2IxMTQ0ZDk5ZjU4YTgxYTQwYzNjOTdjL3RhYmxlcmFuZ2U6MjcwZTk0OTMzYjExNDRkOTlmNThhODFhNDBjM2M5N2NfNC0zLTEtMS02ODU4NQ_391d3392-213f-4449-b230-39b04636ff11"
      unitRef="shares">9449028</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjI3MGU5NDkzM2IxMTQ0ZDk5ZjU4YTgxYTQwYzNjOTdjL3RhYmxlcmFuZ2U6MjcwZTk0OTMzYjExNDRkOTlmNThhODFhNDBjM2M5N2NfNS0xLTEtMS02ODU4NQ_0dd88020-c810-4464-b40d-fd383d82eda5"
      unitRef="shares">96386089</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if7bd6e34afc74cc5a8472acfff2165ec_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV83My9mcmFnOmEwZGEyMTkwMWJkZDQ4N2JhZGU4OWJiY2FiM2I0OWI4L3RhYmxlOjI3MGU5NDkzM2IxMTQ0ZDk5ZjU4YTgxYTQwYzNjOTdjL3RhYmxlcmFuZ2U6MjcwZTk0OTMzYjExNDRkOTlmNThhODFhNDBjM2M5N2NfNS0zLTEtMS02ODU4NQ_625ec855-5b3e-4df6-9d88-97949df0591a"
      unitRef="shares">13438974</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjYtMS0xLTEtNjg1ODU_af199409-8a84-4abd-a25e-eefab0bb9286"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjYtMS0xLTEtNjg1ODU_af199409-8a84-4abd-a25e-eefab0bb9286"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjYtMy0xLTEtNjg1ODU_78ba9af6-ba6b-4906-bb66-1087f9aac6b1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjYtMy0xLTEtNjg1ODU_78ba9af6-ba6b-4906-bb66-1087f9aac6b1"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzEtMC0xLTEtNzQ2ODQ_b30ab6e2-479e-4fee-926d-dba7a9de7c0e" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzEtMC0xLTEtNzQ2ODQ_b30ab6e2-479e-4fee-926d-dba7a9de7c0e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(1) For the three month period ended March 31, 2023, includes payment of issuance costs related to December 2022 public sale of shares of common stock and pre-funded warrants</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjYtMS0xLTEtNjg1ODU_af199409-8a84-4abd-a25e-eefab0bb9286"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzEtMC0xLTEtNzQ2ODQ_b30ab6e2-479e-4fee-926d-dba7a9de7c0e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMjYtMy0xLTEtNjg1ODU_78ba9af6-ba6b-4906-bb66-1087f9aac6b1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjMxYTZiNWFhMjllZTRmMzc4NWRlNGUxZTBmOTA4YTgxL3NlYzozMWE2YjVhYTI5ZWU0ZjM3ODVkZTRlMWUwZjkwOGE4MV8zMS9mcmFnOjMyYjU4MTA5MzMzMTRjMmVhYzUzNzM2NmRjOGU2ZDRmL3RhYmxlOmU5NjczZGU1N2M2ZDRlNDQ5OGUzNTVkZjA1NzExMGZiL3RhYmxlcmFuZ2U6ZTk2NzNkZTU3YzZkNGU0NDk4ZTM1NWRmMDU3MTEwZmJfMzEtMC0xLTEtNzQ2ODQ_b30ab6e2-479e-4fee-926d-dba7a9de7c0e"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>72
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" !N@J16]:S0O=D%  "A'P  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+69_6_B-AC'_Q6+2=,FE4OL0$MO+1)-RPZM[7&EM]UMV@\F,1!=$C/'*>6_
MW^, "5>9AR@Z?BEY>[[UQX]?OK:O5E)]RQ9":/*:Q&EVW5IHO7SO.%FP$ G/
MWLFE2.'-3*J$:[A5<R=;*L'#(BB)'>:ZYT["H[35ORJ>C57_2N8ZCE(Q5B3+
MDX2K]8V(Y>JZ15N[!T_1?*'- Z=_M>1S,1'Z\W*LX,XI5<(H$6D6R90H,;MN
M#>A[W_-,0/'%GY%897O7Q*!,I?QF;D;A=<LU)1*Q"+21X/#S(GP1QT8)RO'?
M5K15_D\3N'^]4Q\6\  SY9GP9?Q7%.K%=:O7(J&8\3S63W+U06R!ND8OD'%6
M_"6KS;>=3HL$>:9EL@V&$B11NOGEK]N*V M@AP+8-H"]":#>@0!O&U#4G+,I
M68%URS7O7RFY(LI\#6KFHJB;(AIHHM2D<:(5O(T@3O=]^2(4&4/&2)MD"ZY$
M=N5H$#:OG6 K<K,180=$//(@4[W(R%T:BO#[> <*5):*[4IUPU#!!Z[>$8^>
M$>8RSU(>_UCXFKC6Z.]*XY5UY!5R'EI'_PRFF5;0[/ZU5=!&H6-7,'WQ?;;D
M@;AN06?+A'H1K?[//]%S]S<;W0\2^PZV4\)V,/7^K0QRZ*::/*^7PD:*AU.W
M_<F&A$8U1.J62-UZ2)]RKK10\9H\B:54VH:'2VF5VRK%1Z,:XIV7>.?U\,9"
M13(TG9# 6&!-'JY4=KN#_0Z-;\AY47)>U&R9BL,T4LP"A_.(:\UXG%D3B88U
M!.R5@#VT4'>ICO2:#*-8D,<\F0IE \,U7)>VO1Z[[-K@T-"&<)<EW&4=N"<Q
MC\PP"FE\Y(FUC>(Z7SID_&'P]##P[SX_C_S!_>2,C!Y]&RXJU!"7NM7$ZM8!
M'J6!5-!(N6FO9V2BH6<2J8@O\U2K-?R&UEHXHGY[9R/&@YHB[WD)6@?YF;^2
M40@]-9I%0<&--.<CDNRB[=$>E+!GY46#F_*RBI?5X1V$(:AG9[L+<@_?D8^I
M/:^XY#DECS"B+<B-X %4'+P#:V=E1X6:LE>>B*(N!&=_7DDK.R[9 >QA+*6M
MG?AX;%/<RA51W->\Q?7-'73C9[E*K:BXW(T$9V\+]/' IIR55:*XP7G+68Y7
M8R5?HC2PMVE<\V%@!3V%9Z*5::*XUWD+.H:,\)C\'2T/#\FXHLNHU[&2GL(U
MT<HV4=SK%$UU &O\PV"X0*][8<4ZA5>BE5FBN-.YEP'D:[R0*>:6CHATV66[
MY[FNE>\4=HE6?HGB1N<YTN #Y8Q0]LOT5S(10:X@DU9(7,F725),)3+X9@4]
MA5%BE5%BN)4!.Q]&Z9Q,ULE4QC:^(P)?AA^?K)L$IW!#K')##+<NNXR1N]=@
MP=.Y..AXCP@]#B:W ^NJ&@]L2ECY'U;+__BY4F9=MEF,%:F$62.W;B0=4?QJ
MW7[R\:BFG)778;6\SBC50FWV'<T"F^_ K9RXXB'.4Y@<5ID<5LODF 4H+%!@
MXI]+91UPCN@\RK3-@T" #(B$&T$K[RG,#JO,#JME=B8)CV-RDV?P.K.WVF:[
M0GA84[S*XK!:%N<N$6IN>N7OH  6&Z:#)4_M><4%#^Z:X'%-02N'PW"#LLOC
M0D >,;R&FT)X7%.\RNFP6OM"^],X&/-BKYY\S#7XUM1,H%;B'^1AMO6P4>L6
M:N: Z*5/&6/N1:<'R_,7&V1E=QAN4@:)2,-B>V\8<SL++G X>Z>P-UYE;[PC
M.S6[;<MAE!G'^E5P18;PT#K2'!%C+F/6$X-36!VOLCH>[E#>,FYWH@]3XG*?
MK'O/>%!3QLKL>/7,#F J0!REH7@E?PCK0'-$RG5=VG7I^:5U784'-^7<.^S"
MK<G.S>TW5^Q(X8A<NTU9VZ-6T!_J=IR]0U SXQ5GPQD)S#[KYCRT?%J>/P^*
M4U>G^GQS>/W S829D5C,(-1]=P$CGMJ<!V]NM%P61ZI3J;5,BLN%X*%0Y@-X
M/Y-2[V[,/RA/Y?O_ U!+ P04    " !N@J161BCQR1T&  #*&   &    'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;*U9;5/;.!#^*YJTTVEG I'DUU#(# 5Z
M[0RE3$.OGX6C$$]M*Y5D*/?K;^48.XYDA][QH8V=[*Z>E59ZGA7'#T+^5"O.
M-?J=9X4Z&:VT7A]-)BI9\9RI0['F!?RR%#)G&E[EW42M)6>+RBG/)A3C<)*S
MM!C-CJOOKN7L6)0Z2PM^+9$J\YS)QP\\$P\G(S)Z^N);>K?2YHO)['C-[OB<
MZ^_K:PEODR;*(LUYH5)1(,F7)Z-3<G3F8>-06?R=\@>U]8Q,*K="_#0OGQ<G
M(VP0\8PGVH1@\''/SWB6F4B XU<==-2,:1RWGY^B?ZR2AV1NF>)G(ON1+O3J
M9!2/T((O69GI;^+A$Z\3"DR\1&2J^A\]U+9XA))2:9'7SH @3XO-)_M=3\26
M _%['&CM0)_KX-4.7I7H!EF5UCG3;'8LQ0.2QAJBF8=J;BIOR"8MS#+.M81?
M4_#3L[.O5^<75_.+<P1/\Z^7G\]/;^#EP^GEZ=79!9I_NKBXF:,#]'U^CMZ^
M?H=>H[1 -RM1*E8LU/%$ P83:9+4XWW8C$=[QOO"Y"'RR!A13#V'^]FP^SE/
M&G?:=9] YDWZM$F?5O&\OO1+*7FA$5.*:W7DRF<3P'<',+OL2*U9PD]&L(T4
ME_=\-'OSBH3XO2N[%PK6R=5K<O6&HL_.F%HA6#64F ?^JTSO60;).U=Q$RJL
M0IFCX'XV]7P<'D_NM].QK0@E$8D;LPY0OP'J#P+]!JDSF6S +O@]G#7KW*Q2
M6B3P =L>#I"$ _S;C+O ;\('6[#"(-Z!;ML0$E W\* !'@P"OY9\S=(%XK_A
ME%5<50D(O>(2MO)VH;E !Q8@GUBH;:,@QI$;==B@#@=1WPC-LF< #*VQIS&E
M= >A;45H'$8]&*,&8[1G9H&XI'ZL9M24;E408U1P[8(:.:#NUJYM0PCVW3#C
M!F8\"/,O(18/:9:Y,,7V>)$7D!U4^ZPZL*8-K.GPAC)<=B"6!Z7B PL\M;=-
M[/L[ &VCB-*I&Q_!+0OA081?JTW2#ZUV[\P+QKNUY[*B-.@!MT61Y!D;9  <
M<0SK^SC8A>>P"X)@JS*[ %L2(\]CL2QEMVF6ZI2[J8R\*)>]5+1NTBV;D6$Z
M.TT240)[H35[[".".D3GO)Q.K;*QK:*H[\0B+8N181H#@++D+1LX ;IH* HM
MA XSBKV>TXJT?$6&">NI<-9"5J):+%'&010WE?3H!&VS$("VJMUE->V1!J0E
M*S+,5B[(HK@[T%SF(!9NG7Q ;%8*@MV3S6%$/-)W>K3,18:IJTNO6UO4"=3!
M2E,_]G:AVF:4>K2O'EKZ(L/\==F9R8I>S00O4E7MM8UZ["Z ,PN;Q3P2TV@W
M"X<9]?HXF+1L1X;I[K)3PGTS;1.9YT461(=5B#TW0MK2'1VFNQ],2K95#8_H
M[970'/GOG!V(@]:BT#K&'&;4@PKN =O2'QVFOPTW[YE.:G.;%^!=A X"C/HF
M<ZN%&R2:>H/MPT<=NB7:$BXU0MLL)H'7<PC0EJSHGMY+Y'FJC6;=- 6)@#ZF
MN.-% GCKQ9^Z%W\PL)MED;/U_/^!NLFW1$C]07DRUR+YN1+9@DOUYE4,'>+[
M2L/K1W?#/4BK?]QQOU"T;NXMP](]# L+#RRES!2,T6M\B#$!Q2(1]-XE'Z,
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M* Y@]?D\JB<3JB<3*L&M ^!7Y"')!"I?[&F4+<@9*):\QP6(& C(XBTPX1E
M!H(RAI78HL*^*];1@ESV> DM2/Y(>L-??X&.\;N,]RV878*)ZOHX1!Y$KF.[
M%_W'?69U1L4ZP4)-8 TFS9I)\S0FCV)PB^GL)=VQ+(B:&?>[5LAKD=(U,2W7
M=*VF&>Z:G4,X:!J%$B/D(<^%M5TC0U:=(:MT- ]D:)PM^)N\(+R<D6WKC:AA
M92E9TC0F><$KWK=-PGZ +U.:IH"_"9^B/)8MVBM+Y]S7"1;H!,,ZP4)-8 WV
M[9I]6[D^MF^,<5%L>"D--KE8*;<D3VA\!F9ER3L#-WQ;55I(WV=*_%,9M[O5
MSH9H8+267J S*-8)%FH":Y#IU&0Z/TWFIRC=D)>X=#KIMSUDM,J>TZUI+79D
M,+#UOL+*H9R:=4U@C:R[==9=9=:GI.![FP7C.2\)>%XXST3<\&,5O7^^R<]0
M8!Y]!Y\3MA3E56Q=9%0H8YZZK-P.(=#Q.I0$.F-BG6"A)K &OU[-KW<BO]5:
MDM)\#+=>AX[SSN9"V:=3WWU'!,0Z X::P!I\#6J^!C]9!9\9^QSE>92Q N#O
M)%\D!8EE+"FCG+H"!]T5:+0*:Z S(-8)%FH":] )C=W)WE 2.KH=^]5J.[_B
M^].8GQY_K,3Q<21X?""B?0;JC:PHL3XM&)B2!7W(RA.M]"1N=$FQ[-:VVU=W
M[M25>%1,K#5FJ NM2=^>, .5](G"F-)"+H; ;F5"<.#8;1*4(4XF02<:UHH6
MOIR1)@T[20.J-0V<Q0<$C>LHKX_#2,J25D4#=B4-T_",@>4ZK8*H-2[6BA;J
M0FNRN9,UH%K7:+)Y'(MF)^_6P(56>ZE)- O8)J8+9=J68WKM.M:UDP@;,BO3
ML#S3.3#G=](&5)Z=C]?QY G3*F94:(W*CZ#CN,AN;P2T!L9:T4)=:$U&=W(%
M5.L5+^IY<B:[NH)K&39L3WV[,_4A:DL/$BS+-ES/:<_]KIUL[DNL3-=Q]Y92
M,U,[+0 Z_Z.N!W4>UWVM:(%6-*P5+=2%UIP$.VD"JK6)?R_OJ0.<3'Q7B; M
M [5?'('6J%@K6J@+K4GI3HV :CGB/SL-=44"Z%B=C;A67>*HF%AKS% 76I.^
MG3@!U>J$\C3450G.$5\>;056'>)D$K3J#EK1PI<STOS_[DY30&I-X;C3D"G]
M]Z[.P[F/)(( 0LAP+:]=%+4&QEK10EUH33IW&@-2:PSJXY"<1MC9[-G0:9]!
M?8E9=T\H,;)L9+7/35AB)]D3RJPLPW#M]IZPO_>YC/A\BH^9[XX+D))[[FF\
M=?FLRK=?)&TO&%V77]#<4<;HJFPN2<2W@L* /[^GE#U?B(]RZN_"AO\ 4$L#
M!!0    ( &Z"I%;3^"!)+P<  #H=   8    >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&ULK5E;;]LV%/XKA%<,+1#7(B7YDB4&4CM!"S07U.GV,.R!ENB8JR2Z
M).W$^_4[I&3+EB@EV?*22/(A]9T+S_=1/'L4\H=:,J;14YIDZKRSU'IUVNNI
M:,E2JCZ*%<O@EX60*=5P*Q]Z:B49C>V@-.D1S^OW4LJSSOC,/KN3XS.QU@G/
MV)U$:IVF5&X_L40\GG=P9_?@&W]8:O.@-SY;T0<V8_K[ZD["76\_2\Q3EBDN
M,B39XKQS@4^GOF\&6(O?.7M4!]?(N#(7XH>Y^1*?=SR#B"4LTF8*"O\V;,*2
MQ,P$.'X6DW;V[S0##Z]WLU]9Y\&9.55L(I(_>*R7YYUA!\5L0=>)_B8>/[/"
MH=#,%XE$V;_HL;#U.BA:*RW28C @2'F6_Z=/12 .!F"_80 I!I#J@+!A@%\,
M\*L#@H8!03$@L)')7;%QF%)-QV=2/")IK&$V<V&#:4>#^SPS>9]I";]R&*?'
MD]N;Z>7-['**X&IV^_7+].(>;F;W\._Z\N9^AFZOT.1B]AE=?;W]8X:ZZ/ML
MBMZ_^X#>(9ZA^Z58*YK%ZJRG 8V9LQ<5;Y[D;R8-;_;1M<CT4J'++&;Q\?@>
M>+%WA>Q<F9#6":^I_(A\?(*(1WP'GNG+AY,6./X^LKZ=SV^*+%5+M(!UI=!"
MBA3!4I54\^PAKW6N.5.GKK#ETP;N:4T?.%4K&K'S#BQTQ>2&=<:__H+[WF\N
MG]]HLJ,(!/L(!&VSCV^@;25".6LC']FW(TUOVHR[)/"(=];;',)WF>%1/]R;
M'0$+]\#"UM1<Q'_#RH+NI172 MI7)+*()PQE!6+SU%Q')H=KQ6)3ZR].8/B6
M"7RCR8[BU-_'J=^:P)D6T8^N::LQBD0*7*.H[=;LR5PSE_/YC.%!QG _""MI
M=1@%X<B=U,$>[* 5[)1!!"*> X26A&@JI.;_/(MX4 =#!A7 #AO?=^,=[O$.
MVU>'R+JVOA(& 6X#.*R]W!]6(^JPZ??= $=[@*-6@!=1))D-GE@ E<XUBKF*
MQ#K3+I"C&@!"JB#K-G@T=(/$7DE@7BO,R9)F#\PLT 7E$FUHLF8&\2.5DF:P
MGCF=\X3KK9.BO!JD;ACXHPIPAYG7@/N >'$K[EN]9-*)"3LPX2HBAQ$F3:!(
M"8JTDY8-IJJT.Z48=$JSIG;!;&I]Q?1OU/O>:K;C8)0$CEO9<7PGV8KR>+<T
MU0D2)F<@RZ0$[CB,BWD]E='2WL1L WIZ9?@% AG!/Y"VAF48W]!YXESC!92C
M]>,-@VK6ZU:XW]2(<,G3N)VH8:6;9:W0BFX; 0:.@AO@&D*'V0 W(2P)&[?R
MG.U%:U:FPHDPK+TZ&/6K^.I&W=%!G(_QE42)VYGRJ^WA!ZO#";!.>UT25B6/
MT\IOZ.6X9$?<3H\W+Y$S3M1U[NN2?HA)%;?+#J1T ZWCDB?Q\%5"FF<;IEZB
MPW K ;^Z&;W1;,=1*,D8/\?&/]=<\1T?KZ3)G][:AL/@)]MNG%&HLVZWQF\.
M&T+<B2,E,Y-V9JZ5G"MS+LC$P<I5R"Z;1L@E*1/\JEI;\(S"UN#Y6B.M9/_:
M6GNKV8ZC4*H TDJLX\MTE8@M8TC3)V98@1N&2ZB&-!8[([6DDB'@/YTP2W10
MDR:YS'*AECPRE\IL(- ZX]J=9](BJXI(U$VZN"G-);.3=F:_8CNWP!T*^&/K
M0R)HOG50##B>F]7U(%GNGWG,E5I#.3#8#"E@RX.0@"Y BB:'PM/M<9W N_ZP
M*NY<5A@WD!0I:9ZTT_PWD#/;?-<+,&?&1T _!67OA.HB?-^K)<A%^*.&#3HI
M"9^T$_Z=%!%C<;$,=Z&U56?1PW8TA4YH"^S$)@=60G>Q-M^2]ADXL:4*UI7$
MO<<?'!Y_>@;2G_@O9YS>=+M/ZOHD' X&#>$L]0EIUR=WN\0OA$10!VO0JD:Q
M0&PF>23M7M\9E?:9FZ+B4#%!X%>+IW7N_]KG2DU$7JB)WA<,]<'PZH:;&IIO
MG<W?Z:M+^6!2E<8.LV 4-@@[4LHCTOX=X7*Q8)&M<O84Y7MAT'50ZL56#G)K
M?#S)/352 ;;(MA:*C<NN69O?G>[5ORW41*O#IMMO4'ZDU#RD7?.8_,0LDE9<
M\__MATOD#,-1]2N%RPZ'?K^A__JE'O*?^5+Q8OB(:C1G#SS+3/49N<<D%['+
M*[^N@S#Q/3*L>.6P&_K8:_C\XI>*R6__C/$ZIX!IGW$'U[[XCJ!O5!N'PZP_
M& 1-*3+*Y_C)P5?\=JD _0WH EU!WS0DKY<@"%!J3BX*+XQ/X.&UW?[OCA].
MS,8_6<=69FQW JE9/TQ9Q-(YD_;P :W6\X1'S[!>$^FY.F/OX( H9?+!'K0I
M9'?]^??\_=/]8=XG>X15>3[!IU/L>'[AD].)[QH!\85?[.E6KWQU?JH(,8,:
M5RAA"X#A?1Q =<K\H"Z_T6)ECZ[F0FN1VLLEHS&3Q@!^7PBA=S?F!?OCTO&_
M4$L#!!0    ( &Z"I%9I7CHOA (  $$%   8    >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL?51A;YLP$/TK)U9MK5050M)NZA*D)! 5M0D9I)VF:1\<N 14
ML*EMFO;?SP;",BG-%WSGN_?\[O!YN&/\6:2($MZ*G(J1D4I9WIJFB%,LB+AB
M)5(5V3!>$*E<OC5%R9$D-:C(3=NR;LR"9-1PAO7>DCM#5LD\H[CD(*JB(/Q]
M@CG;C8R>L=\(LVTJ]8;I#$NRQ0CE8[GDRC,[EB0KD(J,4>"X&1GCWNUDH//K
MA*<,=^+ !EW)FK%G[?C)R+"T(,PQEIJ!J.45IYCGFDC)>&DYC>Y(#3RT]^RS
MNG95RYH(G++\9Y;(=&1\,R#!#:ER&;+=';;U7&N^F.6B_L*NS;4,B"LA6=&"
ME8(BH\U*WMH^' !L^P. W0+L6G=S4*W2)9(X0\YVP'6V8M-&76J-5N(RJG]*
M)+F*9@HGG6FP<+U%Y+F@K"AX\-WQ2CG12BUS;[&*()CIT),7KOS)@P?+T)MY
M85CG!-/[2U"FY\W'.C8-YO-@T01@O&A3[H('UPNC+^#]>/17O^#<]6;^U%]=
MP/F2<*0R19G%)+^ ,\@HK%)6"4(3,32E*E#+-..VF$E3C/U!,7V8,T4GP*,)
M)O_C3=68KCOVOCL3^R2AB_$5]'N78%NV#8^1"^=G%R=X^UW7^S5O_P/>2!*)
MZFI+8!N()(N?4Y8GR(5JTDN5R7?X/5X+R=6=_7.L#0W[X#B[GN-;49(81X8:
M5('\%0WG\Z?>C?7]A/9!IWUPBMWQA:@(C1%B)N31GW02?UP='!-F'ESK OFV
M'EZASJVH;&YXM]N]#^-F+/ZE-X_+G/!M1@7DN%%0Z^KKM0&\&=C&D:RLAV3-
MI!JYVDS5&X=<)ZCXAC&Y=_0!W:OI_ 502P,$%     @ ;H*D5M"8GP9M#P
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M,6>@:F/('>+[<^W06&SFGN,QT:;OX,+,$$&\2K$C@#NK,NT4N[9&KA-6U+J
M$H@FRM"$S-HQXL&@2.-GV+N8IF-6^T[BT'>)/0C#@@4B@#S3R]-(I[&IA)K
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MXYT@_2XQMVJ'- K0)APHI\YQ;FT+DZL-.QMZA(RHTQR*^'D7%AF!'74Y&70
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M91P^BI*\XH>=O>:(SH67 #@/LSF#8N,Y[4NRTD<_,4B]1&['10Z)HV6,%4C
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M9<Z=.#?J#YG[Y4GO]Q[+Q8+7RM^8]=]%\N>(]&5&N?"?K=/>48]EM?.F3,)
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M;J90S6F3^F1-X*1>&97:(\WGU!9U8?;.N^%]7(9$XLX9A-6GZ@U./$GX+@X
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MJO8#O5:6UH,W"]K'J%T"G>=*V8/C"K0;?OH74$L#!!0    ( &Z"I%8!!+M
M@@D  -07   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;)U8:V\;-Q;]
M*X3J%#8PD?6T%<<VX,1;)$'2#9IT@\5B/U SE,260TY)CA_]]7ONY<Q(LB0W
M72"1YW'?CW,OY_+>^=_#2JDH'DICPU5O%6-U<7H:\I4J9>B[2EF\63A?RHA;
MOSP-E5>R8*;2G(X&@[/34FK;N[[D9Y_]]:6KH]%6??8BU&4I_>,;9=S]56_8
M:Q_\HI>K2 ].KR\KN51?5/RU^NQQ=]I)*72I;-#."J\65[V;X<6;"=$SP;^T
MN@\;UX(\F3OW.]V\+ZYZ S)(&95'DB#QYTZ]5<:0()CQ1R.SUZDDQLWK5OI/
M[#M\F<N@WCKS31=Q==6;]42A%K(V\1=W_TXU_DQ)7NY,X%]QGVA'YSV1UR&Z
MLF&&!:6VZ:]\:.*PP3 ;'& 8-0PCMCLI8BMO9937E][="T_4D$87["ISPSAM
M*2E?HL=;#;YX_='9Y<NORI?B5LWCY6F$3'ISFC?\;Q+_Z #_6'QR-JZ"^(<M
M5+'-?PI;.H-&K4%O1L\*_"1]7XR'F1@-1N-GY(T[!\<L;WQ 'KDE;G7(C0NU
M5^(_-_,0/8KAO_N<3;(F^V51@UR$2N;JJH<.",K?J=[UCS\,SP:OG[%TTEDZ
M>4[Z=Z3B6?[]UK'02$(+"D3NT$XAJD*XA8@K)1;.H"^U75Z(8VWQR-5!VB*<
M""0B7W$F;E6NRKGR?//9:YOK2AHA2U?;2(+,MI(C,1YET\%@?<%)*) $XLB$
M5<PF\]PK[LWC\[/S$W$\?'5V(M[696TD]>H& :B534:3FDH^ AAB$&>3F1AF
MX^%4?-QCPW@VI(MQ=C9\)3ZJ$"[04MZ#4U3.L^ C<3R=3D[H+\LY>2*H,W:7
M$=&8C<X;38.)>*=\7AL5($%:<;/T2I&1F;@)X@97Z _QWHI_YM%1,$>#X2SC
M'+QU927M(SR$6A!I&YV020QR(;XH*-?Q<2U3'!/?CS_,1J/!ZP-Z^>WP]4DF
M9$"NDO[2A0@LS?'>/$*1^"!M#3#F;LN /7'5^9&)&CQ>W*\T"F'3T!4DSIU'
M?4,D&;F$TJ6,B@)U-![UIX J8YK$<2P-; L"?A5$YA57J(TH/)8,1--E7392
M\33TQ9ONNC&$" \XRZ52X['F&,))B7_B3GHMYP8*2:OZHT;9P@82!$X\\V3@
ML3X1PT%_.'TAG,<=;K^"XILT1J#!:#1^<+6W8*X\)E*25IDZB#%Q]2FML$;=
MJ=0/S53@Y*'@M<',0PC3>QV$==PRT(Y^1 QJ.)E*H3.?5<BJ,CIG!V#U.C:8
M=+4IQ)SHT2$82KAY%)/^X,7?#9OG9,A'5H)Z* G-N322(2^=Q5W7;W'E7;U<
MH22KF# !A3/)V%-PIPBW,CHNA*1:PP9(4[:*M;L+[\JN,Q+X3YK0I?*(J0.*
MILCH(9640(G=0+9IF,Y>0Y.[TZCU3*Q0GW?*9T*C?96/6%$HX(6F!@[L>ZE2
MEC:K6^8K#;[0\6 #0CK TUB_T%;"&?)4(Z;166J673OOT0.4)/404_<AB1]J
M!";9>M[G,FO5EA(1XUP(%%XFYG5$H40!#11W:C-ZW#B/_2I$&$,-M"Z,#(4V
M_PT+CV $2>(XT;@L-1H,[&.422NFVD'S#;DRM&1MV#MYJ>2+%,KLV1)K\A$P
M:OQ621P-^K,.)RBN1\/^N'O0UB0N-V(V9L*MC&>P*E2*MSOSF#5PU2FB+*/<
ML 922Z$?*V<;U[O@-%YN-%A'U62'P'1X_CJ(;IV$,TS4]OI&4?X?/8@USA <
M2:/_3,V,1%(B(LK,<$6T&IY:A.(,+F$3%2J*CT+D0.J1P: 0 _60HU\Y 3HF
MC#3D1[W)=4P%AVHP-2??TSK+B-U&B<2".E>J"*EAR9P@C<H$8(H6=?!!!P9]
MY8)N!W>+:SLJ3_KBU[^*3K8S>"2]XEZ2BX6FQ9Q7!1AG:0;13>Z M(@=ALCG
MVH<:ERWL?Y<:0+0'E&F?]-#9)H&'#"N".>K%/$_]XMM+BFM3?)T2MA=XX0/U
M@7:,#:$=YRWZ9:W,;HPVS=C.*.[^H]&@/VC; Y%K*_2GVYNN%C PT&VRJQ5*
M#H<&!Z[?%4];O"GE'2QYD%0/])\H(ZGB-'/&H^;FX7W@V[OWGT1XM 52KM(C
M*8R<*R-R(S65@>2QME26*ACEVJZ9$,?T3!%H<E")[2WCGW& N_7U$LW-0X^K
M9Z%--QJ[C!B ,R;J2B9TQ:,Z3XDZ&FZ%Z$;,X17R0;LFTMH$I:N.[^C-G <M
MDD0M3EGJ^GW-FUJ^RX?+TZJ8JZ1W=RW89A4+F<--U,.3[8L)%-,F,QA[>(=2
M"#SAFFEQ.VP"-P\\.)SQUH#F*TM5:%02,E/4J2!:>.7AAP4-(RTF@;DK2QV;
M<>^:X246M6=$P;H!T ?\<RS)!OI/4W/7CI3V)XU5VW:?8?S-UJ%/3C8(@V9
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MW/HL!FS6N%<$&6)BECLL8 DP\ 0>XQNTN5_@T-15K$1C TA 'V&(L4Z)6\3
M31_5F GJ!Z-2_<YI$RD+ ,:^H#013NIB_KEF>VSK%#FW2!C#!0*OL6[%!&A6
M%"C1Y\EDR4&%T;'+7"+(+N-6UO/QA1]6,*X?G>*>5<[<Z&5NPUM-$YB2_62]
M#N@/<BU=*L\T^XV95I*LAPTRJ92++;!^WARA762.$J(> B:!Y80&5^!6AT5X
M\M;H(NU8H%'@$$-\G-F6.[FCU7%J+T@E^6X&)T/Q&RVQ]]991<2%V[6B'7'+
M5%"I ^< 0@LRQ5A8RLM*"<VK[H!E#:;3'"4!C(@,]ZXB'1W?6.DQ@G8=1&H+
MCAKKV-2.A!,W>XRB-DM*-0.C+=).K]QT.M&ZK2DG@9"I2FL0)7K+' ASK\RE
M@]='!HXC@2<Z]?9/K%Q=0L90XB!&'KCJEQ$IXD,R%27:#VA(W4\IQL(1,0>J
M?Q/9EAL]-)SQE,].T^PH2[DGFD1DRF3SE,GAKFO3J'?IK<@MT]6>U05(^?[;
MC79?#V?YTORT/']Z0%]+/L<-+;!U//QP.! N7^?S2[!-ND+/;<"%/#V6^ (B
MQPLPO[#(1/O"#KIOJNE_4$L#!!0    ( &Z"I%9V [)DHP4  &8-   9
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MLA!.D"[WH-\:G(RDQ6 *R#C!3^I@43J"=^P(#I6E6/9!,NIP.^_'VT*FK<&
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M@-26<40- <H35PT%F O4B^T-W$6U@:6;@3Y% ?4)J!4PDK4BARBA7A'R#9G
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M=!#P"S-7D(U'D"9I-H"7=5'( E[V EZ?NW^MM]89JIJ_^QQN\";]>+Z3YO;
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M13:I4[BUAGCEZ)=C $]"UZ4VACE3,>#/G)-FH\%&R3]/188[*GGY3"UZF9-
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M5\K2BO!F03L9M4N@][E2=N^X [HM/_\+4$L#!!0    ( &Z"I%:N;//HS0,
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M!*$T O1_(X0^+(R![EFU_ ]02P,$%     @ ;H*D5K8/:0&- P  G @  !D
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M<BQ_8X:METKN05EO0K.&*]5%$SDN[*7<&46[G.+,^C-221HF]VQ3HSY;AH9
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ML2'9UQU^ 7!I +B^$4(?!L; ^$TQ_P]02P,$%     @ ;H*D5B9;LS6$!0
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M5/>OJJ/XPEXPIESIZXIMYOK*BH4)T.]GG*MUQ]Q9FDMP^A]02P,$%     @
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M?V0=AHJ"8!L8! \)9_^A8331@U4$!,T(5$PQ\"]H#$-FY<9]U08.0<5#\)Q
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M*Q>6#/RHF7886X-U'09@J=F-4]ANW/M%QCNX^Y76O#?\3/4O8OX74$L#!!0
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MH*F^G".8(*8,Y/,II6)[HUY0GGJ/_P%02P,$%     @ ;H*D5D(/AGO- P
MYA,  !D   !X;"]W;W)K<VAE971S+W-H965T,SDN>&ULM5A=CYLX%/TK%JU6
MK30=,"0DF4TBM9E66VFZBIKM[D/5!P_<)%8!4]LDT_WU:P,#<<)X-A5Y2?BX
M]W#N\;&Y>+IG_+O8 DCTD":9F#E;*?,;UQ71%E(BKED.F;JS9CPE4IWRC2MR
M#B0ND]+$]3TO=%-",V<^+:\M^7S*"IG0#)8<B2)-"?_Y#A*VGSG8>;SPF6ZV
M4E]PY].<;& %\DN^Y.K,;5!BFD(F*,L0A_7,>8MO%KZG$\J(ORGLQ<$QTJ7<
M,_9=GWR,9XZG&4$"D=001/WM8 %)HI$4CQ\UJ-,\4R<>'C^B?RB+5\7<$P$+
MEOQ#8[F=.6,'Q; F12(_L_T?4!<TU'@12T3YB_9UK.>@J!"2I76R8I#2K/HG
M#[40!PEX\$2"7R?X_S<AJ!."LM"*65G6+9%D/N5LC[B.5FCZH-2FS%;5T$P/
MXTIR=9>J/#E?<N4(+G\BDL7H_8^"YFJ,Y!7Z4SGH#5HIU\1% HBMD2WRU2U(
M0I/7*N7+ZA:]>OD:O40T0W]M62%4O)BZ4I'5CW2CFMB[BIC_!+%/A%^C %\A
MW_.#CO2%/?T6HB;=-]-=)5&CD]_HY)=XP3,Z7:%E0C)IBH"^WJEP]%%"*KYU
ME5IA#[JQ]4R]$3F)8.:HJ2B [\"9__8"A][O787W!&;($#0R!#9TTR[0FF##
MF>@<Y HN+.'TDK*;^\$ 3]W=845=08'?!!E,!PW3@97I'0AQ@]Y&49$6"9$0
MJ\FM!(DHJ98/Q9^DC$OZ;WFABWOU@.$!K3<X& Z/R'=%^?ZXF_VP83_\)9TS
MD%U,AR<<)N/PB.=I#,;>H)MFV- ,GQ%9K:!;EL2(ICEG.] L.WU@Q3EW!O0$
M9I0\:DH>77 A&/4I0T]@A@SC1H9QOPO!^,1^AY.D*L@>8_"<-#PG5IX?"IY1
M67 HB:[I@S[N)&C%.7=H>@(S2L9>^T[W+NC1&KPG)?I",Z4X:&]POSZM\8QU
MTA\-CIS:&14^X57<-AG8^O*>+UB:%Q)XR[238J_M1%]H9LEM0X&#2WK5VJZ<
M+45/:*84;<>"[2W+^5X][3WP*#BVJCW(Y-KV)]C>H*S86NX)ATY:UM2S!Z4G
M-+/0ML/!X27]V6O?TQ>:*47;^6!K1_$+_AR=OM!/5E)KC,FT;4ZPO3NY(_?/
M+*'6_+/'I2<TL]JVQ<&32UJTU\:G+S3S([WM?'QK.W&^16N\PV_/<. ?>;0K
M*)@<F=0]V(31.V"?"-_03* $UBK+NQXIB_-J4ZDZD2PO]V7NF90L+0^W0&+@
M.D#=7S,F'T_T5D^SM3?_#U!+ P04    " !N@J16BI3=;7,"  #<!0  &0
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MTF!SNV6)XQ>4#<#O:RG-?F,OZ 9Z]AM02P,$%     @ ;H*D5C9[N-GK @
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M)@#'4R'T2\?<.^UGQN0O4$L#!!0    ( &Z"I%:&WHVLZ0(  (8(   9
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M^@)U?L&YW._H!NJ%O-/_ %!+ P04    " !N@J169,9^V)\"  !\!@  &0
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M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6R=55M/VS 4_BM'&9I
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M :79:!2&D[)1;;##<K!#ZV"_D$QN2%[LK+9A6LV[#M.E6.1(K(9M5&(;O55
M&KD$ZE(L<B16 SHN@8ZMZW"YXQRH1&RU2F- IB.T4\<G+R(4(FL.D.LFWVT'
MW\+:35>\A=C@>%L&0?!B6SKJL89M4F*;_! VG0XB?=6&Q"K1%<FD$81Z#2*.
M.JP1P4&5Y056)H<]*8'G:CFA6*5B7*7<Z.P)"!?OVPC9%;LB>L6_ 3*.M.U
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M/E?GQ<E[T9 LR\]Q7YB4+,DO-P1'A.L ]7S%F#PT=(+J]X_%#U!+ P04
M" !N@J16#+-O:5P.  !@X0  &0   'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6R]W5UOVT8"A>&_0GB+10IT99$22:F;&,B:\U6T2="DVXO%7C R8PN11:](
MQPW0'[_41SP:B9Z0P:OFHK43SD,I/J'&/)KQ\X=R];&Z*8HZ^.-VL:Q>G-W4
M]=V/Y^?5[*:XS:M!>5<LFS_Y4*YN\[KY='5]7MVMBOQJ,^AV<1X-A\GY;3Y?
MGET\W_S>F]7%\_*^7LR7Q9M54-W?WN:KS_\J%N7#B[/P[,MO_#J_OJG7OW%^
M\?PNOR[>%O5O=V]6S6?GC\K5_+985O-R&:R*#R_.7H8_FLEP/6!SQ+_GQ4.U
M]W&P?BKOR_+C^A-S]>)LN'Y$Q:*8U6LB;_[WJ;@L%HNUU#R._^W0L\=SK@?N
M?_Q%EYLGWSR9]WE57):+W^=7]<V+L\E9<%5\R.\7]:_E@RYV3RA>>[-R46W^
M&SSLCAV>!;/[JBYO=X.;1W [7V[_G_^Q^XO8&Q".GQ@0[09$70>,=@-&70>,
M=P/&70?$NP%QUP');D#2=4"Z&Y!V'3#9#9AT'3#=#9ANXK#]^FV^^%E>YQ?/
M5^5#L%H?W6CK#S8)VHQNON;SY3KL;^M5\Z?S9EQ]<5G>WC:9>UN7LX_![_EJ
ME2_K*OA'\'8;_J#\$+R^KZLZ7U[-E]?VB+H,WMRO9C=-SH*W-_FJJ-:'.MJS
MK*CS^>+[1OOM;18\^^[[X+O@/*BV1\^7P6_+>5W]T/QF\_&[F_*^:DY2/3^O
MFZ>U?G#GL]U3^-?V*41//(5?\M4@&(4_!-$P&K4,O_0/SXK9(!A.-\.CEN&9
M?_A/]XMF>/+D<-'AP0]'3PZ7_N&ORD^/#SYL&:XZG#T:/3E<=SE[M!D^;!EN
M.@R/-@\^G+K#SYL8/V8Y>LQRM/%&3V5YD5>;&.Y2&I2K8'/U#O[S<W-H8.KB
MMOIO6\"V[KC=7;_>_%C=Y;/BQ5GS@E(5JT_%V<7?_Q8FPW^VQ8W$,A(3)"9)
M3)&8)C$#84Z@1X^!'OGTBU?WM^^+U3K13UQB357=Y^\71?"LN81N+ZS?M^5[
M>YIX<YKU].?311B&DS1,X^:?[:?]\'H?4-_PDI@@,4EBBL0TB1D(<\([?@SO
MV!O>[=7XM;T:O]Y=C0?!R^OK57&=UT7P9E7.BN*J"N2JO+6SBW6NBZNV)'O/
MV?=*O<62O7\6S3^(@W\1V?%!X?CH*-%VU.%!LN6@X?#P*'5\U'@4N\=H\J_!
M')\P"O<?EO/ECQ^__'&'+W_+B_$/P<NKJ_GZ.YU\$8@_BM5L7JV#,)\5>X=7
MC\>WS@B]Y^X; Q++MEBZ]Y<Y' R'X4%<MD=-W*,.#I+DXU(DIKL\?/.UOPDG
M5LECK!)OK.3]\JK]RN =US<2)):1F" Q26**Q#2)&0AS IL^!C8]T3<E*1EH
M$LM(3)"8)#%%8IK$#(0Y@9X\!GKBO0(?O&0_NZ^N@KOFNY3-MQ^MWWUXO;Y!
M)K%L<O02%0Z&T_'!B_7DZ-4N'*33@Q?KXX/&@VEZ,+4[/F@R2 XD33Y#T_(,
MP\%T.FU_%9X^9F#JS<#F^\YE\]5_O0Q>S^IR_5UJ%&]NY"1M"?!J?1- 8AF)
M"1*3)*9(3).8@3 GQN'0WOT>GNC5>0=#F4:U#-4$JDE44ZBF4<U0FAOMO6(G
MA%^G=Z#S0C<=I).#6X3^\_;.*JD)5).HIE!-HYJA-#>KMK@)O;?1O?.)X,_@
MY^(ZGWU^O#74FEVTPD&U#-4$JDE44ZBF4<U0FAMQ6^6$HU/--,A*X!+5,E03
MJ"913:&:1C5#:6ZT;=$3^IL>K*;<G6>_IXS#.#Z<?Y#E1X9J M4DJBE4TZAF
M*,U-L.VJ0G]9M3__R(I9L<ES--E,0-+F-XO6M*(E%*IEJ"903:*:0C6-:H;2
MW%3;JBQ,3C7E0,LT5,M03:":1#6%:AK5#*6YT;:E6NBM.+[EYD;:[>8&6I2A
MFD UB6H*U32J&4ISLVK[LM!?F'UU<M'Q#@=:HZ%:AFH"U22J*533J&8HS<VY
M[03#Z:FF&V@_B&H9J@E4DZBF4$VCFJ$T=UV!K0DC;U?#W>'8G<=])W8\7;?F
MSC3$_WAZ+R) ^T!4DZBF4$VCFJ$T-\.V#XS\?>#^-.1M<5=OYR'A9O5..'GJ
M)H<?[7MI1K4,U02J2513J*91S5":&VM;'48G6_3%KOIBEWVQZ[[8A5_LRB]V
MZ1>[]NL4E6%D*\/(O_RK_TV.'?BUFQS^\_;.*MH!HII$-85J&M4,I;E9M1U@
MY.\ OSZ[Z':7PW^:WA=EM"I$-8%J$M44JFE4,Y3F!MU6A5%\JOD&VA>B6H9J
M M4DJBE4TZAF*,V-MNT+(__:.NXN1W)TEV.]O<7A6G/_P^D=8;071#6):@K5
M-*H92G,C;'O!R-\+MKV1--SN,#)I32JZR [5,E03J"913:&:1C5#:6Z@;7D8
M34XUW4#[0E3+4$V@FD0UA6H:U0REN=&V?6'D7T3X#;<WIMUN;Z %(*H)5).H
MIE!-HYJA-'<?)EL COP%H&]>T>W&AO\$?2_'J):AFD UB6H*U32J&4IS(V[[
MP5%XHIG&".T(42U#-8%J$M44JFE4,Y3F1MMVA"/_\D)N'[VHY<;&\.C=&_Z'
MTSO":!>(:A+5%*II5#.4YD9X;R=(?Q>X/P'Y)5_-;H)PU+9QZBZGZ))!5,M0
M3:":1#6%:AK5#*6Y<;9UX6A\JLD&6A"B6H9J M4DJBE4TZAF*,V-MBT(1_ZU
MA/UO:XR.MU-LNZWA/V_OK**-'ZI)5%.HIE'-4)J;5=OXC?R-W].SBHXW-=!U
M@JB6H9I -8EJ"M4TJAE*<P-N^\#1J7;?'*'-(*IEJ"903:*:0C6-:H;2W&C;
M9G#D7U;(W=28'-W4B(]V);_T/YK>"48+0%23J*903:.:H30WP;8 ''7?1?3E
MW6J^",+$<T\#722(:AFJ"523J*903:.:H33WQUW8CG!\JKU$QV@WB&H9J@E4
MDZBF4$VCFJ$T-]JV&QS3>XF.6_82'0VB@TF%_[2]HXIV?:@F44VAFD8U0VEN
M5&W7-^Z^E:@[J0C^#+:7Z)=?KM"MP457!:):AFH"U22J*533J&8HS0VX;0+'
MI]I(=(RV@JB6H9I -8EJ"M4TJAE*<Z.]]Q/CO-4,=TMC=Y[]6QJC29*$\?AP
M H+V?Z@F4$VBFD(UC6J&TMP0V_YOW'TOT5?EI]UV7[N?<OO4-AM^L_>E&6T*
M44V@FD0UA6H:U0REN:FV3>'X5'N)CM&.$-4R5!.H)E%-H9I&-4-I;K1M1SBF
M]Q+=@<X/<CVZM8$V?J@F4$VBFD(UC6J&TMR@VL9OW'TCT=:91?!GD^$BV/Z,
M5.]-#G1M(*IEJ"903:*:0C6-:H;2W*C;:G!\JKU$QVA-B&H9J@E4DZBF4$VC
MFJ$T]\>BVYHP_HOV$HU;]A*-XN,?*'_I?T!]0XQJ M4DJBE4TZAF*,T-L2T$
MX^Z;B6[?.!IMWC@:A:U)11<(HEJ&:@+5)*HI5-.H9BC-C;,M#>-3;2(:HW4A
MJF6H)E!-HII"-8UJAM+<:-NZ,*8W$8V/-Q%=_Y1RY]?A# /M E%-H)I$-85J
M&M4,I;FYM5U@[.\"GYYA=+[+X3]#[VLS6A6BFD UB6H*U32J&4IS,VZKPOA4
M>XG&:%^(:AFJ"523J*903:.:H30WVK8OC/^BO43CX[U$6^]QH+T@J@E4DZBF
M4$VCFJ$T-\*V%XP[[B5:[M4MK];7Y7</9?#NIKRO\N55\TFQK#\_]<8._SEZ
M7ZC14A'5!*I)5%.HIE'-4)J;<ELJQJ?:8#1&2T14RU!-H)I$-85J&M4,I;G1
MMB5B[%]?R,U!ID=SD&@XG Q'AV_Z\#^@WB%&ZT)4DZBF4$VCFJ$T)\2)K0L3
M?UW8__[=#MR_?S<>3 ]WD_&?MF]444V@FD0UA6H:U0REN5&UI6#2L10LO]RR
M&ZUOV$6M(44K053+4$V@FD0UA6H:U0REN6&VE6!RJDHP02M!5,M03:":1#6%
M:AK5#*6YT;:58.*O!+%Y\>X\^_/B-%G_.IQKH/4@J@E4DZBF4$VCFJ$T-\.V
M'DS\]> W3(O'1]/B<' T*T9+/E03J"913:&:1C5#:6Y2;<F7=%P/V%Q>?[I?
M?-Y,B8/6]\GYI=XS![350S6!:A+5%*II5#.4YF;9MGK)J58!)N@J0%3+4$V@
MFD0UA6H:U0REN=&V;5_B;_NX27%Z-"D.1U&:1.GAN^;\CZAWBM$V#]4DJBE4
MTZAF*,U-L6WS$O\2P6^8%F_!U)D6#Z?Q85;1>@[5!*I)5%.HIE'-4)J;55O/
M)1VW__PR,4ZV4^-W#V5K4-&%?:B6H9I -8EJ"M4TJAE*<_*<VJ8N/=7^GRFZ
M_R>J9:@F4$VBFD(UC6J&TMQHVV8O]3=[V.1X=Q[WW9S3*!XEAQ,._R/JG6*T
MTD,UB6H*U32J&4IS4VPKO=2_-6C_R?$._-KDV'_>WEE%.SI4DZBF4$VCFJ$T
M-ZNVHTL[_KR_YA*;%;/MFX^G3[Z=PJ_UGD&@?1VJ"523J*903:.:H30WS[:O
M2\>GFAR39= EJF6H)E!-HII"-8UJAM+<:-N"+_47?-SD.#Z:'&]N'$_'Z>&$
M ZWV4$V@FD0UA6H:U0REN2FVU5[J7[#W#9/CI.4-%4=38[2I0S6!:A+5%*II
M5#.4YB;5-G5I]W5Y!U/CH'URC*[!0[4,U02J2513J*91S5":FVC;VJ6G6H.7
MHFOP4"U#-8%J$M44JFE4,Y3F1MN6?.E?M 8O/5Z#ETR&+3L!^!]0[Q"CS1ZJ
M2513J*91S5":$^*);?8F]!J\R?$:O' 0'B35?]:^244U@6H2U12J:50SE+9-
MZGEU4Q1UEM?YQ?.[_+KX)5]=SY=5L"@^-/QPL/Z><;6>*'SYI"[O7IR%9\'[
MLJ[+V\V'-T5^5:S6!S1__J$LZR^?G#?^0[GZN#G'Q?\!4$L#!!0    ( &Z"
MI%9@C^<UZP,  (H0   9    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;,58
M;6_B.!#^*Z/<ZM1*+7GAI;0'2$!W=95N=:@L=Q].]\$D UA-8M8VL-ROO[&3
M!FC3:*DBE0_@.)YGYGGB<6;H[81\4BM$#3^2.%5]9Z7U^LYU5;C"A*F&6&-*
M=Q9")DS3I5RZ:BV11=8HB=W \SINPGCJ#'IV;B('/;'1,4]Q(D%MDH3)_0AC
ML>L[OO,\\<B7*VTFW$%OS98X13U;3R1=N05*Q!-,%1<I2%STG:%_-_9;QL"N
M^(OC3AV-P5"9"_%D+AZBON.9B##&4!L(1C];'&,<&R2*XWL.ZA0^C>'Q^!G]
MBR5/9.9,X5C$?_-(K_I.UX$(%VP3ZT>Q^QUS0FV#%XI8V6_8Y6L]!\*-TB+)
MC2F"A*?9+_N1"W%D$+3>, AR@^"%@?^603,W:%JB6626UCW3;-"38@?2K"8T
M,[#:6&MBPU/S&*=:TEU.=GHPU2)\NAZ1$!&,14*[0S&K[S4,HXB;(8OA(<TV
MC+EQ<8^:\?B25LRF]W#QZ1(^@0MJQ20JX"G,4J[5%4W2^-M*;!1+(]5S-45K
M?+IA'MDHBRQX([(F?!6I7BGXG$88G=J[Q+*@&CQ3'065@%^9;$#3OX+ "YHE
M\8Q_WCRH"*=9*-^T>,VWE#>"7<]?*S^4DJ5+I%S1,-_#\;H)V]OIX8[)"/[Y
M@R#A06.B_BW3-_/?*O=OSH<[M68A]ATZ !3*+3J#7W_Q.]YO9>+4!'8B5:N0
MJE6%/OAS;811L"1A-$97L+/928*P+4HZ;;([$#&-L&!<PI;%&X0+VH$;%<$:
M9;8_+\MDRGQWK6]SZFT'7J/3O3WY]-SML1BO3?Q&*R@6G9!L%R3;E20?46G)
M0\/*)F661W#Q.)VITK@KX<Y]O#6!G3#O%,P['YP)G3JEJ@GL1*J;0JJ;RDTR
M2R6&8IGR_TB#\%BK4"@-8@'*[IU,)&;$*3UZ,R^=HPW<H1?_BUU>&<H[B78+
MHMW:B5Y!;F/74=)S$961K_;LPQZ9A"8DV>O'[]*YLB]3<5P)]$Z!;@N!;BO#
M##S_%CY_WW"]I]=S2+E Y1!,8I:64:[$.C<!:@([H>U[AX+%^^#3(@^@)K7J
M0CN5ZZB^\ROWR32KRW+H"*B0 Z[4AM&>*26?P;6/WVV>_;PX':K]OI=7<. 5
M5/+ZMA-%=0E3W-+C14Q_/B.JX<]^R#6AG8IQ*"7]CZXE_5J+R;K03N4ZE)-^
M=3UY=DZT7N=$NRPE*MV>2\L]ZNH2E$O;["IZ_VU2G74]Q6S14 ]M&_EB?F0:
M;=LM'F"R+IUZFB6GPCK&!4%ZC1NB*+/&-[O08FU[Q[G0U(G:X0I9A-(LH/L+
M(?3SA7%0_/TP^!]02P,$%     @ ;H*D5D=I<FMM!   5!8  !D   !X;"]W
M;W)K<VAE971S+W-H965T-3,N>&ULQ9A;;^(X%,>_BI655K/2TEP(4+J 5 @S
M.])46[6:F8?1/)CD %:=F+4-E&^_MA-22(,'.AGM"^1RSL\^_W/BVV#+^)-8
M DCTG-),#)VEE*L;UQ7Q$E(LKM@*,O5FSGB*I;KE"U>L..#$.*74#3ROZZ:8
M9,YH8)[=\]& K24E&=QS)-9IBOEN#)1MAX[O[!\\D,52Z@?N:+#""W@$^7EU
MS]6=6U(2DD(F",L0A_G0N?5OIGZH'8S%%P);<7"-="@SQI[TS<=DZ'BZ1T A
MEAJ!U=\&)D"I)JE^_%M G;)-[7AXO:>_-\&K8&98P(31KR21RZ%S[: $YGA-
MY0/;_@U%0!W-BQD5YA=M"UO/0?%:2)86SJH'*<GR?_Q<"''@$'1.. 2%0U!U
MZ)YP:!<.[:I#>,(A+!S"JD/[A$.G<#"ANWGL1K@(2SP:<+9%7%LKFKXPZAMO
MI1?)=*$\2J[>$N4G1X^2Q4^ML9(Z01.6JOH3V&2PA1Y5429K"HC-T:U0E;32
M+P3ZK&U)AL84*U=EQ2@(](]YV[KG)";9 MVQ!"B2#$4@@:N. _K <29;"9:
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M=/5.SY!=5BVOFFBQM&UF)C0V+3O,\"L!I#' _;D0>CLQ!,UW1_P=4$L#!!0
M   ( &Z"I%;M63.:*P,  ,\+   9    >&PO=V]R:W-H965T<R]S:&5E=#4V
M+GAM;,5674_;,!3]*U:&)B8!^>H7K(U$"].0AH0H; _3'MSDMK%([,YV6_CW
MNW9"2$NHAA2)E]9V[CT^]_C&.<.-D \J!=#D,<^X&CFIULLSUU5Q"CE5)V()
M')_,A<RIQJE<N&HI@28V*<_<P/-Z;DX9=Z*A7;N1T5"L=,8XW$BB5GE.Y=,8
M,K$9.;[SO'#+%JDV"VXT7-(%3$'?+V\DSMP*)6$Y<,4$)Q+F(^?</YOXGDFP
M$3\9;%1M3$PI,R$>S.0J&3F>8009Q-I 4/Q;PP2RS" AC[\EJ%/M:1+KXV?T
M;[9X+&9&%4Q$]HLE.ATY X<D,*>K3-^*S7<H"^H:O%ADROZ231GK.21>*2WR
M,AD9Y(P7__2Q%**6@#C-"4&9$.PF=-Y(",N$T!9:,+-E75!-HZ$4&R)--**9
M@=7&9F,UC)MCG&J)3QGFZ6BJ1?QP/$8A$C(1.7:'HE;?:7&N1,S)FS&7CV8,
M9))1I=B<Q<7RX05HRC+UA1R3^^D%.3SX0@X(X^0N%2M%>:*&KD;NAH$;ESS'
M!<_@#9XAN19<IXI<\@22[7P7:ZX*#YX+'P=[ :^I/"&A?T0"+P@;^$S^/SW8
M0R>LSB&T>.%;YY!2"<>SUQJ?2TGY O#-T63V1.IQ-_3)+I]OJ$S([Q\(2:XT
MY.I/D[[%_IWF_<UM<::6-(:1@]>! KD&)_K\R>]Y7YO$:0EL2ZI.)55G'WIT
M)S3-B+)-60@1UP1K*KW ZUD\<Z^M([_7Z0[==;VDAJ!.][0*VJ+:K:AV]U*]
MQ>*IC%."38^7RQIOS:4],BC>G":R>Q'?>TXM@6T5WZN*[WUP2_?:E*HEL"VI
M^I54_99;NL#KUKIU$/H['?TZIN]UFAMZ4!$=["4ZQ>\MXXLCL@ .$CF;QJ8)
M?IB8TI*:3_*^WMX+_MX#:PEL2X?32H?3#^[MTS:E:@EL2RK?>[$87LO=70+6
M+^.!W]EI[X:@?K>[T]]NS1KE(!?6,2HDL.*Z, O5:N5*SZT7VUD?&[=J+=<+
M3&%UT0HL&%<D@SE">B=]?.-DX1Z+B19+:\!F0J.=L\,4'3=($X#/YT+HYXG9
MH/+PT3]02P,$%     @ ;H*D5KC]ZV:4 @  ]P8  !D   !X;"]W;W)K<VAE
M971S+W-H965T-3<N>&ULK57+;MLP$/P50@V*!&@C6;*5(I4%^-&@.00PXJ0]
M%#W0TMHB0I$J2=GNWY</6;431<VA%XN/G>',FKM,=EP\R0) H7U)F1Q[A5+5
MM>_+K( 2RTM> =,[:RY*K/14;'Q9"<"Y!974#X,@]DM,F)<F=FTATH37BA(&
M"X%D7998_)X"Y;NQ-_ ."_=D4RBSX*=)A3>P!/58+82>^2U+3DI@DG"&!*S'
MWF1P/8M-O WX1F GC\;(.%EQ_F0FM_G8"XP@H) IPX#U9PLSH-00:1F_&DZO
M/=( C\<']AOK77M980DS3K^37!5C[Y.'<ECCFJI[OOL*C9^1X<LXE?87[5SL
M5>BAK):*EPU8*R@)<U^\;_)P!- \W8"P 83/ <-7 %$#B*Q1I\S:FF.%TT3P
M'1(F6K.9@<V-16LWA)E_<:F$WB4:I]);EO$2T />@T0?T23/B4DOINB6N3MB
MDGT^!X4)O= 1C\LY.C^[0&>(,/10\%IBELO$5UJ,H?2SYN"I.SA\Y> (W7&F
M"HF^L!SR4[RO3;1.PH.3:=A+>(?%)8H&'U 8A%&'GMG;X6&/G*A-;&3YHG\F
M%LV)S"B7M0#T8[*22NB[^[,K8XYQV,UHZOE:5CB#L:<+5H+8@I>^?S>(@\]=
M=O\3V8GY86M^V,>>WD .0M\AXI*@=!)6P&!-5)=MQQ5;+M-UMFF0^-MC+WT1
M)P)'K<!1K\"EP@K>*,\QC7KD]46<R(M;>7&OO(7@6V(;I:[!(YG066CQB^P,
MGPE\&6%*Y$2A?]1#2A ;VUHERGC-E"O"=K7MWA/;M)ZM3W57=TWX+XU[$G2)
M;0B3B,):4P:75SICPK59-U&\LIUJQ97N>W98Z)<)A G0^VO.U6%B#FC?NO0/
M4$L#!!0    ( &Z"I%9%RWF";@,  )$+   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4X+GAM;+56;8_:.!#^*U9:5:VT;-X@P!8B+7#5G=16JW)[_6R2@5B;
MV)SM0._?W]@):8! ^;#] K8SS_AY9FS/3/9"OJ@,0),?1<[5U,FTWCZXKDHR
M**BZ%UO@^&4M9$$U3N7&55L)-+6@(G<#SXO<@C+NQ!.[]B3CB2AUSC@\2:+*
MHJ#ROQGD8C]U?.>P\(UM,FT6W'BRI1M8@G[>/DF<N8V7E!7 %1.<2%A/G4?_
M8>Y;@+7XA\%>M<;$2%D)\6(F?Z53QS.,((=$&Q<4_W8PASPWGI#'O[53I]G3
M -OC@_=/5CR*65$%<Y%_9ZG.IL[((2FL:9GK;V+_)]2"!L9?(G)E?\F^MO4<
MDI1*BZ(&(X."\>J?_J@#T0*@GVY 4 ."4T#_ B"L :$56C&SLA94TW@BQ9Y(
M8XW>S,#&QJ)1#>,FC4LM\2M#G(Z_XDGY+)0B6Y!DF5$)I$>654Z)6),952PA
ME*=DP?)20TH,(C]&/&HMV:K4=)4#T8+,15%@BI9:)"^9R%.0BKQ?@*8L_X#N
MGY<+\O[M!_*6N$09!XHP3IXYT^H.%W'\=R9*A9NJB:M1I*'J)K6@624HN" H
M)%\$UYDB?_ 4TF.\B\%I(A0<(C0+KCK\0N4]"?T[$GA!V,%G?CL\N$(G;!(6
M6G_AI825!4BJA7SHBDV%[7=CS9/PH+8T@:F#=UZ!W($3OWOC1]['+F&OY.Q(
M9K^1V;_F/3Z<LBZ1%3*R2/-,[>)>T/<";^+NVO2[S/QQ-&C,CH@-&F*#J\06
M;,=2P*-Y1YXH2WN,]UX83[MX5HX&+0*G%,\M>D$P&'<SC!J&T4VA(_3D6B;5
MM52M:]E%.[HMO)UF0=#O)C]LR ^O'N\%<('/W,4#/GS- _Y*SHZ$CAJAHZM9
M^FX+#+ZG=(?W>0.'EQ#?W':>")9>I?$I9'SS[LTH\(./*_,D=\5F='::_/Y@
M' T][S1WYY9A. R/#(]$C1M1X]\D*JVJ2Y>L\<VRSBVOR_*]GU72N^U.F:)G
M1=URNWZ5L'K34?L.>?=^="*KVVP87!#5*OW^[Q-U)6'UMK^4U6EV)LMM-3=8
M^C:VYU/(K.2ZJN+-:M-7/MINZF1]9OI-VS3]=%,UJUBC-XPKDL,:72('/$*R
MZO^JB19;VT*MA,:&S XS[)E!&@/\OA9"'R9F@Z8+C_\'4$L#!!0    ( &Z"
MI%;&[K*Q5@(  !$%   9    >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;+54
MWVO;,!#^5PYOC ZRR''2KG2.H4E;&FA':+?U8>Q!L2^QJ'YXDARGL#]^DNR8
M#)J^[<762?=]]]WI3FFC]+,I$2WL!)=F&I765A>$F+Q$0<U052C=R5II0:TS
M]8:82B,M DAPDL3Q&1&4R2A+P]Y29ZFJ+6<2EQI,+035+S/DJIE&HVB_\< V
MI?4;)$LKNL%'M-^KI786Z5D*)E :IB1H7$^CR]'%;.+]@\,/AHTY6(//9*74
MLS<6Q32*O2#DF%O/0-UOBW/DW!,Y&;\[SJ@/Z8&'ZSW[3<C=Y;*B!N>*/['"
MEM/H/(("U[3F]D$UM]CE<^KY<L5-^$+3^<81Y+6Q2G1@IT PV?[IKJO# 2 Y
M/0)(.D 2=+>!@LHK:FF6:M6 ]MZ.S2]"J@'MQ#'I+^71:G?*',YF7]V]WREC
MH$(-CR75")_@LBB8KQGEL)#MQ?L*GERAI8Q_3(EUD3V>Y%V461LE.1+EGNHA
MC$<#2.)D#.^!@/&AS+],Q&GO$TCZ!)) /3E"O72*;VI98 %/5&LJ+?R!>[IC
MHA:O"7V3S8_ A:EHCM/(];A!O<4H^_!N=!9_>4/KN-<Z#NSC(UJOJ99,;@PL
M]\4>P(P:E@]@]0)S)82K\IQ38P:N\#FO"^<-WQK5;L(]VE(5\//.\<+"HC"_
M7DMQ_!]2G/0I3MZ\CNL=ZIP9A*5F.<));8K06N&^7^V<EN\\\/DG9)O%PWB4
MDNVA"G+0X?ZQ< VU8=( Q[6#Q<//;EIT.X"M8545FGZEK!NAL"S=FX7:.[CS
MM5)V;_@YZE_!["]02P,$%     @ ;H*D5J]1X[RL P  [@\  !D   !X;"]W
M;W)K<VAE971S+W-H965T-C N>&ULS5==;Z,X%/TK%BN-9J2=\ID W02I3;N:
MD69VJD;=>5CM@P,WB55CL[9IVG^_-A 24HJV$EKE)<'&]W#.\;W@.]MQ\2BW
M  H]YY3)N;55JKBT;9EN(<?R@A? ])TU%SE6>B@VMBP$X*P*RJGM.<[4SC%A
M5C*KYNY$,N.EHH3!G4"RS',L7JZ!\MW<<JW]Q#W9;)69L)-9@3>P!/50W D]
MLEN4C.3 ).$,"5C/K2OW<N'Z)J!:\2>!G3RZ1D;*BO-',_B:S2W', (*J3(0
M6/\]P0(H-4B:QS\-J-4^TP0>7^_1?Z_$:S$K+&'!Z4^2J>W<BBR4P1J75-WS
MW1=H!$T,7LJIK'[1KEGK6"@MI>)Y$ZP9Y(35__BY,>(H0./T!WA-@'<:$+P1
MX#<!E7-VS:R2=8,53F:"[Y PJS6:N:B\J:*U&L+,-BZ5T'>)CE/)'SI3OG$I
M40$"+;=8 /J,ECI9LI("XFMTQ13YG!%:&KO1$M)2$$5 HMOGE)899&@M>(X6
M/"]*A:NMT5$W)D#?ZX&_4DJ0E5Z[T@]0W$3F.FBI>/JXY30#(=''&U"8T$^:
MBS1!<F8K+=90MM-&V'4MS'M#F(^^<Z:VFB?3)+OQMC:I=<K;.W7M#0)^Q^("
M^>ZOR',\OX?/XK^'>P-T_';C_ K/?P//[,N[M^46"T;81J*[=CO^^J:!T5<%
MN?R[S^6:1=#/PKQD+F6!4YA;^BTB03R!E7SXQ9TZO_59-!)8Q["@-2P80D^Z
MB2P/CD''L;3K6-8D,M.)3/>)7.4D^DA8DYV?^HRKV4PJ-N9E^I3$4S^:.E$\
MLY^.37F]T/4#/XK#H%W8$3QI!4\&!=_F!>4O '5IH1^%T=3'=!#FO5L\$EA'
M\;15/#V+FIB.:=A(8!W#PM:P\*QJ(GR5ZE[D.[[CG)1$SSHGB-U)U%\142LW
M&I1[#U)_>U+#O:Z)!T:4_MK<+Q_Z^0["O7>C1P+K*(];Y?%95$8\IF$C@74,
M<YW#P<@YJ]IHZ!PG_23R)XX[/2F.GH5N'#AA]$9UN$=G07=0\H)BS7B!?F(A
M,-,G-X)7A!+UTLMW$.N]>ST66E>Y=U#NG45]-#3&,FTDM*YIAQ.H.WA>^_\K
MQ'^5^%$8>DX8^J<E\GIE' 2QXYV6B'W4.>4@-E5#*37EDJFZ-6AGVZ;UJFK5
M3N:O33-;=60'F+H3U@?_#6$245AK2.<BU*Q$W5S6 \6+JC];<:6[O>IRJQMR
M$&:!OK_F7.T'Y@%MBY_\"U!+ P04    " !N@J16&='<"RL#  #N$@  #0
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M5>_!O?=1V+RGPLTO7.,G4$L#!!0    ( &Z"I%:7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ ;H*D5E*F T^_!
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MTOKAUJ8JB@M8=VT@!<^?7V![?OGNRT]02P,$%     @ ;H*D5I@;6I[[ 0
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M5HTBJT:15:/(.OY/65^L7?WUWQ[=/6],U1[S6?]+S>P-4$L! A0#%     @
M;H*D5@=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " !N@J16<_K08>\    K @  $0
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M965T-"YX;6Q02P$"% ,4    " !N@J16X5Q6=%@&   C)@  &
M    @('$'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
M;H*D5M/X($DO!P  .AT  !@              ("!4B,  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( &Z"I%9I7CHOA (  $$%   8
M          " @;<J  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " !N@J16T)B?!FT/  !+*0  &               @(%Q+0  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ ;H*D5MZ0;T&*!P  41,
M !@              ("!%#T  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( &Z"I%9%+!XB!0@  '$4   9              " @=1$  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ ;H*D5H1IKF)'
M!P  4Q,  !D              ("!$$T  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " !N@J16^<"AU!,#  "]!@  &0
M@(&.5   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( &Z"
MI%8KZ;,MP (  .T%   9              " @=A7  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ ;H*D5@$$NT"""0  U!<  !D
M         ("!SUH  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " !N@J16T6CO+#@'  #5$0  &0              @(&(9   >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( &Z"I%:0;5\UR04  %\-
M   9              " @?=K  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ ;H*D5G8#LF2C!0  9@T  !D              ("!]W$
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !N@J16;0G+
M" ()  !O&   &0              @('1=P  >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( &Z"I%8FSMNFRP(  #X&   9
M  " @0J!  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
M;H*D5K3U.](1!@  &!   !D              ("!#(0  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " !N@J16<_A@:40(   M%P  &0
M            @(%4B@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( &Z"I%9 6N>UOP,  %X)   9              " @<^2  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ ;H*D5ND:6V"K!
MT@P  !D              ("!Q98  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " !N@J16<*(AV,X"   9!@  &0              @(&G
MFP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( &Z"I%9T
MO3M5P (  /$%   9              " @:R>  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ ;H*D5JYL\^C- P  8@D  !D
M     ("!HZ$  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &Z"I%96MZC3  ,  .,(   9              "
M@::W  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ ;H*D
M5K%DTX=T P  B X  !D              ("!W;H  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " !N@J16\U;>W!H#   0"P  &0
M        @(&(O@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( &Z"I%8@801U%P,  $4*   9              " @=G!  !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ ;H*D5OGJ;:'/!   H"$
M !D              ("!)\4  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    " !N@J164B:!>60#  !X#   &0              @($MR@
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( &Z"I%84B!]#
M2 (  !T%   9              " @<C-  !X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ ;H*D5K^RQP*E!    1<  !D
M ("!1]   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !N
M@J160@^&>\T#  #F$P  &0              @($CU0  >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( &Z"I%:*E-UM<P(  -P%   9
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M970T-"YX;6Q02P$"% ,4    " !N@J16"E^X&'4"   3!@  &0
M    @('!Z@  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M &Z"I%:4/D[+AP0  "\:   9              " @6WM  !X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ ;H*D5K[V7P@D P  H0D  !D
M             ("!*_(  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    " !N@J162W\RB:P"  "S!P  &0              @(&&]0  >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( &Z"I%;B!]AR5 (
M !L&   9              " @6GX  !X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ ;H*D5KH)'\L)!   "QD  !D              ("!
M]/H  'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " !N@J16
M#+-O:5P.  !@X0  &0              @($T_P  >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    ( &Z"I%9@C^<UZP,  (H0   9
M      " @<<- 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%
M  @ ;H*D5D=I<FMM!   5!8  !D              ("!Z1$! 'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !N@J16RQ"];,L$  "\%P
M&0              @(&-%@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+
M 0(4 Q0    ( &Z"I%;@+BWIYP(  (,(   9              " @8\; 0!X
M;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ ;H*D5NU9,YHK
M P  SPL  !D              ("!K1X! 'AL+W=O<FMS:&5E=',O<VAE970U
M-BYX;6Q02P$"% ,4    " !N@J16N/WK9I0"  #W!@  &0
M@($/(@$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( &Z"
MI%9%RWF";@,  )$+   9              " @=HD 0!X;"]W;W)K<VAE971S
M+W-H965T-3@N>&UL4$L! A0#%     @ ;H*D5L;NLK%6 @  $04  !D
M         ("!?R@! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
M    " !N@J16KU'CO*P#  #N#P  &0              @($,*P$ >&PO=V]R
M:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( &Z"I%89T=P+*P,  .X2
M   -              "  >\N 0!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !$ $0 DQ(  %P\ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>151</ContextCount>
  <ElementCount>247</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - License, Collaboration, and Funding Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements</Role>
      <ShortName>License, Collaboration, and Funding Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Fair Value of Financial Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CommonStockWarrants</Role>
      <ShortName>Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/AccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/LongTermDebt</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CommonStockWarrantsTables</Role>
      <ShortName>Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/CommonStockWarrants</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/StockBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/NetLossperShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Summary of Significant Accounting Policies - Schedule of Compensating Balance Arrangements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Compensating Balance Arrangements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - License, Collaboration, and Funding Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail</Role>
      <ShortName>License, Collaboration, and Funding Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities Measured at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities Measured at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Fair Value of Financial Assets and Liabilities - Aggregate Fair Values Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Aggregate Fair Values Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Fair Value of Financial Assets and Liabilities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Fair Value of Financial Assets and Liabilities - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/PropertyandEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Long-Term Debt - Summary of Long Term Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail</Role>
      <ShortName>Long-Term Debt - Summary of Long Term Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Long Term Debt - Hercules Loan Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail</Role>
      <ShortName>Long Term Debt - Hercules Loan Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Long-Term Debt - Summary of Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails</Role>
      <ShortName>Long-Term Debt - Summary of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Long-Term Debt - Schedule of Future Principal Payments and the Final Payments Due (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail</Role>
      <ShortName>Long-Term Debt - Schedule of Future Principal Payments and the Final Payments Due (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Leases - Schedule of Components of Lease Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail</Role>
      <ShortName>Leases - Schedule of Components of Lease Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Commitment and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitment and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Common Stock Warrants - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail</Role>
      <ShortName>Common Stock Warrants - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail</Role>
      <ShortName>Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-date Fair Value of Stock Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-date Fair Value of Stock Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.x4pharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Stock-Based Compensation Summary of Stock-Based Compensation Expense Classification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails</Role>
      <ShortName>Stock-Based Compensation Summary of Stock-Based Compensation Expense Classification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail</Role>
      <ShortName>Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Net Loss per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail</Role>
      <ShortName>Net Loss per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="xfor-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail</Role>
      <ShortName>Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="xfor-20230331.htm">xfor-20230331.htm</File>
    <File>ex-311q12023.htm</File>
    <File>ex-312q12023.htm</File>
    <File>ex-321q12023.htm</File>
    <File>xfor-20230331.xsd</File>
    <File>xfor-20230331_cal.xml</File>
    <File>xfor-20230331_def.xml</File>
    <File>xfor-20230331_lab.xml</File>
    <File>xfor-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>xfor-20230331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="476">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>77
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "xfor-20230331.htm": {
   "axisCustom": 1,
   "axisStandard": 20,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 476,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 151,
   "dts": {
    "calculationLink": {
     "local": [
      "xfor-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "xfor-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "xfor-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "xfor-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xfor-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "xfor-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 413,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 28,
   "keyStandard": 219,
   "memberCustom": 34,
   "memberStandard": 24,
   "nsprefix": "xfor",
   "nsuri": "http://www.x4pharma.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.x4pharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - License, Collaboration, and Funding Agreements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements",
     "shortName": "License, Collaboration, and Funding Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Fair Value of Financial Assets and Liabilities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities",
     "shortName": "Fair Value of Financial Assets and Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.x4pharma.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xfor:AccruedExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.x4pharma.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xfor:AccruedExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Long-Term Debt",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.x4pharma.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.x4pharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Commitment and Contingencies",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.x4pharma.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Common Stock Warrants",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.x4pharma.com/role/CommonStockWarrants",
     "shortName": "Common Stock Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.x4pharma.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.x4pharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "xfor:ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "xfor:ResearchAndDevelopmentIncentiveReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Net Loss per Share",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.x4pharma.com/role/NetLossperShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensatingBalancesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensatingBalancesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables",
     "shortName": "Fair Value of Financial Assets and Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.x4pharma.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.x4pharma.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Long-Term Debt (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.x4pharma.com/role/LongTermDebtTables",
     "shortName": "Long-Term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.x4pharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Common Stock Warrants (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.x4pharma.com/role/CommonStockWarrantsTables",
     "shortName": "Common Stock Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Net Loss per Share (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.x4pharma.com/role/NetLossperShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "xfor:ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail",
     "shortName": "Nature of the Business and Basis of Presentation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "xfor:ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Summary of Significant Accounting Policies - Schedule of Compensating Balance Arrangements (Detail)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Compensating Balance Arrangements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensatingBalancesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "xfor:ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - License, Collaboration, and Funding Agreements - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail",
     "shortName": "License, Collaboration, and Funding Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnSaleOfOtherAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ifeef5c014ddc40deb4afa45ea2116298_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities Measured at Fair Value (Detail)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail",
     "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities Measured at Fair Value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ifeef5c014ddc40deb4afa45ea2116298_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i1ca029d12cad45af98e015984da7cdeb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Fair Value of Financial Assets and Liabilities - Aggregate Fair Values Financial Instruments (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails",
     "shortName": "Fair Value of Financial Assets and Liabilities - Aggregate Fair Values Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i600de8e95d2f4f32915317e0807fd211_I20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Fair Value of Financial Assets and Liabilities - Narrative (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails",
     "shortName": "Fair Value of Financial Assets and Liabilities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i600de8e95d2f4f32915317e0807fd211_I20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Fair Value of Financial Assets and Liabilities - Fair Value Assumptions (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails",
     "shortName": "Fair Value of Financial Assets and Liabilities - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i08cceb6ad460483886bad3c9fcd6710e_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Property and Equipment, Net - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.x4pharma.com/role/PropertyandEquipmentNetAdditionalInformationDetail",
     "shortName": "Property and Equipment, Net - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Long-Term Debt - Summary of Long Term Debt (Detail)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail",
     "shortName": "Long-Term Debt - Summary of Long Term Debt (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Long Term Debt - Hercules Loan Agreement - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
     "shortName": "Long Term Debt - Hercules Loan Agreement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ie15dfe94dd9d4fe39d6d8e1f3b74ce9a_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Long-Term Debt - Summary of Interest Expense (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails",
     "shortName": "Long-Term Debt - Summary of Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ie15dfe94dd9d4fe39d6d8e1f3b74ce9a_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Long-Term Debt - Schedule of Future Principal Payments and the Final Payments Due (Detail)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail",
     "shortName": "Long-Term Debt - Schedule of Future Principal Payments and the Final Payments Due (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Leases - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i25e5f6ca21c44724bd4163d8dc79dbe2_D20230101-20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "xfor:CurrentOfficeSpaceUnderLeaseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Leases - Schedule of Components of Lease Expense (Detail)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail",
     "shortName": "Leases - Schedule of Components of Lease Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i9d0d898499ff4bda99b5eb41e4b472d0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Commitment and Contingencies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail",
     "shortName": "Commitment and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i9d0d898499ff4bda99b5eb41e4b472d0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "id108597db204485299a9f94cb8127d3a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "id108597db204485299a9f94cb8127d3a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Common Stock Warrants - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
     "shortName": "Common Stock Warrants - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DividendsCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Detail)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail",
     "shortName": "Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i8402c14812aa4792af598dc3f27820a4_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-date Fair Value of Stock Options Granted (Detail)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail",
     "shortName": "Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-date Fair Value of Stock Options Granted (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i4221465155da49fe9746bea8dd9a5099_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "xfor:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i1ca029d12cad45af98e015984da7cdeb_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i1ca029d12cad45af98e015984da7cdeb_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Stock-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Stock-Based Compensation Summary of Stock-Based Compensation Expense Classification (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails",
     "shortName": "Stock-Based Compensation Summary of Stock-Based Compensation Expense Classification (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Income Taxes - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.x4pharma.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Detail)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail",
     "shortName": "Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DividendsPaidinkind",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i543a1b3b9f974153b5b0d78f5aa7e65a_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Net Loss per Share - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail",
     "shortName": "Net Loss per Share - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i543a1b3b9f974153b5b0d78f5aa7e65a_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail",
     "shortName": "Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i06ba2f0164234d80aef6eb30ab849e77_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "true"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "i06ba2f0164234d80aef6eb30ab849e77_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "true"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Nature of the Business and Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230331.htm",
      "contextRef": "ia73c66c5b551427086b52093d7c4c3a7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 62,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r257",
      "r386",
      "r395",
      "r408",
      "r409",
      "r423",
      "r429",
      "r433",
      "r466",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r250",
      "r257",
      "r284",
      "r285",
      "r286",
      "r362",
      "r386",
      "r395",
      "r408",
      "r409",
      "r423",
      "r429",
      "r433",
      "r462",
      "r466",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r250",
      "r257",
      "r284",
      "r285",
      "r286",
      "r362",
      "r386",
      "r395",
      "r408",
      "r409",
      "r423",
      "r429",
      "r433",
      "r462",
      "r466",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r407",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r407",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r432"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail",
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r104",
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r57",
      "r129"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r133",
      "r392",
      "r400",
      "r401"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r24",
      "r27",
      "r86",
      "r354",
      "r396",
      "r397",
      "r443",
      "r444",
      "r445",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r452",
      "r453",
      "r454",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r80",
      "r81",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r65",
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r34",
      "r42",
      "r94",
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r100",
      "r113",
      "r132",
      "r148",
      "r189",
      "r191",
      "r193",
      "r197",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r314",
      "r316",
      "r331",
      "r432",
      "r464",
      "r465",
      "r508"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r125",
      "r134",
      "r148",
      "r197",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r314",
      "r316",
      "r331",
      "r432",
      "r464",
      "r465",
      "r508"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.x4pharma.com/role/StockBasedCompensationDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r310",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r83",
      "r84",
      "r310",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r47",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of the Business and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r44",
      "r127",
      "r410"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r39",
      "r44",
      "r46"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r39",
      "r93"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise Price (usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of Shares of Common Stock Issuable (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r311",
      "r312",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License, Collaboration, and Funding Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r20",
      "r105",
      "r118"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r60",
      "r212",
      "r213",
      "r403",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitment and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r452",
      "r453",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r432"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 500,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively; 122,207,488 and 121,667,250 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r450",
      "r494",
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal income tax benefit"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r450",
      "r494",
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State income tax benefit"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r101",
      "r102",
      "r112",
      "r151",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r341",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument variable percentage"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r17",
      "r95",
      "r245",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate of loan"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "terseLabel": "Interest rate increase percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r18",
      "r151",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r341",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Principal payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r18",
      "r66",
      "r67",
      "r68",
      "r69",
      "r94",
      "r95",
      "r98",
      "r111",
      "r151",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r341",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r467"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail": {
       "order": 3.0,
       "parentTag": "xfor_LongTermDebtIncludingAccretion",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount (premium).",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "negatedLabel": "Debt discount, net of accretion"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r42",
      "r187"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.x4pharma.com/role/PropertyandEquipmentNetAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Embedded derivative liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r500"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r135",
      "r136",
      "r330",
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Fair value of derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Warrant liability (Note 4)"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r261",
      "r289",
      "r290",
      "r292",
      "r296",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r70",
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends on common stock declared or paid"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPaidinkind": {
     "auth_ref": [
      "r70",
      "r109"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid paid-in-kind dividends (PIK) declared for classes of stock, for example, but not limited to, common and preferred.",
        "label": "Dividends, Paid-in-kind",
        "negatedTerseLabel": "Dividends, Paid-in-kind"
       }
      }
     },
     "localname": "DividendsPaidinkind",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r143",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r165",
      "r168",
      "r172",
      "r173",
      "r174",
      "r178",
      "r320",
      "r321",
      "r389",
      "r393",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders\u2014basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r143",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r168",
      "r172",
      "r173",
      "r174",
      "r178",
      "r320",
      "r321",
      "r389",
      "r393",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders\u2014diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r332"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeFinancialInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument embedded in host contract.",
        "label": "Embedded Derivative Financial Instruments [Member]",
        "terseLabel": "Embedded Derivative Liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeFinancialInstrumentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued employee compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost of stock based awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost of stock based awards, recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r65",
      "r123",
      "r139",
      "r140",
      "r141",
      "r152",
      "r153",
      "r154",
      "r156",
      "r162",
      "r164",
      "r180",
      "r198",
      "r249",
      "r293",
      "r294",
      "r295",
      "r301",
      "r302",
      "r319",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r354",
      "r396",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r42",
      "r64"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r235",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r323",
      "r359",
      "r360",
      "r361",
      "r419",
      "r420",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r322",
      "r323",
      "r325",
      "r326",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r235",
      "r251",
      "r256",
      "r323",
      "r359",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r235",
      "r251",
      "r256",
      "r323",
      "r360",
      "r419",
      "r420",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r235",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r323",
      "r361",
      "r419",
      "r420",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r90",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Aggregate Fair Values of Warrant Liability and Derivative Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r235",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r359",
      "r360",
      "r361",
      "r419",
      "r420",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r195",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r243",
      "r247",
      "r318",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r416",
      "r456",
      "r457",
      "r458",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r446"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Gain (Loss) on Disposition of Assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "auth_ref": [
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of other assets.",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "terseLabel": "Gain (Loss) on Disposition of Other Assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r130",
      "r207",
      "r388",
      "r417",
      "r432",
      "r460",
      "r461"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r208",
      "r209",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r28",
      "r99",
      "r106",
      "r121",
      "r189",
      "r190",
      "r192",
      "r194",
      "r390",
      "r415"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r149",
      "r298",
      "r299",
      "r300",
      "r303",
      "r305",
      "r307",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r150",
      "r163",
      "r164",
      "r188",
      "r297",
      "r304",
      "r306",
      "r394"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.x4pharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses, other current assets and research and development incentive receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r96",
      "r108",
      "r142",
      "r186",
      "r340"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r34",
      "r240",
      "r246",
      "r421",
      "r422"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense, debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Interest Income and Interest Expense Disclosure"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r32",
      "r185"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r351",
      "r431"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Lease not yet commenced, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r507"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease, renewal term of contract (years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease, term of contract (years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r14",
      "r148",
      "r197",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r315",
      "r316",
      "r317",
      "r331",
      "r414",
      "r464",
      "r508",
      "r509"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r103",
      "r116",
      "r432",
      "r449",
      "r459",
      "r503"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r126",
      "r148",
      "r197",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r315",
      "r316",
      "r317",
      "r331",
      "r432",
      "r464",
      "r508",
      "r509"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityPeriodicPayment": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments of both interest and principal.",
        "label": "Line of Credit Facility, Periodic Payment",
        "terseLabel": "Line of credit facility periodic payment"
       }
      }
     },
     "localname": "LineOfCreditFacilityPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r3",
      "r102",
      "r114",
      "r234",
      "r244",
      "r419",
      "r420"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail": {
       "order": 1.0,
       "parentTag": "xfor_LongTermDebtIncludingAccretion",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Principal amount of long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Including Current Maturities",
        "terseLabel": "Long-term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedTerseLabel": "Current portion of long-term debt",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r61",
      "r151",
      "r238"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail": {
       "order": 1.0,
       "parentTag": "xfor_LongTermDebtAndEOTPayment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r61",
      "r151",
      "r238"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail": {
       "order": 4.0,
       "parentTag": "xfor_LongTermDebtAndEOTPayment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r61",
      "r151",
      "r238"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail": {
       "order": 3.0,
       "parentTag": "xfor_LongTermDebtAndEOTPayment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail": {
       "order": 2.0,
       "parentTag": "xfor_LongTermDebtAndEOTPayment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-Term Debt [Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r18",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r39",
      "r40",
      "r43"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r29",
      "r43",
      "r107",
      "r120",
      "r124",
      "r137",
      "r138",
      "r141",
      "r148",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r163",
      "r164",
      "r170",
      "r189",
      "r190",
      "r192",
      "r194",
      "r197",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r321",
      "r331",
      "r415",
      "r464"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r165",
      "r166",
      "r171",
      "r174",
      "r189",
      "r190",
      "r192",
      "r194",
      "r415"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r189",
      "r190",
      "r192",
      "r194",
      "r415"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r346",
      "r431"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Fixed operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease, liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r344",
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r350",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate-operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r349",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term-operating leases (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Payments for Repurchase of Common Stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Employee taxes paid related to net share settlement of vested restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r144",
      "r496",
      "r497",
      "r498"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Acquisition of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r36",
      "r448"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r59",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r56",
      "r128"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r58",
      "r117",
      "r391",
      "r432"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "negatedTerseLabel": "Repayments of Secured Debt"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r82",
      "r122",
      "r516"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense, Policy"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r440",
      "r447",
      "r517",
      "r518"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r440",
      "r447"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash, current portion"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r402",
      "r441",
      "r447"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash, non-current",
        "verboseLabel": "Total restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "terseLabel": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings"
       }
      }
     },
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail",
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.x4pharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings",
        "terseLabel": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings"
       }
      }
     },
     "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r70",
      "r115",
      "r399",
      "r401",
      "r432"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r123",
      "r152",
      "r153",
      "r154",
      "r156",
      "r162",
      "r164",
      "r198",
      "r293",
      "r294",
      "r295",
      "r301",
      "r302",
      "r319",
      "r396",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensatingBalancesTextBlock": {
     "auth_ref": [
      "r23",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes disclosure of these arrangements and the amount involved, if determinable, for the most recent audited balance sheet required and for any subsequent unaudited balance sheet required in the notes to the financial statements. Compensating balances that are maintained under an agreement to assure future credit availability are generally disclosed in the notes to the financial statements along with the amount and terms of such agreement.",
        "label": "Schedule of Compensating Balances [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCompensatingBalancesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense Classification"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of Long Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r48",
      "r50",
      "r168",
      "r169",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Principal Payments and the Final Payments Due"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r258",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.x4pharma.com/role/StockBasedCompensationDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail",
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.",
        "label": "Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]",
        "terseLabel": "Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Stock Option Valuation"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested ending balance (in shares)",
        "periodStartLabel": "Nonvested beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield (in percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (in percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (in percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.x4pharma.com/role/StockBasedCompensationDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail",
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Number of shares Options, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Exercisable (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, Ending balance",
        "periodStartLabel": "Aggregate intrinsic value, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in usd per share)",
        "periodStartLabel": "Beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Vested and expected to vest (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Number of shares Options, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.x4pharma.com/role/StockBasedCompensationDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share Price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails",
      "http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average contractual term outstanding, Exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average contractual term outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average contractual term outstanding, Vested and expected to vest (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r47",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r22",
      "r65",
      "r123",
      "r139",
      "r140",
      "r141",
      "r152",
      "r153",
      "r154",
      "r156",
      "r162",
      "r164",
      "r180",
      "r198",
      "r249",
      "r293",
      "r294",
      "r295",
      "r301",
      "r302",
      "r319",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r354",
      "r396",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "verboseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r180",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r65",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r65",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Stock Issued During Period, Value, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r55",
      "r432",
      "r449",
      "r459",
      "r503"
     ],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r347",
      "r431"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r339",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r339",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r339",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r195",
      "r196",
      "r243",
      "r247",
      "r318",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r456",
      "r457",
      "r458",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r181",
      "r182",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Class C Warrant Liability"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesFairValueAssumptionsDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail",
      "http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetail",
      "http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r167",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares of common stock outstanding\u2014diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r165",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares of common stock outstanding\u2014basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "xfor_AccretionOnLongTermDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail": {
       "order": 2.0,
       "parentTag": "xfor_LongTermDebtIncludingAccretion",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion on long term debt.",
        "label": "Accretion On Long Term Debt",
        "negatedLabel": "Cumulative accretion of end of term payments"
       }
      }
     },
     "localname": "AccretionOnLongTermDebt",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_AccruedExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses.",
        "label": "Accrued Expenses [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedExpensesTextBlock",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xfor_AccruedExternalResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued external research and development expenses.",
        "label": "Accrued External Research And Development Expenses",
        "terseLabel": "Accrued external research and development expenses"
       }
      }
     },
     "localname": "AccruedExternalResearchAndDevelopmentExpenses",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_AccruedLeaseConstructionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Lease Construction Costs",
        "label": "Accrued Lease Construction Costs",
        "terseLabel": "Accrued deferred financing fees"
       }
      }
     },
     "localname": "AccruedLeaseConstructionCosts",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/AccruedExpensesScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_AggregateBaseRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate base rent.",
        "label": "Aggregate Base Rent",
        "terseLabel": "Current base rent"
       }
      }
     },
     "localname": "AggregateBaseRent",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_AllstonLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allston Lease Agreement",
        "label": "Allston Lease Agreement [Member]",
        "terseLabel": "Allston Lease Agreement"
       }
      }
     },
     "localname": "AllstonLeaseAgreementMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_AllstonLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allston Lease",
        "label": "Allston Lease [Member]",
        "terseLabel": "Allston Lease"
       }
      }
     },
     "localname": "AllstonLeaseMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ClassAWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A Warrant [Member]",
        "label": "Class A Warrant [Member]",
        "terseLabel": "Class A Warrant"
       }
      }
     },
     "localname": "ClassAWarrantMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Additional Exercise Price of Warrants or Rights",
        "label": "Class of Warrant or Right, Additional Exercise Price of Warrants or Rights",
        "terseLabel": "Class of Warrant or Right, Additional Exercise Price of Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAdditionalExercisePriceOfWarrantsOrRights",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail",
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "xfor_ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued",
        "label": "Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued",
        "terseLabel": "Class Of Warrant Or Right. Aggregate Proceeds From Warrants Issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAggregateProceedsFromWarrantsIssued",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_CollaborationLicenseAndFundingArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration, license and funding arrangements.",
        "label": "Collaboration License And Funding Arrangements [Line Items]",
        "terseLabel": "Collaboration License And Funding Arrangements [Line Items]"
       }
      }
     },
     "localname": "CollaborationLicenseAndFundingArrangementsLineItems",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_CollaborationLicenseAndFundingArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration, license and funding arrangements.",
        "label": "Collaboration License And Funding Arrangements [Table]",
        "terseLabel": "Collaboration License And Funding Arrangements [Table]"
       }
      }
     },
     "localname": "CollaborationLicenseAndFundingArrangementsTable",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_ContingenciesAndCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingencies And Commitments [Line Items]",
        "label": "Contingencies And Commitments [Line Items]",
        "terseLabel": "Contingencies And Commitments [Line Items]"
       }
      }
     },
     "localname": "ContingenciesAndCommitmentsLineItems",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_ContingenciesAndCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingencies And Commitments [Table]",
        "label": "Contingencies And Commitments [Table]",
        "terseLabel": "Contingencies And Commitments [Table]"
       }
      }
     },
     "localname": "ContingenciesAndCommitmentsTable",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_CurrentOfficeSpaceUnderLeaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current office space under lease agreement.",
        "label": "Current Office Space Under Lease Agreement",
        "terseLabel": "Current office space under lease agreement"
       }
      }
     },
     "localname": "CurrentOfficeSpaceUnderLeaseAgreement",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "xfor_DebtInstrumentPrepaymentPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Prepayment Premium, Percentage",
        "label": "Debt Instrument Prepayment Premium, Percentage",
        "terseLabel": "Debt instrument prepayment premium, percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentage",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "xfor_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denominator",
        "label": "Denominator [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]",
        "label": "Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Assets And Liabilities Measured On Recurring Basis [Table]",
        "label": "Fair Value Assets And Liabilities Measured On Recurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValuesFinancialInstrumentsDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails",
      "http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_FundedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funded",
        "label": "Funded [Member]",
        "terseLabel": "Funded"
       }
      }
     },
     "localname": "FundedMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_GrantAndIncentiveReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant and incentive receivables.",
        "label": "Grant And Incentive Receivables",
        "terseLabel": "Grant receivable"
       }
      }
     },
     "localname": "GrantAndIncentiveReceivables",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_HerculesLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules Loan Agreement [Member]",
        "label": "Hercules Loan Agreement [Member]",
        "terseLabel": "Hercules Loan Agreement"
       }
      }
     },
     "localname": "HerculesLoanAgreementMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LongTermDebtSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_HerculesSecondAmendedLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules Second Amended Loan Agreement",
        "label": "Hercules Second Amended Loan Agreement [Member]",
        "terseLabel": "Hercules Second Amended Loan Agreement"
       }
      }
     },
     "localname": "HerculesSecondAmendedLoanAgreementMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in lease liabilities.",
        "label": "Increase Decrease In Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_IndemnificationAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification Agreements Member.",
        "label": "Indemnification Agreements [Member]",
        "terseLabel": "Indemnification Agreements"
       }
      }
     },
     "localname": "IndemnificationAgreementsMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance costs Related To Sale Of Warrants And Fees Paid For Amendments To Loan And Security Agreement",
        "label": "Issuance costs Related To Sale Of Warrants And Fees Paid For Amendments To Loan And Security Agreement",
        "negatedTerseLabel": "Fees paid to amendment loan and security agreement and issuance costs related to the sale of warrants"
       }
      }
     },
     "localname": "IssuanceCostsRelatedToSaleOfWarrantsAndFeesPaidForAmendmentsToLoanAndSecurityAgreement",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_IssuanceOnAprilSixteenTwoThousandNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on april sixteen two thousand nineteen.",
        "label": "Issuance On April Sixteen Two Thousand Nineteen [Member]",
        "terseLabel": "Issuance On April 16, 2019"
       }
      }
     },
     "localname": "IssuanceOnAprilSixteenTwoThousandNineteenMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnDecember920222Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on December 9 2022 2",
        "label": "Issuance on December 9 2022 2 [Member]",
        "terseLabel": "Issuance on December 9 2022 2"
       }
      }
     },
     "localname": "IssuanceOnDecember920222Member",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnDecember92022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on December 9 2022",
        "label": "Issuance on December 9 2022 [Member]",
        "terseLabel": "Issuance on December 9 2022"
       }
      }
     },
     "localname": "IssuanceOnDecember92022Member",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on december twenty eight two thousand seventeen one.",
        "label": "Issuance On December Twenty Eight Two Thousand Seventeen One [Member]",
        "terseLabel": "Issuance On December 28, 2017 One"
       }
      }
     },
     "localname": "IssuanceOnDecemberTwentyEightTwoThousandSeventeenOneMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnJuly20221Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on July 2022 1",
        "label": "Issuance on July 2022 1 [Member]",
        "terseLabel": "Issuance on July 2022 1"
       }
      }
     },
     "localname": "IssuanceOnJuly20221Member",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnJuly620222Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on July 6 2022 2",
        "label": "Issuance on July 6 2022 2 [Member]",
        "terseLabel": "Issuance on July 6 2022 Two"
       }
      }
     },
     "localname": "IssuanceOnJuly620222Member",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnMarch232021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance On March 23, 2021",
        "label": "Issuance On March 23, 2021 [Member]",
        "terseLabel": "Issuance On March 23, 2021"
       }
      }
     },
     "localname": "IssuanceOnMarch232021Member",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnMarch32022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on March 3 2022 [Member]",
        "label": "Issuance on March 3 2022 [Member]",
        "terseLabel": "Issuance on March 3 2022"
       }
      }
     },
     "localname": "IssuanceOnMarch32022Member",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnMarchThirteenTwoThousandNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on march thirteen two thousand nineteen.",
        "label": "Issuance On March Thirteen Two Thousand Nineteen [Member]",
        "terseLabel": "Issuance On March 13, 2019"
       }
      }
     },
     "localname": "IssuanceOnMarchThirteenTwoThousandNineteenMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnNovemberNineTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on November Nine Two Thousand Twenty One",
        "label": "Issuance on November Nine Two Thousand Twenty One [Member]",
        "terseLabel": "Issuance on November Nine Two Thousand Twenty One"
       }
      }
     },
     "localname": "IssuanceOnNovemberNineTwoThousandTwentyOneMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on November Twenty Nine Two Thousand Nineteen One",
        "label": "Issuance on November Twenty Nine Two Thousand Nineteen One [Member]",
        "terseLabel": "Issuance On November 29, 2019 One"
       }
      }
     },
     "localname": "IssuanceOnNovemberTwentyNineTwoThousandNineteenOneMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnOctoberNineteenTwoThousandEighteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on october nineteen two thousand eighteen.",
        "label": "Issuance On October Nineteen Two Thousand Eighteen [Member]",
        "terseLabel": "Issuance On October 19, 2018"
       }
      }
     },
     "localname": "IssuanceOnOctoberNineteenTwoThousandEighteenMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on october twenty five two thousand sixteen.",
        "label": "Issuance On October Twenty Five Two Thousand Sixteen [Member]",
        "terseLabel": "Issuance On October 25, 2016"
       }
      }
     },
     "localname": "IssuanceOnOctoberTwentyFiveTwoThousandSixteenMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance on september twelve two thousand eighteen one.",
        "label": "Issuance On September Twelve Two Thousand Eighteen One [Member]",
        "terseLabel": "Issuance On September 12, 2018 One"
       }
      }
     },
     "localname": "IssuanceOnSeptemberTwelveTwoThousandEighteenOneMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab Equipment [Member]",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_LegacyWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Warrants",
        "label": "Legacy Warrants [Member]",
        "terseLabel": "Legacy Warrants"
       }
      }
     },
     "localname": "LegacyWarrantsMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_LesseeOperatingLeaseLeaseNotYetCommencedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount",
        "terseLabel": "Lease not yet commenced"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAmount",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Annual Base Rent",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Annual Base Rent",
        "terseLabel": "Annual base rent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRent",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Office Space",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Office Space",
        "terseLabel": "Office space"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedOfficeSpace",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "xfor_LineOfCreditCovenantMinimumCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit, Covenant, Minimum Cash",
        "label": "Line of Credit, Covenant, Minimum Cash",
        "terseLabel": "Line of Credit, Covenant, Minimum Cash"
       }
      }
     },
     "localname": "LineOfCreditCovenantMinimumCash",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail",
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_LongTermDebtAndEOTPayment": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt and end of term payments",
        "label": "Long-term debt and EOT payment",
        "totalLabel": "Principal amount of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndEOTPayment",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtScheduleofFuturePrincipalPaymentsandtheFinalPaymentsDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_LongTermDebtIncludingAccretion": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Including Accretion",
        "label": "Long-Term Debt, Including Accretion",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtIncludingAccretion",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtSummaryofLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_LongTermDebtNonCurrentIncludingAccretion": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt non current including accretion.",
        "label": "Long Term Debt Non Current Including Accretion",
        "terseLabel": "Long-term debt, net of discount and current portion"
       }
      }
     },
     "localname": "LongTermDebtNonCurrentIncludingAccretion",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_MinCashTestDate1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Min Cash Test Date 1",
        "label": "Min Cash Test Date 1 [Member]",
        "terseLabel": "Min Cash Test Date 1"
       }
      }
     },
     "localname": "MinCashTestDate1Member",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_MinCashTestDate2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Min Cash Test Date 2",
        "label": "Min Cash Test Date 2 [Member]",
        "terseLabel": "Min Cash Test Date 2"
       }
      }
     },
     "localname": "MinCashTestDate2Member",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash interest expense.",
        "label": "Non Cash Interest Expense",
        "terseLabel": "Accretion of debt discount"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_NonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash lease expense.",
        "label": "Non Cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NonCashLeaseExpense",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Numerator",
        "label": "Numerator [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_PreFundedWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre Funded Warrant [Member]",
        "label": "Pre Funded Warrant [Member]",
        "terseLabel": "Pre Funded Warrant"
       }
      }
     },
     "localname": "PreFundedWarrantMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail",
      "http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_PrefundedWarrantsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prefunded Warrants",
        "label": "Prefunded Warrants [Axis]",
        "terseLabel": "Prefunded Warrants [Axis]"
       }
      }
     },
     "localname": "PrefundedWarrantsAxis",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_PrefundedWarrantsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prefunded Warrants",
        "label": "Prefunded Warrants [Domain]",
        "terseLabel": "Prefunded Warrants [Domain]"
       }
      }
     },
     "localname": "PrefundedWarrantsDomain",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance or Sale of Equity, Net of Issuance Costs",
        "label": "Proceeds from Issuance or Sale of Equity, Net of Issuance Costs",
        "terseLabel": "Proceeds from sale of shares of common stock, and pre-funded warrants, net of issuance costs (1)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquityNetOfIssuanceCosts",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_Q12022PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Q1 2022 Private Placement",
        "label": "Q1 2022 Private Placement [Member]",
        "terseLabel": "Q1 2022 Private Placement"
       }
      }
     },
     "localname": "Q12022PrivatePlacementMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CommonStockWarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ResearchAndDevelopmentIncentiveProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development incentive program.",
        "label": "Research And Development Incentive Program [Member]",
        "terseLabel": "Research and Development Incentive"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveProgramMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ResearchAndDevelopmentIncentiveReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development incentive receivable.",
        "label": "Research And Development Incentive Receivable",
        "terseLabel": "Research and development incentive receivable"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveReceivable",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_ScheduleOfAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Accounting Policies [Table]",
        "label": "Schedule Of Accounting Policies [Table]",
        "terseLabel": "Schedule Of Accounting Policies [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountingPoliciesTable",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "xfor_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of reconciliation of cash and cash equivalents and restricted cash to cashflows.",
        "label": "Schedule Of Reconciliation Of Cash And Cash Equivalents And Restricted Cash To Cash Flows [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTableTextBlock",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Awards Grant in Period Weighted Average Grant Date Fair Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Awards Grant In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Options granted, weighted average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsGrantInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "xfor_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Forfeiture Rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Forfeiture Rate",
        "terseLabel": "Expected forfeiture rate (in percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationScheduleofAssumptionsUsedinBlackScholesOptionPricingModeltoDetermineGrantdateFairValueofStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "xfor_SoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Software [Member]",
        "label": "Software [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares Warrants Exercised",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Stock Issued During Period Shares Warrants Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFERREDSTOCKREDEEMABLECOMMONSTOCKANDSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "xfor_TemporaryEquityRepurchaseOfConvertiblePreferredStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity Repurchase Of Convertible Preferred Stock",
        "label": "Temporary Equity Repurchase Of Convertible Preferred Stock",
        "negatedTerseLabel": "Deemed dividend on Class B Warrant price reset"
       }
      }
     },
     "localname": "TemporaryEquityRepurchaseOfConvertiblePreferredStock",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xfor_TwoThousandNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_TwoThousandSeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Seventeen Equity Incentive Plan",
        "label": "Two Thousand Seventeen Equity Incentive Plan [Member]",
        "terseLabel": "Two Thousand Seventeen Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenEquityIncentivePlanMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ViennaAustriaLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vienna Austria Lease.",
        "label": "Vienna Austria Lease [Member]",
        "terseLabel": "Vienna Lease"
       }
      }
     },
     "localname": "ViennaAustriaLeaseMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_ViennaLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vienna lease agreement.",
        "label": "Vienna Lease Agreement [Member]",
        "terseLabel": "Vienna Austria Lease"
       }
      }
     },
     "localname": "ViennaLeaseAgreementMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "xfor_WalthamLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Waltham Lease [Member]",
        "label": "Waltham Lease [Member]",
        "terseLabel": "Waltham Lease"
       }
      }
     },
     "localname": "WalthamLeaseMember",
     "nsuri": "http://www.x4pharma.com/20230331",
     "presentation": [
      "http://www.x4pharma.com/role/LeasesAdditionalInformationDetail",
      "http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompensatingBalanceArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.H.3)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13728-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r434": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r435": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r436": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r437": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r438": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r439": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0001628280-23-015763-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-015763-xbrl.zip
M4$L#!!0    ( &Z"I%9IR!5=T@<  !PD   0    97@M,S$Q<3$R,#(S+FAT
M;>U:;6_;.!+^?K^"Z^*Z*> W)4[3.&F ;I+%!MAMLT$6O?MTH"3*(D*)6I*R
MX_OU]PPIV4[LM.[VNN<-KD =29P9#CD/GQE2.OWNXL/Y[3^O+UGN"L6N?_OA
MYZMSUND-!A\/S@>#B]L+]M/M+S^S47\8L5O#2RN=U"57@\'E^P[KY,Y5X\%@
M-IOU9P=];2:#VYL!F1H-E-96]%.7=LY.Z0E^!4_/_G;Z7:_'+G12%Z)T+#&"
M.Y&RVLIRPCZFPMZQ7J^1.M?5W,A)[MC^</^ ?=3F3DYY:'?2*7'6VCD=A/O3
M@>_D--;I_.PTE5,FT[<=R7DZ.HZ/W[P6AV(4Q2+F473 ,W&<T5TB_A7!R0'$
M@XYU<R7>=@I9]G)!_8]'^_VCP\J=S&3J\G$T'/Z]XT7/3C-=.O1GH!\N@YDU
M8T[<NQY7<E*._9 Z0;5M3K329OQBZ/^=4$LOXX54\_'WM[(0EKT7,W:C"UY^
MW[4(0\\*([,@:.6_!7R">_YV%EP^@ATE2]$.(=HGIR_O<QE+QPZB?O30X\V^
M)IA<8;ZYLZ.-SIY?WMQ>_7AU_N[VZL/[)[TMN)D@4DY74*N^_<1N]O6JRZYY
MK3B[X1->XB;O7_2[+!'&R6S.7,[=RQ>';TZV'<9)Q=,4:Z*G1.;&!Z_QQ(=%
MEBE",NY%;_YG0XWZ[2#^_-X?3DLT[!_2-%RQG$\%,V(JQ0QLXG)IV:\U-\"N
MFK,;46GCF"[9C]H4+!KV?F4Z8_\8(4K<%#P1M9,)5[;+KLJDCS@=/X<X[>]<
MG'[@%M%!'(HYNROU3(ET(KHA7"8$*=5PH=3(#.B!RY+Q<L[JTIE:8 3(%3YM
M('J<%;@SDBN6\02/#-,%F,WI(+<F4(+HK>5F3B(%OQ/H=\6FQ;,4SJ!+Y7,.
M^B"!1!KD&(B54(<GJ3!LELLD9[:FGZ7^3!C1&*$!%-(J)"/*:S/I<@S05B+Q
M#I+="J[I%,.<0BUE\7QU&IX+! _^.A 4+),E@DQX60:U"_Q!',UFI5V6&8B$
M4RF$ZT35*6P"."L1[ )TDLBG0MP)L@1EI9:8;.!@'W4-V*>^QNJ21*T@ "!J
MH,5W9[T_";<YRY2>V1:E1DRD=2C0'./T,/@-+[LK8+.M,VO>/A>\C78.;[</
M@O/RQ9O]Z.C$-HAJJ@.B")UE$K=[]I6/W!7C1GB,(.8R5H)BR02 &2MI<](@
ML0(,22Q)]ZFTB=*VAAYQI]$J@*4R.A$I'ENV!VRD F + +B\3W)>3@1[!UJZ
MJ14D4!;WHL,]$;R(#M-P%VXEU8)E "G99\1=*]@-6")?MNXH>]!1AHYHG(\1
M#0E*\%]10!WM[Q!*^>Z@-.H/CV@>+H1%N8]H^:3V>2AU*=\FO+;;JU#BBP5@
MT?044JFN#0R GZ;2>M:#E"B]':J9EWRYRKE&*.YQUN32)5:Z#1]3HP1WPA>K
ME4S])M/6L96IY$;2 &3(^#X+E&2IMI2%_<JT/F5[CL0N%@YA>^F5*M24,D&=
M3]2.87DGEMD<&J$V6"UI<!4+$@3[0E^D7\&V.X7C>'=PW+#M0QAOS5=K:-Z>
MZ;8&-1;"5*:$56YUR8G2N07.J:XD '.3MF "O"6/I9)N3OE]4[>TM#SN/*3"
MJG@@NE*7^LQQWPRHJDT%2%M?CR2)-JEWP%>H$U&BS%! -EI$14N&1%!]!_1B
M:<D*Y/U<\)OL#GY;'KZ<<E5[LJ+HBBQ#B2BGB(O=4.HMJHDMR#?<;J[^/%ZA
M".*TH<:,=>V>]F";], 7TH(*Z.SS>QX6MZ6Y7X(BS 3\\7"C#IX!Y-+=@5Q+
MF2&8ZZ"@C7=3MOF6C<C[ J*D;*Z3I#84^I74N<%JH:W#<SI\A"V;P-#OX32'
M[3VAD@'#H+!'THWCV"\)?V9 QPEEO?#K5? JYW919Q#Y><R+U&<%/Q\-8\^9
MDG="-0<(C^2[7SU%7XGSG=J('>X<SO_P1LP?+:;M*NDN:8I8<Q6I2\8BK'U!
M\;%6Q2Z\XZADG39VD>_] Y@L"NF<$)_(";%&14'MJ81_WL@>\ P*MD3Q^$OU
M=+L(Q>^UA/M^P=5EXH\:7OU_O_7-\OP[A1(-):,$V&B+2YOE1 I H\G5BWW/
M3/ [2KZA9//IUQ>;_L"S/1;Z(L U6Y1PP+"!VG@*12L6S/8D.)L2%2I &"K)
M;J@ +-*_K0O@ [/D!]-DE(T':,\IN^_>AN@=DGAFP!I=1%UXK@-N_/%T [!N
MR(&RG&HU%90(2SYI3ME-0X^BJ)2>"[3.<AT(D3^ +^#V7ZD2^CO^EN\"D^99
MD?W"YVS$NO[-=.NT\[NZQJ48"T*8'CQ3O+)BW%Z<()54BL_'LO3VO=)),[Q8
M.Z>+,;UJGE)*0BW3O(CU$ _-S5OHX^/^T?"(7D0[@_]IVW'SCKKOWU$/7+K>
M-CKJ'^V_?K)YV(^>;/N4V<,AR&VTE=F!=SFXC8FQ%2_?=@XZK4(#Y?%^=<^B
M=GV'>2!T/YZ;,"U_/B3\9P O7XP <?^[X0WP L_-C'QBL$,:ZI83U(#+KX8*
M0Z8C+M:.]:\T>QMF+#9GU]A"2F)SGSW.<RDR=GDODIIVHNQ#J-!(<.\Z'$J
M0];:7VTQ]UO-XWI@!G[1?L&7$QN^$%G1>O212:7#5S;C<,PY%6N?G2S=]W0Q
M7*KP&&.HW;K*9[Y4:7[#=S/^"YZS_P!02P,$%     @ ;H*D5K?YEH_.!P
M$B0  !    !E>"TS,3)Q,3(P,C,N:'1M[5IO;]LV$W__? K.Q=.E@/_;B1LG
M#9 E*19@_;/,0_>\&BCQ9!&A1(VD['B??G>D9#NQT[KKNL<+5J".)-X=C[P?
M?W>D=/K-Y;N+R?_>7['498J]__F['ZXO6*/5Z7P87'0ZEY-+]OWDS0]LV.[V
MV,3PW$HG=<Y5IW/UML$:J7/%N-.9S^?M^:"MS;0SN>F0J6%':6VA+9QHG)W2
M$_P%+L[^<_I-J\4N=5QFD#L6&^ .!"NMS*?L@P![RUJM2NI"%PLCIZEC_6Y_
MP#YH<RMG/+0[Z12<U79..^'^M.,[.8VT6)R="CEC4KQJR#XDH^.CN#\X&HZ&
MT<OC:#0XAL.H!R!&0WXT_+6'3G90/.A8MU#PJI')O)4"]3\>]MNCP\*=S*5P
MZ;C7[?ZWX47/3A.=.^S/H'ZX#&8VC#FX<RVNY#0?^R$U@FK='&NES?A9U_\[
MH996PC.I%N-O)S(#R]["G-WHC.??-BV&H67!R"0(6OD[H$_HGK^=!Y=':$?)
M'.HA]/KD]-5=*B/IV*#7[M_W>+NO,4XNF*_N['"KLQ=7-Y/KU]<7YY/K=V\?
M]3;C9HJ1<KI M>+K3^QV7Z^;[%SPC/W49F^T=3SA31:#<3)9,)=R]_S9X<N3
M7<=P4G A<$&T%"1N/#C")SXF,A<8CW&K]_+_-LY>NQ[$W]_[_6GI==N'- W7
M+.4S8 9F$N9()2Z5EOU8<H/ 50MV X4VCNF<O=8F8[UNZT>F$_;+D+U/N<EX
M#*63,5>VR:[SN(UQ.GX*<>KO79R^XQ:C@W'(%NPVUW,%8@K-$"X3@B0TNI!K
M3 O8 Y<YX_F"E;DS)> (,%'XG('1XRS#.R.Y8@F/\9%A.D-:<SK(;0CD$(.U
MW"Q()..W@/VNV;3X3* SV*7R"0?[((%8&DPP*):C.GHBP+!Y*N.4V9)^5OIS
M,% 9H0%DTBK,1)34YM*E.$!;0.P=)+L%NJ8%#G.&:H)%B_5I>"H0'/QS( @L
MD3D&F?"R"FH3\8?BV&S6VF6>()%PJH/P.E:E0)L(G+4(-A%TDLBGP+@39 G*
M2JTP6<'!/N@:82]\@=4DB5*A  )1(UI\=];[$W.;LD3IN:U1:F JK</JS#%.
M#X/?Z&5S#6RV=F;#VZ>"M^'>X6UR+SC/G[WL]T8GMD)451T01>@DD7A[8%_X
MR%TS;L!C!&,N(P442P8(S$A)FY(&B67(D,22="^DC96V)>H1=QJM E@*HV,0
M^-BR \2&  1; ,#579SR? KL'&GIIE0HT1OP5N_P ((7O4,1[L*MI$(P#R E
M^XRX:PV[ 4ODR\X=)?<Z2K C&N=#1*,$)?@O**!&_3U"*=\?E/;:W1'-PR58
MK/4Q6CZI?1I*3<JW,2_M[BJ4^") 6%0]A52J2X,&D)]FTGK60RG(O1VJF5=\
MN<ZY!A3W.*MRZ0HKS8J/J5$B=Z(O5BLI_ [3EI&50G(C:0 R9'R?!7*R5%K*
MPGYE6I^R/4?B%A8=PKVE5RJPII1QJ3A1.P[+.['*YJ@1:H/UD@:O(B!!9%_4
M!_$%;+M7.([V!\<5V]Z'\<Y\M8'FW9EN9U#C0IA)05CE5N><*)U;Q#G5E01@
M;D0-)H2WY)%4TBTHOV_KEI:6QYV'5%@5]T37ZE*?.>ZJ 16E*1#2UM<C<:R-
M\ [X"G4*.989"I&-+5#0DB$1K+X#>G%IR0+)^ZG@-]X?_-8\?#7CJO1D1=&%
M),$24<XP+G9+J;>L)G8@WW"[O?KS>$5%)$X;:LQ(E^YQ#W9)#WPI#51 )Y_>
M\["H+LW]$H0P$^B/AQMU\ 0@)_8'<C5EAF!N@H(VWE79YENV(N\SB)*RN8[C
MTE#HUU+G%JN9M@Z?T\DCVK(Q&OHMG.:P@T=4$L0P4M@#Z<IQW"^!/S.@XX2\
M7/KU(GB5<KNL,XC\/.9!^*S@YZ-B[ 53\A94=8#P0+[YQ5/TA3C?JXW8X=[A
M_$]OQ/S1HJA727-%4\2:ZTA=,19A[3.*CXTJ=ND=QTK6:6.7^=X_0)-9)IT#
M^$A.B#16%-0N)/KGC1P@GI&"+5$\_J5ZNEZ$\%LIT7V_X,H\]D<-+_[=;WVU
M/'^NL$3#DE$BV&B+2YOE6 )"H\K5RWW/'/@M)=]0LOGTZXM-?^!9'PM]%N"J
M+4HX8-A";5R@HH4ELST*SJI$115$&%:2S5 !6$S_MLP0'SA+?C!51MEZ@/:4
MLOO^;8C.,8DG!EFCB5$'SW6(&W\\70&L&7*@S&=:S8 28<ZGU2F[J>@1LD+I
M!6#K/-6!$/D]^"+<_I(JH;WGK_@N<=(\*[(W?,&&3?]6NO;9^4U=Y5&$ZP%,
M"QU3O+ PKB].,),4BB_&,O?FO=))-;I(.Z>S,;UFGE%&PE*F>@GK$1Z:JS?0
MQ\?M47=$+Z&=P?^B[KAZ/]WV[Z<[3FRV#4?M4?_HT>9NN_=HV\?,'G:1VX8[
MF>UXEX/;.#&VX/FKQJ!1*U1('O>+.]:KEW>8!P+WP[D)T_+W(\)_ O#\V1 1
M[G\?OOU=8KF:CH^,M$OCW'%V*F3YE5#@>.EXB]4#_2=-W</IBLS912HA8:^7
MQ/ N%&,^B4PH6>'FTI#@P?MP&H$R&](O=ICXG29Q,RH=OUP_XWN)+=^%K&D]
M^+2DT.';FG$XWYS!QL<F*_<]4717*CS",91N4^43WZ=4O^%K&?_=SMD?4$L#
M!!0    ( &Z"I%8.>X'KNP0  #T5   0    97@M,S(Q<3$R,#(S+FAT;=U8
M;4_C.!#^?K]BMNA8D)JWIH62=BMQ!71(R\M"$7>?3M/$:7R;QCG;H?1^_8T=
MREM!P*YVN[?]$#7V>&8\\\SCB?OO]DZ&HS]/]R'3TQQ.+W[[>#B$AN-YE^'0
M\_9&>_#[Z.@CM%T_@)'$0G'-18&YY^T?-Z"1:5U&GC>;S=Q9Z HY\49GGE'5
M]G(A%',3G30&?3-"3X;)X)?^.\>!/1%74U9HB"5#S1*H%"\F<)DP]1D<YT9J
M*,JYY)-,0\MOA7 IY&=^A?6\YCIG@X6>OE>_]SUKI#\6R7S03_@5\.1#@_OC
M;LBZ[7$G:.^T6YT8TYVQ'P>8A-UVZ ?COP)RTB/Q>HW2\YQ]:$QYX63,V(^V
M6Z7NS7BBLRCP_5\;5F[03T6AR9BDQ?7?6L>R)I034J9%&86D2+-K[6#.)T5D
MM]>H-2VD8Y$+&:WY]M<S,TZ*4Y[/H_<C/F4*CMD,SL04B_=-12EQ%),\K045
M_Y>1BV3$OLYNW"<].2_88COU'O:O,S[F&L*6&SS<P*M<CRGN3*[(]^'^V>CP
MX'"X.SH\.?Y:YY](X:N4_%TIS=/Y-P]!^\D0G%9254AVM0"=,9#LGXI+9LM*
M,0VID#H#7L!9E3,(0G2"]L9X$T1JQ<]97$FJ9G)H_SK.L)@PV(VUF0YVPG83
M4 &2LH0E3=@P*];7NJV6W[LO;8>"WB9@D1B-AAS(5,<W:H89EA1DV K-V\@4
M* 3=A?V+@IO"/]=4_XI*/6&P0;,7[KD[=,E6L+7=,YHVFXO,K )G\'V,/Y-A
MK'*$,YQ@T833S-USFQ14SE+*&&5/\RL&)VG*8PHR1?6/-@FAG&+,:"[&7#7A
ML(C=!]D;BFF)Q7R1N*;-W&Z"4SAWX4@HC2DNK!SP HN88W[?BM%UHZ0)#.,,
M,B;9> XT3]5@\*0SU,T%+,=,65!E7(&01A@^%V*6LV3"UM<ZW=Y7%]Z;RK?$
M)*&CQLE9JJ-PZTF]]1 GZ!<Z<HS0BE@N<%<'OX>1:G7=C@G#Z"[[!D+!=D_!
MIPHEU7D^AS-6$ND <<"!D%,(?.>3H2&+@Y*<$ E80H$CE 2<,&C:D]UB999Q
M&M(&)L,:23%:.J$!U)J 1NO0D-7=J?4 V8_=N(-X6N4T&I/;N8'GC.OL,6,J
M ]$[ MO 30/6VX'.1G)+G _YK[/3,R6T!+^?'9JM'Q*:O""X36O<Q*0%:65B
MSD"3N"6<ILC-6RF9,A!H&D',<R %Y!;1'DV4! &:,>O36SHDU8EMA"U[DE25
MUP@2A')K73VB2O?[LMP*FI2G87)8P"77!5,*+LTY(=)5'JAU'BNJ'JDH-@2-
M#.D,-=T237 ZG2B?RAYHQ$AXF\0V$4:"<_-ZA/.:M'[^C#Y9>M:/A,6BQGED
M@VFD&H/UM38=!_8)RZV+Z>C\WO)SE7CX\7QZ;7P?=6PO;>0%=*WJ"^;5('GN
M^2@,_[-BHL_8I[OYMX;AF7;]BQJ/5K?[BL[#2GV[H%F-$=?D0?R*,&Z<2DX[
M+VGK2['<7"7!P%LSN2)&^O)X+W\CFI;H;GXWCD55:'.[]S@A;^J5[U_$E:*^
MAHPDR]'D>NEJ;K%J++06T\B_6X)C)?)*+R]YX3;OYEE?+-HKSL%_4$L#!!0
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M>.8K6)EE*&#U(#*%.G<'/3< 8+\LCB9, ,\IYRPWDB$#'V4"B@_,:H-2II?
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M090_ B?, -B.B"S6#* P V0>JT*&$I1E.A&6L80SJ3.62:6PIOX NS)IBR"
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MZ7[;_KT/!J<Y5X2EC2MO.'[ C4]U=/QN_ZRQ]>]6W2?JG&H8^Q$ZNCJ!\9_
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MV]MC2[\_,3)P%3"WO_6\L-H&!(Y)V4;8UM^/?H.603ZB_A"@9[_5\]LDQIL
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MA3P?K;3(8Z[PTZMV1:!2UKWXEAARO,P'^T">EU!S;%:.W;$K*CTFE:;@O1S
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M\9TRQ$T. +FRB4JM!=96:1J/MS64IMC,ANHQ'PZK%'KH$/S0;T6AWD=_W-C
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MH'@^IS:#90*+F*?>[9#R)!:$AVAIB@G76G+A79L(+5+B^,KKL*#H827 CR[
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M<_3!&J(BI18@*61<\AX9RAQB*7+816*$765M0]&Z6EA%H!M+QPK9(EZNQ#^
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MGFK$$U'(2,$0$T9SRIU6G*YM/.>J "]>5A\@)J>2U87(ZJQWLG'2)4V1TB*
MK'J%M $]2B;,C,(19BW7:KRW_\ 2"^L*T)M5,X,UXJ#6RJ:P7/$,!/>T%X]!
M:HM8'/BZLG\ME?T+9JM*N?80<.OGJ)'Q,CJ:",!M+IH48\Y4[3%2QEOO+!-,
M\M)B1>?=/YZYFED)__7"+P2+D@GLD_2<&J,QL&@;G<'4 R:(>YP[5L+_8,(_
MP[4HBUA&(1&1R2.NO4?&:XXT8TK)9$7,A7RRC4G.YVEZYL*_ B3L9Q%B^ HV
M5OS=[(38&;Q"YG2YP&<[QG8,M=#\UH0&AEQC;:ME@;']4?LXBAH[[35]K/7B
M76NLO0A%=V%&J1^ O*\.8_NTV[.]LYW_#IN#L_?Q=-CSQ[8?]]-6MU,,D6O%
MM[V88J\7P\&@Z[]69=<6 M='\WYBQD23L$91 DAS8C4RPB:D! 4]V?OD+5E8
MW;4EUH^?IXP_28:9!0EY1<SN*>FS'F*.&&HQ0THIAH!?YP0U4B-K+-.<.4*S
MAQBM4_%,DTBM /OZ60#BRK&O"_O88-!KNN' @L37!MUL*VOG<K=9YH^[+2#P
M<\:R!]21KS(B/NDX_<\#=?[Y;$V/9!7<_&:;K;Q(#[M;Q1(]F%JA?]A^TU<[
MU.)VJ*_S:0YC,H)&CY34%G:HH)&6WB+C0L0<4#XZ^<+LAG?NQ$N'PF>,A@\8
MGE&AX1.BX0Q?3\PF1IA",,$2<4$#LCPE)&2D/KK -!,%&E*Z@#I4-Q:DRI;Z
MP/YZDV$+S6_C9X\>@?+UK\SI//%_:HI_&GNU_K'MQ9N0_9$UR64,*0[/0[,U
M',0P6;/0\SN%(S%8FZ$[S&]^]KK +7N_PMO?V]@[R$MKL4H!O787W+&]#HQ;
M?_S>T5XWVLYPM9W]>CL[N:IXBS0\68]$\!1Q(V$[R_')0E!J#3:1X_3S0XFG
M7@?;)4I5*^&>*R$&QE*D$5%#<J@J3\A901&-CG,2-$LVK&W@]2O"F18:O/HS
MO'QBFV6UYU5[WE58=T_5K\*Z!\>ZV8@K;TDD,6,=QKERAT;:LYRAD\.V)7PP
M1MQIUWNTE5"QGT6L V.H4,$3)(BUL Y<0C8;.2-)U%#+DD@N[WEJ/N[NI>QY
MJZ39W\=5?074^H_%'S'4+/3 'L52M>_G;-O3ZGRM.QST!Z# 0Q]NI]/?P1VV
M7'.S"SB/P_7+>T5]9J_=#LII>.B(P?'L;Y:3WQBV7>SMIV(WZ.]?3'EE U[P
MMC%?^,L8 I/K"%(<P[9A+$8F2(DP=5S@J)5/:EG7RXA"SBV;:L4\Y(J)R0>'
MDT=12H&XUPI9'C@*DH+.C35/,1?BX*)NI/HUU[A;,LX%0O:R'#=4&]6]-ZJ%
MA\M6P/.4P#.;[U?#=B0812R'?("&DX%')013;'.</+.WWZH>:\54U.;QUXO5
M/GD6-!)*PT:EDT&6.8NDHY;$0+QSH)\Q5E>LVJ>6_EC\]^*\=ZSF3:FX;=L[
M:G9*OX(9#U8?<]*GT=:U\;^N]_O&96VQ>DSUF$=ZS ,PI^*)KYH#>)O_.9>B
M13;SXUBS/J<1L)TS$/%:ISN ]Q4N%9U:$]IZU+.MVJGM#;(=9G <^Q&V3SL,
MS6RI@7TSY)0AQ:?">\?FKU.S8SN^"3?"UC:(;>AS?_W:T1HU2%'HPVFWW\S0
M^JH76T4UK]??FV%P/&9^4W>-X!-?W&(=M  XV+6W3$^+>-QI^>DDZ!ESU=2_
MN?7%1L^(!8W96FIBY(GEE"*11Q)Q,EA;3;Y0O3:^Z;AW8>H[BLCUHOV*;((.
MOK*M[_:LO_;[Y7&!09DP; U-OFX 'W_ U)4#]A]>>_O7YON]S:V=#X>[6YM_
M']1KNXVMZY?8U,S+)YGXJ_NQM=_8WFD<[&S7X-/!_M^[VYN'\,?!(?QG;Z=Q
M>%#;?P-_[6_]W[_V_][>>7]0V#O5Z]K.NP^[AY]6K;N_[78 0;I#>$;HUVOQ
MAX_9Z:]TX&H#[QCT_[5R??HP!L-_727%-Q">7^PE"[RM](Z;X&=!,F&<6O:T
M'U^-/[P>LZUFI^AM<=/KT>B/0%?,Q_P4[RM_'L&'P>M4F(P@HS..T8M'X+)>
M@,L,9RY_8V8=2W7MSWB=7/O;SQZKUK6A=WKJSW^CRJQ,6YE9?%OU.B:KTU:F
M5J6M9IVQN[;G\<=5BYL]=73J.4/^B"X4RZOUOU^JG^9"A;UI>,W\!O(X-D[U
MJUVEK#I<GG<6L0_7)HB  >IUO\\:BF^BJU]QVS,9N$UH:U8&;*O8'M_:9D"[
MG>+SECW-:E$UG+<93N^'[6&K4.K*4I];TQGGBG']^V=9YZI!_>F@%@.X'5/3
M-Z]/!',+('S6XU947BM&[& VK$.]+KXOLSY<&LAKMAMZG^V&/;>1+4\B;K
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M,Q$%(C$#IK$!Z1 )(BY@$0! M?)K&X+4I5IPEK@G <TJDO^%7UDM@!=^9;4
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M5< 4 76.V>0?D&-*YXPO)!HMK7<T2_X,,-4NNYW?ZJA_96OQW/(TGSL%@RM
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M7U<&BB<1ROW!<>R]+%O$([.+RT!4C#<H.[Y0=K*_?Z7JW,&K_W!S<)$T_8@
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M8+7ZW9H?]GKP1'AA[/1@:'.[LJX'DW":[4WYW78T,O2*D1DUHWC=9*Y^ML@
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M3@(;CTW@1$>5_5-7P9@Y37:F0G+&JWI)CN9FX7/ZG&K:PC=J=6T4J9WIYE3
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MF%Z5-?.>$>S9NS]]CW)6[/*6K/+J3F <U34_-;7EX&>'YMF@^?WPT6:OZVM
MOSV@+SJ0,98D-\%6@>I<*86TU18%$XE@1EB6BP?"QZLU(?R4=CP-NVF-C34V
M/@;3G<7&VOJZ,N"<9\(R6 ISI)&">4-Y^H ).X&HQQH05#M8WZI#I54Y^#TF
M=)9$^=]E1/_MTE'(!\A;=FT1=-"V;OQ^6N5Q"D8[*0]9I>DMB[I5U>I;51[
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MSF)1V&YW9-OM\TFH5NJ-^L/CXG\CVQ_&_D8!3^KT^O!Y/_YO! ^#*\^.8[>
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M08B"6".Y(I%PS:7#T2:O*(;=4"(:7^/'):[D('P#L#LL3R7'4_G^DE_<S&%
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M=.Y1].ZT5]LLMK*[?.4, 8SW'VJF<7#EC 8L4<R)Y_XY4)&IV$Q<^J=<Z;P
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M,KYXJ?"&$6;MJQ&NO()!#5+KU+?;%&[Q1!,9N3;$\,2I"T'D6$]X$#;.^'L
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MQY="DSTL%9DX%$-X3BO ,_.B4#41&G1VW/+'^;Y^'%0%T8IQB:RB<UDG;:.
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M%$AV].<Z(NTX0XX#H=$\I-+1GU_NI;ZC<\_>R#-=[;_V<J7*&Q;=J/=9S]C
M,Q&)OZ<24>^T;@U+YPM4('J-:4P614YM3I 3D5%$ Q6PC"AA Q'ZQ4M#:AM/
MC3V_K(VGQIZ58,\\)=+*<AN,0HZH@#BA <%:PV%#0J01%E8?Y7(>$+*Y>'K\
MBX+/KV/G":U<P[,;BO-6;(=[W7)^#X&7C-^S1. GPOZVQU)1X>\/$C#7N'P#
M7&Z^6N"$3OAH7&1(V>003]@@:WE$T;. M=54)K^R#,S+ >KI(7,-2K\L+:Q!
MZ1Y :9XLID"%YU&B&"E01.<)<BYP)+#CPN2DKM34H'0[NKA^&57OFN]C+M/'
M9?Z/*EJ]BDVZGU#"Z^XIE9P1*YVPEIH8>6)*"T"R2").)J^DY#,W+V9N^NX3
MZR]_ZLO))([5A>?@J-/>H$RQ\7L_MLO@_W%,U'BQFKEK'%&%+V^Q;M!KCX;7
MWS(C+40LB_-X>(@HHQ6)N#HVLS^/^Y>A+D<1N7ZT7Y!-T-C?;?O,G@]>_/MJ
M'Z&#XX<K4(EKQ^+A^[X\8/__>/'7?[?>-[9>[7S<WWVU]?;#1K';?+5YK;2L
M2\.;L'Q^*/;WBE=[S>V=YH>=[?S;A[VWN]M;^_#'Z]WF5O/5[M;;XL,^?-#8
M:>Y_6/M._?:Q:T>A!13J7\M$<JK1#]TNL5GQA<6?]QQR^U<_1\</S_]J6^"=
MW;#SOU'K-'/0[=; MWLY3'I= FKW/HQI9*=YW-S?$@>?_N[LO?E(@!JRP^TO
M</_KD\,W!^2P<W#>//FC<[A_W)X/J#V@0 F!:AY^.N"'^W\#-0Q?]O;;[8-/
MS2^')W]W#D]V:>/-87OOS=^I<=(X_TR)I)0%@XR*"G')%#)1Y=J?$2OBF/1I
M'.L :WX,6YF&2ZH\E7G$*>>,)&TPYU):"8]R0![GPV__>K_WU\[[_8-BJ[E=
M[+S[N/M75J:-HKFSO\@S;KP S5&1:NY^V+3Q0Q])Z'YA4;OXC'VBC#&/<! )
M<4$%[#<2+[V@HPCPI5R,W'Z,Y7PR?64VC3B9NXVB&\<YH\I<'^,,$M,$!=/,
M! \<;*XW!=-W"C;7F]+<0Z0U/);=[;'?_T[PN]WYP\;>+#3^AF'ACYIA]F81
MR+^5^4!Z(WA$N)F_Y_.(O*Z#TY]&</JCFGO>1CN(Q[UV*%J=TW[O:Y5F:675
M>G^A?-2_3&D5S9B2PO*$7> T)B<TSAG?(W%22W'CM/_7TL8W_=[@,G7B8^>%
MOB-YK,S=G>:7QLG11>/BS\[!I\;9P<7[D^;%EFCL[WQK7.SRO3>[O 'DL?GF
MSR_SYNX#^NY\;[MQT>@<'A]<_''2?--@C>TOW^#>"W@F/S@Y.F]^.L 'G?<Y
M F:^1@IP'>. @B*/J8>=CD[(<1P0XYHE3B4&(O#B):7ZO@MV/\'<^S6._0HX
M)CG1)L+&ED; +VJ-E"DH2Y,BE@5GEB<QJ''L?G%LOM2(HA2VS9HA3+,O ?<!
M.<4H2$]R1'HF&'5/!\>>O>/]ZU$?-&Z4LX1V0Y%:W_+OUP?\_&*^JXL@1%@N
MV*%%#-YQ%JWV3%$A.>/4<ZK<JLC44ZC \200JK58C2YY8TSD*$AC<S4Z8%K!
M822QP8II#1.8O5 WJ%I,<UU7FW\VFLRB\$)(3[(1GDGF"%;.@&Q0YJS49%5T
MHM;DE6GR/-<(6&LKG$1& L/@+@5D 9F1=]K;9+!+-)6:+'^:;:Q0DY^]2W?V
MM!L-8__R<.).?.(9.CTNHI#B #M,!2>LYD9+1S'A AA$9"$!#-7&F8<'FO,%
MRA!A!@3((2(T!ZY(K)'!^900B(,.$4B@E+EH%UL//\3:/_D^5#5*KPRC01"A
M.*/>*$4"QHP$:PR(0&U_> Q57; _!!Z53A%%D565>8ZT=@X1FV1.(\N$-^NF
MJL_>RO"AEX9GMG]]TL9??C=BN*6.4\"5A+GPL#.5EA&N%3P)!^-K'O#@X-)\
MM< #DF:2".^0$$ &N,<>.9(<2DX+'B25T>H7+VEM-WC&FDIHKN*14M3!<AS@
M5RN P>/$ Y;<7Y-+N=;4^]74>1J@89TGP8%^2B\05\(B%T!=4_)>8NXI$V'-
M-/79VP7>6E>;!&X ,,IK0H6QF"8.=$ K(3AWA!@=.3:BI@(/#S"+_AHV>],X
MP9$1RB/N7$3.)XQ8B(&&! 0AI1<O)5]5$>_:)+"&JHJEI=YB9I0&KAZ\<2$'
M*BL>?9!$URX)CZ*J\UP .ZMLL@0EG1BHJK'(TF204%H[[D.TSH.JLI_.>+5&
M)H&?X>_7NE3<R+'J22NTYIAZ4&5"\S&_H38) WK-$E6:8LOKX_TUT_;%X_T4
M,(U$.80]S:G$ \Z.E!)%BIVV*F(;&##_#<;)BLC_C?7E">WA?V$,(+"B4Q,(
MK.R!"YN =F,",,"#5;!8N-HQ8.TP8'[%A]4>)^D-L'%' 0-<0IHRB>!SZPRW
ML$Y7&,!^FIX_% 8\?^M ' Q^+[:\'W7&-;%#+A[M6U7\;%G,O-.#QEZ4'_QB
M]H/?'H'$S,S%]LQ4P._M6&91ZH:MF1FY%N]JJ%L9U"VZ)DA&/,4:L(TJ@G@,
M$3EK$TI"D6 T-@J7/E!,B 6H6PBNK(T03U'?5T58:GU?0WV?IS8DP912;A&1
M@2'.F )JDS2*,? D8>IU"*7/XY((BT?1]U5;,F[(Q,9)"ABT.O1&.>7!1&E_
M;FOSA./&5C] ZXVAZV3W:<9AC7RW0+Z]1><+3T7@QC&4=#[2I1@X3W0&$:TQ
M-[ ()IDK%VBYVBW="O3DD>T^-6+6B/GTK&0E8M9$<F5P.D\D'=?8&A:0,3X7
M@HD.61<Q(D1Q(6C0I2\;V2!X54XRCP^H-\@ANSR?IYQF?WWH;%_;WS."%?%;
MSFD=BS*=:2Z6V2M.EZ8'*\[LH/C'+?3[3GGFOJ?H-]E2/FN%OWMZNGU_]IF[
MI'QR DFJ\K&6,$CKZ!&Q2@7F,=-<@+K2Q<HITV1:I43<1@:2<D%&QFWRBGN?
M0Y04M1YTF1(IHJ_2L4]D@-8R<*\RP#XGDAA70J*D*.S]A7;(81J03=$8+'R*
MW(,,L,78ADL9@,$M$P,.C_LQ%AV8[N-!$;L!P*-,0%9!^R0+62DR>6XW &(&
M.?M]ZVMLG\^ESUV>=_MF^; %??%]Z"7T ;!W>5I8^=!I8;_![&0S7'\4PTX%
M[8,U2<I)&I,R IV/%X>=QEGCXN]6DQZ<-?;?T>9):#7HSD4SI_D_.1)->MAJ
M;.^<S4O\X7ZS<W"Q=='\M,L.3[:^-;</:)/N7ASL-]C!Q1%0DR_LL+,+S_PC
M-2]V/\/66^98*]CC18TX4Q(Y"U(/PJ2(H][ !?/I7[VRD3JAI<KQ/@FV\BYR
M+;B@46@3%W)X;KUZ]?[CSG:Q\W]_Y33+'WXBY^OWN,/2?+ _;.M]IX+]X(]C
M&+7C7AI+W=N6=;G@60L$+].D7U?ZMCX;ZGGP42&,+2RY 99<9R1!QC, 6V-B
ML O)A!^%(X[G;L(&!VN8!M9L$DKOF ;64',?F54%D?>1!I:I^VFLKM/ _EII
M8,L%IDX%>X-4L).1>I1TL(_G,3.%_<YINW<.;-[/E+@JF;N+W9A:=7[8.J_B
M YQ][8S%\'UEBYIADJ]&_?Y3\0NX*],<FW/?D3UXWM[^N_.]-^]8\Z3\GP.K
MY(U/S5;SXG4+V.5QXV+G8MZ<>[C]41SN;XGF]BX_W/:T6?Y_W#DX.?IV0'=9
MX]/NM\:;G8O&?G-9_EC#DW F>*2,"X@G!3PU<(:T85PF'[3T,;L\JI5%)#V)
M#+*W<1/Z"=1[T@"PJJ.<&@ >$@#FSW- V[73#"/&E$&<)XHT$0P9%X.'^>/2
MJ!<OY88P3P, GGU2E,M=.U#KKFUG"VLLR7^F;B%^C>U>=78SV=?7Z5/NB\-<
M-;Q6\_%^/!U;W;!].1D3LVR-92O#LL48+A6(\@*PC'/B$ ]4(BVH 3&+RI!
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M_&>--BFUZ6'-:,--5+A6U=NHZCQEX"DHF;Q"B0>#@#XH9!T7B"4C+<68>^&
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MSX-XCKS!9TIY]5Q\*^/C6P(1CB));RGQG"O*70#+C 4=O#+!17HCAUY-A.^
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MO.H[#A94U9!U?LA5J]SQ%W/!K^XA;/)X]*/=ZQ[ECUS/\5X5\;SO:$H8^1O
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M*EOUZXWK^&P>C[YN'V6Q/(J5O);3$-C8/]K=8;]Q/'0=L $K.,AF&R")[52
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M>+J8W7JK2,8CPWD B HZ&BP,<3PQF8@4-;M=)6R:9;>&&*F2#4ACIG,C0HO
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M+A8 Q!Y0F;,7)QS-$Q".J(6T5#DD"&6@S"T#*U E9$D T8B<B)1K7+'Y6$F
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M:J+Z?W1S &FG/3BYBZ/JV9MV*^V+&B_F/Y.UK(V[FT+>N)G<%.3A0'+1-(;
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M\O[#ZX_G^,&GN]RR>S@B>N)/\1+H'6[FX^&Q]"G:AJ X98T;4Y.J;K4#5J2
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MV\:6(&Q1"G)N5\)?%L%<>0M8=1;IARW@+[FW@@7UO=L7=J-RY5W!7@C EAY
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MWGL%?YY/85_FLI !V'+YX1T(@@Q"1I6MZ]?+[ZVM/[,QAY878(*@OC4*6(#
M+PH;8H#?_7!RW!]:43A5,S:<Y4<:UWA'Q.$]N*%#!(K]F\K#$KGD-XQ%[*'1
M0JM\Y%M):Z@*_'&#T8(.8X9H]W..7"-_?E04]8[X?,E%U+$>QS=U#)P6@E1-
M'?,E,7.T?XJ9O4LE5R/!5>3LE]9_0'81LN_%?Y%UM/$[GW-0EG1Q>T-Z!S^Y
MJ#JP?GT'CEO-*MBJ;.> <GU Y+WM>G(1?2.@B_H?)3BVHU-,$0PGM$Z,YJ,-
M0D)(OY05<CRG5 ?]KWO\'W)U'6=EV_&SR=)V:1:8<XHD'Q-XP!MSCO&A&!F/
M^L<5T\3FWS@KU\M26.8B6,V=-**6Q>_#98;BDS,@1[Y^5^1=93>H(4!>SAH-
M&1!6<\Q:PB;9D-GX/CUS ]PO/BXX),WV_.Z3!F>>(YM"1$H4T7:-$61MMY:C
M8RXM2FNIY6J.J22$?P<^8$9D.C=EA+Y)^CZ$H;^C&?)KAOM]F:5 T70?;))/
M,<77*3T<J@6/9]#DAW\J.4(/_GH\BT/4SF*6P#8D28D43M';0."#,"BNO%F2
MW4@8OVK(]$V %-.C*[4D[0VL$\/Y_9,$Q IO )90\(-A*5%&WY:9!,"WG )?
M8K;O6N%,@:I15'D&WMB*I47W"1.?"58QT \:^,YG(QXW0TX0_@%SH>!.43J>
M2C5^F(S[1]:"T/D.O(-Y'-+$"/S=-$@HB7$#;/[#L.\$S_1A!' ,L!,\7;Y1
M^)@V840.E!0EP#V7%&WA.%8@" (RA'"&PKP$6843=<A6PO6@T!JUN8&V? 6]
MQ:'U=\I%QF)&IO;HT3>&N'# 9L0/$/H7JJ&0L@9=0\%S/#"+"P3"5QHWD]1?
M"LHV8@&' S583?GNA"'X(XLRY AT^&C$4&8WS9.&>-NT6Y/"1H\:%EK,,"0;
M%_;(I^HR3E-D:%UT$^>@%ZLU-T?D&9(@0Z9CN6L49BA%*O0J]N*5%L#(D;!@
M5]YAYFA?[,J-TN%MD(+=0=NXHL(7GI<2,;.A&H8M+9&>6-&'=S2F$2E3/=Q#
MUR)A@"&3"2!4IG29<9B7!*%)*0+K]+BPBK76+,-J!%V7Y*0#=2U#A#8Z!2FH
M;I#GMA@F(T.#ZV=,TG)MQEI-X: 2U.-FJL*+&)&93S$_45S 9=E0FVUL&8&\
MU'P*2\]QTM7O*5P19GF<]))PH0/<*1HF S^6 ZO,4+%OUBRV_DY<#]Z8]47S
M4HA#IR:6H>T/%#WS*>QWJ2NHV(\W?J'/>4XY5/H'[C^!2Y1'/1ZN9:ZJ&=_#
MD[QP@DL\+;FP!+VX2R$'R4IZ#)J:P"^Y$W*BL2]P*4.\.#%2 N3)Q8Q&X.4X
MSD[?^FQ*=]X5%&:?0/"0J12I)%CY+-DH0Z(PQI6B BFH]"KG"SK3TKMY%!G0
MYS(/YH6OE8NWR/(E<&B<H6Z"6T8GF%=4&A^KFL%JG#H_6F,0@58J,#\2P%F'
M?%^F6(6GV%.E"AX\[ES'RZ;NYLU]LL1^+.>N67CLBX3;T41[B5KC#5HPVU3-
MG#Q:">QG*@\U\I$GV91SC!/]$PTA;;^@,09*&ZPS2GF2)"2!(SE"EHC(<<#Y
M6$OZD][WPT['&0[ )N%\T:[C<4Y.^J/)W::M;!SB<M0?';=_?-<A+J/^<#SY
M_HL=]\^&1UL]]ELG=TR>VN2.K0>I=#-/NIDG#W"DH^_*=%M<UX,[I VS+G;'
M,IG-!K-P5RP3.,2'5_RT=QP.B*&7[2$(UC?XR%UX6^YT!YSUABT^4CO=EGM[
M/CKR!Z/!#BA_C6QZOT 2U5=NC^O?,=P^,MS0GYP</PK#/1" XN/)Y',J/.'8
M!D51,;(5@_>4BK#&?\4_DTM62GN9#:5;_^RIX"INRY5C?S@X>Q+XW4^30"-_
M,-X5+O@[$NG)6W,,O%K4Q &USW&V7_IY[RH:MM7%^\=Y)\.=8:KWSD1ZXB1Z
M/AX\C@7[74&_1OW1\3Z+B'?W;3=L'1<X%+8<G?C'P]%=(7RVBH\<BLGQ#:@\
M^TC8@3\:[3XJZ7XQ9KZ3C7*@PHAA);Z#,-I#3-!MV7('CGP,/-#O8:,<+G%&
M.RB"[TB=OZ:)\ES$PH^VD'6ZLM4C?^% Q\@?CG9'%3Q0J^, "73D3XX/*M#1
M+JKV7ER\EHHG!.P*>?(,%?2&$@S)4I(F_GKAK6XM< IL_V+&QG$'$;_G%'I^
M\CCVX%_.XM"@@^B&W+.\>)K>])E_/-DA(_@@WG07(_E&J@Z/_?')G?&K]R9&
M<J<)0X^8Q]E:_OA.QPGBH%'][;?HBR=76]&PQ?V^<\/1V!^,=AVFL'^&6<=U
MA\1U9U0[\7A,]^2K>G:1Z0H[FG:6YD]GL,)WOX]/8++"EF<R.?*/QKO.%7LZ
MLQ6ZR]%=C@U50*?^Z='1X5V.YA$;>LE.!Z$%U^]0*V]M>AR='@YJY49:W\/!
MT1.W[W-];XJ(SFUSZ*-BD;QB/,'MYP7XVY54,_+&Z,0"U_@.HAJ/%B&<, U8
M8HJV"2KCR(7*, B#V$:;9BD;AX(5QGA %E6,L4.< D_;FM]:Y$G/&/1/+$K(
MNRSM55]C%Q\S($/!DTHXDX(=\;?-G+%C8GR/D--ZTX"!%.;X#FE;Y_?YN$]>
M04+15CUL@8!?]$=F!HE\VK]G3FKE]A9LTL=D[*T*^'8;]C$2IA[T1SLRM;#8
M:+0;6SM?_P:V'CMLO=6AV'$\T:[2X7N,<UJ?HM.*#V$  P]PJ,Z%J>$Z6%W@
MS(ZYM3Q-)FVEC(,@[$"X+$O@:N13(\+702SVG99O3*W-P=*R0:\W51")"'11
M/!$(*&9RV\L,HF>F4&T&,0D"@ZRE)2Y!",XUOJ(@%QJ JW8L+E_TK]X="+YE
M8GX8(-J7Q;V'5_2R68_  P4;JN_M>C0CYVAN*[#BXSEVQ7S;\<"W)BY ?W44
M2["."UN'"1)4,M O54FMAZ:ET=98R57 :U!J08X(4[30&9PP;A=NZ%EE[-OZ
MV1;>/(A49;C"!DI^PU2HLT>="K6K<!#HSX^,(T4'M2=88W]8E#=BIEL ^! -
MBV:5@8BPV%<6,IF@6_E2$GCK&IS;WS2^)MR2-".XT6EV#=;N='ODNBHRW8W&
MG@)Y=1UGB<'4"JJ0= 9Y3A!XVI#^JI"PMX+343BCZ2@(4\M WZF6Q<CS6T6=
MAB!###$'4^\V##3!K3HXO#&1S,:TF*I5ANC5B.0VQT_2S-C >K:>\(H+B<BH
ME0Z G,!8XO>-?>VB>2VSBLD)_YXRMS$[D*V=,GJ>%?4B)8%P09[0Y$_$2HNN
M"<7.'6+)T+3PS7A!6'DAW$,,87DX)B\Q$EDCG(4(6!C14$E8BV/M]KU?5!B4
MA9DTDY9SE2.^;AX77S2^G<#6DC*"<\O@_N!+:2/:CO8K1C1/'*CCIZ%& HTQ
M!^534L2M88'^.CP<VGTX@H86J+["<3G# W&;PD::GP7P_#W.V+G*\B4#_9(C
MDZ$^P[\U_83O1:06E ,2]XAD@:&D Z#*] GT2%-8RAP12V>PO(S@2;5)\=,V
MIN<)1@(Y7-G#>/9/DX$.U\6(CKC\J?<@8PF;93K!*Y\\XE"2ZMD,CW"TU;.?
M22V$<$U]Y-LI@2RG<)&"I;C1&8B] FBQ1*# 2U^/(XH4TA'G:>;R5<*:!>4A
M()B(-%CXVHH$\C)"?>V22=S$_'.Q!'J+.5J1([G@/S:R>^7&X\\^$##^J/8Z
M9K#K+(^_!O@"$V4 QEQJ4Q6$02R<#%<S!%D-3P!+LUSF<$KX9Q"MI%^*%QU7
MWB-79N429YIJSA-14A"1<G4)U 8A@>&=ZUC=(*?AH*UKDMRY*+A ;!-$Q55J
M6?V9([30RYDF<7'%'@2^_<VK<RV!@;M(C.)0!.!Y]RE!N03I*'JGZ@#9JZ#9
M#!_)F)C;/9'1,S2.+B,:@SJ%'\UYLEG]LC2H*G+BX8F%?83%2V;]VW'Q?7%Q
M#?57(%H=.TTX=@,!.^+<IXC1XF0&-$+=ADBS*BR7]!<<XBR8_"FB)".*+M4I
M(J$"O-R@7H)X[EK4&/FG<1$E&V9P78'VE")EE.W</*%!C5D!@KJ4 +;77[3Q
M%?J.$Y0ZN,$,"4V1BU]5^L_5O!H%(.4'IIPQ=N4GSAP+TH+RVXX9'TA2: AW
MG]&4(PFP(S]ZQF#3-&MF" /(7-=+FN<M>S<_ +%LRQI;"C?&Z0SY6 :=B(Z=
MDE.[9/T)[BD;9>CMR+STDA7SEF)NW_&1-TT6VI,HT@=.419*>>_ &/%.]97'
M$(_UU'=$C@]X^ G8_V$>+[1/NBF>>-=PXF2XOT/F7Z*)AH[%>1BB&XVWXP,<
M7AC+%)!/SIB0_RBC2QM[>2VN^)YC:K_?D3<"\LT4IQAQY 8<3![QM _4(3RI
M!&/7\(E:4)#1GMT"!$H8+YS@WN_@A2J<-HQ'Q3.)^/&!RW,[K9!<T82^@#.#
MDPP'$11V; A'3^?!%V7B)?RK/PT!2<$*2+W,M@!!BWNA: H/7:&LK^^F?,5M
M9DM"0EV^2078Q? 0-SH2DJW-^6-)O^ZP=YJO,J4!]1AL,YN#@[R*"W \B)>[
M<JM-Y59G!UUN]7B"!/D]CQ4( M_[DF8W*<9;TD@NP[6YFM=!3E/)V)*6&*"Q
M:'5N <4,QA$S#FW:J5MA#-IGCD-80KQ;?#E-W(D#\.0ZXR=P%6)69W#;4?[8
M&\X#6^B)09ZO\$.J'G*N]MJ%9*F0\R@G6%V$N43P[@+.EU#9">VJ@.M'(76X
MC@H?2\/%*U>2S#T,K"_8KJ(@JHEST\(Y+ANPP:8WB<F%**8QZ7H>:^'*,3XI
M_H;(%ON.W!FGMB^S*KYW'AT)H+C<(44I#W<)A60]<:$5NZN<C&(OK,#741VJ
MEN'7F@&@IC I*,@,UMKJ/$V19!_I&?=4%3;:ZOP>M0CB(C5),M^:IR/)GQ1J
M)ZUN)< 57CP@EXPY_*A'LYY'&9D;KJF69VF&21EZADP^Y((O=5.U2]POTD6Q
M_,(CP-J^NW.1UMT-Y:/]-90_S<'F P(QS\<T\6^^P/@&6G;EGAO!?[#"";Q"
MMI&;;82R#3UT_=/'EV: J3-9&]SAC^ 4></1M*<YW'NMD3[.0\[S70 W>\/!
M\]F/SX<_XK<^<D08+=U/O?\D?8$"?HFV*24SEV!HD+4HXS#ER06(KIIY&UP'
M<:+S@&W[T&'D(N,$'^S@>?PC":WKS"25L<)5_EHI5+E2">T4/P?C&-0BYTD+
MMY)LY,Y;]^:@PW$,F">C]!*< VU&/D7!2LM,J5F8Q;@UF^S/87VRP("EJIZ
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MB83F5C&<[8 0'KB^7":&A]V1(=KTCI>\2&&S%+N>$@?IR+;_?&X[)LG;:*N
MDO,18DGPQRRMV<'F%5.;H"8N+22!=9/QJ?>A 5MY0W:Z$;L/^J_-OUV;C#)'
M::&#FH85I"):<X =D;V2X6)3/8>^[WU2BK4N;0#;RCFHZX'R0[Q[T7WWG'/<
M'H/'>.,T*)M<1P%-07J@/:4GT^+Y2!0%^3>!2RB$03O1F-FN0?B80 -Z5 9A
MG!R$H6\Q7*;*:!'V\-9C4"0&,,5E9B9D%;0!*EYB,W6)8GA3W+'!,'1"D%)W
MZ'1V.'<,A3C7M3JOSKRRN$/@$CFG#1VK-4[A1C5I(OLMC9+D3*^G81M\:]K=
MVA?9>VA=CIY(?JWJSCZ=*&9M)8<@[;TN:;6WXTOLO4IU[4/IC? 8)8P'U="A
M)1F) =%@!79J#P<TV"2"ZY\U]G$ZRM0T9]=SV2V'UO?.#=Q080"'F V<L &\
M#U$_;L>+TL5!# 7EFW :1<NNL@0[O.3Q34E&AN!=AQ?3[O]6-2R/FW7D;*J^
M1XXYU]Z9N:G^YNRX?[Q6@3/FNI.N!F=)/WGV,[6Z8Q%]5HLPV?(/03O86-#1
M6L9!,AE$4I G,19L$%@0#5XA\7*#0OE&TQP1J;F#P)6W)O)'A2Q.EP$^A<T8
M^RQ73[R QW2L<V^L S9LG,(E1<?23JE&=S&MMX)0_!T?QB.Z'+0*#HDU1WMO
MU!J3$+LZTKJ6X"-A#4+^>EL(\,<3>.\M5H V=$3D2=AM"GN'FRD3CW  5 \/
MTW?Q!/"TYV0+<#F%$^.'!X#'B"866;*=(+WGV]#0\ZXM)+2); LY]YG*\%E?
M4/C=SO(J+I=;P. @2F[;%*];[+:1U7>K0>[88UOV:,P14B+!R#O;&B!9P:(C
MU,,3ZOL4]CLZBA-$&LNI(]_]DD^"6%K4BDM7+'?O[:>(LU++ZL^LEK;W5<]P
M4]Z;5^?:B<3!Z 3]"48S"/E*5KY<7F6Y>*DV,4]I,5L<+:$]?*1 B6SU1 [G
MZT"UM)FHG"8MDP%?UP[-%EBJ*Q%UX:'!<>?<=,?']\?'C]9#WY%G:W4N(@73
MOFC08?"&IF)1M0>URVKIH[!T-=0QXT5 #?!ZL(*IDFYNI16_B?(#Y@D;<8S0
M@*2PVOJ+-KY"WW/*S8BNBCC$]JM*_[F:2[-:P%!\A$[$[AW' [0+:&JP.'>N
M?YOE[M3U2O%-QZH/)DF^9W-W77/I&V&9O_D!45PLRAK3"J\BUF$LM2=&"T^I
MB&8I4U(MV[@3/CHQ^)ABL(;85L$\LP&:'DW"KN& VG ]BPL!3]:C(#N"/J*P
MZ-!A.NZZ)ZO)L!9A =^*@4NM0YK &U!XU^!O-U1$>PR+2RKF1J85@L.?D<]3
M!]EU9%&ARYNRF[1CEWL.J3X"G%!78OGLY_'H<$HLNQOWO04TWS>Z/:0X;6EX
MIHL,!#!77T7E7,9-X/2=N+Q7VXU*;LBKLT9<'0#%*9^IP9Z0D:<BGDYC(% Z
MDMT;R616FE24I>&&(BU?AUS$0*:*TEQMG$/2D>Y^1:6>?\0>+UNN5MJ%9H("
M$=GQ8SHQ^" Z#",(/-:^J2..H)TZ.MP;'4RK',U+S\N%AL' &@;JD".P(H'/
MD!PJ4^A*!<GRR@,=E5^J-%S+D:&#YO1<MN!Q7*ILD:''& JR!'6_V>?<2&D-
MKB[+XV*.QDT:+$N<!P3.9U LL>;2_D %^?+J'V7PA:3Q:@&>(CYQEF34'XR#
M/;&=:P\JCW8$C_@H];8-U='H0C/"310GI6X/LH@V5'2DJ^?K[>@$8, N6"E)
M25,R9LO!LC+?HB0,&V2I;H6Z\S+@DTMY"Z&$?%T@4\A;:"XF.8&"T[-IADO3
M6&>F97.-+@<5J&V"NA.I:W?M=-RRW7U!FOB=\+\H,\1SP>,9P6CYNK<=EF3A
MQ9Q6I-K4L7JO-)\4ATBH%2NEOOZ_4N_K>\EI!>L#B"UP0BTO]AM(EBQ)O0^P
M.]U7"DP.J_GMMY>F==3]EFX?]2MY.(YK5)X6%_J&(*Z*.\Q=>BVH)M"!R;$=
M?&1GFB67"^H&/':[ :4K*KB\1$@C;ATKKH+<&<%2!9@P*'8\5IG/$]Y/K;)?
M"<8TD7%@!<]"2J/"W#5=\MG:P"&C+'DR\>>*D:P#0:V_U3Q*H:: H8DL=ZZ!
M4-AAW3[#>F4W<%V*JWC!6@YG4.MV%9((>/RZ[\SD2IE]G,'?;O\X@_B8"+4>
M^X;@&8K85=ID:A)MY938DK'#LJ>)(GWO5>76D1PP1=.^K(9&D3MP&OQ>O4K=
M4UDP)TEDP'11K8-<+7&2-"9VV-'4VIB[/PH9Z%G307CDN!P:8=TTW-0G<#;N
M1@2IBN@SD5/$XPH*% XZGF'+E=M3E/HH37*^HB1JO6)U+8/(=NL=)GJL8 5'
M8%VC).".%\! @JX3<O^H<RS2SFB/KF']-=0TA@QJ[VHW?7!!M:?6U8'21&OJ
MB;B1E_HT=?T^K/XZSA(C)T52-#;:(MS@EHW"OFT-M;)D[4K74*<B-0L(KTW:
M>=%0G\)]9)5?W3[URFH03)S#FE=[NMS68CC/Z%*MT\/7?9C\ -VKPY4?^ @,
MK*A"]P*;#:."6N((RKUOT>%S;3QWJ^R_%Q(+W@E2%U6K$=$7*8G8;C[ZFI(:
M%+7 $5IS-E-O[ZQK;H^[S&F4.!>X% V]*<B23HH3^P*W[$.LGE^K:<3L===#
MKL&L">"8R]?2K4CBW&U:Q'W:IL4FM#5;4KZA%5$?H:6;VW G(9(-C2 L8VP[
M"&O$EN?L4Q/(CJZ8'37<,*5>>O;=U*<[JM[@A5FT0P*KE1';%IUU7QR2-52S
MG7;-Z (;1F(R9EA]\V;T(Z%:U'1T!;6FO>ARVR91-]S@#/?S7<NNE>6IZY69
MVZ], LY-8E,K6+I^%0AA"@T;3&!G4WI<=%,^?%//@;\NRN .1NCU.P:WI&FU
M+N4!J"1N66LC^"M+H\#MGFTX!3*CURB**\2.ZWAFFKUO8P)B'G>R8A5J;+LF
M1FQ-U7Q# ,K2(H#[=43Y6A=6C;^Z!JQ[[&1M'+U<F<+H-(8[U;*$=HL_#?)5
M8P\5(VI41SAWA+PW0AK:47:RG"(.![[L55Y>>N<+!^!78K^ZXZ)]TC7)#3AQ
M\TM;)K1D!)NB/JH<97Y'Y8>E<D73NF3V;Z4O"'G_EJZ8CIKW"2.P=$GDWB60
MQM<QF0R+'"R8>L-*1Y;[+ F9"CZ;$6S_P*@Q1QVKI0:,U&"A;:A.D^#C.@K=
M(X6,]]H*N^N"YM]:)FO FC51J=QQJ5(!XB&0.G&.M?<@B+V5$DGRQK@ 6S7!
M$;,;WY50;BRA''<EE'^]"SV+R9Z)M11U<72P&$\E"TQ3\Z7S^4I6KC''$M;'
M-]81MKOZE0?2G8C+>,EV:A I4* 47(CG4Q2D%H7,R5R[[N4E_CZ=$Y;H(EAE
M3>4 >Q;G=['<IHJK/P00,BU!$63 OUQCP1-]-$8D^<HU4/*&@/%ZOWM1:'Q%
MBGVU=*3K\2T6=I^CX;58=*3FX#0LN8@AF"F!TU2(Z1>$*ZTBXUP4(ZRTI/)E
MI]/>MAJXK@36(JTD6[>.,UT#9,%:HO58 N%5MT?1= M=[@R$T",)(F?J#7FO
MBJ=\S0Q4JC,&3$?Y"'M"NK8J8\!\\;L0Z)8?JZ=RZ0D(4[7*TH8Y1O%LVY,R
M^-9UC+_MS@J3FPZ\G>L3\F74SA]-DB@X>P-6:V_M QL2=>;^D+F+I\0YW36?
M<KMP:NLP)L;KJ8--U%%4.:H*5R>,L0'6R8-71P\TX?W7AME50ZD<(X5_JE8)
M[[OL:3GR]7%[!K%65VUL&&AEYS[54P$V3\))L(V#<.R,.&<^'*?X-#KU^AOP
MBE2NNQXWT#"43UZ KZ-9?#[/N;#Y.ON4EGEUR-0(*(1&._MND@-Q8$EU:J\V
MZ.Y"3Q[4HJ,F+AYHW*"<8+#-4$$D/X_C$PFAYXP%N\T8K(P3!#N,5/Y*SVAI
M1&TRLP4;YA-NF"?HE'M4RB+;RY-D.AX7$[75'#W,F,+'P1'>,7_Z\@JSWF0M
M8Y/2G"P'.WIOAMQ@> ;)GEY2>9<4U51+<7"X$!?UF)(>,W-2 [$Y=VA/LJI_
M8*E9L03+,XL8.Q]O)UT$T4QX__@N$AK0#+F1@7U ](;V!,,X#\MYL>0Z20DM
M9"&GS+A917!OB_+R$M_IO(:1ZQDFMZ+,Z/F>2:Q6:@^=M(R6+33EL<+;4E:)
MT41?EZ51:%_1/$(]Q@ W@,-;\&E,<J3N)34#Q]SBZRQ7SR1AQ'QZ*HD47BV+
MI8('6=:*JP+B@U<J5)02E)DU0U^PBGF/?*$E? (B!P18R:#W$J^);?-/I7IT
MCM7R8/@PP)2MLZQ\R1D\X.O3BEB<8BU515!RF]C2E"VYK@HS#,Z<7!MXV4@-
M&SYJWP$;UM6+1U2$5R9*IE_BZ\L4*T_,R53JPQJ/L?WD;^ 3'O9));DXMK;&
M"C+.L#9_P5P9?  S!\Z8.0\1>!_7RXK0 O&G+@LA5MREXD%$_3-3+VMU+C&4
M7H>U\,U;:?#&J1UAU+9!9]9.I+A IW$'-(% =F'/$T]#PL 4BV-IT?RJD:FF
M$JK7HH95DE89MRI*K7);.S%=[:B/M>]M5PKW$./46QHFR/O]:%M07E6GOJ%1
M\T&,T9?&&-TR6+-/M4@",QLD<TP'8)]HC@6N4L3H-.<3_I,*HG4;W*]6OI@0
M<Y ;AXDTLXY<&_0[+-M;FE$SX.R#&0:2JUQBC2O^&4PUY)=JP<4??[MXZQ6K
M-,H) C# 2=YLC5W2H]+*Y'/;#X!FD-A5OEE,90E_!$FD,++PK_\R.CIY,<>H
MU?#T!?OT+>,,&ESSS5EJ\NWK'J8[6+VIDJ6YDFC??;WWKLVLBVLV<QKZ[4WV
MN-]XG*V3%)TS9.(98$.I0K-15SQF<C'K)76&GCJ#PP*1*\RP4D$_@H?$K(4\
MVD=#YLKV#-2@DDR)HP MM3Q"6*[2^4$%6D5\+;Y5?)EQ'(_B$FZT L\(+ T;
MMZP@2XKT_STE2.E/2]/E;\+3-*XY)S@GC:EB,U"L:O!.8@67!"5T1JL9TZ7O
M_:)FA#I/%Z<E6F/GE-9ZH%LG9[)+"U9-];H1W*=;WQ7FTD+H\!M6B( "!D67
M5HJ)NOJN>\^44J]'5@27IE)2Y"LV?L'Y)EP\ZE/L5T=^L9'@NFN'O_]R'AW3
MKT=""?BMQ]UD"S18EXYHVS2:IK5Z@2+ :Q4+7:W"O=Y G5EA,DM[9WR=+1N"
M^G0Y51!>K9,5R^W6KR?2>@'/5N[4:9.CL=5['8GOC\055+9*/:1KAU3 V"C%
M]*7>.NOT]4@WKW/?\RYY_2#):VLS<H#;P5DE S,/(NI#S;GW9LG]=GJ61$^^
MJKZ"=5-@Y?1J ]ITN[?1U0(]^WE\=-"U0(_H)7[FM+AR:O2=_#;G/-LL<P,4
MB<KC.HY*!\N@HHQPNDZUF,'7$4*=]&K-^A:J_L;M7?3&9A]R24T[U(HBY/RZ
M:M=BFV/#-0:8\VE(V&%#(34LL96&@7EJ?<GRN7;^]!TW:Z;>2'IJPP,;.RW:
MEB;[O:U$@[U?;=LS:D"UHA@3@)ED0TV,A@Q-\ JQ6H?C^,TMF&U+_D:ZV6'%
MZT?D=(K13H,\K38HP7OF!YIR^Z-R"M5H'^50=;0M6;6W6/EBZ1N8#;(?-%0\
M^'0+9YZCM%:[F"].?)E*D_8H&;?Q<-P/=ST<9R*?C6"9PD%S:K:0I?%.NJ-J
M;E0N'=<,FMO0^IA1\*O"TI&TY:D--*1LH'B'AI@ZHV^RY92Q<J-6>K1P83-R
M4GBD^YQ;)J!@1BR.3&5 -5ZE1WE?9U^4LS/^*B]PA?N)FC?49/]P=A1'>),\
M\XTP\VNV,X5W%PO,M19%:1834$I2C&8:*+IV8'WOI;,4\\\DW#CSDLBJ&\/7
M$;P@H.HQT6P&ML$Y;W.J=.;QS&4.IVFR!7AY,PM@5)2BH;&E@$X/25V#C;OJ
MC-"<L0UUM8]N\,[E"S02T@T..TIB7\3I-O*!U+4B=(.E:E=$[1VJMPD(B<UB
M)M\1J,RR%5N#9K)70"6M$' F''W;#21CHDE5FD!PQ)71#2>Q48 U'8,9AP(6
MP)IP%(.$NY,QU8X5(YMZOP^"JRYFWTM4RLG(P8EL<NXSP_Z0(.6B6D><^E*?
MNK-(M,*0BP?X368,E4%H-Q>FB>P[LH[?6&>G"P(='6%NQ*YOV!?.V=&\0P=L
MK9"UL0!7:72KW6>@R7S?]')YM:*Y;:H'1H& _G!Z"9-)9.&4J91,,UP5?6JM
M?'N%UZC8UAB\*W:#F[?4V0<'+D]&?C<5VS[>;&V!J.'8NQ0MM+-QB]O3G/TK
M"5:0RV+(:G1O"^SV'3"#4># &;[@\1-0A'"%31JN/8U,0"R7+.*EJG;\LEBW
MOX7G_@DBI8CB.KZ8M1V(H9CQ=!614U>N4??>GI]KL#V]Z=<EUAW ?F#WZ"7K
M'9E_?XM,224RYUS_KA_V^JUY6-_[ 'YISJ6SV/,L;7QT2$X[.P4NG&-T:=1<
MG% M>S">J!0V5\K4 _"25D5L;BN0-J!.)3 "V>9%%O]  (#CEOA^?5%N[)[$
M;V5!7.:+>Z1=%T5,@XOM= ZL-IN519!PC(+JPFBJBZJQ#GG/XL[@]]RQBT:$
MVZ>^U/O^J!_WFUHB"ED>6,3&BC!8 P%@3#&W)Z8!0,FQC!RDMPTM#["/?VMI
M>R#>6&!5G%.H8KL2/C4$HB@HWS 1V D#K]])C7D #_CJ6^'+[2"Z4, $Q+20
MM[4)^BH'6XKYE2_>K@6:XGZ==/4-O&ZA=.KX#C08FP-%U<'8P1S#??2CHLO8
MWV.^,"YJD*?5H&.,K$=!6UV80T6$'=+*XQ*H*-%.CTF%=31Y:)HXO3!NF)Q;
MG=9#Y3N%K;D3 #0TPH1F126KWA'U,8@JV,7F?EF\V:E*U2SF'I,=* S./*V-
MR"P,0\&\CKSW1]X [.S+0&I8P+I<('*& Q;.%C8/ORV;C;ZL$[(/6LDD&LXI
M:5V+26%6(L\JT0W;JDB$;2INX2ZS4%?'D%8U->_T2.PCF[GTKM8I<RQ,' $R
MSP6M62,5_IIED?>V\L(/^- X- Z)1:\/?WW[H<-IV5R;<7S0M1F="+B3"(A3
M8^<NZQ$0DM0-%?LU/>QT2@H^ ?NP[B5D'9\3)CCI9%?X5X E:0V553F! (91
M3Z3L7QQXCB.U!S=?P#<Z)7)_)<].HZPFXD(+8NZ)7T?Q,7,6FD,;] _8$[?4
MX31OD2UT98XS;$!&:3A]R5PM:T,@9@@J)@QQ7(CNLJIQ<:749^NBOOTI#M-
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MPU"3HJK5^L:R@/X7;421\L?7R +W78M6D21=<]XIO&^T[ T)UI2P=I9K]DD
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M;L4Q5=WM/(_Y:48$I2[_FZ79JU I<&^25O1,>"C!&TA8#&OF5%X8%(Y:F)!
MGH",US'Y-_3I3"49";%$\ RS6ADPK E</5]09'.=8C6]2@ZZ0GW?N,1KVK;,
M,]'2&C_A#SB<68EEXHEFY9)DYHPPXHE:*/U3B22 0,#@:+&LB";^S#0CDI^I
MGUHT1<GQF<^OF3!3AA;6KF)X%238"ZB,O]Y(V.]G'N]L%^^'??4J+A:E+IEB
MP (^:"=:>]\5!MA!NE$MV<$G2\'2I!)7P4%;J%R/7$- 3@<%!J,4C:'>#N?X
MWK,L%-P*@3C(1;6(@'.5G7C,FLUBK8EJ.THOEXD%C+/1=9C<'Q5OKA17V^F(
MZ=>EA%@X68+BP531Z%E3NL]$1TAI6L?&2\O(A)7"DTV<T5'\?K.CQK*IV.I-
MEI(S4]/&8RT_;'G1G?$#]6$'S@QHXD&G8JL> S11=)YJQI8K!^A"#ZL_K[F7
MR4(R%K"S8H9LB$@\C;ON$'[O7TW827!DY9N"-20@3JKJ764W$I&GXG^-I/%G
M%J.E1^7$&34J"#LV"QO.R=D"-F>D\;Y;:1>$>\>&&B5H-HA3G6US;%U.:9OQ
M:?4Y@L;WVFSS(<:,A:DG8[T9;:J",=M^L4DL$&JZ:IBWLW[?]X!(=\*<,C/V
MZJU8%I.7.RZ:$1FY[']?JH]U7T8#G()&<!2,7QQ[RS,\;\F!QG80(4MEIUG,
M=/@W5<[6L31UNTS+S!=Z./&S!<#DP6D%B1OK99#C(&ORC3.^\4W8!E=_%^[W
M]A'+!@J'P(><09TX9$;G7U6 4T?K!QYEBFTGA?$':=- TWB=-A;@RTX.%IO.
MX=#FWV8S]&<%0B]7G(-5]=]RS4$3?$_#IIJF"9F'X;W0!41K. /MXX9X%@.Z
MZ%<E\'E1&\NP812#AO/4 6CN*FCJ5PH:+JC%OTTL"JZ.J+6VI-% 2?X)PG3C
MXBJ-$G[C%2,RKG5A<=^/0:02$5X!?;1Y\^?O&-4.O>ZWY^<_\APC"SCGU]5#
M'3QP79*WT02^:$8>Z\_UZ&,$HS*M:CA%NEP:R;#6*V4-/<TCSSDIR+/!-6S!
MCX;-YS@28$'1(U1:6:ZG'],D#X9:6^G)9^M\>(FA*1S#G6 /*T/6+N LT58@
M6G,]/K9(T3L0L-CT(SDM>#3T&7>$9DRBHLMZ+,.DG1'9=KT/[@!UWBMDSD*C
MKS6I/)JO1^5[FOVW86#AO=KP]#]5ML#C%"9TN-:%ZZXC^M58<ZMIW'NC@05J
M%_'-\IC<E:AZY(*OD!F<W0W7R2+DC6Y!QFOL\]TXSK!Q_NK+]_]U\:HWG'AP
M<B#;XY", [N9R-E-;4$,G(C"W-*_X/&HNLE8I5A?IDO9FACP#B"$;0,361"N
MG4#@GH#WLN$"3(5D--ZK+!:LCAP-H-LI*=6FN.MQ'0&NZR!Y.)P54;C:0* 4
M&>;.4#:MYUAW[N4FRX*Y7'#EW+9W[5=Q(>>&^6]=J<VSG\>G!UUJT]W0[W9#
M'=30"E"N'F6"JE/?.FI^=ZR'"F"1&>PNI1!4TA@TW^2J>2<)D-R@16+&MJJ2
MNECV?8+C"$E]KXE!8CPW25'7YXL%GH-@8Z>H6DND\!F9%?[1XF,$"8B4B#2\
M2B]!QI@BY"80"&/E=SSPT+H[S,O8!E?(:N3 3\S134E&28%2O@1&6 AR>-#=
MV\>@V55PS102PA@H<$>$YPK\'6ZU(_05:]6SF=PK%QW9[A%)RJ!!QG:<]C4&
M_"XIRX(1CCAP<CA:""XS6#37?TJ81D./LV^&7XM3">389H[*.(<:8"#X;@O&
M]RBEC*J[M?OA)36DD4P+!N66,5+S\N/[HHHK5]&\E9XT&:8&1U = F5'Q:?J
M,EO&-FJ JOH:RYG1*,/T<, SQPA0/8IG,YK181?AO+MCH,<RXF,I!Y/I>#R_
M99J!M6W*EB\^_F*JEDW(T!UD4&<G/=H92=M1]IXI6]1S^ 9M&$B.\OLZ0\K,
M,"^37IIVTU>(2_>)(:#?9BG&X/$)OU0H_^K36TMZ'A'8T?,>D:+GT_BRS+C%
MV9!1<C/=P=_G10IC2I&XXV)VF%Q"1C)'/R)!Z<-0!EX?KMPH&&G.B46OIW09
M_H#;/G'H&=]-&7HF075;^\Z!ZXXI[C7,$8'\1%KAB#F3:G5F6798[8]-I"0(
MOY CHDDU*]/(>CLR./;*)LH;TL$OO(Y ]T8@=!=R-"U-:U 4%P@NP[6(7$=B
M6A!B\2?\AMRC7Z$=%1PN- Q0\R2:"E2OKENX4D$";A%X3?DE-TBZ8^ :$JD\
MZ H50(% "-+EZ?[HAEJOO-^_Y&!4*P36[CCJ09"U*X5B-< )-W:Q!_4>&\_9
M%"WI4;UZ;%MKL1(P=DX=>%QN5V!\!K/V7H2-0,TEC_7K4Y_0>4OIA\GNZ"=S
M_V)CS0?781D,E2SD\HE0.J*J 8(U<%D?O94@I7D7)DUD %,PF%'4AN[IG '#
MWH84%F.0T("Z]( ?I#[&KQ?(Z&WISC=]^BQ5FBIM"'W%&26J*V\8=3N5*H^F
M>:*M [+W@$%WQT]V"PI93+?E=UQ(ZB:6YO@_+#BA82DIX:)P_(EJ!M=*\QKJ
M3_8;7OBBEA0#8R61OYK#64^*;+U-ZF#%(MG0 NQ*32K7A,+A"L13T_DS$G:A
MD=?I*F.AA)E,$YCLCF](31@_&J[7(HY+>6T;+J] =5$M/943ZNK$ !R=N38+
MJ&ZQ=2FR@ENX:I>-TR9R ST/,D9%;2>PB6!Z]VXQ%(E:X[>MUY$U4%.7J<P#
MI](?<:;PW(N:B#*=O28;@QB+<185##^OO@;X=1]_N5W=&!''*1Z3P:I?=8N2
M-:PSYVLH6:5PS"D86P3[WZW+X(I22J_3UYO(W%@"1]/,S8]HW'2*NEJ\D2T>
M4>V#=JU7]\G.A'.^!S873O&BIJ?J(>_K8T-TV!^%+QP,?=M)Y.JW^CK:2]E"
M<76K0V1;%-X]7(5JM1_=\\+4:[+&L$ACVE**M)ED#2WN+3=VUA;+<7^M[SHU
M<.IZ^%2JCEO$]%H].IL@]5!0LLPNJ4-TWV_.']51&U)1IZ^0;T2FK0>XS420
MQI"L,-E(C5L@8SF0D& Q@I$'2P8*A-Q)P(@;X%SJ#GA;4^!79ER[I";PP\9J
MW@:3A$Q.OL4(MN'K.D)Y&'Q/ <N7P9H"V&),<7/-JU/U"T>)[X*_(R]+:D]/
M6[&W.DNDW)H5%W9ZY,%-=:"<JQWASE_&8N*C_8!P&FVZDOR.69G3W>4!S118
MR3(&670FAU "6LN[E*SU6;4@F?*!>)#P8ELH<IOYZ"2=*BOL2C<WE6Z>'73I
MYB-*-RV.JRUWHGT(M3(20)[*S'(;X\_2RTQ#<?(3MC?IM0=TXWI &UN(;FD-
M8L$0N'[Y4W!$+V;6C><1F1DU.I8IGE)]I!G:2IOEK#6Z:@T+B((R1_@;:ERD
MD58@V\2DDYE9NCM&:Q4Y>S[Z6W6"$\0P@E[/W(I0KZ$R,KV]NN7:!%8ILE)B
MF<7>>+V\F8*B21OH)(-6G49I&7/GSA&[Y?QO&DT1;1< I\^P")'O#MV3/+M9
M7O%$&(K@F)MI;H/ODHP88*J0,<0.Y6[< %OD:6@:J+5>!$J0<HAYL%@9*EN^
MJ-+;[42Y&UM:I"4!2HHJ;+:$AY:75QC]CJ^S)2Z3^Y+&]9J-Y[A.2?L?T2OH
MWW\DUUAE8#NQS5&[%&315XP@:U37[EW0UA)5>X-I5]S<!?5'W?H*;@(>O9NE
M^#><3,<,XY@FVE+B7L0<^0Y7U["I&SL722/SH;T_-RV8;KP"?3'YD/OOHPC;
M#^F554//.EY][Q<]WB+PIGD6X!_)!2O*_%H13RRN5@4P>,"O(,QD2AV+^8K1
ML" A<ZJV-ML6C5F+( <]@E("+"PPRM# HF-'L .-M<;*AA"!\NR2FJ4"&EXX
M#1C]@:#,Z.*-!V9*"[PM2U=SN-^1<[983RB>&TH=5'O#@;>"=501YZ0)GWO5
MG//+F;2,13CV0>X#X8/+E)H$.!UC_T[G6YUYIQ )"W?P:1G42LK1-%;DVJEK
M)&JR<A]&=NH&;7*;C&J]IK<*+P$$FBINCR: >4-2$9TN5S7,_Z2)@3*B"Y'@
M@$?"I2X<<(L&BEV5U7?20?MEW%TLFX*FCG6%"H(V*"A]6H7HP8TWJ@K)L1XX
M6A>8#OC6+>+M/1N%6'7)&2WF <<I$I%YE;'\K[[G><8#A:51WI!ZD<>$.!O/
MYV6:N9/.?[S=":5;.;52R]%>!1Q>6 </LA/0:^()!-.JL+.1"W+X"% H01\T
M8'Q%75/:R-A][PV[HCZL]:;2'4Y]O)3>E1R0) S=2V7@\*T(-5:QL;U$>Z\Y
MHFY$!^\'%3O*K\2O9JPD)Q9BN<(,Z^2&6JG\$2P*&F)E-)"$) -,GW&N"=8+
MTF;9O"Y^-@DY^X(YH2].E1D[VO?.C7I 7((M1(O&&';-,1$*.@8A8D*;7_!J
M;8+9I=!]J)A4N$\DG]D /U50,2EP!ZR$>#<Z7% Y4W@IX0 $C/2!V3W7::H+
M+-J#@ZUAZ@>*-4&V+YC$.SI#'^WFD)_B!M@1ATK"3%0K.FL$+9&A:O78T9ZX
M%S4@(-A.;ZT<JQWFI3U*^SV.R+NH@"MRHH9_2?J5UH08LB5A*8AQX.O%L?%4
M7H+<PILHH!S+7&>K"KPANFO'-W@X8#VP;?G1?1?CS] Z&Q&3; ".C#S3#.0F
M> M$"^,,-P=AI3Y1T&#@<>'*GHT8'#<(?.H,*VZ"I\W76=82R,QR:1BM?&'1
M;E%_T6JIT&"K+G_=CQ"*&G*ZQ(4(<"S1 K'0"M*FNM*L_AD"OW]=) QYMM)\
M]Z-O>B:L'/4=D6UII[\'@HJ5O8G$ZH5$92Z_IT+$*"N0XRAX#4I/"VD,D-OQ
MSGJY!?)?P3;.@I)SHG2KA[TO\FXSJB[6K'/0"].=R-HN"%*EL<5!)JS--\,6
M%>Y\<"]HL3:072)ZOEMWT)#CJE6BW*SAB#B_D>01I=B,95=+RY*O(C4L%89E
MVCK53\Z#"5)GA8QB(' H!=PJY-QB("[6H8*V2@Y-5Z"C;3M?!*(_-Q;I^!O4
MJU.[LR?,MFND$1DF!MLJ6_3(41<4+F23%(UJ=)>9+9OR)P9[ FRZ4D8O4$UB
M<26->UCZC=<WEGE[3&MD$)++VC"CUXB19$,;.A+C3O(#SN$DUS6>@4;XH7(O
M8!5E!BE7,Z8&5MWA-2JLBC&@@&_?%P/@3?W8S/W3!QO7:<:7>3N2B1*'G]NO
MM5&5Z&6:9]<G/N=Q\46@UAQH^'H"."N72%969L[\=<L)#9@\NAR#K]GMK-+W
M/C@G0!/MY'#HZU3>EJLYC4G9F9EPX9:5JFPCX5-G7[8KT(!$K5'GIA*M$<)B
MK&;C+N94X8?"$YABYI;!T,<64"*0(&%U+NGR2EFGA,^:40?JS6[LP_#DMOK*
MP69R9EUB9YT)&5M/RH?/0!'/R)DI \+RUJ!\[+PW+8->6(NC,A*C!+QUQ8=C
MDAFX17>A%:-4#Z#3X0N-^L8 #GCF#O:4;RY7HQR4S=N-<W"7#52O!)9-ZNQ!
MJ#R62U\Y)MI4+6^P^GI1I7GLWD\>96B>QF+MEE)3JY5,N($C<)R<"8A%%GD<
M&N R# UF*.DR,+#@7LR2$O%BEZKZJFYRU\:<]*3+2=]V<BT>/NB1 MP[ANH7
MY?+60OH!$[]T4"2-\XGQQ ]B!;XTKN[CQVAWM,%<H-P&SUU#$C;8Z13H6G&
M>DFE+$&H=.B[7AKOVNPZ\A2;Z*5^J#N#W"+!-G3*$VR&*8IK 5C8%Z.*2W6D
MMJ"IJ(_=Z[73!WVPE,!;VSGH>@AWVT[/I<9 W:+I$HG!W1_:X:F,YJ'R:JQI
MRFC\JF_JEAQ"@W\7H.I-+[';*/P27-(?0;#G%(.-*$,XE:&Y$NZ@W!R0FJ<2
M\= ?'[T]^E\*.(*[S<\$C9IIIPA38E^46N@[RL.;I#+9":7H>#WPB\S$=B+;
M'%N6;U,Z0NQ^$X"1(@)-&V)*MUH78S!)1B'1.3=]VTFBNQ. A++K",]<G+[M
MGZ,-5)W Q8BP;G]UT6PKKW,*)MH*:#B<W_)2-E0Y;*89P:8*<K,3]WNJP/P/
MF)\V@X_RV'LMA7^PR+?Q4H8<>)\(7_ER9=KI/[Y^^TFWTU-801MIA7S3%R@T
MUY1 :POX4*>!'+!D@Y@IQB2.@)&TA<%X-4]LO'H,Z6,17;%"%FWLBKAR&EM=
MOG1O MKB]4&ON1D?2Y7T<"-S(!_&$O20,A][Z0@NY"MRX_+*S$X$%[F4##6/
M,^,Z?5P_#8?B%"VA#?O6Z9GA^[@6 #0$2C_,VDL20/?M483P(*)=]08G+=TX
MB8Z1P$*#C<<([A%BYK(AWB7WWZ)[D+E.X:$XQ&3\0D>B:H) YXP;K\],MTHY
M8Z##7]]^<-OP2")4$?VHY1)%:XC"NZCFX1'.F3Q*D!D:OL9PN^W3K%-TAD,2
M3#(=3'YD*\+_S#5/A"L)X[F/EF8Q3OC>4-F!VRD<%^ZI8Q-$PT[(S>0;5K^G
MY&Z9Q5=5%(%UZ%=3/WD5C1OO#?\I1-\TXW'*6,O+@L]=I_&<Y6*B7"'  0WZ
M7'FME.+ZFRK4VY:JZ=[R4QWHKZ \ DL4#C<Y VM:<:8<R>L+>A#_>(F81T4'
MR7N/F >(-H']S&16)6H) KC#+[C' R?Q5"Q!@44FIE;(K'6V'N'"ZX"9V]<L
M$Q3T2':IBD CNP:4S_WN84!%3Y@5P0\ZJMX[52V-*-* QDQ&F#)I09%9%>;*
MU-V%%!*D:"6KDUC[[;KX<(;A*O0DXOFT!.UG#3BKP76'D[&[,&=DRU0J4[M,
M5D8!AQG)CH F1JEW'')_'%(H]87CP'^6::CSMV))A/%U3$H_S"G6F3A4HLQ!
MJI88 "6>Z*ATCU2RP$W:_FJ*B'0DN'\2D*LO/FR'K_2 FFQ6<K.QA#P][8A7
MIA^1SP'_(&J)OVX_QD!5Q),".V(]B+AJ\4EM28;K;TK8!\-N5;_/]<L0UJBC
MW3T:!-0DA1%JQM20Q ):<_H*+K"QD%.X''DFB,^O_*>9\Y,U-T&0M903M^?0
MPKXD'3"P;5&"=&S73-AD^P<+J JPB:884IQFUTJR_%?Q-%XVPA4US5)KABS:
M@W:%'5-AGS>&ZBZE*I+JX##>KU+J6)7BP)O"S7.1>(#CH8,T%63: Z40^VS6
MHR@YA9AU/S<ZE;.L9)&#!:R7G).DA@1@49J@2E7K^"BL$J\\QFFG#9UZ5BHW
M=0+@X(TP6?>)66\_>9:\-">-/E354Z61E=C^9.MF](0]AK]Q02<+#7+A$DP[
MC,42%A)@RQ63U!'YZ--%,48&@'][Z'N6<XS"N7DJD,DE_&35*Q;P.66$G(8,
M2B_!$@)9LZVK]"M[<>HMX_0Z2ZXMJ!\" "I![#/T-[^M@]2DJR83NSHKE";>
M4T>H;C^@1'A&J)RV18'\VW7$$^F20+\[X%..,<, :BZ2'!F-O*S.N;2Q\8-(
M'OQQA;E!IW^PJ3%.B@P13L9V<K)@Q&P0JYLEAKXITB2RU\I104(5#L8?8ZF3
ME='RSGJZRF3;I(+9>0;7@^F0-L'< #O+O)<Z2HJ!L+,YS.9DQ=KL39%'#?G#
MHI) 1,AK>8-O,OQID.?9#>*^W<I[#L^9(])1&#KB^OHE=4J9CE;)PK2*:Q)8
MBUTC:_DAWR9PJW>3$B8J0O9PIP%?!05.B8_AG0FV1$K\@G+).H!!H0K808!X
M\YP:3G7022L.K3 <S8//P,>K%*>2Z]P.51R;)U W!8X%XJ+N9AF#(KNV9*ES
ME%"9?6 U8E>-UQ76MJ8<&MQ3:N(R49P"VTF5%B]":ZX3L6)?($RP_9#RS:0^
MP?8!PR^1)E3;_%7I,83W!9>J03V7&R!'NX*S9S\?#0ZGX.QQ3JBI@*(J__0$
MYRV%1[47SRGZ;6S+,P69NHJSUEEP>/;YN4><I"$8-"8$]QB9EITW <C#SSEV
MZ[B?./I@0\95-ZK9V;^S@$8L5\9EY]54*]4 9/D:_*ONQHQ)[]AN6+NJPH"I
M,>YQ$G\!10[V0^1M&B).BE-7YJU/']X7JUX#:9@&(Q!_5\TTQ(-J)ERQACC3
MC/0288%\0Z.X-/YR"T->$'AY5J>";>AO&@_..)%]KX7_R-:=T0:I\T@_@B@8
M%V:0.[!#(JT*## XU:AUM-I*%P.7UF%%BF\Z?K&P7DIPL'LNGJD>+ 4^4"G'
MG$S+4+U\W!AZ"E.;& [0!4Z%6\/.R^9V+3O-'J02^D/4[$X&Q;4@^UXC+N77
MV&#VP6%0/B6M;$6_.ZF %-MV/[:(VG *B7^F6*>NZ<6GW$"(F)OEL=L]-*8.
MQBS*5+=6Z)IWMR:'T4G)3]-U(%S\CQG$*Y4L;',TE7%DP*3*0*H!PUU5P>!<
M07%#/@,0 0CQ3^V^-329+Y(@9),<N,@X2%)J2= J\+BBE0%=,1=@GWQ4"$@.
M]J=+2<S,TRVI++ 0=A9+[V15>!S+3 LS*J44D(2U">>)/<Z9=+<Z ]$#IVG'
M?E=XDAOF5^CHQGH.*;YP;QK8;JOC%?<6"#Z-X:V7X,_;#D#GKK<(J>TN, 4M
M&?S L"CWJ=IKJ2EL8) R#3D ]O)<P37&-FOX(%4J*LQR'"'A,CZ!<"^PQFC6
MJD$;:+1?^".OW&M0$ ;03IJ&7#\4Q>)E8TU=;D"!=:S".Z?I?@2B0/66J3B.
MU'1TK38J[KE2+&P--.0LRZMK:%UX*V$J]5VX:IIA)V,-P7@)$.R.(?0XG@"\
M,@^^*-V@ZE#X(K518E_\?[ R%L2]VH[)68\3/W^#0=92]&Y,,-OSUFB$&1NK
MP?[B0FD.)-@P!/:V@R>IA];K+[-["9_BIMF?Q+-TVO#P)*,,_D#0(46!_0T:
MK=X^QXEG51N8-8_4VA1;6$1PS-N5G 8@VH89&*< AS%%:DW3XWX\L$@NX2N6
M,>T0:7P)KT:$^+[$Z7;M,B8K3(.U5/I+:]AVTJ)! I$[].#/"T27$O%;X6OU
M-4S Q[K6J(A(4/K>.N0DNWDNQ*N%#W)A]/8>=?]C<^VRQL_XL\SC(I)8>16Z
MJ!XIQ4OUNL3PE"\FI]AW4HC=H$ -:H"&_Z@ ^%+YM&%>@3I.=+^]M*0VQ*Z#
MPB4R6%F_DT# =[_G?W^%1#T/20@.)V=COF.Z!Z'V)=N.4)'*9G=6Y&FH0\M@
M("1B!C"2OVMKPG$!W$U7]FP0Y^KNR#KZ$.QCIFXT<MIH,/"!:\@G /^@%+#F
M-9(10J!XG5'KQ3#%T]K3WA&X&=[\/EQF:"*/!L,S-AS-0U^_/<=O_$<))(6/
M)XQ:R'''6Q:FM]3_U-]R74$"EC^86__Z+Z.CDQ=S$VZ?!V&>72;9M,0+,@<M
M3DL"\3X:C$92HV\[AK#FOEV0H'MENBQD$X7T\>98Q[KFWIO5VNBXDX").19;
MU^U^O1(?K]$R41+EP"APVD- 00?GPK[:$76:S0@GI(QDK41L0L.E17(N@KW8
M9M]![X&P:.A0*O_B;,U <*#V0F0"62 =+$D=6)U:2'_$N47FQW44#N59V@ -
M@*O1TL+9#D4%1]&5Z/ C_@&'NLV/W>_(2F2D;XY9/3Y0;,#AI\;&9Z@JVV+=
M#-R@:N*9=0(0^-!@>B<K%T6OR'3JLX%P^$.[AC_+8DF!]+Z6<O1P]_L:CPP]
M7C@-,OHVR7%M20G::!$O2UT9X\[VBE-'V^$_7&5)9.)CK:=@3#GE0IJ#?8)\
M'%M,1_HA6KC:HF$'R'6W+5)2FRS5-I;>2P7L\4#-()UC1^E Z5Z@(1W  CS%
M #/<YBCJ9OIN(MP'BMY@5HED3JZ$\6I0#!1_:9EJ81!D)=!I'8%:W,"[SH"S
M]@B>&;7I<.1[+^&6D3,N5A+"N3IA%FS,C-HV0PDS\<P974RXL(5:QIYP"@11
M:,6%GL?(-@'2E,632L$@Q9[<:EB;^T3I A%*IT0XV$JU"6K'"*/HA,L(FY<*
MR_KD)&M]D1A+9ZDT\T:B$HC$:31BD-;[I=<B,?S/8I8UKT"L,Q&3)(<-.K*6
MQ2CWM!<FP&=,&$\&H&EI;PH<="A^G3\YZ&-4_ 9E&#C0+7+<TIUL@Y-!ZX5U
MQZGR:F1$8S.+T1Z7<!T++ YX;NUT<&)Q"-V/Q*QFVYE1YK(87IG[,,3OEXYP
M_5SJ4TU73L!S27=-PH;N&X#^94$1\H(4E-85-C[U17L19M4HQ]!_6U'K[)0+
M*^@KSM'R0K45+H;B=?9%25=W\^F(NMUTV-;@<O=Q@Q8WWFV,YO+RF.*V=H/L
M3XDR842 ;"X>-*6W& F<ZFWYG!:%TV6IG2SUL,M2;U=ZMR=FP<W_9^]=>^0X
MKBW1OU+PS!G(0+)'E&79'@$&>"C)UAG+)"1Y='&_95=E=:=8E5DG']VL\^LG
M]MJ/V!&96=V4U&3QWH(!B]U=E8]X[-B/M=>J#!:49646C5G,L"7\^/T<%B@_
M@-0R(+.'0SDS?/X<GC7>E&_?T4DOZ=%/ZM]'/Y0&U0+31XQJB?O\$**9"C;S
M#Y\6%%-^SLE<V,1F%N)$CCUR?8CH)Q?X A*ZG]3AV<PS"1.EODFOP2&=P%<K
M4,*$/U':\;YZIQ>01U(^?>+*'(6HL=PP7=SL^]W[O"\?ILGY@ S[IL4',I$6
MNF>\(KVLO$'XTHY4"23I@9BW7/,A$58:2%2D4@:+>WU4#*-S2Y?/@6>N(HG)
MWH>0:O)P)[T#6\#N]6?>CH%\((0!A#+6'#;M['<7W>1S*;.]NR*-(/-&(\$V
MYA"GFALWZ+H\<)0I^#/IY >S'&D^+BH$F1I1O),!VQE)NP!N_S#6^^NX%DI7
ME=@='<H-$+YW$15\1):.'%9Q"3WQ'A+F&[:<^9#GLH4T!8N8B[I)B87NO2X)
MIT6!+![K'6LFJ)(AKGK?\*(HO,FF#SD"(M>Y<[5ZL1-SQ\5N@@3BO8<J!$]D
MQ)55P]/0<@**,AM,3M_KP2810K#)*!:!SB,_W-+IP7N(^T>I"/=HI]=^N0F!
M!5 :#[ZOWQ)+XCY+4E=&Y<>?S]0;D(1EKD1RL$%+#?7,\!C"4-\</1X4891-
MIXBC*J45 W9VNV?;$;GON>V=#=!)UB(F0?2@N\D.Y\?-U"<46LM3@JJ=C;N'
MMWY\.+I70KHH>BSRUB;="T*@<E"#X5$[NJ?7E' MF_6)0F:&=636D=NV/]!C
M4JN#(>D+I_%*Z&1'KU >@^MUAK;V(2ZWD^MQ3H"5OK3F_C(E>1V9>"V'9M$.
MA$3#="Y.CC$/Z\J-:S;N0#<):$1@4X17_VYNRD^_8(R-H_<8!\A)8Y<N-S E
MZ+[0TCQ=<R1-MG'<X8AF=CCPZ*.Z,P>#=/BCN0:22R?RTTZ8#;=OBTD345,X
MC8N#+_/S=//C[.,UE<Y^IHPMO!1)'LR:9=]09Q6LZ1RBCC_30F<.>N%DE%DM
M<>6*;._D>2?N9?C0/CCO=Y6(*H!'4IHCD>XOXX$5HP4BJ=S4-_N90K4C[:=S
MB #982 O"_-I#4>$&PE3H21TH"QI(C9+_'6$\PZ^0]4U9;KJL"@\UHX!@YQ=
M9NJDQ34MW8:SE[TLAR=>#E&BC:-S97=DQXY0DF)D#$<%0BR5])MU]JV$Y*S-
M92*?;B)SY6JT^<XS:8.JK"1FXT$C<^PXL/!?=ML3[[:!NG!N8OV TE<\,Z[5
M-#)I<+.16M8X5?SWRV0][8ZB+0$.!XV(13W#?"FP[*I8F&7?$A)!3MG7!/"
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M9*A1DL=25XRVXW:-'/0(F3?.AM(DQI$^\[AC;M"6E^ #$5F:!5?H6.HMN^-
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MJ$(9OGXNR^&7 Y,\$#--\+LVK54BSCXMNF;M[5H8]]HO:RJ;N^SUV,1><G6
M9+'QKO9@\K1P?^AHZZ\9.L#[=PWZIPKD #5AE9!]R[!-9ULZ^!'J"/=)FB2V
M5S+J98Z/U%Q'0JF$#Y6"+DR':PML7=X]#.2(] # MFHU$>M X XOI4>8+BJE
MUATA '=.H"Z!NCH!8,MV9T).I$-LC:,L'<L0%5_>-FX,:!9*_1BERPD0HI>^
MC+A53>$VS;<SI(/A&L"&84 F*!"MX\^ 4"+@@U>K@\R$;P9[T$N;7$)R9VQ<
MX<9-GV XHO(2O2S($ $OD91*H70M!Q;,S=GQ]#D(4=C/:'+17V.G+U<S0<T
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M5E02VB6J=@*(Z <KBFI/WXVK%4K-/>7.-<P$6VB\5](VMOI[@BP@</(#>^5
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MV\SF/.+9+]/RG@RSEQD)C@_@^ XI6V\LPW>9DO<T)<A^: +94A];00BR+7/
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M%\7RO$,Y"O1-<K\6#"HOBHX>U\$.N^#*<%H\?QAN'VFXJE_%2D2*D+JIFK7
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M1T5!?WX/4="\T_1]W;^AWBPC1Z=D[%<5 <@J%'.:U8](AKWF9-@C&^C.J9Z
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M-!VA\;[8?-:UT)1+='"((G8O2*Z)G<Q5M_!:8>DU:^66691]8KKH\$O17$A
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M"=E/#J;#3R2"=,JOE@,<&LZGN#GTIK*4-F(OFZ;=SW8$SH^FX/X 6(-;U7O
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M_!M]XC]&_)L<C1[9=K>%@]7:<4:IW::M0-MV/7)=$HHQ"D )#B(!$&L.RJQ
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M?A21]@]"[?.'/W^F;1/?:K3Z/?GZ(01\&>(0^N/SO_SY"Q8QW%/U<X/SREV
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M')M(5&&L=N$CKMMY1(66)LZ.TQQ/PA;?L=PD5QU%#?ZBB=!T? _!.;1"TJ6
MH!,9/>B .=$=)Q]ANY S]YQV@PLPC.R#V&UM7RT,/+8[W(4")^AL:L-$0C'*
M=UJJSP"R(*F15@8JW*>)\\&Y#;O.C2'#CJ@JW":?-V/S2'3NV!G%PO^S2@$O
M'/9?9#\A89H6OE&Y8#02X5E#G]*> -NW5Z%9,+YG@&>=VF YWO '0)O"/D!
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M"IVA"QP\*Q-A0CR_NELOAL("#W2FMXI"1O PA+#LIV]RD7\GE#ZMS*_B$?J
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M32KX:U5_F>*/<#()8R "R,;S'-!QJ#K(Z#?T+TD*A.[FU%68C')WU"@-*C*
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M#4YN/UAO(9>VNNIVCH6PCJ<D091Z'IJSA,B- QYR#I&Y[)H?1=]-T9"\DWZ
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MN8!Q@N:)209!UNL^6M7KG#Y&W3Q0MLTYY4,I[J%@\UJ K8DD>PVVH70BB&1
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MQDU&'Y+9_Q!0ZUU"#<^*C\+7)<3WRQ+;M6% 7(R"#0$Y>1#:V%+;NDGPG!O
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M/CA/HLH\.PXZI=IG?];A.)<M_F 9MW"N<Q73DN(-4+6TQ:]'=)P-_G"-;:'
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M7$]GL=E1?EX^"FDUD#N=COL!/X2;SW0TWXYFE8^?1@,<TJ1:'/PXN.M'V$]
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M@$0% .<H!P 4    >&9O<BTR,#(S,#,S,5]G,2YJ<&?LNG=44]^V+XY=451
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M=VY>DM?&DQ^LJT8M&0:U*QFGMF%%#4Y"D50/LGQ\$@ F99;X"/1J9EBZ;%5
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MUCG%<R3#AL[JN=:+[T5>AZ(9L$JNJRL8CD96;4O3IT]T:[]=WD/@]K=#-"$
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M=#C$A[]1[0GHWW2I??ZC82^F=,B9/ NJ&4\Z[ZR</OSDYN#?:3]MLQV4'8B
M24[43LLG-*W,=]3Z,"A(A^T,V:5UDV(C,D5S7+*[6_6'Z!'/RTR=W/HR*#M0
M>TN'\D@__HY7G?E[7,O]^+2Z[L3+/VI*[*"H"4G.5E^9$<S:U6+_C_YK6Y*!
M,F52'^OA?*0!_BTJ?&G:MM] 6Y;M;E[[U'@)H9_-LUT>T/Z:O?CZT,"] H-$
M0NC.3<!83U]$YO5H=BKTU5@KU]C+K,B6R5S\J+!BR:ZFCCV1.-":'KY\H$OP
MKU8=(@QN77RZD>?B]G2]X1[VP68BXDXO3,DS0B)\5$(?2T+8R]@>*HCI<Y ^
MWV)V/Y#ZSN7U\,4//U673YK>>[RJM\LV,V*DR[\D8X.GC5(,^=.+EFQNES\O
M83W!87J][GKJ%Q#I<<+CF?4Y)<6MQ@PC-SO*OYCX2Z7+5Q:--=6<0Q>\,TN0
M\$^\0Y5SYV$=*TCBW;5*>S)BJ1SQO FOT1MH/T^L?7@]R2S!R2E<O)LE74I*
M(<8D%-Z\B%GFTE&_]\SB\C1S(I]6<BJF9/BL=HE>\)JYZ-!;S6@<E6=Y-+'6
MW5U[O:A-QY8TT>@C,E/3*@K]KH/4[KW6[9?V(,E9M(Y75F'J25+ 4 *P ;&Z
M=6\Q31Y/+_X:&*#[_1N7&6QYZ<8'H\4O7X+GI1Q#3@;K^8R:"VEH(569P%C1
M@[ 3,>(4.P='_?):_;*(R*E00!K/NLNC=BT5?7;?1]1[(\_2 I(.NJ,^O4?*
M20*?68.3G9.RO:D%WY(Y3%DG6 9Q1P);.=>&\ SEMGZ8V8A<*_QM'30$5#PG
M89-2D)-5)_OY^&]&;139_6IXKET!>(KO0ZHUUL^C3$GWJ$9Q+AO:%'SG,NVH
M*?*KL;^9JB([FYRSV#K8(+(EP>.'@12/3KO\RV#QD 45N-EJTCON\F8H>_-'
M?D3-#V7.G/)LIP11"W!8%)>YW/!\U+/[YU5BR3OCNX=[?CH&GS!GJT'U(+=1
M9U 5C(H-=]Y8, C+TZK7RR&*^Y1:J.JG(;(-6K+[4%_,QXM+'E5?<)[*$4HJ
MXW<N*'SV@T-NZ,2/6?GQ;SKC@6=[_XM;]XIJ0H_6?5FZ1 51Z5*5*BT@O8DN
MZ2V4T$.3#@D)O2,LI?<:.B@! H&$'D)'Z5UI 1**](Y*E7X=>^Q[QMWWC''O
M'F><EWO_#_/Q_S;G]_OF_"@1_R1]VQGUX;H(+>X5=J:L&10>LG8B0? +>5V'
M/Q+>2_/OH=&NI9>=N.M)ZX+P_QU$1/[_62+ZF(0,:!&&?CI_,+[[,C;^^\&"
M?NN^QA$E&*6RP9%9C9%G&T@R@/,ITPPPIL0;C-<7(K2O2\E6ZH/'="1,AYQ<
M'O@^\1HKV+AP*>ER&NTX87MCN^OBN-3J8;<<[/,PHLUV)0[\< 3'D0O*C7^V
M=T*U8LKM(R-CT5Q.->B3\9HB#H,F@%!Z&Y*J4QD983P $7X %<?04 W&+F $
M"EHOS,7,MB0*IC\+2^3PGBOJX\YIU0JO !<W6]A >S#@:4).'KG(([2>_!2U
M[[<XN;G)O8ZB=X+K^:IS%MFA6A6R.RUP'F(>V(_^5,"[4$@>7L^_&8@ZWTN)
M>F/WO-7;O+SVHB4ZZU[.&N@_]D*Q96B!/D&#BL#5R*^$H)0.U.%'*DK7]M1)
MU;X]5:"#?1 :K?!)E^>8GM97)X4.I=<(F+TOF/EW2\CEFLAC(O@[V--L*'Q$
M1TQ$0$:]9W[IF8##28+//[65:%-BV@8C/6BL J6_/V^G8O)Y:-RK1N%=O F'
M#>DN[H\S 1&?X7<IUX:0CC!!#<:_[4UGK43Y![O-]X8SY')3G9?S()K\T(9B
MT(85SLQ%4%A#Z:=Q*SV#_%^F/J"(AU:V1P7%+0:J:O"ZU^1K&VN.4(3O0A]B
M8Q/QNDMJ4'<M2#BT#6QW9ZZ#>$&Q'[.89/ICU#:4%3WUC<7U_]2>VZG VE-8
ME0VL>-8AR.KT@62)$S&]1_K.B+<%",#Q';8ITWI#)G>@:>MH=(XN8F,-,TS7
M=T#(TFK'3&Y(\O_C=KVQG1-"[ L3@6'2_7^QD-,! %^#Y@@XK$9$=Z6)18+R
M5F:?-$[$B:>-8=_R&B\QOE1$9VCI_?9@I-1SD#6&U^>!L7O&7!B^BH"]!YO\
M!D=&2?]U3S.KIT3EZJ1\1,FN +=EGCO9:S=])%F^(;*I&-^@,L)?D5 3>#E=
M^3PL+V;"%9$/2.*H?.XQV(5KWF="NQJF<VK6!357"80^2EBK? X[#5"Z/5!=
MM"RM3W1A&VW)T\- Q^M<]^B1:9'KX\NB-EP(O%U@,]6L&#SW_AB]-- (+IBW
M3.\B[\SPL>$=S(6(#H;\?8I^]N-RHP!@>MM,:MF/JWFP9M)H3+@# ,?D6FF3
M4HKAM[_U+DECYZ^IC]U&6F[(Q-#WU>L-2;*N ._ M *"MEI\]^?A )#\/$*O
MZ?6Y5JYDQ]G<Q6\TE#AVL'$.OMB[T*J2I 1LI5QDWI"E@)DI)QLD"(Q(H8'S
MV&[RCZ_D^_UA&T%]3<LQ=^7!1%-&!M/QN6:ARNDBM_.#V=3E1GJI\Y?@ M3U
M5DCEQ+NJ0Q#6J3P5ET_C) #RSQ<4O2U.Z]XB]O<3G3:QPYE2_?_%5@F6PGFB
M*>(T"M ]AH8(.P1ZJLU3R6E'H7]Q(N!K9$2#M0:$R^ZDB+>V5F%RLN#;\]3S
MV)B6Y^JQ!GP6#+OAB*$/EATAGIG1,( [0%9HK=.QE(D1P<IMN_\SF5[L0K7Y
MDYF)(0:F<1@7BW:>FN [A=<@*[X[;,G.%+3W"B97[X41\:%HV&/SDSL':V/B
M4HCBN ]B0JY53]+7; $GZUILP $)#QU)'CH<"<3O507&U",RN0M_"UI1Q+']
MBY%#*T:)B ;J@BS115QXLX]AGH<'=9*#+6YV_4"\+M5&L%?Y"#V,K]>TUES:
M%&SO!R])=>U7_6'=])X'D6+4@42M,M?8KYDVHO_F634WMI':*6'8I\\9C5',
M;Z-_G'&@60@P*00':$@;\FP)S(NQ>,@:_*T-\Z53LTCL1B=1?#?&&6;**(T]
MWAT?BNEI:!8#K'T09KJ%C$V>]>S*U4CSZ_LNT,^^5TN;'0,9+G<SK&27=]1,
M31<K43XN]Z8Y8.::#9B$VFFW?Z2?V_PV%QVW/YOPL<0B8MCN,BJI%HNF#UV^
M&)WH-S;J3N*/;!6*V:S(6<A4X6*ZS3<(H1_OERN'I"A_540;\'H/9V\:9)1\
M:AX:UAKY8A]@.ISUGEX$NM14!;G0@6VVG_4DIC1$;*TXC4ZQ8?R,"TW:'L?V
M$\.&C8^;S(5G2@:_CS]N_K=?3*3LC+E?>K5LK"[]E*H3MN(^\6_1]J)7H%GH
MX245EUJ]]Y L%!:NF5;0"]3NAKX09S?NB]VP'I^WLH ^4DZK<P1>\!&J#E/R
M^N7A VV/8F.5M^MPL1\D9"]6CTM6Z)Y3A7XH*/MMR81TR(P^J:GAJL@KBUD7
M;/@Q;MW(<N]L7M+UN"Y2U_S37FX]O>M617J:91UJ"&6?"5^ZHP42>C\N&^O)
MC."/A8S7?[^]C)05MB@KY6&/$:=:CJ<JS!>RLQ!) KRTLU6",/^S"X!*4:>S
M:L(9>T_5!()KA<8!5AK"GNFC;,(.K)6!;ICRJ.//+GNTQ6O\)R%I "[A 0U_
M+]DGO44&/W6'T@KV@S(%F[DJ=M1NR"0!29<*E-<CKN0+8;_YK-8ZOD<J_M_"
M:JFPS!98$"6,=TB0>-IH@Q5\-8GB;Q2&(I=37![==GO3LW$VG6I *U8U!7RR
MN<I<C(P30O?GV.N4RJ(U;X>>OC:<."&\9 J"V1?U1<^\*'2!!RVLX[ 0;6$>
MS^95R'/M=MDV=) L8!/O^>.X"95)]02)W"FZFP&3S]!;U1 OLZT+;UAE:PO!
M.2O!46$^=+*-]Q0->P$"(C]PQA 6UN,JS;D%E#A[1R'61#94D<ZA5M@%: &+
MFUYO\WC)NJJ3:X_9<@V@\I!/-&;#3KN/:-D6%](8Y<Y/!1C\#G8#>,B[M0P^
M80=&/*5N3IQ0W_>96XZPLT+D.CECZ?*DI3*IX^ZS8EM8IK[!!]*\9W2BT<V0
M"@^+C<<5&J1_ZJ_J=J Z4UHK>L_;-.Z&;KS\!?G,/("G;6(C&"4B*V-\SJ ^
M]L0#Q[D$+G?V2.G[;? ?/Y,J0F"+9PAU314D:G;(!EHTF7=2:_O2D9?<;C!E
M8;<\8N"&;-QB%GM#-KJQV*-E14C*?#T^O>A&M PH,W/33IKKN(S]]LVJI 95
MW4;MJ#MI_$SB[->"4I>;_(+"5SIU62)A_'-C;6_&VIB#;QM+Z'3&<";]9S1^
M;'GR6/I4Z]@W=R\T!P%5,$1@-M-D06G=6V;13%FY$;/)SSI]MC(+>N1B".NE
ML"N6+6N);:GEU:%S2[.OEB0/X<GEB<:J)H.2^S8DGT)=I2GI:==X.4HFA17D
MO%'F_)QRUQ*N J%N"-8^UA% %E>P8G6P.ZDLK\WV5:]S1X,E +7G6OHL3W%,
MDHB4?53QR?N7F9.&P%DY95"VXG>\/7>E!<W>Q6%ZJY(+]+W+@),PK:1,?VO9
M$A>C7_B_Z$RBY-2MP>82.XANGH61EFIEMEJ+3P*]]6T1C='NXQ-1BX@H5_:I
MEBLMYP^+U2*9PC'9]5AN"^H4.P?_[E)!:C>\F.DV7*,HU@/-5U))3-'*#YQR
M*,8T\3SZ OYI:+I[QV9*DTXV(&X\,'4/R,36/'S)DOD1D5UI1 IB5X0U^[O)
MK^0;.U>XJ(KUI,XV=TYPM?@(I3DJ2@=>#=\7PL1BK^BEGTW%/1?HZ5'G$.$D
MUMW'6_+AW3$$;TVZO<VR<'RJT7U(&\7$H$9SH8B&\58R*68PB],.6HV46_7E
MT?8WN84K+V[J9(^.<LRPT '@QE+<A*C=^^GI#".',EB)VKGMK_\R_N<4EIPW
MK&7L8!!8XOZ+)&:87H@0>(XU^)29/,8^-%IDSNQP]+MR0S5R5=G:=]CU2F!5
MV.[IZLMW")AZQ0T9XX)O@6)M)7> MN22O:Z*!>&HF?])/Y.J@5YEQILI \-8
MWD!ZS6QQE/U7Q3P<X [!RM8*3LDUV&O??0\=9$TU$F1"]')3.1T5\DZH%]%E
M>>5;MF?7C*-HVPPW5IUDM\5C!V=]>X1-R),C)LG?I+Q3ZR>\Z>!13<@K;833
MNK%$YMUY:GR1.SYT0_;QNPNS0A'*;,C<E=,P[T0,XLAE]C[KH.&EB=QUQO;!
MBFD@=WZNF-NL*BXT+W[]#<D7N!EL"'INE(\QI"[\NO@<*_*D4 9Z27>LUKDY
M0BO4JH9+B&&S6%/6%;7$AZ1>?9Y16T?:@](%PCDC"B= $;+.$+TM/B,:4+HT
MNMU(W8"A Q[)0Z5K_.^#1_SV%X\H[8:&!-<H<Z1&JX7NW3T%3'D,B1AFJRKW
M%1DQ*+CHT#;Y(O/ @-QB@T;OI4X@J1BYC5)Z8(9&!S Y3QCHTSQHK3/Z$;@/
M3K@A&T[8J%0>]-+8#,60^J0@2LY28ULR=PF5+R>E@"TVHA5W$Z*_MBC\M \(
M3O 1,*0V+K9(N5?A4BU>Z]'M?K;Z0<5B2-*G53(Q*IGKZR26!Q4L&08PC#_Z
M,(\QZ?%6\\U.Z,F/F3E8B(TR> O[][\LS+E)(K[$$P8B,,,$]\.]"VS\#JUM
MX&XQK=+#.<[^9Z3'?3VLXD;Q.EB7YXB.]4MJJ#"8&:1(].?K>('2R6_(]D/0
MI7L8?[$3XH!:$G6UC>+XW&G;"!0\F66AN>;3/ZF3'>P5!#KQ-!^#KRWN> &%
MF4555*95'PD1_80*^U.=]'J<[L/ZY0.O(-\BYX'DVWQ>[H_#T?%@0^M%"&92
M2G;'"M'4INVH$*H$KO2\#N<;LK<8SVDD,5:-!"[[R_;G2PV8C<\<,"_[L6+D
MS2N7<C)Z-!2Y*Z1;R@]*?_Y> "_[+OJEOWB92_&*RX<-E3*WT]1#T=LF*#4Z
M!N:7@<.$N1AH9,U]I2L^S:?Q;E7G4QMX3QDO-XUR&*<UO'>Y<"(0\LLS>S_I
M!J8^_#-. Y:G_I5,@S_WE,=4L*E8TNP<$+8'<*LC3<RJWQ4>P&D#YQ>7GAI?
MDCH.!9+3XU2 =1F=TVIHV3W[;O]A[0=]"*ZV62/*M!NRXJ8Z\QNR_*\=L1EM
MV*?"H255[8OUS8=ZM0O93YM"S^@+/[5IV0%M CF'/Y9A_G$Y7&F-BESP:PTJ
MX$OVPF%+WGLX) "&D(-[@5(W9%6 ;&'!]P9N13WH;;?]S.T]:>(?218@!*(%
MS<9X/4N>QXS7/187E::L>_8F?&="1"'6AQ8[HD,ZEQYO=YF$]0QD'C77%;0T
M+%NB>TH]K#U+-6FZ&G84"Z+*W2IGGW@SB 7UJ317B+0TQD1U04T$DLOJL[?S
MC%0TC&7!^>;3W%(A=7,)5])YOYW-'8XRD%*O(6)00:YYH,;>K0"1LK+<6N_H
M$K&(+_!^#8M&'M+I!K]_Y/CTK8G440M>B$=*@'ZGJO"/^W\9B-1#R^\@?#1[
M)S_*-)9G)%B*)?GN, NTDUNEY<?L[-HV43Z<4:CP.\\8N]/QUEK8DE;<!:S>
MR,79._@K1L>8<Q%N7S,YEZ9&MP+2U[+$<6;*'9</:9AY:C[]@/M>5C-#T56>
MSN=YR%A\S$/,$9/WR?XM+?):4-RBHN'D93C)^^>"7Y\<9LQX/-XACJ?.)P*E
MYKMMQCL<#C^^R*(Q,Z,W/Q> OZE@T#&*BTU6M%+!.=+"F_7A2V:8S71^TIC^
M?3?N<IJI0/K2]#0?1:M4[ 0'GA;Q0KEWVD;9IW]7,^MGY1VHD897N +UPQ&A
MQCQS:!'G@BGG4K( 'YHJ4TBV/ELZ..06YOT^B4,V*P,SB#K67%IIL$?S*PD8
MZH)+WXAP(!4R\U4;)(:V?EF.)E#U1[?O9<V>&_5;]+[N][\0(*:87(NT[KV,
M<+!0/\B"=O87Q#9AM[Q!HLEB\:A"2Z&P<A2:3OM( "'FI#U0$"$+ 5-B6KM;
MYQC4$/$#T=2@DW:6G).J^O6%N!]YIELLSE8%4L%[^L0^'PA]T-@]3$+9RQXW
M<T3M7JQ%)14'9=F#,,[SI!1,6(AF HNLKOL<[X(TE0S%*^RI=,D?]_;Z\[A$
MD)IV74;#C#):=M=^<EBU[K;HFJM_I<\58&JMM_I(0U[*?K$V 7)#)LLT'-:P
MF_OM=UFQ3H6\:1F7TL=V7;"5J*+[]&_^[:2(L1Q>,_\D* N-7--@=(%M"_R*
MY^)]==*(<G\)G]$]%4HE5 F%Y[?)PG&]<NX2/C>#X/)D%"!D_H$F<P&6C,X-
M;:W\J! KMOH2&RVL'D_R7GL ]!B=G9#:P]EUITH>CY CL5.NA.6<YARD^H2\
M=DE%3G*O@-,B)T56JUD$1062YQ9"7/HY4\T*<*#)%&,OT625KS6W"EOHV.6*
M_"*DYK7:&H,!HC(Q)>%?3JI$!E; ,\2NUN]N]!CGF+A!Q3]*!0UB_XLX&9:_
M!F)8<<0\/7 )'TOPW-;((0]>0 @#VSU8"B_S7+)CI\H2?\/>P3F_1U!M7@$:
MIW90-IY+[[8G59LW4/0F.%$VP/NZS__3TGQ]>DS]XNF3BK-%NZ_9NR?DM6/6
MHW/XC>1KQ[<Q>!PZP!4PN2!)>,@3E9TSNU/QA,1+J2^S0"^95Q@GHO&D>#6H
MZ&%GY#)IBE$8Q0.H"^P>CIU@:-H>X['+*^?DZDQX"ZF=RI9J(L"KXUV'N>>^
MQ*+C:*07O46F(])>Y"Y$VQ[AQ*0&ZD4N&$+$MNM$7F:'PZ'&*Y&>)AX&R;2J
M*<FQZ6^_%R!',IR;U42H^,%ZE^3\0,WT8,N&&[(-68T1ZI4OV37[69G1*6_5
M8H1/%,20..,CXPN7&[+,[/W6&[*C=^L=V;TYH1=SRJ^\ 5=/5QW!K\^"1,_2
M.WXK2H]V_K#-5 _][<9Y>;2:TC]2;>7MW)$6^E596F?2XJ[3MO0;YD_5^S.1
MXW'=MH(KG&8/&>8T_+43$K'9T(:!'/O##RAGVQ'53_,#,: I1QH19CXX_V"]
MV/6["U48NO0+>O:\OM[9>?>%K;(3EH:%]3?\N"YUPYL4").IJE(RSZ@40M3]
MVS#?>=RU;&.QEEP#:ZXH,;3TWHO@<,6D?BFA-XALS;][1J/?_/<"EN9-N0:M
MC]CC]'.T9[EW['JD> HOILNFV[-%3RWN#G[O>U.*^3D:)2!='.-1)-4]!\I9
MF69(\-4V]12N@+4WKX@GEA:H"'D6\!+>]JH<\O7!J=$!+.NF:]A%[AQ!DQCW
M@WU\O"8"POOJB=0XU\X4D2<ITW-+)U![Q&9#M+$2VF' TC:QY&VJ2^DB(6Z9
M+:_I#:N'=\?HS'W)ELQSS,+Q,))/I"F+A\5&.=U^LC?D6"S"6BA:'VS>3PC'
M4IH\ 30!0=^N*YQ77+)((A"^AIS;WLW!1.[B<4DQ22R$4[Z)4^#Y#1FI<-+<
M!&B%<SU."V<7\_V@DR,/J6&5])[J=#"Z2S6MWLO9S\:5WBT+!66A2ERL*-[C
MJ/7[8[/U=8L???KOWO3_HO?Y\MYR.U0])_:S?BPJ?%VWQ\2APU6X.89[5K 5
M\XC+*7\[[B>]E$333+?'.E;K<^*5LZ?)OY./CXDAS6/;ANO8KSD?3L3GY[//
M19=:/WU5&JD4\K&S98ESR@C*2^AF6J&P;SEN^PBQ3N*'-3=SKFT4\\);'++7
MRG.XVPK=#.;6_%AZ4P:Q5LBE.I\RXC][U^>G]I+7D<<#_F+Z0O.*G!J3+K]L
M<?'1C4:;E28*-)=9,Y=^=6Y4HSKOYI\Z:I]%U)\Z:-I;S*;MMKHX*HN^#$-7
M5,(P 0QP35"$)@"AXT2;-*77#6PQ5F_T7'.X%^=M9+C*$\(BX!NBD__7H?B$
M-N(]E8B)0G_!J8)),6&AO(DYPG+O-5')QA:614-,[F1,!:4R9]4C,>]>ZM07
M19_1]J_.9$:^\^(=&;BWSFY,/@;S:).#(@WJ,Z)=>V9IS8"?!1K*)[0&S$P1
M&D]^YQO8F0FM]N_JY[8T>>*^S2:<&4CN*7L8,C_Z)CR/%7C+)^\&/!-1ERD?
MZ=\6'0)EM/WNZ<9>CH?\P#]S+M+J(<V)/',\=%V>Z:DU0^HRNDX9"U#3?@S?
M?KI3:5D"*G':/6XOFBCL1(VH#WY.6A^U5_;L[C[!^S9KU:64)30?0VR:4/\2
MC5# .BDA7QGB?30FHI1RW4F-D0JOX/IUR7ATQNHQH%BDPJ,["%VVGC7X.).J
MC+"A\ZH"58&0%:/YD=3C0=FJ\(KZ!)D)*R$).F][T=2)%#95V97\DMR#M.46
MC\_&)/C,U-5*6GZKB-L@+(36^^C6<,ENT_3*NL =W@F+^#P;C4-T5J="R[Y@
M^USES>3T2E-C&XE#JLWSJ!]\<29AA)_N<5>^A>18FW)ZIN#J4NZIZS43[Y[C
MF5V@7V6D6<U?N1IL:3G:2<F0V1U&@J^JXW%:[U:S\Z\B3$?*F.?4A$,<2,85
MJ2;[4"FC1%8;8HP 0.Z^BU)^EUI4E!.;&'DQ<6$:<7N'Q&!_%7=JC/[T2T((
M.U WX9S!,OQ[I.U3[*! %Z5CT%<62SW"(4.%$"159I=]X%>\3N"W<4)3P0N]
M*F[ D67:OI&U)3# V<$1HZS9Q;V$T9)U>::M].7;4%^P-*XQ,+?&\=C]E[1@
MH:16Q(SDKNQ*U74[\MI39.QGTZ;?AH 6*?MLLUCW2&"Q31YD/<I6-8(K?M4"
M>U?[5%%W'9RY86UPKX7*88]\0BJZYMU$R%H\PF5\)2X6(5D2Q[5/_DCLSH6W
MA'WM6,8PH/GS4#.TK[W(D#&D^6\;=A,'RX/-$AWF2Q'Z"A6M0LW>G+QL6^7(
MN \TLA4T7/LC=N;XO"81P\YYO "'EE7DXE^K#F]]M"I;2Q\LTZ^75Z7'V"#7
M[@*@ $H6]WEIE5^^+S1&M)T8#G<Z5^$#J2BI7TE.K=)5VEL"H14AT^K%SDZZ
MV:8^D,LYR<CS;NVO]I->"Z>E-5Z+$0J=A_$B#E5U>SCS'SHV9Z>]7<MP Y)!
MY6#HL*#UGLK9IJ+:#9DFZO89A_DUS7I8X97;A8[P#5FNZ^7BE4"^PNI+='R-
MQ.V=4KY501$V4@HFK[\]KPWN#(5(UDFYY#L)Z^Q;$I67^[,?@7\:XXY;Z4KO
ML>C8PHV-69 CVF)6M*!CKP4"SP()\5#E4Y6];R=LOD?6C[)/7<LE27G8-8!K
M-4PTS8'IQ>*3N4RV&S+8:'9KG*%VS^6^>18P#ZKBG)OYN&&V^&&,P.PXW]5&
MD&-!U%-'WVL=3Y4*AK0WZE#4FFJ+IDFW72V*M"*W+@T;=GSE%?,(WWDY$(@;
MS7D["RA]+OI#Y#(-H(U+'3R^0.EY;-8DY"LD#FXG)]BO&>MA;.Q$Y".!PCK-
M$1H8\?IDPTL@U>''0!HY#K5<C"YHUT>R?RN[9*+(:B<G.L'W[T </3@Z^G?E
MB.40P]Y K5";0B 7QL^)F'$GOTSA_ALP@P+^KC.X.N$9A7'UR1KN"8&9!H"C
M^RQ9]7A!,M<PI@L\[</L/CEU6XSJM3+:_X7#]TG^;]^_0$035"M5<2^0(2+?
MD/174:F$AX-4F)DAP9T/3@S->-^(UB8 ZT<_6QY+?)]PZ<9S&SUL]U5NBP[3
M/?E8L1NR=TZ#&AA5A$X*WCNVV_S=1 [M#_GB!-W+&S(:/#>BA0NZYB0X]JR9
MOMA$3/"[[7A-$VA#0)#)BT0_;&(_U[838B1/.QSZ/4X@]#ECWT4-WRL6I-\O
MV8X!Y6MZV=DCH:>MH?*A<BU1ZW&/_R-U0FBFN2%[,1FJ$#K\&2 -_5&3B7VT
MJA-Z8>'_VQR;E!^XL?[CAHSSY2YW+68+EIZCEYQ>CT4SCIJM<\D$7M\"[/0,
M%WRJ;>:?<GK(_&3[&YHW6ZO5SIU>[%M[H?/?L/=A=PBJB1MOH'EH%AAVD3HN
M/+X>IB[]LH%Y!H^TTA?G&ESAL,N2*Q<PQ,E9!*EVOV8$)[?R+'VOW'O=?V>@
MNK!KL!\(N6! ,CUF^V\+[/]X=_E:6!2R\VM"!WU=;\AB2,E4:K:M%R2WP9YS
MK6$BRY\F$=N[AL':[6$I?1_/0_O[G2X)<6?(X$$&2MRB$S-QOEOO[/9C&6PA
MADJARGSZEK6HFWR4"-\VS[A!K-VT%YHO.SME,DR"M:M%+GS?<,)WGZ+.M]*^
M<5\E=L8,5Z51:PLD AVSFNWK52L9;>&^&94;MH9MB9N<-KX$P;.I;QE5(GM.
M>Z-C#Y6'&HI:E,1,_:&\-JXM[%L)MF>^BGTR:B JWO4A"OL)T/VNXE6FLN,/
M,5S]Q0%VRC&&U,KKYV5EF>6P'&(8.*O2G/A@>)?^O8+(+8E6>^*ANIZCA_PC
M>0;>A86(:;QG^ \2;+?.U>/:I,;M4M.N\+B-L;[XJOEPR?:U".66NTZI,&4!
M"<>%R&RN?*+ER$]A7#$P)S;,4912Z*\-P1RH=&H\!Q*-<4N2"F^Z2=2<7>%S
M'K92M'*0LLF3*H_>DZG=)1@LF+"?=D1=S!0NYI/[=NX0U*0D2(STXG*N\W!7
MB+3S'WF1#A0&<D#!)X8LI?2(?W8DDX,\]</HZ?6B#U)*L-Z7@G961;-$>9SA
M?;^F7T7B@BRQJX%%#8CJF:FOL#V3-BQD$2]W1<?".T:2?W$4Q!T[GTL%7C&&
M40.@(.1L)=/7>\]B(! "C@/$X:+#3&C_1'LN@)0:T43"I#R?#@_3:#D+9PFW
MF;G:1O5E78M.+B@WO/"]-YBA3$FGV3)PYOH.2O(<3]8V#YF=S!W2/N7R52\%
M\U5, ]( CSIZ\J:(()UQ4)'1KDYQ!J0[.^J6%1=U"]Q;JF:0<,'CR.U6V]AY
M\GB/HDN6I#;S46=B&M<$W;ZM>U)GX<*?Y,2CGY#=)$0RW.HQ,_$I7]#NWM^A
M-3^.L3_C+35S%)GA,[GW:7[H=J6<T)W"U#)]^ZVO\3.2S%XL=[[--1H-.T+9
MNRTGX$T5/J?R;MZDO3A08/N$;XI0Z?1)8>U\::(-.#T=TJNR]=&2-G&*/W[A
MU6S=<G1K2<\SSQ0E?2D8/9I6>P=KF*QAI [ R?5()?TU0<_?JZFD@_::WQ&-
M"5IH'Q=I-7RX. )NPQVE)!U]#;?G]URS#+1P;[B31R1YYV:F_F[:R5(IM5 1
MF%>BM]]8U"&^4->;1.HRS7N2:U_TL[S?2]][O#T:H?9>,\4W6]Z9=4:[ZVMX
M^9Q?4*MVQ YN9YPK,N](;?-]?464T"YMN%=B%$#(S9Z+5UW&R%0&X9\S8?!H
M_[Z)I]BX*9,)C=MT9GI@>6PY>@1<H0BJUPXOD74,O"&K3D#I'2D5JP]-K#JA
MOSF4C,%AHR9. DT6E9-G1A9K1J"[D/5.XOM/"B9;TY#*:J<7*"4?MT5"(F_K
MZD]Z5E$KVV$KX555XUN_8DK"_B96#)C&S5-CBM.+$@%=,JL9<V(/--VRA8\'
MKVRMILR(/6+3QK9:PRX>3.0"0[:CX=AWFT?C2R@OUO6BNKJ4?&YYM_K*BL +
M'"!W82P#*@^QTGL\_8?V^H_U\T;:W/L:,B+3G4M<.GT3N0JDS.0(Z4N</<?\
MG:]8!A^8>BPI)=T9H*%SQ.T:$KTL,G$&)!59^(S/;O%>TK692,?OZ,&N_]QW
M20(_',[";LC^J':QJEQ<>^@A[\\;LL[INQ<\,[]ASHOOD_8M+Y^+74>8GY9"
MM,ZZ<&<-]5'3L*H&R-[]U]D0Z_QWVIR2NU,#&:,#5*7G/6.^Q<4Y*\%N!:6%
MJ!?7&LUS?E)$[P6:E19K6^G*-:"F>%Q47EU5MN_H(A_:7"RG08-A29$UCNGI
MQ^_A#MDY$79[EIY1!M&IX\>,7&O+KR7CO!:JW2Q113/'D,JU*L<[<MNMGG"Y
MO@;# K7VJER=L6I;+H;LE-9]E@]BPD07AOD[;.7'9IDZFA'FO^[SV4Z65E[Q
M[_!!SA$LD1+#]?6,VL/:8@]:)=JL-KA,8R;:/$,FTD:HAYJ('G@WWIV"WKC4
M]7F4C$ER1@1AK0B%V9<<KRGQL/PW 92L'B?][@4&N^+#22Q#UO&F;$D'*T\K
M4-3E^\E,>DMCT?A#HS/?R@80,\;N)&7GO4V=6T7;KQ?K%?HL<<(+9]-/KU.E
M1MS6SUBNYZ;^I9'\<9;K<$,F9?TK%Q#G<OT5*NX<DK=:LX)C,L\.'!0GU?V]
MZI F!P?(S_.N8FU7V25YC$L*7Z@F@#5Y-9]ZQC2D:-!;J4F6W&F8G!T(4@-Z
MUU5&R=Y]9<4S:T8[#_L>,D':DX>5>2K80:KDMF^[P(?BC<K-K2!W]9M5AZN?
ML#P?'#7$);?D*=M'ZM@(WX??SBEMW&&UXKA(S38^4(/DM?A,<2> 5*($,_.3
M)VF. \X3T+6>/L["44;(WG$N@2-_ZYS3("'Y4KAU"V3N<O'\UE^;;_]?Y?$_
MWCT.W*.9=<+IH>UPZ+YVXV.&BM&1T$/9I!P/51*-E..FB0'+*X]V\&B@3WTM
MKTIVJV>X=_X40-"_/G@KG6U/D(5NWM!F7[6?+KH&'NN UB^!*O\&&IA,W8JP
M$6J[5>JXNO%\*WG=T?:5F.Q.$LU2["I\(LWE<<?EW4]M+%N!%M.\?T]$"O7B
MWV0+LBW: QKC*KKC60W>#]%5SH;)IJH@>[XC!ZC'U"N7_#L_>K?>MNW7XZLO
MW:H_=V4RQ5LF8+3] _.@097'57SB8Z8AIP"A4$"FR45TXWEN:&'HY^D<X5!)
M4*BL=:Z'N]_)@$)>DSG[Z[K5HX@PF.;H9\R ?!&+'0G*;J57N2"ZK)\=U;@G
M0Z@HX9[W0G@[XXQ=':@!C&_LX[V__FP:GJ64E!;>?(@<ZIQ@B6+ETPX_:I,&
M!C%/VP+K!>SL'GX2TTF5?),K);<-,;NS5C/<O;J>LQ\%I$Z0'+DUAG::_RQF
MG+Z8DI!1PY#85*B)TVF18-:J,?M2EJN:$*'88\A;=FRV0V\4\GRPO%E_)S<A
MT[8S_Z5V%W4N9.YD,86Y0&>V%UNPYS-#'%F^)^^X([22L0^6U9 D-<';"W>Y
M"6_LZ?ECRY]K]_+'0@Q1A7B@#IE.Z.8-F7A"@VKSS$Q&N55B_-=B)3GOH^:^
MA5]""QC%=\I4)<6*1Y%! R?,-V1R-C*L7:5Y$_^:<W?.1@UEE7*MB%>Q][2H
MUBA<$U-/EE/1DLX)]_N>84KY2IPU":5J05-E3^H.7FRX3$P>-;/P?N^."/26
MLV,=NI;<$+V.6C')0&5^S6V 0E":TI2.\O(2ND#3/1'TWTMFNEK]HDG_MNYR
M\RSD80PRH/S0NN3X/[_R?FM&2(3R%7E.6;>WCS/CE<J[F:VPM5-.Q?%'K7X8
MW@Y)]O*RZ1K6)CS./"$[>*RJ+:LZ7]L>TQ/KOI;/D>Q9J5K[:R^-B;T^MR5G
MOW%YB5-SA&X3:_2&-*U<-)&'THGACGI2WF<:@U3*6^5O9[&%>((T*==YUYE$
MR)FMJH)2T'Y;@L^=V?UZ<K)F=LJ%YB/@Z6XOG8*_#WWIJ?/X-'#I8?V<VH.P
MF"(P-HY][,.^QN1<NED6%PXR$\>C=;*I=,@$"+$AH%+;[8EQT51;8ULKSIJS
M@=BUSB;6!,-12,E@5,1FR)1Z"V]]IP%?-E1M]FLD0E8+[+[-*&"<)X'U=]DV
M_M?]V_9>U/AK_+FV[7ILN2J6S^@>9'H/% 6 6AM$[8$Z5F_M>J;43L^>$+&G
MI2\N+U;> @>#(!!S_C_LC@W%,6X4,M5+7Z<[D"Z)I.!^$E?2ZZ,;LI2YKV=8
MQD/ELW0A1FC[J"2N);KP@/R9A[F2*7.0%;[R[W;;!;^'5OJ36L6E='V5&R!]
M<7$N-+FS;)2OS_TY-&IOCMYQSV+ 8RZ.OKH.:I5FWYU;GS,BZCW@G& AW#VW
M![ <[48'L7U3[MS#F!Q6% *LK(E?2?E(UIA,F)IOI'WU3X)VYZROP@1SS\%N
M1*)[8C$S<"2#;@!53!NET2^NOW.'1BU%_: WAJ:,,V;D6%]?Q) DB2/'B5K@
MZYFR9P1O!5K][>(_@%M/_C2\[,ON*P1L:Z.L@J_=7_RO4<B=0!$7C8O_$87,
MU1T3=1F]:*LFOSNE*O?V1%-+4_IRIP+-=^1_C'1MC8;JZUQ:<NO<8;!C\C<E
M( 5^!4N^$4QQ$OB&'7.OM:8MKD@>&E/,%67/UZT8Q%G2)%$;G7IETY*'UO=U
M.5SQ-HT2U1@I"V%!;_/];*#R/':"@T2%[R<4@A,LC!EFM^9G]H\P@8(64D?Q
M7'74Q)JR?J,M,_4Q9ERR:XP%WG -O:D;,?K>F?\D4O/!7+$QQD128L:_;NGU
M0R_67#])/\'ZU5$EA4&YB?$%I@'3KH>KVM/VG0[:/?XJIKY4'^*S>2H#6")=
M9NV*-+@8J572&XJ,4^1@:0$\J@ETWC7,Q35S>>@G]D#"%L@ 5&L@7KT$_*K
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MZKFORBY>8O'JB8:B<UW<B^4F2X[5@-Q/OQAX'!EM:Z6":1X,@D<A*-7SBJT
M-)'J7DTMEU4)<KHR[)<]_%H'L99,*,@34H,56@^VFPOMJ3M:%6MWX_;@J4 K
M#RS:*"UO"92M38KYO6C"HYSB^:7D=LT]--=9#<)C]R"V8%9+]1F<3PUOZL27
M1,); '4QVZ'Y]@5S=JD)EXU6$GRU!6]R[C]L+?9_:2W$.577%DP$Z%;3Q1K\
MI_50Q.33&*X:0>^Y-(20Y9 <?VQ4B#S9"[JI:EM+_A@P*#B^BZVG-$^]"*YA
M::CS.K%?Q#S7=J"QH\3?<A3]Z@8RGM8M?%W:^YE2-#,+>.^7KO^U_R Z*/2!
M)0NJ7B'&:\KM&XK9.U:;^%[7Z&M%@^+7OG1U)8H5>Z":P5NN70I:9:LTT<?[
M\8H0&::V?(C.LP1%_34XNPL[@%:]>-R&CR='P#H1,3;;S4-;2K*B8+D)@6ZX
M<$/$V[ JL1YX;17\WK[&:O)=6.&-7BYF'N%!<+F=_*6>9^?Q>UGTYA)-#?;=
M*!PI]C?"^%V1/M03<=Q3<H1-,=$\Y/'^0A.Z 6"<-=Z!'E7K!/GJ:O?AE&*A
MH= H)Z+@C0ZML$\4>*4*Q:-":($K,_][8/9M7/,?^+7(:T\["@L7,Q<GE^]V
M DA&A(538LB1FN59\H^)[L?<5-@1X7+.&2#\D7#U;I"C";06-R-D]'G^9_%:
M_($>\6HU@928'.NM0'K* 84QB*V >,\\-]6%5CKY6DMZS%O1IU7V#XTX=3;L
M;*3F4RQ>;G#<I#6(! *9AK2/#VO")0<FO*N"*>Y%-)AT<N(1P]R!OD)-5/6^
ME3SE>*DQ]AJMTX]Q^6B52]39(R+(37SS/,5,4*%3  V2)_RF FR"@ @%^;6V
MKGSV@^:VWRJ?\1G,B90+C *)NRJ^FV:\JWD:<4!OD.BS%L;$.>=[%NJ^S--A
M&ZY*F,19P(LICV)Q/\7D@@*TAHQ(X:E;CDRLG9XCVKVX<K_<;_R^W#I1P=_U
M!C>U.WL>FG< 'L>M9,N;LX/HC7=/@@;PZ&Q4)VIH78C S4WV7M)S035T56&:
M>YQI4U6R_I:9--RN<XX(724BEPGO-9#2RE2HXD15 KH;H"(^X1>@TZ]2'&W,
MF\<-IW]GHQ-ST$K#K+@KO>BK 2IV,"A5MX$2!2E+$&2/-2JF.$V5[I@DC!ID
M=*E>=Q,9Y43RAG+(URL3/<N#>+[/0UC.Q;_/O"GX\/&$"&(6+W*XX[]?T'S+
MK1#D-K#X$\NMDJM=_DIB_"R<)\Y;L4#/MZT#*63HPD3"'@1-(IH6=MVL,?#=
MJ5N=TL"L%HV]XWW15]11*QL &7U!0< OS_TB54PXC TM;%L);&T^W4#M;S7U
MIY6>G=5RH@B7"Z '66.COF8#*3:OA];%].;.7<UZ:DL5ZU.T+W&))+_RIS?O
M6['#M</Y-.NDQN-I8V,3H* BE/N6\R@M3G% ?)[ZJ\(A2WNI]/2TPC>>KD^L
M-J-"3X((<76],!LHBG6<.D<V3.B:^E8RS2V9&,%%ZT[245F(=VND5E.H5[<F
M'PXWCKI((S>)\)-*A#DQ(-T*3:!$TQ!6A2BD,!##P'OJXER[%L*L" <'P@+W
M1A7=M@4M8Q*%+7,E6,"D(='(+*N.&0=:@?NDKU+AB,\3UH:U4('=9M3ZZ@XV
M/3O8-B!LGT0U_ NO8I2KUO,H8Q+K*:MXL:5??BS$N3S;VF%FJ8U33 O=@+C
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M0RD"NCC4DYGQ$%WK5TZ,<*I!9N\/5$4[)?HJZ:>W,\99<%RZZTK3F5N_T>[
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M41$1^JQ;O0<BNY0;Y?8MJ:?F^[N'3A2C](C5@UX:"O)ZM?&X!;<9H6&CQ0^
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MJ0?RH"%MV.>V[R!T\MN!VUAM7=/HVOS\:J/8Q#7)\V['GUC=RW5E!HQG!-:
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MFT2^ZKTC)Z(PC31%4R%O;6ASG>E<HP8^+X+ 75V['.&F),V#AVMH($%>SVT
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M63O109-,P(%E4CAWK"W5^@#@N*BYF>'-R^.D2PHQQ>FET/.%G+;S:F 72:\
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MXKSO@?Z7"R"Q'P)PM2RS -HV5288HP>A/5:E M,2+!9,F:P&-C4^VQ6:5;N
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M1E38Y8T$=,&!]")6!PZMBYYV!L:O NV^FC\Z=G'Q SY.V2.>/M!)U:]0-<E
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M36DUM[H!*33-DTZEQ:Z&_K/[WWTV2X7A(4WYN6_J(D+WVG'//._=^1#-MY2
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M.NBIH\A&!"HEW*IZ@ CV(&A&R;M5>6#OU*U$?#FI%H',D=Y_>!H[>/+2K^A
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MZ24!Z01$!RG2 E(26D -G9 @"00IZB@U]!9""2J$FD()! @!E=Y[#560WFR
M!1QW]G'//NR>LR][W^_3_][O]_ONN4GZJ67YN/0)*\OX <L/YZ[)W',9]K.9
MDUOZL@7N^#)@8)93R=0-=D0LU%UOR>2T,P8:%^=96N:[YE5%Y/^DMTTY$S[I
M?=+.:T1]K475(@]!G><QSIG!E;X,F]<(OJ."MC)]506/CQI]S]WB>0)45;Z(
M"5BFOSYSQLK@K-D/%1E_)[6  Z&G/?ZI-5W#PU/,U^NR"F.M7K(>+T? <N]S
MM1J%'JP4JD1T?13M3/+\MSOX76&8_8<'&RKV]"E__9OFP9*:-V<,4TVL+^+2
MD,&,B/-SB&:^/@4?A4WJ+\MQHY3S])"F?+?9S=M@I_"<%9IG+NTK=+^5A3^J
M_C<$@?*7VNJG9\R-OJWFPB3RT^4*NVS8@(VK5M51Y9I!<KPB]!LYCE\F'Y1H
M)N&,\ZF]A3Q#TGEMRO ,TP"@CP#)W83@-;F42R!-52RJ<7[$.K4/=T6_^GD^
M][FOO#*O:(""M/G$83FH.B[-R7^6'<M,)QGP<"&:6-+>VSUN*ZWD\:,6,>?J
MEY8NP*J"YZV%\J>)93_-ILQ<YJ!?-W%50_08;+V1BV(IS^+9T1VQ.%/-B'Z+
MOT,@S\_[B*6D;LAKH=:K62!:_T&2L,G'P)@""RP8W& 'E:7 ;UMB&FUB<;,2
M>V!$K<JC0^!QON=9Q>[_E?MUDH%^)T+^RV!7WH%I0,K:EZW),H#]<2_W@85?
M^:?!TB3OU?D7N'END39MJ':::LOZ=M-*F._JA$E+T"6>T !'_<%%RTJ/K%R$
M^&6\\+F;%S<H!:DJF,_*JU@A77_:)F$>XE-YZ"J846FIK[*ADODS,#!@"N%>
M\NXI7$:L8G[5 #G<%^S2/G<OZ?_#MRK)VX%*>%\_?]W[X=<:UAL?#7M6',]D
M\T?F*RDI'LD"B8C(X3J_3]D: =\,G8*W!-'%=&61@OG$*Z<7BAJE#6?M!"N/
M7[U\:FWQF&'(=RCX>C>F,[DP0J;4$]!B&G/HU7E*%&XM*/-$2.U=/C;DG4=B
M,&#_6.S"8O@SE0\M[B]#TDI/JB6\#/KGZ>6B;D( .H9;?!$]](#K5YT!'>M/
MK$VG/G>D:#;8X@4U=4DQ 31!Z9-J" )EZ_R2\=0D IE;%SI@[%EO4^\X=R0$
MA:,X/PS?<;9Q\4.E/3_(B581DKHI$M*9T.Q&G'G_9!;JM#HDMXK4V!_'U=0.
MGD/<Q#S97MWJKX7:]Y'D!/V;B0C#"S+<$DG#&A4W2EJIG^<='5?6>OMY!9IX
MI8TWSIFGV*"K?U5IMQ:/:8QO1:\9Y--F?.$FU7:[Z,G9+.0;"8OL%]]Y\T0/
M?"1LQ\M<>%0FL-\#OODRNVQW%'S-Z%^7*D/#TQ^5O52E$*04*@._)#NN6LT+
MM5@G\N;=6O-JAK;K:DV<M7V=%)-]]P5(][QRRI3UFU;-T5<HB),[(^+W&=RV
M"C>I+!:K:=S*Y9?3L&#E0$E];><NQ)D)AZL( 6^Y;VW'_QTM>HVYC[VM"P7U
M;E1-Y*]3+YZ:XN7HH)I3#[W6-70SQA;8I<Y2\? >.B >AD_)QEA.]P,&]W5I
M.]&)57F9I?;*"OH%)==3C+:<C_.'^D<;'-0]LJ-]%L]G7;KU_=.\_)9:.S5A
M]N!I#O6I_'LLH)'DAH.!19]DB9M>VX=4*_QT?</-M9A9/1TD#O0&PTI1B=KN
MX %EL:U@#5*^@N4G::C@?^A>L5?_Y0=KO!\+ME-9RQG50)?,.4KREAS![LKP
MCL1K<]SG)W ^PW?]TV=B]5/7K WK=G"ME03W(!PM\CYPT:&UA7I,T+WC$^K?
M%[_LL^WM=^P!.C<D!>#P^FNKD^3LQ7(A1YO0,'-C$=*CR5T!LO9_K@BM_+ML
M;&UENU;>T\1+$1 [U:S,I#+1[H7X8;,R!5#)^!NL*_*/'AT,Y7AW@OOG$OM!
MEX7"P?5%UQFODLASADX\R_/8PG<_P9F7%(P5:_$^EK*9OB[@SEY/PNH2+H*!
MTC85[^-_78JE\.# 8Y<MY>YHSE]*26#C_((B&P%>G8,B&A\Q!.U<Z2HYC/."
M#?JZZ(VX5QB;DB"I3X]\])@:X&DSW\PP\2"&9:6965DS.$U!6_'(RZ6M^PM^
MOK1?2L](C+RNU?AMV-5INP88VD#'\N0P* _O$UY/0+[S 3H*H\S),P:6T=PI
MSK7%*XC"%^)2IT#T"K-*1Z=(RYB\J%R?DCV2:[]3<[UT$1+SI)-<TRA(KX_E
M)W>E&H[X];]-"Y(.>=Q1]J+*G%YJ:BQKC)?3Y<Q N=,Y.K:816]PO/+7G%DN
M0-=\/$KW78#9\QO3<)94>5XLAV9N4GXU0J(3@I*SFA" GO46-BU'4J <Z8_D
M]>A:O\^0]JQ@[\>R7[#OWUC3\AC,7_^/_S\>+G5.WS(">=_3$LTETWWP7F,D
M!O%UV_,KBRZV"8U(;;7?9X8GOSQI_J([76_;$+K#8(Q9EM=>3(,[^-OS>$E*
M7^[P(?8VS6X'NF)U:ON 8@!GI.<',\Q7OG>A[N@/0\\"TUBAC.Q'*05Q7_'/
MPVI2ZJIFS:)2K)HJ[D\/T8]$V+I \Y_8B0QO-/AU@; *"TRM5TY-J$U<M)S9
M6:!UTUIGOC)_G_GQKUGFZ-(=UNOJS !"D5PA8P)+[H&6WN=#N6I^WG%;V_ 1
MV4J?6X_F\#F[_KYU++<7(>2J88S1G$,W7=C:'LL9-%3<9O'Z"TOO:T_]>MUS
M?5Z(7F>Q6L"' F5WBL?L_WCA>CX'(%#[@[LCU')-.^620,'J%#%B;./Q,SHY
M?Y I+2VO@)3B^W)G*R.(=@LW>57F.';J[NB.MNP+AE*O6I3BT$110*&:3?S&
MJ%QI21;4FBHXX:F^'Y='P\@\I41<V[;(2_S;7?]&>Y8>M.IQHC/%G!EV(T8_
M":+M0/HA8@J'&1P\L70?7BW)2'WU1Z,YZL_@GN'V!4/P\H]3!:'PB^NE<J%(
M ]/$%AJU Z<@UFEN);0'QG*8!O9K2LF=(H=-PB"-]T13\'7D%*?%E'K/YU6<
MJ-E>S-!(\J<AIMBJ67"QGU'=S?&I9&_I(Y'Z['1_]6MT(*$DT#,T.5/>M  ^
M'3TIY HT-B[DKJS5@C3<\R4+Z*E4:;O$-P@(,\=>E>J"(Z^]429=Y3DK=1R0
M\!&YFZHR.*(6.#P#O5C[:HU**K>B<_0D()R^.HR-3S]92A:_[+1'YZ<%LC*-
M.F4CGI9"W.<42U(,(39W7A27L?E]M)Z-1K"AUT8#]YOQA90A@W.*:O&:@*V1
M30W.LM=_>_FRBKP4#$<VM;O3V_,]1B*2'SZU6+$.5GEVHYLWL*RZ1WWD-9MO
M(2G#[&&'0FJ2NO)<U<5BG=.V2A/%RDHS^26@+JX%.%UG8B#ZD&3GO>\=(2BD
M79SP7<-?,.,565I]=&S/AW#I.X0BQN>[L'!X[(RMWQBF(>>=<;!=PW+ <^%D
ML;;I]<A;VQ<S;Z<V6O9F!MA:SGEG4P=A()G)XAU0L%2FDJQ#H<-X#*AB(/0;
ML OE<-?PDL*^OC/;(%1&W:_8;'+OQ13N^5>1PU9Y@6%\)=S4J8RCP\L[@L5I
M1][4.J'1"ERW6)_]-0T;RZCQ2FE"L38?O!4SU2\.]+<!!L>YUU]39^Q+"E[!
MZ\2"*RJ&06AJ?HQ^Y"%(]XTW=!E_9:?"[^CU+]4Q8/:KQB\:1]U=+F$=F&)]
M"<7>4YY8,>1U?2CGV(^T0+\]C*"@9-PZR^:!H>IFZ[TAV_E9?O$!+QS%%7BI
M\IC7]O6'R90D]$'R/6QMN9R8P)KF6Q?+*SVZ?^U7MNV^.'QS$.[?$"'M//27
MG-<FK3!"D,.>Q/N@+<K,+/*^(+5[0]<B5C!,E#U[;Q&+&N(.6^,*6%:=$_-_
MNP'0K54<-C.?:+)>WR@B-E(:T/>$HI+[-77/FLZ-DJ]A[7;'T(K&,F\@EUJ8
M$+5VIF6AT]U?'%OX[SGPRJ 2;\0-N#Z767C=2EMBTO-/)&LZ__JUUM2A2$\S
MGPLR^8VP5:= Q7B_KW[NM<(@H<4QOAZ0J:[Z%VH6#,<,XKHS2:E_C \3EL[6
MUN-R%2E3^^04]P]!I>CK^.\S)X[3_UI;5-2$\%3>S<H-4="/>!7[Z65EI+LX
M\5AUHF <5F%$"]<UK6H,C9@B7]()7+;_P>38+R@QN6<D\,6PVR3#5&#@3EF>
MQ9W14J"2Y3U6_=7P@^.94\?Y.6Z3*/#%0W6<Z "?K-5M<PR1$DG<-+<B,_N9
MPQCF#O+B$_R)T>:>V0\I-:MP[LB'D^%R8AG>R#)=XYS+UWR5 $OMSVX2O_38
M77;L2Z]EV%DJ@MM%>A3^&OPOCU$J$Q[F0^=**.J*FJ[2YAT5'4]S=AG&[[6W
M=HE31"]ABS)A'Z;[U<N^'GM3.CZ#AN?=]2LF8QOFI>$&J6L3BX4A"SK=(2$N
MH4#M?7][%R>#)KU*2UV"KVK?OBIVM!,DKN @T$6VT;7HSA9KREF[=C,]7].A
M7J\F]&*V 5C-MF'*PD]]:V]\7H.=&U%U5L8D-DJ//N)3'N6D/0)3SAOLW%.@
MU$?Z'$ G;.R&F'^VMQ.X:TN27#\TYK%GDN8S]9&)ZA-(Y/>R20VZ$S_.%P+=
M37_TW+I97MWZV7NS6&V0LK*7@_#?A5+4Z00A;.\818=^WMBD.;G%=ZB?[O[)
M8[,MQ"]UR(LEE\55Q_LCM7EM)X$=K1..,+:'!M.%A-XY(9>])@^R$!C 3S:C
M6"ZU"^+64OIFYTMA:FF/2>$UNC(D7JG(R61K9B]&7>DSKY/?6S=)B1"E&@C8
MBX$=AQ*<F(T#)'EY>'MWPH;_4':TN,/2C,Q\^8/.+L0Q/8,EOSJ8$J<&B@K'
M4UEQ;:VO)Z_+[K->:C_NDU^WSS8(4RJK#7.O<5'SB,ZV)H5=RB5+%_7"<]M_
M^.X+\DR.ER)RT+0_&99$JY6[SWFE.V &R,X"0BV[VO,@4C+_$%%G?>[2_]0)
MGN>__EJ<KK-NK5 12Q1+@(DLS38/Q_T*XV$48BA7,EEOV^&9/UR)MX.>&\'K
M5'Z?J3 QG1N_?_IH9'CD>^*$B[#Q[EDG:'A)B@^@0<T59:EU5_>H4'[Y\8Z7
M>UKOZ_^C:W"=B/^[SSJ9_G""N'[![_<9WN@?T--YW(GA]SW;7M;W6521E>JU
M_VV7IP,VE(0!)'Z3I*%LJ]B:THOA%7IL2$&Q9U">+"1JREBVT-9#+)M1JG+?
M$1TO!+B9OJHO%M%?$=HLH+L>I<-\@BTF%NR'SU/^.?QV7;>4]H?GH%,>0^=H
M)R?[&)Q<LU_0W-;%_Q%Z@+Q&,^/V%+)27-=:4C))F-*@\4I\ZC3=#"DLV;EN
MF.$#B-G;=;M'[<$IV09X(B2^J7]V0'T#0;_?^_5D(BM@C;G1P!#JMS%RMREN
MBP?91;QW8B0<WW&G*LZW3"L8\*Q3FEN#;XRSE)[PX*<R4#ESPW,U,84#(8OH
MUE]&VPWK(:0\_SR7\Y72*3T5OEHT9=<\8[S]G/EDO5) 5OA$>DSHGQK[DLSX
M/\7&]]9'BSJL.6\LEIA]??VEL!RT(5A0,^;9/8.PBO*K%1;[&PNSW&LB?7%_
M:])1G]#;NV4^^]W/[]A.G1>0;V9JVJV%:M?1T(X.F:M-2X-/:<CV90(S++0R
MK4O!6A-*E^[DQ+Z>4L40-T'#3J"!"/(^\]G(C,>S?1V6ZS2#AK"C!L 2"LSC
MEVX1W_TW&Q7AP%>UK(KEK>C-#\))ILE?!\#_SF]]MI3"O0G>?9)RV(>)Y=TZ
MV_?@_]9&__!U+3_6Q4*>>=B^2GKL6'DKG.;+L/T1JY83/7PK?GEIV?JA<_'<
MO8%?8_Q>P54]W*^9P>2XA[I1"ZJ?7WRTJQ9HKHE[7HOTN0CITN/R2OT&@.%0
MGSXYI-WZN+^CW14*]9EC]RG(ZZ'WS1LC 792'Y/.QZW1*S+U1><O)T4- R86
MSPK7M''P8UJ;/MJ.0Z6>8]9#)BA$!;S[38I!<,K<]&+KI/JW>Q^E/H.M/+9"
MUEIN<HZ5!!:G35QO4NJ7MM/E_B\$&@J,;6<L;QX6ZPHX:1Q'-OC6-3BR%BB)
MW&E4A"2I=%)B[X8X+S5E<EL=([7^C1OV=)NF<%Q:?XTZ/2NRQ]<.--D#?'UF
MX@.'_"FJA4NM.GN;A<Z;A]SZDV%1G\SQ=\!DJ?8E&YO9V(5E)26/4M=S\9[N
MMZK_M;.-V[H]U[!AM)_QD/+6N6D&D-DUIE2?8_ROJ5,RNV79XJEB[:^A82^?
M\IVLYMXI.1:YL.CGR-A1FWSLC3>!G9K-(3V*"DTDD8'HRZ8PQ7$S;F5H0DEF
MM;Q&-@EBM[!,49SC?Y9D?5@]:%\\#ECG85QZ.^ EH^.C!G:[L;$6=KOH14]D
M$'!\^L7YUPW8ET-F"?ELQYRH;*FL^\HS2]1-;Z=!0\%6*WV3O]AR<7V)H9<J
MN>]LZ/7WM&U!VWIM5+T@17X^>5<3F, IDML4>K1*2N&/\T_E\_Q<*^]::2X"
M>=!!SL"8'1N'RA"V OQ)A"S@:M:@VXEW_,^FQ-1XK<[R:0H^O\1053 K6ESL
M2+UNEF:33[K>?>Q<$]$IU.'R];+^,-M->Z?CXE" AL]):+"'T%"A9&AKPW7W
M=?',+1MH/3-UG.$RQ(!^+$DTZ2UHYC7;SZ!<4"1CKAL:V+ZTC"*F2(?73UN1
MG+\Q4R+KRS1Y?.N&@JQ>[H&WR-G-74I3$;'V8_;W75/TJI,NBYE"U<>6A4Y/
M0;!!Y2;[S7WI!V@#N9;MU(5W+"/Y(,#9=!W,?,1#&RLIFV%/&#L5.)!Z:;_U
MM@@VH<;,P^ZQR&&5W(Z%G*1"OY/=!:U$"B2/#*F@"^Q076,+O2XGMY:&@MUX
M:4EJ@LZ[<[N?8?.+V"FV>&0P_"Z&X'GOO3TPV85\<QWG?5[R_$="_HN>VL%(
M5//1N^Y6]*K5(GJEG38089:2(8;L<'GIYCS=$%&_W^<(H,(2 ZM$F[)]8)YL
M?OWF#Z55N2:3ORC',7Z0 =>(,DUI 4LW,>)>DF*M_V?B5&X27JPI9'(0X_S1
M)8AUE&#(71'23[0"JSD1XGGE'NAR+BU$6"[SDH\C]EG"._G0XVF/I%5;3U<1
MC.^ON-+XU(]E3IP%!7(+AP6];*RTZCP3^6;38]QPKXHJ<V'85[0?]&#Q:X-7
M)-=L7XDKKS2I4,V4=MO1K+ ^6-MD4%?^8F"S@##(><\:I;.TL?B\"F/WB/+6
M&C953O]T!&!H=+>%$(G0MQ)ARV+>%3UU7*;C"]2[S/W$#>T#E(ZN@@,J?VD*
MRM\383FJ_1&[U<.[;A D[QGJ3=T+1??K!9U-<,X9[@DZP2%4S063UPM=^S60
MKE.R*EWM)/=E]W>NH9>S##6=ZZ]<FR99=N&3,*NUFB15O4K<CR=)A%>-^^)B
M4ZZ787@B71.CX^-1I&;XY_=['KMY@'Q'P3;N1\!]YA!JW"/Y#L>6+\=*08]M
M,WUZ=TBC83+TR--;L.CSFQS/JQ9-C;3'E\J%3CMPD&O%SH#6'I%AC8,HDXL4
M8=FU!I7F$K:VM2^0*KC]8TM;3/L2P[3L76YLHNQ\AKKA4.N-)4JL8'_G6Y!F
ML<[1)M"R;]P?XX@P#2@TLAR<I'9DG@=);*HG/[VP_+R"? @WA>GE[LVJMD]B
MT2:MI@'W;?(08K!C8FHL8-' M[=/$0(4[Q!@9=9?R]<J*<# @L-R#$/ZF,(:
MZ3B V0XT2>FNBJ#]%SBO?1.A;'P'C;D';VCYB3?LW0M,GFZ=6<QPX><[=*-1
MERA%55!*O65,<B=K+UD9Z"&>5VI"@,1TE\E_,*^!X4:1*/JFUQ8EVS51[TPH
MN+!&B&?$X.8QNF8HOXQ1_ZY[H7/TKVNR!Y$V!'LG3./Q^9*D#6X^VCQ_[_"8
MT'ZV>N/T,JG?(:2 U3UI+RCZ\TE)?6I&R9N*[QEX<O)3+A'X[<M5GA^[?NJD
M&4UM'9);4VJMR7,70X2,<N"U(_%E_E7.-VIEHJ8E9V!)(_-'B5\_8;<4#ABK
MSSI_1'WAY.A3^>7;<[#\;Y_5+"3CR(3P\?[O,WUR&S-NK*L?W+%^],T^G18I
M\^XK>F5+=XX;?>$3V4FOZ(4>,];6NR_N*K6:7BV_\KFCP7&%YH"=.AL4,<;O
M^7X0?$\EO92D#PV0]7V !O;/O(>7>90+F1[KYB!Y-[S6D$A"[DN"UZ];7"RM
M#4-U[4_3*G-''5,R3OR&F==AD8Z'U1?*:9 I"5L.-M?= N06%PXGXN:7-VAD
MGR<=C!':XQ8/$FSW:A(O['"T7RD2A7%=M!$3P]-R^J:*'?UUATW<7:ZMQXJ.
MS \-![".,+!6>[T2OVC?%3O:^<DMQ;E0N^040/(P"I;FJ7H</H2(N%"3%5'?
M]O@JF!)X-/ZGR&I?YA ]Z_'X]\G6/;_C$=\UUDZS6W=8ZI?[C[N#S]5GXV<M
MB]P[T)Q/KRU(V+>KIMVK<!P?@T(#9+Q<9ZG9/@ @BN-^2N64C%U>1,"7B#%[
M?P'MV@;_S!O%$/BM<Q9;3:[5V#Q^GLSUK=SU$-A247JSH*[\&Y]#N==#YGK_
MU-<C4[_*?4;/-]!&5%#N!XZX+I'N,S1HHB]GD,N0)_&Z+J:?VG['XJ2G!"2>
M,2%]S3AW^)*URJW^7Z_+_#,HP;+OC3"S,W4 /THS)/*C*4(TTC5A<1JK&I/)
M^!R(SZC2YVK-?VY/S/72968(<[5PN,>*]/K-R"P+<[X\BO!9&KSYY0:BX.SV
MO+R_"N_^Q?%?"3##O\+<0[O9"*X:]<4V-X(%]ZT4^96I$S&[K?+K'- R&2^[
M@*/Z/01=$WZ09EY/^[/('D\==IFC=E.CA/QK/%6W70KR#R@RM=ZM=D.109A'
MBV<12@(N)X;@!D=10V2\.K]%7@YJ)4/S*[L^I7WCX9 98S]2,C8I]5=UB.>^
MVE[[.Q$=)Y7M@_$IFTKM"X$Y_Z:G]?E6[DEX!DHF&Q<;DR[6.:6L24CO6.C4
M0Q,@ S. -9CH!S-_+9\H/8RVF\.]EUZE%H?Y$-"< U1X!?Z6G[XZ!%UE"2WV
M+BBAJQ3XU->VA"ZG6>#L2'?J!7]V:&WJ>'ZZ(8IQC_Z3E-\(F@UVQQW<98G)
MN'9P#3Z^#_XY-&;ZD0;67?5;!*V=7M(U3YY( )9;&M)5S;7!ER-LYRNGY+=,
MR#&!U4#K7AUD-Y^.14&V!, LZ*]E&4/'8B>YK5!05V7_I'B4R,A0I&1A_OXX
MBS^+!^+>0(&E=$Z(E5L5S44"M0,40X['?+<.FE$NJ5V7]@9'?-8K8ZNZITR0
MWSVZ3+$77D[+=?[T'CV.K]VH/KH4]^!()?=(4*6O]I8F:]A^]K^2=<>":69I
MP8H;+KBM7VN=_R:D>4@":#QP(\TGR]+N9%W/Q@:BPMA.U-8)GV3J!X37FZ&6
M3O-H"TSF %H&EC+D1/M1@9VHK#=0\I;=E_/)[E^WJ=\M?6]Z*J#C"]R9D<G?
MG9V,Q#MO^JHG!_BVCI\UNB'&-[T0%]*RX&_6W\66>M=)7YSLIA*!(?"^23F)
MO+U;EO6D4O&RTE>8[I:D4*E]LN-:OR[1CRY/+G6-2:U71QSJ3+Q'U&V4ELG(
MBU#R!)O0^OP+!0VJ*F/S88R^<7E C+A<0#&D##K<7C[<9]7\ _NCA#4VW-G[
M*6,(#-R#4@3Y9?*/*1'2N?6$K)#%I/4@4>I^N:B[Q0)%/>$NWYQI\\OYG *7
M_JI?H.A%FDP6Q"7;,;#EB6NYV7"?<9UC?% +W49\D<+'L"@S\KY5EMVD6T4\
MO5C=D;G'@]U\E:2,:O@Q0 6L'?'<D9VT;.6>ZHN7T=8R5!^,F]GTG.!M9'YK
MV -=96)1,'!3H%+:IX91BB8(?D+PW7];LKLQWJ4)NL#K'16.A.G4"99=GPJ2
M&A<*''[P8;3)29/I5Z>8N*-'FB;6K%F0XGJ90(T(GXCAN^D%L7Z+SL_%-(Q3
M.%3&#IALB!N1O%CNC9Q1E1P'N0:287A5MN64ESP  ]B;;&&1K*R-XK[[I^3Q
M7HT421O&!$M3:AF23$=$PB)=^(\'@&7OW5#8#_].ZPZ7QR^7,U*:B5TZ62][
M$FXE]O44-@-O08TS6E:YX7-,,X92$J1X; EH9?.'0B!9\-+%26!0<LVRE 9C
M\,U&9WO-I]I_NV86WM1E1X\NI=TE#[B64@8:;H)<L*!:P8K-MDYV<E#LT_5]
M,X9#8>2])3'UG-&<%C7Q'O/*K>+Q]CVBYVZQI_!ZKU7A>AM^MC4&$'GN_D)=
MU:PT-7M9-FQ16>  =M?N\9&8XE (#!)P=WK^_FNC:&?7#YO$V?1YOLNUXN==
M=V<X>05=I]=8_E7,H,[4.ZZ#)G1HLT_ L!P^W@KQNM.9'QCQ1A]$D/L8F5&%
M.< :3N3AJ@(80Z$;NL^_\/RSH@T*VH+G:]1]@13*/7UUWFI'^C37]:Z">V.;
M+,PMP&/0D]R#'7L1'BK0U^@O\H,\-$M-RE?I*85.';PBU*N5=E8C/JQ[ZDA5
M6/@A.RXELZ0NZ)]^TRY 1;KCV"QBN:DTNJ>]VH@.IG\J+RTVFZPN3%X+>9P1
MK*+5B;JJ >]:8*0%, BJNUK3LU?-'U?US>L\45Z$3G">\'4LL%6IR*0VIIQK
M<Z/40\Y7UUT&2Q,9B,4+U@Z1W.^835SDL7J/^NLI3.O\V "4(<ZR13%)#<1;
M4VN8IYGY,/UEY>0RAAZ2\X$CRV?[2[-"X%.?LS[;HZO6L-Z4SE1X_QLM^6JP
M"RYOD:],)D@NL^$I_)?_X-91&2XP.=YW0?3+70$/EX#/N1!$F?16\\?UAX4Z
M]&L.R6O'A004N%=!8(S#Y@IV5?]"MN2(DN.IC]B JU*SA/X I5:.U$$P'WS1
MO0%*CL<U+3Y5>*.L*TY<P]@-LWCXP K4D-@*G$^!]W\NT$UT>5RG[F18"^]F
M]IW/1<7S<"Z6,JAHT*#W]UK5L.<5:X>&=9HWK>$B^X [.V4KV>%N&VO9@[I_
M]/&FTC@9[0= HKMW&TW@5WW6!O07K[M%Y3E\2-$:K[9U1'8GD@V>V;6[QNZ!
M%)K'3;[K;K.NE1I:N,OBAXAM>KV;<<]8IDVXS9;&4DS*Z",-HV8)S9AI[Q\U
M#TTP]<S'UAB/&171PK+6*B>X[9A$0Z,_Z:_WR0S<1RKO63=;T8"SPC=ZJ8 O
M>1CU: (E,]]4KQBP[ZF>$BRNP,$0$SBR(._HR7C:U6:8BJI<=2RLL!C^N\)D
MHJQR#,KWMA@3(>'"[$\U1?[B>_A6U>F.7\J=LG%EK1]D$TGP=6>"^5!L0_*3
M'[/H*@$T*+6#B?@/.QN-NO7:MJ5-9>H-_[[2N?=NW2TX21[H>P K*_G7MM7'
MBP<GD*<NV=!0DM&80R$I.@J8>N;$+(+$=*XGSA;R^FL[,<>4=9CCP;"J]EZ]
MA[6T+4PP_?<9[XBG^'F-=<KAQ4 O,=7XE(J_ [2EOG__T!EQ&&Z7X3JX/Y"Q
M3"[(NCIWOP3PY*&WI#KL9Q2]1'VQE;(KM-P$5W=LK[9$:/S,PP0)+EQ74:R<
MQMVI;Z%]4>X]+!+5-^WC5;JB 78[=@F8[.PLM1<TTP";D$PP[J*-ONTHP%X>
MI0GK@6N\7T@\2 KUE5W;W++;&D^2NSQ^QW/<?>8'T5=%S0>+<=N@=@X_GZWJ
MBZ5E-A>$%;?F^;/SX<B2TT@R]1V#P(_9X"K%3[HTGNV;(D[)0^=NIJS6<%8L
MDA.O%9P7DV_+3'Z\7O(*\#G S#Z3&2"D#4&H*VD\GDI_T+;C-G9;Q76_I:D6
M#G.")4PJ4$;HT[ST>B%VK\Z+DBUPU&!G5-[])!D-PT%(1WYR>[(/ETWDU/ M
MKJ'XPV!T8-&;4.,7P6=5;JTW:ZQ=[M-]:4\XS\:]K YS@_X:22E2DYM0_JKS
M7!#U>0%-$4J:2ADT(0"%KO?>IVLR*J!ON)6+]&J+C%[L#R-D=,_B,V #!W?W
MM7OSU#6U=BHG @>?_.6K<I@?8-F3F^OS\1:@+D=6_A:G-))JV*CN7OC\FZJ#
MZ&1CC4O1_?4OJ[_/^ <XA]F?_NOT5B?HTX"DX,<?8*_?9PS"/MOD<F2&G)2W
M7"=9I?EA*ZC2&]WC3O:SO\^<6[F+FDIIV%0])T<TH1E@;EHEJS1#3L&='G+M
MG-J!_<O8VORWC]?SD6@5P<O)1ZCSQ%+K $&$%COA>[ AK2-Q0Z%^8U]9!3_4
M/QFPC/-5G R Y*8$[I][V2QKGF]=0LG9,/R.SUTZ>.KXU!210?4LQ"S1S Z(
MXG^5%))'F;J7Y^=\>N8L)O'EOH9O:]W7$U6@QRGM_4I[48A9-S(O-5)62$$E
M.QZ,4<P_X$KJDM*T.\MP81&5HW>%+&6IAZXEEET:*O.7-650<^14#*P'#MER
MQXY[S!<F'CIFE734Y5]K>UG:]KJMCM'G9R5VSB*HK96&UAZ,%)O61?:FON5;
MP>JH/"*KU=4.+S%@_@7^1W7X5U9N4+#ZI("->48"^+S"-5K<,11]YR!4I"!F
M$FP!'?/O%1632.2C2+NO2KPIC=@O,:]TI&=XBV7(;"?6S.WWOY7@$CX1!O;X
MQ*5[YT2CUG?40EK(1IZ>9-1L9[QV&27,(M)!<.9^]DR$WR1TA'B232M47LP_
MU_-]5VH=5*+^*RD+CO)7HC9R!P]7$$U?[SS=#98H.%IJQ1L(I)+"ZHTHA,G*
M,>Q\:A%=N7[>U"8[!1KM5VQM;=D(CE)0KSP_A'):\?X&FWR+;&32Y@-6U!4A
M%''G5X2ZKT*WN)+QIG/6HG&M]S72G@9J1SEI7XU<1,/O+J1B)^;#U[<F3!NX
M,QCHXW'L@\85^E"!I_%R6<#<?KR%65UPOQMOF&&!UA>-<@V_7B@?7-OS7ESE
M97+\*AG^B*=_$0LWS"!0^DQ"B/[QQ@L&*D[BN<>D9J+Y!_(@.QP$OE(..++D
M#+"G4U/0ICZ(B;/2=R(+IAY$.BVB+$=LIAI5J"%[B1TW:*7NUIE3M+>=PDQ\
MPRY>B=<9!3YF7D!_O[)P KM/$WJBKUKG_Q.^/4>04DV2RGJJACI=3<[\I&/3
MYPYL+G"B B1YN.WBSR_:2"S[-2XP$X/?B,X_*1^X*L#&_HKVTVZNJ8^.Q,[!
MB2&N:EZ>D^Y?L^?E7$<IRHU_I-U?J2BW&!JR=;;,#F\ZR$W=Z+9::JP2JC+V
M<O0?UVH5]*-G__"Q&)!9)YSEVUC%N.-01[_/]/XC;CL!1I(B<*9P7D=\;\Y.
MP)7)%:4)P\H @37MVS$,X&-E@(X+JDZK"\R(Y_^^Y$!;E9X/&%<=[_$=NB/_
M9G3_Y@H7@B%LX?RRO5OH27E*M4#(9[>R_EB<:>%; S>"_B+T],@KMWP7!EG0
M-*,15GXU*X[BCTJO8-$D0VUO%7X,OVV*]@7']Y&%Q(4K(K3V-UWLOMV< F^S
M4O/Y75V;[/)V0D;^I+Z7O"[GU52TS%5<RZFUB>FQ?!!M=^*./M\4<-YG3E^Y
M1M-]2K5[H.G N6#5+$-O7K2[.J"SSMO7^3C@RHBX?N93-CTK:,U#MBAA8UW:
M G]'SEYN[,YS/Y7#"O4/,W!SHX#69*C.]UHGL:5O;XZ;-P[$IK_F>KOF4>2\
M*%_YQH\]N.WA_XU[7'GE^1\4[HK91P\?1*B\B@='3E&(ITI/)6;9#$[P8U<.
M!?/\I G#1,2?DU-=,2[XX"Q!Z\??Q5_6-L Z X+[E-?Z:M'KM&TSE'C#*ILW
M,H(B?0>=]=&"[4H\O#NMQ'!)L1-+X^?)9Z%\%(I7MU?:<.2]/=6!^CMN<Y*J
M @8@EZ*^':5(BPM"Z8L#5^/$Y^/U-\@E;L1)9FX>3M?2',!*5(<.*T8]BWN@
MY7*6.OA1UX_>@A&"]D&])QX[W[#Q$7[,;L5[_=VC!>$@ORYPXB!E5D2_*";Y
MJBJOW[UI=7$;U,>R_H';PL_8>5UO=>'@4JC-< ]E?W32/STH5PDS)[A'E@5H
MS3W!Q2I81WNS Y1KBQH @^$)MDGG$_?,TU?4Q6C6NJK8N^X8 E_SAJD[QG]7
MY,T$EF]Z6KH3/1=N=7U)(Y<"?,\6&WRI.MVKOE<F"_<%GMM@E[!4GM[1F<]U
M[A.+,:D/Z4\H-@WW.&5PE&KA03L":Q\"K%0[4S@>-GI\MT%K#SUA2VQ0YO<:
MG0[EL--V)5>-RUS)H:!)1V)BC;RW>QJ78F\JYCZGN%UO#R,5*TFE,GEG<1V4
M!.!?6\L"?O/*;\93"'@-E'5[.EF#+M5BS^ZIDFAL!(07E,LL#WW(H]+8P9)[
M'4+)8C1+[4I9+X)KG)W6XVL58RI3E>0%4L!(%AZ?NKN,U2MH)%V_T]KWO%&&
MN&Z].X:; .:D"F;7:>UJW\/Y/G14V"QUB1/;,$*_?_&]E@2;T5?Y"&4D,)DC
M3IBT HT/3UYECQ\(S 66$;<O26)ULNLL2@O@[STN2-P7];9ZL1(=V#(Y&7$>
M*K0<KTUXHJ]AMS>? Y$/Y'<7T&N\I'\BI^DW33'T/AJP#A%$'+G-)P+T]%R9
M-/>)5ZE\OJ!''HTJ=/?N2@5/1AP!-9V8SM9(C:VX_O;<Q3J]I<[NXS*S.^,?
M5(74M3K-M'L)( I%0[N@S- W<&4@G]2=CZ(?SN2&K(1W=5C<_1"JQWJZ\\^C
MU3&+]?O7DJ"53%-SMSS3?E+<SAO3_7K4!5^CU2X=Q_J 4KX)B_$RLBW9PG&V
M"E&,RMW[-8P^M.[(WU.]>Q!D(K/I7:%3W.5(^:*EYZA?R*.L;L^S*G.S_]1)
MQFXV]^0CE#)WC*IA=A<^;\_%=W>+S^BII>WCT5\E?HXO^::/2.!1<:.^3*1\
M69*EU?&Z+_2C)%_)B5L5M^V*Z)A".=_\0*]L!T.\]#, X));<UO_@')=G -O
MX\XE3Z8H_ 4KT)G6T;FJA=":1;*$K3@)RUH'>77'N9]?:L9$(U]/SQ5,.N N
MQ585$*Y96\&$_FN!&>C29CPK[8/G*UX'(4/LML&'*X&>@.GR=94,>^EYC4I;
M,GC()+'AN7_(=/$#+UF3IP#0]U7FT.8!IC"+N)2H$>OTNK?7*&9>&K\S3]Q7
M_TS<;&?Q;3^^QJC>0B&J [S!X\NQ]&K([.TK&[0_7KEBXW)Q)5&T5 T2X$EZ
MH(CSCP0W^^U_LH/YQDHFO5L5NS+$% 90\U%;^D:5?[4D'5M)+O*CZAXGWCQ=
MPQ=-FT^!P[/S8VH?FF(R/+JLG1C# <VGR5AY2C-!;H:LW^'GKS57FLXV85SP
MQ(N*QD2+<8H=&R?T@"IF&*D(U>'$'FV[5C=AP2&,'S50T^Z?\\=(E6.=8^??
M9^3W_T7NV57M];R,=/H11$M <89N7C7^+R]TMSZED"H+C(TC[DU@8S6]!\H,
M$/)KIVDO:%,RU#\-[4?I*'8C5%Z;V*+A81,N-.6K*YLDS)<\!N^<)(5.L5X"
M&B]E6F\_M"<YD8^43V.42:7>WA]8 FZUK2D3TO_=*425F4R5$RC,XGEE^DC5
M@(N!@0D]U/E0!//UZWAR!\<O50&G9JX+7;FY:!GB-_5AA/-0J3.Y:J&XT39
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MM3VNY2(X:N<%-B&W5]K)23MZ[WMNRGM/-;UN=:9%PBI2$0\_P/2"X;!%VM!
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M+EL2-T"4MCO9]>5DE-@G^U=!<=&XGWI5 ;I\^Y+:>X@&J16D_+[DR(UCW%S
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M@8@8<:(7-"@D>.__N^.M"A5 6#;!.K5E(RX\S^^!"'%?[SZI91?\0#0I&?]
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MIL9/.P)SAY!6>6\\$.'A>]U;"0]$$\[N]QQ5;"SV@1NX.W15_IN4QHX3H<$
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MS6:HYJQHY6S8](OZ$(7=41+Z)2+CYJ2:,$ Z^*,/#P2F/X2&;EJ.CLJ5 %D
M)=A23:2/^%-&>78^;8'/,I$(\23,,#G!!IH'PN#LVG<)(96SU]+3G*RED@L6
M<Y78]ZL!FIN-PJ;SVO%_,Y3W(H<4Z/KFCJ!"C/08,97LW+^&M"-VVQ$%9&E-
M?#IX$*YT@M>8BBPZH'Y+"-2^7Z$7765T9V'ZY7V&0_D;EVO>80 7'IF<%D;)
MMM*_]_R7)+7Q@<];^H--4)<AL?[=91KUU9#EDJSHGX<\MR.\5^7O;(JJLD_&
M9*YN]0IX75ML/*_3#)T;1/M*ENA"):RV>IH.Y$DW;K,$4<[S6I/NK^14%4$>
M9W?_9M%"%#E!OS-W*](UDHME5!0QVF M00G1VL,,=9$\.:WO"^Y!ZF8EBU]F
M72VI"G"YD#7.>#!S3$GR-X*LV&F3JX5G\H5"+GY@K[)+2T?"=K_N4PN'V6\&
MZ'F=*%V*F:;J"TY+!H57H)OKL7C,W^W**1SG+\C2-YJ'.P*\_/,Y9-C==@H-
MUGM6!J$&C*5B(.["?.6$;U?^Y0BO!J40.NIYNCT,&GG"@IVM')H4\)*1IR[@
M*?PQO9&K^P&X-K6BK?J5D:GPR!%=Y7N<\1MD#$*W9/J1D,R45W">F%P1,%GZ
MP4K/L@_5&TH%O:8T9\7J<]DI6XP;#%T5?V0U%>YD]>232!8R'*M0KGVID494
M[UWK24;I:29S9:DZKA(.4HC?1=[2>UIG17EG.M]8U3?B@74E2%OG9@>'I*:.
MO\077CC\\K* .##/5Q,R/,5]N"U,0:1&%XP,(KT9E($CMF:F"R^@2^%UGH^?
M(<;X:8W&[3).XL(7*FW!*W :OA*!/!W+-^_!0I<1_$\@N7K*!4IFQNV<?WL"
MMT.5"+)TM//=XQ+SR!F9(41AOF+3:9/Q-SG'+!+F!2>2^"JX#S&F9P&WLK5
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M,K5^VCKH<]R '4+P<#L'$"B/(#B=E344"0X/MZ(\IA),:W)"V=&" :EYWK:
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M>T>A-;/FC5D1V1O\*9DFT=ML!IEIN@M6[[&M&F94_Z"37:,T3)X7^M2 9A+
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M5X+X-E9WY/Q2M0MI@:>\4Q;IYYK3W!"]*&,PMPZW:@+5E6$L,;4I%$R)N<Y
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M;\_0I;R A\I/JC@)R3+UD>X6S"1/W5-X"[4O)TU!9FH/.SL&EN[SQ<_6!+*
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MC_NKZ"I_0GVY<H;&UHK:D,X81/(;1  \5<3R$+[*G-7L>E%H^ZUR3;_@M4C
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M/"E.581-& $PPY+6$[%H@38;-\?_O&;@DT&Y]#K+HR:^YEL^YZSY>X?!?F?
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M0]Y4F=%$[^V)@BU,:R^Z @D$6F;Y%0ZI Q#S:^660Y;E05"BVKB9ECQ_ RB
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M>3!1MI&U7/!RF7'.-U)=V,Z43>D+OO%^D+J#Y;W<<=L#\;S) _Y"[F(A4]?
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M!VB]*'#]Q,W$W]O_5+I!!55G=#1EY,QF6[I/0E^TBC\X6?Z('%GTR%KM.="
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M8\]@F4*:@L8NX<"E.V-O]:/BM<W/:TU+.1*LWLMT;^Q 64XZ/_CTF@"7+BW
M?\"A)-'#PKPK^WB$Q3%]YR,?_R0 5ONI2@,?DUC?5S>RB+?1\'_WIM6R^5+S
M'I9C*]L F^RJD5%[SXD=%"%T&IW$W5/IE5<;"$T_8.PP#2/]^I7J+U?>%0CW
M5N>!4J9JU^2/2)A;*UV+,L!-9<1!G+ T?\,S"*>9J%//'UE,?9I: \)'#D7@
M%(]0HSIA8J0?)2VZRF)!M]S8TE7/8%]T3& /Z@(E?<KD$OTN'?)XU*4; 6=+
MA1:KS2D[8Z]>[8BZ1[C7,*0O,_CV--1_I=7?E2S+M]=*]_R&=_+UKGNH*NN@
M! U;M%"C!.XU5@*JN:X[)&_U3?&G!D;4^^#L&79629@DI,"MV^Z2^\&$OMLQ
M,>U/9UJ9_["08#_*[*&,+R[%1$</V;C >&,R]YP1 +!R== W@PHI#N^KTD6E
MDO(<-7[OWZ*[UDGF2-Y,/V22 !%IKF*J _PQ6EK(,7VXK(+UM%>S#RBZS",(
MYOZE3JCI!=-,X_@15E#>L$#!9^]>FCH]-/GCQFQ%L[\^@1H*=/S3?;.>?^Y8
MN:N,9M&XZX1%6?+F<TQ)#RKYHY&/#NE9Y:1325&,DRS#SM-D\]=BSN0ZJ2B3
M0%5I6+757*4XL#^VPF$VVQ?!J=Z0X-U&E9&8'FO*MKF79HWUB_:JQPH'UJ*+
M8"LSO=WA$VMOTYOM&7U2' D04["%N7@M2.AT=P*74>*W9=)QT5/Z^_,BGCJE
M7DT]=NMU8TB@TM$LO2ZOK=;C(&=%'"[SQQ^63YKMRWK,]!#.R=-\' //5RGQ
M5%<YDRGU<EW1O$$31P,84?OT,5A!F5E6QE*<1/$B]!Z?Q7S>MZX7B,A$""H1
MA5E3G%+LVP) SX?0ZI$&DQ7BB.;)AS@W:+)$S^Q5J/G6@=5*7!UO/F@8Z6LC
MM:@@G+:S%[T=#.X?MC :!G/6Z:>4-;.!MM"*\@+1O'%QIW#0'OP+=_H:44YU
MBN[V'3VG]_.<SJT'W"T&T_^VT7"UU_]FH^' J8VG/\\=>-HO;$Q;?L_/TL.-
M\GVJ?Q D_T-A[73D\3[*;+J]4P'BH"$[\,)+-@HQ-+13<'<B4YCW(>]VA\HO
M!:=3,D(\:A6TSE0S>P%+K-^<''M"J)95*: ]N+#C_$ATN<5!O;^KW>Q9;C'&
M=<NN]$D&- A$WHOS%?MY[HA[-6 4(O;$@4_B 41\J:0JR2-3\HBN!T!RM')E
M=#O>^'ENHQO&GA>>=4JZHQSJ!>+P.>Y5\*%B$"L:?L8_SVFP55U=?%I^F2EK
M52TF/<!4"+J88"00C=[*6JAE*/F;U27VK'HNZM2GO8*.#C8$B637@ !SEB$"
M13:\?SIWCIDKBJQ.N-HSH_8,G1P&BS1L=ENF3Y!#MK_@Z-@_N^\B%FKP+$]"
MX:\_SPTZL?]YO#I\K'E+0$W@AZ+CR:,7,?*8(O&E-(?9S!],2-V9KX(T?GQ&
M@-5\R=$X?/.!&?6V71%Z!S5[BG'%J<;&)/C>[;'X9+Q2R$W.<LI>Q4"I71%?
M]*C,'IZZF7S@BE "KMX:7%(P5B:+LW)<]TZ L$Y5N.A+2B7MD2HR*;0B?M)T
M;BPKAXR[C+01BZ9,&$UA:(RW9_.>:[?U(FQ?HPK%N^%C0^)BDQ]&C9(R[((O
MS>#S";G8&W5R-AGO'X ??>ULX+4+?1_GQ]V(WQCJ-3<VFM>]!L@LWI,PRJM<
M-3=U:34JOY(\3NXRRF^L<BX"<!R7)"A_U2XCS+%=W'%.H.)[D^+F5.3#0K@J
ME%[7JS-Y%?-X\7ECZ5>A&V63G=>^*#IAE4^Z&>I4=EEHN_<5Q9I.I7=NZ@\T
MO-3%<Y*M&P[@#"YX.>>NO47"'=\K7;O26)]&M0G\9GSWA-1Q7ZF9@[T1<&YQ
M 2!>M1-GZ'6X=8;WL?,$)#QVPO=>_/%#C/2LTRCM]9&J96U#K+!FLQM3B::(
M2(A&@F_ZO:[O8,AL?FI \@YVC$6)G'447<:\J=5#_VJLL1M7@!>G0K/!DRZ"
MJ.3]-DA,V$C_2--THA[\'72?BOA;/[G-(I[L9#=EQRNCK*TIZOF+#4 CY(F;
MZ _:M^^IPN+:V\JI5['82G#+T,6\<='I$[B;KVI2"G:-6W:S42%3K(?>(&.Q
M_< ^JZZ-M[#A>!=;CRZ;6Z3L.KC.MJW)_F+(Q1ETS5F6<$R-]NE*0DQ4()P.
M-^V3WG>K@!M>U5>(7D_YV_R3R>?JS2KO]59#FL-MVO;RZT.\/!4PW\R@,LQC
MKMD(15"[["4]U('#'L_%Q(];".0$5N/A]BV+ _NJ/M*33-AM>KI3>PK>U9X*
MD0T-EC\.=!3HV:W7)7!=SZ8TZO&0E>$C=H04-=,3,.Y]D]J  *A;+1;D+F1M
MXE;0QFQ@W(-W!0XCZH!;.ZK5CK9)<S?4F7 XY2PRV\BP%1N6E[F+)VH3#IN?
M>$W3H,)8,VH^Z#6NFF"'>F..9-M]E8Q-M4<;DP&756Y2U(7[')53+1A:5@\I
MYD 53F/G\5' 48]:9=;0[&B.^?6"C9>Y4B1GCLGRC6/6H?0J:XE!1+-=%:K=
M^"X5XK1+J@YI_GYI;-2>'SB@Z F3=RD&=D<SD93W$F1/J_WJISKA,TC$D4[4
M5%LAXGEVL)WWTE)7"!]9:Z_]=HV@4M44EX4H\ *+S-L5?*C-/3,6(YJ:B5O5
M+[,82N!RHJDNF$] _*)AX++/D;)U*0SZJ/2.B)?"7D;TRQ#)<A[NC)1"G1Y\
M)\D1B$2P*[]O>*!5<_/IX<: G*)J/_ 90,4'ALTYLI;36AW#=S=F8!R0>*0W
MQ.W8J.^+BO?S7/=:W9_G4&X\>KL'/'S]\R=6NS.W7_*[&,?7O;K]^=G7+1'+
M"@ON0XER;6YRSV)9B_VFG;>#G(5;_2408> R( [&_NG3UU1MFPV4AL8#7R^"
M>*G0D [4>%WO[2E^0(+WK!J9$^[@L>)VYSC1[<O3J&&A5=="PB]Q;CDHS$P[
M.A$27Z5B_%C^Z4M*D<U;DB& S5SQYF:N0@ZF(,8^WEJT[)NB9&^#8*^TFS49
MB(=V/]NHVN17,D$M.H1NU#!JEK1]ZK+6\%Q"Q=R^L"1+;VKP6.ZO&]%C? _K
M2;_7[E7YDX'J']D?2P[:V@0>*/$UM(E4!;(EN*<(9:@\BA)!3@46/"8X::Z1
MTQHH7SC7?5,45&B3*PY <)GAZ#JF=CSQ4Q?$*8QP"^-2<4@?(2G.]BXB%F*^
M#[OGT"&_%4W .62$3,:7EB-8=_LY;#,LU.W3W<+VIE?>$7C05>_CR-G4RJ_9
M@U_H5B<83++,EY90V&(F":37U:-0BKT9Y]XCXNXGH=9HM;LBYFG/&CO6_-M6
M8W%87*+7XGLF\W%T-F0387$S@W75M=%#^L#^E&"9MU?0<@CC/'R_LV.+Z8OO
MRP+IV.]:5'F)8<7_:#-U3CN*O'3^('L3%ZROJ>C?=KSDR\P")9&L+99VV;8%
M/XP]EV]"'A-EOHMNHKF+YY>S30_;W%U#A#ZJL*G<#TNNJ703R@0^/4TVS>FM
M#Q7[K*LD($!R4+RC&J,S9'.W9NO@T>:A"G@K?3'F6%X@9U Z:,BZ=8;HB-<#
M$%>[=FL[S&II68"\)+1M@W'=A!CQ)G> *P[IBLMC&,2_&5@((Z$#]35X=U3M
M2#(@_8Q:ZJN1O(I])8^J/XZB/4B-"$M+4)=2B+7U'7'YE-?.]E6I*21W28]U
M-:5$@^BR&$/I?=VWF)NVZU6F#4"!HRV=Y8VAPD'A K=@AHZ/8P(5HD'97='1
M^GG.8_/S2"7F><Z SH")Y)J^KQ)T,2+>>5U[*-PL.-.<%>P4);/J$W8KEO(Q
M=<+#K$%DCYQL-/7FG06LD^Y7ZB[PFTZ5<:Q+<JQ>)WZ#.EW5O#FIDFR,^> ?
M]H*?H?R,]<E#=V5KQ2<-!%=CT8]Z):('=[-]YR3T1X*A'C*^!7)L+ONB'_K)
M%_A/I/C61D*DP22R[ZS6G1427\H]N!G)/^CGN7"G ]7:K2GR@)KS(*;94X"N
M3W1<CQ2B7I_E"8GR86">%&0W2E@4F%>\9LA<-9>7[K,(-N4_:R'?H7:4-FP<
M0@*6)TX)KF3.>?!6S,K!FF38;;UB4U.=:+,,7*7HFXUJZR>33_T!&34EQM$I
M2OGT9\@VB[K:Z^P=:>[##]R74R!!?M'<=&?#E0N@5TYS_7+P.H@X@\B$Z)$G
MT+; /M,3A4R\7NL,^=-FK//(9RV+^RU'6O<Y>[,,FEB'X5NT#_H5V&^FJ%P,
MO3*R4W>K5<L:D6F$R0RO3$LDY"0RUH09U4A6/(G:%:?GYCL&.:[YZ)26CAW&
ML>1\S>C*W(-J?27"N_VD! 6?[P2WM,2J(RPZW%6[,['%'';NZ9'9Y7DUMD<*
ME15%KH6(I-I?3#5IOT48U*>2*.%*Z;'L%R9YLB91KCBGK'0Q%-(QYVS[>"*M
MAMU\ER.F:AS'*@"\=+7[5<+;'5,]:<Y6=MZEH$_YF'BZ!X@H0SZ=?J )L]15
MPS1?8<0/PU<=:L.K4N7+LE.TEV#*.NB)*JFM7]>T@UO^ON,V9:'3MH'B*#.4
M?1&]6Z112F42KFQ-K^K56[)5E'\<8KKI!0K9 ;8--C=,I+U(:A)<C1M-W&M4
MX1LGHV# YI)D CT=@]F2+I(N^<C$P\,;^WI4X6[A=/&=I(+OB/H%/EFC!.-2
M93YW$9>.0*6^,Y;>B?EJ,B^N6=Q5"6,Q.B7%*JR)!:/O]0V@"KRK?3C7'T?6
M9#7QTO#C]@NS^B^E'_[^]XB7,ZCB!23$W>9HY<LI,=(H93V+AK+Z>2[#XHO7
M_>6-9]]W#WLX8F2PS/]I0N._K*C[S7CN/-G,_XBW_;([T&DVT?*%UBYZ8VTU
M 63WX$N0Y\]S4K<V%=U&>2[]GQ9 ^)_E$GA7>-%F]+S<*+[[ZYC#B&__UP@.
MMM<&_U2&S] _SP7/?=\.^-Z0&%'_XFW'&>XYO.M[WEFP^(K3F8_*(VSZKW\_
M\7Q%T(>M/]MG[W@'444<PWAT>YQ:6!>46R.?G!ME$5B=)::-:.QVL4561EZ!
MX%]!Q2PD6IL N_C NT%09L,UUU* C2!H/)CQ-'L8/BVO4FC\IH+H^_)JJ_NR
MU>)FZAO2]$=C0[+'?1.3^LZ7E)SC)5!N?2C-V:OC6!#;\# L9-A+-+YXO_LU
M#,YMPWR5LFB.Q?H*+5V=BX=T4(J9-_ 6X&;#D3X)7>!#"X9U_3:FPJ)XNV$3
MF_$FV?SVPXZ(ZUR+;P:F>TKHU:T<Y?7$I<[4K>2J1RMP0%G>Y",'TV@9.>P'
MZ\78-\PBUEI0>/.9"4+(H_G,QG%9;"9(0/+-O;XQWZL%KB)R;ZJ6[[XP%W76
M[U"J+.S[-/6ZBQ'*:Y2]:]7G^^E3(H-'^6(2FU:8</784K>QYJR\_(L8'C7.
MSA@*V$BJ>LQ57Z^.KJ<B,%?G\/7:0ZYQK]__]1[\K>MC85$0<HW%PF=V3!WV
M\E 4]\+(2,U.:1@,@2%7*J,](08#D2M^O%IMSWCXYXW0%5AOJ_&L8)TA+7SC
M\>3([AW*^/:DN+P VU45^OL>3:'&'\GX6V/18P#9MP.<T +/S6A6AZON ['0
M'3/4G8:I(!-C&U0I]R7&;N2LV*CI*YXM/N/$=&K1\^5K"[<<0E#?8K[GMCSJ
M5_[^X7-C9SE3V9?22W[7D.)J6P)CT$YA_IYH1)<9OR^@N4I]!XW'@;=-D_*1
M0@\S((PN/4 &1V8_@BA)9-D=[B+;S=U'02";-[/$JDL[P^]^KG;5<#QZKMSJ
M[ZY+U>U:(RM>A:\=-C@/[4;8T:'F,M1G\.O#4Y:H&W*WWW]X]?I-V.LV+XIR
MUT/VB,A0"?^^1FMU/GM)_6ZBR2MOY:3PNIO/(%ZUN>2B%1N9.$Q>KVZA(=$4
MTUJ!IT:Q# T%4><TIO#!UMBS$[C 374>H%=]\UQ8Z,!5;]XJJ,R^JSRI'$6\
M-UV6R?L6%U6N'C,^E+=_'7-O,K;TC-7KCJMKN'_'MVMZ4W[",E)Z(FF9R4UK
M_$VIN>&K*[$GZ<R#=5-23?Z%,4U)C]94\!]*BG-S,\M-]/)RHDL&!R6EYA#*
MWY)X&;1"@*Q> ]O*K#=1Q,W=N[;&K?B/8B;O0!*:0G0%(];53B1QF"%$M8;I
M@V<W49=)L0[J"DI3$I(_-*DM.1I/EBIS)DJA)]+N.-[W&(QN,U;M/NE*DUZ+
M493QD1PW8F\OHUMY:&3?PCK%2Y(%JB8MAWM]4H@R6O?D[=71:_:M]O3>0S0R
MAS@27QRYRL<_AO,RWG0</E07.10OF<LI'OP:V*$\+]#^:?4;^C;=D9/<W]E.
MW@7A'S6&%VML%%<6Y7T5!$_$.2SUJ2\D"8T&20B,BLN:.Q1VV]MW?0^Q,!M2
M\V4>$)+E$O( EJ/Y!Y+N[8'OE?@&T_1R:?.#H\5>:A5Z)K6CV%LL\HJ<X@W;
M+^U_X +CNTC3V<2<$LR,U$9H%=QQF1%2S?+'C.;'_BK%^TC0C\E.<T7$H+-C
MVM("X8.'PI"!.GZS^>&AI36E@(,Y6%+%LU\R-,*OHH,9!X(O60KW%(VZTV5K
M<2]''6EKY$(#G]F^5O9]9^):H)YH)N'7+7_W;7!_E FTR\?ZO;XL(E"*XQLL
M+)"Y$^&4/Y*+<]VQ0W]*>] 8X'R'4!7NA][I$8MKJ,0I"Z2RD"^-ZIN*"+"F
M0GXQR.1TUJ5/F5I7,=>5FED'?MA2M0.;57B("0_I1RLJ\HRSLZ:=:&Q'#WV7
MVD$((5.$W+1]0 ,#E'=1<C(7:S_=QE(A;&O$69W9S:_;Z3Z_D_]C-LE.VC//
MWN]X03_&XM#D(,%AQZ\$E',WX3=!T+^T"G(/(*:$PT7L70VSNF$27XLXD)7?
M&034/)0;*"5?(MJYK91XM[O;?Q9-6+)J<MG\)ED6D%.W@SJS)V=]G1V%!CVM
M)XZO!FF!-IL.%A5V0%=WZ?28,]G9=B]Z&,\L5#0OPAGNBC*O7$O"?DGU(GXP
MC'OQZLTW?$\VKO$SDA+5\84HXCTE[F"'8A^VGFN3 0MFR7_)OOV]8"3YR9JL
M[NLX9/U@7%S8CJ"JB0Y&(M9IB[_E\IWK#F@M+7NL%)N1KV#F>8WI%"3)878E
M1&NMB79847G$^9S%*/>6859Z-[)FR1<A!:Z8\J@ <GF;;0,]F3%E@[D!JSL-
M&@XQQ\W,O<U^;V?J+GD1XQ+@7/P]RH""JW'(7VSK=5X;"J6VJ%/X0BUSU@PL
M5\N3:U96%C?];R]$DGV''$V1N8UX9"JX8GR2=#HI&0=7@T)8]IK7&&___#.R
M WC1OJL:M!E?.@2 +F6QFFUVC']'XFHG-FWRQX#Z!?]4UKEF+2^^9W>I'.RG
M[JQ:RP^M89OX'N-^ A2_FAVI!M90ZS&'!F8<>4Z(!JE[U%?R?%J(68V-]3]Q
MF5,)"B <@NKK00_E'D89Y$TF)(W7+RBB;UQ2>H4^DU9^_/RRK]_LP)!(X%YM
M(PI^::Q-NKNYH]^F[1SE:4$]L@BD]=O@@*BP^F6?L?.F'JR'&ACI_MUVR4BC
M#_N^K)ZW8U.OS-16L++AMV0%V$9G*/43<[S6 EH6 39"%2K7P*=9\?H:,3'4
M2CBBP0$38J., )00TBC#XRLRTH?VNEIYZ* =".V$D,%_#*PI) Q&$U_V)>B+
MW6R_+NZ6@7125_X4G]0@7&)L%L8X'D21'XMJVQYPM18]&Y@C]>RV!*"%!1ZS
M#3A8RT!V ZVS%.]ZH.=YHI.]?86:-XG&/XCXX.%9[ZUN!1SP8A)CJA,YV]NI
M]QM$:.&E?%?7&<,,F<*)Q)2'SADWI EB/*6L) ,9!M*!JCNO3VN6I0V;DFZ[
M!'H^B7@E*+[X&OW\6E:7C?"C]783GAZ4"6F=<^T;,M[\6(/,#6IQC<FQ*X&O
MABSO98=O6=<SC+3HH9)]/8M']<]:CS?,"5O)OVZE;I9SX[+O]:IP6>PVJA\Y
MHT,VE.:N5O%&V91./BE<2GD[)1GDP^CRW"90AFERZ] W$^C['BP 8&>6;?O-
M9H]:ZBAOB=7S64IKY2H$SLVYXYQ9U&OC1."; P*9N.E!!?$S^DK%X5(E [2W
M%?-14\&F_1/%6_!<W&]C=F*]WC(]O4MA2WZ_G2S"S,&(1<H:";CV8?3\PI_/
MC(KE7?:L0ADMX2#M9'Y;&VU783RB"R*'9- 4Q:1[I&R$"LS5U8/JQ M:=HU_
M;U$?*+KEE-A;CP#C.P+-DT-_"4$OU&:]PF&N1./O;E[:K&#@,LKQ$5$^@W6^
M-A3SIEDC/JDQWEPA$9X,V5Z6;9(^'(C?J"&1*]5-_QRBJ]HXV@Y8LE' #:Z=
M=M$2;S;-%U4"*]O9G0?VC'V"D0$>./!@5T8UR+.%[B,T:&=R7(*/ZT>]ZS>C
M9AVTU'P1DBNC0S^0<ILJXXA!NST9HXP$WJ.?Y^Z:;P6P&Q+ -OH5^G=N.&V]
MODC\;%&%?9\<Q5I#?YE$T+)IR#9$'DX81Y-Z!O6ZLDR8H$&7;4HDS9^T*=9/
M)T]#  FH=+9EU]^0!W-AK7=T8?RKMTTGY@H#PFAD:;HZM[8A/4.1(^LA+$#"
MC<U%)L31;TPW(A9S"'(WS=%Q\.KIAG&./QT022F%55L(S-@KU<RH*WV]R3VZ
MMB1B^&6@FBPI7Y[[DJL0[%@=3!M30:+*CW_,=#8HLM76_CIW*>5.[,4OG,)S
M*;P-*C(PAT#E7<:Z%-%&&02_21O*J&L<1BM]V &G2 6Y\[_P=PF9@A/F/1Y&
M[&D[@*[-I^6^JP[&JYOG(+^J-(D69>\U!!,PRZ<31A4B:I&Q=8&26,U1L/C:
M:F"F8=J@\*UXMH5X1<%,[A.@/( #F:2!2LUK;*R(L";4&YEHOK RHVC:C=IA
M>SQN1LIP\ATL,,4%<Y&JJ#:/FT'TU&J-S)ELWLT#^U,_F=7M]%9^%$PT"?3
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MF+N(-+QQA]*0*W_9I_+M:SIY=4I7K0Q CRIU?%1GJ*Z*[)-J(81JZK$M.PV
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ME"Z=%TYV9VH<'/9;@,0>=CZ_?0!<['DPZLNZE>V5P>;04.9LJM.2 DNM271
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MKT[9S3<#6I**V\O@I4$]^R)L-XZ6%YF#3=SP<CSL ]FW?_)!B&14&X;(Z2;
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MD.7.P=T98%^47HO+U  =\@LW+T/6 SN9KI#?YW]@ <P</->.VOA0,,!3MN8
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MO]#MS ^"HI=0/8Q-5H^>9E$+SEKEK^WSRGZE/TUD/!2:7]4N76+(:E1^?QK
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M8@-J<P>Y##M7N^N$30M<O]_Y_FUCM22M$&1'-1X#!E34)=F4^UHC-E;NXF7
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M.N_K*_D4EIX-P4S-@DSIAG1,V1L^;N!GM+U%F=,K<VDC1:@?%=^07<)DK 6
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M; JT>4XN-0^RT3'X1L;2/73:J0A-L ^8^P9;Z=M[R=08?Q/U.$3$G_BO"W@
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M>&&6/1UX*T6+9/@,^KO2/JO*C 8;)#HG(Y08.'Z>_!5#]7G;^"*%0 ?ZE5A
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M<,DHQ#Q*M7R<7W!.TCU:4YD)$4UJ\'-MGN:?SGIZJ.^IK(JX[8@I7F]V'D6
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M4I,'Z0CJ?&KMG<WJSJ#T6NBN%,[I69QI&^[^<NCK4$W8"/H%%9MV$:\O36^
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MP'T%9,B$CA[/!.X-7')[%\D$-OMQRSDK6T\C97B]#0/FZV._<(\[SO 5^@"
M97 M'OYY6\//4_Z':I?&RX*_N)75RFAI&-CS%)C3F-.N;>=75;QV/3:^YCJ.
MSHJ5<G2IXI2C5G=[)7<=QXN+.\V(UQNQ_(Q*^_A;E__$65LONA:OZ)PNX4!0
M\O(K2M@3UHJ9F_J1?8D7^R-O]62TJ];K22EY$%[H;%,CD^OQT(RU<,IA]+Z
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M],/N<LY[/WQV/[GLFUYKV2NU^1>FGWF=G1!.3K8]!.H:(>Z/?GESX>(6A^A
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MN;3,[^T:0[PQ;EC"U:#CR;@[&F]79R<8KO#U-98I/<:>;E&'(DYADU%54RW
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M'MET4ZVWUFG$6C,8:6M9IY!"LAI#%Q77^:V[GEV$,K=&2H>S*F)HL^QU^#2
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M.7XN(!M?R*I[7^260<(,2J0=Q'X'7CXB%#.AD]2-HP4VH,).>7@%@(2AWYB
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MMR+I(TLXR5;L)<'!*U^GM\RF^Z4+I$D6,RR=+.P"6ME^U8E(?%23+/?+E/O
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M#534N61GH1)2_JD@,6\ 0.W08DW14Q7F$N8K6U1&]-M@':[;F4\ @9Z?(OU
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M>/[XGW=0OB(O%"(N!XW&^OSDW]1N^B&"!*>8[[(O?+%O2W(@54SN&\)G.VQ
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M&984I'JF*^*Q9R06]<Q2'K>?[F.%+@QCYS$<M<E:TQ$9M'/LFS:?K;132L[
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MU!\IRQ06!FZ6!DI:!3D-C(W$O8!4^@[^NO35#H/&]5>P8)P<YK(GYL6J"_E
M10F*M")/F&(\4YN!]%Z2$KH!0Q__?#3$D9*B:0Q>II. UNF=1,2[S*[!P8'A
MF9ZQ,5DKI-IO^XZPH?#HDHY=FS._,Q'_6?67J<(?#$>=\D5UBL&/(MDV1YY\
M/.E$GVVMA\1W:YNY2(UQO5="FO7 =\S\8-ZB%J1MU5!E1\]OJI)QNOS%7N"*
MZ>3^=YT CKO<"M@C8#]X*?Z-AG71&.[/G4/5F\:A7!+'T4$_VTU&=^A!-?1H
MHZ+.S- 0 7^'\-C2KB.DO'&(GW'4UYKY2P-38MM7U%R%&%PFJR R?$Y?=&[
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MARM1%/67'42A[6CBRSK([/$"?YVXH_BZPVE+8V.3I1HHGUTEZNIG8_Q,-VU
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MX%>B"!Y.[*S:Q@0M9>WA?*1?Z!WPSRTL->;\]4, _SI.Y>>B3%I0=/EM[R*
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M;6PGUJ.B;K']NH"LUM/6+R96/Z!VV.&VB%TEL9,ELR]C5SY1'OP1#XZH:%:
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MQVN:/RV*%^D5=LC/?#$2)B!R76#<D8-1)MD(7B[)CY5JVBI?=4[3W,LV3B6
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M?5\:Y+>O?XG3=IEL]N1- UYNT.1:CHP-YI;G:8K2T"-(A0/T@\8CC58>;O;
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M9?7KTY:L"7J<*)*V?RNML:;.M)*O!-)#^'5))/KYYIA38K.C6K1T=\IG2)C
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M+<3QF?F?$T4!2&B)+A/T(M\TYWUEP^,S)5BTB[C ?-&PZVFA2F.]EFX_:".
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M1CR03B&%JL"/X90PP3-U'MFH,G=/'U;-U+U>0"S8;I+XE_/NNOFQ\M&C5_&
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MSL,6^031X#9WR5R5(][6X/Z#W*&%E%0YG@:/6N-;2Q$P4S\JE?^=>'J/HBA
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MK\7^KSJA6&++[^7XCBQH?@<M@+XT:[[ZSQ68R9\K\8)?D7^N%-V?PORY4O7
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MF/2D).?D1=PT?PQ)#&6TL)L:),_:DE%B*)\/J\([J7?Q#8$AZ@ZN8.V"V-E
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M]5)8BY;."#P5Q0S&RWP[4^-.M*&?J&'OVB$4CL1--RY920E)%;')SC8++>!
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MP3],M..6GA@[B<M!AW6IZ,=*AJU)S@V.<&%OWF?9(J1A9AA>%IY%STM;26G
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MH3) K0XI[<OPH"YR_&!4BL=\)B5OW5J]L!RE*0+J/UU$K:3E;YNW 4EN@L/
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M9J44!C,+U.2:/&DP"AN[_3<1RWX:$9/U_0Q<D?O0]B[7()>[;%65?A/I+(?
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M9_<)UZ3R+3DVY77+*AP^X?6+#_'-(Z]A@LUPL\7/.(5FI*XL?*,U,5=(/G
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M)Y\H;[ !"-*YD%>XI>;6=LR"Q)AC+<G <?)O4LNJM9[^WI,LK_/=N]V9?CX
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M2>@%VF-\'U<YK.]?6=<)-8A9@W]ODCLMOLAQ/1YV\Z4'L2PH_5IIV2"0PJ+
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M0.Z.5+Z$SLF;)D5&Y[';58=7CU&OHBR=S?KQT[$5%2W&*81C,\NI]^7X,BO
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MQD3$5&"2+Y^]>!\/>1K]ZH>1CWVS4G%Z-3#.HQ^\QNDQQ!(N%R.+"!92-XI
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M<JB05?E:MB)D+"#6P36[_ XP6Y0;.<K2&CILZ!-M,*;6MZ!O*7^H 2OSKOI
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MP%7)O8? RY[Z&C867)<_2ZA<=Y8M4A$#]WVSDL KSB";!U_5Z^2H1W[]<I:
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M6.[ZKC@L]-Q70.F[\2"09M'>> 0G/2'D^**\VCE7^(,NHX6\\R-ZX\+K$6,
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M*1^>XZS]#49*]164K+UE=&B+'>\1$]#CO+HI;5SL$R_RJJ5^@3[S&M9+])@
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M$.2FB/-39%F-&WG?H5Y0<Q%R46O^WI-7D1D]'Z)IQT;WN'2):9DP*&O[&+G
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M\>CM2ATAO"%HH9#;\/X_\N>YB.4]T7F7C>H#W(*NS8$CS48^HR&QD4%'-MH
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M $.VYJ>P2@:LV>_8C/XJ#-0]47"&#M4H/*\38X8FS60FY(38YMS_8P'G9W&
M(+66?SN@50 -,]Q%SS?27B5=;?L!TMVN;C9O&WXU9$AB#]AKV_C7O^Q;[LJ8
MYV<J6&YWS[7Z,N6%%<"=8O!NO/6G$O[103])F_BYPLMQ@!0W_4?6-S@E4_;2
MJCAYJBH4%T!^UK-'@"42CUT>:]'Y8X=GX4V:5J;#/75[TXN!VR+.VY@TSYM[
M>W5T. > 342P#1K7:.[AUOD!MT?]UQ\#SO"$](X@&^TF^[;]'W.O=@4'^E%K
MY_Z-I 5>G@^YCW^0/@P2#A[/>+?[?(TSR\6!=;$IJ!QSS4C;5<_>?.B])Z7S
M/(,5*#]2'E8PQ>WUH:/:NCM_0_VT)P$-*@^8\&K7&!>;UAX:&9AVV??@*>BM
MS&*X62LCN;38;='Z/<-9>\7AJ6_VB>>ZXU,>Y'X^KD&1;@ASE?-S'.G1[^OJ
MI57[,+1K&!#.I$>=_.E+@M9_ J/K#?'=.F%U)M2X)G6^5+9_,Q,Y=<<C]:2=
MX@TA860..C=HF\W@<HS=:<=S&W_E6J]R#F*.M#G_1EQP09?C YES,H/=N2);
MM3IUQG<B?P@\[3_V/G0BO.V6'[T<KL# $X!,9*FT1IR=K,RDE'.:RFONKPH#
M3%@Q%M),[QU&LX&?5I;*M&UE1TV)APZ/DV)K!-71B@Z."UG1!UC29F,":8YG
M/S?C+=@\S8-+)N]UI6[%RY<< ;R9=%M"F=P9^4#H$4'!9[.,=#8KH-C8O?))
M/,JE6+<[7WR'?0H9]G1^Y=>M(W;+BON?RIDQ7\L).:_<NUL:MDHP.K4>D1?-
M3C;%WW]?<K1ZI:)XSO%!10/?BZ_[1^V&[CC*HN4A-&1H4$LB3"I47[SON7-0
MD)L=N\'O2X&3\-WD,B?:<OM.]M+NY=^7%GS.-09RU!L&L1=,6CDT9%O_[TM!
MOXI*-14>V?P<4&2R<_%O7BN6;&YR&#'RN0K6^QZ,!O]35?[[4G#>NMA%Y_ME
MS9[1_HV N.]V@K3%&\XG>3_[/LL?5#5?V"<M(_'Q$]-+M]9?$B,#7XB4!1+A
MW/F'Q9L#BF7&#?H*!1'%DCO>!!,I#Y9RY([2!'#TYT]E &M;_GBK5!KGGT:*
M[F6%#A>$W*DF#],IA0(LG^?&Y)"U7.2;U&*&O9D7-<L$N&G+M7M/N3\:_'+
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M(TN>4G35/<_ZH/-TB&-WFB*VNMSQ6U=<QY29$VVH]BWPOM)7BYX,ZF?'6OQ
M;M7' ,T0?"9\M]:K:UAER\3M2)EW<+)$_,O.K;1L\XB>!O"A3(>'E!RS;SYE
MN'OCJ>]\AO1<ZG:,W!T["X'@=D@YW^K1.37.;C'H+&"D+LLF?E^G%]=QU9U?
MGTBU)LYKK:-(J1K1))AD*C]'O_1-N)^%VP)G5O&DVX1)91QW171/&Z\=CE-Z
MZKQ 0NJBB0/-H2$Q-#6]T#LC1HE^T7#T/%#SGXL'"S=&<]*H5-L 3DGS2C1?
M!N6<TNDW2E#HMDB_/:(\T _P>ZDI+? D$7 M7_Z-^]^Y7\JM,H")B5I=S"EI
M.[_6ZVV*G%DL8GN;(X6U+!_B2P?@;M2^Z#3I$3U#4&6C2U=(8+#Y+GX)2^4Z
M5Y%&Q'7&M7$$=TZ4D5/UZ55E??7O4K-[;]MEU!I18T*J.N,#Q!+Q"_.-+.9#
M6@&\E.+#.K5O_0&A:TY.--4W![H&;Y938^K-G)W+F,03G/D*G H(^SB>7B4(
M<Y\&SE0DV*LT=!SW$;:LAYAS%Y<""M@AC?+EK@N+4D:Z6$^BEX)5&Q3]?U^*
MTAY>^/HMNV@]33\%*'/=@1?'L*5T1_H<?8=I-L.G(5 U&*2$)Z/U'9;FU@@W
M;_E;36L5^NW<,OGBU.I4E;7$SST^=W;TY O;G^'A+C#A #!4DLA_.97H@^8K
M..S(?6(V7Q KK^3C:8LLNXQT$.8Q!\[#[-L#F,#GK3(0VL^.C%D"H'YO4RI=
MV!5P>6ATHZC('FI)NB*_J1T[&&SP0.:""T=<J)L6V65HYLW@&$2]8@)*+>;#
M$</GQ;M.<(O*?/F%FR%#E,].&H57#8;G+00PKHG'L='.QG?]>>=3H@YP^DG-
M*?+>LT.]M?6[H7Y*]:84:$9&Y@N4N?T\O"-Z#P[[[." 6F\.F#J=8%7AZ-TX
M]+ ."4&ZIZ0D/RDN/_/'8[3?#/+X@6Z]_)-@<R@L2EC2^K#>$3(V6R%:??[\
M]R5I4ML2HUF@UO'/*\<NKZYJ\-SZ49+UX^NC>):$K>X//4K-T+D\!/?UT=C>
M%*X=UW0+V5II=A9_=#(]R-TVF?/JVS]O9%:9%9%6>#2'OB-+NUNL68]2%&T%
M=C7 BBJ6)7-4O?"T2*5%67EM9-L5G^8KMJ/K$9_]B'&(A?F#K'OW[AG64F+<
M'HG,AZ%"3G"N,K(=$[;%#89F6[5K@J*FTZVP1XPI'FX=9F[NT;\OP0SGLWJX
M-BPX!=MI5\GH$/4Y[06JA\T;9N[3]NCJ(W<(!MDW+BO^\S;D95^/2+(T!*;#
M*(1@Z.+PH%6VC)4(:6 E-MPJHG]X1/=0*_IIV:<&/SU([:7QPGNG! .7A[L0
M-_&CP[N3W&QZV.L":8";VC(.=CUVN[56NTT@*Y/9V4WY3K^D$M"K&+24'9*O
ME6'A'GGL1]K8%<^%6T_01> AWP^Y=*#S,CGH#9:(*F'AU0::$863:[4Q?COE
MR(V2T( :L K#VWOW6)QMGVJK?H9.</W@)EE\+W'HR,D*5#6T$7=9%T\!D$D6
M;U+VR.CH7N_LR8^L0O*T4QT'K[]I7%7:U(OJ57?C38;=T.D"_QO1'B].L3["
MI!J5Y(I5Z\^>6?J)#5*1OK6-U@_)W],4"NFIKRX]+[*J2T9NOHC'O;=J[OJU
M_HK"JY"*-SL9D@Y^J#3ZJ7,"?K[J9"')-]M0OTZ]\)'D6QQ(4JW1KH^OFBG#
MF/<C*JQ=:Q]8,.:K?P1<U6ZM?!M^D888#)05XF]VS*!5#J;U*1 $YB<2[Z+_
M4@D9_RPD;K_VO'>F1B9:HT<2X^A^]8NL6ZUUZQ,W4\2D@];T)ZF_IJ%T(\\)
MRTBFY*3-/5"%E<D=(EU^=@@#F6F^ZMHX =B>RZST@I*$!<V*W93%)^\:/HXL
ME6"\;KUO(7)]._GHX@Z&P'Z,4&PN]>UU?%1HK4E9]92N1>]+!AO]@G[_L[,@
M0ID+MXILFDR&]I69$K=)N9:Z7*<D!I<]5/RA$?J/9^&N5O6.=K3U"6N&3<7?
MEPYX<8%4/X,,FO)1OD"OEH%/3;J,J9WP"ZA=:L%7TD43X7'G<D"F<89KI4G]
MYY_:1C8 80]-:'@4#S!V?V,T%D]VVO[!&@D< JI3C,+M6N?+(]S*6H+%ICEJ
MMI\B[/O[]+33BCKB9#<U<:65V>>2-2J,#4S[OM6G1K#X* Z(V_?'/'!]WGN]
MXS"8#%><-G7PAR39<W/5X;[FM/S/,Z>>ZI3I> EGD:[L&*#5.IO$U+&3;9U%
MV5H(27.G,/"JC'%3_E\.7\9;KHNCGB),CN94!VMKAQW3*M\S8Y!5*YF8T978
M&/=M#RR3H,Q09N]Z:UM,UZ92)ISS;=BKNEHSF83\U:4>!=@CC-6YSSZ?C&??
M,?A]3/"[,3\4_B'\NLR-)C@ZO;FXF/'LDY2\%:GFQ)(LA&.93S[54?Y]J2MO
M#+# =OTFE,537O&#^TJ#)6U&4-+&;QVD*&+V "17:?$%,C[2#I#FZ/2>#\[J
M-5$::)3VA.O9'IW]Z.J,>Y\SYHL87LRMS8 ,?\Z0TAI3_K,L?@'SGO*AO]2Z
M. ::669H)M1)[ BKJ2D\<%#E3KC"-;V.1+.W-S;=M_I89&,K0A'52B[L__A.
M.].I_EIXM-S*>TE[MR1!R-RA[)K_?L?H=Z'U1GF?A /;DN2+&S%"Z@[AN0IM
MR^U= B0(Z'*]BF2__D(<4;C$MW"Z$5':Q0,T-2_G-%N%:A0][N=XAW_M>&^*
M;U\V>%-=1T5:=#L^;*:9:(;$+#?Y^M8/4V.$[LD5&*+8>(O&:67\5H.9UD7U
M<OD-13.: =<7&QW)GN!;F\K[5^#+?8%V=VN]D;?]2Q8 JQDU*=5(CW2BQ5K,
MFQ<MPD7APG"E>\^6((4N.D[E9@S(8FLVDHY$XJDRSMD4E,W]-3IU %5KZ $%
M"Q[PG71.K]A.V+ST15#GO&D3^^@E$$/LHHAIC/ .>ZS.Q_$[U]Z[=DMFGMME
MA0=P/K-0E%,$B')K3TTLH*R"14V''@^X/[RH7P43YW:FO ];ZUT1"%=A_DKG
M6^:T9&F2?OZ.HUGWO?(6-$^FGY4G1&0?4$J=N,&=>3#?$ZV@TF9T?]3)]1UY
M5\C17\B<C)5B,]#J+[MUM?ZJ^?:GIN.%>8ZH0HP:^80:;0^OK5]P8KS>]2;1
M_Q;?&!4/3FFK3!\G=Z&BG80B=;72_ W:OK_4-S6CW7$G]HTTF8Y,EQ1 ')5-
M09:%"/IPQXU,FY@Y\22OL@<["N\'QS]1[@J?_ 4R=P _*"SLTFEC#*!-.SP=
M?3&?.37/H]Z7#,=,*(ATGM$+XZTUNVCD0"#!)M[N,",1FX /MA;=>:1G&:<;
M<V)BJW/=?'R@H*9Q5513S\@LF&&F:,&RPE@G3L '4:']Z(H]F&^C?F.E/<L*
MC\5C(T6V5EQ)#M;ZL0:J+N(8\E'J64T2/RL@\V+$EV47ZR-(E:NF6IQ39S;!
M#Q)?2JH^:#D%\Z:MUC7$2T=BDM:=TIG_:5CNG3]N>.7-C@Y)(K7TX3<#OIQS
M, DB4SU(-Z.1'KXYGE_9K.\8^K7R",?J3[I*133L9+26GLD)K-AM OO>RG'L
M#^10!\6]RV.SZQ)W$BL&6R96%1F=K+JLC./>[,MP33>S;N>ZO6786+=T.#:=
M]09/5?S(2]S_+OD$KT_F<3O;!<7:#K#N<O385$@%&#G:B?4_SGJNIX40,NT5
M[@(S-!GPE'$M9)M."G86FGVRWA97FF G[EF:/T-L0(0DIPY:903+X7&TU7FS
MX=-::+$&OIY#?(O5?U?J6AUWA6%TCX&P0CN*,@,AA4PM5(CMSN_EB")6'VT=
MG> _P/>I=?FH+OBPSV0NJL\S1E2&24^R7TWV^ESCU&LO7I^</L/Q.GLF@-:O
M3O2#[J?[/KE%I)=P?M/!CY4ZT6=#]7!F=UL_4<AGY$/#S4W(C/..+B\0PA/N
MN0%J*5(R,,9"9#-:,PO!L9%LEQ6 7V5E9)";+O[:V)D(TI'4\DN7A]> Z#7D
M=)C"$WRTIPRO2U+:>GF(Q::)[BD_@OTEBKBM(6><>B>ZA%_CSG1&F+YU-'O1
M#;BG25(AJ%-7;$^2]>+YWG#[0.L+G*^N@1>**.=+(;+K/0_H5\>%\)Q];%+@
M\I'S"OV.;I9&PP(]+W55>+6L%62[7YI67H()6=5#JU?V7H0@Z6A2!X8<#3?O
MAZ;<%U,6HYK S&@B))9/+/5V/N.3"SH0C@%NH&!G:#_=MH/#^U?].J[!K]O8
M8L]3F=%&FL)UVYY8",]PC(JSK.2?ZMT=*3'Y5BH21>:0'R,8>L:MWI5I46T)
MIV-LZ]LM^7M"$6Q/:LX9=@SUBN@46]%>()[#-VN/@N@77")E"48#5W0+/)(M
M[21A205:.;XG!(V7U]4=^2J&/(<[TLH#2>&V6$0E9)[7I+KOI#8=G7?_^C75
MQ).MI'MN-8ZJ>SJ;S6P^R-:&RB60+@VDJ6&Z:R"P%IM2 A*OO!GHVKU&!>5(
MA\@!K=._B=4WN/O5%H^.=?YP"K[!7A%G;2#K#(;NF(][65>606P1%:OJ(] A
MO2DB (VV1^)$%A5NZAQ\D?[SF2_U:XU-("S<A-H(3P*TJ^>9U)ZXNQFG>:H!
M];X9#@*<P@F*AFAY+XV\:UL')+X>Z9>BRC#W*P_@3>[5?N6^<YF%_,;T@;Q;
M6O4)U"I>'^[,<OT_PE0).X_7/6XP1TNC,\:-DZ3ND+K%YEHP?;?;R".M?_Z=
MF&"%KWR<F1O#K'ZSH\I)<<5WJ3($/O,(TML-5KS19"EX'*-:43Y@/<=X7T[<
M(".3.*@OPPN0!WE$=)-YLS=J!96%:.LC"/UIRM#6D%:I>"/4?.][PN3^B-.\
MPI)#SU=Q7G7D2ET!+$KXA^D1U&'28SV"2"2.;B-N'R@56YA&-2-K%KC9$6)+
MU)-2'['TLDE7.18AV,:[-6W5V6KE/<N3JD&+?6=W?'RK351TE78X"L2G8B G
MRF!7!7PP:QQS(U.FEE66OA# =Z9,]ZUN)9*HE1995_[Z^VF  -8G7G/,0KX:
MHV;=Z+QY(TM:9^SVC/3CAFGT_JK'JJ,04(#@-ZJ.K1&'WR9.8,T5RVHLTT%[
MC10Q<HI%/,9BS$@K.>G-- HIE):8A\],&T;Y'I-//CM_9;GY3;[E)"Z.,#([
M[\$0;F'_>2K)/!;[H$>0-(A2'>JET0:I#UHK$*BC9HIMYI&%AL5$^&"CP'PG
M%3YG9S+8.G''0<]QH.  ^[POYG9LB\%DGY8IBGY#**E/,8IDFX(5Y(,3?#SS
M)^A 5@>@6M'7;:[>A<P:5CFN]38 IZAY5DI^LPH -'^MK,+,9=J"R2Z2.<,L
MPU)RM9YAH#.ZQ_8M+V?1GO6"41MPUA+PL0N^X1;M>5,G+K\F'^$8A9S9]CVM
M/O)4]!O^_+G[S[>8 ^OQI+#RJWB-M#)K08?RSBDJJW(,BX1%8\JT\\0$VW&2
MZ*.T+BMXTM8"158=807/)"_M4X:Z&A)'BA<L3.GB\EOR/_RVQ&7*5\H/43.&
MBI>IELSHZ_8?<#/V[948^7_&AQ=:4U[0WP:""LT"/HTE'2SC33K]?&@2A4JG
MPC??(.JVWN7K.@<5E>;'P Z=5A:E"GC-J^=G('S?L["]&78MI\U2LTW91F(U
M=C.=41M@&^;S9ZAF'HH,D@ 2?PDXL;*)\0\O:5<9OOM?E6TX7]4%SE:.>7U#
MYSQ:Z?\FX%EW9_C4:YB@AKGW[7B=^7B&\5>*U[CKILIEX9\ZERY=7@X0_O5]
MH/ K<\NC9;Y@M?:%GV8/R];;?U]*2_V\6V9<,))R_^^,ASE)BA3"2?CZS[DZ
M]&[$9C3=S;S#:/N#RLA1A>OVY6R*=9N$:_Q7,8?)KI42)K59,(QQ2G8=K!9O
M-H?J;$MZF02),34O?F>@]:'AD7[\/+OBBDU.^*Q @]0 !L]K&=0T,!-QV;'R
MIYJF\ S0A@7;C9+CJ2ZS3+GW:;9P@,"0+)R?V]<M4X!*"DY.2_Y'5C(T?.!*
M'6PMB2]S0M3,]D2R+BWTFF>+YS6IR?&N6HI8//;OTC8%GB*7YJM\!OAN0[4S
MR?N_C%7C<%\(O"QM!TVA\3]S[@1[+&=%"*TUW&ZM/7C[Z'A79WD &JJZN=_@
M^$/JV:OU@[7?EYZ/\ZT>_ZRJVS[B?#Y=GS=]6RT>Y1E+=3AL\%?9?C)M\CV&
M36@^4']"X2A:HD69+6#/FE!XP*I0=L[SJ##H'#1($C\S*VJDN :GL0&[>3:)
M?M)2:@8Q,OIYH\M.8\ Y9HH+H3CKNCT+*6I+CL4O,_EB0J*6;5Q6+O\%2"_B
M?!4['S]1O/&>>'K'<07D&+B4&( V:KRIV^+I8K3()*6+_:I(?I(DF>^EHU1D
MXV23@XSB@"X);/"%K\BZ+*Z2%@N<!LYXU3[8S&O(RX_^JG7?YR.)8$C0UR_@
M831NE\'NMS<2"[7<"UOQCKE[,G8;JS\D$<U%\DW?_(=K9CC2W&E6*8)SR3CF
M;2QY[]?/BN;T43=%C)&:IT [.(6Z5??72G!CT')045FL>M;+ND^,Z;N?AZ4&
M&^JED>HUIHD45@XWU,TZZ[Y6'<A]^6KG3S5V%PE.7 D6#8S\X;;A?-3B0F</
MX#LF-J6Z!V=^/52#)]0(H[FX1@S3!-+6%##)D;,8GBX()5UT^\;J;W>Q>1"C
M%%YHF9FTFF":PY[KW39(+N1-\IT\]L^L5U9R_=!?7%&3-N_YEIQ\S.*\#BP!
MXN1XW W<?=0>ZGR,W1 1!=\!,!2 MRX,'4\:5']?>F$T3%.Y5<G'D3 5*O=J
MN_Q)T-%^'T!B&)BM-9*4[8\3?1BFTA<4K&CRTI"<*&WJK5[<4Y\,!3(X_U43
M;Z;I:[H[OT9PU\FR!+^;JJNLO\HC$&7!_!*>HSS=KELM\Q[#?BVVU\2GT&]R
M8H4:;_D,>P,QU;YAFP9\>V;CF /M<PLX>SL02#_T7;^Z[]K7/3Z>E/G[TAU]
MVR-/EMH*![789IO>_EYY=775VKD_Q1YII#5"4E>CS&$H,P=ENKD0OT=+LOE/
MYN(3W<)AT]*Z8(_X,NRU+W.L+U^R%XE6T#;^2A[)B.B-=US]^/K&EZ?%0NC.
M?_F-*#WTP78YE&>>ZB/]HADC].+Z\'PQW:/?1NS=T9<7UF)U1>_V<<Z)$?"(
M>T59!CW<_7\!N[D!N_S:PN;.O#]L\'N25(50W!BOIM3M$P'"?-8M@T2LYYHA
M2B\3)K&A+Z<?M>53V*&C[4[6L#(9YUUJ-!EQ4) MY/D*??-E8W#(;01AY7[;
MH64M\G[ =&K13TJB-&/:8+0I@Y:2PZ*I4DQ@B*&<^8KA5W#\>-R8Q#XO=751
MP0IKAM%T3%YO)?Z+H_O#))[;O1/[GL2Z5'=K+2R8^>I@6$N3NI](ESN-)L,K
M*LG-M>Y04\/Q^2/':(UZ=(_2 J]*38N[*H_[!/MZ2)*DFHC(45^][=> NZ.?
MDQN$\GV^!V45^ !0YG+*DLB]/)#F4*/CH7Q^*3SK'RY<#4M ]'""^=<HO)3K
M/;=2=GHY%*K?"^W3E_P""DHJ20?5<:K*",G/J,::#T0<0Y^UL-5J6&TOSAK<
M6)C+X'*^R$(9H4;:/F_7OC?=!/DD>0Y,ASMCFN/\DM&6KK7=5UWXUO<!D'EI
MF C%)N4*69!$KY^W,196"-LUJ+=H#TYR Q5-=HK)84P?>*,\Y=BJ%>3H*X;_
M$O,-]=@:PKTB"XH@>5-.X&EA#!S>.?>Y+KTW3U#/:(YL_682#V7CUC1-;ZBI
M$13639K4C5 V"^I# 0CB4'@H>;Q%_OJ^YMG$CR@20 )#(?&_2/#'<4H6_4M/
M?!\@FMT9'%Y!(\HQQ*>O][<R%@1SL^5K(HX41FP-=QAVWB0_3SDL[@G0@<LQ
M;=)Q,D[3(B/5!&Z63A5+H,?%9.@C813.; AFHCZZ5)?*9\)F$$+=&&CX!H3W
M7X^?YY^%(]:5%#!C!@-:61';05XARP!T,-M!;&D5THE+#[^Q&""-[0Q+&@=$
MR@S'^6V6M?3'/XXA]7"@6IH+0#C+9$OF)XV5DBCH@@V<Y0;.*7-!#!-1*8QH
M!)J4P=LEWN@+^T?9GS.RD#!+&>QNH1SR3E5;%*\3"-DH,7-Z*T4J+0;"5/T)
MYDQ?:W?<< 1Q><7)-JB2O\RNO\)WN].FM"4-[Y@J6XQKG1<T[=[18U',B6^?
MR([#-NTSDBWTK5V@BS23]+#H6[=3TY/EQ*?'QP^9H\KUKI!-LM(N3)>)+_)V
M"LT;L^J+NB._ ;<*M<9>X12B8:;^4:=Z04G.2+J]+!N\XC6K6W17./.5I]>%
MQ63RJ8(?/)QBIUT68P0L@[8#-7B$.QH'OS4UR"K AZ@60&O?]EFYA'P]-T&\
M87JHA1366TL1FB+1YC&3D"A'>=H"=2P8 ZR;Q;VW=X>I>"Y__7TISXU;;^R.
M=BB7IW,AE!'%_OV^8\6@V=L2X\=.GA9TW[',Q2+#UJ>\5PJ>_9.8=9TQ,R'J
MG%KY*@EWXEL4%)JG:%3V@'CN//A-?R7\N1.-\V'YAMSM!^-?)7AF$FL/W/VS
MUG0:LV(%:V^R8S3/.8E7 ])0L"081UGQJM'S-*<ZJS%M+QTX.F+Z/1])X>:-
MH,'LUU(W$M[*\+"'6:=##71">/FKD>AP[FK:GF'GEE'_C*#I/P+O_^4=LPIJ
M+6;X\%Y#<?C4GTHH\]747PS$[O.:)&U*\:.(L$2?C[\O30-XI<O+UX SBOJ!
MPP\.'Z60K_#G^V?@VH:>S=!GEU%2:D6;+URARO#_G!1V_ ^=GQ^M_U=+"_W_
MK$ETA;%W_(#T(_2E\0.9J#/6P2;@/%?:)XBMMKI:$*VSZ@M/C"!\O(W.E3+&
M?UT?(Z?H;:^)"?%T('+Y<XUD).8FW/J2>+<K)'3":E-T7_U='3\!88G?^[[T
MO=_[X&#3\Z!VP6<O/2LK]C'%!)N0'BI"'"5+I0>=.HLD2TD0(\0AJD:FDQO+
MTO5D>9Y04PLD)O\&DF\VDX?FA1)!06PSUS'E-2?ZA-QJ"X<TFY3</.)'ZYYZ
MZ?1)R]8H7-2YVAFDTC?CCJHETX)5@A?48EQ)QVYF0Z2!OQ5<O2&(4;U^D,T/
M"U35#<J:OAOO;L2@@IE,*[AJ-KE<9O9DJ83KI< \^]5BFQO]+_ZL+/&URY X
MD9CN]/P)2_ZA^#U43G!(7P'KA6+'N4"<$3T%8,O\#[V#71,6GN %THPAU;YV
MJ/]_6?J:I6=#CZ*%^9P)*4M] /5U[U &*'TRUP,+72NM\ RPL198]UB4,"5X
M^TLUFR+2=%.)T:.G>A+<&JF4:FO=+\7['"(@<^T&:$<&X8P:=]$_3G5_IH6K
M38MZ *_$%CM0%::X-EJ7.?A3<F%5^7;3N;E\VZP&.N094IFSRX*<I%V@#:/:
MI]3XMZE]TT,[63=$+)D*]/X, \\(]UG(WA3FJ1.GR7BQ=SFG%$C#GDR'LHC+
M;<,\3:IM>8Q "HJ\)HA$VL!"^$6@E.T$@@HXW>:P9988ERYV-^WVX)Z5$=AC
MV"@LH'PU&=SY<H"(&T:SMPDE;J]!4'\R;!<*&#DC3E- >Y;V-OM\*J^\[>0\
M5DT06W?]L;RWY]KK[%[ZOY0NJTMPPG^V SD(SEVS@-R 7\U.I?T(&- ;:'*0
M-PJ/:SMI+O."#B1!-CYFYZ26?/ ;7.\ ONM8\*5AO[$1Z%MPW/"\!C9!@W"X
M450_XCYB&2#5)H1>U2L/>;2$U.P5F1.+WOSQ]4^_M0$%<_89LR@U"U;!=7_-
MB2=]J6?17??._U+/\ECPTV.4TB%H1R6)6&V!SDXR)69:VRI(QC-@J7#S4G@_
MW921([F&E_O7=&E\@J/M7C5E^">L);\D[C\E*LSBY_*6VNQ_7[IOT39T8,))
MNM66*_+[$OC5R-]@NYBE@*)7:N$GSU-P8]0$R#__)_P 7OGIF9P,-I86I&,I
MNB/4UD+V%FO'K'GKC)?R^V)IA]R*9*H='-MBLA[J>FHV^HRXWP OZ4<RJR==
MEQ1(<K.%E7:_52\9Z(J\[&E#%/%^I.^N\$7HH)U*'=%N5A%6PPXIJ$8[L\9)
M@5'$XT0A:%\A11BO%5:3Q^E+4 :(JE(Q,L-H1Q_MIG7'J*^N[BH/%N!X&]AP
M,532WV"@U#T74 X* TV]6^]]M]HC");Y*B\H$X<OZ(F(YB;6[.?\3',*+)<4
M&-'5+G27U1C_I(%V;!+I]/JUV>1; PDNPA#HNMP&]A;I=?%UE5B"87<@GGRJ
MK<9(5KZE%1ZG3>%N> U/Z-](YK0@VN]:BJ[Q.VT'?.N1O4H]X VY.[!*$7W'
MV01"Q'X<Y^3GQ%?C!SB^*UEZS8M;ECT)UZM=E5)7DG09/'=PA:\(: >,3!<[
M*NHYK@A[W/H(8*R5<R ^LP3SXUO.%E/8$,;PXJ+^R;+ZIL$1@RZ]J,2U]Y:\
M !!W6$ 6]FC_I4+-@>$)K>9\TS[DUNQW!,6P9J>@QBK4G GNQ6_ _W7DJ6EJ
MR8T$S#3E4['2H]/+5LK <Z%"HNCO2^8M&LE;)+<TK_%BOK+?E\8")?0\\^=7
M_<[Z:GW>WV_V 1ZBG4$631!P2.BZ[0S0:_"AG.Q]OKEUT/8 6GE1EO97X[W)
M8MC/*E)I!#G=DU=&1E'EO@!</M9OW*<P,P'U-(,1EYO;5QR];*.CF9Q2 D,Z
MBQ;O)%=.23LF"[:'),F9#(;444ZS,Y(FQ)TDKVLX(W-\UAA71UXEWI/=J\B>
MBAW>B/ /ZM0N4\T&&&F;SFL=YE8[.3D7#)N;_XV=)'L.PK^ <D\Z4RLFI%KA
M/D=CW)*LMBPU?#UN: 3K',N%-W6./XE_V"[I#UA>$C8_+2\Q4N6Z\ _N!LE/
M]4+\W-CX0,@7_)ZGX0;=8C%[J8R!PIEBG0>#0/XZD*TYNF6%\YR7M$"GNVL%
M*C8H#=_3]SKXG/4V,O)MT#*=7]K1#K>O$T+(QK$*/_K8Z??0%NC[*NS7DD%_
M[^VR1RF)+W"WNED4$Q#4>[?TS9KI4&<F];P 0@F3JMV56W$1W:0]%!A6-+HU
MYN 4=:ZIN4T=^*'5K-CHG=Y<]SFRPN#W);GY1ITGF0)*TZDOZC5MLYVK0A<D
M%5V[<FY(T.?9;<?FVM6Y3M<DZ,V3MMYRUIQE(+$8AD(DZI2[#!ZR8T8L6/-]
MMK39\1)3Z3G<%[(X3!WJR)[R[)[Q"%9MJ#W!<>]T2D@%1RR*5\5OD-F#4'':
MFU086W5-#D"D3< Q:6MMH,T+)%Y(DG1255U]0;F"KQ4)]-/^RGQ<,]A'+T;#
M/2^LE,+UH5F4"6_'+G'0F' I>6#R."&GPB*LT,EXV-2N^&FE_E1)T5/CD@G8
MH+U6J\#Y_BH5GN%,-9\1\N6:[,HN,=RC\_3.X;Y=$RECKK$D57(=OENQ>K*B
M*(3#<O3NSL7%H8$!(4M[W*2 /PL'!Z(.8GG3ZMQ*&2O3.8H3BVXW^6QH^$5+
M:,$5?>W4]\V*^2HP1]<C7EUC;K+9T+O6__QZ/]4C4(_O*_B;WP^>U+C\XH]3
M,-:R-\+LBZKQK=16,/4 =9 FQQ\^BW@V)]$E@8PS(W-LDS0DGP1DW>=?B)*Q
M"9\["* W9O:(T"N/M247X@B'[=,662=_BONX-)>89"ZH.'%]1QN)<E@I$=65
MG=L_ER2:4(!T@)O8I[%)"S6"9G]N:8/'U%I3FLX /UE=H5#&D@(*-WBK%P=-
M\QV;8'$$P\ X[P96$1!UQ@6"B*,1@*)B1P'![9J9E4/P&\'KW^]!DD>!?#-+
MF^O==)VF/>A0YY[8M.11JWGIW_M@>-#Y$WB\'$ESO907,)'QRMM)<C5X-1=;
MMX 8U^]+UEILFD=;'_LY\O?JZI;#N"*)7>BL>,%PLR((Z#3JV(RH-8E3A.I$
MQ$;>B'7,>_V EM ^345,"X98KG2:5.Q5A >/KM9QB.CV=_OI'N:Q[(4E\8?N
M,@F<HH0*((O, 7Q6&+J!\52 0@]/7" :?O:+>E(8]R#MGZ[LT+<Q@E7N1C5C
M+4DXZW.[)_M5PK!0<<V@R:POPF:X^BI6;%"7K9*O;O[PT+@-C[P-6!5BFF4)
MLAH.^V'4ZD6540\ ',_DTON;TPL\%DR,2N8Y_T[/J)]L\N1Y7)I\-!C'R&!O
MJ+3LAZ0,!*"0*XX81<G<RA*HQLJ ^U]+)@J4<IS,+W1"4CW<F.2WAA/[JJN[
M&>^,%$KP:K93MEZY(8:7\<S.3GM24B ;-8-))4EXOM8O[2X=Z$P0R /@-UJM
MW\@AXC%@%I_B+1P5?:Y+**X:HY<>>].+W6]+>A=HN)_,,KO/1F^V/I"@?#;T
MU-1:1-O1)C1OO/E_;?3[;YA!%JT, YM[/&.,/J\A=\(G,A7E-%@7VG %<SH[
MG;E1:@GJ'A6ZGILUA+B,5*^[;]CI#._([H+FZ2@\H]F^*BO8@KUE, PJ76P<
MH&1 B<$T^OA)!H,'S7MGD$T;36=+(*V2]'Q#(SWS>Q4HL#T>$4!IK';R]5D<
M07.V"E*H_3-"R><R//N+XN]4Y1!D?5KFKIV2W7U>-:L1WOR@/IOB9M+L:;E&
M0;M>;4R]6I5 :AU8"=$08UJWN.35V@'3EIV<?E>KEU7+QB+*FS(X_^-6()2:
M0%4=R#O EM8#A@VU_#K#&U/"C:(;LTI JK*LTA.(&![^W?UZUF\]&<1_H;P9
M6M*8P[EM9TV?<PTT$<\N3,DN--,+U+]W-[8&)V.3DK\(9,]PYBD8ANG'P=QN
M#F5IV99TE^8YLZ:9XHF:=>:-;O=E(K8>/!\T5/*1WF5VS\$X=&$1F_;*)/#+
MF'N/WSKN=6IEI7;%(YU?G0O$ZZP88F/8QHB;X$:66$<NNL&4&I?'6WL@F;S7
M$[UT]L;R>_;@O$EK;/' 38./0>TC-@8"6HQ.(\]1%:[1C +E' PE3=BA5M/T
MPCT]Z^+ZH^/@7)%BC_?\<E?J6JSN9,7O*;5ZZ""XO[*/=J,?N]Q#G0\++5PQ
M1&:7Q0,",F($^&)R_.>N#[QX;>^X^UWQ8=O]$.T>%ZD(I]75'#M.$+AN7A^J
M5SH%BT^P<]ZY&O"CCY!?&NTOFR:!5/A\30)BHZ=75H9R=W9>-01!PGSQW9!S
MA4WG ';_H=-)>G[JC]BP4_OCB<2B.5:3(8?NJ%Y=>C>.Y$NC&9VFB--=WZHX
M%,D0G,:U W#@G 0Y#$I7?9UGDN+HNL0>CYQ29!-^=.VOT9T.FX&"FD$S-KL[
M6-\/BWWI7L/C,-'T@!S;XHXI-C/:C/KF>P!P_LQZ1$=DE['*D$0-!CFC,^?]
MX?W3A2@(S[2OT/&[[G9LR$^/;@B12O)]T R>(<B$;K6QK3$:G30=Q#E_&OCG
M\(LL^O"T(=XIY OU/F2\ +U2_8H;L W[\,![KP5>&659>J^UI: 3R)RO4DRZ
M>;+^W/6VQX]!>5]\TAUN>8*Z$78(0PC!XX90*YB3V.<+=_0)_<-0*'Q./#R2
M:?@UP^7M,4>UO6YJ*?U#/"+ZQXE12)/0"Z"/@VJ 6R'3&F^>E'60QL/M:?GZ
M;-8Y61,N=[5OE*GHR,@UWD$)C(EBM%S])Z-\?7-:P088Q4&.6S+Y* 1@_XFK
M,'.YVZM9!I,8B/NF[Q##=)&]/P(+61YWQV_0M="LGB+B 4O#IFZU8%UY.#T/
MG=J%"Y:]V0FZB=2I4K5AX*G<'C(+0%%F&KX&8AQ4;[JER#C$6$K.49M5=B14
M#>S6_>.*QC)K/4*@2F56\"-L6'RP]$6LM.2;,D#QX_YXY^05CVC0('G9YG+P
M^+3;\>&Z \RM+JV[,S;3H2MTJSGW?[1WUG%Q;5F^KWMSHT@"! @>W"%X\!O<
M"0Z%NQ56:"! $H)3N&MP*:IP"B>X5W O"![<7>K=[I[;W3/SNM/3\F;N/'[_
M[L_::W_W.K;.V6?M?#PBGW4VQ6%H:>;A4RB>Q<9HK4T.\1AXD$\N:-W2U.\>
M^?T*YHL<F8BVRA7G$1Z8^0X:P)WB:$(ZD96:F6,[SP+4_G!A<"5U6$FW:[E-
ME4E# JXW4:S%<7I^7JX\>W!F+04GB;*ID27Z23\K]$,.&%_/_W7>-+_ 47&8
M7!C4V%KYETLO/]1Y!FE39%$+EZQ;8]8;4V]GJ?14-.D<W<K95L6G<QT:YB;L
M5#<EG5F .D)3QVL=3"=7LQ9MF(1AKET)^=#-)S,G=)DG/A;%": N(!\$N:C:
MAW1\/!13JHO:3]LI"NF529,(U2;NF7:TUX6[1H&J2.KMRP>*%J@GTC2!/C0#
M=*,C.>G?#K;:"'367?19G8[XITZ%OQ6"?QD1CKV %5=ETANF8S_H:&9;;&H(
MW$^@0_)=5$KNX:$S1ZMI\N80-'V"OR:RKY27J27Y67V&#1?]ABB.N4Z]&+8K
MBW'$"U3_]&IZ3=XO3_RO5#91(\-E/9I,KPZ>%D8+2D IM9B$V.F8;$W5UXHT
MD^]8<W('';Q8)1T0X&Y[P0$Q+3-V4.;'<=LWJ\=VL]=_E"!9IN;$BB4W)*=!
M+5>VSLI.CT,E0CTW9D&[X4RZNFTDO\]\:._V:;BSK+B3\":;%2;!ZQC - :=
M@:SL,^-*VVN6K\+QX3RQGF/U="'P2N/!FMGGIE0AH7R"O+8Y$)GD'&X(^/V+
M<Z"$C7C42"6-C9AM:5YR6$M*W*23!75%&GC166\[BZX?N,ZK//W0]N<Q.[8Q
M%HVP$X,Z^?D\<PE;C0E^*OY:' VX+>GX:LU4(O/C;Y>8&WRX>D\$(G@SV8@P
MDRPEED#>UE,1QN<_07H<RX/,7>=.@1&I5<S:-.0%9P,XU.[LI)V(XZ!/YM%L
M9$H^@^J,>'M9PZYY>$8=VD,4.&2>'.'@<A(VVX81; R4)Q6_NU)-5)8J*(VJ
M63;QO575A0E-/X'\SX%W^UN_E0';0XG9Z+DPG[H)/8 XST&Z(8T/!BHSAYZ.
MGS@X#OD09]UT4&I*C#&.@+\032F.9RH8JA?1K=S% (Z,9<;@$;QJ1@/8U%0&
MFHZ"][,ET0"DD]X0SH"N)=!9O]:%?(KV$^*$T79CK4^V.NIYU3%#^[>-NPI,
ME\JEPQ$XF8(PCT)G&)&LA55Q_&8%K@V=JDF^PC'*O"]I]/+H=6QV+IL@=!]4
M3X8&Y&Y\3 '3BS^^>Z95.  6[QLR5K."N6E4JV+5!#_&<C5#/>^JSX;DH2"-
M0B<BO$I^) *6?!@L11L%=1L,Y9L,KIHZ:DF2&AKBZAL,68'P@Y!GQSRVP/$J
MF'*;"B**&%++)\SUA:EHQ3EU2V[186NIWDZ70FNR<[71W@I#9";"W ?GNL5E
M0&IF+RS\D$)O*QE_N;+B8R3(W."E?;2+@'_AF/9'^H>;<II5MD9=29^0/R=\
M. _:T=;6[JS=<1U*7-,;STY+GMT%ZW,+)\=%5\5.)=4F@L%[,^2G[5[:[4T_
M:>;1-W:/+SI'P?KBG&7-LQHRP[;ULP3B&N%A@28S\68;M<A2=Y?CF1\>@Q15
M==E?R7:<,OF(O>(MYW8E#4&2[#-EA+_B8D@_QU![("A-R\]A]NU@T-RD,S&P
ML,3TV:EPC9$PO!$B/P->UAVA6F;E%<E5BD.<A( M,G\T4.*%M1#M)W8K=_%V
M<=T94PEOGUVN=4Y)G1VNY,#,,;/(='H[&A;ZX)OVU8!YKVB\YW:]3*<*A-VC
MRSY'OTE?+&?J@Z*:B@8!?V\2GE)^8:C87FC8)?F%^C(OCS[.\#Y.P?BB%O]@
M*L16%^%]M0N:4"\HS9Q^!+**(L'^B;^;70N:'&9+0@37XN^+@MF"H=6E\:+)
MQXH6BVEY75]X&_K9I+JVL[:#K!$G$LN*K;U2V&KD98C5 7SZ9^N:R&7M&JT(
M)F[M2L&@)H7,D7G^4)5\%3KZ8HMJJ8!U1@3S['B';2+,V91_NWV"CD9RNFD[
MMYFQ%,J;KI20)=(D+V4N]JKX8U<=QN1);42"E.B=(;V08KTMOA7-!2W*KZO7
M#.O#!]T)Y/;5KC$?*5^@#@7IO7HZ!!*A5RD/<MIR+?(^&;'$!W E)73HN.O%
MU8=P@N,(9.NZ2=N7U->4X!JY*\]'3'7.$^,>:N9PJ]L-:BZW3C0Q5ZC4IRK9
MT^A7.@T!RT]\P)D<.O%5PZ^M\;YH(TV:SN--W?C*GQ*L"4]I_2AX9R9Y3&%6
M_L:.NR<QE&JJ3IR.L@ZV7J.-Z2HR)>_#N^R7GE&>6!_2>>3_O@'8)E-3++1A
MI\/RH:!$-24B0J]R83'B<UFYVD$,_K;AW;U%B;#^8]/$;KAMML&9S6KUB<'F
MD"Y27<0J2B5GE&8K6=4BL_,].SO^"UYF\C.&57DC,S/3M/??(+7 '4_!0DXR
MWPW<T<"Q^)1#;,;ZXMGP>.XRED)ZNDIXHFT J^PSW<65&"^['ME7M2XRI\Q=
M3*H,XMY)W#F/,F4W8KS@?:IY%&+0;N6?@^DJHDP0PN$F"RYT/.3C]=@L;->Z
MPTM4J(D58V"HH&;NP*L"6EY,0D&YH.[B]NY]TF]*FOP3S"G).UY 1'J\5]NS
M.T!"?U>*4![1P#*OT&DV_''I4F?\3N1X>M6J2=9D6RTX^KZ[&E2NPF0VA# T
M6U++WAUKOC@E;?1,=0-?5_@.D+X@!B^898T74]:-?\M+#^XZ=]E87\Y?Z.9N
M#H:(5>-Y4>5-R\K9Y@.[%'Y."9E4#CCA*'9&Z,OKAM+=9]:#>45-U=A'L7L+
MK%/KX*F$F->$O3=26$J>8G%FUJ;'I()=3BMVU%THFH4MPQ^D$K*%1(-T?K)9
MJ7KRUE_=2;/#HZ"[1%X#6NU#,BPY'*,0FB=@2**WUF;/BRC\4MN]A0&>"Q]H
M?AAL;LER'5<UE E3B1GFR#V*3;7%+PXDZL/Z,M,^2UBV#D%4K]C3&W<N61G/
M, VU>297@*OM)S2Y>Z/D9D.31Z3N,-76F:VF*Y3&6 TO]&"OI$>+]%9/?2I'
MJFM(P^6@ =V54@U,L7FM!?T*Z@P5N-PS7,229US[?5406Q45O6Y66Z=VK^K2
M!7N".?@T32$GN-)+FE$#IFMMDT,O<?C4K+?=>?:D%A;*6:+WQ)@#O\^'QS9U
M/-M=PL@UM;C!H1+NP.>N'W;]KHU7KR15CV F_G ("0L-)GIVO\))B?JI>O3
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MZ3)[M'Y.H%N:[7'FK=K!L#"YQYJ*,\<ETYM<$I-CYLRM^#G9#E^07#5F)&Y
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MI3_X*#W1EH(=2.;(_N;+6>EHV37["6*;/,$]HU8TEDJDB732Y>7F>R^D;T=
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M-M8H\K(1L5DAP63]+LA+WT$VW?W ^S=(Y18TH%))*TX?^P-B6^TK8NZM&1I
M-6(]'TZ6!+:S52]W*S/-/\=Y^RK.Z&]U]H^K:EM1<*5>N'*P^?&V)<>2XNX!
M&-/+A^,K&C"E>77':,+0&_*I1)"4X'+0E/Z<Q&)4F")S.]&](EYI'"CHVUV$
M4P)1^*Z/']A%VTDNOOKVE)G<!* !'FA +AO%X./=B",)<?SA]/_]]J9>[&A
MV_;\5:0R&M!4_:1NDF+-.F+ \+!4,2K3]_!J;=5)Q$<OX?*UZ&>LW*N2G]&
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M/$TACS.%I,Q2[I8)S*&OJ1%#)1M ?IO]+BS=]@V!$!K-S>6J#N NK MN!=@
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MZCJ4<9%(#E-<)8T0.22*8IAE,HY%1%26*S_GD6WC4YMZC1>$%1#4$OIZB>P
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M4L#9HBJ:9"V^E:77-\?:>-]$RG"B59I"3H2&6,:V7&020R0UCI',&<-Z-(>
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M[+-BB[<;6X#*/+J3IORK>EXK,:^^C!_-6_2@6SL:?=N,2Y46G((T8[;V1<8
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MW&\+F^G^L]9HD?=F#LF^-G7\'O2O\\6+^>FIDJ"2B)&<I !E" /,L +<3-!
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MLC/_0AY(<U@;CZ<"P8M$7KZMC\IH@= <TUSH8VZ6+.HFJ,TD8BE%"(-,Y"7
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M2>N.+>ZP<Z@Z\-WXG:_?VH,.M#Q.OPQ,W'^B+O'X!(S3-2-])(;M(K^/RNW
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M$6 JY1+F.2ZPGUJ.KP63(ZU:B6K=V)OHU3J9-[;ZYY7Y=88;8PT*\=!GIK7
M6F7\7=*8WZI_?>YB7KN0O+\&?5!^6A!\$;/6_-H?/9<M")YS&6YA#_+/>WNS
M^J[6CL7#3ZZ?U/ P=D4M!G[1VZ"\K,,GC9:0==:!;B;6^0L"2V^8%</[I7E4
M=7Y6K1UF15XHGDD)B TX-M_$'- R)T!HA3-(6*;]2F6?:6-RW\'.PO:P@F6R
MMWS3+'<]-R'/0>SV[;L1N!$W V[ S+\TQV548I7F.-/"N*4Y+KMX4IJCY]*
MD)DO*[W]W7RXFE5E(32%9EH,9"X1P"+E@$G) )54,U8JB;13 L*99T^. AKK
M/,(FCL#J']0W0C#T8&X,"XGK.X+!(RXD'(Z1(C[<8?$+Y#CO>&^(QM$MXP5?
MG+?U(*SBPB5A4Y)W;+ZNJHJ]7SZ_;#<?U'>UR-IW*Z.E$(0"3;29FIAU.^ "
M*9!)#@G'I<B14Q"R0UM3XZ?*ML2S?GD?EFYSD$@(#4Q?ULJZ&N-=4AMZES2
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M:_3>&YCLQNHX;X*,"G0D1HUCTZ@4'!7&8\Z.^_!XN4"H">W03.=<: $R6J8
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MQ-M)\<O69CXF;A3Z_V?$S5X[1RC3L9/D]'=U-SR1/ZI9<'7W#U!+ P04
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M4GQQ4WH4,'C,GM->'R*Q) S%!-X4B,H%6WPJC*?&]FD'LL:9M3*<=6JMB0[
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MP 5BT:8<N$9>A&\_2/QINL:UD-T!LKDJQSZ1>S>?5?F]K2F&R^'$(24ODU7
M/,K-M3..T_(B'UPD)H+C_$[;X)9CMP<>/FYM5C=X:B+[3K!S]Y:'Q+PHQM:K
ML4NI85R$@-)",:GX)!4QDO:!SR$79@Q67]4E@H[10 ?[X^LP7:Q/S:Z%^[Y<
M'D!/G,DJR*@A*5ZGBU',Y24QPU!Y1196^=BZ(_51@L8MGNH&?^V5UP$2+R^
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M<;$CY""+EBJ CZD.#LT%@JCW43GCA$2EO#.W8;BE)N/^L_N&T/'*G+>3[-C
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M?_*9OEK2.JRS$"]+5%(,)B()+%'@KF2]N$-' UQZEU(JUKC60P_V)'%<N]<
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MQPCC#U--SV#[RV*^7$[(=V<E.PU%UNIJPRQ$278T<>--YK1V3.L2G\<IZC3
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MC$DR,T1KW+#;I>^VK[V[Z?1?OBVW.GB'-5$DE_*VO"$ZPN6_,"PFA=N@DO5
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MQ-"P/%999P3*FQ$S0@7.;2B0=!W[*XG1*).J"P=<*I8)HX9YV;XSB7W5.DX
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MIY!S1P"Z'6OS8\XH0^>V<!*8"H$R=$K3?20K2XQEXX-3,>_6@K_7UXY;G1L
M0HTEW<')='TXTR^OG3&R++E2 K0/ZTT)'AQJ S:@UTYX*;?[5X[?['>?@'$!
MTT><<[A&.H#3X8*[8WN6MRQ7&J:]X FT<(72%QTAY% @QR#JP@3C;&J=-P[
MQ\B[= ^'U79&.+:..\#Y.Z34>IHH]UX7M?Z835?+=^__N#D#@HJ1V5(GE)/Y
MV^PHU681DLQ96FU*L:VSQ2<)&CE]'!TO\Z&4UP$2GY7NCX1[5Z^WQ::2*% 1
MAH6Z<DM!=%G7J0?%ET"!C#RY?WV6ZG&OX/H(%4ZL^P[0?F^P_\_ARW05+J]'
M_I-)X^(KYC?SQ9NKU=4";UZ^36*H!JLL6!DM*,\#4 S.P+LHI#-6<X>-P;TW
MD9W[Y\8H^O'*H@%4.G::?K!PUW\L_U9O.'^9_8Z+Z3S_$]<C'_/%5UR$C[C^
MV:NPPC=ANEBO>)HPJQB=7IR.02?KD%$-41<+(F=>;/ YF]WF))Z4[)&SOG'@
MWSDZ.O#UKS]_N9Q_0WQ/;F":\'%9_3:??:5P#C<2^3 G_W'_Y_5J[+?YZE^X
M>H=I_G&VWK.75$&N+ <976U5+^0[9'UVE(L/0@03>?--+4,Q,W(<-.[9T0=$
M7K*M7/L6.H,W_U1_CT^",]H(QD$H)T Q7Y?>& <Q6E.$3THWK\B<EL-Q^ZM>
MJE4=#Z;S:MNZR1+GY8)BU\]?ZK\M_Z!?FLY^N@SIW_1S^C\OWZY_4+O:IK./
M?Y]G,H3Y*R2*/Y,ZU^=XOG^.S\OZVZ[_7]<Q .;6S6"G)WW %K.1]=!'XYI.
M6K D"PB9/"B=/25,)8/60DF55;"Q]=W.2VE<"XS'5*0#9C4%SI8A!<[20LZ"
M&S2<F6(:B^ZOQK5],3M<X]H^ZN\@%GQXTY,35R)Q"S$4#<K7@U4D#2FC,Z48
M+4UK[.Y_I7L&K6M[@>#)*]U]--(!G :YOO'1,&Z,!EUJUU?4%/-9Q8!YY"D%
M:X/ZZTIWORO=O6!UBBO=?73< <X?CJ*ADX4YYQB4Q".=/%R R]Y 2#:$J')
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MO*E+_*S5UG*'CK>V[B?(.=:E_7RUJ+;[!G,-3N@K-G;P$T4K9;J:.&FB<RR
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M_\__^O]02P$"% ,4    " !N@J16:<@57=('   <)   $
M@ $     97@M,S$Q<3$R,#(S+FAT;5!+ 0(4 Q0    ( &Z"I%:W^9:/S@<
M !(D   0              "  0 (  !E>"TS,3)Q,3(P,C,N:'1M4$L! A0#
M%     @ ;H*D5@Y[@>N[!   /14  !               ( !_ \  &5X+3,R
M,7$Q,C R,RYH=&U02P$"% ,4    " !N@J161X#(Z%-A @"IOA0 $0
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M @!X9F]R+3(P,C,P,S,Q7V<Q+FIP9U!+ 0(4 Q0    ( &Z"I%;RU*ID=KX
M $('"  5              "  4(G" !X9F]R+3(P,C,P,S,Q7VQA8BYX;6Q0
M2P$"% ,4    " !N@J16'YFJ?C5W  !]4P4 %0              @ 'KY0@
K>&9O<BTR,#(S,#,S,5]P<F4N>&UL4$L%!@     *  H A@(  %-="0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
